<SEC-DOCUMENT>0001069530-23-000009.txt : 20230228
<SEC-HEADER>0001069530-23-000009.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228160703
ACCESSION NUMBER:		0001069530-23-000009
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CASSAVA SCIENCES INC
		CENTRAL INDEX KEY:			0001069530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911911336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29959
		FILM NUMBER:		23685172

	BUSINESS ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731
		BUSINESS PHONE:		512-501-2444

	MAIL ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PAIN THERAPEUTICS INC
		DATE OF NAME CHANGE:	20000309
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sava-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Inline XBRL document created by Certent Disclosure Management 1.0.0.0-->
<!--Created on: 02/28/2023 20:51:24 PM-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:sava="http://www.cassavasciences.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <head>
    <title>sava-20221231x10k</title>
    <meta http-equiv="Content-Type" content="text/html" /></head>
  <body xml:lang="en-US">
    <div style="display:none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="ct-nonNumeric-0e304a11-bbcc-4ad5-b368-a6d07b61420a" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="ct-nonNumeric-c0ad6956-b080-4e1f-9d5c-c9773583c40c" contextRef="Duration_1_1_2022_To_12_31_2022">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="ct-nonNumeric-32324d6b-f2e3-4a0f-9ae2-4e97aa53f39e" contextRef="Duration_1_1_2022_To_12_31_2022">0001069530</ix:nonNumeric><ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="ct-nonNumeric-17afd52e-4a19-4dbd-b019-91148f64b848" contextRef="Duration_1_1_2022_To_12_31_2022">Yes</ix:nonNumeric><ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="ct-nonNumeric-5dd58f08-72e3-49a8-bbc9-2abf4a5c73a8" contextRef="Duration_1_1_2022_To_12_31_2022">Yes</ix:nonNumeric><ix:nonNumeric name="dei:EntityVoluntaryFilers" id="ct-nonNumeric-0fd78f32-8b4b-4615-82ac-704df8a8ec92" contextRef="Duration_1_1_2022_To_12_31_2022">No</ix:nonNumeric><ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" id="ct-nonNumeric-426b8df1-d620-47b0-b66f-3739456c5617" contextRef="Duration_1_1_2022_To_12_31_2022">Yes</ix:nonNumeric><ix:nonFraction id="ct-nonFraction-de6cc757-c8de-42c3-99b4-15243e637ef0" name="sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" contextRef="As_Of_12_31_2021" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-df8c0a4a-fcf8-445d-a1bd-210c9fac8742" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-d8c20985-8ceb-42dd-996f-4a0a47c0e08e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-7580528a-87fd-452f-94c7-806f4337e589" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-a109bcc7-7b2b-4ca9-b816-fa1fa8e5a4b9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-afdfdc90-7985-4059-ac0e-4428e6895644" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-5bcdce4c-9682-486d-b80b-c542fbc7e4b0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-9273aa42-9a73-4159-90cd-fce2d9937049" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-c9a5eb2b-dc7d-4861-bb84-a923cff12f6a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-8d886509-becc-4809-98f7-33fa6d1e2229" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-c6fa6d0d-7a6f-4f1a-86b9-487d2fc5526e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-d3752495-f9b1-4d21-9b8b-e7a3f1bfd9f6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-ec90904b-e73c-4265-b905-29b18c11c1e7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-2482011d-65b9-477a-825f-eea0d38abc1d" name="us-gaap:CommitmentsAndContingencies" contextRef="As_Of_12_31_2021" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-c85d098c-43ef-4402-ad21-3eab6b4c27b8" name="us-gaap:CommitmentsAndContingencies" contextRef="As_Of_12_31_2022" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-c36d2911-beed-46e5-a06d-8fb8d4dd3d41" name="us-gaap:DeferredTaxLiabilities" contextRef="As_Of_12_31_2021" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-1da80672-2d90-4cfe-a52c-83cd81fc610f" name="us-gaap:DeferredTaxLiabilities" contextRef="As_Of_12_31_2022" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-eb885844-bf4c-4fb5-ba17-aadb840ba669" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-eedb89d9-ad7e-4f41-a736-d7fd924e0c16" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-c5477bfe-2785-4f75-a69d-a809395650e8" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-6454e79f-5eac-4ce6-b83d-d54ce1ad34ec" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-372e6af5-4c00-48eb-bae0-4471ae3a22e5" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-2bbe3c9f-b94d-448f-b6dc-323b380f9a96" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-f679e88d-5156-4cf8-ac0b-88135755453e" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-4e0ecb2c-bd96-4ebb-bced-daa182b0ed24" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-edb04fec-6821-4e71-b08a-24673be2beb4" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-d4c3c33b-3414-43d4-982a-455cfcd1d850" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-5793b5c3-1cbb-486a-b34d-eb398efe6a99" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-0e0796a2-6853-4ce7-b9dd-66419cd567a2" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-0db0de42-f4bd-4029-b4ac-4141a7fa729c" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-60c0c054-0845-4646-97f5-4ee1a9062712" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-6a872f17-c446-49cb-b5c0-521df86f5620" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-d329d997-53ed-4249-8a3e-3c0e4ed13b4e" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-5ec1ab38-faae-43c7-9586-d76cf41a362f" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-96f181e2-9fe8-4966-8d28-9554ea90c3ec" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="ct-nonNumeric-c9c2841b-7ede-4662-83a9-7a4f7dcefb27" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" format="ixt:dateyearmonthday">2037-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="ct-nonNumeric-ab3e4de0-d223-4a28-a263-17c41929c12c" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" format="ixt:dateyearmonthday">2029-01-01</ix:nonNumeric><ix:nonFraction id="ct-nonFraction-59321846-f327-4f04-bbc4-4fc6ff45a6d5" name="us-gaap:PreferredStockValue" contextRef="As_Of_12_31_2021" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-2be3e229-c641-48c7-81d3-b5714626c15b" name="us-gaap:PreferredStockValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-0a18ef04-da81-4da9-b08e-4f541d5d87fe" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-a9cc683b-ce22-4d24-8a07-e6387b6743b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ct-nonNumeric-11a67b5d-6030-4b4a-89e9-be45bb42951d" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt:dateyearmonthday">2026-12-31</ix:nonNumeric><ix:nonFraction id="ct-nonFraction-f72a1e5d-aec7-4a71-a833-c2f28f7c3aa7" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-b3474d5b-40e6-4751-af80-757d598097ba" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-b9904651-ff3f-47a5-b170-f86d82d7e2fc" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-eff39773-9f57-43b6-b38b-6e48c8992dac" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-127faa7e-439c-4f35-a3cb-ac23fc2037ad" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-68a04647-00b0-4839-9b0a-b55ed1d8a1f4" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-d6b508b8-e5f6-4fe3-bc4b-333dafca92c3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-8f3d3aee-e688-4a58-8c82-2dcaecba5338" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-42361762-5433-4b01-ab66-912546a855b8" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-f94615b8-ca86-4b50-bf26-783b381cf0ce" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-54c7ab99-4813-4b1d-b474-b37c9a524dcc" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-710cf88c-85ca-4d71-9477-12fb47d6f033" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-066675fe-3f2a-440e-946b-8efc90ddb585" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-81530414-bf2f-4aaa-b26e-077e1df6e132" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-23845146-836d-4a7b-8df9-875e29e06cb0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-aea819c2-5b65-4213-bc0e-bb07a6069a77" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-f8301e49-4c2c-48ac-8f2f-9428fb07e149" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-ed009123-4af1-44d6-8158-b2dbd107c848" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-474b8871-4327-4d19-9f77-fb3abc9b7840" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-6d603b54-7185-48ca-b5ed-9fc404d6c467" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-8a742db3-f945-4ab7-8e73-11b06c08c252" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-1dafedde-6946-46d3-ac0a-4c7e0c43d181" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-973e7776-7e8a-4f63-b1e9-ffd2515ee290" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-73e54030-2cd6-4c79-a8e1-8c37360ff959" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-0987ba20-66f7-4bf9-b131-7ab51e4f204f" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-9588f41e-4c12-4cd8-a47f-0b8a2f1e1a6c" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-11ab857d-4a58-4fa0-adba-79c7330d2414" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-27e5a001-2996-4703-ae33-f911acb2c051" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-3c6cc885-b3d3-4198-9eb0-166e06c19899" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-76ef54f7-3e1c-4b2f-a533-2721893b12a5" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-864a6697-b067-4537-bbe4-cc70a3df80eb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-955b4d43-5e21-4308-8bea-88e35c283798" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-ab248c3f-9fd0-4817-9180-ea9ab4b4557d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-919cbe35-3e67-4ee3-829c-05770b6d8549" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-9267357c-efdf-4dea-8df4-bf960417e97f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-0d5dde46-8f93-44ec-a3a8-40b8d2a7bf84" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-f2dbc5ec-044c-49d1-9f0d-50a8037a6db2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-0f5134fe-cbd1-471e-8931-4e1628ea7e4e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-645041b0-469c-42d6-b90e-61c9bd3dbb17" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" id="ct-nonNumeric-16a796f0-25d3-4e27-b50c-84d331cdfb35" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" format="ixt:dateyearmonthday">2042-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" id="ct-nonNumeric-8869304f-1756-4722-a383-48272eaadb6a" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" format="ixt:dateyearmonthday">2024-01-01</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sava-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationResearchAndDevelopmentTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationResearchAndDevelopmentTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationResearchAndDevelopmentTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEightEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2018_To_8_31_2018_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2020_To_3_27_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-27</xbrli:startDate><xbrli:endDate>2020-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2021_To_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_13_2020_To_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-13</xbrli:startDate><xbrli:endDate>2020-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationOperatingLossCarryforwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationOperatingLossCarryforwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_IndefinitelyMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:IndefinitelyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationOperatingLossCarryforwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_ShortTermOperatingLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:ShortTermOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2021_To_11_4_2021_srt_LitigationCaseAxis_sava_ShareholderDerivativeActionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_27_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-27</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_ShortTermOperatingLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:ShortTermOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_4_2021_To_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-04</xbrli:startDate><xbrli:endDate>2021-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2022_To_6_30_2022_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:Exceeds5BillionMarketCapitalizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:Exceeds5BillionMarketCapitalizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_13_2020_srt_StatementScenarioAxis_sava_FirstValuationMilestoneMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:FirstValuationMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit17"><xbrli:measure>sava:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit16"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit15"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit14"><xbrli:measure>sava:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit13"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit12"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit1"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
    <div class="headerContainer"></div>
    <div><div style="border-bottom: none;border-left: none;border-right: none;border-top: double windowtext 2.5pt;padding-top: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 14pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 14pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">UNITED STATES</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 14pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 14pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SECURITIES AND EXCHANGE COMMISSION</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Washington, D.C. 20549</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">_______________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 16pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 16pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Form </span><ix:nonNumeric name="dei:DocumentType" id="ct-nonNumeric-0c5fe495-2496-42af-a3a8-aa9104feb034" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 16pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">10-K</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">_______________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 3pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 3pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 5.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 94.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 5.4%;"><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 94.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Mark One)</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 5.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:DocumentAnnualReport" id="ct-nonNumeric-1a6aa34c-b496-481d-8ded-cc678eea403b" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt:booleantrue"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#254;</span></span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 94.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">For the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-c0ad6956-b080-4e1f-9d5c-c9773583c40c;">Fiscal Year</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Ended </span><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="ct-nonNumeric-11df01cd-472c-4bdf-8d62-6875a3c467db" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt:datemonthdayen"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="ct-nonNumeric-83eb4d07-bd42-4a9f-92af-9bae4db4057a" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt:datemonthdayyearen" continuedAt="ct-nonNumeric-83eb4d07-bd42-4a9f-92af-9bae4db4057a-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December&#160;31</span></ix:nonNumeric></ix:nonNumeric><ix:continuation id="ct-nonNumeric-83eb4d07-bd42-4a9f-92af-9bae4db4057a-continuation-0" continuedAt="ct-nonNumeric-83eb4d07-bd42-4a9f-92af-9bae4db4057a-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">, </span></ix:continuation><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="ct-nonNumeric-e5ed7c20-7435-447d-a003-d3248845a5c1" contextRef="Duration_1_1_2022_To_12_31_2022"><ix:continuation id="ct-nonNumeric-83eb4d07-bd42-4a9f-92af-9bae4db4057a-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></ix:continuation></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">or</span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 5.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 94.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 5.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="ct-nonNumeric-7610ff56-b855-484d-a2d0-e9a8b1563732" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 94.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">For the transition period from </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">_____</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">_____</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Commission File Number: </span><ix:nonNumeric name="dei:EntityFileNumber" id="ct-nonNumeric-f451a28e-5ae5-4139-9ff5-d4c6ccf0f119" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">000-29959</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 3pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 3pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 22pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityRegistrantName" id="ct-nonNumeric-713f19e3-653e-4f20-bf35-8f93c871dcba" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; color: #1F497D;font-family: Sansation;font-size: 22pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cassava</span><span style="white-space:pre-wrap; color: #1F497D;font-family: 'Times New Roman', 'serif';font-size: 22pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #1F497D;font-family: Sansation;font-size: 22pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Sciences,</span><span style="white-space:pre-wrap; color: #1F497D;font-family: 'Times New Roman', 'serif';font-size: 22pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #1F497D;font-family: Sansation;font-size: 22pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Inc.</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Exact name of registrant as specified in its charter)</span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 50.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 49.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="ct-nonNumeric-1e58b247-270f-4102-a985-6f0110555f96" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt-sec:stateprovnameen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Delaware</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 49.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="ct-nonNumeric-47ad67a3-798d-471f-8fdd-77d8fc3c6639" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">91-1911336</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(State or other jurisdiction of</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 49.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(I.R.S. Employer</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">incorporation or organization)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 49.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Identification Number)</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 3pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 3pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="ct-nonNumeric-9afa33d4-2c80-48a4-9bc5-3814c8fc0700" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6801 N. Capital of Texas Highway</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, </span><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="ct-nonNumeric-5ef44b32-b157-434e-a129-9ba788df5752" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Building 1; Suite 300</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, </span><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="ct-nonNumeric-3de8d719-5ca0-4ce4-8a76-37b2837c4bea" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Austin</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, </span><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="ct-nonNumeric-a31b818f-14c7-4336-b30b-96aac7f8a28c" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TX</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="ct-nonNumeric-19d24242-1053-4897-a2d6-2eb5b812d0c2" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">78731</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> (</span><ix:nonNumeric name="dei:CityAreaCode" id="ct-nonNumeric-abf9d838-2e9a-431c-a686-a13a28e78bfb" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">512</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">) </span><ix:nonNumeric name="dei:LocalPhoneNumber" id="ct-nonNumeric-f81255ca-4ea0-4435-b762-bf0d79580dcb" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">501-2444</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(Address, including zip code, of registrant&apos;s principal executive offices and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 3pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">telephone number, including area code)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Securities registered pursuant to Section 12(b) of the Act:</span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 41.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 15.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 42.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Title of each class</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Trading</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Symbol(s)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Name of each exchange on which registered</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 41.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="ct-nonNumeric-a4291b4f-63e7-4a36-b48e-2f5bbddef721" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="ct-nonNumeric-d4e6f5b4-a8dc-4b66-880a-858541a9f5f6" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SAVA</span></ix:nonNumeric></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="ct-nonNumeric-604e7b84-6500-423c-8c43-f00ec82fdb05" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NASDAQ</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Capital Market</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 3pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 3pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Securities registered pursuant to Section 12(g) of the Act:  None</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.5pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-426b8df1-d620-47b0-b66f-3739456c5617;">&#254;</span></span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  No&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.5pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  No&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-0fd78f32-8b4b-4615-82ac-704df8a8ec92;">&#254;</span></span></span></p><p dir="ltr" style="font-family: Wingdings;font-size: 8pt;line-height: 108%;margin-bottom: 0.5pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-17afd52e-4a19-4dbd-b019-91148f64b848;">&#254;</span></span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  No&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.5pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.5pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-5dd58f08-72e3-49a8-bbc9-2abf4a5c73a8;">&#254;</span></span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  No&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.5pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.  (Check one): </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="dei:EntityFilerCategory" id="ct-nonNumeric-d33fbec7-a83f-4500-be76-207de00ab116" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt-sec:entityfilercategoryen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Large accelerated filer</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  </span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#254;</span></span></p></td><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accelerated filer  </span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></p></td></tr><tr><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Non-accelerated filer  </span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></p></td><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Smaller reporting company  </span><ix:nonNumeric name="dei:EntitySmallBusiness" id="ct-nonNumeric-68a2f873-3736-42c3-87e5-7cf59c678ad2" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#61472;</span></p></td></tr><tr><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 50.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Emerging growth company  </span><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="ct-nonNumeric-2ec7c5b4-2e3c-4060-9167-a1bc6640f65f" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#61472;</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 4pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 4pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Wingdings;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></p><p dir="ltr" style="font-family: Wingdings;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #2B2B2B;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the&#160;Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" id="ct-nonNumeric-bc3fdf7e-e4a1-4025-b981-98a4bd4fe60d" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt:booleantrue"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#254;</span></span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 3pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. &#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: Cambria Math;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#9723;</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 3pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b)</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: Cambria Math;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#9723;</span></p><p dir="ltr" style="font-family: Wingdings;font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  No&#160;</span><ix:nonNumeric name="dei:EntityShellCompany" id="ct-nonNumeric-958f990e-4a37-420e-945d-2572f1f90a3e" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#254;</span></span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The aggregate market value of the voting and non-voting common equity held by non-affiliates was approximately $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-70e38567-b98d-4817-877b-1ec9fe389f96" name="dei:EntityPublicFloat" contextRef="As_Of_6_30_2022" unitRef="Unit12" decimals="-8" format="ixt:numdotdecimal" scale="9">1.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> billion computed by reference to the last sales price of $28.12 as reported on the Nasdaq Capital Market, as of the last business day of the Registrant&apos;s most recently completed second fiscal quarter, June&#160;30, 2022. The number of shares outstanding of the Registrant&apos;s common stock, par value $0.001 per share, on February&#160;23, 2023 was </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-16a4e665-6dc1-4f8e-9a09-676e06da9a0c" name="dei:EntityCommonStockSharesOutstanding" contextRef="As_Of_2_23_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">41,735,557</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.5pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.5pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">DOCUMENTS INCORPORATED BY REFERENCE</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">1</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:nonNumeric name="dei:DocumentsIncorporatedByReferenceTextBlock" id="ct-nonNumeric-d05d6a2c-57d9-40e6-93f0-17c7e37ab55e" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Portions of the Registrant&apos;s proxy statement for its 2023 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), to be filed with the U.S. Securities and Exchange Commission, no later than 120 days after the Registrant</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8217;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s fiscal year ended December 31, 2022, are incorporated by reference to Part III of this Annual Report on Form 10-K.</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><div style="border-bottom: double windowtext 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">2</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">FORM 10-K</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">INDEX</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">Page</span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 100.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART I</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 1.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="#Business" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Business</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 1A.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Risk_Factors" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Risk Factors</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 1B.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Unresolved_Staff_Comments" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Unresolved Staff Comments</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 2.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Properties" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Properties</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 3.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Legal_Proceedings" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Legal Proceedings</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 4.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Mine_Safety_Disclosures" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Mine Safety Disclosures</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 100.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART II</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 5.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.01in;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Market_For_Registrants_Common_Equity" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">75</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 6.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Selected_Financial_Data" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">[Reserved]</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">76</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 7.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#MDA" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 7A.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Quantitative_And_Qualitative_Disclosures" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">84</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 8.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Financial_Statements_Supplementary_Data" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consolidated financial Statements and Supplementary Data</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">84</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 9.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Changes_And_Disagreements" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">105</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 9A.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Controls_And_Procedures" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Controls and Procedures</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">105</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 9B.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Other_Information" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Other Information</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">108</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 9C.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#ForeignJurisdictions" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Disclosure Regarding Foreign Jurisdiction that Prevent Inspection</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">108</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 100.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART III</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 10.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Directors_And_Executive_Officers" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Directors and Executive Officers and Corporate Governance</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">108</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 11.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Executive_Compensation" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Executive Compensation</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">109</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 12.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Security_Ownership" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">109</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 13.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Certain_Relationships" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">110</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 14.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Principal_Accountant_Fees" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Principal Accountant Fees and Services</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">110</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 100.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART IV</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 15.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Exhibits" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Exhibits and Consolidated Financial Statement Schedules</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">111</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 10.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Item 16.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 81.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-align: justify;"><a href="#Form10KSummary" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form 10-K Summary</span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">112</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="#Signatures" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Signatures</span></a></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">3</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART I</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">FORWARD-LOOKING STATEMENTS</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This Annual Report on Form 10-K </span><span id="_Hlk96433783" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and the documents incorporated by reference</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> contain forward-looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. We intend that such statements be protected by the safe harbor created thereby. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and &#8220;would&#8221; or the negatives of these terms or other comparable terminology.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The forward-looking statements are based on our beliefs, assumptions and expectations of our future performance, taking into account all information currently available to us. Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Such forward-looking statements and our business are subject to numerous risks and uncertainties that you should consider before investing in our Company. These risks are described more fully in the section titled &#8220;Risk Factors.&#8221; Accordingly, you should not rely upon forward-looking statements as predictions of future events. Examples of such forward-looking statements include, but are not limited to statements about:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the number of patients with Alzheimer&#8217;s disease we expect to enroll in our on-going Phase 3 studies, the enrollment rates for these studies, and the length of time to complete patient enrollment for our studies and the expected safety profile or treatment benefits of simufilam for people with Alzheimer&#8217;s disease</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our reliance on third-party contractors to conduct the clinical trials and make drug supply on a large-scale for our Phase 3 clinical program, or their ability to do so on-time or on-budget;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">limitations around data interpretation from results of our long-term open-label study, as compared to efficacy results from a fully completed, randomized controlled study design;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the ability of clinical scales to assess cognition or health in our trials of Alzheimer&#8217;s disease;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">any significant changes we may make, or anticipate making, to the design of any of our on-going studies of simufilam in patients with Alzheimer&#8217;s disease;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to initiate, conduct or analyze additional clinical and non-clinical studies with our product candidates targeted at Alzheimer&#8217;s disease and other neurodegenerative diseases;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the impact of pre-clinical findings on our ability to develop our product candidates;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the interpretation of results from our pre-clinical or early clinical studies, such as Phase 1 and Phase 2 studies;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our plans to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">further develop </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SavaDx, our investigational blood-based diagnostic, and to evaluate a non-antibody approach for SavaDx;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability or willingness to expand therapeutic indications for simufilam outside of Alzheimer&#8217;s disease;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the safety, efficacy, or potential therapeutic benefits of our product candidates;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to file for and obtain regulatory approval of our product candidates;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our strategy and ability to establish an infrastructure to commercialize any product candidates, if approved;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the potential future revenues of our product candidates, if approved and commercialized;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the market acceptance of our product candidates, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">if approved and commercialized;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the pricing and reimbursement of our product candidates, if approved and commercialized;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the utility of protection, or the sufficiency, of our intellectual property;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our potential competitors or competitive products for the treatment of Alzheimer&#8217;s disease;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our need to raise new capital from time to time to continue our operations or to expand our operations;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our use of multiple third-party vendors, including a Clinical Research Organization (CRO), to conduct clinical studies of our lead product candidate;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">expectations regarding trade secrets, technological innovations, licensing agreements and outsourcing of certain business functions;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our expenses increasing by unanticipated amounts due to inflation;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">fluctuations in our financial or operating results;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our operating losses, anticipated operating and capital expenditures and legal expenses;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">expectations regarding the issuance of shares of common stock, options or other equity to employees or directors pursuant to equity compensation awards, net of employment taxes;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the development and maintenance of our internal information systems and infrastructure;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our need to hire additional personnel and our ability to attract and retain such personnel;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">existing regulations and regulatory developments in the United States and other jurisdictions in which we operate;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">4</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our plans to expand the size and scope of our operations;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the sufficiency of our current resources to continue to fund our operations;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">potential future agreements with third parties in connection with the commercialization of our product candidates;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the accuracy of our estimates regarding expenses, capital requirements, and needs for additional financing;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">assumptions and estimates used for our disclosures regarding stock-based compensation;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the expense, timing and outcome of pending or future litigation or other legal proceedings and claims, including U.S. government inquiries</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">; and</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">litigation, claims or other uncertainties that may arise from allegations made against us or our collaborators.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in regulatory approval and subsequent commercialization of a product. Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will affect us or our operations in the way we expect. The forward-looking statements included in this Annual Report on Form 10-K are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by law.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, terms </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">such as </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8220;we believe,&#8221; </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;would&#8221;, &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; and other words and terms of similar meaning</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reflect our beliefs and opinions on the relevant subject at the time we use such words and terms. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our research programs in neurodegeneration have benefited from longstanding scientific and financial support from the National </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Institutes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of Health (NIH). The contents of this Annual Report are solely our responsibility and do not represent any views of NIH</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, the Department of Health and Human Services, or the United States government</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="Item_1_Business" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 1.&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Business</span><span id="Business" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Overview</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span id="_Hlk32321201" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer&#8217;s disease. Our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the brain. Our lead therapeutic drug candidate, simufilam, is being evaluated for the proposed treatment of Alzheimer&#8217;s disease dementia in Phase 3 clinical studies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Over the past 10 years, we have combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer&#8217;s disease and other neurodegenerative diseases. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our strategy is to leverage our unique scientific/clinical platform to develop a first-in-class program for </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">treating neurodegenerative diseases, such as Alzheimer&#8217;s</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently have two </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">biopharmaceutical </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">assets under development: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our lead therapeutic product candidate, called simufilam, is a novel oral treatment for Alzheimer&#8217;s disease dementia; and </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our lead investigational diagnostic product candidate, called SavaDx, is a novel way to detect the presence of Alzheimer&#8217;s disease from a small sample of blood.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our scientific approach for the treatment of Alzheimer&#8217;s disease seeks to simultaneously suppress </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">both</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> neurodegeneration and neuroinflammation. We believe our ability to improve multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#8217;s disease. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our lead product candidate, simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer&#8217;s brain. Published studies have demonstrated that the altered form of </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">5</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FLNA causes neuronal dysfunction, neuronal degeneration and neuroinflammation. We are currently conducting a Phase 3 program with simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease dementia.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe simufilam improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering the downstream toxic effects of altered FLNA. We have generated and published experimental and clinical evidence of improved brain health with simufilam. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Importantly, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">simufilam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> is not dependent on clearing amyloid from the brain. S</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ince simufilam has a unique mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with those of other therapeutic candidates aiming to treat neurodegeneration.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam has demonstrated a multitude of treatment effects in animal models of disease, including normalizing neurotransmission, decreasing neuroinflammation, suppressing neurodegeneration, and restoring memory and cognition.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Phase 2a Study</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2019, we completed a small, first-in-patient, clinical-proof-of-concept, open-label Phase 2a study of simufilam in the U.S., with substantial support from the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">National Institute on Aging</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (NIA), a division of the NIH. Treatment with simufilam for 28 days significantly improved certain key biomarkers of Alzheimer&#8217;s pathology, neurodegeneration and neuroinflammation (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">p&lt;0.001)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Biomarkers effects were seen in all patients in both cerebrospinal fluid (CSF) and plasma.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Phase 2b Study</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In September 2020, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">announced </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">final</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> results of a Phase 2b study with simufilam in Alzheimer&#8217;s disease. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In this clinical study funded by the NIH, Alzheimer&#8217;s </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">patients</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">treated with 50 mg or 100 mg of simufilam twice-daily for 28 days showed statistically significant (p&lt;0.05) improvements in CSF biomarkers of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">disease pathology, neurodegeneration and neuroinflammation, versus</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">patients who took placebo</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> In addition, Alzheimer&#8217;s </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">patients</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">treated with simufilam showed improvements in validated tests of episodic memory and spatial working memory,</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">versus patients on placebo</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Cognitive improvements correlated most strongly with decreases in levels of P-tau181, an exploratory &#8216;research use only&#8217; non-safety related biomarker that suggests brain changes from Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Open-label Study Strategy</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Much of the value of our open-label study is to support simufilam&#8217;s long-term safety profile in patients. We believe a well-designed, long-term, open-label study is an exercise in prudent risk-management. Clinical results serve as a tool to help inform and manage the inherent risks and uncertainties of drug development for undertaking a large, expensive Phase 3 clinical testing program.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Open-label Study Top-line Results</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: left;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2020, we initiated</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> a long-term, open-label study to evaluate&#160;simufilam, our lead drug candidate,&#160;in patients with Alzheimer&#8217;s disease.&#160;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This study&#160;was funded in part by a research grant award from NIH. The study </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">was designed to evaluate the long-term safety and tolerability of&#160;simufilam&#160;100 mg twice daily for 12 or more months. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Another study objective was to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In January 2023, we announced positive top-line Phase 2 results for our open-label study. The study enrolled over 200 patients with mild-to-moderate Alzheimer&#8217;s disease (MMSE 16-26). Endpoints were measured at baseline (study entry) and month 12.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Top-line Results &#8211; mean scores, baseline to month 12 </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">lower is better, except for MMSE)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">:</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ADAS-Cog11 scores changed from </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19.1 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9.2) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19.6 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13.3)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">MMSE scores changed from </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.5 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.6) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.2 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.4)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NPI10 scores changed from 3.2 (&#177;4.6) to 2.9 (&#177;4.6)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 12pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">GDS scores changed from </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.8 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.8) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.4 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.9)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s is a degenerative disease of the brain. Over time, cognition progressively worsens in the mild-to-moderate stages of Alzheimer&#8217;s as the disease takes its toll. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ADAS-Cog scores that change minimally (or improve) over 1 year </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">is</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> a highly desirable </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">outcome</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in a clinical study of patients with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">mild-to-moderate Alzheimer&#8217;s disease.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">6</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Response Analysis &#8211; baseline to month 12</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.19in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.190in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ADAS-Cog scores improved in 47% of patients; this group had a mean change of -4.7 (&#177;3.8) points (lower is better).</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.19in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.190in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In an additional 23% of patients, ADAS-Cog declined less than 5 points; this group had a mean change of 2.5 (&#177;1.4) points.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.19in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.190in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients with an NPI10 score of zero increased from 42% to 54%, indicating reduced dementia-related neuropsychiatric symptoms after 1 year on simufilam.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Analysis of Efficacy Endpoints</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Efficacy outcomes were analyzed by an independent, outside biostatistical consulting firm led by Suzanne Hendrix, PhD. The pre-specified primary efficacy endpoint was change in baseline on ADAS-Cog11, a cognitive scale widely used in Alzheimer&#8217;s clinical research. Exploratory endpoints included the Mini-Mental State Examination (MMSE) to assess disease stage by cognitive impairment; the Neuropsychiatric Inventory (NPI10) to assess dementia related behavior; and the Geriatric Depression Scale (GDS). The Full Analysis Set (FAS) population (N=216) was used for the statistical analysis of efficacy endpoints.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s is a progressive disease. Severity of disease is typically assessed by MMSE score. In this study, mild patients are MMSE 21-26; moderate patients are MMSE 16-20. Mild and moderate sub-groups showed notable differences on changes in ADAS-Cog mean scores, baseline to month 12 (lower is better):</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">mild</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> sub-group, ADAS-Cog scores improved, from </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15.0 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.3) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.6 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.8)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">moderate</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> sub-group, ADAS-Cog scores worsened, from </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25.7 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9.2) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">30.1 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13.1)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe the improvement in ADAS-Cog over 1 year in mild patients taking simufilam is well outside the expected range of historic placebo decline rates from numerous other studies. Figure 1 presents a model of historical declines on ADAS-Cog in early disease (MCI + mild) and mild disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"><img src="sava-20221231x10kg001.jpg" style="width: 6.771528in; height: 2.19685in" alt="Picture 9" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Figure 1:</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> Statistical model of simufilam versus historical 1-year placebo declines on ADAS-Cog in early disease and mild disease</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Safety Data</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam 100 mg twice daily was generally safe and well tolerated in this open-label study. There were no drug-related serious adverse events. Three treatment-emergent adverse events (TEAEs) occurred in 7% or more of study patients: COVID-19 (12%), urinary tract infection (10%) and headache (9%). Reported TEAEs are based on all study patients who received at least one dose of drug. The top three reasons for patient discontinuations were withdrawal of informed consent (N=14), adverse events (N=13) and patient non-compliance (N=7).</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">____________________________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>1 </sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Figure 1: Forest plot</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> model by Pentara Corporation. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Data was sourced from non-randomized studies (i.e., ADNI) and randomized, controlled trials </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">conducted by other sponsors in patients with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">early (i.e., MCI + mild) and mild Alzheimer&#8217;s disease.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">7</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Biomarker Data</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exploratory biomarkers were analyzed from cerebrospinal fluid (CSF) collected from 25 patients in the open-label study who agreed to undergo a lumbar puncture at baseline and again after 6 months of treatment. CSF samples were analyzed blind by our academic collaborator at City University of New York. All CSF biomarkers were &#8216;research use only&#8217;, non-safety-related exploratory biomarkers. We previously announced results of this bioanalysis in a press release dated July 29, 2021.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> P-values shown below are baseline vs. 6-month levels by paired t-test:</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF biomarkers of disease pathology, t-tau and p-tau181, decreased 38% and 18%, respectively (both p&lt;0.00001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF biomarkers of neurodegeneration, neurogranin and neurofilament light chain (NfL), decreased 72% and 55%, respectively (both p&lt;0.00001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF biomarkers of neuroinflammation, sTREM2 and YKL-40, decreased 65% and 44% (both p&lt;0.00001)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Of the 25 patients who provided 6-month CSF samples, 24 subsequently completed 1 year of treatment with open-label simufilam. This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12 (lower is better; </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">ad hoc</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> analysis conducted internally). We have not conducted further CSF sample analyses in the open-label study.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Limitations of Open-label Study and Top-line Results</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Data results from our open-label safety study do not constitute, and should not be interpreted as, regulatory evidence of safety or efficacy for simufilam in Alzheimer&#8217;s disease. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Rigorous evidence for drug safety and efficacy is derived from one or more large, randomized, placebo-controlled studies. The open-label design and size of this study may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our open-label study add complexity or limitations to the scope of data interpretation. In addition, &#8216;top-line data&#8217; is a summary of the clinical data prior to the completion of a full and final audit or quality-control of the clinical database. We communicated top-line data so that stakeholders had timely access to a summary of the study&#8217;s findings prior to us receiving the final dataset. Final data may change from initial top-line data.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">8</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cognition Maintenance Study</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In May 2021, we initiated a Cognition Maintenance Study (CMS). The CMS is a randomized, withdrawal study design. ICH</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> defines this type of study design as follows: </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#8220;In a randomized withdrawal trial, subjects receiving a test&#160;treatment for a specified time are randomly assigned to continued treatment with the test treatment or to placebo (i.e., withdrawal of active therapy)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> &#8230;&#8230;..</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#160;Any difference that emerges between the group receiving continued treatment and the group randomized to placebo would demonstrate the effect of the active treatment</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#8221;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The CMS study design is intended to evaluate simufilam&#8217;s effects on cognition and health outcomes in Alzheimer&#8217;s patients who continue with drug treatment versus patients who discontinue drug treatment. It is a double-blind, randomized, placebo-controlled study of simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease. Study patients are randomized (1:1) to simufilam or placebo for six months. To enroll in this study, patients must have previously completed 12 months or more of open-label treatment with simufilam. Figure 2.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 2. Cognition Maintenance Study Design</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="sava-20221231x10kg002.jpg" style="width: 6.520833in; height: 2.016557in" alt="Picture 13" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patient enrollment for this study is closed. As of February 17, 2023, over 110 patients have completed this study. A small number of enrolled patients are still being treated in the randomized portion of this study. All randomized clinical data remain blinded. Our goal is to announce top-line clinical results for the CMS approximately third-quarter 2023. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">____________________________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>2  </sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), Topic E10, Choice of Control Group in Clinical Trials.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">9</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">End-of-Phase 2 (EOP2) Meeting with FDA</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In January 2021, we held an End-of-phase 2 (EOP2) meeting for simufilam with the U.S. Food and Drug Administration (FDA). The purpose of this EOP2 meeting was to gain general agreement around key elements of a pivotal Phase 3 program to treat Alzheimer&#8217;s disease dementia. FDA attendees included Robert Temple, MD, Deputy Center Director for Clinical Science and Senior Advisor in the Office of New Drugs; Billy Dunn, MD, Director, Office of Neuroscience; Eric Bastings, MD, Director, Division of Neurology, and others.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In February 2021, we announced the successful completion of our EOP2 meeting. Official meeting minutes confirm that we and FDA are aligned on key elements of a Phase 3 clinical program for simufilam. FDA has agreed that the completed Phase 2 program, together with an ongoing and well-defined Phase 3 clinical program, are sufficient to show evidence of clinical efficacy for simufilam in Alzheimer&#8217;s disease. There is also agreement that the use of separate clinical scales to assess cognition (ADAS-cog</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) and function (ADCS-ADL</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) are appropriate co-primary endpoints of efficacy. A clinical scale that combines cognition and function, such as iADRS</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, is a secondary efficacy endpoint, along with the NPI.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> ADAS-Cog = The Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognitive Subscale, a measure of cognition </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> ADCS-ADL = Alzheimer&#8217;s Disease Cooperative Study &#8211; Activities of Daily Living, a measure of health function</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">iADRS = integrated Alzheimer&#8217;s Disease Rating Scale, a composite measure of cognition and health function</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">10</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Special Protocol Assessments</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2021, we announced we had reached agreement with FDA under a Special Protocol Assessment (SPA) for both Phase 3 studies. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These SPA agreements document that FDA has reviewed and agreed upon the key design features of our Phase 3 study protocols of simufilam for the treatment of patients with Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">An SPA agreement indicates concurrence by the FDA with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, etc.). These elements are critical to ensure that our planned Phase 3 studies of simufilam in Alzheimer&#8217;s disease can be considered adequate and well-controlled studies in support of a future regulatory submission and marketing application.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The first clinical study protocol under the SPA is titled &#8220;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of One Dose of Simufilam in Subjects with Mild-to-Moderate Alzheimer&#8217;s Disease</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#8221;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The second clinical study protocol under the SPA is titled &#8220;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects with Mild-to-Moderate Alzheimer&#8217;s Disease</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#8221;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Phase 3 Drug Supply</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We previously announced we have entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik is expected to supply us with large-scale, clinical-grade quantities of simufilam. Evonik is one of the world&#8217;s largest contract development and manufacturing organizations for pharmaceutical ingredients. Other vendors supply excipients, the finished dosage form (i.e., simufilam tablets), drug packaging, package labeling and other critical steps in the supply chain for Phase 3 drug supply.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Phase 3 Clinical Program Overview</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our Phase 3 program consists of two large, double-blind, randomized, placebo-controlled studies of simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease dementia. Highlights of this clinical program are summarized in Figure 3. In June 2021, we announced the selection of Premier Research International as our CRO to help conduct our Phase 3 clinical program.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 3. Summary of Our Phase 3 Clinical Program</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="sava-20221231x10kg003.jpg" style="width: 6.408147in; height: 1.172222in" alt="Picture 14" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">RETHINK-ALZ and REFOCUS-ALZ</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In Fall 2021, we </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">announced initiation of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our two Phase 3 studies </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">of simufilam, respectively</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of February 28, 2023, a total of over 1,000 patients have been enrolled in our Phase 3 program. The target patient enrollment for the Phase 3 program is over 1,750 patients. We anticipate the completion of patient enrollment for both of our Phase 3 studies by yearend 2023. Patients continue to be screened in clinical trial sites in the U.S., Canada, Puerto Rico, Australia, and South Korea.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The first Phase 3 study, called RETHINK-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg in enhancing cognition and slowing cognitive and functional decline over 52 weeks. Secondary objectives include the assessment of simufilam&#8217;s effect on neuropsychiatric symptoms and caregiver burden. </span><span id="_Hlk96769600" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This randomized, double-blind, placebo-controlled study plans to enroll approximately 750 patients with mild-to-moderate Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Details of the RETHINK-ALZ Phase 3 study include:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Approximately 750 patients with mild-to-moderate Alzheimer&#8217;s disease to be enrolled.</span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients to be randomized (1:1) to simufilam 100 mg or placebo twice daily. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">11</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients to be treated for 12 months.</span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The co-primary efficacy endpoints are ADAS-Cog12</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a cognitive scale, and ADCS-ADL</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a functional scale; both are standard clinical tools in trials of Alzheimer&#8217;s disease. </span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A secondary efficacy endpoint is iADRS</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a standard clinical tool in trials of Alzheimer&#8217;s disease that combines cognitive and functional scores from ADAS-Cog &amp; ADCS-ADL. </span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other secondary endpoints include plasma biomarkers of disease and NPI</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>4</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a clinical tool that assesses the presence and severity of dementia-related behavior.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2021, we announced initiation of a </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">second Phase 3 study, called </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">REFOCUS-ALZ, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">designed to evaluate </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the safety and efficacy of oral simufilam 100 mg and 50 mg over 76 weeks. This randomized, double-blind, placebo-controlled study plans to enroll approximately 1,000 patients with mild-to-moderate Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Details of the REFOCUS-ALZ Phase 3 study include:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Approximately 1,000 patients with mild-to-moderate Alzheimer&#8217;s disease to be enrolled.</span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients to be randomized (1:1:1) to simufilam 100 mg, 50 mg, or placebo BID. </span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients to be treated for 76 weeks.</span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The co-primary efficacy endpoints are ADAS-Cog</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a cognitive scale, and ADCS-ADL</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a functional scale; both are widely used clinical tools in trials of Alzheimer&#8217;s disease. </span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A secondary efficacy endpoint is iADRS</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a widely used clinical tool in trials of Alzheimer&#8217;s disease that combines cognitive and functional scores from ADAS-Cog &amp; ADCS-ADL. </span></p><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other secondary endpoints include CSF, plasma and imaging biomarkers of disease and NPI</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>4</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a clinical tool that assesses the presence and severity of dementia-related behavior.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Phase 3 Entry Criteria Includes a Plasma Assay for Phosphorylated Tau (p-Tau)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe plasma levels of pTau proteins can provide independent confirmation of Alzheimer&#8217;s  neuropathology. RETHINK-ALZ and REFOCUS-ALZ studies use a &#8216;research use only&#8217;, non-safety related exploratory P-tau181 plasma assay to qualify mild-to-moderate Alzheimer&#8217;s patients. At the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>th</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> International Conference on Clinical Trials on Alzheimer&#8217;s Disease</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(CTAD)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 2022, a poster presentation indicated a 30 ng/L cut-point showed 100% sensitivity and 88% specificity for Alzheimer&#8217;s  diagnostic in 22 autopsy-confirmed samples</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>5</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The plasma assay we use does not rely on age, APOE-gene status or complex algorithms to provide a result.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Open-label Extension Study for the Phase 3 Program</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2022, we announced the initiation of an open-label extension study for our Phase 3 program. This study is designed to provide no-cost access to simufilam for one year to Alzheimer&#8217;s patients who have successfully completed a Phase 3 study of simufilam.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The open-label extension study is expected to generate long-term safety and tolerability data for (oral) simufilam 100 mg twice daily over 52 weeks. There is no obligation for a patient or a physician to participate in the open-label extension study.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Each clinical investigational site and each patient chooses whether to participate in this open-label extension study. Patient enrollment for this study began November 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">_____________________________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> ADAS-Cog = The Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognitive Subscale, a measure of cognition </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> ADCS-ADL = Alzheimer&#8217;s Disease Cooperative Study &#8211; Activities of Daily Living, a measure of health function</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> iADRS = integrated Alzheimer&#8217;s Disease Rating Scale, a composite measure of cognition and health function</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>4</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> Neuropsychiatric Inventory (NPI)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>5</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Source: </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">pTau181 Plasma Biomarker Performance as an Inclusion Criterion in the RETHINK-ALZ and REFOCUS-ALZ trials in mild-to-moderate Alzheimer&#8217;s disease, Mammel et al., CTAD 2022</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">12</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SavaDx</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our investigational product candidate, called SavaDx, is early-stage program focused on detecting the presence of Alzheimer&#8217;s disease from a small sample of blood. For business, technical and personnel reasons, we continue to prioritize the development of simufilam, our novel drug candidate, over SavaDx, our novel diagnostic candidate. SavaDx is a research-use only, non-safety related exploratory biomarker.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The regulatory pathway for SavaDx may eventually include formal analytical validation studies and clinical studies that support evidence of sensitivity, specificity and other variables in various healthy and diseased patient populations. We have not conducted such studies and do not expect to conduct such studies in 2023. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SavaDx is currently designed as an antibody-based detection system for altered filamin A (FLNA). Working with third parties, we are evaluating the exploratory use of mass spectrometry to detect FLNA, i.e., without the use of antibodies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">About Alzheimer&#8217;s Disease</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s disease is a progressive neurodegenerative disorder that affects cognition, function and behavior. As of 2021, there were approximately 55&#160;million people worldwide living with dementia, a figure expected to increase to 139&#160;million by 2050 according to outside sources. The annual global cost of dementia is now above $1 trillion, according to Alzheimer&#8217;s Disease International, a charitable organization.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Our Scientific Approach is Different</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Over the last ten years, we have developed a new and promising scientific approach for the treatment and diagnosis of neurodegenerative diseases, such as Alzheimer&#8217;s disease. Importantly, we do not seek to clear amyloid out of the brain. Rather, we seek to stabilize a critical protein in the brain that has many downstream effects.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our scientific approach is to treat neurodegeneration by targeting an altered form of a scaffold protein called FLNA. Through years of basic research, we and our academic collaborators identified FLNA as a structurally altered protein that enables both a neurodegeneration and a neuroinflammation pathway in the Alzheimer&#8217;s brain. We have shown that the altered form of FLNA is pervasive in the Alzheimer&#8217;s brain and undetectable in healthy control brains.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Using scientific insight and lab techniques, we believe we have elucidated this protein dysfunction. Through this work, we have produced experimental evidence that altered FLNA plays a critical role in Alzheimer&#8217;s disease. We engineered a family of high-affinity, small molecules to target this structurally altered protein and restore its normal shape and function. This family of small molecules, including our lead therapeutic candidate, simufilam, was designed in-house and characterized by our academic collaborators. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our lead therapeutic product candidate, simufilam, is a small molecule (oral) drug with a novel mechanism of action. The target of simufilam is altered FLNA, the brain protein we seek to stabilize. Importantly, since simufilam has a unique mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with those of other therapeutic candidates aiming to treat neurodegeneration. We are currently conducting a Phase 3 program with simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease dementia.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Given the biopharmaceutical industry&#8217;s challenging track record </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in Alzheimer&#8217;s research, we believe there is </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">an urgent need to consider innovative approaches to combat this disease. We believe our scientific approach may broaden the range of possible </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">treatment</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> approaches for this complex disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Our science is based on stabilizing a critical protein in the brain</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proteins are essential for cell function because they participate in virtually every biological process. If protein function is impaired, the health consequences can be devastating. Technological advances in medicine and improvements in lifestyle are making our lives longer. But with age, genetic mutations and other factors conspire against healthy cells, resulting in altered proteins. Sometimes a cell can rid itself of altered proteins. However, when disease changes the shape and function of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">critical</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> proteins, multiple downstream processes are impaired. There are many clinical conditions in which proteins become structurally altered and impair the normal function of cells, tissues and organs, leading to disease.  Conversely, restoring altered proteins back to health &#8211;called proteostasis &#8211; is a well-accepted therapeutic strategy in clinical medicine.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For over 100 years, scientists have ascribed various neurodegenerative diseases to proteins that misfold and are rendered pathological. In Alzheimer&#8217;s disease, certain proteins, such as amyloid and tau, lose their normal shape and function. Such misfolded proteins can break down or aggregate in clumps and form plaque or tangles in the brain. Destruction of neuronal </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">13</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">synapses, accelerated nerve cell death, and dysfunction of the brain support cells, are all widely believed to be direct consequences of misfolded proteins. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FLNA is a scaffolding protein found in high levels in the brain. A healthy scaffolding protein brings multiple proteins together, coordinating their interaction. However, an altered form of FLNA protein is found in the Alzheimer&#8217;s brain. Our experimental evidence shows that altered FLNA protein contributes to Alzheimer&#8217;s disease by disrupting the normal function of neurons, leading to neurodegeneration and brain inflammation. Our product candidate, simufilam, aims to counter the altered and toxic form of FLNA in the brain, thus restoring the normal function of this critical protein. Our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the brain.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">One drug, multiple effects </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam binds to altered FLNA with very high (femtomolar) affinity. This drug effect restores the normal shape of FLNA and the normal function of key brain receptors, including: the alpha-7 nicotinic acetylcholine receptor; the </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">N-methyl-D-aspartate</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (NMDA) receptor; and the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">insulin</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> receptor. These receptors have pivotal roles in brain cell survival, cognition and memory.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In animal models, treatment with simufilam resulted in dramatic improvements in brain health, such as reduced amyloid and tau deposits, improved receptor signaling and improved learning and memory. In addition, simufilam has another beneficial treatment effect of significantly reducing inflammatory cytokines in the brain. In animal models of disease, treatment with simufilam greatly reduced levels of IL-6 and suppressed TNF-alpha and IL-1beta levels by 86% and 80%, respectively, illustrating a powerful anti-neuroinflammatory effect.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">By restoring function to multiple receptors and exerting powerful anti-inflammatory effects, we believe our approach has potential to slow the progression of neurodegeneration in patients. Thus, we have designed simufilam to slow, or potentially even reverse the deterioration of brain cells.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our science is published in multiple peer-reviewed journals. In addition, our research has been supported by NIH under multiple research grant awards. Each grant was awarded following an in-depth, peer-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">reviewed</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> evaluation of our approach for scientific and technical merit by a panel of outside experts in the field. Strong, long-term support from NIH has allowed us to advance our two product candidates for neurodegeneration, simufilam and SavaDx, into clinical development.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Currently marketed drug therapies for </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s disease have limited therapeutic effect</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe the FDA has not approved any new drugs for the treatment of Alzheimer&#8217;s disease since 2003 except as follows: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In June 2021, aducanumab (marketed as Aduhelm</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) received marketing approval from FDA for the treatment of Alzheimer&#8217;s disease using the accelerated approval pathway &#8220;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">based on the drug&#8217;s effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with a required post-approval trial to verify that the drug provides the expected clinical benefit</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#8221; Aducanumab is delivered via monthly infusion. It is a proprietary drug of Biogen, Inc., a biopharmaceutical company. According to Biogen, the drug&#8217;s launch price was about $56,000 per patient per year in the U.S. In December 2021, Biogen reduced the price to about $28,200 per year. In May 2022, Biogen announced it was significantly scaling down infrastructure to produce Aduhelm in response to limited insurance coverage.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In January 2023, lecanemab (marketed as Leqembi</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) received marketing approval from FDA for the treatment of Alzheimer&#8217;s disease using the accelerated approval pathway &#8220;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">based on the drug&#8217;s effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221;. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0.3pt;margin: 0;padding: 0;">Lecanemab is delivered via bi-weekly infusion. It is </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">a proprietary drug of Eisai R&amp;D Management Co., Ltd. and Biogen, Inc.</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0.3pt;margin: 0;padding: 0;"> According to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Eisai, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0.3pt;margin: 0;padding: 0;">the drug&#8217;s launch price as of January 2023 is about $26,500 per patient per year in the U.S.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0.3pt;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All FDA-approved anti-amyloid antibodies for Alzheimer&#8217;s disease currently lack Medicare coverage.</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0.3pt;margin: 0;padding: 0;"> In</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0.3pt;margin: 0;padding: 0;"> the United States, Medicare coverage is limited to drugs that are deemed to be &#8220;reasonable and necessary&#8221; for the treatment of disease, as determined by the Centers for Medicare &amp; Medicaid Services (CMS), a federal agency. As of February 2023, the CMS has declined to provide Medicare coverage for </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">14</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Currently marketed drugs, called cholinesterase inhibitors, focus solely on treating symptoms, mostly in patients with mild-to-moderate Alzheimer&apos;s disease. The Alzheimer&#8217;s brain</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> has low levels of a neurotransmitter called acetylcholine. C</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">holinesterase inhibitors </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">prevent an </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">enzyme</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in the brain, called&#160;</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">acetylcholinesterase,</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;from breaking down acetylcholine.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Currently marketed cholinesterase inhibitors include donepezil (marketed by Eisai&#160;Co.,&#160;Ltd. and Pfizer,&#160;Inc. as Aricept</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">), rivastigmine (marketed by Novartis AG as Exelon</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) and galantamine (marketed by Janssen Pharmaceuticals, Inc. as Razadyne</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">). Cholinesterase inhibitors may benefit some patients for several months, after which the targeted brain receptors are desensitized, and drug efficacy is lost.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Another approved medication for Alzheimer&#8217;s disease is memantine, a non-competitive antagonist of NMDA receptors (marketed by Lundbeck as Namenda</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">).</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Simufilam is our Proprietary Drug Candidate for the Treatment of Alzheimer&#8217;s Disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have generated and published experimental evidence of improved brain health by restoring altered FLNA with simufilam, our lead therapeutic product candidate. Simufilam is a proprietary small molecule (oral) drug that represents an entirely new scientific approach to treat neurodegeneration. Published studies have demonstrated that simufilam targets an altered form of a protein called FLNA that is </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">pervasive</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in the Alzheimer&#8217;s brain. Altered FLNA causes neuronal dysfunction, neuronal degeneration and neuroinflammation. We believe our lead drug candidate, simufilam, improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering downstream toxic effects of altered FLNA. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Importantly, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">simufilam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> is not dependent on clearing amyloid from the brain. From time-to-time, our scientific research includes the use of exploratory biomarkers, typically labelled &#8216;research-use only&#8217;. These are understood to mean investigational diagnostic products that are in the research phase of development and have not been proven to be effective or linked to a specific indication by the FDA.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following is additional detail on </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">simufilam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8217;s drug development program.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">IND submission to FDA</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Over the past ten years, we successfully conducted basic research, in vitro studies and preclinical studies in support of an Investigational New Drug (IND) submission to FDA for simufilam, including requisite studies around safety pharmacology, toxicology, genotoxicity and bioanalytical methods. In 2017 we filed an IND with FDA for simufilam.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Clinical</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> safety of simufilam in a Phase 1 study</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Following FDA acceptance of our IND in 2017, we investigated the safety, dosing and pharmacokinetic profile of simufilam in healthy </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">human</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> volunteers. The design of our first-in-human Phase 1 study was based on regulatory feedback, clinical and scientific rationale and observations from previously conducted preclinical </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in vitro studies. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In a Phase 1 study, simufilam was evaluated in 24 healthy human volunteers in a single site in the U.S. for safety, tolerability and pharmacokinetics. Study subjects were administered a single oral dose of 50, 100 or 200 mg of simufilam. Drug was well-tolerated in all subjects. Importantly, simufilam showed no treatment-related adverse effects and no dose-limiting safety findings. Pharmacokinetic measurements demonstrated that simufilam, a small molecule, was rapidly absorbed. Dose-proportionality was observed over the full dose range of 50 to 200 mg.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: black;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Mean PTI-125 Plasma Concentration Concentration (ng/mL) 0 500 100 1500 0 4 8 12 16 g 200 mg Time (</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Given the absence of any observable dose-limiting effects in healthy adults in a Phase 1 study, a strong scientific rationale, and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">multiple</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> peer-reviewed publications and research grant awards, we believe this program demonstrated favorable proof-of-principle for the development of simufilam in Alzheimer&#8217;s disease. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">Phase 2a Clinical Study</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2019, we completed a first-in-patient, clinical proof-of-concept study of simufilam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in the U.S. Our Phase</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2a </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">was an</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> open-label, multi-center, safety and pharmacokinetic study of simufilam. Thirteen (13) patients with mild-to-moderate Alzheimer&#8217;s disease, age 50-85, received 100 mg oral simufilam twice daily for 28 days. A diagnosis of Alzheimer&#8217;s disease was confirmed with Mini-Mental State Examination (MMSE) &#8805; 16 and &#8804; 24 and a </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">c</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">erebrospinal fluid (CSF) T-tau/A&#946;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub>42 </sub></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ratio &#8805; 0.30. Safety was assessed </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">by ECGs, clinical labs, adverse event monitoring and physical examinations. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF was drawn from patients before dosing started and again after 28 continuous days of dosing with simufilam. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF samples were then analyzed for exploratory biomarkers of Alzheimer&#8217;s pathology (T-tau, P-tau, A&#946;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub>42</sub></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">); neurodegeneration (NfL, neurogranin); and neuroinflammation (YKL-40, IL-6, IL-1&#946; and TNF&#945;). All CSF biomarkers were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8216;research use only&#8217;, non-safety related exploratory biomarkers.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> A</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> consulting</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">biostatistician</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> conducted an </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">independent</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">analysis of the data set.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A key objective of our Phase 2a study was to measure levels of exploratory CSF biomarkers in the brain</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Key results of this study include (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">:</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">15</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total tau (T-tau) decreased 20% (p&lt;0.001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Phosphorylated tau (P-tau) decreased 34% (p&lt;0.0001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Neurofilament light chain (NfL), a marker for neurodegeneration, decreased 22% (p&lt;0.0001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Neurogranin, a marker for cognitive decline, decreased 32% (p&lt;0.0001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Neuroinflammatory marker YKL-40, an indicator of microglial activation, decreased 9% (p&lt;0.0001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proinflammatory Interleukin 6 (IL-6) decreased 14% (p&lt;0.0001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proinflammatory Interleukin 1 beta (IL-1&#946;) decreased 11% (p&lt;0.0001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proinflammatory Tumor Necrosis Factor alpha (TNF&#945;) decreased 5% (p&lt;0.001) </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The ratio of CSF P-tau to A</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#946;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub>42</sub></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a widely accepted biochemical value of Alzheimer&#8217;s disease, improved in all patients (p&lt;0.001)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 4: Simufilam Treatment Reduces Levels of Exploratory CSF Biomarkers in Patients with Alzheimer&#8217;s in a Phase 2a Study.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="padding-left: 0;text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;"><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 81pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.5pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 45pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.5pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 45pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.6pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 81pt;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Neurogranin</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 22.5pt;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NfL</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 72pt;"><p dir="ltr" style="font-family: Calibri;font-size: 16pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">T-tau</span><span style="white-space:pre-wrap; color: #000000;font-family: Times New Roman Bold;font-size: 16pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><sup>+</sup></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 45pt;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">P-tau</span><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;position: relative;top: -4pt;"><sup>181</sup></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 49.5pt;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">YKL40</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54pt;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">IL-6</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 45pt;"><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">IL-1</span><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#946;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 61.6pt;"><p dir="ltr" style="font-family: Calibri;font-size: 16pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">TNF</span><span style="white-space:pre-wrap; color: #404040;font-family: Calibri;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#945;</span><span style="white-space:pre-wrap; color: #000000;font-family: Times New Roman Bold;font-size: 16pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><sup>+</sup></span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><img src="sava-20221231x10kg004.jpg" style="width: 6.40625in; height: 2.375in" alt="Picture 5" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Neurogranin* NfL* T-tau+ P-tau181* YKL40* IL-6* IL-1</span><span style="white-space:pre-wrap; color: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#946;</span><span style="white-space:pre-wrap; color: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">* TNF</span><span style="white-space:pre-wrap; color: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#945;</span><span style="white-space:pre-wrap; color: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+ -32% -22% -20% -34% -9% -14% -11% -5%</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FFFFFF;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Percent change from baseline in CSF biomarkers measured by ELISA.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Eight CSF biomarkers of disease in Alzheimer&#8217;s patients were significantly reduced with simufilam treatment.  *p &lt; 0.0001, +p &lt; 0.001 in paired </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">t</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> test comparing Day 28 to pre-dose baseline. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consistent with over 10 years of basic research and preclinical data, we believe our Phase 2a study showed clinical evidence of simufilam&#8217;s mechanism of action and drug-target engagement, including:</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Impr</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ovements in biomarkers of Alzheimer&#8217;s disease in CSF, plasma and lymphocytes;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consistency across biomarker improvements in CSF, plasma, and lymphocytes; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Significant reductions (p&lt;0.01) in both nitrated and phosphorylated forms of tau protein;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Evidence that each individual patient showed biomarker responses to simufilam;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Evidence that simufilam reversed the shape of altered filamin A in lymphocytes;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Evidence that simufilam reduced levels of amyloid bound to alpha 7 nicotinic receptors in lymphocytes; and</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Early clinical validation of the drug target &#8211; altered filamin A &#8211; as a facilitator protein between amyloid beta and both neuroinflammation and tau pathology. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">Phase 2b Clinical Study</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2020, we announced the completion of a&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">double-blind, randomized, placebo-controlled, multi-center clinical study of simufilam. Sixty-four patients with mild-to-moderate Alzheimer&#8217;s disease, age 50-85, were randomized (1:1:1) to 100 mg or 50 mg oral simufilam or matching placebo. Treatment was administered twice daily for 28 days. Nine U.S. study sites enrolled patients. A clinical diagnosis was confirmed with the MMSE &#8805;16 and &#8804;26 and a CSF T-tau/A&#946;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub>42</sub></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> ratio &#8805;0.28. Safety was assessed by ECGs, clinical labs, adverse event monitoring and physical examinations.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This study was substantially funded by a research grant award from NIH.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">16</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Phase 2b clinical study was designed to evaluate safety, tolerability and drug effects of simufilam on exploratory biomarkers of Alzheimer&#8217;s disease. </span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The primary endpoint was improvement in biomarkers of Alzheimer&#8217;s disease from baseline to Day 28. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF was drawn from patients before dosing started and again after 28 continuous days of dosing with simufilam. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF samples were then analyzed for biomarkers of Alzheimer&#8217;s pathology (T-tau, P-tau, A&#946;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub>42</sub></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">); neurodegeneration (NfL, neurogranin); and neuroinflammation (YKL-40, IL-6, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sTREM2, HMGB1</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) and BBB integrity (IgG, albumin). All CSF biomarkers were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8216;research use only&#8217;, non-safety related exploratory biomarkers.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> A</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> consulting</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">biostatistician</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> conducted an </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">independent</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">analysis of the data set.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In May 2020, we announced that&#160;an outside lab with whom we had no prior work experience conducted a bioanalysis of CSF samples from our Phase 2b study. The data set from this&#160;initial bioanalysis showed unnaturally high variability and other problems. Overall, we believe data from the initial bioanalysis can be interpreted as anomalous and highly improbable.&#160;With its validity in question, we believe the initial bioanalysis serves no useful purpose. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Backup CSF samples were subsequently sent to City University of New York for bioanalysis. All bioanalyses were conducted under blinded conditions to eliminate any possibility of bias.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In September 2020,&#160;we&#160;reported final positive&#160;Phase 2b&#160;clinical&#160;study&#160;results.&#160;Simufilam was safe and well-tolerated in this study. Simufilam significantly&#160;(P&lt;0.05)&#160;improved an entire panel of biomarkers of disease in patients with Alzheimer&#8217;s disease&#160;compared to a placebo group. In addition, Alzheimer&#8217;s patients treated with simufilam showed directional improvements in validated tests of episodic memory and spatial working memory,&#160;versus patients on placebo. Cognitive improvements correlated most strongly (R=0.5) with decreases in levels of P-tau181 in CSF. The study achieved a 98% response rate, defined as the proportion of study participants taking simufilam who showed improvements in biomarkers. Importantly, we believe these data are consistent with prior clinical and preclinical results, the drug&#8217;s mechanism of action and over 10 years of basic research.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To our knowledge, no drug candidate has demonstrated the ability to reduce an entire panel of biomarkers of disease in patients with Alzheimer&#8217;s disease. For this reason, clinical data generated in our Phase 2a and Phase 2b studies may not be directly comparable to results generated by our competitors.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Key exploratory biomarker results include the following (all p-values versus placebo) (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 5</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.26in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.26in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.13in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.130in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Core markers of Alzheimer&#8217;s pathology are total tau (T-tau), phosphorylated tau (P-tau181), and amyloid beta42 (A&#946;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub>42</sub></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">). In Alzheimer&#8217;s, tau and P-tau levels are elevated and A&#946;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub>42</sub></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> is low.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.26in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">T-tau decreased 15% (p&lt;0.01) for patients in the 50 mg drug group. </span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">T-tau decreased 18% (p&lt;0.01) for patients in the 100 mg drug group.</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">P-tau decreased 8% (p&lt;0.01) for patients in the 50 mg drug group. </span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">P-tau decreased 11% (p&lt;0.01) for patients in the 100 mg drug group. </span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A&#946;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub>42</sub></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> increased 17% (p&lt;0.01) for patients in the 50 mg drug group.</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A&#946;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub>42</sub></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> increased 14% (p&lt;0.01) for patients in the 100 mg drug group. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.26in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.13in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.130in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Elevated CSF levels of two proteins, Neurogranin (Ng) and Neurofilament Light Chain (NfL) indicate neurodegeneration. </span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ng decreased 36% (p&lt;0.01) for patients in the 50 mg drug group. </span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ng decreased 43% (p&lt;0.01) for patients in the 100 mg drug group.</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NfL decreased 28% (p&lt;0.05) for patients in the 50 mg drug group. </span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NfL decreased 34% (p&lt;0.01) for patients in the 100 mg drug group.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.26in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.13in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.130in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proinflammatory IL-6 (Interleukin 6) is produced in response to tissue stress and injury.</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">IL-6 decreased 10% (p&lt;0.01) for patients in the 50 mg drug group.</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">IL-6 decreased 11% (p&lt;0.01) for patients in the 100 mg drug group.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.26in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.13in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.130in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Elevated levels of neuroinflammatory marker </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">YKL-40 </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">indicate microglial activation. </span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">YKL-40 decreased 10% (p&lt;0.01) for patients in the 50 mg drug group.</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">YKL-40 decreased 12% (p&lt;0.01) for patients in the 100 mg drug group.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.26in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.13in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.130in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sTREM2 </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">is a neuroinflammation biomarker that has commanded substantial recent attention from researchers</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">for its role in Alzheimer&#8217;s disease and frontotemporal dementia.</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sTREM2 decreased 43% (p&lt;0.01)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">for patients in the 50 mg drug group.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">17</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sTREM2</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">decreased 46% (P&lt;0.01) for</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">patients in </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the 100 mg drug group.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.26in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.13in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.130in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam Significantly Reduced Levels of HMGB1 in CSF.</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">HMGB1 decreased 33% (p&lt;0.01) in patients treated with 50 mg simufilam</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">HMGB1 decreased 32% (p&lt;0.01) in patients treated with 100 mg simufilam  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.26in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.13in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.130in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam Significantly Improved the Integrity of the Blood-brain Barrier (BBB).</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF IgG decreased 30% (p&lt;0.05) in patients treated with 50 mg simufilam</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF IgG decreased 30% (p&lt;0.05) in patients treated with 100 mg simufilam</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF albumin decreased 15% (p&lt;0.05) in patients treated with 50 mg simufilam</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF albumin decreased 28% (p&lt;0.05) in patients treated with 100 mg simufilam</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.26in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.13in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.130in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam Improved the Albumin Ratio, a Test of Blood-brain Barrier (BBB) Permeability:</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">BBB permeability can be clinically evaluated by comparing levels of albumin in CSF and plasma. The albumin ratio is a test for BBB permeability because albumin protein is not synthesized in CSF. Hence, albumin in CSF necessarily comes from plasma through the BBB. The albumin ratio is frequently elevated in patients with dementia and various other disorders.</span></p><p dir="ltr" style="font-family: 'Courier New';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.19in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Courier New';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.188in;">o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the Phase 2b study, the albumin ratio was unchanged for Alzheimer&#8217;s patients on placebo. The albumin ratio improved by approximately 5 and 7 points for patients treated with simufilam, 50 mg and 100 mg, respectively, over 28 days.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Changes in the Albumin Ratio by Treatment Group</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="padding-left: 0;text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 25.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 25.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Treatment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Day 0</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Day 28</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 25.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Change-Day 0 to 28</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Placebo</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 25.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No change</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50 mg simufilam</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 25.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">- 20%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 38.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100 mg simufilam</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">18</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 25.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">- 28%</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 5.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Simufilam Improved Levels of Exploratory CSF Biomarkers in Patients with Alzheimer&#8217;s in a Phase 2b Study.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="sava-20221231x10kg005.jpg" style="width: 6.9375in; height: 3.301389in" alt="Picture 1" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% Change  Baseline to Day 28 -55% -45% -35% -25% -15% -5% 5% 15% 25% A42 T-tau P-tau181 Nurogranin NfL YKL-40 IL-6 sTREM2 HMGB1 Albumin IgG Placebo 50 mg 100 mg +p &lt; 0.05 p &lt; 0.01, # p &lt; 0.001, p &lt; 0.0001 vs. placebo</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">18</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 6. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Study Response Rate, Defined as the Proportion of Study Participants Taking Simufilam Who Showed Improvements in Biomarkers.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="sava-20221231x10kg006.jpg" style="width: 6.9375in; height: 3.342361in" alt="Picture 2" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of Patients Who Responded to Simufilam on CSF Biomarkets Tau/p- Tau Biomarkers 98% Biomarkers of Neuroinflammation 98% Biomarkers of Neurodegeneration 98% Biomarkers of BBB Integrity 95% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A further objective of this study was to measure drug effects on cognition.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients were tested at baseline and again on Day 28. Changes in episodic memory and spatial working memory were assessed on CANTAB, a validated, computer-based battery of tests. CANTAB is designed to measure cognitive skills regardless of the subject&#8217;s language skills, speed, gender or education.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Only directional trends were observed in memory improvements, due to limitations around study size (N=64). The final data analysis shown in Figure 7 excludes three patients who we subsequently learned showed no detectable level of simufilam in plasma and two patients who missed 25% or more of their doses by pill counts. In addition, outlier subjects with the most and fewest errors (by baseline score cutoffs) were removed from the final analysis of episodic memory (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 7</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s patients in both drug groups showed directional improvements on tests of episodic memory and spatial memory after 28 days of treatment, versus patients on placebo.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Episodic memory improved by -5.7 (lower score is better) for Alzheimer&#8217;s patients in the 50 mg drug group, versus -1.5 for patients on placebo. </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Episodic memory improved by -4.5 (lower score is better) for Alzheimer&#8217;s patients in the 100 mg drug group, versus -1.5 for patients on placebo. </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Spatial memory improved by -2.31 (lower score is better) for Alzheimer&#8217;s patients in the 50 mg drug group, versus -0.4 for patients on placebo. </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Spatial memory improved by -3.35 (lower score is better) for Alzheimer&#8217;s patients in the 100 mg drug group, versus -0.4 for patients on placebo. </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Improvements in cognition correlated most strongly (statistical R=0.5) with decreases in CSF P-tau181, a biomarker that, when elevated, leads to tangles in the brain. Simufilam decreased brain levels of Ptau-181 by 8-11%, versus placebo.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">19</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 7. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Episodic Memory and Spatial Working Memory Improvements</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="sava-20221231x10kg007.jpg" style="width: 6.9375in; height: 2.811821in" alt="Picture 11" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in Errors Baseline to Day 28 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 Placebo -1.5 50 mg -5.7 100 mg -4.5 37% Effect Size 2% Effect Size  -3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 Placebo -0.41 50 mg -1.65 100 mg -3.33</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">SavaDx</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our investigational diagnostic product candidate, called SavaDx, is an early-stage program focused on detecting the presence of Alzheimer&#8217;s disease from a small sample of blood. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For business, technical and personnel reasons, we continue to prioritize the development of simufilam, our novel drug candidate, over SavaDx, our novel diagnostic candidate. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SavaDx is currently a </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8216;research use only&#8217;, non-safety related exploratory biomarker.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The regulatory pathway for SavaDx may eventually include formal </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">analytical validation studies and clinical studies that support evidence of sensitivity, specificity and other variables in various healthy and diseased patient populations. We have not conducted such studies and do not expect to conduct such studies in 2023. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SavaDx is currently designed as an antibody-based detection system for altered filamin A (FLNA). Working with third parties, we are evaluating the use of mass spectrometry to detect FLNA, i.e., without the use of antibodies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Over the past ten years, we discovered that altered FLNA is a hallmark feature of brain pathology in patients with Alzheimer&#8217;s disease. We believe SavaDx may reveal early traces of the disease, potentially even before the overt appearance of disease symptoms, such as memory loss.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A diagnostic test usually measures one or more biomarkers, which are biological indicators of disease. A deep understanding of the biology of disease is required to identify and develop a diagnostic. A valid diagnostic has certain baseline characteristics to be functional and useful for clinical practice. It must detect disease in patients and, conversely, not detect disease in healthy subjects; and it is preferably quantitative, giving some indication of severity or stage of disease. Collectively, the ability to selectively detect disease indicators can be useful to provide diagnostic information (i.e., detect the disease) or prognostic information (i.e., predict the disease or its future course). </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Currently, the most definitive method to diagnose Alzheimer&#8217;s disease is through autopsy after death, which is not particularly helpful. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Methods to detect </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s disease during its course can </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">be expensive, invasive, subjective, risky and/or uncomfortable. Importantly, because of the expense and invasiveness of current </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">tests</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">,</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> most people are not tested until they show obvious cognitive decline.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Current approaches for diagnosing Alzheimer&#8217;s disease include measurement of amyloid-&#946; (specifically, A&#946;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub>42</sub></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">), total tau (T-tau) or phosphorylated tau (P-tau) levels in CSF or plasma; structural neuroimaging techniques, including magnetic resonance imaging (MRI) or computerized tomography (CT); positron-emission tomography (PET) imaging of brain amyloid (AmyVid</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">); and batteries of cognitive tests. Usually, a combination of more than one test is necessary to provide a working diagnosis. When such tests and techniques are used together, the totality of data can be sensitive and specific for the detection of Alzheimer&#8217;s disease. In practice, however, such tests and techniques are only used after overt symptoms of impaired memory.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">20</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe there is a profound need for a blood-based diagnostic test for Alzheimer&#8217;s disease. A quick, simple, inexpensive test may benefit the medical community in many ways. Advantages may include confirming the presence of Alzheimer&#8217;s disease earlier, when lifestyle changes and potential therapeutics may have the most impact, or conversely, to rule out Alzheimer&#8217;s disease at such early stages. Other potential benefits include discriminating Alzheimer&#8217;s disease from other causes of dementias; helping to identify stage of Alzheimer&#8217;s disease; selection and enrollment of appropriate patients into clinical studies of experimental product candidates; and better alignment of a patient&#8217;s specific diagnosis with a targeted therapeutic.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">It is widely accepted that in Alzheimer&#8217;s disease, pathological changes in the brain occur at least 10-15 years before clinical </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">symptoms</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> appear. These &#8220;pre-symptomatic&#8221; changes include deposits of certain misfolded or impaired proteins in the brain. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> long-term goal </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">with SavaDx is </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to identify people with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s disease, potentially </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">long before clinical symptoms occur. Early detection may be critical for any intervention to cease &#8211;  or at least slow down &#8211;  brain damage before it is too late. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Importantly, a non-invasive screen for latent Alzheimer&#8217;s disease prior to overt symptoms could be conducted as a general health screen, not just in patients at risk by family history or in patients already showing cognitive impairment. Once a disease-modifying treatment is found, early detection is likely to be critically important. Early detection and treatment may also be critical in identifying such a disease-modifying treatment, as many believe one reason for clinical study failures in Alzheimer&#8217;s disease is that treatment has routinely started too late in the course of disease to make any impact.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Moreover, w</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ith repeat measurements over time, SavaDx may provide a probability of cognitive decline or disease progression. Even if SavaDx does not provide a precise numerical cutoff value for </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s disease</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, we believe it may be important to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">incorporate</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> data from SavaDx into the overall diagnostic framework for neurodegeneration, and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s disease in particular</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. As with any diagnosis of disease, some people may embrace a way to detect Alzheimer&#8217;s disease long before clinical symptoms appear, while others may prefer not to know &#8211; at least until a treatment is found</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Diagnostic development program.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Diagnostic development differs from drug development in many important ways. As a result, diagnostic development requires substantial differences in planning, study design and study execution.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Some of the ways that diagnostic development differs from drug development include the following:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.44in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may need to choose among a wider range of regulatory pathways for approval of SavaDx, depending on factors such as intended use and user, test type and complexity and role in patient-care decisions;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Drug studies usually deal primarily with one office within FDA, but the regulatory pathway for SavaDx may require us to consider the policies of multiple federal or state regulatory agencies and offices;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unlike drug programs, statistical analysis with SavaDx does not focus on efficacy and safety endpoints. Rather, study endpoints for SavaDx will focus on sensitivity (true positives), specificity (true negatives), positive predictive value (percentage of correct positive diagnoses of known positive cases) and negative predictive value (percentage of correct negative diagnoses of known negative cases).</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SavaDx is an investigational diagnostic product candidate that has not yet been reviewed by FDA. Clinical testing consists of collecting blood samples on a limited scale to test and validate SavaDx using antibodies. Our ability to test such samples depends on multiple factors, many of which are beyond our control. For example, optimal sample collection depends on risk of sample degradation, storage requirements to preserve samples, cost of sample storage and actual vs. predicted time of assay validation. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have conducted four early validation tests using SavaDx. In three blinded studies of test samples, SavaDx detected more than a 10-fold separation between Alzheimer&#8217;s patients and normal healthy control subjects (N=232 test samples). In these three proof-of-concept studies, SavaDx demonstrated nearly 100% accuracy and specificity. The three studies deployed a research grade antibody manufactured by an outside vendor.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A fourth blinded study of SavaDx failed to generate meaningful diagnostic data. We believe the fourth study deployed a faulty research antibody sourced from an outside vendor. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commercially available research antibodies can present certain technical flaws, such as improper validation, significant batch-to-batch variations or inconsistent storage, any of which can jeopardize results of studies and experiments. For these reasons, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and in order to increase consistency of quality, reliability and availability,</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> we have attempted to develop and validate a</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> proprietary, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">fit-for-purpose, monoclonal antibody system for use with SavaDx. This effort remains a work-in-progress. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">21</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In July 2021, we announced positive clinical data with SavaDx when used to measure plasma levels of altered filamin A before and after simufilam treatment in patients with Alzheimer&#8217;s disease. In a Phase 2b randomized, controlled trial sponsored by the National Institutes of Health (NIH), simufilam significantly reduced a plasma marker of altered filamin A in Alzheimer&#8217;s patients treated for 28 days. Plasma levels of p-tau181 also dropped significantly in these same patients.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The legal system for intellectual property around diagnostic methods is highly complex and uncertain. In the U.S., patent courts have struggled to define a clear means of patent eligibility for modern age diagnostics. Generally, a simple process involving correlations between blood test results and patient health is not eligible for patent claims because such processes incorporate &#8220;laws of nature&#8221;. However, different outcomes from different courts, including Federal Circuit, district court and Patent Trial and Appeal Board decisions, have continued to create a sometimes vague or conflicting legal framework for determining the eligibility of patent claims for diagnostic methods. As a result, we cannot be certain how SavaDx fits into the current U.S. legal framework for obtaining effective patent claims. Furthermore, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">claims for diagnostic methods can be complicated to enforce.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently have no issued patents in the United States with respect to SavaDx.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Expansion of our science to other indications.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">It is well known that protein misfolds occur in a wide variety of biological processes and diseases. We may leverage our scientific insights in neurodegeneration and neuroinflammation and advanced tools in molecular biology,  biochemistry, and imaging to expand our science to other diseases. New indications and new drug development approaches may complement our initial focus on Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Preclinical programs are always visionary, sometimes innovative and often of high biomedical potential. However, by definition, such programs are exploratory and risky. Moreover, most preclinical programs fail for scientific or other reasons, regardless of the amount of effort or resources that are brought to bear upon such programs. For these reasons, in general we do not intend to disclose our preclinical programs until such time as they become material to our pipeline of product candidates.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">We own worldwide rights to our neurodegeneration program. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We own intellectual property, including patents, patent applications, technology, trade secrets and know-how in the U.S. and other countries. The protection of patents, designs, trademarks and other proprietary rights that we own or license is critical to our success and competitive position. We consider the overall protection of our patents and other intellectual property rights to be of material value and act to protect these rights from infringement. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We seek to protect our technology by, among other methods, filing and prosecuting U.S. and foreign patents and patent </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">applications</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> with respect to our technology and products and their uses. The focus of our patent strategy is to secure and maintain intellectual property rights to technology for our program in neurodegeneration.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date. SavaDx is being developed in-house with outside collaborators. We own exclusive, worldwide rights to drug and diagnostic assets and related technologies, without royalty obligations to any third party. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our patent protection with respect to simufilam and use of simufilam for Alzheimer&#8217;s disease and other neurodegenerative diseases currently runs through 2039 and includes seven issued U.S. patents. In addition, we have patent protection with respect to simufilam for use in treating certain cancers that runs through 2034. Our patent estate further includes patents and patent applications for related compounds and treatments. Corresponding foreign filings have been made for each of the U.S. filings.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Our Development Team </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our product development team is led by seasoned professionals with a proven track record of innovation in drug discovery and development, as well as substantial business expertise. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our Founder and Chief Executive Officer, Remi Barbier, has over 25&#160;years of biopharmaceutical industry experience and has led teams responsible for pioneering several pharmaceutical innovations, including abuse-deterrent drugs; the clinical development of multiple pain drugs; an innovative antibody program in cancer; and other programs in </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">neuroscience</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and other therapeutics areas. Before founding Cassava Sciences, he held leadership roles and was founder or co-founder of four life science companies, three of which are now publicly traded or acquired.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">22</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our Chief Medical Officer, James Kupiec, MD, has two prior FDA drug approvals and previously served at Pfizer, Inc. as </span><span style="white-space:pre-wrap; color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">VP, Global Clinical Leader for Parkinson&#8217;s Disease and Clinical Head of the Neuroscience Research Unit. Dr. Kupiec also held leadership roles at Sanofi and Ciba-Geigy Pharmaceuticals and before that was a practicing neurologist.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #0A0A0A;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lindsay Burns, PhD, SVP, Neuroscience, worked on the development of several product candidates in neuroscience and other therapeutics areas while at Neurex (acquired by Elan Pharmaceuticals) and Abgenix (acquired by Amgen).</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Michael Zamloot, SVP of Technology Operations, has four prior FDA drug approvals and has worked in drug operations and supply chain management at Boehringer Mannheim (acquired by Roche Diagnostics), Athena Neuroscience (acquired by Elan Pharmaceuticals) and Ciba-Geigy (acquired by Novartis).</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Michael Marsman, PharmD, SVP of Regulatory Affairs previously held senior positions at Impax Laboratories, Millennium Pharmaceuticals, and Syntex, where he had shared responsibility for the regulatory approval of several high-profile drugs. He also previously led regulatory affairs for our Company for nearly a decade until 2019.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">George (Ben) Thornton, PhD, SVP of Technology, has led research and development teams at Johnson &amp; Johnson as well as translated basic science to the clinical setting at biotechnology start-ups such as GeneMedicine and Apovia.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our management </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">team</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> is further supported by scientific advisors who are leading experts in the field and share our commitment to advancing new treatments for </span><span id="_Hlk96434098" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">neurodegenerative diseases, including</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Alzheimer&#8217;s disease. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our Strategy </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our goal is to develop product candidates to diagnose and treat neurodegeneration, such as Alzheimer&#8217;s disease. Key elements of our business strategy to achieve this mission include: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">building a lean company that is narrowly focused on developing innovative product candidates for Alzheimer&#8217;s disease and other areas of neurodegeneration;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">validating our unique scientific approach with competitive research grants and publishing our scientific data in peer-reviewed journals;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">applying our development capabilities to advance our product candidates through clinical proof-of-concept studies and beyond;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">using our expertise and experience to continue to focus on discovering new indications and product candidates, validated by experimental evidence and leading experts in the field; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">continuing to outsource preclinical studies, clinical studies and formulation development activities in order to allow more efficient deployment of our resources</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also conduct basic research and development in collaboration with academic and other partners. Our research and development expenses were $68.0 million, $24.8&#160;million and $3.1&#160;million for the year ended December&#160;31, 2022, 2021 and 2020, respectively. These amounts are net of significant reimbursement received from NIH. See </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221; for additional details regarding our research and development activities.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Competition</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The drug discovery and development industry is characterized by rapidly advancing technologies, intense competition and a strong </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">emphasis</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize, such as simufilam or SavaDx, may compete with existing therapies and new therapies that may become available in the future.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Historically, the drug industry has attempted to treat Alzheimer&#8217;s disease by developing drugs that block the synthesis of, or </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">remove</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> or dis-aggregate, beta amyloid and, more recently, another protein in the brain called tau. Essentially, the prevailing doctrine says amyloid (or tau) must be cleared out of the brain. This scientific approach &#8211; known as the amyloid hypothesis - has been repeatedly tested by our competitors in late-stage clinical studies using a variety of antibody backbones, epitopes, target conformations, biomarkers and in various stages of disease. More recent competitors in Alzheimer&#8217;s research </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">23</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">are focused on modulating proteins in the brain that have anti-inflammatory or other properties, an approach known as immunotherapy. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In contrast, our scientific approach seeks to simultaneously improve neurodegeneration and neuroinflammation. We believe improving multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Regardless of scientific approach, improvement in both cognition and health function remains a key criterion for a new drug in Alzheimer&#8217;s disease</span><span style="white-space:pre-wrap; color: #211D1E;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to receive full, unconditional marketing approval from the FDA</span><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a hurdle which, to date, no drug candidate has met with clear and compelling clinical data</span><span style="white-space:pre-wrap; color: #211D1E;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in nearly two decades</span><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our competitors may have significantly greater financial resources, an established presence in the market, expertise in research and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">development</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing-approved products. These competitors compete with us in recruiting and retaining qualified scientific and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">technical</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> personnel, establishing clinical study sites and patient registration for clinical studies, as well as in acquiring or developing technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The key competitive factors affecting the success of simufilam, and any other product candidates that we develop to address neurodegenerative disorders, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, patient and physician acceptance and the availability of reimbursement from government and other third-party payors. Our commercial opportunity could be </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">reduced</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">effects</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, are more convenient or are less expensive than products that we may develop.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our competitors also may obtain FDA approval for their products more rapidly than we may obtain approval for ours. For example, in June 2021, the FDA approved aducanumab (human monoclonal antibody; Biogen, Inc.) for the treatment of Alzheimer&#8217;s disease using an accelerated approval pathway. Aducanumab&#8217;s safety and efficacy profile is complex and subject to debate. Since its approval in 2021, aducanumab has had modest clinical utilization due to its high cost, lack of widespread reimbursement and other reasons. In January 2023, the FDA approved lecanumab (humanized version of a mouse monoclonal antibody; Eisai Co., Ltd) for the treatment of Alzheimer&#8217;s disease using an accelerated approval pathway. Both drugs are delivered by infusion. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In recent years, we have observed ramped-up worldwide efforts aimed at developing blood-based techniques to detect and monitor Alzheimer&#8217;s disease. The key competitive factors affecting the success of SavaDx, and any other product candidates that </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> develop to diagnose neurodegeneration, if approved, are likely to be their measure of accuracy, such as specificity and sensitivity, as well as their convenience, patient acceptance, price and the availability of reimbursement from government and other third-party payors. Our competitors in the diagnostic area are pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Despite increased research effort, the field has generally been hampered by lack of reproducibility and an unclear path on how to move academic discoveries into clinical utilization. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition to blood-based techniques to detect Alzheimer&#8217;s disease, competitors are examining the use of novel tracing agents and imaging techniques to map the course of neurodegeneration. In 2012, FDA approved Amyvid</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (Eli Lilly Pharmaceuticals), which is a radioactive diagnostic agent for brain imaging of amyloid plaque. Amyvid can rule out Alzheimer&#8217;s disease but does not confirm its presence. That is, a negative scan means little or no plaque is present; however, a positive </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">scan</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> does not necessarily indicate Alzheimer&#8217;s disease. In addition, Amyvid cannot be used to stage Alzheimer&#8217;s disease because some people take years to show cognitive decline after amyloid plaque develops, while other others rapidly develop advanced Alzheimer&#8217;s disease within months. Since its approval in 2012, Amyvid has had modest clinical utilization due to its high cost, lack of widespread reimbursement and need for specialized training.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Manufacturing</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam must be manufactured for clinical trial use in compliance with cGMP regulations. These regulations are extensive, stringent and complex, and may include requirements regarding the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. Our manufacturing vendors must have facilities to make simufilam in strict compliance with cGMP requirements and FDA or comparable foreign regulatory authority&#8217;s satisfaction. Our third-party vendors may also be subject to periodic inspections of their respective facilities for general cGMP compliance by the FDA and other foreign authorities. These </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">24</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">inspections may include review of procedures and operations used in the testing and manufacture of simufilam to assess compliance with applicable regulations. Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. Any of these actions or events could have a material impact on the availability of simufilam. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our suppliers </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">may be forced to stop producing, storing, shipping or testing simufilam if they fall out of compliance with government regulations and standards.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We do not own or lease any manufacturing facilities. We outsource formulation, manufacturing and related activities to third parties. For the foreseeable future, we will continue to rely on third parties to conduct certain quality control and assurance testing, shipping or storage of our product candidates.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently rely on one non-affiliated contract development and manufacturing organization (CDMO) to manufacture simufilam and expect to continue to do so.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe our manufacturing strategy will continue to ensure sufficient drug supply for a Phase 3 program, including both drug substance (i.e., active ingredient) and drug product (i.e., oral tablets). In March 2021, we entered into an agreement with Evonik Corporation to supply large-scale, clinical-grade quantities of drug substance for simufilam. The goal is to ensure the integrity of the drug supply chain on a worldwide basis, in compliance with FDA standards. We believe raw materials for our drug product are readily available from reliable sources. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our suppliers must comply with </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">current good manufacturing practices (cGMP)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> enforced by FDA and other government agencies. Our suppliers </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">are subject to unannounced inspection by regulators, including pre-approval inspections by FDA, to ensure they are in strict compliance with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">government</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> regulations and standards. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our suppliers </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">may be forced to stop producing, storing, shipping or testing our drug products if they fall out of compliance with government regulations and standards. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have limited or no control over our suppliers&#8217; compliance, or lack thereof, with the multitude of regulations and standards that affect our </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">drug</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">products</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. We cannot control decisions by our suppliers that affect their ability or willingness to continue to supply us on acceptable terms, or at all.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Government</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Regulation </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our operations are subject to various levels of governmental controls and regulations in the United States and in other countries where we operate, including Canada, South Korea and Australia. We attempt to comply with all legal requirements in the conduct of our operations and employ business practices that we consider to be prudent under the circumstances in which we operate.&#160;Government authorities in the U.S. (federal, state and local), Canada, South Korea, Australia and other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">promotion</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">diagnostic</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> products. Generally, before a new drug or diagnostic can be marketed, considerable data demonstrating its quality, safety and efficacy and/or specificity must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by each regulatory authority. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">U.S. Drug Development </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the U.S., FDA regulates drugs under the Food, Drug, and Cosmetic Act (FDCA). Both drugs and diagnostics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Product candidates must be approved by FDA before they may be commercialized in the U.S. The drug approval process generally involves the following: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">25</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Submission to FDA of an IND, which must become effective before human clinical studies may begin;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Approval by an independent institutional review board (IRB) or ethics committee before each study may be initiated;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Performance of adequate and well-controlled human clinical studies in accordance with applicable IND regulations, code of good clinical practice (cGCP), requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Submission to FDA of an NDA;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A determination by FDA within 60 days of its receipt of an NDA to accept the filing for review;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Potential FDA audit of the preclinical study and/or clinical study sites that generated the data in support of the NDA;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the U.S.; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Compliance with any post-approval requirements, including the potential requirement to conduct post-approval studies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The data required to support an NDA are generated in two distinct developmental stages: preclinical and clinical. The </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">preclinical</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Preclinical Studies and IND </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. As sponsor, we must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to FDA as part of the IND. An IND is a request for authorization from FDA to administer an investigational product to humans and must become effective before human clinical studies may begin. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in vitro</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including cGCP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to FDA as part of an IND. Some long-term preclinical testing, such as long-term toxicity tests, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by FDA, unless before that time FDA raises concerns or questions about any aspect of the program. In such a case, the IND sponsor and FDA must resolve any outstanding concerns before the clinical study can begin.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Clinical Studies </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">clinical</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the study sponsor&#8217;s control, in accordance with cGCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical studies are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to FDA as part of the IND. Furthermore, each clinical study must be reviewed and approved by an IRB for each institution at which the clinical study will be conducted to ensure that the risks to individuals participating in the clinical studies are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical study subject or his or her legal representative and must monitor the clinical study until </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">26</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">completed. There also are requirements governing the reporting of ongoing clinical studies and completed clinical study results to public registries. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sponsor</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> who wishes to conduct a clinical study outside of the U.S. may, but need not, obtain FDA authorization to conduct the clinical study under an IND. If a foreign clinical study is not conducted under an IND, the sponsor may submit data from the clinical study to FDA in support of an NDA. The FDA may accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with cGCP requirements and FDA is able to validate the data through an onsite inspection if deemed necessary. We currently have clinical sites outside of the U.S. in Canada, Puerto Rico, South Korea and Australia.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Clinical studies in the U.S. generally are conducted in three sequential phases, known as Phase&#160;1, Phase&#160;2 and Phase&#160;3, and may overlap. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Phase&#160;1 clinical studies generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical studies is to assess the metabolism, pharmacologic action, tolerability and safety of a drug candidate.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Phase&#160;2 clinical studies involve studies in disease-affected patients to determine the proper dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy may be observed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Phase&#160;3 clinical studies generally involve enrolling many patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These studies may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Post-approval studies, sometimes referred to as Phase&#160;4 clinical studies, may be conducted after initial marketing approval. These studies are </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">used</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of Phase&#160;4 clinical studies as a condition of approval of an NDA. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Progress reports detailing the results of the clinical studies, among other information, must be submitted at least annually to FDA. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Written</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> safety reports and the investigators for serious and unexpected adverse events, or any other findings suggesting a significant risk to humans exposed to the drug must be submitted to FDA. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Phase&#160;1, Phase&#160;2, and Phase&#160;3 clinical studies may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the drug </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">has</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> been associated with unexpected serious harm to patients. Additionally, some clinical studies are overseen by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board. This group provides authorization for whether a study may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical studies, companies usually complete additional animal studies and must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their shelf life.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">NDA Review Process</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Following completion of the clinical studies, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical studies are then submitted to FDA as part of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">an</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> NDA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA is a request for approval to market a drug for one or more specified indication and must contain proof of safety and efficacy for a drug&#8217;s purity and potency. The application may include both negative and ambiguous results of preclinical studies and clinical studies, as well as positive findings. Data may come from company-sponsored clinical studies intended to test the safety and efficacy of a product&#8217;s use or from several alternative sources, </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">27</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA must be obtained before a drug may be marketed in the U.S. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. According to FDA&#8217;s fiscal year 2023 fee schedule, effective through September&#160;30, 2023, the user fee for an application requiring clinical data, such as an NDA, is approximately $3.2&#160;million. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA reviews all submitted NDAs before it accepts them for filing and may request additional information rather than accept the NDA for filing. The FDA must decide whether to accept an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by FDA under PDUFA, FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA and respond to the applicant, and six months from the filing date of a new molecular-entity NDA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Before approving an NDA, FDA may conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities fully comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical studies to ensure compliance with cGCP requirements. Additionally, FDA may refer applications for novel product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical study data, which could result in extensive discussions between FDA and the applicant during the review process. After FDA evaluates an NDA, it will issue either an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A CRL indicates that FDA&#8217;s review of the application is complete and the application cannot be approved in its present form. A CRL usually describes the specific deficiencies in the NDA identified by FDA. The CRL may require additional clinical data, additional pivotal Phase&#160;3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical studies, preclinical studies or manufacturing. If a CRL is issued, the applicant may either resubmit the NDA, addressing all the deficiencies identified in the CRL, or withdraw the application. Even if such data and information are submitted, FDA may decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical studies are not always conclusive and FDA may interpret data differently than we interpret the same data.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Commercialization Plan</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our product candidates have not received marketing approval from the FDA, and we do not expect to have any approved product candidates in the near term. We currently have no company experience in marketing drugs and have no personnel, capabilities or infrastructure in sales, marketing, third-party payor programs or commercial product distribution. When and if any of our product candidates are approved for commercialization, we will need to develop a commercialization infrastructure for any such product in the U.S. and potentially in certain other key markets. As a matter of strategy, we may also rely on partnerships or collaborations with larger biopharmaceutical companies to provide commercialization infrastructure, such as sales and marketing and commercial distribution.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Advertising and Promotion</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for direct</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">consumer advertising, communications regarding unapproved uses, industry</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sponsored</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> scientific and educational activities, and promotional activities involving the Internet. None of our product candidates can be commercially promoted before receiving FDA approval. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by FDA. Healthcare providers are permitted to prescribe drugs for &#8220;off</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">label&#8221; uses&#160;&#8212; that is, uses not approved by FDA and therefore not described in the drug&#8217;s labeling&#160;&#8212; because FDA does not regulate the practice of medicine. However, FDA regulations impose stringent restrictions on manufacturers&#8217; communications regarding off</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">label uses. Failure to comply with applicable FDA requirements and restrictions in this area may subject us to adverse publicity and enforcement action by FDA, the U.S. Department of </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">28</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Justice, or the Office of the Inspector General of Health and Human Services, as well as state authorities. This could subject us to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which we promote or distribute our product candidates.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Post</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Approval Requirements</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">After a product candidate receives regulatory approval, it is often subject to pervasive and continuing regulation by FDA, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">including</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, among other things, requirements relating to drug listing and registration, recordkeeping, periodic reporting, product sampling and distribution, adverse event reporting and advertising, marketing and promotion restrictions. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">market testing, known as Phase 4 testing, or FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to cGMP after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies. Registration may result in periodic announced or unannounced inspections by FDA or these state agencies, during which the agency inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, other regulatory actions may be taken, including, among other things, warning letters, the seizure of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, refusal to approve pending applications or supplements to approved applications, civil penalties, and criminal prosecution. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA may require post</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">approval clinical studies to help assure continued safety or effectiveness of the approved drug. The FDA may also require a labeling change if it becomes aware of new safety information that it believes should be included in the labeling of a drug.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition to the FDA, manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the U.S., including the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services, the Department of Justice, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, the Affordable Care Act (ACA) and state and local governments.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.39in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For example, in the United States, sales, marketing and scientific and educational programs must also comply with state and federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.39in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.39in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">29</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: changes to our manufacturing arrangements; additions or modifications to product labeling, if and when approved; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The Hatch</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Waxman Amendments</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Orange Book Listing</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In seeking approval for our product candidates through an NDA, we will be required to list with FDA each patent whose </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">claims</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> cover the drug product. Upon receiving regulatory approval, each of the patents listed in the application for this drug is then published in FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the &#8220;Orange Book&#8221;. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated NDA, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredient in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or efficacy of their drug product. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The ANDA applicant is required to make certain certifications to FDA concerning any patents listed for the approved product in FDA&#8217;s Orange Book. Specifically, the applicant must certify that: (i)&#160;the required patent information has not been filed; (ii)&#160;the listed patent has expired; (iii)&#160;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv)&#160;the listed patent is invalid or will not be infringed by the new product. The ANDA </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">applicant</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> may also elect to submit a section&#160;viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">of</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">use rather than make certifications concerning a listed method</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">of</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph&#160;IV certification. If the ANDA applicant has provided a Paragraph&#160;IV certification to FDA, the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">applicant</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> must also send notice of the Paragraph&#160;IV certification to the NDA and patent holders once the ANDA has been accepted for filing by FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;IV certification. The filing of a patent infringement lawsuit within 45&#160;days of the receipt of a Paragraph&#160;IV certification automatically prevents FDA from approving the ANDA until the earlier of 30&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">months</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. The ANDA application also will not be approved until any applicable non</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">patent exclusivity listed in the Orange Book for the referenced product has expired. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Disclosure of Clinical Study Information</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Sponsors of clinical studies of FDA</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">regulated products, including drugs, are required to register and disclose certain clinical study information. Information related to the product, patient population, phase of investigation, clinical study sites and investigators, and other aspects of the clinical study is then made public as part of the registration. Sponsors are also obligated to post certain information regarding the results of their clinical studies after completion. Disclosure of the results of these studies can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">30</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Other Regulatory Requirements</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may be subject to federal, state and local environmental laws and regulations, including the Environmental Protection Act and the Clean Air Act. Although we believe that our safety procedures for handling and disposing of controlled materials comply with the standards prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. In the event of such an occurrence, we could be held liable for any damages that result and any such liability could exceed our resources.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may also be subject to regulations under other federal, state, and local laws, including the Occupational Safety and Health Act, national restrictions on technology transfer, and import, export, and customs regulations. It is possible that any portion of the regulatory framework under which we operate may change and that such change could have a negative impact on our current and anticipated operations. Failure to comply with these requirements could result, among other things, in suspension of regulatory approval, recalls, injunctions or civil or criminal sanctions.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Third</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Party Payor Coverage and Reimbursement</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The commercial success of our product candidates, if approved, will depend, in part, upon the availability of coverage and adequate reimbursement from third</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">party payors at the federal, state and private levels. Third</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">party payors include governmental programs such as Medicare or Medicaid, private insurance plans and managed care plans. These third</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">party payors may deny coverage or reimbursement for our product candidates in whole or in part if they determine that our product candidates are not medically appropriate or necessary. Also, third-party payors attempt to control costs by limiting coverage through the use of formularies and other cost</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">containment mechanisms and the amount of reimbursement for particular procedures or drug treatments. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Some third</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">party payors also require pre</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. While we cannot predict whether any proposed cost</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">containment measures will be adopted or otherwise implemented in the future, these requirements or any announcement or adoption of such proposals could have a material adverse effect on our ability to obtain adequate prices for our approved product candidates to operate profitably. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Human Capital</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our approach to human capital resource management starts with our mission to detect and treat neurodegenerative diseases, such as Alzheimer&#8217;s disease. Our industry exists in a complex regulatory environment. The unique demands of our industry, together with the challenges of running an enterprise focused on the discovery, development, manufacture and commercialization of innovative medicines, require talent that is highly educated and/or has significant industry experience. Additionally, for certain key functions, we require specific scientific expertise to oversee and conduct research and development activities and the complex manufacturing requirements for biopharmaceutical products. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We consider our ability to recruit, retain and motivate our employees to be critical to our success. We are an equal opportunity employer, and we are fundamentally committed to creating and maintaining a work environment in which employees are treated with respect and dignity. All human resources policies, practices and actions related to hiring, promotion, compensation, benefits and termination are administered in accordance with the principal of equal employment opportunity, meaning that they are made on the basis of individual skills, knowledge, abilities, job performance and other legitimate criteria and without regard to race, color, religion, sex, sexual orientation, gender expression or identity, ethnicity, national origin, ancestry, age, mental or physical disability, genetic information, any veteran status, any military status or application for military service, or membership in any other category protected under applicable law. By focusing on employee retention and engagement, we also improve our ability to support our clinical trials, our pipeline, business and operations, and also protect the long-term interests of our stockholders. Our success also depends on our ability to attract, engage and retain a diverse group of employees.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">31</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our base pay program aims to compensate management and staff members relative to the value of the contributions of their role, which takes into account the skills, knowledge and abilities required to perform each position, as well as the experience brought to the job. We also provide cash incentive programs to reward our management team and staff members in alignment with achievement of Company-wide goals that are designed to drive aspects of our strategic priorities that support and advance our strategy across our Company. Our management team and staff members are eligible for the grant of equity awards under our long-term incentive program that are designed to align their long-term interests with that of our stockholders.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our benefit programs are also generally broad-based, promote health and overall well-being and emphasize saving for retirement. All management team and regular staff members are eligible to participate in the same core health and welfare and retirement savings plans. Other employee benefits may include medical plans, dental plans, vacation and sick-pay plans, flexible spending accounts, life and accident insurance and short and long-term disability benefits. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our Compensation Committee provides oversight of our executive compensation plans, policies and programs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2022, we had 26 full-time employees. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None of our employees are represented by a labor union or covered under a collective bargaining agreement. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also engage numerous consultants to perform services on retainer, per diem or an hourly basis.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Lawsuit Against Perpetrators of &#8220;Short and Distort&#8221; Campaign</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 3, 2022, we announced that we had filed a lawsuit in federal court against certain individuals who executed a &#8220;short and distort&#8221; campaign against Cassava Sciences. The 150+ page complaint alleges that the defendants&#8217; disinformation campaign caused a precipitous decline in Cassava Sciences&#8217; stock price, a multi-billion dollar decline in its market capitalization, and delayed the Company&#8217;s work in developing a treatment for Alzheimer&#8217;s disease. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The complaint identifies over 1,000 false and defamatory statements made by the defendants in submissions to the U.S. Food and Drug Administration as well as &#8220;reports&#8221; and presentations that defendants published online or on social media. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The matter is pending in federal district court for the Southern District of New York.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Publication Corrections</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">An erratum or corrigendum is a correction of a published text, generally a human, production or author&apos;s error, that was not caught in proofing. Such errors generally do not impact data conclusions. We note the following corrections in our published works.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In July 2021, we presented clinical data for SavaDx in a poster presentation titled, &#8220;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">SavaDx, a Novel Plasma Biomarker to Detect Alzheimer&#8217;s Disease, Confirms Mechanism of Action of Simufilam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221; </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">at the Alzheimer&#8217;s Association International Conference (AAIC) in Denver, CO and virtually. Publication correction: The AAIC data and data analysis are correct, however, visual errors that were not caught in proofing were disclosed by the Company in September 2021. This error does not impact data conclusions.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2017, we published in Neurobiology of Aging an article titled &#8220;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer&#8217;s disease pathogenesis</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221; (Vol 55, July 2017, Pages 99&#8211;114). Publication correction: Figure 12 contains an image showing 12 control bands. It should show 13. The data analysis was based on all 13 control bands. Other human errors in this publication have been noted and are expected to be corrected and published. These errors do not impact data conclusions.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2012, we published in the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Journal of Neuroscience an article titled</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">, &#8220;Reducing Amyloid-Related Alzheimer&apos;s Disease Pathogenesis by a Small Molecule Targeting Filamin A&#8221; </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(JNeurosci 2012;32:9773-9784)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Publication correction: </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A duplicated panel appears in Figure 8B of the article. This error does not impact data conclusions and the publisher printed a correction.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Corporate Information</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We were incorporated as a Delaware corporation in May 1998 under the name Pain Therapeutics, Inc. In March 2019, we changed our company name to Cassava Sciences, Inc. Our principal offices are located at 6801 N. Capital of Texas Highway, Building 1; Suite 300, Austin, TX, 78731. Our telephone number is 512-501-2444. Our website address is www.CassavaSciences.com. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Information contained on our website is not a part of this Annual Report on Form 10-K and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">32</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We use Cassava Sciences, the Cassava Sciences logo, artwork and other marks as trademarks in the United States and other countries. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork, and other visual displays, may appear without the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>&#174;</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> or TM&#160;symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We file electronically with the Securities and Exchange Commission, or SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of the site is </span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">http://www.sec.gov</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">You may obtain a free copy of our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and amendments to those reports on the day of filing with the SEC on our website at </span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">http://www.cassavasciences.com</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, by contacting our corporate offices by calling 512-501-2450 or by sending an e-mail message to </span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">IR@cassavasciences.com</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">33</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 1A.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> &#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Risk Factors</span><span id="Risk_Factors" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">RISK</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> FACTORS </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Financial</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Additional</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> risks </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">and</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Since 2017, we have concentrated a substantial portion of our research and development efforts on the treatment of Alzheimer&#8217;s disease, an area of research that has seen significant failure rates. Further, our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and likelihood of success.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">We are heavily dependent on the success of simufilam, our product candidate which is still under development. If this product candidate does not receive regulatory approval, we will be unable to generate product revenue and our business will be harmed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">We have a limited operating history in our business targeting Alzheimer&#8217;s disease and no history of product approvals for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">We cannot give any assurance that we will file for regulatory approval for any of our product candidates, or that if we file for approval, our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">There can be no assurance that results of smaller Phase 1 and Phase 2 clinical trials or open-label study with simufilam will be reproduced in our large Phase 3 studies that are required to demonstrate safety and efficacy in order to potentially receive regulatory approval.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Clinical results observed in our open-label study with simufilam are not regulatory evidence of drug safety or efficacy.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">We may encounter substantial delays in our clinical studies or may not be able to conduct or complete our clinical studies on the timelines we expect, if at all.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">If physicians and patients do not accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0.32in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Government Regulation and Other Legal Compliance Matters</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Our financial condition and operating results could be adversely impacted by unfavorable results of legal proceedings, government investigations or allegations and other claims.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">If we are ultimately unable to file for and obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Our ability to market and promote our product candidates will be determined and limited by FDA-approved labeling.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">If we fail to comply or stay in compliance with the complex set of federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">34</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Government agencies may establish and promulgate usage guidelines that could limit the use of our product candidates.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Intellectual Property </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">If we are unable to obtain and maintain sufficient patent protection for any product candidates we develop, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">U.S. intellectual property rights around diagnostic methods is a complex, evolving area of law and effective patent claims may not be available to us for our investigational diagnostic product candidate,&#160;SavaDx, in the United States.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be materially harmed.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Business and Operations </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Our reputation and operations could be adversely impacted by allegations, regardless of their merits.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Our ability to continue to operate without any significant disruptions will, in part, depend on our ability to source materials and clinical supplies via our product supply chains.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Our reliance on third parties for both the supply and manufacture of materials for our product candidates carries the risk that we will not have sufficient quality or quantities of such materials or product candidates, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">We expect to significantly grow the size and capabilities of our organization and we may experience difficulties in effectively managing this growth.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Ownership of our corporate headquarters and property leasing to third parties are subject to numerous risks and uncertainties.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Our internal computer systems, or those used by third parties on whom we rely, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Our business involves environmental risks that may result in liability for us.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Business disruptions and lack of appropriate levels of commercial insurance could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Social media platforms have significantly altered the dynamics of corporate communications and present risks and challenges, some of which are, and may continue to be unknown to us.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0.32in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Related</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> to Financial Condition and Capital Requirements </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">We </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">We have broad discretion in the use of the net proceeds from&#160;any of our financing transactions&#160;and may not use them effective</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">ly.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">We have no product revenues and may never achieve revenues or profitability based on product revenues.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">35</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to the Ownership of Our Common Stock </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">We d</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">o not know whether a sufficient market will continue to develop for our common stock or what the market price of our common stock will be, and, as a result, it may be difficult for investors to sell shares of our common stock.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">The market price of our common stock has historically been highly volatile and we expect it to continue to be volatile, which could result in substantial losses for investors who purchase our shares.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Anti-takeover provisions in our charter documents and Delaware law may prevent or delay removal of incumbent management or a change of control.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Changes </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">in our ownership could limit our ability to utilize net operating loss carryforwards.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Since 2017, we have concentrated a substantial portion of our research and development efforts on the treatment of Alzheimer&#8217;s disease, an area of research that has seen significant failure rates. Further, our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and likelihood of success.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span id="_Hlk67332082" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Since 2017, we have concentrated a substantial portion of our research and development efforts on experimental methods for the treatment of Alzheimer&#8217;s disease. Prior efforts by biopharmaceutical companies to develop new treatments for Alzheimer&#8217;s disease have seen very limited clinical success. Notwithstanding these substantial challenges to date, we seek to improve brain health by addressing the neurodegeneration and neuroinflammation components of Alzheimer&#8217;s disease. Our lead drug candidate for Alzheimer&#8217;s disease is based on a new approach of stabilizing &#8211; but not removing &#8211; a critical protein in the brain. We cannot be certain that our novel technologies will lead to an approvable or marketable product. In addition, because FDA has limited comparators to evaluate our lead drug candidate, we could experience a longer than expected regulatory review process and increased development costs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We are heavily dependent on the success of simufilam, our product candidate which is still under development. If this product candidate does not receive regulatory approval, we will be unable to generate product revenue and our business may be harmed. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Since inception, we have not succeeded in getting regulatory approval for our product candidates and we may never do so. In recent years, we have invested a significant portion of our efforts and financial resources in the development of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">simufilam and, to a much lesser extent, SavaDx,</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the treatment and detection of Alzheimer&#8217;s disease, respectively. Our future success is substantially dependent on our ability to successfully complete clinical development and obtain regulatory approval for simufilam, which may never occur. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">simufilam and, to a much lesser extent, SavaDx</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. This will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in one or more national jurisdictions and obtaining commercial-scale manufacturing supply. Substantial investment and significant efforts will be required before we can generate any revenues from any commercial sales of our product candidates. We cannot be certain that we will be able to successfully complete any of these activities. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">have</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> a limited operating history in our business targeting Alzheimer&#8217;s disease and no history of product approvals for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are a clinical-stage biopharmaceutical company with a limited operating history </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our business targeting </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s disease</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Since we commenced operations in 1998, we have had no product candidates approved for commercial sale and have not generated any revenue from product sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To date, we have not completed a pivotal Phase 3 clinical study in Alzheimer&#8217;s disease, obtained marketing approval for any </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">product</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> candidates, or conducted sales and marketing activities necessary for successful product commercialization. Our long operating history as a company without product revenue makes any assessment of our future success and viability subject to significant uncertainty.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We will continue to encounter risks and difficulties frequently experienced by clinical-stage biopharmaceutical companies in rapidly </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">evolving</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> fields. We have not yet demonstrated an ability to successfully overcome such risks and </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">36</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">difficulties. If we do not successfully address these risks and difficulties, our business, results of operations and financial condition will suffer materially. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To date, we have invested substantial effort and financial resources to identify, procure intellectual property for, and develop our programs in neurodegeneration, including conducting preclinical and clinical studies for our product candidates, simufilam and SavaDx, and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following: </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our product candidates may not successfully complete preclinical studies or clinical studies;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be safe or effective or otherwise does not meet applicable regulatory criteria;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our competitors may develop products that render our product candidates obsolete or less attractive;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the product candidates that we develop may not be sufficiently covered by intellectual property;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the product candidates that we develop may be challenged by third parties&#8217; patents or other intellectual property or exclusive rights;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the market for our product candidates may change so that the continued development of a product candidate is no longer reasonable or commercially attractive;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our product candidates may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;a product candidate may not be accepted as safe, effective or useful by patients, the medical community or third-party payors, if applicable.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may not be successful in our efforts to further develop our product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. SavaDx is in the early stages of development. Simufilam, our late-stage product candidate, will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have never completed a product development program in neurodegeneration. Further, we cannot be certain that any of our product candidates will be successful in clinical studies. We may in the future advance product candidates into clinical studies and terminate such studies prior to their completion. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If any of our product candidates successfully complete clinical studies, we may seek regulatory approval to market our product candidates in the U.S., Japan, Canada, the United Kingdom or the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We may never receive regulatory approval to market any product candidates anywhere even if such product candidates successfully complete clinical studies, which would adversely affect our viability. To obtain regulatory approval in countries outside the U.S., we would need to comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, manufacturing and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our business, financial condition, results of operations, and our growth prospects could be negatively affected. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment or diagnosis of neurodegenerative diseases or other diseases, we cannot provide assurance that any such product candidate will be </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">37</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates. </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">There can be no assurance that results of smaller Phase 1 and Phase 2 clinical trials or open-label study with simufilam will be reproduced in our large Phase 3 studies that are required to demonstrate safety and efficacy in order to potentially receive regulatory approval.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Results of our Phase 1, Phase 2 and open-label safety studies with simufilam are not predictive of the results of Phase 3 clinical trials. Simufilam may fail to show the desired safety and efficacy in Phase 3 clinical trials despite having progressed successfully through preclinical studies and initial clinical trials. Many biopharmaceutical companies have suffered significant setbacks in Phase 3 clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on data from analyses of Phase 1 and Phase 2 clinical studies and open-label results may not be reproduced when implemented in large, well-controlled, randomized clinical trials. Even if our clinical trials for simufilam are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Clinical results observed in our open-label study with simufilam is not regulatory evidence of drug safety or efficacy.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Data results from our open-label safety study do not constitute, and should not be interpreted as, regulatory evidence of safety or efficacy for simufilam in Alzheimer&#8217;s disease. Rigorous evidence for drug safety and efficacy is derived from one or more large, randomized, placebo-controlled studies. The open-label design and size of this study may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our open-label study add complexity or limitations to the scope of data interpretation.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may encounter substantial delays in our clinical studies or may not be able to conduct or complete our clinical studies on the timelines we expect, if at all. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned, enroll patients as planned or be completed on schedule, if at all. Moreover, even after our studies begin, safety or other issues may arise that could suspend or terminate such clinical studies. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely initiation or completion of clinical studies include: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">inability to generate sufficient or necessary preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical studies or to support the filing of a New Drug Application for simufilam;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">delays in confirming target engagement, patient selection, or other relevant biomarkers to be utilized in preclinical and clinical product candidate development;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">delays in reaching a consensus with regulatory agencies on study design;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">delays in reaching an agreement on acceptable terms with prospective and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical study sites;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">delays in identifying and recruiting suitable clinical investigators;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">delays in obtaining required IRB approval for each clinical study site;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;a new safety finding that presents unreasonable risk to clinical study participants;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">a negative finding from an inspection of our CRO, clinical study operations or study sites; or</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">38</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the finding that the investigational protocol or plan is deficient to meet its stated objectives;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">delays in identifying, recruiting, and enrolling suitable patients to participate in our clinical studies, and delays caused by patients withdrawing from clinical studies, or failing to return for post-treatment follow-up;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">delays caused by disease epidemics or pandemics, such as COVID-19;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">difficulty collaborating with patient groups and investigators;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">failure by our CRO or other third parties, or us to adhere to clinical study requirements;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">failure to perform in accordance with FDA&#8217;s or any other regulatory authority&#8217;s Code of Good Clinical Practice (GCPs) requirements, or other regulatory guidelines in other countries;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">changes in the standard of care on which a clinical development plan was based, which may require new or additional studies;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the cost of clinical studies of our product candidates being greater than we anticipate;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">clinical studies of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any inability to successfully initiate or complete clinical studies could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to, or we may elect, to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may in the future advance product candidates into clinical studies and terminate such studies prior to their completion, which could adversely affect our business. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Delays in the completion of any clinical study of our product candidates will increase our costs, slow down our product candidate development and approval process and delay, or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The FDA or other regulatory agency may put a clinical hold on our clinical studies and our business will suffer.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A clinical hold is an order issued by FDA or other regulatory agency to suspend an ongoing clinical trial, typically due to newly identified deficiencies with our studies or our drug candidate. For example, we are aware that in 2022, FDA placed clinical holds on drug candidates for Alzheimer&#8217;s disease from two competitors, Cortexzyme Inc. and Denali Therapeutics Inc. The grounds for imposition of a clinical hold are complex, variable and somewhat arbitrary. If FDA imposes a clinical hold on us, no new patients may be enrolled and study patients already in a study may be taken off our drug candidate unless treatment is specifically permitted by FDA in the interest of patient safety. If we are issued a clinical hold, FDA will expect us to address the cited deficiencies and submit a detailed, written response. A clinical hold may require us to spend significant resources over many months to address the root causes of FDA&#8217;s concerns. We may not find and successfully address such root causes, which could adversely affect our business. Our response may not be adequate to lift such clinical hold, or we may disagree with FDA&#8217;s assessments of deficiencies. If we are on clinical hold for 1 year or longer, the FDA may consider our </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">39</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">IND for simufilam to fall into Inactive Status, which may result in termination of the clinical program for simufilam. T</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">o the extent we are not successful in lifting an FDA clinical hold, our results of operations and business will be materially adversely affected.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If physicians and patients do not accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Even if FDA approves our drugs, physicians and patients may not accept and use them. Acceptance and use of our drugs will depend on a number of factors including: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">when the drug is launched into the market and related competition;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">approved label claims;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our drugs; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">perceptions by physicians regarding the cost-benefit of our product candidates; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">published studies demonstrating the cost effectiveness of our drugs relative to competing products; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">availability of reimbursement for our products from government or healthcare payers; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">effectiveness of marketing and distribution efforts by us and other licensees and distributors. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Because we expect to rely on sales generated by our current lead product candidates for substantially all of our revenues for the foreseeable future, the failure of any of these drugs to find market acceptance would harm our business and could require us to seek additional financing. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may not be successful in developing our product candidates in neurodegeneration. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our product candidates in neurodegeneration are still in development and will take several more years to develop and must undergo extensive clinical and scientific validations.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Even</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> if we are successful in developing any of our product candidates through clinical and scientific validation, we may not be able to develop a drug or a diagnostic that:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 1.00in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">meets applicable regulatory standards, in a timely manner or at all;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">successfully competes with other technologies and tests; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">avoids infringing the proprietary rights of others; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">is adequately reimbursed by third-party payors; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">can be performed at commercial levels or at reasonable cost; or</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">can be successfully marketed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To the extent we are not successful in developing our new product candidates in neurodegeneration, our results of operations and business will be materially adversely affected.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.10in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Interim, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time are likely to change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final dataset.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">From time to time, we may publish &#8220;top-line&#8221; or preliminary data from our clinical trials. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Such data from clinical trials may materially change as more study data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary top-line data should be viewed with caution until the final data is available. Differences between preliminary or top-line data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furthermore, other parties, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">40</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We are conducting Phase 3 clinical trials for our lead product candidates outside the United&#160;States, and the FDA and applicable foreign regulatory authorities may not accept ex-U.S. data from such trials.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are enrolling patients into our Phase 3 clinical trials in part outside of the U.S. The acceptance of data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or applicable foreign regulatory authority may be subject to certain conditions or restrictions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the U.S., the FDA may not approve the application on the basis of foreign data unless (i)&#160;the data are generally applicable to the U.S. population and medical practices, and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations. There can be no assurance that the FDA or any applicable foreign regulatory authority will accept data from patients enrolled in our Phase 3 program outside of the U.S. If the FDA or any applicable foreign regulatory authority does not accept such data, it may result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our lead product candidate not receiving approval or clearance for commercialization in the U.S. or elsewhere.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We currently have no in-house capabilities to manufacture or commercialize our </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">product candidates</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> and we rely on third-party commercial drug manufacturers for clinical drug supplies</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">. If we are unable to develop our own manufacturing, sales, marketing and distribution capabilities, or if we are not successful in contracting with third parties for these services on favorable terms, or at all, our product revenues could be adversely impacted. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely on various third parties to manufacture, fill, label, store, test and ship our product candidates. We plan to continue to outsource formulation, manufacturing and related activities. These suppliers must comply with cGMP regulations enforced by FDA and other government agencies, and are subject to ongoing periodic unannounced inspection, including preapproval inspections by FDA and corresponding state and foreign government agencies to ensure strict compliance with cGMP and other standards. These manufacturers may subsequently be stopped from producing, manufacturing, filling, labeling, storing, testing and shipping our product candidates due to their non-compliance with federal, state or local regulations. We do not have control over our suppliers&#8217; compliance with these regulations and standards and we cannot control decisions by our suppliers that affect their ability or willingness to continue to supply us on acceptable terms, or at all.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Disputes in the past have arisen with some of these third parties with respect to fulfilling certain conditions and obligations. There can be no guarantee that such disputes will not arise again in the future, which may lead to termination of an agreement. If an agreement is terminated, we would not be able to commercialize our product candidates until another manufacturer is identified and we have entered into a manufacturing agreement with such manufacturer. We may not be able to replace a commercial supplier on commercially reasonable terms, or at all. Replacing any of our commercial suppliers would be expensive and time consuming. Failure by any of our suppliers to perform as expected could delay or prevent the commercialization or potential regulatory approval of our product candidates for an extended period of time, result in shortages, cost overruns or other problems and would materially harm our business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently have no sales, marketing or distribution capabilities. We have not established commercial strategies regarding any of our product candidates. In order to commercialize our products, if any are approved by FDA, we will either have to develop such capabilities internally or collaborate with third parties who can perform these services for us. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we decide to commercialize any of our drugs ourselves, we may not be able to </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">hire and retain the necessary experienced personnel; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">build sales, marketing and distribution operations in a cost-effective manner which are capable of successfully launching new drugs;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">obtain access to adequate numbers of physicians to prescribe our products; or</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">generate sufficient product revenues. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, establishing such operations on our own will take time and involve significant expense. If our commercial operations lack complementary products, we may not be able to compete in a cost-effective manner with competitors with more products to sell. If we engage third-party collaborators to perform any commercial operations, our future revenues may depend significantly upon the performance of those collaborators.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">41</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we decide to enter into new co-promotion or other licensing arrangements with third parties, we may be unable to locate acceptable collaborators because the number of potential collaborators is limited and because of competition from others for similar alliances. Even if we are able to identify one or more acceptable new collaborators, we may not be able to enter into any collaborative arrangements on favorable terms, or at all.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, due to the nature of the market for our product candidates, it may be necessary for us to license all or substantially all of our product candidates to a single collaborator, thereby eliminating our opportunity to commercialize these other products independently. If we enter into any such new collaborative arrangements, our revenues are likely to be lower than if we marketed and sold our products ourselves. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, any revenues we receive would depend upon our collaborators&#8217; efforts which may not be adequate due to lack of attention or resource commitments, management turnover, change of strategic focus, business combinations or other factors outside of our control. Depending upon the terms of our collaboration, the remedies we have against an under-performing collaborator may be limited. If we were to terminate the relationship, it may be difficult or impossible to find a replacement collaborator on acceptable terms, or at all. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The majority of Phase 3 studies in Alzheimer&#8217;s disease have failed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Despite billions of dollars invested by NIH and the biopharmaceutical industry in research programs to develop novel therapeutics for Alzheimer&#8217;s disease, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the FDA has not approved any new drugs for Alzheimer&#8217;s </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">disease</span><span style="white-space:pre-wrap; background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> since 2003, except, however, that in June 2021, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">aducanumab (Biogen, Inc) and in January 2023 lecanumab (Eisai Pharmaceuticals) both received approval from FDA for the treatment of Alzheimer&#8217;s disease using the accelerated approval pathway. Since 2003, many new types and classes of drugs have been developed and tested in Alzheimer&#8217;s disease, including monoclonal antibodies, gamma secretase modulators and inhibitors, &#946;-site amyloid precursor protein cleaving enzyme (BACE) inhibitors, receptor for advanced glycation end-products (RAGE) inhibitors, nicotinic partial agonists and allosteric modulators, serotonin subtype receptor (5HT6) antagonists, and others. Virtually all of these scientific programs have failed in Phase 3 testing, or earlier testing.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may not be successful in our efforts to expand our technology or product candidates in other indications. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in Alzheimer&#8217;s disease dementia, our primary indication. We may expand our research efforts outside of this primary indication and into other areas of clinical medicine based on genetic, biological or mechanistic overlap with the primary indication. Conducting clinical studies for additional indications for our product candidates will require substantial technical, financial and human resources and is prone to the inherent risks of failure in drug development. We cannot provide any assurance that we will be successful in our effort to expand our technology or our product candidates in additional indications, even if we obtain approval for our product candidate in Alzheimer&#8217;s disease. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we fail to successfully identify and develop additional product candidates, our commercial opportunity will be limited to Alzheimer&#8217;s disease or other neurodegenerations. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Identifying, developing, obtaining regulatory approval for, and commercializing additional product candidates requires substantial expertise and funding and is prone to the risks of failure inherent in drug development. We cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any additional product candidates through the development process, or assemble sufficient resources to identify, acquire, or develop additional product candidates. If we are unable to successfully identify, acquire, develop, and commercialize additional product candidates, our commercial opportunity may be limited.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Early indications of safety and tolerability from our small clinical studies with simufilam may not predict the results of later studies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Results of our small, &#8220;first-in-human&#8221; Phase 1 study was designed to assess the initial safety characteristics of simufilam in healthy human volunteers and this study was not designed to, and did not, evaluate safety, tolerability and efficacy of simufilam in patients. Additional large, well-controlled, multi-dose studies will be required to evaluate the safety, tolerability and efficacy of simufilam to treat patients with any indication, including Alzheimer&#8217;s disease. There can be no assurance that such future studies will demonstrate the safety, tolerability or efficacy of simufilam. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our Phase 2 clinical studies with simufilam were designed to assess the safety characteristics of simufilam in patients. Our Phase 2 program was not designed to, and did not, evaluate large-scale or long-term safety, tolerability and efficacy of </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">42</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">simufilam in patients. Additional large, well-controlled, multi-dose studies will be required to evaluate the safety, tolerability and efficacy of simufilam to treat patients with any indication, including Alzheimer&#8217;s disease. There can be no assurance that such future studies will demonstrate the safety, tolerability or efficacy of simufilam. The failure of simufilam to show safety, tolerability or efficacy in any future clinical studies would significantly harm our business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have never obtained FDA approval for a diagnostic test and we may not be able to secure such approval in a timely manner or at all. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are developing an investigational blood-based diagnostic test for Alzheimer&#8217;s disease, called SavaDx, which will require FDA approval prior to commercialization. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our diagnostic product candidate, marketing, sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by FDA pursuant to the FDCA, by comparable agencies in foreign countries, and by other regulatory agencies and governing bodies. Under the FDCA, a diagnostic must receive FDA clearance or approval before it can be commercially marketed in the U.S. The process of obtaining marketing approval or clearance from FDA or by comparable agencies in foreign countries for new products could:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">take a significant period of time;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">require the expenditure of substantial resources;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">involve rigorous preclinical testing, as well as increased post-market surveillance; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">require changes to products; and </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">result in limitations on the indicated uses of products.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully develop our diagnostic test for Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span id="_AEIOULastRenderedPageBreakAEIOU26" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The field of clinical laboratory testing is highly competitive. Diagnostic tests that are developed are characterized by rapid technological change. Our competitors in the U.S. and abroad are numerous and include, among others, major diagnostic companies, reference laboratories, molecular diagnostic firms, universities and other research institutions. Most of our potential competitors have considerably greater financial, technical, marketing and other resources than we do, which may allow these competitors to discover important biological markers and determine their function before we do. We could be adversely affected if we do not discover proteins or biomarkers and characterize their function, develop diagnostic and pharmaceutical and clinical services based on these discoveries, obtain required regulatory and other approvals and launch these tests and their related services before our competitors. We also expect to encounter significant competition with respect to any diagnostic tests that we may develop or commercialize. Those companies that bring to market new diagnostic tests before we do may achieve a significant competitive advantage in marketing and commercializing their tests. We may not be able to develop additional diagnostic tests successfully and we may not obtain or enforce patents, if any, covering these tests that provide protection against our competitors. Moreover, our competitors may succeed in developing diagnostic tests that circumvent our technologies or tests. Furthermore, our competitors may succeed in developing technologies or tests that are more effective or less costly than those developed by us or that would render our technologies or tests less competitive or obsolete. We expect competition to intensify in the fields in which we are involved as technical advances in these fields occur and become more widely known and changes in intellectual property laws generate challenges to our intellectual property position.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We will need to develop our own proprietary antibodies or find alternative approaches that do not involve antibodies to advance our SavaDx and our diagnostic program.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To date, most of our tests with SavaDx relied on the use of commercially available antibodies, which are complex molecules that can recognize and bind to an intended protein. Commercially available antibodies present certain technical flaws, such as improper validation, significant batch-to-batch variations or inconsistent storage, any of which can jeopardize our studies and experiments. Because antibody underperformance can be a significant drain on time and resources, we have attempted to develop and validate our own, fit-for-purpose antibody for use with SavaDx. The </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">complexity of developing our own antibody gives rise to many technical issues that are challenging to solve, and we cannot be certain that we will be able to successfully complete any of these activities, in which case our program may be harmed. We are also evaluating an alternative approach to detect Alzheimer&#8217;s disease that does not involve antibodies. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">complexity of such an alternative approach also gives rise to many technical issues that are challenging to solve. We cannot be certain that we will be able to successfully complete the development of a detection system for Alzheimer&#8217;s disease that does or does not involve antibodies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">43</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have concentrated a substantial portion of our research and development efforts on the treatment and detection of Alzheimer&#8217;s disease, an area of research that has seen significant failure rates. Further, our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We focus substantially all of our research and development efforts on addressing neurodegenerations, such as Alzheimer&#8217;s disease. Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen many failures and limited success in drug development. Our future success is highly dependent on the successful development of our product candidates for treating Alzheimer&#8217;s disease. Developing and, if approved, commercializing our product candidates for treatment of Alzheimer&#8217;s disease subjects us to many challenges, including obtaining regulatory approval from FDA and other regulatory authorities who have only a limited set of precedents to rely on. We cannot be sure that our approach will yield satisfactory therapeutic products that are safe and effective, scalable, or profitable.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our Phase 2 clinical studies with simufilam in patients with Alzheimer&#8217;s disease are generally not designed to show a statistically meaningful difference in cognition or other health functions between those patients who receive placebo and those who receive drug.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Clinical research data is often analyzed with statistical probability (p-value) to address the question of whether a clinical observation is related to a treatment effect, a random effect or something else. This, in turn, requires a clinical study to incorporate a sufficiently large sample patient population to infer the appropriate statistical analysis. By design, our Phase 2 clinical studies with simufilam generally do not include a sufficiently large patient population to generate statistical probability on measures of cognition or other health functions. This feature may make it difficult for investors to properly interpret whether clinical observations in those Phase 2 studies with simufilam are important or meaningful. Conversely, our clinical studies may generate statistically significant data (i.e., p&lt;0.05) on exploratory biomarkers, or other endpoints, that have unknown or no clinical importance. In general, the distinction between statistically significant data and clinically meaningful data is a complex area of research that continues to evolve and may be subject to differences of opinion among scientists, clinicians, biostatisticians and other professionals, as well as among government regulators.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">In our open-label study, we observed apparent differences in treatment effects by stage of disease. These observations may or may not replicate in any of our subsequent clinical studies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s dementia is a progressive, degenerate disease. Severity of disease is typically assessed by stage of disease progression, a continuum that ranges from, approximately, mild cognitive impairment (MCI), to early stage, to mild, to moderate and finally to severe disease. Over time, cognition progressively worsens in the mild-to-moderate stages of Alzheimer&#8217;s as the disease takes its toll. However, we do not have a clear understanding of how our drug candidate simufilam impacts patients by stage of disease, if at all. For example, in our open-label study, we observed apparent differences in treatment effects by stage of disease. These observations may or may not replicate in any of our subsequent clinical studies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may encounter difficulties enrolling patients in our clinical studies, and our clinical development activities could thereby be delayed or otherwise adversely affected. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The timely completion of clinical studies in accordance with their protocols depends, among other things, on our ability to enroll enough patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical studies for a variety of reasons, including: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the size and severity of disease in the patient population;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the patient eligibility criteria defined in the protocol, including biomarker-driven identification and/or certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical studies to a greater extent than competing clinical studies for the same indication that do not have biomarker-driven patient eligibility criteria;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the design of our study protocol;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to recruit clinical study investigators with the appropriate competencies and experience;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">competing clinical studies for similar therapies or targeting patient populations meeting our patient eligibility criteria;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">44</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to obtain and maintain patient consents;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">physicians&#8217; patient referral practices that are out of our control;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to adequately monitor patients and their caregivers during and after treatment; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the risk that patients enrolled in clinical studies will not complete such studies, for any reason.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our clinical studies may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Before obtaining regulatory approvals for any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical experiments and clinical studies that our product candidates are both safe and effective for use in an intended population. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical studies, and results of early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. The results of clinical studies in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical studies of the same product candidate due to numerous factors, including changes in study procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen, and other clinical study protocols and the rate of dropout among clinical study participants. Open-label extension studies may also extend the timing and cost of a clinical study substantially. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical studies. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier studies. This is particularly true in neurodegenerative diseases, including Alzheimer&#8217;s disease, where failure rates historically have been higher than in many other disease areas. Most product candidates that begin clinical studies are never approved by regulatory authorities for commercialization. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have limited experience in designing clinical studies in neurodegeneration and may be unable to design and execute a clinical study to support marketing approval. We cannot be certain that our current clinical studies or any other future clinical studies will be successful. Additionally, any safety concerns observed in any one of our clinical studies in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, and results of operations. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, even if such clinical studies are successfully completed, we cannot guarantee that FDA or foreign regulatory authorities will interpret the results as we do, and more studies could be required before we submit our product candidates for approval. To the extent that the results of the studies are not satisfactory to FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional studies in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidates, which may also limit its commercial potential.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If our drug candidate causes or contributes to a death or a serious injury before or after approval, we will be subject to medical reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our drug candidate in Alzheimer&#8217;s disease is aimed at elderly patients with dementia, some of whom may be frail due to advanced age or underlying health issues. Under FDA medical reporting regulations, we are required to report to the FDA information that our drug candidate has or may have caused or contributed to a death or serious injury. Any such serious adverse event involving our drug could result in future FDA action, such as an inspection, enforcement action or warning, or in more serious cases, a complete shutdown of our clinical program. In the context of our ongoing clinical trials, we report adverse events to the FDA in accordance with applicable national and local regulations. Any corrective action, whether voluntary or involuntary, and either pre- or post-market, needed to address any serious adverse events will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">45</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The market opportunities for simufilam and SavaDx, if approved, may be smaller than we anticipate.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If our clinical development programs succeed, we expect to seek regulatory approval of simufilam and SavaDx for patients with Alzheimer&#8217;s disease. Our projections of the number of patients with Alzheimer&#8217;s disease is based on our beliefs and estimates. These estimates have been derived from a variety of outside sources, including scientific literature, patient foundations and market research, and may prove to be incorrect. The actual number of patients may turn out to be lower than expected. Additionally, the potential patient population for our current programs or future product candidates may be limited. Even if we obtain regulatory approval and capture significant market share for any product candidate, the potential target populations may be smaller than anticipated, and we may never achieve profitability without obtaining marketing approval for additional indications. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that additional competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced, or more effective than ours, any of which may harm our business operations. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Drug discovery and development is highly competitive. Moreover, the neurodegenerative field is characterized by intense and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition to Biogen, Eisai and Eli Lilly, several large pharmaceutical and biotechnology companies are currently pursuing the development of products for the treatment of neurodegenerative diseases, including Alzheimer&#8217;s disease. Many of these current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals, and marketing approved products than we do. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our commercial opportunity could be reduced or eliminated if other competitors develop and commercialize products that are safer, are more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products significant advantages over any of our product candidates. Competitors other than Biogen may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity, and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate, or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Government Regulation and Other Legal Compliance Matters</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our financial condition and operating results could be adversely impacted by unfavorable results of legal proceedings, government investigations or allegations and other claims.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are, and may in the future be, subject to various investigations and legal proceedings.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In recent years, there has been a trend of increasing government investigations, legal proceedings and law enforcement activities against companies and executives operating in our industry, including those arising from whistleblower programs operated by the SEC and DOJ and the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">qui tam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> provisions of the False Claims Act. For instance, we are currently managing inquiries from U.S. government agencies, as well as civil claims under federal and state laws, relating to and/or arising out of research and development of our product candidates, including grant applications, securities disclosures and other aspects of our business. New claims or inquiries may arise in the future.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In response to government document requests and other claims asserted against us, we established a comprehensive document retention policy that strictly governs how we handle, store and protect our documents and data. Failure to comply with our document retention policy would expose us to risk of enforcement actions and penalties under applicable laws.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">46</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For additional information regarding legal proceedings, see &quot;Item 8. Financial Information&#8212;8.A. Consolidated Statements and Other Financial Information&#8212;Legal Proceedings&quot;.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Legal proceedings are inherently unpredictable, and large judgments or penalties sometimes occur. As a consequence, we may in the future incur judgments or penalties that could involve large cash payments, including the potential repayment of amounts allegedly obtained improperly and other penalties, including enhanced damages. In addition, such proceedings may affect our reputation, create a risk of potential exclusion from government reimbursement or grant programs and may lead to additional civil litigation. As a result, having taken into account all relevant factors, we may in the future enter into settlements of such claims without bringing them to final legal adjudication by courts or other such bodies, despite having potentially significant defenses against them, in order to limit the risks they pose to our business and reputation. Such settlements may require us to pay significant sums of money and to enter into corporate integrity or similar agreements intended to regulate company behavior for a period of years, which can be costly to operate under.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any such judgments or settlements, and any accruals that we may take with respect to potential judgments or settlements, could have a material adverse impact on our business, financial condition or results of operations, as well as on our reputation.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise. Even meritless claims could subject us to adverse publicity, hinder us from securing insurance coverage in the future or require us to incur significant legal costs. As a result, significant claims or legal proceedings to which we are a party could have a material adverse effect on our business, prospects, financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Additional future litigation against us could be costly and time-consuming to defend. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Innovative drug development is highly litigious, and we may become subject, from time to time, to additional legal proceedings, claims and allegations that arise in the ordinary course of business or pursuant to governmental or regulatory enforcement activity. Regardless of merit, any lawsuits against us, individually or in the aggregate, may have a material adverse effect on our business, financial condition, results of operations or cash flows. In addition, any litigation to which we subsequently become a party might result in substantial costs and divert management&apos;s attention, time and resources, which might seriously harm our business, financial condition, results of operations and cash flows. Our insurance policies might not cover such claims, might not provide sufficient payments to cover all of the costs to resolve one or more such claims, and might not continue to be available on terms acceptable to us. In particular, any claim could result in potential liability for us if the claim is outside the scope of the indemnification agreement we have with our third-party partners, or our third-party partners do not abide by the indemnification agreement as required, or the liability exceeds the amount of any applicable indemnification limits or available insurance coverage. A claim brought against us that is uninsured or underinsured could result in unanticipated costs and could have a material adverse effect on our financial condition, results of operations, cash flows or reputation.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we are ultimately unable to file for and obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The time required to obtain approval by FDA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical studies, and depends upon numerous factors, including the type, complexity, and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. We have not obtained regulatory approval for any product candidate, including our product candidates aimed at Alzheimer&#8217;s disease, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons, including but not limited to the following: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA or comparable foreign regulatory authorities may disagree with the design, implementation, or results of our clinical studies;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">47</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we may be unable to demonstrate to FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio when compared to the standard of care is acceptable;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical studies;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of a new drug application (NDA), or other submission or to obtain regulatory approval in the United States or elsewhere;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures, and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the approval policies or regulations of FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and growth prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our ability to market and promote our product candidates will be determined and limited by FDA-approved labeling. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The commercial success of our product candidates will depend upon our ability to obtain FDA-approved labeling describing their features. Our failure to achieve FDA approval of product labeling containing such information will prevent us from advertising and promoting the key features of our product candidates in order to differentiate them from other similar products. This would make our products less competitive in the market.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless, and negligent conduct that fails to: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">comply with the laws of FDA and other comparable foreign regulatory authorities; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">provide true, complete, and accurate information to FDA and other comparable foreign regulatory authorities;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">comply with manufacturing standards we have established;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws; or</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">report financial information or data accurately or to disclose unauthorized activities to us.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Activities subject to laws also involve the improper use of information obtained in the course of patient recruitment for clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. Further, it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we fail to comply or stay in compliance with the complex set of federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are obligated to comply with the laws of all countries and jurisdictions in which we operate. These laws cover an extremely wide and growing range of activities. Such legal requirements can vary from country to country, and new </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">48</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">requirements may be imposed on us from time to time as government and public expectations regarding acceptable corporate behavior change, and enforcement authorities modify interpretations of legal and regulatory provisions and change enforcement priorities. In addition, we rely on numerous associates, independent contractors, consultants, commercial partners and vendors who may put our business and our operations at risk of material impairment if they engage, or are alleged to engage, in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, in violation of such laws and public expectations.   </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The laws and regulations that govern our operations include, among others:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Clinical Laboratory Improvement Amendments (CLIA) of 1988, which are United States federal regulatory standards that apply to all clinical laboratory testing performed on humans in the United States, requires that laboratories obtain certification from the federal government, and state licensure laws;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA laws and regulations , including those relating to off-label marketing;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Health Insurance Portability and Accountability Act (HIPAA), which imposes comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions, including penalties for violators, enforcement authority to state attorneys general and requirements for breach notification;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">state laws regulating testing and protecting the privacy of test results, as well as state laws protecting the privacy and security of health information and personal data and mandating reporting of breaches to affected individuals and state regulators;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the federal anti-kickback law, or the Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the federal False Claims Act (FCA), which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government and which, under its </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">qui tam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> provisions, allows private litigants (called &#8220;relators&#8221;) to file claims under seal on behalf of the government and to receive a percentage of recoveries obtained as a result;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, and false claims acts, which may extend to services reimbursable by any third-party payor, including private insurers;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the Foreign Corrupt Practices Act (FCPA) and other worldwide anti-bribery laws, including those that prohibit companies and their intermediaries from making improper payments to government officials or other third parties for the purpose of obtaining or retaining business, and laws that prohibit commercial bribery;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">import, export control and economic sanctions laws and regulations in the U.S. and elsewhere;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Federal securities laws, including provisions of the Exchange Act and Dodd-Frank Act under which whistleblowers that report alleged violations of wrong doing can obtain up to 30% of related recoveries;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the federal Physician Payments Sunshine Act, which requires manufacturers to track and report to the federal government certain payments and other transfers of value made to physicians and teaching hospitals and ownership or investment interests held by physicians and their immediate family members;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Section 216 of the federal Protecting Access to Medicare Act of 2014 (PAMA), which requires applicable laboratories to report private payer data in a timely and accurate manner every three years (and in some cases annually);</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">state laws that impose reporting and other compliance-related requirements; and </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">similar foreign laws and regulations that will apply to us in foreign countries in which we may choose to operate in the future. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">49</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Government agencies may establish and promulgate usage guidelines that could limit the use of our product candidates. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Government agencies, professional and medical societies, and other groups may establish usage guidelines that apply to our product candidates. These guidelines could address such matters as usage and dose, among other factors. Application of such guidelines could limit the clinical use or commercial appeal of our product candidates. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the conduct of clinical trials, study participants report changes in their health to their doctor, including illnesses, injuries and discomforts. Often, it is not possible to determine whether our product candidate caused these conditions. Regulatory authorities may draw different conclusions and may require us to pause our clinical trials or require additional testing to confirm these determinations, if they occur. In addition, we have not yet completed long-term safety studies with simufilam to determine if this product candidate is safe for humans. Adverse events or other undesirable side effects caused by simufilam could cause us or regulatory authorities to interrupt, delay, or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by FDA or other comparable foreign regulatory authorities. Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, and/or result in potential claims.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may be subject to legal liability associated with clinical trials.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our business requires us to engage in the conduct of clinical studies in human volunteers and in patients in the United States and abroad. There are circumstances under which a participant in one of our clinical trials could impose liability on us. For example, a clinical investigator who is a participant in one of our studies may intentionally or unintentionally deviate from a clinical protocol and cause harm to a clinical trial participant, or a clinical trial participant may seek to compel us to continue to supply drug to them after the completion of a study but prior to FDA approval.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Claims may be brought against us for negligence, breach of contract, harm, injury or death, or other legal theories based on the nature of a study. Clinical trial liability is a complex and somewhat unsettled area of law and may vary by state and by country where we conduct clinical studies. Furthermore, claims may be brought against us by a clinical investigator, a clinical trial participant, or another party associated with a clinical study, long after the completion of a clinical study. Defense of such actions is a fact-intensive process that could be costly and involve significant time and attention of our management and other resources, may result in monetary liabilities or penalties, and may require us to change our business in an adverse manner.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. Conditions in the insurance markets relating to nearly all areas of traditional corporate insurance change rapidly and may result in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are and will be required to maintain product liability insurance pursuant to certain of our development and commercialization agreements. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations, business, and reputation. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical study participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our product candidates, if approved for commercial sale.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">50</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If our product candidates receive regulatory approval, we and our collaborators will be subject to ongoing FDA obligations and continued regulatory review, such as continued safety reporting requirements, and we and our collaborators may also be </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">subject</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> to additional FDA post-marketing obligations or new regulations, all of which may result in significant expense and limit our and our collaborators&#8217; ability to commercialize our potential drugs. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any regulatory approvals that our product candidates receive may also be subject to limitations on the indicated uses for which the drug may be marketed or contain requirements for potentially costly post-marketing follow-up studies. In addition, if FDA approves any of our product candidates, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record keeping for the drug will be subject to extensive regulatory requirements. The subsequent discovery of previously unknown problems with the drug, including but not limited to adverse events of unanticipated severity or frequency, or the discovery that adverse events previously observed in preclinical research or clinical studies that were believed to be minor actually constitute much more serious problems, may result in restrictions on the marketing of the drug, and could include withdrawal of the drug from the market. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are not able to maintain regulatory compliance, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Any of these events could prevent us from marketing our products and our business could suffer. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Enacted and future legislation may increase the difficulty and cost for us to commercialize our product candidates and may reduce the prices we are able to obtain for our product candidates. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Legislative and regulatory changes and future changes regarding the healthcare system could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities or affect our ability to profitably sell any product candidates for which we obtain marketing approval. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the Medicare Modernization Act) established the Medicare Part&#160;D program and provided authority for limiting the number of drugs that will be covered in any therapeutic class thereunder. The Medicare Modernization Act, including its cost reduction initiatives, could limit the coverage and reimbursement rate that we receive for any of our approved products. Private payors may follow Medicare coverage policies and payment limitations in setting their own reimbursement rates resulting in similar limits in payments from private payors. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposes a significant annual fee on companies that manufacture or import branded prescription product candidates. It also contains substantial provisions intended to, among other things, broaden access to health insurance, reduce or constrain the growth of health care spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, and impose additional health policy reforms, any of which could have a material adverse effect on our business. A significant number of provisions are not yet, or have only recently become, effective, but the Affordable Care Act may result in downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Affordable Care Act, as well as other healthcare reform measures that have been and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may compromise our ability to generate revenue, attain profitability or commercialize our products. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Affordable Care Act is a highly complex piece of legislation that continues to evolve. We do not and cannot understand or anticipate the full impact and potential implications of the Affordable Care Act on our business or on our drugs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">51</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our relationships with customers and payors will be subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm, administrative burdens, and diminished profits and future earnings. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which we may obtain marketing approval. Our current or future arrangements with payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we may obtain marketing approval. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&apos; rights are and will be applicable to our business. Restrictions under applicable federal, state and foreign healthcare laws and regulations may affect our ability to operate and expose us to areas of risk, including: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the FCA, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute to defraud any healthcare benefit program or specific intent to violate it in order to have committed a violation; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">federal laws requiring drug manufacturers to report information related to payments and other transfers of value made to physicians and other healthcare providers, as well as ownership or investment interests held by physicians and their immediate family members, including under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign laws regulating marketing activities; and </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">state and foreign equivalents of each of the above laws, including state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry&apos;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">52</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">A federal court ruling may mandate significant new disclosure requirements for clinical data dating back over a decade which may lead to costly or burdensome disclosures.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A federal court ruling may require all clinical study sponsors to report a decade&#8217;s worth of previously exempted clinical study data to the federal government for publication on ClinicalTrials.gov. In 2020, the U.S. District Court for the Southern District of New York invalidated a prior interpretation of NIH regulations that had exempted many clinical studies conducted between 2007 and 2017 from reporting requirements mandated by the Food and Drug Administration Amendments Act. If this court ruling takes effect without appeal, or if it is upheld on appeal, it could require us to submit an onerous amount of old clinical data to the federal government. In many cases, we were the responsible party for generating such clinical data, but such prior data may be difficult or not feasible for us to access as a result of our strategic shift away from analgesic drug development in 2019.  We may no longer have control over, or access to, prior clinical data that we may legally be required to report to NIH in the future.  Furthermore, it is unclear whether such new disclosure requirements apply to inactive, failed or abandoned drug development programs. As a result of these uncertainties, the government&#8217;s ruling may leave us in a conflicted position or out of compliance with new disclosure requirements.  We currently do not and cannot understand or anticipate the full impact and potential implications of this court ruling on our business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Intellectual Property </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we are unable to obtain and maintain sufficient patent protection for any product candidates, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by filing patent applications in the U.S. and abroad relating to our core programs and product candidates, as well as other technologies that are important to our business. Given that our product candidates are in early or clinical stages of development, our intellectual property portfolio with respect to certain aspects of our product candidates is also at an early stage. For example, we have filed or intend to file patent applications on aspects of our technology and core product candidates; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in some cases, we have filed only provisional patent applications on certain aspects of our technology and product candidates and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furthermore, in some cases, we may not be able to obtain issued claims covering compositions relating to our core programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture for protection of such core programs, product candidates, and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our core programs and product candidates could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">U.S. intellectual property rights around diagnostic methods is a complex, evolving area of law and effective patent claims may not be available to us for our investigational diagnostic product candidate, SavaDx, in the United States.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The legal system for intellectual property around diagnostic methods is highly complex, remains uncertain and continues to evolve. In the U.S., patent courts have struggled to define a clear means of patent eligibility for modern age diagnostics. Case law interpretations from the U.S. Supreme Court have left certain important scientific advances in the area of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">diagnostics</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> without effective patent claims. In 2012, the Supreme Court held that a simple process involving correlations between blood test results and patient health is not eligible for patent claims because such processes incorporate &#8220;laws of nature&#8221;. Since then, different outcomes from different courts, including Federal Circuit, district court and Patent Trial and Appeal Board decisions, have continued to create a sometimes vague or conflicting legal framework for determining the eligibility of patent claims for diagnostic methods. As a result, we cannot be certain how SavaDx fits into the current U.S. legal framework for obtaining effective patent protection. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently have no U.S. patents or patent applications with respect to SavaDx, and we believe it may be protected in the United States only by trade secrets, know-how and other proprietary rights technology. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furthermore, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">claims for diagnostic methods can be complicated to enforce. For patent infringement to occur with a protected diagnostic, the patented method must generally either be performed by one person in its entirety or performed by multiple parties all </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">53</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">under the control or direction of a single party. Accordingly, even if effective patent claims are issued for SavaDx, it may be impractical, impossible or even undesirable to enforce potential infringement claims.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we initiated legal proceedings against a third party to enforce a patent covering our product candidates or other technologies, the defendant could counterclaim that the asserted patent is invalid or unenforceable. In patent litigation in the U.S. and in other jurisdictions, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">inter partes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our product candidates or other technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and growth prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the U.S. and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and growth prospects could be materially harmed. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition to seeking patents for our product candidates and other technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. We consider trade secrets and know-how to be one of our primary sources of intellectual property. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants as well as train our employees not to bring or use proprietary information or technology from former employers to us or in their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">54</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If any of our patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents with respect to our product candidates. With respect to our intellectual property related to our product candidates, we cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, or enforce all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents to which we have rights may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and growth prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad. We may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (USPTO) or become involved in opposition, derivation, revocation, reexamination, post-grant and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">inter partes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">review, or interference proceedings or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">55</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates and other technologies. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may not be able to protect our intellectual property and proprietary rights throughout the world. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Filing, prosecuting, and defending patents on our product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the U.S. over the lifetime of our owned or licensed patents and applications. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">56</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in either the patent laws or interpretation of the patent laws in the U.S. could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the U.S., the first to invent the claimed invention was entitled to the patent, while outside the U.S., the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act (the America Invents Act) enacted in September 2011, the U.S. transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&#160;file any patent application related to our product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our patents or patent applications. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">inter partes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings as compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Various U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may be subject to claims that former employees, scientific collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants, or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our patents, trade secrets, or other intellectual property. If the defense of any such claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may not be successful in obtaining necessary rights to our product candidates or other technologies. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Many pharmaceutical companies, biotechnology companies, and academic institutions that compete with us in the field of neurodegeneration therapy may have patents filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. We may also require licenses from third parties for certain technologies for use with future product candidates. In addition, with respect to any patents we co-own with third parties, we may wish to obtain licenses to such co-owner&#8217;s interest to such patents. However, we may be unable to secure such licenses or otherwise acquire any compositions, methods of use, processes, or other intellectual property rights from third parties that </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">57</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we identify as necessary for our future product candidates. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property which may prevent or delay the development of our product candidates. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The field of developing innovations for neurodegenerative diseases is highly competitive and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors, the intellectual property landscape in this field is in flux, and it may remain uncertain in the future. Additionally, no products utilizing our underlying science and technology have yet reached the market. As such, there may be significant intellectual property related litigation and proceedings relating to our, and other third party, intellectual property and proprietary rights in the future. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our commercial success depends in part on our ability to develop, manufacture, market, and sell any product candidates that we develop and to use our proprietary technologies without infringing, misappropriating, and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may become party to, or threatened with, such actions in the future, regardless of their merit. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">inter partes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates and other technologies may give rise to claims of infringement of the patent rights of others. Although we believe that we do not infringe on any third parties&#8217; patents or other intellectual property, we cannot assure you that our product candidates and other technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may not be aware of patents that have already been issued </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> a third party, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">such as</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> a competitor in the fields in which we are developing product candidates, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">who</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> might assert </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">infringement of patents it may hold</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> by our current or future product candidates or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates or other technologies.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">58</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">pending patent applications that may later result in issued patents that our product candidates or other technologies may infringe. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated, or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Competitors may infringe on our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may become involved in inventorship, priority, or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent in which we have an interest is invalid or unenforceable, the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Intellectual property rights do not necessarily address all potential threats. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we may own;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we might not have been the first to make the inventions covered by the issued patent or pending patent application that we own now or in the future;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we might not have been the first to file patent applications covering certain of our inventions;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned intellectual property rights;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">it is possible that our current or future pending patent applications will not lead to issued patents;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we may not develop additional proprietary technologies that are patentable;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">59</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the patents of others may harm our business; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to Our Business and Operations </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our reputation and operations could be adversely impacted by allegations, regardless of their merits. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe that our reputation has significantly contributed to the success of our business. We also believe that maintaining and enhancing our reputation is critical to many of our core operations, such as conducting studies, working with outside vendors, hiring qualified employees, members of our Board of Directors or science collaborators, raising funds for future operations, or working with potential industry and government collaborators. Maintaining and enhancing our reputation will depend largely on our ability to develop innovative drug products, continue to generate credible scientific data and respond appropriately to our critics, which we may not do successfully.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our reputation may be injured by published false statements purporting to be fact, or by hostile actions made by or paid for by parties who represent investors who seek a decline in the price of our securities (&#8220;short-sellers&#8221;). Such allegations and statements may be published on internet forums over which we have no control, such as social media, and may be adopted by the editors of scientific or technical journals that have published our research, potentially resulting in retractions or expressions of concern by the journals. Regardless of merit, allegations and false statements may spread quickly and erode confidence in our reputation. Maintaining and enhancing our reputation may require us to make substantial investments in legal actions or other activities, and these investments could be expensive, time consuming, and unsuccessful. If we fail to successfully maintain our reputation, or if we incur excessive expenses in this effort, our business, operations, future prospects, cash flows, and financial position may be adversely affected.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our ability to continue to operate without any significant disruptions will in part depend on our ability to source materials and clinical supplies via our product supply chains.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The widespread outbreak of COVID-19 in recent years generally did not significantly impact our ability to source materials and clinical supplies to date.&#160;However, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we are broadly aware of some general supply chain disruptions in certain markets due primarily to the restriction of employee movements and, in North America, due to labor shortages, supply chain disruptions, an unexpected rise in inflation and transportation constraints.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> In addition, uncertainty regarding the emergence of new mutations or variants of the COVID virus, the likelihood of a resurgence of positive cases, the speed at which treatments and vaccines are administered or mandated and governmental actions in response to the pandemic could result in an unforeseen disruption to our operations. In addition, o</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ur ability to conduct clinical trials require the use of a host of critical ancillary supplies. Clinical ancillary supplies are general consumable or disposable products, such as sample collection tubes, latex gloves, instruments and other products routinely used in a medical or clinical research setting. We rely on independent vendors globally to supply us or our clinical collaborators with ancillary supplies. Any disruptions, gaps or shortages in the global supply chain for ancillary supplies could increase the cost or complexity of our supply chain management and delay the completion of our Phase 3 clinical program.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We cannot reasonably predict disruptions, gaps or shortages across our product supply-chains. With prolonged disruptions, there exists the possibility of a material adverse impact on our business, clinical operations, future prospects, cash flows, and financial position.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Should we be unable to obtain key materials and clinical supplies on a timely basis, it&#160;could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our current dependence on single source suppliers for our drug substance and drug product could materially adversely affect our ability to manufacture our product candidates and materially increase our costs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely on single source suppliers for materials that are critical to the manufacturing of simufilam, our lead product candidate. This reliance subjects us to risks related to our potential inability to obtain an adequate supply of required materials. Our operating results could be materially adversely affected if we were unable to obtain adequate supplies of simufilam in a timely manner or if their cost increased significantly due to inflation or other factors.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">60</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Further, it would likely result in production and delivery delays if we needed to find alternative suppliers for simufilam, which could lead to delays in our clinical trials and have a material adverse effect on our business, results of operations and financial condition.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Changes in funding for the FDA and other government agencies, or changes in FDA&#8217;s Guidance for Industry, could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent our product candidates from being developed or commercialized in a timely manner, which could negatively impact our business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We rely on the FDA to assist us with the development our product candidates. The ability of the FDA to review and approve new drug products can be affected by a variety of factors outside of our control, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA Guidance for Industry are non-binding policy documents that are issued by FDA from time to time to assist sponsors with the clinical development of drug candidates. Even though such guidance documents do not set legal standards or impose binding requirements they are nonetheless broadly followed by sponsors, including us. In addition, sponsors who adhere in good faith with earlier guidance documents have no assurance against enforcement actions if the guidance documents are later replaced with conflicting guidance. We have relied heavily on current FDA guidance to advance simufilam through the drug development process. Any future changes to existing FDA Guidance for Industry for Alzheimer&#8217;s disease may have a material adverse effect on our business, may add significant time, cost or complexity to our drug development program for simufilam, or could cause us to cease or delay development of some or all our product candidates. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Disruptions at the FDA and other agencies may also slow the time necessary for our product candidates to be reviewed and/or potentially approved by necessary government agencies, which would adversely affect our business. For example, in recent history, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. If the timing of FDA&#8217;s review and approval of new products is delayed, the estimated timing of our drug development program may be delayed which would materially increase costs of drug development and harm our operations or business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our reliance on third parties for both the supply and manufacture of materials for our product candidates carries the risk that we will not have sufficient quality or quantities of such materials or product candidates, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We do not have any manufacturing facilities. We currently rely on CDMOs for all of the manufacture of our materials for preclinical studies and clinical studies and expect to continue to do so for preclinical studies, clinical studies, and for commercial supply of any product candidates that we may develop. We currently have established relationships with several CDMOs for the manufacturing of our product candidates. We may be unable to establish any further agreements with CDMOs or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on CDMOs entails additional risks, including: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the possible breach of the manufacturing agreement by the third party;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the inability to produce required volume in a timely manner and to quality standards.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the U.S. Our failure, or the failure of our CDMOs, to comply with applicable regulations could result in clinical holds on our studies, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures, or recalls of product candidates or product candidates, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and harm our business, financial condition, results of operations, and growth prospects. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">61</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any product candidates that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development or marketing approval. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also rely on third-parties for the supply of the raw materials required for the production of our product candidates, and we expect to continue to rely on third party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.01in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our employees, principal investigators, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and vendors. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activities that violate (i) the laws and regulations of FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad and (iv) laws that require the true, complete and accurate reporting of financial information or data. In particular, clinical and business arrangements in the biotechnology and healthcare industries are subject to extensive laws and regulations intended</span><span id="page105" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of financial arrangements, incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the conduct of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or furnish under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple mistake or human error. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">62</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Failure to comply with laws regarding data privacy could expose us to risk of enforcement actions and penalties under such laws.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.57in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may be subject to privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Our ongoing efforts to comply with evolving laws and regulations may be costly and require ongoing modifications to our policies, procedures and systems. Failure to comply with laws regarding data protection by us or our partners or service providers would expose us to risk of enforcement actions and penalties under such laws. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Within the U.S., there are numerous federal and state laws and regulations related to the privacy and security of personal information. For example, at the federal level, the Health Insurance Portability and Accountability Act of 1996, as amended (&#8220;HIPAA&#8221;), and its implementing regulations establish privacy and security standards that limit the use and disclosure of personally identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information. While we have determined that we are neither a &#8220;covered entity&#8221; nor a &#8220;business associate&#8221; directly subject to HIPAA, many of the U.S. health care providers with which we interact are subject to HIPAA, and we may have assumed obligations related to protecting the privacy of personal information. States are increasingly regulating the privacy and security of personal information. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which took effect on January 1, 2020, gives California consumers (defined to include all California residents) certain rights, including the right to ask covered companies to disclose the types of personal information collected, the categories of sources from which such information was collected, the business purpose for collecting or selling the consumer&#8217;s personal information, the categories of third parties with whom a covered company shares personal information, and specific pieces of information collected by a covered company. The CCPA imposes several obligations on covered companies to provide notice to California consumers regarding their data processing activities. The CCPA also gives California consumers the right to ask covered companies to delete a consumer&#8217;s personal information and it places limitations on a covered company&#8217;s ability to sell personal information, including providing consumers a right to opt out of sales of their personal information. Additionally, the California Privacy Rights Act (&#8220;CPRA&#8221;), which became operational in 2023, significantly modifies the CCPA, including expanding consumers&#8217; rights with respect to certain sensitive personal information, and creates a new state agency vested with authority to implement and enforce the CCPA and CPRA. The Virginia Consumer Data Protection Act (&#8220;CDPA&#8221;) went into effect on January 1, 2023. The CDPA provides consumers with new rights to access, correct, delete and obtain a copy of the personal information a covered business holds about them, and to opt out of certain data processing activities.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Because we are developing our lead product candidate for the treatment of Alzheimer&#8217;s disease, a condition for which there are no recent examples of new drug molecules that have received full FDA approval, and our trials employ endpoints or methodologies that may be considered subjective, there is a heightened risk that the FDA or other regulatory authorities may not consider our clinical trials, or the endpoints of our clinical trials, as evidence of clinically meaningful results or that our clinical results may be difficult to analyze.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If our product candidates advance to the FDA review process, we will need to identify success criteria and endpoints such that the FDA will be able to determine the clinical efficacy and safety profile of our product candidates. Because we are developing a novel treatment for Alzheimer&#8217;s disease, a condition in which there are very few examples of new drug approvals, and our trials employ endpoints or methodologies that may be considered subjective, there is heightened risk that the FDA or other regulatory bodies may not consider our clinical trials, or the endpoints of our clinical trials, as evidence of clinically meaningful results to patients. In addition, the resulting clinical data and results may be difficult to analyze. Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoints to a threshold of statistical significance (i.e., p-value &lt;0.05). Even if we believe the data collected from clinical trials of our lead product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Pre-clinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us, which could delay, limit or prevent regulatory approval.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If data from one or both of our Phase 3 trials do not adequately demonstrate the safety or efficacy of our lead product candidate, the regulatory approval for such product candidate could be significantly delayed as we work to meet approval requirements, or, if we are not able to meet these requirements, such approvals could be denied. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are evaluating two doses (50 mg and 100 mg) of simufilam in on-going Phase 3 trials. If data from one dose in our Phase 3 trials does not adequately demonstrate safety or efficacy, the regulatory approval for the other dose could be </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">63</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">significantly delayed as we work to meet approval requirements, or, if we are not able to meet these requirements, such approval could be denied. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We expect to significantly grow the size and capabilities of our organization and we may experience difficulties in effectively managing this growth. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As our development plans and strategies develop, we expect to add a significant number of additional managerial, operational, financial, and other personnel. Future growth will impose significant added responsibilities on members of management, including: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">identifying, recruiting, integrating, retaining, and motivating additional employees;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">increasing employee headcount;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to contractors and other third parties;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">expanding our operational, financial and management controls, reporting systems, and procedures; and </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">managing increasing operational and managerial complexity.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors, and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical studies may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development, and commercialization goals. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Ownership of our corporate headquarters and property leasing are subject to numerous risks and uncertainties.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2021, we made an all-cash purchase of an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. Title to this property is held by Austin Innovation Park, LLC, a Texas limited liability company wholly owned by Cassava Sciences. The purchase required a substantial upfront cash investment and may require further commitments of our resources in the future. We have assumed or entered into lessor commitments with independent third parties for portions of our office complex and will continue to do so in the future. Commercial property ownership and related leasing activity are subject to many factors that pose substantial financial risks and uncertainties, including tenant default or non-payment of lease obligations by tenants. Macro-economic or other factors outside of our control could have an adverse effect on the demand for leased office space in our locale or may cause a decline in the market value of our corporate headquarters. If we fail to lease unoccupied office space at favorable rates, or if we incur excessive expenses in this effort or incur excessive leasehold improvements or property ownership expenses, our business, operations, future prospects, cash flows, and financial position may be adversely affected. In addition, our property is located in a semi-rural, wooded area of Austin, Texas that is subject to natural disasters such as extreme weather conditions, including but not limited to floods, tornadoes, wildfires, winter storms, lighting, heat waves and drought. Such natural disasters could damage, destroy or impair the value of our property or reduce the number of tenants who are willing or able to continue to lease office space in our property. We may incur substantial expenses as a result of our property&#8217;s exposure to natural disasters, which could have a material adverse effect on our business and prospects.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">New SEC guidance, or pending or proposed guidance, around climate change and environmental, social and governance (ESG) matters could result in material costs, complexities and changes to our development programs and business operations, or may negatively affect our reputation, or may impact our ability to attract investors who seek sustainable investing.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Social issues such as climate change and ESG continue to receive significant attention from the general public, the SEC and institutional investors. For example, in March 2022, the SEC proposed climate change disclosure rules that may require </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">64</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">us to broadly disclose extensive climate-related information in our SEC filings, including but not limited to the material effects of climate transition risks over the short, medium and long-term and their impact on our upstream and downstream operations; climate-related metrics in our financial statements; litigation risks related to climate change; sustainability reports; greenhouse gas emissions that included an attestation report from an independent source, etc. We do not currently know how disclosures related to environmental or ESG matters can be appropriately tailored to a company of our size and our scope of operations, if at all. We do not currently know how to identify, measure or integrate climate change risk factors into our business operations, or how to align those risk factors with proposed SEC reporting mandates. There can be no assurance that we will be successful in our efforts to comply with any pending or proposed guidance and disclosures mandates related to climate change and ESG matters. Failure to comply with such guidance and disclosures may adversely affect our business and operations, which could result in financial, legal, business, or reputational harm to us, or may impact our ability to attract institutional investors for whom sustainable investing is a key investment criterion.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our internal computer systems, or those used by third parties on whom we rely, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the ordinary course of our business, we collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems, as well as extensive cloud-based applications and data storage. These applications and data encompass a wide variety of business-critical information including research and development information, commercial information and business and financial information. Despite the implementation of security measures, our internal computer systems and those of our current or future CROs and other contractors and consultants may be vulnerable to damage from computer viruses and unauthorized access. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering, and/or other means. If a breakdown, cyberattack, or other information security breach were to occur and cause interruptions in our operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information, and a material disruption of our development programs and our business operations. For example, the loss of clinical study data from completed, ongoing, or future clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical studies, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, financial, or proprietary information, including data related to our personnel, we could incur liability or risk disclosure of confidential, financial, or proprietary information, and the further development and commercialization of our product candidates could be delayed. There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business, or reputational harm to us.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our reliance on third parties requires us to share our proprietary information, which increases the possibility that a competitor will discover this information or that our proprietary information will be misappropriated or inadvertently disclosed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our reliance on third-party vendors requires us to disclose our proprietary information to these parties, which could increase the risk that a competitor will discover this information or that our proprietary information will be misappropriated or disclosed without our intent to do so. If any of these events were to occur, then our ability to obtain patent protection or other intellectual property rights could be irrevocably jeopardized, and costly, distracting litigation could ensue. Furthermore, if these third-party vendors cease to continue operations and we are not able to quickly find a replacement provider or we lose information or items associated with our products or product candidates, our development programs may be delayed. Although we carefully manage our relationships with our third-party collaborators and CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, clinical operations, financial condition and prospects.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our business involves environmental risks that may result in liability for us.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In connection with our research and development activities, we, and our collaborators and vendors, are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">65</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">discharge, handling and disposal of certain materials, biological specimens, chemicals and wastes. Although we believe that we comply with such applicable laws, regulations and policies in all material respects and have not been required to correct any material noncompliance, we may incur significant costs to comply with environmental and health and safety regulations in the future. Although we believe that our safety procedures for handling and disposing of controlled materials comply with the standards prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. In the event of such an occurrence, we could be held liable for any damages that result and any such liability could exceed our resources.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Business disruptions and lack of appropriate levels of commercial insurance could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our operations, and those of our third-party research institution collaborators, CROs, CDMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, disease epidemics or pandemics, such as COVID-19 and other natural or man-made disasters or business interruptions, for which we are partly or entirely uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our day-to-day operations are located in a single office facility in Austin, Texas. Damage or extended periods of interruption to our corporate, development, or research facilities could cause us to cease or delay development of some or all our product candidates. Our insurance might not cover losses under such circumstances and our business may be seriously harmed by such delays and interruption. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Social media platforms </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">have significantly altered the dynamics of corporate communications and present risks and challenges, some of which are, and may continue to be unknown to us.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As social media continues to expand, it also presents us with new challenges. The inappropriate or unauthorized use of our confidential information on media platforms could cause brand damage or information leakage, which would cause legal or regulatory issues for us. In addition, negative, inappropriate or inaccurate posts or comments about us or our product candidates on social media internet sites could quickly and irreversible damage our reputation, image and goodwill. Further, the accidental or intentional disclosure of non-public sensitive information by our workforce or others through media channels could lead to information loss or could lead to legal or regulatory issues for us. In addition, there is a risk of a fraudulent third-party hijacking our information technology systems without our knowledge to access our confidential documents or to use our company name, logo or brand without authorization. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm and costs to our business. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We expect to rely on third parties to conduct our studies and some aspects of our research, and such third parties may not perform satisfactorily, which could delay or harm our studies, research, and testing. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We substantially rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical studies. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it will delay our product development activities. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that all of our clinical studies are conducted in accordance with the general investigational plan and protocols for the trial. Moreover, FDA requires us to comply with the norms of Good Clinical Practice (GCPs) for conducting, recording, and reporting the results of clinical studies to assure that data and reported results are credible, reproducible, and accurate and that the rights, integrity, and confidentiality of study participants are protected. We also are required to register ongoing clinical studies and post the results of completed clinical studies on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If our third-party vendors do not successfully carry out their contractual duties, meet expected deadlines, or conduct studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">66</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. For example, one of our vendors failed to fully comply with certain Good Laboratory Practice (GLP) norms in its research facility, which required us to repeat a lab study at a different research site.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also rely on other third parties to label, store and distribute drug supplies for our clinical studies. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our product candidates, producing additional losses and depriving us of potential product revenue. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We do not own any manufacturing facilities and we rely on third-party commercial drug manufacturers for </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">clinical </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">drug supply. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We do not own any manufacturing facilities. We plan to continue to outsource formulation, manufacturing and related activities. We rely on a limited number of third-party suppliers to formulate, manufacture, fill, label, ship or store all of our product candidates. These suppliers must comply with </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">current cGMP</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> regulations enforced by FDA and other government agencies, and are subject to ongoing periodic unannounced inspection, including preapproval inspections by FDA and corresponding state and foreign government agencies to ensure strict compliance with c</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">GMP </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and other government regulations and corresponding foreign standards. These manufacturers may subsequently be stopped from producing, storing, shipping or testing our drug products due to their non-compliance with federal, state or local regulations. We do not have control over our suppliers&#8217; compliance with these regulations and standards. We cannot control decisions by our suppliers that affect their ability or willingness to continue to supply us on acceptable terms, or at all. We may not be able to replace a commercial supplier on commercially reasonable terms, or at all. Replacing any of our commercial suppliers would be expensive and time consuming. Failure by any of our suppliers to perform as expected could delay or prevent commercialization of our product candidates or result in shortages, cost overruns, or other problems and would materially harm our business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We are a small company with a limited number of employees. We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate, and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, particularly our President and Chief Executive Officer, Remi Barbier, and our scientific and technical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region in Austin, Texas, and doing so may be costly and difficult. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity option grants that vest over time and/or a cash bonus plan. The value to employees of these equity grants that vest over time or cash bonus plans may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may need to cease our operations if we are unable to attract and retain key personnel.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are engaged in developing early-stage technologies and will continue to do so for the foreseeable future.  Unlike larger organizations, we rely on a very small number of highly skilled, and highly sought after, employees to continue the advancement of our development stage technologies. The knowledge and skills contributed by our key employees may be irreplaceable and the loss of a key employee may cause substantial negative financial, operational and scientific consequences for our business.  As an example, any research grant awards from NIH depend in part on the continued participation of certain key employees, known as a Principal Investigator. The loss of a Principal Investigator may result in the loss of one or more of any research grant awards from NIH, which would have significant adverse effects on our ability to continue to conduct, conclude or fund our research programs in Alzheimer&#8217;s disease. Likewise, the intellectual property that is intended to protect </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">67</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our development stage technologies is still evolving and its evolution remains highly dependent on a small number of employees with specific expertise. The loss of a key employee may jeopardize our existing or pending intellectual property or may prevent us from accessing the technical information and knowledge necessary to extend our portfolio of intellectual property. Furthermore, we believe the adverse effects that may result from losing a key employee&#8217;s participation cannot be compensated with any specific insurance policies, such as &#8220;key person&#8221; or &#8220;business life&#8221; insurance. If we are not successful in retaining key employees, our business and financial condition will suffer, and we may need to cease our operations.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If our current research collaborators or scientific advisors terminate their relationships with us or develop relationships with a competitor, our ability to continue our business operations could be adversely affected.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have relationships with unaffiliated research collaborators at academic and other institutions who conduct research at our request. These research collaborators are not our employees. As a result, we have limited control over their activities and, except as otherwise required by our collaboration agreements, can expect only limited amounts of their time to be dedicated to our activities. Our ability to discover drugs and biomarkers involved in human disease and validate and commercialize diagnostic tests will depend in part on the continuation of these collaborations. If any of these collaborations are terminated, we may not be able to enter into other acceptable collaborations. In addition, our existing collaborations may not be successful. Our research collaborators and scientific advisors may have relationships with other commercial entities, some of which could compete with us. Our research collaborators and scientific advisors sign agreements which provide for the confidentiality of our proprietary information and the results of studies conducted at our request. We may not, however, be able to maintain the confidentiality of our technology and other confidential information related to all collaborations. The dissemination of our confidential information could have a material adverse effect on our business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our business may be impacted by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties beyond our control.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">War, terrorism, geopolitical uncertainties and other business interruptions could cause damage to, disrupt or cancel the conduct of our clinical studies on a global or regional basis, which could have a material adverse effect on our business, clinical sites or vendors with which we do business. Such events could also decrease patient demand to enroll in our clinical studies or make it difficult or impossible for us to deliver products and services to our clinical investigational sites. In addition, territorial invasions can lead to cybersecurity attacks on technology companies, such as ours, located far outside of the conflict zone. In the event of prolonged business interruptions due to geopolitical events, we could incur significant losses, require substantial recovery time and experience significant expenditures in order to resume our business or clinical operations. We have no operations in Russia or the Ukraine, but we do not and cannot know if the current uncertainties in these geopolitical areas may escalate and result in broad economic and security conditions or rationing of medical supplies, which could limit our ability to conduct clinical trials outside the U.S. or result in material implications for our business. In addition, our insurance policies typically contain a war exclusion of some description and we do not know how our insurers are likely to respond in the event of a loss alleged to have been caused by geopolitical uncertainties.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Related</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> to Financial Condition and Capital Requirements </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have incurred net losses in each reporting period since our inception, including a net loss of $76.2&#160;million for the year ended December&#160;31, 2022. As of December&#160;31, 2022, we had an accumulated deficit of $283.6&#160;million. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have invested significant financial resources in research and development activities for product candidates. We do not expect to generate revenue from product sales for several years, if at all. The amount of our future net losses will depend, in part, on the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">level</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of our future expenditures and revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indicator of our future performance. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">expect</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to continue to incur significant expenses and higher operating losses for the foreseeable future. We anticipate our expenses will remain substantial as we: </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">continue our research and discovery activities;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">advance our current and any future product candidates through preclinical and clinical development;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">initiate and conduct additional preclinical, clinical, or other studies for our product candidates;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">68</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">work with our CDMO&#8217;s to scale up the manufacturing processes for our product candidates;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">seek regulatory approvals and marketing authorizations for our product candidates;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">obtain, maintain, protect, defend and enforce our intellectual property portfolio;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">attract, hire, and retain qualified personnel;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">provide additional internal infrastructure to support our continued research and development operations and any planned commercialization efforts in the future;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">experience any delays or encounter other issues related to our operations;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">meet the requirements and demands of being a public company; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">defend against litigation, claims or other uncertainties that may arise from allegations made against us or our collaborators.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our prior </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">losses</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. In any quarter, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have broad discretion in the use of the net proceeds from </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">any of our financing transactions</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> and may not use them effectively. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have broad discretion in the application of the net proceeds from our financing transactions, and investors will not have the opportunity to assess whether the net proceeds are being used appropriately. We could spend the net proceeds from offerings in ways that vary substantially from their intended use, do not improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from our financing transactions in a manner that does not produce income or that loses value.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We have no product revenues and may never achieve revenues or profitability based on product revenues. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing, and marketing product candidates with significant commercial value. This is a significant endeavor that few early-stage biopharmaceutical companies can successfully achieve. Our ability to generate revenue and achieve profitability depends on many factors, including: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">completing research and preclinical and clinical development of our product candidates;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand for our product candidates;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">identifying, assessing, acquiring, and/or developing new product candidates;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">addressing any competing technological and market developments;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">maintaining, protecting, expanding, and enforcing our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">attracting, hiring, and retaining qualified personnel.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by FDA or foreign </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">69</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">regulatory agencies to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our clinical studies or the development of any of our product candidates. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may require additional capital to fund our operations and to complete the development of our product candidates. A failure to obtain this necessary capital on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our operations have required substantial amounts of cash since inception, and we expect our expenses to remain substantial for the foreseeable future. To date, we have financed our operations primarily through the sale of equity securities, research grants and payments received from prior third-party collaborations. Developing our product candidates and conducting clinical studies for the treatment of neurodegenerative diseases, including Alzheimer&#8217;s disease, will require substantial amounts of capital. We will also require a significant amount of capital to commercialize any approved products. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2022, we had cash and cash equivalents of $201&#160;million. Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our projected operations for at least the next 12&#160;months. Our estimate as to how long we expect our existing cash and cash equivalents to be available to fund our operations is based on assumptions that may prove inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may require additional capital for the further development of our product candidates. Additional capital may not be available when we need it, or on terms acceptable to us or at all. We have no committed source of additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, limit, reduce or terminate our research and development programs or the commercialization of product candidates, if approved, or be unable to continue or expand our operations, or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, results of operations, and growth prospects and cause the price of our common stock to decline. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or grant licenses on terms that may not be favorable to us.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Global credit and financial market conditions and inflation could negatively impact the value of our portfolio of cash equivalents and our ability to meet our financing objectives.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our cash and cash equivalents are generally maintained in highly liquid investments with original maturities of 90 days or less at the time of purchase. While, as of the date of this filing, we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents since December&#160;31, 2022, no assurance can be given that deterioration in conditions of the global credit and financial markets, including inflationary pressure, would not negatively impact our current portfolio of cash equivalents or our ability to meet our financing objectives.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our operations are subject to the effects of rising</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> inflation</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The United States has recently experienced historically high levels of inflation. According to the U.S. Department of Labor, the annual inflation rate for the United States was approximately 6.50% for the 12 months ended December 31, 2022, after rising over 7.0% in 2021. If the inflation rate continues to increase, for example due to increases in the costs of labor and supplies, it may affect our expenses, such as employee compensation and research and development charges. Research and development expenses account for a significant portion of our operating expenses. Additionally, the U.S. is experiencing an acute workforce shortage, which in turn has created a very competitive wage environment that may increase our operating costs. To the extent inflation results in further interest rate increases and has other adverse effects on the market, inflation may adversely affect our consolidated financial condition and results of operations or business prospects. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="_AEIOULastRenderedPageBreakAEIOU29" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">70</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Risks Related to the Ownership of Our Common Stock </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We do not know whether a sufficient market will continue to develop for our common stock or what the market price of our common stock will be, and, as a result, it may be difficult for investors to sell shares of our common stock. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If a market for our common stock is not sustained, it may be difficult to sell shares of our common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The market price of our common stock has historically been highly volatile, and we expect it to continue to be volatile, which could result in substantial losses for investors who purchase our shares. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For example, the closing price of our common stock has fluctuated from a low of $16.33 to a high of $51.06 over the 12 months preceding the filing date of this Annual Report on Form 10-K. Some of the factors that may cause the market price of our common stock to fluctuate include: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the success of existing or new competitive products or technologies;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the timing and results of clinical studies for our current product candidates and any future product candidates that we may develop;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">failure or discontinuation of any of our product development and research programs;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">results of preclinical studies, clinical studies, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">regulatory or legal developments in the United States and other countries;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">developments or disputes concerning patent applications, issued patents, or other proprietary rights;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the recruitment or departure of key personnel;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the results of our efforts to develop additional product candidates or products;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">actual or anticipated changes in estimates as to financial results or development timelines;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">announcement or expectation of additional financing efforts;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">sales of our common stock by us, our insiders, or other stockholders;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">variations in our financial results or those of companies that are perceived to be similar to us;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">market conditions in the pharmaceutical and biotechnology sectors;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">general economic, industry, and market conditions; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">securities litigation, regardless of merit.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In recent years, the stock market in general, Nasdaq, and the markets for early stage companies and pharmaceutical and biotechnology companies, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we are currently and may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business. </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">71</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If securities analysts do not publish research or reports about our business, or we are the subject of negative publicity, the price of our stock could decline. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not control these analysts. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable evaluations of our company or our stock, the price of our stock could decline. If one or more of these analysts cease coverage of our company or fail to publish reports covering our company regularly, our stock may lose visibility in the market, which in turn could cause our stock price to decline. In addition, if we are the subject of negative publicity, whether from an analyst, academic, social media, industry group or the general or financial press, our stock price may decline.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">General Risk Factors</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As a public company, we are subject to reporting and other obligations under the Exchange Act including the requirements of Section&#160;404(a) of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the Sarbanes-Oxley Act (&#8220;SOX&#8221;)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, which require annual management assessments of the effectiveness of our internal control over financial reporting. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Section 404(b) of SOX also requires our independent auditors to attest to, and report on, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the effectiveness of our internal control over financial reporting</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by SOX. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with accounting principles generally accepted in the U.S. Any failure to maintain effective internal controls, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">or if our independent registered public accounting firm is unable to attest to the effectiveness of our internal control over financial reporting</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, could have an adverse effect on our business, financial position, and results of operations. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Anti-takeover provisions in our charter documents and Delaware law may prevent or delay removal of incumbent management or a change of control. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Anti-takeover provisions of our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law may have the effect of deterring or delaying attempts by our stockholders to remove or replace management, engage in proxy contests and effect changes in control. The provisions of our charter documents include: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">a classified board so that only one of the three classes of directors on our Board of Directors (the &#8220;Board&#8221;) is elected each year; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">elimination of cumulative voting in the election of directors; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">procedures for advance notification of stockholder nominations and proposals; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the ability of the Board to amend our bylaws without stockholder approval; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the ability of the Board to issue up to 10,000,000 shares of preferred stock without stockholder approval upon the terms and conditions and with the rights, privileges and preferences as the Board may determine. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, as a Delaware corporation, we are subject to Delaware law, including Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless certain specific requirements are met as set forth in Section 203. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These provisions, alone or together, could have the effect of deterring or delaying changes in incumbent management, proxy contests or changes in control. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">72</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Our amended and restated bylaws provide that the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Laws of 1933, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span id="page109" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our amended and restated bylaws provide that the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">While the Delaware courts have determined that such choice of forum provisions are factually valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.10in;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation or bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the exclusive-forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could harm our business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Changes in our ownership could limit our ability to utilize net operating loss carryforwards.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2022, we had aggregate federal net operating loss carryforwards of approximately $133.4&#160;million, which begin to expire in 2029. Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in our ownership may limit the amount of our net operating loss carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50% within a rolling three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards. Any such limitation, whether as the result of past offerings, sales of our common stock by our existing stockholders or additional sales of our common stock by us in the future could have a material adverse effect on our results of operations in future years. We have not completed a study to assess whether an ownership change for purposes of Section 382 has occurred, or whether there have been multiple ownership changes since our inception, nor do we plan to do so due to the significant costs and complexities associated with such study.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">We may sell additional equity or debt securities to fund our operations, and have outstanding securities exercisable for our common stock, which may result in dilution to our stockholders and impose restrictions on our business.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In order to raise additional capital to support our operations, we may sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock which could result in dilution our stockholders. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in prior offerings, and investors purchasing our shares or other securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional shares of our common stock or securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in prior offerings. You may also be diluted upon the exercise of outstanding stock options as of December&#160;31, 2022 to purchase 2,529,448 shares of our common stock at a weighted average price of $12.13 per share, and the future issuance of up to 4,070,688 compensatory equity awards authorized under our 2018 Omnibus Incentive Plan and up to 58,017 shares we may sell under our Employee Stock Purchase Plan.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">The estimates and judgments we make, or the assumptions on which we rely, in preparing our consolidated financial statements could prove inaccurate.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. Such estimates and judgments include development expenses, valuation of stock-based awards and income tax. We base our estimates on historical experience, facts and circumstances known to us and on various other assumptions that we believe to be reasonable under the circumstances. We cannot provide assurances, however, that our estimates, or the assumptions underlying them, will not change over time or otherwise prove inaccurate. If this is the case, we </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">73</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">may be required to restate our consolidated financial statements, which could, in turn, subject us to securities class action litigation. Defending against such potential litigation relating to a restatement of our consolidated financial statements would be expensive and would require significant attention and resources of our management. Moreover, our insurance to cover our obligations with respect to the ultimate resolution of any such litigation may be inadequate. As a result of these factors, any such potential litigation could have a material adverse effect on our financial results and cause our stock price to decline, which could in turn subject us to securities class action litigation.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 1B.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> &#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Unresolved Staff Comments</span><span id="Unresolved_Staff_Comments" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="_DV_M81" style="text-decoration: none;"></span><span id="_DV_M83" style="text-decoration: none;"></span><span id="_DV_M84" style="text-decoration: none;"></span><span id="_DV_M85" style="text-decoration: none;"></span><span id="_DV_M86" style="text-decoration: none;"></span><span id="_DV_M87" style="text-decoration: none;"></span><span id="_DV_M88" style="text-decoration: none;"></span><span id="_DV_M90" style="text-decoration: none;"></span><span id="_DV_M190" style="text-decoration: none;"></span><span id="_DV_M195" style="text-decoration: none;"></span><span id="_DV_M198" style="text-decoration: none;"></span><span id="_DV_M200" style="text-decoration: none;"></span><span id="_DV_M202" style="text-decoration: none;"></span><span id="_DV_M204" style="text-decoration: none;"></span><span id="_DV_M205" style="text-decoration: none;"></span><span id="_DV_M207" style="text-decoration: none;"></span><span id="_DV_M208" style="text-decoration: none;"></span><span id="_DV_M209" style="text-decoration: none;"></span><span id="_DV_M210" style="text-decoration: none;"></span><span id="_DV_M211" style="text-decoration: none;"></span><span id="_DV_M213" style="text-decoration: none;"></span><span id="_DV_M217" style="text-decoration: none;"></span><span id="_DV_M225" style="text-decoration: none;"></span><span id="_DV_M218" style="text-decoration: none;"></span><span id="_DV_M227" style="text-decoration: none;"></span><span id="_DV_M228" style="text-decoration: none;"></span><span id="_DV_M314" style="text-decoration: none;"></span><span id="_DV_M315" style="text-decoration: none;"></span><span id="_DV_M316" style="text-decoration: none;"></span><span id="_DV_M317" style="text-decoration: none;"></span><span id="_DV_M319" style="text-decoration: none;"></span><span id="_DV_M320" style="text-decoration: none;"></span><span id="_DV_M497" style="text-decoration: none;"></span><span id="_DV_M332" style="text-decoration: none;"></span><span id="_DV_M353" style="text-decoration: none;"></span><span id="_DV_M354" style="text-decoration: none;"></span><span id="_DV_M356" style="text-decoration: none;"></span><span id="_DV_M447" style="text-decoration: none;"></span><span id="_DV_M451" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item&#160;2. &#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Properties</span><span id="Properties" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We own an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. This property is intended to accommodate our anticipated growth and expansion of our operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet. The property was over 60% leased at December 31, 2022. We also occupied approximately 25% of the property as of December 31, 2022. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item&#160;3. &#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Legal Proceedings</span><span id="Legal_Proceedings" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">From time to time, we may become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA, and may receive inquiries from government authorities relating to matters arising from the ordinary course of business in the future. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to us. No information is available to indicate that it is probable that a loss has been incurred or can be reasonably estimated as of the date of the consolidated financial statements and, as such, no accrual for these matters has been recorded within the consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Government Investigations</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 15, 2021, we disclosed that certain government agencies had asked us to provide them with corporate information and documents. These were confidential requests. We have been voluntarily cooperating and will continue to cooperate with government authorities. No government agency has informed us that it has found evidence of research misconduct. No government agency has informed us that any wrongdoing has occurred by any party. No government agency has filed any charges against us, or anyone associated with us. We cannot predict the outcome or impact of any these ongoing matters, including whether a government agency may pursue an enforcement action against us or others. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">FDA Citizen Petitions</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2021, an attorney representing anonymous clients submitted a Citizen Petition to the FDA. This Citizen Petition requested that the FDA Commissioner immediately halt the clinical development of simufilam, our drug candidate for Alzheimer&#8217;s disease. The attorney subsequently disclosed that his clients are short sellers, that is, investors who earn a profit from a decline in our stock price. In September 2021, the same attorney filed another Citizen Petition, which requested that the FDA Commissioner immediately rescind previously granted Special Protocol Assessments (SPAs) for our Phase 3 clinical program with simufilam. FDA has not halted the clinical development of simufilam and has not rescinded our SPAs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 106.7%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In February 2022, FDA denied both Citizen Petitions and their supplements. As of January 17, 2023, FDA&#8217;s denial letter could be found at: https://www.regulations.gov/document/FDA-2021-P-0930-0228.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 106.7%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Securities Class Actions and Shareholder Derivative Actions</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Between August 27, 2021 and October 26, 2021, four putative class action lawsuits were filed alleging violations of the federal securities laws by us and certain named officers. The complaints rely on allegations contained in Citizen Petitions that were submitted to FDA, and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">74</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On June 30, 2022, a federal judge consolidated the four class action lawsuits into one case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on August 18, 2022 on behalf of a putative class of purchasers of our securities between September 14, 2020 and July 26, 2022. Briefing on defendants&#8217; motion to dismiss was completed on January 23, 2023.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> We believe the claims are without merit and intend to defend against these lawsuits vigorously. We are unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 4, 2021, a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s board of directors. This complaint relies on allegations made in Citizen Petitions that were submitted to</span><span id="OLE_LINK1" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (and subsequently denied by)</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiff in this derivative case does not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since November 4, 2021, three additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, and one in Texas state court (Travis County District Court). </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All four actions have</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> been stayed pending the resolution of the motions to dismiss in the securities class actions. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On July 5, 2022, the three federal court actions were consolidated into a single action.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s board of directors. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the 2020 Cash Incentive Bonus Plan in August 2020. The complaints seek unspecified compensatory damages and other relief. On January 6, 2023, the plaintiffs filed an amended complaint. Although the plaintiffs in this derivative case do not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 4.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> &#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Mine Safety Disclosures</span><span id="Mine_Safety_Disclosures" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not applicable.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART II</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 5.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Market for Registrant&apos;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span><span id="Market_For_Registrants_Common_Equity" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Market Information</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our common stock is quoted on </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Nasdaq, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">under the symbol &quot;SAVA.&quot;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Holders</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of February&#160;20, 2023, there were approximately 25 registered holders of record of our common stock. We believe t</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">he actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Sales of Non-Registered Securities</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Purchases of Equity Securities by the Issuer</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Dividend Policy</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently expect to retain future earnings, if any, for use in the operation and expansion of our business and, </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">75</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">notwithstanding our special non-dividend distributions in December 2012 (of $0.75 per share of common stock totaling $34.0&#160;million) and December 2010 (of $2.00 per share of common stock totaling $85.7&#160;million), we do not anticipate paying any cash dividends in the foreseeable future.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock Performance Graph</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following graph compares the cumulative total return to stockholder return on our common stock relative to the cumulative total returns of the NASDAQ Composite Index and the NASDAQ Biotechnology Index. An investment of $100 is assumed to have been made in our common stock and each index on January 1, 2018 and its relative performance is tracked through December 31, 2022. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder returns shown on the graph below are based on historical results and are not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="sava-20221231x10kg008.jpg" style="width: 6.382128in; height: 5.3in" alt="Picture 3" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 6.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span id="Selected_Financial_Data" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">[Reserved]</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">76</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 7.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span id="MDA" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">This discussion and analysis</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and accompanying notes included elsewhere in this Annual Report on Form 10-K. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">This discussion contains forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, and intentions, that are based on the beliefs of our management. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Operating results are not necessarily indicative of results that may occur in future periods.  </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Overview </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer&#8217;s disease. Our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the brain. Our lead therapeutic drug candidate, simufilam, is being evaluated for the proposed treatment of Alzheimer&#8217;s disease dementia in Phase 3 clinical studies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Over the past 10 years, we have combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer&#8217;s disease and other neurodegenerative diseases. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our strategy is to leverage our unique scientific/clinical platform to develop a first-in-class program for </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">treating neurodegenerative diseases, such as Alzheimer&#8217;s</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently have two </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">biopharmaceutical </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">assets under development: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our lead therapeutic product candidate, called simufilam, is a novel oral treatment for Alzheimer&#8217;s disease dementia; and </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our lead investigational diagnostic product candidate, called SavaDx, is a novel way to detect the presence of Alzheimer&#8217;s disease from a small sample of blood.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our scientific approach for the treatment of Alzheimer&#8217;s disease seeks to simultaneously suppress </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">both</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> neurodegeneration and neuroinflammation. We believe our ability to improve multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#8217;s disease. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our lead product candidate, simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of FLNA in the Alzheimer&#8217;s brain. Published studies have demonstrated that the altered form of FLNA causes neuronal dysfunction, neuronal degeneration and neuroinflammation. We are currently conducting a Phase 3 program with simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease dementia. We are currently conducting a Phase 3 program with simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease dementia.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe simufilam improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering the downstream toxic effects of altered FLNA. We have generated and published experimental and clinical evidence of improved brain health with simufilam. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Importantly, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">simufilam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> is not dependent on clearing amyloid from the brain. S</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ince simufilam has a unique mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with those of other therapeutic candidates aiming to treat neurodegeneration. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In Fall 2021, we </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">announced initiation of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our two Phase 3 studies </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">of simufilam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of February 28, 2023, a total of over 1,000 patients have been enrolled in the Phase 3 program. Patients are now being screened in clinical trial sites in the U.S., Canada, Puerto Rico, Australia, and South Korea.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The first Phase 3 study, called RETHINK-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg in enhancing cognition and slowing cognitive and functional decline over 52 weeks. Secondary objectives include the assessment of simufilam&apos;s effect on neuropsychiatric symptoms and caregiver burden. This randomized, double-blind, placebo-controlled study plans to enroll approximately 750 patients with mild-to-moderate Alzheimer&#8217;s. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">second Phase 3 study, called </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">REFOCUS-ALZ, is </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">designed to evaluate </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the safety and efficacy of oral simufilam 100 mg and 50 mg over 76 weeks. This randomized, double-blind, placebo-controlled study plans to enroll approximately 1,000 patients with mild-to-moderate Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our investigational diagnostic product candidate, called SavaDx, is an early-stage program focused on detecting the presence of Alzheimer&#8217;s disease from a small sample of blood. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">T</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">he goal is to make the detection of Alzheimer&#8217;s disease as simple as getting a blood test.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">77</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Financial Overview</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have yet to generate any revenues from product sales. We have an accumulated deficit of $283.6&#160;million at December&#160;31, 2022. These losses have resulted principally from costs incurred in connection with research and development activities, salaries and other personnel-related costs and general corporate expenses. Research and development activities include costs of preclinical and clinical studies as well as clinical supplies associated with our product candidates. Salaries and other personnel-related costs include stock-based compensation associated with options and other equity awards granted to employees and non-employees. Our operating results may fluctuate substantially from period to period as a result of the timing of preclinical activities, enrollment rates of clinical studies for our product candidates and our need for clinical supplies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe that our cash and cash equivalents at December&#160;31, 2022, will enable us to fund our operating expenses for at least the next 12 months. In addition, we may seek in the future to fund our operations through additional public or private equity or debt financings or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain financing or reach profitability, the related lack of liquidity will have a material adverse effect on our operations and future prospects, and we may have to significantly delay, scale back or discontinue the development and commercialization of simufilam, our lead drug candidate, or delay our efforts to expand our product pipeline.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect to continue to use significant cash resources in our operations for the next several years. Our cash requirements for operating activities and capital expenditures may increase in the future as we:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">continue our ongoing Phase 3 program with simufilam;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">manufacture large-scale supplies for simufilam;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">conduct other preclinical and clinical studies for our product candidates;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">seek regulatory approvals for our product candidates; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">develop, formulate, manufacture and commercialize our product candidates; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">implement additional internal systems and develop new infrastructure;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">acquire or in-license additional products or technologies, or expand the use of our technology; </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">maintain, defend and expand the scope of our intellectual property;</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">incur costs related to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">legal proceedings and claims, including U.S. government inquiries; and</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">hire additional personnel.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Product revenue will depend on our ability to receive regulatory approvals for, and successfully market, our product candidates. If our development efforts result in regulatory approval and successful commercialization of our product candidates, we expect to generate revenue from direct sales of our drugs and/or, if we license our drugs to future collaborators, from the receipt of license fees and royalties from sales of licensed products. We conduct our research and development programs through a combination of internal and collaborative programs. We rely on arrangements with universities, certain collaborators, CDMOs, CROs and clinical research sites for a significant portion of our product development efforts.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Components of Operating Results</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Operating Expenses</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Research and Development Expenses</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We focus substantially all our research and development efforts on research and development in the areas of neurology. The following table summarizes expenses by category for research and development efforts (in thousands):</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.04in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 7,262&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 5,935&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 1,575&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contractor fees and supplies</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 59,767&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 17,970&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 980&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other common costs</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 1,003&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 908&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 498&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 68,032&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 24,813&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 3,053&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.04in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 57.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">78</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expenses include compensation, contractor fees and supplies as well as allocated common costs. Contractor fees and supplies generally include expenses for clinical studies and preclinical studies and costs for formulation and manufacturing activities. Other common costs include the allocation of common costs such as facilities. During the years ended December&#160;31, 2022, 2021 and 2020, we received $0.9 million, $3.9&#160;million and $4.2&#160;million in research grants from the NIH, respectively. These reimbursements were recorded as a reduction to our research and development expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our technology has been applied across certain of our portfolio of product candidates. Data, know-how, personnel, clinical results, research results and other matters related to the research and development of any one of our product candidates also relate to, and further the development of, our other product candidates. As a result, costs allocated to a specific product candidate may not necessarily reflect the actual costs surrounding research and development of such product candidate due to cross application of the foregoing.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Estimating the dates of completion of clinical development, and the costs to complete development, of our product candidates would be highly speculative, subjective and potentially misleading. Pharmaceutical products take a significant amount of time to research, develop and commercialize. The clinical study portion of the development of a new drug alone usually spans several years. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect our research and development expenses to increase in 2023 and beyond as we seek to advance our product candidates through the clinical development process and, potentially to seek regulatory approval of simufilam. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect to reassess our future research and development plans based on our review of data we receive from our current research and development activities. The cost and pace of our future research and development activities are linked and subject to change</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Critical Accounting Estimates</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of our consolidated financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and interest income in our consolidated financial statements and accompanying notes. We evaluate our estimates on an ongoing basis, including those estimates related to agreements and research collaborations. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our significant accounting policies are described in Note&#160;2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, and we believe that the accounting policies discussed below involve the greatest degree of complexity and exercise of significant judgments and estimates by our management. The methods, estimates and judgments that we use in applying our accounting policies have a significant impact on our results of operations and, accordingly, we believe the policies described below are the most critical for understanding and evaluating our financial condition and results of operations.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research Contracts,Prepaids and Accruals. We have entered into various research and development contracts with research institutions and other third-party vendors. Related payments are recorded as research and development expenses as incurred. We record prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, we analyze progress of the studies including the phase or completion of events, invoices received and contracted costs. Certain judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from our estimates. Our historical prepaid and accrual estimates have not been materially different from actual costs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Legal and other contingencies.&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is subject to lawsuits, claims, allegations and investigations regarding simufilam and SavaDx. The Company believes the claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> However, litigation is subject to inherent uncertainties, and unfavorable rulings could occur. If an unfavorable ruling were to occur, it may cause a material adverse impact on the results of operations, cash flows, or financial condition for the period in which the ruling occurs, or future periods. Refer to Note 12 to the Consolidated Financial Statements for further information on contingencies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2020 Cash Incentive Bonus Plan. I</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">n 2020, we established the 2020 Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under ASC 718, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8220;Stock-based Compensation&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">79</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;is considered probable of being met.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in our market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;our market capitalization increases&#160;significantly and (1) we complete a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan, to render payment (each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which may ever occur. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, we have concluded that&#160;a&#160;Plan&#160;grant date has not occurred&#160;as of December 31, 2022. No actual cash payments were authorized or made to participants under the Plan through December 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based Compensation. We recognize non-cash expense for the fair value of all stock options and other share-based awards. We use the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. Significant judgments and estimates are made in determining inputs to the Black-Scholes option valuation model. See Note 7 to our Consolidated Financial Statements for significant assumptions regarding stock-based compensation.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Recent Accounting Pronouncements</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See Note 2. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Summary of Significant Accounting Policies, in Notes to the Consolidated Financial Statements in Item 8 of Part II of this Annual Report on Form 10-K for a full description of recent accounting pronouncements, including the expected dates of adoption and estimated effects on financial condition and results of operations, which is incorporated herein by reference.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Results of Operations &#8211; Comparison of years ended December 31, 2022 and 2021</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Research and Development Expense</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expenses consist primarily of costs of drug development work associated with our product candidates, including:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">clinical studies,</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">preclinical testing,</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">clinical supplies and related formulation and design costs, and</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">compensation and other personnel-related expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expenses increased to $68.0&#160;million in 2022 from $24.8&#160;million in 2021, representing a 174% increase. This increase was due primarily to costs related to conducting the ongoing Phase 3 clinical program of simufilam, costs of an on-going cognition maintenance study and open-label study in simufilam, and costs related to the manufacture of clinical trial supplies compared to the prior year. Higher pre-clinical study costs as well as increased personnel costs also contributed to the increase. Grant funding received from NIH, recorded as a reduction in research and development expenses, also decreased compared to the prior year. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the years ended December 30, 2022 and 2021, we received $0.9 million and $3.9 million in research grants from NIH, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect research and development expense to increase</span><span style="white-space:pre-wrap; color: #FF0000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in future periods as we manufacture drug supply and continue our Phase 3 clinical program, the Cognition Maintenance Study, an open-label extension study and pre-clinical studies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">80</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">General and Administrative Expense</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, bonus, benefits and stock-based compensation. Allocated expenses consist primarily of existing facility costs. We incur insurance, audit, investor relations, SOX compliance and other administrative and professional services expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq. General and administrative expense increased to $12.0&#160;million in 2022 from $8.1&#160;million in 2021. The 49% increase was due primarily to higher legal fees, personnel costs and insurance expenses compared to the prior year. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In addition, 2022 expense included over </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$1,000,000 of depreciation and amortization, compared to $500,000 in 2021, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">for the </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">two-building office complex in Austin, Texas, purchased in third quarter 2021.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect general and administrative expense for 2023 will increase compared to 2022 due primarily to anticipated higher legal and professional fees related to ongoing securities class action and derivative lawsuits, governmental investigations as well as higher </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">operating costs such as compliance costs and depreciation and amortization</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Interest Income</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest and other income, net, was $2.8 million in 2022 compared to $49,000 in 2021. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The increase in interest income was due to increases in interest rates in 2022 compared to the prior year.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect interest income to increase in 2023 compared to 2022 due to the increases in interest rates.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Other income, net </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">record the activities related to leasing office space to third parties in buildings we own as other income, net, as leasing is not core to the Company&#8217;s operations. Other income, net, was $1.0 million during the year ended December 31, 2022 compared to $434,000 </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">during</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 2021. Other income, net, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">was higher in 2022</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> as we acquired the two-building office complex in August 2021.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation and amortization for the office complex is included in general and administrative and research and development expense, and thus not reflected in other income, net.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Comparison of the years ended December 31, 2021 and 2020</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Refer to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations&#8221; in our 2021 Annual Report on Form 10-K for a discussion of the results of operations for the year ended December 31, 2021 compared to the year ended December 31, 2020.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Liquidity and Capital Resources</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Since inception, we have financed our operations primarily through public and private stock offerings, payments received under collaborative agreements and interest earned on our cash and cash equivalents balances. We intend to continue to use our capital resources to fund research and development activities, capital expenditures, working capital requirements and other general corporate purposes. As of December&#160;31, 2022, cash and cash equivalents totaled $201&#160;million.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2022 Registered Direct Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 22, 2022, we completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#160;million after deducting offering expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2021 Registered Direct Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On February&#160;12, 2021, we completed a common stock offering pursuant to which certain investors purchased 4,081,633 shares of common stock at a price of $49.00 per share. Net proceeds of the offering were approximately $189.7&#160;million after deducting offering expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">81</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2020 Follow-on Public Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November&#160;13, 2020, we completed the sale of&#160;9,375,000&#160;shares of our common stock in an underwritten public offering at a price of&#160;$8.00&#160;per share. We received net proceeds from the offering of&#160;approximately $70.3 million&#160;after deducting underwriting discounts and offering expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Common Stock Warrants</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2018, we </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">issued warrants to&#160;purchase up to an aggregate of&#160;9.1&#160;million shares of its common stock in conjunction with an offering of our common stock.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During 2021, we received proceeds of $0.7&#160;million from the exercise of 0.6&#160;million shares pursuant to warrants. During 2020, we received proceeds of $4.9&#160;million from the exercise of 4.0&#160;million shares pursuant to warrants. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were no warrants outstanding following the 2021 exercises.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">At the Market (ATM) Common Stock Issuance </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On March&#160;27, 2020, we established an at-the-market offering program (ATM) to sell, from time to time, shares of our common stock having an aggregate offering price of up to&#160;$100&#160;million&#160;in transactions pursuant to a shelf registration statement that was declared effective by the&#160;U.S. Securities and Exchange Commission (the SEC)&#160;on May&#160;5, 2020. We are obligated to pay a commission of&#160;3.0%&#160;of the gross proceeds from the sale of shares of common stock in the offering. We are not obligated to sell any shares in the offering.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were&#160;no&#160;common stock sales under the ATM during the years ended December&#160;31, 2022, 2021 and 2020.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">NIH Research Grant Awards</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">research</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> has been supported by NIH under multiple research grant awards. Strong, long-term support from NIH has allowed us to advance our two lead product candidates, simufilam and SavaDx, into clinical development.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In May 2021, we were awarded a new research grant award from NIH of up to $2.7 million to support clinical readiness activities for a Phase 3 program with simufilam. In April 2020, we were awarded a research grant from NIH of up to $2.5 million. In March 2020, we were awarded a supplemental research funding grant from NIH of up to $374,000. These non-dilutive research grants are intended to strengthen our clinical program of simufilam, our investigational drug to treat Alzheimer&#8217;s disease. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All of our NIH research grant awards are paid out on a reimbursement basis and require milestone-based technical progress. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were no remaining funds for NIH grant awards&#160;as of December 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2020 Cash Incentive Bonus Plan Obligations</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2020, the Board approved the </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">2020 Cash Incentive Bonus Plan</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (the Plan). The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee&#160;determines the Company has sufficient cash on hand, as defined in the Plan. Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s market capitalization, including all outstanding stock options, was $89.4&#160;million at the inception of the Plan in August 2020. If the Company were to exceed a $5&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, and conditions noted above for payment are met, all&#160;Plan milestones would be deemed achieved, in which case total cash bonus awards would&#160;range from&#160;a minimum of&#160;$139.1&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$322.3&#160;million.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s potential financial obligation to plan participants at December&#160;31, 2021 totaled $7.3&#160;million, based upon the achievement of one Plan milestone in the Company&#8217;s market capitalization in 2020. No actual cash bonus payments have been made to any Plan participant, as the Company has not yet satisfied all the conditions necessary for amounts to be paid under the Plan. During the year ended December&#160;31, 2021, the Company&#8217;s market capitalization increased substantially. These </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">82</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">increases triggered the achievement of 11 additional Plan milestones. Collectively, the achievement of such milestones could trigger potential Company obligations to Plan participants ranging from a minimum of $93.7&#160;million up to a hypothetical maximum of $225.0&#160;million, with exact amounts to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No actual cash payments were authorized or made to participants under the Plan as of December&#160;31, 2022, or through the filing date of this Annual Report on Form 10-K.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Cash</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table sets forth a summary of the primary sources and uses of cash for each of the periods presented below (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 58.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 58.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 58.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr style="height: 0.16in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 58.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 58.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in operating activities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (77,514)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (30,196)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (5,382)</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 58.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash (used in) provided by investing activities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (2,712)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (22,214)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 360&#160;</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 58.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 47,804&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 192,341&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 75,447&#160;</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 58.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net (decrease) increase in cash and cash equivalents</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (32,422)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 139,931&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 70,425&#160;</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in operating activities was $77.5 million for the year ended December 31, 2022, resulting primarily from the net loss reported of $76.2 million, a decrease in accounts payable of $3.4 million, accrued compensation and benefits of $1.7 million and a decrease in accrued developmental expenses of $0.5 million, partially offset by a decrease in in prepaid and other assets of $1.2 million, and stock-based compensation expense of $2.1 million.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in operating activities was $30.2 million for the year ended December 31, 2021, resulting primarily from the net loss reported of $32.4 million and an increase in prepaid and other assets of $11.0 million, partially offset by an increase in accounts payable of $6.2 million, accrued development expense of $2.1 million, accrued compensation and benefits of $1.8 million, other current liabilities of $0.7 million and stock-based compensation expense of $1.8 million.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in investing activities during the year ended December 31, 2022 was $2.7 million related to renovations and fixtures for our corporate headquarters.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in investing activities during the year ended December 31, 2021 was $22.2 million related primarily to the purchase of a two-building office complex in Austin, Texas, a portion of which serves as our corporate headquarters.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities during the year ended December 31, 2022 was $47.8 million, consisting of $47.3&#160;million in proceeds from our registered direct offering of common stock in November 2022 and $0.5&#160;million from the exercise of stock options.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities during the year ended December 31, 2021 was $192.3 million, consisting of $189.8&#160;million in proceeds from our registered direct offering of common stock in February 2021, $1.8&#160;million from the exercise of stock options and $0.7&#160;million in proceeds from the exercise of common stock warrants.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Cash &#8211;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Comparison of the years ended December 31, 2021 and 2020</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Refer to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations&#8221; in our 2021 Annual Report on Form 10-K for a discussion of use of cash for the year ended December 31, 2021 compared to the year ended December 31, 2020.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Realization of our deferred tax assets is dependent on future earnings, if any. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these net deferred tax assets with a valuation allowance.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">83</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Property and Leases</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.20in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2021, we completed the purchase of an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. This property is intended to accommodate our anticipated growth and expansion of our operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are outsourced to professional real-estate managers. The purchase price of the property was $22.0 million, including closing costs, funded with cash on hand. The office complex measures approximately 90,000 rentable square feet. The property was over 60% leased at December 31, 2022. We also occupied approximately 25% of the property as of December 31 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We leased approximately 6,000 square feet of office space pursuant to a non-cancelable operating lease in Austin, Texas expiring in April 2024. We terminated this lease on February 22, 2023 with no continuing obligations.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have an accumulated deficit of $283.6&#160;million at December&#160;31, 2022. We expect our cash requirements to be significant in the future. The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our product candidates and the resources we devote to researching and developing, formulating, manufacturing, commercializing and supporting our products. We believe that our current resources should be sufficient to fund our operations for at least the next 12 months. We may seek additional future funding through public or private financing in the future, if such funding is available and on terms acceptable to us.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If we raise additional funds by issuing debt financing or equity securities, our stockholders will experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our drug candidates in certain territories or indications that we would prefer to develop and commercialize ourselves.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 7A.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Quantitative and Qualitative Disclosures about Market Risk</span><span id="Quantitative_And_Qualitative_Disclosures" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are exposed to market risks in the ordinary course of our business, primarily related to interest rate sensitivities and, to a lesser extent, currency fluctuations related to our clinical operations outside the U.S.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Interest Rate Sensitivity</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are exposed to market risk related to changes in interest rates. We had cash and cash equivalents of $201 million as of December 31, 2022, which consisted primarily of U.S. Treasury securities and money market accounts.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain investment vehicles with high credit quality and short-term duration, in accordance with our board-approved investment policy. Such interest-earning instruments carry a degree of interest rate risk. However, due to the generally short-term maturities and low risk profile of our cash equivalents, an immediate 100 basis point increase or decrease in interest rates during any of the periods presented would increase or decrease our annual net loss by less than $2 million in our condensed consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 8.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Consolidated </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Financial Statements and Supplementary Data</span><span id="Financial_Statements_Supplementary_Data" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 93.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 93.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 6.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">Page</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 93.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><a href="#Report_Of_Independent_Firm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Report of Independent Registered Public Accounting Firm</span><span style="white-space:pre-wrap; color: #0000FF;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(PCAOB ID: </span><ix:nonNumeric name="dei:AuditorFirmId" id="ct-nonNumeric-dd3e3ef8-66c0-4881-b751-1e58a81b8c32" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; color: #333333;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">42</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #333333;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 6.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">85</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 93.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="#Balance_Sheets"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consolidated Balance Sheets</span><span style="white-space:pre-wrap; color: #0000FF;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 6.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">87</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 93.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="#Statements_Of_Operations" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consolidated Statements of Operations</span></a></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 6.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">88</span></p></td></tr><tr><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 93.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="#Stockholders_Equity" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consolidated Statements of Stockholders&#8217; Equity</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 6.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">89</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 93.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="#Cash_Flows" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consolidated Statements of Cash Flows</span></a></p></td><td style="background: #CCEEFF;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 6.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90</span></p></td></tr><tr><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 93.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="#Notes_To_Financial_Statements" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Notes to Consolidated Financial Statements</span></a></p></td><td style="background: white;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 6.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">91</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">84</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Report_Of_Independent_Firm" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Report of Independent Registered Public Accounting Firm</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To the Stockholders and the Board of Directors of Cassava Sciences, Inc.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Opinion on the Financial Statements </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have audited the accompanying consolidated balance sheets of Cassava Sciences, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, stockholders&apos; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes&#160;(collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&apos;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and our report dated February 28, 2023 expressed an unqualified opinion thereon.</span></p><p dir="ltr" style="font-family: NotoSans;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Basis for Opinion</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These financial statements are the responsibility of the Company&apos;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Critical Audit Matters</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p><div style="padding-left: 4.5pt;text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;"><tr style="height: 0.05in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 71.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 387pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">85</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><div style="padding-left: 4.5pt;text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;"><tr style="height: 0.37in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 71.75pt;"><span style="white-space:pre-wrap; "></span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Description of the Matter</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 387pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Prepaid and Accrued Development Expenses Related to CRO Pass Through Costs for Clinical Trials</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As explained in Note 2 to the consolidated financial statements, the Company contracts with a </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">contract research organization (CRO) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to assist the Company in conducting clinical trials, the costs for which are recorded as research and development expenses as incurred. A portion of these costs are pass through costs, which are costs incurred by third parties contracted by the CRO to perform certain services for clinical trials. These costs are passed through to the Company by the CRO. Depending on the timing of CRO payments, the Company records these costs as either prepaid or accrued development expenses. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These prepaid or accrued development expenses are based on management&#8217;s determination of pass through costs incurred by the third parties based on the status of the clinical trials. At December 31, 2022, prepaid and accrued development expenses for CRO pass through costs were $2.7 million and $14 thousand, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Auditing the Company&#8217;s prepaid and accrued development expenses related to CRO pass through costs for clinical trials was challenging because the recorded amounts involved management&#8217;s validation of the completeness and accuracy of </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">costs incurred for services provided but not yet billed by third parties to the CRO</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p></td></tr><tr style="height: 2.88in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 71.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">How We Addressed the Matter in Our Audit</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 387pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s process of accounting for prepaid and accrued development expenses related to CRO pass through costs for clinical trials, including management&#8217;s review of the progress of clinical trial activity in comparison to budgets and invoices received from the CRO.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To evaluate the adequacy of the Company&#8217;s prepaid and accrued development expenses related to CRO pass through costs for clinical trials, our audit procedures included, among others, testing the completeness and accuracy of the underlying data used by management to determine the prepaid and accrued development expenses. To evaluate completeness and accuracy of the data, on a sample basis, we: (i) obtained confirmation directly from the CRO of key clinical trial contract terms and conditions and any amendments thereto, as well as pass through costs incurred to date, (ii) agreed data used in the calculation to the contracts with the CRO, and any amendments thereto, and/or the data obtained from the CRO, (iii) corroborated the progress of clinical trials through inquiry of Company personnel who oversee clinical trials, and (iv) obtained and reviewed subsequent invoices received from the CRO to corroborate the prepaid and accrued development expenses at the end of the reporting period.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 1.75in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 71.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Description of the Matter</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 387pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Loss Contingencies</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is subject to lawsuits, claims, allegations, and investigations regarding simufilam and SavaDx. As described in Note 12 to the consolidated financial statements, such allegations and claims could result in adverse consequences. At December 31, 2022, the Company was unable to determine the likelihood of a loss, if any, associated with these lawsuits and investigations and therefore was unable to reasonably estimate a loss or range of loss.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Auditing management&#8217;s accounting for, and disclosure of, loss contingencies related to the lawsuits and investigations was challenging because management&#8217;s evaluation of the likelihood of loss required judgment.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 71.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 12pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">How We Addressed the Matter in Our Audit</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 387pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s process of evaluation of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the accounting for and disclosure of these matters. This included controls over management&#8217;s assessment of the likelihood of incurrence of a loss and whether the loss or range of loss was reasonably estimable, and the development of related disclosures.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our audit procedures included gaining an understanding of the status of ongoing lawsuits and investigations, reading the meeting minutes of the board of directors and of the committees of the board of directors, reading summaries of the proceedings and related correspondence, requesting letters from internal and external legal counsel, meeting with internal and external legal counsel to discuss developments related to the lawsuits and investigations together with our forensic professionals, and obtaining written representations from the Company on these matters. We also evaluated the Company&#8217;s disclosures in relation to these matters.</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;vertical-align: baseline;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;vertical-align: baseline;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ </span><ix:nonNumeric name="dei:AuditorName" id="ct-nonNumeric-1ea9acc9-5848-43a8-aefc-7f709fb14d7d" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ernst &amp; Young LLP</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;vertical-align: baseline;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have served as the Company&#8217;s auditor since 2002.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="dei:AuditorLocation" id="ct-nonNumeric-09c25620-29bd-4b74-91b7-845d44be1737" contextRef="Duration_1_1_2022_To_12_31_2022"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Austin, Texas</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2023</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Balance_Sheets" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">86</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CONSOLIDATED BALANCE SHEETS</span></p></td></tr><tr><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(In thousands, except share and par value data)</span></p></td></tr><tr><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="6" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ASSETS</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Current assets:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-81476662-9405-416e-9311-977caca6c97b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">201,015</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b54c9479-bb75-454d-850f-da8866b1ed2c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">233,437</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid expenses and other current assets</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-49ae83e7-6c53-4c10-90d1-4257c974fafd" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,211</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cc932389-46aa-45b1-b265-dc72af95472d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,045</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total current assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-854b19af-ac93-4cfc-a833-14f348a98919" name="us-gaap:AssetsCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">211,226</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8b18780a-a908-4e2a-9909-f932a87ec4e9" name="us-gaap:AssetsCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">244,482</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use assets</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-baec01e8-a159-4e4e-ba7f-bb6a16e703c8" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">122</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-11c36bab-e436-4f25-938c-1d707fd0c3b6" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">210</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment, net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1e7be90f-33c7-4959-8b02-5bcbca03de38" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,864</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5aee8551-74d5-40c7-abbd-58b4c5ab35a2" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20,616</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets, net</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5557985a-8029-4409-90b0-fe4a2b703c58" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">622</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bad59371-a202-4637-8076-2d3ec212f30f" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,075</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c5ee752e-4f5b-4b58-b3e8-37616594d952" name="us-gaap:OtherAssetsNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">399</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total assets</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-00091c28-aff0-4b26-91fe-3bf0a0fcbb35" name="us-gaap:Assets" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">234,834</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b91e792a-7f21-4e42-b7ec-0811efdfc93a" name="us-gaap:Assets" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">266,782</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="6" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">LIABILITIES AND STOCKHOLDERS&apos; EQUITY</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Current liabilities:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts payable</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-58efd822-46ba-40db-a454-344857888008" name="us-gaap:AccountsPayableCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,017</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-75ff5715-25ae-40dc-981e-3f58f29527cd" name="us-gaap:AccountsPayableCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,126</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued development expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-882a1274-3736-4f16-98e0-caf7297fd819" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,280</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e05693fb-446a-4cb4-ad34-af74d826a44e" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,803</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued compensation and benefits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-541b498b-2f32-4a12-bb9a-1cc56349015f" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">170</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fb317e33-201c-4ef6-abd7-1838440cc51c" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,877</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities, current</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6746de89-dc94-40cc-ae06-a7e6b10e062e" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">104</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dd466847-0580-4e98-a804-c6b80ce13cfb" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">97</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other current liabilities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a4dfacf4-d89c-4875-880d-e3362f9b0f2c" name="us-gaap:OtherLiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">492</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-188fb8d5-d0ae-4448-87db-d0a06a8ecf9c" name="us-gaap:OtherLiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">631</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total current liabilities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-107eb91b-1fd0-49e6-857e-e288feaa6de7" name="us-gaap:LiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,063</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c8cd4fff-185c-4b10-bcbc-10e4691e8f30" name="us-gaap:LiabilitiesCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,534</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities, non-current</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-035e1b2f-eaca-4b0a-86a8-fb2e5f646caa" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">35</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-91434a00-e271-4172-88b6-1beb0ced2d04" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">139</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other non-current liabilities</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a2132bd6-7203-46da-89a0-6c3af3ac61c3" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">197</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c1fb24c8-efba-4de5-9561-117c3ad78e58" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">194</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total liabilities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8b756573-450e-46fe-afa4-4e2be516e4e4" name="us-gaap:Liabilities" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,295</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0f328b47-b630-4625-a888-ac77b7246576" name="us-gaap:Liabilities" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,867</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commitments and contingencies (Notes 10, 11 and 12)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c85d098c-43ef-4402-ad21-3eab6b4c27b8;">&#160;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-2482011d-65b9-477a-825f-eea0d38abc1d;">&#160;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stockholders&apos; equity:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Preferred stock, $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c2caca6a-b3d1-4ab0-a373-f7208602487d" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2021" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-5d1aa434-57f3-427b-8fd6-e0e3beb04a89" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2022" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value; </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1839e692-c74c-4b1d-b22d-59f14d003087" name="us-gaap:PreferredStockSharesAuthorized" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-d4447d5b-712b-45af-aa07-ce03308d6f5f" name="us-gaap:PreferredStockSharesAuthorized" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares authorized, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37fdca10-68ba-442e-a07e-79e7bac33417" name="us-gaap:PreferredStockSharesIssued" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-b193d2a3-9ad2-4727-bf61-5dc52069ef0a" name="us-gaap:PreferredStockSharesIssued" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-6aaddbcc-ea24-4c63-ac28-966dba2523e2" name="us-gaap:PreferredStockSharesOutstanding" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-0b33955e-dcf0-4f31-af0b-f1f3ecbdfa2d" name="us-gaap:PreferredStockSharesOutstanding" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> issued and outstanding</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-2be3e229-c641-48c7-81d3-b5714626c15b;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-59321846-f327-4f04-bbc4-4fc6ff45a6d5;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock, $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9ca2019c-184e-42e9-bc97-89e700d739ab" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2021" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-81cd21e4-57c5-4e73-bc30-1a9a5d46e616" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2022" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value; </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5401e40a-4bc5-4956-bf54-a79b8dfbd9fd" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-6ff34702-9fe9-439b-b614-61c29dded341" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">120,000,000</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares authorized; </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-930f2b18-9c78-4b53-af8d-78f585c8bda9" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-01db6178-39ec-4617-94a1-4a12fc20072c" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">41,735,557</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4b612c29-822d-4ef9-bf03-a7219849db33" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-fe138c09-553b-4a28-a489-14b18cdfb0aa" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">40,016,792</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares issued and outstanding at December 31, 2022 and 2021, respectively</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-01bdda67-0f4e-4501-b0de-9fde0a852e20" name="us-gaap:CommonStockValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">42</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-076e0cb6-e510-4ef3-bd32-5437192ea3fe" name="us-gaap:CommonStockValue" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">40</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additional paid-in capital</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-74d4a0c1-a267-4e7a-8396-4c6e0508b1bd" name="us-gaap:AdditionalPaidInCapital" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">511,049</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3d7c4d33-37d5-482a-9521-46a4543ce1b4" name="us-gaap:AdditionalPaidInCapital" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">461,181</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated deficit</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-98c00456-cd2e-41fa-a6c7-8edfaea41b5f" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">283,552</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-484a3fc2-7590-45d6-a481-65052c31c200" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">207,306</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stockholders&apos; equity </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dc6f55d7-c697-41cc-be92-cf760e1aa0f3" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">227,539</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eddcf17b-521b-41c0-a284-8161e4a70989" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">253,915</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total liabilities and stockholders&apos; equity</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-937c1f23-c787-4f52-aa2b-ada70f86bbca" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">234,834</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9e9be844-5e80-4168-8623-b34256d1c637" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">266,782</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying notes to consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="Statements_Of_Operations" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">87</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="9" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="9" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CONSOLIDATED STATEMENTS OF OPERATIONS</span></p></td></tr><tr><td colspan="9" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(In thousands, except per share data)</span></p></td></tr><tr><td colspan="9" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating expenses:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development, net of grant reimbursement</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d02475b9-c59f-49ea-9470-12907b9d731b" name="sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">68,032</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c738d885-8214-45df-81a1-f19271ef7a1f" name="sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,813</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-173c86fb-6af7-4e77-a28f-5611237e5671" name="sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,053</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ba26d6bf-3c22-43ca-bda6-8ef44fc98d35" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,988</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ef3aff21-b006-4fad-99f1-53844c624bc1" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,055</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-89ca0e25-7fb3-4f8f-8ef4-eb0ea9034f14" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,739</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gain on sale of property and equipment</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-263267bc-2542-4e4d-83e1-378864808664" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">346</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total operating expenses</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c18d5f71-12f9-4119-a8c3-c745538ef709" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">80,020</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0113d379-99fc-497e-be12-9742a52799ce" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">32,868</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-932f2270-7f35-4f7e-92a8-5cbd2bec6085" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,446</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5c7b0461-1a70-4e29-87b3-721fde6ae2a5" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">80,020</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-81cdb769-7c23-4f57-b3db-83a682cf08a2" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32,868</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cb855186-aeef-4aaa-b0f5-3ec7d81529d3" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">6,446</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest income</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f1e9dbf7-ce4e-48a6-8cbb-f94f1badc41b" name="us-gaap:InterestAndOtherIncome" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,777</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9a747ee5-784c-4489-92e7-5e3980b164a7" name="us-gaap:InterestAndOtherIncome" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">49</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-964aef9e-a005-4920-887a-671fb2c539fe" name="us-gaap:InterestAndOtherIncome" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">112</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other income, net</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-25b29c8c-cc6d-4354-8a1e-a00a53e637df" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">997</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ad1ae878-ff70-4355-9c4b-d8866cfb4168" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">434</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-10333e9f-e73d-497e-b026-f9aafc692f6d" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">76,246</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-428486f2-f747-4a15-ab07-5b4a98d930af" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32,385</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5e120bbb-02af-4cf5-9547-db04448bd8f0" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">6,334</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f9f0a55a-c8f8-4748-b46a-161bb2bb87fa" name="sava:NetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">1.90</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c2f4fe6c-ab34-4f7c-ad60-a210d210ad86" name="sava:NetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">0.82</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-17b0ad83-8c42-428f-8431-bbd3d92a3b99" name="sava:NetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">0.24</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares used in computing net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cd342426-a51c-47ac-b805-3796e491f51c" name="sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">40,202</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85f62dba-777d-4e90-83e9-b164d0ce64b6" name="sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">39,405</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-db33be43-1882-4190-b385-053ed71b8f78" name="sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">26,105</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 61.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying notes to consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">88</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Stockholders_Equity" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.02in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td colspan="17" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span></p></td></tr><tr style="height: 0.07in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.13in;"><td colspan="17" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</span></p></td></tr><tr style="height: 0.17in;"><td colspan="17" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(In thousands, except share data)</span></p></td></tr><tr style="height: 0.04in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.04in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.04in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.12in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accumulated</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.12in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">other</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td></tr><tr style="height: 0.12in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Common stock</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Additional</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">comprehensive</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accumulated</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">stockholders&apos;</span></p></td></tr><tr style="height: 0.14in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Par value</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">paid-in capital</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">income</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">deficit</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">equity</span></p></td></tr><tr style="height: 0.13in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Balance at December 31, 2019</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e3cdf0de-8fe1-449d-9423-cb8b42fc0230" name="us-gaap:SharesIssued" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">21,841,810</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-38db4701-6909-4b99-9bbe-af265a5a6959" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bff70054-ec98-45c9-8ddb-e0b3184f8682" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">190,664</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-f72a1e5d-aec7-4a71-a833-c2f28f7c3aa7;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f9c1694c-227f-4288-b90e-85fb3e98cd2c" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">168,587</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bb27fdaa-2e16-40c0-a079-276cec583a07" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,099</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation for:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.15in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options for employees</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-127faa7e-439c-4f35-a3cb-ac23fc2037ad;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-8f3d3aee-e688-4a58-8c82-2dcaecba5338;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bc0a07b6-638c-4cdb-874e-4a29d34cd920" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">961</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-d6b508b8-e5f6-4fe3-bc4b-333dafca92c3;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-42361762-5433-4b01-ab66-912546a855b8;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-46e61d79-36ea-42c3-bfc4-37254b419246" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">961</ix:nonFraction></span></p></td></tr><tr style="height: 0.13in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options for non-employees</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-d8c20985-8ceb-42dd-996f-4a0a47c0e08e;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-7580528a-87fd-452f-94c7-806f4337e589;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6393f07c-97aa-4528-97fb-af9417f754c2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">27</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-df8c0a4a-fcf8-445d-a1bd-210c9fac8742;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a109bcc7-7b2b-4ca9-b816-fa1fa8e5a4b9;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-21779b89-29d5-4b3f-8242-f2227f20fc93" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">27</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock pursuant to exercise of stock options</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-22258803-6f73-478b-a88d-c16ae2e59ce1" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">71,105</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-955b4d43-5e21-4308-8bea-88e35c283798;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-13757ea4-6d91-4621-8eab-14b7eae7eae0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">256</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-864a6697-b067-4537-bbe4-cc70a3df80eb;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-ab248c3f-9fd0-4817-9180-ea9ab4b4557d;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c9b49a2c-3f70-4cdc-a84d-03a3482add77" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">256</ix:nonFraction></span></p></td></tr><tr style="height: 0.13in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock pursuant to exercise of warrants</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-adcc66fb-3f9a-4f13-965f-0a1bc91b7f02" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">3,950,072</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a1ec60d2-73bd-4b43-b52d-35d89a77b402" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4e5c1168-dbf0-467f-88eb-47bdf3eb4121" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,936</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-973e7776-7e8a-4f63-b1e9-ffd2515ee290;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-73e54030-2cd6-4c79-a8e1-8c37360ff959;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3c0e9c35-8c10-4456-8aeb-83c1c5022d1d" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,940</ix:nonFraction></span></p></td></tr><tr style="height: 0.28in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock issued in conjunction with follow-on public offering, net of issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8a25d3ab-8bde-4c80-9f7f-aef12ff7951e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">9,375,000</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-84690ecc-c0f9-40c3-8064-c74440620031" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c5c4c553-b0af-4134-a341-18c8d7652ac1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">70,242</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-f8301e49-4c2c-48ac-8f2f-9428fb07e149;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-ed009123-4af1-44d6-8158-b2dbd107c848;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-da4d2483-6504-4676-95dd-857fadc1a7cf" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">70,251</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-edb04fec-6821-4e71-b08a-24673be2beb4;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-d4c3c33b-3414-43d4-982a-455cfcd1d850;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-4e0ecb2c-bd96-4ebb-bced-daa182b0ed24;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-f679e88d-5156-4cf8-ac0b-88135755453e;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9414f9ac-1192-424a-a7e7-ba322eb96c45" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">6,334</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ada7d970-69af-4173-8197-651259246042" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">6,334</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Balance at December 31, 2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e6da0348-d5a2-4c11-94b7-c6439d56698c" name="us-gaap:SharesIssued" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">35,237,987</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f07e645e-a469-42f5-b49a-7420da3e7064" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">35</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4f33d49b-1136-4ecf-a89e-125b66f6994d" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">267,086</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-b3474d5b-40e6-4751-af80-757d598097ba;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7ba1c231-8925-468b-93ac-f262bcfb682f" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">174,921</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dc62ce4f-e725-460f-882f-5ed8ab3ed38a" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">92,200</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation for:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options for employees</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-68a04647-00b0-4839-9b0a-b55ed1d8a1f4;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-54c7ab99-4813-4b1d-b474-b37c9a524dcc;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f7cfe373-ad18-4877-92a2-40ee5b3eb05a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,706</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-f94615b8-ca86-4b50-bf26-783b381cf0ce;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-710cf88c-85ca-4d71-9477-12fb47d6f033;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dcd29bf5-fdb7-421b-bd48-ccf15a09c133" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,706</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options for non-employees</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-5bcdce4c-9682-486d-b80b-c542fbc7e4b0;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-9273aa42-9a73-4159-90cd-fce2d9937049;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b2312527-21f7-499c-b00f-a4fd3a09c660" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">53</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-afdfdc90-7985-4059-ac0e-4428e6895644;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c9a5eb2b-dc7d-4861-bb84-a923cff12f6a;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ed88ad26-730c-4ae5-b12b-1eb343a97bfe" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">53</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock pursuant to exercise of stock options</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e63d892b-8d39-4142-88b3-9c451902b922" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">143,153</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-9267357c-efdf-4dea-8df4-bf960417e97f;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1c479fbf-d09a-46ad-a228-e5cc1ddc7b25" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,824</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-919cbe35-3e67-4ee3-829c-05770b6d8549;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0d5dde46-8f93-44ec-a3a8-40b8d2a7bf84;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d98e28cb-f7e2-4182-9c87-cfcf4bd29fa9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,824</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock pursuant to exercise of warrants</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-47163b09-f2f6-4938-8338-aadf97952d4e" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">554,019</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1dc63614-051a-418b-97ba-7d35c6874a42" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e42f9ec-d937-4075-afed-29634e5dddd9" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">691</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0987ba20-66f7-4bf9-b131-7ab51e4f204f;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-9588f41e-4c12-4cd8-a47f-0b8a2f1e1a6c;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-318ea7ce-01f7-473b-864a-010f50a993a6" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">692</ix:nonFraction></span></p></td></tr><tr style="height: 0.29in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock issued in conjunction with registered direct offering, net of issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e91e9a19-a55c-46fd-8158-377a09831c62" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">4,081,633</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-000fa3ee-33c4-4077-9dd6-e1de51f614ed" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9a9478dc-72c6-4ca5-9978-f837bafcf5b3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">189,821</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-474b8871-4327-4d19-9f77-fb3abc9b7840;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-6d603b54-7185-48ca-b5ed-9fc404d6c467;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-18a9cd3c-4d3a-4083-bbac-bf93af2f1584" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">189,825</ix:nonFraction></span></p></td></tr><tr style="height: 0.13in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0db0de42-f4bd-4029-b4ac-4141a7fa729c;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-60c0c054-0845-4646-97f5-4ee1a9062712;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0e0796a2-6853-4ce7-b9dd-66419cd567a2;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-5793b5c3-1cbb-486a-b34d-eb398efe6a99;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-771e6692-5b16-4083-b4d3-f80f1041a81b" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32,385</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2a138d40-8aa3-4b8f-a08d-3e63bda51bfa" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32,385</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Balance at December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-96410f80-6339-427a-a0f9-1c28662a9fab" name="us-gaap:SharesIssued" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">40,016,792</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-698c239b-6232-4aeb-b12f-2f5f35c542d6" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">40</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-943f93a8-9d8f-4c52-b5e4-65dc9aad6c73" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">461,181</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-b9904651-ff3f-47a5-b170-f86d82d7e2fc;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2fd52861-10f5-4ecc-b913-c335f96aa984" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">207,306</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-20922f82-df9a-441e-b2c1-e3396913d0c6" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">253,915</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation for:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options for employees</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-81530414-bf2f-4aaa-b26e-077e1df6e132;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-23845146-836d-4a7b-8df9-875e29e06cb0;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cbf3c599-df62-4f2b-abf1-beb6cefbfabf" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,972</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-066675fe-3f2a-440e-946b-8efc90ddb585;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-aea819c2-5b65-4213-bc0e-bb07a6069a77;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f76d7243-5653-41f6-b868-d9ae3ed16456" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,972</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options for non-employees</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c6fa6d0d-7a6f-4f1a-86b9-487d2fc5526e;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-d3752495-f9b1-4d21-9b8b-e7a3f1bfd9f6;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f335b414-0e86-466d-b458-bbff3e320dc2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">94</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-8d886509-becc-4809-98f7-33fa6d1e2229;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-ec90904b-e73c-4265-b905-29b18c11c1e7;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8255c392-41b3-43d9-965f-48ba5d47272d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">94</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expiration of restricted stock Performance Awards</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dafe5b85-e62c-416c-ae93-97da9705d7d0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">57,143</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-3c6cc885-b3d3-4198-9eb0-166e06c19899;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-27e5a001-2996-4703-ae33-f911acb2c051;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-11ab857d-4a58-4fa0-adba-79c7330d2414;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-76ef54f7-3e1c-4b2f-a533-2721893b12a5;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock pursuant to exercise of stock options</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-feb6d510-5526-4531-8fa3-950db57b5669" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">109,241</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0f5134fe-cbd1-471e-8931-4e1628ea7e4e;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0b4b6c27-0464-4554-9e4a-eac09f6915d1" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">475</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-f2dbc5ec-044c-49d1-9f0d-50a8037a6db2;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-645041b0-469c-42d6-b90e-61c9bd3dbb17;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f8cb5ba2-d637-49dd-863b-99740c941e60" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">475</ix:nonFraction></span></p></td></tr><tr style="height: 0.34in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock issued in conjunction with registered direct offering, net of issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-25f49f74-496b-47c2-b0a7-0a15f1b8ef05" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,666,667</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aff7f90b-e464-424e-9a47-77d8d30305c8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-32c9295f-b529-4e2f-bc0c-5d03d7262983" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">47,327</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-8a742db3-f945-4ab7-8e73-11b06c08c252;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-1dafedde-6946-46d3-ac0a-4c7e0c43d181;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b3493439-331d-4689-be74-eda1991069a4" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">47,329</ix:nonFraction></span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-5ec1ab38-faae-43c7-9586-d76cf41a362f;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-96f181e2-9fe8-4966-8d28-9554ea90c3ec;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-d329d997-53ed-4249-8a3e-3c0e4ed13b4e;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-6a872f17-c446-49cb-b5c0-521df86f5620;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2aa423f7-a3ca-4ef3-ab0a-1380f9d5a1d0" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">76,246</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7ffd6a1c-0193-4402-98a4-09c47d25b75a" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">76,246</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Balance at December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-33e8e328-64b5-441e-9943-be4f99df27d0" name="us-gaap:SharesIssued" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">41,735,557</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f1695a02-d6e4-408c-ac54-f909550c363e" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">42</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b2df147b-d5a9-47b1-bb33-5475bbfdcd76" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">511,049</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eff39773-9f57-43b6-b38b-6e48c8992dac;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-72211e0f-8f36-49cf-beb0-d391275e7e07" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">283,552</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-77028949-5b06-4ebf-b94c-bbedbcef30c1" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">227,539</ix:nonFraction></span></p></td></tr><tr style="height: 0.05in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying notes to consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Cash_Flows" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">89</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.02in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td colspan="9" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span></p></td></tr><tr style="height: 0.07in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.22in;"><td colspan="9" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p></td></tr><tr style="height: 0.18in;"><td colspan="9" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(In thousands)</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.05in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.26in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from operating activities:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5154526c-af88-4575-b065-0c1e49afefd0" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">76,246</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-51c342b9-28b8-47fb-b323-bde884d640ef" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32,385</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8909ecb2-2f98-4b19-a33d-55653b6b9edd" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">6,334</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-516b1268-6ce7-48f0-8fcd-04c04b27e07c" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,066</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dec6c3ab-8be4-423f-ae1c-6bc71f1589f2" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,759</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cce08b5b-828e-4e58-840e-dc01ba716133" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">988</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-434bf574-7190-4c9e-a44d-0f6dd88ced11" name="us-gaap:Depreciation" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">804</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ae6821b6-0572-4c04-b926-c3a701dc8a66" name="us-gaap:Depreciation" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">310</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9e2ce832-7eec-4967-80b2-84ebc8bed99e" name="us-gaap:Depreciation" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of intangible assets</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d82b7404-dc93-406a-bfe3-5b4ef8c3a4dd" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">497</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3c993d19-9e69-411f-a90a-875c5e7f6c39" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">224</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gain on sale of property and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d9631add-ee72-4ad4-a5b4-4c13c62cd4ff" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">346</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in operating assets and liabilities:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid and other assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e2c52b7-416f-427b-8bee-c94f33640cb1" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,189</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2f151b5d-7913-42d7-a0af-3750a14fab45" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,956</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8018909e-8873-46aa-9cf8-bedc0419998d" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">220</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use assets and liabilities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a4e0fd0-7ca4-4c14-864d-7e1fa8bc9320" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ad5705e6-c2e4-4621-9c0c-ba9823280555" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">28</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e149c7ae-c277-4270-b0cd-1ec6f2da9ad9" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts payable</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bf7c6a89-dbd7-44e4-a472-f791060d0824" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">3,449</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-73be590f-3399-4424-bfe5-bbb295fc7907" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,215</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f76571e6-fb47-4e11-be56-5068456eec90" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">458</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued development expense</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e8b13cd5-d624-464b-8c50-a8e2046014e4" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">523</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-73a9e004-4ca9-4ba0-a208-1517d3facb2c" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,084</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ff32304c-cdbe-47e9-ae3d-322e79e0967b" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">58</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued compensation and benefits</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b246ab6b-951d-441b-8845-00917387d2b4" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,707</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-34f79c5b-3434-41d8-b43e-222e3ebb4483" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,794</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-124bbc1f-c70e-446f-90e6-090fdf7325fc" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">25</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other liabilities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4cc1f2dd-308c-4169-9b7e-d0e8834c711b" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">136</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7cee2f7b-9d66-449f-932b-e1a2755c81b7" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">731</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-47380f5a-a70c-4f6a-b501-33fca24d1e0e" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">85</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in operating activities</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3f734f7a-bd6c-4bda-b1ae-0ce5b3e9b71f" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">77,514</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c6e64ac8-df97-4e82-b84a-9ec36ddec4d6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">30,196</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-785f6e62-85e4-4e6a-b420-7461dbeffbfe" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">5,382</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from investing activities:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Purchase of property and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7d870bf0-a036-4093-b53c-7d045d81294c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,712</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2cdff020-2699-47d2-bc40-3f9be508592b" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,214</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from sale of property and equipment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dc6aae91-9929-4a9f-a20b-6df3b849ad28" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">360</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash (used in) provided by investing activities</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-11e54dab-05a3-41f4-986a-e55bc37bcff5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">2,712</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e85033f2-acff-487f-81f9-0f6b2a7ed84a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">22,214</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-931e4591-a80f-421e-a616-7aa21881410f" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">360</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from financing activities:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from issuance of common stock upon exercise of stock options</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c1bdcd1a-4419-4448-81d1-b14d152f0c02" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">475</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-771240d3-9fec-4854-94e6-67a1c09a214b" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,824</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bcd9406c-388c-434c-beae-c23811786026" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">256</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from issuance of common stock upon exercise of common stock warrants</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e0b48985-4c0e-41bf-bf32-09be870e0912" name="us-gaap:ProceedsFromWarrantExercises" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">692</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-466d7ed5-1540-42ed-8551-32e8d61cb477" name="us-gaap:ProceedsFromWarrantExercises" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,940</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from common stock offering, net of issuance costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-121365fb-4e36-4722-bfb4-c3f282a24e20" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">47,329</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0626b5a1-2c77-4028-8bee-36f80806af28" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">189,825</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4a940cdf-f035-4765-bb71-37ccb2db10a3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">70,251</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7aeada19-8cc8-448e-8f6d-8c8f424a346e" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">47,804</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6d97f12a-d0dc-4713-a397-79ba924f2599" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">192,341</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9782095f-8386-4534-a7cc-65a551309686" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">75,447</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net (decrease) increase in cash and cash equivalents</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-597bac15-f572-43c0-baba-7d65929019e8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32,422</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a2b7923d-17ea-4ee5-9254-eda4271c9bfc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">139,931</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-76cb60ef-df23-4a8b-a8b2-42b3fd0b2c5a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">70,425</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents at beginning of period</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-14582589-ad3b-409a-b130-6f0bc2fc1cbf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">233,437</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9fd42c4e-9293-4fbe-83da-ece28a28a0df" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">93,506</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-73a2b1ff-b7c7-4e7f-b1c2-34321f8e128c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">23,081</ix:nonFraction></span></p></td></tr><tr style="height: 0.22in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents at end of period</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8ed4d72f-568c-4e92-ac20-f85131190f83" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">201,015</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0db68a3c-07e0-4ba5-8386-3681a434f776" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">233,437</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e3887d9-4eeb-47f1-a330-c2db656be715" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">93,506</ix:nonFraction></span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Supplemental cash flow information:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Non-cash investing activities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.19in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Purchases of property and equipment included in accounts payable</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c7bb5e07-abc2-40f2-915a-904f9c9c55e3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">340</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #FF0000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 65.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying notes to consolidated financial statements. </span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">90</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span><span id="Notes_To_Financial_Statements" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ct-nonNumeric-a760b771-6a87-4195-85d0-d6b0f2ff130a" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-a760b771-6a87-4195-85d0-d6b0f2ff130a-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">1.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">General, Liquidity and Basis of Presentation</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-a760b771-6a87-4195-85d0-d6b0f2ff130a-continuation-0" continuedAt="ct-nonNumeric-a760b771-6a87-4195-85d0-d6b0f2ff130a-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discovers and develops proprietary pharmaceutical product candidates that may offer significant improvements to patients and healthcare professionals. The Company generally focuses its product discovery and development efforts on disorders of the nervous system. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Coronavirus Disease 2019 (COVID-19)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The widespread outbreak of COVID-19 has not significantly impacted the Company&#8217;s operations or financial condition as of February&#160;28, 2023. However, this pandemic has created a dynamic and uncertain situation in the national economy. The Company continues to closely monitor the latest information to make timely, informed business decisions and public disclosures regarding the potential impact of pandemic on its operations and financial condition. The scope of pandemic is unprecedented and its long-term impact on the Company&#8217;s operations and financial condition cannot be reasonably estimated at this time.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Basis of Consolidation</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">&#65279;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Liquidity  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-80bbec2b-2ffb-48b1-bcf7-ab37c1e1fd45" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6" sign="-">283.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million at December&#160;31, 2022. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company may seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are no assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next 12 months.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-a760b771-6a87-4195-85d0-d6b0f2ff130a-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ct-nonNumeric-c2e05d1f-031b-49c7-a5a9-e722e8cc862f" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-c2e05d1f-031b-49c7-a5a9-e722e8cc862f-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2.  Summary of Significant Accounting Policies</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-c2e05d1f-031b-49c7-a5a9-e722e8cc862f-continuation-0" continuedAt="ct-nonNumeric-c2e05d1f-031b-49c7-a5a9-e722e8cc862f-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="ct-nonNumeric-026e378d-f468-47f1-9e4d-ad4a50014632" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-026e378d-f468-47f1-9e4d-ad4a50014632-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-026e378d-f468-47f1-9e4d-ad4a50014632-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and assumptions</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="sava:ProceedsFromGrantsPolicyPolicyTextBlock" id="ct-nonNumeric-db2ea440-c1c9-4425-aa14-8ac4214abab3" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-db2ea440-c1c9-4425-aa14-8ac4214abab3-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Proceeds from Grants</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-db2ea440-c1c9-4425-aa14-8ac4214abab3-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2022, 2021, and 2020, the Company received $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-50454448-d7bf-4b09-9d65-51d00529aae5" name="sava:ReductionToResearchAndDevelopmentExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-01ddae7b-9237-430f-b01e-3b2ab431fa8e" name="sava:ReductionToResearchAndDevelopmentExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">3.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2e18fb2f-24e5-4eba-984c-bebd14edceae" name="sava:ReductionToResearchAndDevelopmentExpense" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">4.2</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of reimbursement from the National Institutes of Health and National Institute on Drug Abuse, respectively. The Company records the proceeds from these grants as reductions to its research and development expenses.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">91</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-c2e05d1f-031b-49c7-a5a9-e722e8cc862f-continuation-1" continuedAt="ct-nonNumeric-c2e05d1f-031b-49c7-a5a9-e722e8cc862f-continuation-2"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ct-nonNumeric-f733ac84-abb6-46d2-a8e9-6e853bfdc0ce" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-f733ac84-abb6-46d2-a8e9-6e853bfdc0ce-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cash and Cash Equivalents and Concentration of Credit Risk</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-f733ac84-abb6-46d2-a8e9-6e853bfdc0ce-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at one financial institution.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ct-nonNumeric-97ca764b-b17e-4af5-abc8-1ee8a08dc486" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-97ca764b-b17e-4af5-abc8-1ee8a08dc486-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value Measurements </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-97ca764b-b17e-4af5-abc8-1ee8a08dc486-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 1 includes quoted prices in active markets.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 2 includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does not have any financial instruments where the fair value is based on Level 2 inputs.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">financial instruments</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> where the fair value is based on Level 3 inputs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 inputs at December&#160;31, 2022 and 2021.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ct-nonNumeric-11586f83-f908-4e76-900e-41f89c180b09" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-11586f83-f908-4e76-900e-41f89c180b09-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Business Segments</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-11586f83-f908-4e76-900e-41f89c180b09-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-645a6f7e-ca16-4b3c-a101-e2fb0ecdec60" name="us-gaap:NumberOfOperatingSegments" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit17" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> business segment: the development of novel drugs and diagnostics.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="ct-nonNumeric-eaaf6494-97e0-4778-bda5-e9347336e2ff" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-eaaf6494-97e0-4778-bda5-e9347336e2ff-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-eaaf6494-97e0-4778-bda5-e9347336e2ff-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(&#8220;Black-Scholes&#8221;) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each </span><span id="_cp_text_1_372" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For all options granted, it</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-ace1e61c-55a6-4cf4-a4fe-f85c4f2b9ed6" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has granted share-based awards that vest upon achievement of certain performance criteria</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (&#8220;Performance Awards&#8221;)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">92</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-c2e05d1f-031b-49c7-a5a9-e722e8cc862f-continuation-2" continuedAt="ct-nonNumeric-c2e05d1f-031b-49c7-a5a9-e722e8cc862f-continuation-3"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="ct-nonNumeric-cbcfad27-c70a-49e2-b5ef-a9fdb85c9ce7" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-cbcfad27-c70a-49e2-b5ef-a9fdb85c9ce7-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Net Loss per Share</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-cbcfad27-c70a-49e2-b5ef-a9fdb85c9ce7-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company computes </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options and warrants. There is no difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ct-nonNumeric-e50e6e4a-2cd6-4108-9ae6-5eaa63ea58fc" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Numerator:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a890b622-99b7-4fb0-a06d-df898fd7e963" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">76,246</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c105cf41-720f-448f-9641-8a8e3f252e57" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">32,385</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-49611192-2fcd-433f-b6e2-5e53c6f9e90e" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">6,334</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Denominator:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares used in computing net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-145be4b7-01de-434b-b966-87ed86f2824d" name="sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">40,202</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5440c773-5581-41c5-bd13-a537eedb9863" name="sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">39,405</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fd64f1aa-a9c1-432f-9f57-c6f6a341657e" name="sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">26,105</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2bfbcd1c-2f63-48b3-b88e-90aa8705666b" name="sava:NetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">1.90</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d9c15bbc-b3bd-462c-8c44-9f6d87567042" name="sava:NetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">0.82</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-02b1a8c5-2f14-48ee-991f-de114645c481" name="sava:NetLossPerShareBasicAndDiluted" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal" sign="-">0.24</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Dilutive common stock options excluded from net loss per share, diluted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0dad55dc-9c87-4e12-8009-5386dc659f7c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">2,055</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aba3e800-fbda-4fec-ac33-0dbe615d5168" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">2,211</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-08822609-3cac-4ccf-900e-2fdeb916f82a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">2,145</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock warrants excluded from net loss per share, diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-92b96fe9-e0a3-4dab-87cc-6b648bbf8d1c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">554</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company excluded common stock options and warrants outstanding , along with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-df9e723b-9f80-454e-aac5-0e3afa227468" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">57,143</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted stock awards, from the calculation of net loss per share, diluted, because the effect of including outstanding options and warrants would have been anti-dilutive. The </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ee4c0b80-c90b-4ea1-bc08-75ba8ada4b11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">57,143</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted stock awards expired during the year ended December 31, 2022.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Tahoma', 'sans-serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ct-nonNumeric-34ce1393-af1b-4eda-ba40-b583535b889a" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-34ce1393-af1b-4eda-ba40-b583535b889a-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value of Financial Instruments</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-34ce1393-af1b-4eda-ba40-b583535b889a-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments may be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><ix:nonNumeric name="sava:ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" id="ct-nonNumeric-35edde5f-8323-4313-84d1-cbeeddfeab0d" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-35edde5f-8323-4313-84d1-cbeeddfeab0d-continuation-0"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Research Contracts, Prepaids and Accruals</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-35edde5f-8323-4313-84d1-cbeeddfeab0d-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have not been materially different from actual costs.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ct-nonNumeric-35d51175-3ae9-432d-a69c-9b69a9ce3dcf" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-35d51175-3ae9-432d-a69c-9b69a9ce3dcf-continuation-0"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Incentive Bonus Plan</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-35d51175-3ae9-432d-a69c-9b69a9ce3dcf-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants.  Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718 &#8220;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met.  See Note 11 for further discussion of the Plan.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">93</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-c2e05d1f-031b-49c7-a5a9-e722e8cc862f-continuation-3"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="ct-nonNumeric-e6bd170a-9a56-4433-a2e3-26a6a3fb2749" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-e6bd170a-9a56-4433-a2e3-26a6a3fb2749-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Leases</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-e6bd170a-9a56-4433-a2e3-26a6a3fb2749-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;consolidated balance sheets.&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize right-of-use assets or lease liabilities</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#160;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ct-nonNumeric-dbac76ca-823c-4fe4-9717-07aaf2a90a64" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-dbac76ca-823c-4fe4-9717-07aaf2a90a64-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Property and equipment</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-dbac76ca-823c-4fe4-9717-07aaf2a90a64-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-50f57131-a555-4102-a968-3a39d40b2fd0" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years and approximately </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-69707852-7b4e-424d-8916-9b8a934869ab" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-f5933e12-7aeb-4a50-8d8e-22f779235b55" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.4</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ct-nonNumeric-0397d26a-6461-4e33-abde-a548573525e2" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-0397d26a-6461-4e33-abde-a548573525e2-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Intangible assets</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-0397d26a-6461-4e33-abde-a548573525e2-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which approximates </span><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ct-nonNumeric-3ca93393-ec7f-4491-809c-925be227881f" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.3</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years at December 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="ct-nonNumeric-6ed6180a-9ae3-48ec-b684-969120cf603d" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-6ed6180a-9ae3-48ec-b684-969120cf603d-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Income Taxes</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-6ed6180a-9ae3-48ec-b684-969120cf603d-continuation-0" continuedAt="ct-nonNumeric-6ed6180a-9ae3-48ec-b684-969120cf603d-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-6ed6180a-9ae3-48ec-b684-969120cf603d-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for uncertain tax positions in accordance with ASC 740, &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span></ix:continuation></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">94</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="sava:PrepaidAndOtherAssetsDisclosureTextBlock" id="ct-nonNumeric-18a25781-5d13-4485-b049-a01adbb5021d" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-18a25781-5d13-4485-b049-a01adbb5021d-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">3.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Prepaid and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Other Current Assets</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-18a25781-5d13-4485-b049-a01adbb5021d-continuation-0" continuedAt="ct-nonNumeric-18a25781-5d13-4485-b049-a01adbb5021d-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid and other current assets at December 31, 2022 and 2021 consisted of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="ct-nonNumeric-8ad92adf-333a-44bb-9112-a117d05b7f35" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid insurance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-86176a02-fa62-4add-9632-410654d5ec12" name="us-gaap:PrepaidInsurance" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">874</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e02913c5-fe54-4306-95af-4c0bb5c7c186" name="us-gaap:PrepaidInsurance" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">662</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contract research organization and other deposits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-00cc27f4-dc7b-4563-9f16-1feb9b2b85ff" name="us-gaap:DepositContractsAssets" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,177</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-de2637a3-1ada-41a0-8f6f-8bb20dbc7af9" name="us-gaap:DepositContractsAssets" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,330</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-edf3fb1c-b91e-45e4-a032-8f4ae1a6e695" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">160</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-be70dda5-ccb4-41a2-86e2-fb6cd88a7b4d" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">53</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total prepaid expenses and other current assets</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-20e2932f-73f8-47fe-9156-a92faf5bb4ba" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,211</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3342a5ed-8cb2-4981-a4eb-9adaca2550ca" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">11,045</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-18a25781-5d13-4485-b049-a01adbb5021d-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:BusinessCombinationDisclosureTextBlock" id="ct-nonNumeric-b31f6ca2-63b2-4990-9937-ffa4c8e0b1dc" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-b31f6ca2-63b2-4990-9937-ffa4c8e0b1dc-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">4.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Real Property Acquisition</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-b31f6ca2-63b2-4990-9937-ffa4c8e0b1dc-continuation-0" continuedAt="ct-nonNumeric-b31f6ca2-63b2-4990-9937-ffa4c8e0b1dc-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On August 4, 2021, the Company completed the all-cash purchase of a two-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#8217;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are being outsourced to professional real-estate managers. The purchase price of the property was $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e768600e-cfe4-4a35-9186-e8059e43dea8" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="Duration_8_4_2021_To_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">22.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, including transaction costs. The office complex measures approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-50a9d6be-f489-494b-ae69-3289f6899eec" name="us-gaap:NetRentableArea" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit16" decimals="0" format="ixt:numdotdecimal">90,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> rentable square feet. At December 31, 2022, the property was over </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-171e4bb4-6cf4-4159-98e6-1ec68e14268f" name="sava:PercentageOfCurrentlyLeased" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">60</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% leased. The Company also occupied approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f0e60cc9-5622-47d9-a53a-4e24045106d6" name="sava:PercentageOfOccupancy" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">25</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the property as of December 31, 2022. The seller was a third party not affiliated with the Company.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The purchase was accounted for as an asset acquisition under ASC 805, Business Combinations. As substantially all of the fair value of the gross assets acquired were concentrated into a single identifiable asset, the Company concluded that the screen was met, and the transaction is considered an asset acquisition rather than an acquisition of a business. Pursuant to the cost accumulation method as prescribed in ASC 805, the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values. The value of acquired in-place leases is measured as the sum of lost revenues that would be incurred during a&#160;prospective lease-up period that would be necessary to achieve occupancy similar to that at the time of&#160;acquisition. The value is calculated as the average number of months of lease-up multiplied by the gross monthly market rental rate (base rent plus reimbursements) for each particular suite.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The assets acquired are summarized as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="ct-nonNumeric-0de8c33e-4c7f-41fa-8da0-b51529716c20" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.07in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.06in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Land</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85b85c05-85f5-4014-a78c-d203061e7e2d" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,734</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Buildings</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7b95ea96-bb03-4033-876f-129c9e17ca06" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,980</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Site improvements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d6696bdc-3414-4070-9496-9c22979979c1" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">453</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tenant improvements</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af65a15b-8d48-4f90-8dcb-85d562f70195" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">567</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total tangible assets</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a001de5e-b8e6-42f6-a822-1eda26123841" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20,734</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.16in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease-in-place agreements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7476b078-a628-40f0-a841-bd699bb762b3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,053</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasing commissions and other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-54f563c8-756b-4152-902c-b6e5ef9baa6e" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">246</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd5992b5-dc16-404d-950b-0b1f39e9b30a" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,299</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consideration paid</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-73e09a75-d37b-4e80-abf8-7780e5184e3c" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,033</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.06in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company records the net income from building operations and leases as other income, net, as leasing is not core to the Company&#8217;s operations. Building depreciation and amortization for space not occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">95</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-b31f6ca2-63b2-4990-9937-ffa4c8e0b1dc-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> were as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="ct-nonNumeric-6b0151ed-0135-4fc0-8671-80dd94a81713" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f1c498fa-cfa0-4d20-9e00-f7410db7291a" name="us-gaap:OtherNonoperatingIncome" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,459</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a673b6e4-8679-4126-bed8-6aeb7025db61" name="us-gaap:OtherNonoperatingIncome" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">911</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property operating expenses</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b566d1d3-20b3-4ff8-adb8-0b6a5bcff1b2" name="us-gaap:OtherNonoperatingExpense" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,462</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5705f9d8-6bb0-40bb-88f4-809dc16b2865" name="us-gaap:OtherNonoperatingExpense" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">477</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Other income, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5b84c109-74ad-47f5-ba66-8952ce4e5cb3" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">997</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7ef69bd8-57ad-4f04-8aa8-469ae0d89a15" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">434</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">      The Company had accrued property taxes related to the building totaling $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1b4aafa5-cfd2-4dc2-bc71-39e9524ffd2a" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">433,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c23af27c-63d5-4079-a970-6017d60523aa" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">450,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at December 31, 2022 and 2021, respectively, included in other current liabilities.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ct-nonNumeric-6c57fc52-32c9-49d9-81c2-1bbd4abd1cd9" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-6c57fc52-32c9-49d9-81c2-1bbd4abd1cd9-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">5.  Property and Equipment</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-6c57fc52-32c9-49d9-81c2-1bbd4abd1cd9-continuation-0" continuedAt="ct-nonNumeric-6c57fc52-32c9-49d9-81c2-1bbd4abd1cd9-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The components of property and equipment, net, as of December 31, 2022 and 2021 were as follows (in thousands): </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ct-nonNumeric-13525d58-dc28-4dad-9915-07b9882742f2" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.06in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Land</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-101c5c73-3b1e-45d8-b01d-0e3c20347264" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,734</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a9773c33-26dd-4014-b3cd-090c1e81d9bd" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,734</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Buildings</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ddfc58c7-c287-491f-9d72-0ddc0fd6aad3" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,980</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c5dd5f80-89ce-4b07-9680-7b58a629f161" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,980</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Site improvements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-83a68623-8e1d-46ff-8734-f1762cafe510" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">470</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e7c3b7f4-5d3b-4713-aa00-f1090e970bc8" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">470</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tenant improvements</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-abe6a0b6-57bd-4bc2-bcda-d441957703c1" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,016</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6f4c16b9-1a43-4078-a74e-41c26d7e7ceb" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">567</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-859d9d94-de3e-49f9-9ef3-9e31eca33800" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">851</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c162dc3c-010f-48ef-ab8c-ee99031c685c" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">178</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Construction in progress</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7ee05ae1-6540-42fd-acf4-5003e8294c47" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">13</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e0afd582-cdce-40ba-a682-e2de4542f1bc" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">83</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross property and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d1bc58d-7a48-4e09-89d3-273fba42cd42" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,064</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-950bbea4-f9ee-46b4-939d-d000b6659d8e" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">21,012</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated depreciation</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d3d0f58d-c7fb-4cdf-be1b-27f23dc2d3db" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,200</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-39a6cace-929d-4cdf-a8d2-30c3d65ad843" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">396</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Property and equipment, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-55a63b32-5ae2-4e0f-baca-c8b4e69e57dd" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,864</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fdeea608-5224-422c-a64e-01115895c43d" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">20,616</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.05in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation expense for property and equipment was&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c74a19d8-fcb4-458e-95fd-de3d2d0fb1f2" name="us-gaap:Depreciation" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">804,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d119fb45-fc30-4532-8e99-a428d8d1ebca" name="us-gaap:Depreciation" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">310,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;and&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-96ac4af8-b0d4-416a-9f3b-283f4f307b65" name="us-gaap:Depreciation" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">22,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;for the years ended&#160;December&#160;31, 2022, 2021&#160;and 2020, respectively.&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-32a0cf2d-df3c-463b-be14-626e135b68ad" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-08660c5f-4f57-4185-a1cc-1cfaa61725d6" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> sales of property and equipment during the years ended December 31, 2022 and 2021.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-6c57fc52-32c9-49d9-81c2-1bbd4abd1cd9-continuation-1"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the&#160;year ended&#160;December&#160;31, 2020, the Company sold surplus manufacturing equipment to an independent third party and received proceeds totaling $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-10127f1f-8cf9-48f5-96f7-ae6e996f7b99" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">360,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#160;The original&#160;cost of the property and equipment was </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9e28f4f4-46cf-41ff-99a2-47a88e8df2ac" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2020_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">892,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;and accumulated depreciation was $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1d6f715f-ff63-47cc-9b54-1b40b9b094e1" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="As_Of_12_31_2020_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">878,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">,&#160;resulting a gain on sale&#160;of property and equipment of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-16222dee-fff0-4e7b-be6e-46ad3633c00d" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">346,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;during the&#160;year ended&#160;December&#160;31, 2020.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">96</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ct-nonNumeric-f84b82a4-e30c-43e6-a632-fbb05b1d0722" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-f84b82a4-e30c-43e6-a632-fbb05b1d0722-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">6.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Intangible assets</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-f84b82a4-e30c-43e6-a632-fbb05b1d0722-continuation-0" continuedAt="ct-nonNumeric-f84b82a4-e30c-43e6-a632-fbb05b1d0722-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The components of intangible assets, net, as of December 31, 2022&#160;and 2021&#160;were as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="ct-nonNumeric-dd70f45a-ff01-4cc2-a5fb-2cde74438461" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.07in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr style="height: 0.20in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease-in-place agreements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ba09da73-b75c-43cc-8a02-b91190bd59cf" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,053</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-252584d4-0acc-4215-9aad-f3bd556fb636" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,053</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasing commissions and other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-395041a7-a9ca-4564-abab-e7b72464f3ac" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">290</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-14bb2bff-48c0-45f5-bfe1-2e87175ec85a" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">246</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-10902f56-c5ee-4505-8bf2-535c5a48270b" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,343</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a077a338-be8a-4582-a358-ad1d20b4b64d" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,299</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated amortization</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-968e1a65-327a-4951-9942-1ee306384319" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">721</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-969b16a9-ccc5-4d31-90f6-084aa271e6aa" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">224</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Intangible assets, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d13e9f80-55ec-49fc-a70d-bb3a1b7097df" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">622</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-196554f0-e17f-4e6a-86b0-3cee5d81ef99" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,075</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization expense for intangible assets was&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-487eafaa-2d6d-405a-8baf-95dd875bc787" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">497,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3cd31542-86e8-41e2-b7f8-d1ed717188e9" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">224,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the years ended&#160;December&#160;31, 2022 and 2021, respectively. There was </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-153fc9d8-76d0-413e-9ef3-02215c3a10f3" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> amortization expense for the year ended December 31, 2020.&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization expense for finite-lived intangible assets is expected to be as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="ct-nonNumeric-f7d84405-3f49-4940-a1e6-0adbd7fa8f5c" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.15in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.19in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">For the year ending December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a2925334-75cd-4fde-aa1d-1ab1307b68b9" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">451</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1c666267-c616-4f3a-9827-6daa76816e2a" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">167</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6375cc47-a267-4c0e-ae57-7c2886301626" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total amortization</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-175aec1b-3bcc-4492-8be7-f9afc2b9318f" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">622</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:continuation id="ct-nonNumeric-f84b82a4-e30c-43e6-a632-fbb05b1d0722-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ct-nonNumeric-fe191c47-3d57-4462-ab29-41a8de586fec" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-fe191c47-3d57-4462-ab29-41a8de586fec-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">7.  Stockholders&apos; Equity and Stock-Based Compensation</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-fe191c47-3d57-4462-ab29-41a8de586fec-continuation-0" continuedAt="ct-nonNumeric-fe191c47-3d57-4462-ab29-41a8de586fec-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Preferred Stock</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2022 Registered Direct Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November&#160;22, 2022, the Company completed a common stock offering pursuant to which certain investors purchased </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85b96dc5-164b-431f-bc60-31ed41848a4a" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,666,667</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock at a price of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d898e7c0-b889-471d-8fab-c97c119ca19c" name="us-gaap:SaleOfStockPricePerShare" contextRef="As_Of_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">30.00</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share. Net proceeds of the offering were approximately $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a1965f39-ebae-4d44-b75e-d197e15b3401" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">47.3</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million after deducting offering expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2021 Registered Direct Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On February&#160;12, 2021, the Company completed a common stock offering pursuant to which certain investors purchased </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4337d88b-019c-4b0e-918d-d86d5fba3554" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">4,081,633</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock at a price of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7761cb21-b883-4a80-9435-07511dabb2f3" name="us-gaap:SaleOfStockPricePerShare" contextRef="As_Of_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">49.00</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share. Net proceeds of the offering were approximately $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-46e59d54-f4eb-46af-af27-316d418cb3b2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">189.8</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million after deducting offering expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2020 Follow-on Public Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November&#160;13, 2020, the Company completed the sale of&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fa8543b0-b350-4d47-860c-ecd81432b78c" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_11_13_2020_To_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">9,375,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;shares of Cassava common stock in an underwritten public offering at a price of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-34301cf6-0003-46c2-928a-dd639023be5e" name="us-gaap:SaleOfStockPricePerShare" contextRef="As_Of_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">8.00</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;per share. The Company received net proceeds from the offering of&#160;approximately $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-30a21f3d-ecb6-47f6-8b05-662773804681" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_11_13_2020_To_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">70.3</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million&#160;after deducting underwriting discounts and offering expenses.</span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">97</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-fe191c47-3d57-4462-ab29-41a8de586fec-continuation-1" continuedAt="ct-nonNumeric-fe191c47-3d57-4462-ab29-41a8de586fec-continuation-2"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 106.7%;margin-bottom: 10pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Common Stock Warrants</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2018, the Company issued warrants to&#160;purchase up to an aggregate of&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f97acd70-45c2-44af-bdb9-65fd3df52931" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember" unitRef="Unit1" decimals="-5" format="ixt:numdotdecimal" scale="6">9.1</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million shares of its common stock in conjunction with an offering of its common stock.&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During 2021, the Company received proceeds of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e3228323-a347-47b9-add8-55e9296e6494" name="us-gaap:ProceedsFromWarrantExercises" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.7</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million from the exercise of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-691217d4-2c32-41b6-aaba-755698f4a7c7" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember" unitRef="Unit1" decimals="-5" format="ixt:numdotdecimal" scale="6">0.6</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million shares pursuant to common stock warrants. There were no common stock warrants outstanding following the 2021 exercises.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During 2020, the Company received proceeds of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-114eb582-e529-40ff-9199-5ab0cb1da877" name="us-gaap:ProceedsFromWarrantExercises" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">4.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million from the exercise of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2e4fb523-cbac-40ac-b7e9-81767737facf" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember" unitRef="Unit1" decimals="-5" format="ixt:numdotdecimal" scale="6">4.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million shares pursuant to common stock warrants.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">At the Market (ATM) Common Stock Issuance </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On March&#160;27, 2020, the Company established an at-the-market offering program (ATM) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7a3c28eb-d792-4a8c-9b65-5e95abd3a656" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="Duration_3_27_2020_To_3_27_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">100</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million&#160;in transactions pursuant to a shelf registration statement that was declared effective by the&#160;U.S. Securities and Exchange Commission (the SEC)&#160;on May&#160;5, 2020. The Company is obligated to pay a commission of&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85d08b6e-743d-4cab-8171-4f47f9c100ff" name="sava:PercentageOfCommissionAtmOffering" contextRef="As_Of_3_27_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">3.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%&#160;of the gross proceeds from the sale of shares of common stock in the offering. The Company is not obligated to sell any shares in the offering.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e6e41dd4-9232-4ea3-838a-b1199197311f" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-4dbf876c-1344-4eea-a7c6-0c56e3366ba5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-66017c5f-781d-4fe9-b8c9-b0dbd6ecd62f" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;common stock sales under the ATM during the years ended December&#160;31, 2022, 2021 and 2020.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2008 Equity Incentive Plan </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the Company&#8217;s </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2008 Equity Incentive Plan, or 2008 Equity Plan,</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2008 Equity Plan</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> expired in December 2017. Share-based awards generally expire </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-5d2cbf90-ec89-4cda-96dc-d9668e601cf1" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEightEquityIncentivePlanMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ten years</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> from the date of grant.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2018 Equity Incentive Plan </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s Board or a designated Committee of the Board is responsible for administration of the Company&#8217;s 2018 Omnibus Incentive Plan (the 2018 Plan) and determines the terms and conditions of each option granted, consistent with the terms of the 2018 Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the 2018 Plan, including grants of stock options and performance awards. Share-based awards generally expire </span><ix:nonNumeric name="sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" id="ct-nonNumeric-27c969f4-d975-4fef-8ed9-3dca57894823" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ten years</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> from the date of grant. The 2018 Plan, as amended on May 5, 2022, provides for issuance of up to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4f3fc0ac-e6ec-47b2-a351-fa2c047923c1" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock, par value $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6f0054dd-4fa1-4107-b4f0-f88a3bcec055" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember" unitRef="Unit13" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share, subject to adjustment as provided in the 2018 Plan. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company may then use its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">98</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-fe191c47-3d57-4462-ab29-41a8de586fec-continuation-2" continuedAt="ct-nonNumeric-fe191c47-3d57-4462-ab29-41a8de586fec-continuation-3"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock Options</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following summarizes information about stock option activity during 2022:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ct-nonNumeric-63efec09-be0f-477a-bd79-75354121fe7f" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Exercise Price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Remaining Contractual Term in Years</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Aggregate Intrinsic Value in Millions</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-614db9c0-a736-4850-a3d8-971dc2934f5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_12_31_2021" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,663,727</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9fea8806-fa49-42fb-8ad9-d24960ddbcce" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2021" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">11.56</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1e9c8125-38f1-458b-a39d-98e61f97e701" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">104,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5ba35cad-856d-4024-b794-e877ae04b93c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">36.50</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e2b0f4f4-3bcd-4465-94e4-5100f9944044" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">203,640</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-545f09eb-4f87-4a5d-b5b3-f307d9fe9e8e" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">15.56</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options forfeited/canceled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-74d22dbd-2b80-4747-ba09-2a833de81c50" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">34,639</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-23f5b4c1-0223-426e-b1b8-1414f9c822ea" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">20.59</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e79f5a9-15eb-4da8-b22b-2f4169f2bf47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,529,448</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-610ef7d9-33d5-4d19-b194-e8bcb033774a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">12.13</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-389c86fb-5523-4b97-a715-c651918e708f" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.94</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bea41aeb-f3c7-4633-893d-7c9644cb4540" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">49.6</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested and expected to vest at December 31, 2022</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f07a707c-5d7c-48e5-9f3c-2cdde068c025" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,529,448</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cdf6b801-4490-46c8-93e1-8b7bf4109fd5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="As_Of_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">12.13</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ct-nonNumeric-d4237110-ab31-47bd-829d-fc2d8f387a14" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.94</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9bba3571-8d5d-44ec-9f97-2a18107f66f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">49.6</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exercisable at December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7a64947c-96e2-40a2-9a6e-016be21ac4c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,270,464</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b9f3fead-4a2c-4af7-9e8b-c726e67f2424" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="As_Of_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">10.02</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ct-nonNumeric-8063abac-646b-4b60-bf8b-cf65f07f4224" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.43</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-55911beb-dd3e-41c1-937a-f880090909c2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">46.9</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Of the stock options exercised </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">during the year ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 31, 2022</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-db912761-56ae-46df-a405-f132120861d3" name="sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">94,399</ix:nonFraction></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stock options were net settled in satisfaction of the exercise price, with no cash proceeds received.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following summarizes information about stock options at December&#160;31, 2022 by a range of exercise prices:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.20in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="ct-nonNumeric-5c5ac3a3-396b-4357-8059-bd8b6eb0ffae" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="6" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options outstanding</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options exercisable</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">remaining</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td></tr><tr><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Range of exercise prices</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">outstanding</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">contractual</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">exercise</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> vested</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">exercise</span></p></td></tr><tr><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">From</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">To</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">life (in years)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">price</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b4a2b64b-cd9a-4d03-ad87-0f5a7bc3f630" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">0.95</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a5238fda-2a2a-4845-9350-b251609a7363" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">1.88</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fd7af10c-7aba-499b-87ef-1f6202403111" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">585,833</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-f07c81b3-41e3-4a10-8661-d533108bffa5" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.6</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a82fe05a-1a9b-4dcf-b7fa-74006b8a93c2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">1.51</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dcdd1a90-24d2-4251-b824-0f72386bd195" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">505,833</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c1f671f8-b9a6-49e0-a51b-9fb31da6383f" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">1.46</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ca3ed199-e0b7-4ac3-b18d-7ca6c1318742" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">3.24</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-953f8fd3-73e5-43ce-8d3a-0ec5992a6d16" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">3.24</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e022fa7-c680-44bc-9b66-ab5dcfdd491c" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">550,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-957a03eb-5e97-4dea-8f16-1941f1df09a7" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.0</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6b49feeb-1b76-464c-92a3-11e98a8ca8f5" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">3.24</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6ab502c-3f5f-427b-a2fe-902cf557f2d9" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">550,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-91c0302f-4aa0-4f6c-a324-f0810149c9d0" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">3.24</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e25fcced-62e3-4469-8da0-f42955169cc5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">4.09</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2c240e1d-2fd9-4adf-b8b7-c5e5c649ec4c" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">12.04</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-86bd5fe4-84f8-4223-9926-66173b60f2a3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">536,951</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-36ef09a2-bef3-4bb9-8861-216cbb079008" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.1</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-99f9729f-a144-4552-a888-d128ca7c904c" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">7.09</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a8eec33f-987e-4140-b8d4-cbdb1a203e77" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">512,888</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-721e97d1-766f-4639-b360-1cf408a5ab88" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">7.07</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-485b8914-1f35-454d-858a-1205515a3d7f" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">12.39</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8a9eba69-f398-4b79-9412-767bbbae378d" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">35.00</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c385d4f8-28d2-4efb-b412-38a237774108" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">655,874</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-020c166b-6ec5-4998-99ee-f90657dc2510" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.6</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bcda7541-3abf-49bb-bfc4-6d673021fedd" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">20.82</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-533360fa-0e4c-46ac-864f-e06d9ed6b246" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">653,290</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cfeb4888-813f-41c1-a383-8b80271f32f4" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">20.79</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-73caf96b-a770-483b-bc03-e13ebc9b6775" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">36.40</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-08484b4c-b816-48cc-ab69-25fe7e925997" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">77.00</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f398eda0-be55-4a38-9f11-0c5e90b29179" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">200,790</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-24180801-3b27-4956-bdc0-3c0c860f750a" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8.8</span></ix:nonNumeric></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e43e0098-b7a2-4254-b152-471ec33e443d" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">52.64</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd8e0392-a957-4750-84a0-08eb68dc31ef" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">48,453</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-96385b58-c4c0-47e7-b277-bd8e78b0ce0a" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">62.61</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-76a8ea2a-c0be-428b-8f86-b87117e70667" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,529,448</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="ct-nonNumeric-dea42c07-e3a1-4bc4-a231-2bf20f1deb6b" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.9</span></ix:nonNumeric></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d956d13c-aa3c-46f9-aab2-2dad396449ba" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="As_Of_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">12.13</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8b259ad0-eff4-480c-96c9-bb21656691fc" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,270,464</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-15665781-2619-4f88-bd8c-e63dd21b035d" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="As_Of_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">10.02</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#8217;s common stock. Factors utilized in Black-Scholes to value each stock option granted, and the weighted average fair value of options granted during the years ended December 31, 2022, 2021 and 2020 were as follows:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="ct-nonNumeric-0f4343df-3399-4923-9c67-6364769d50fd" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Volatility</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4f4e7e34-5770-40c1-a5e9-0d67dabcd1b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">151</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1ca82d12-3cc9-416b-a44f-1cac61291460" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">154</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6b7008e3-3dcf-4904-bf88-97e08fd13648" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">147</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5cc4ba6f-c49e-4f1d-9f04-73a12de124ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">151</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-02c2cdda-671b-4273-babd-61a0f3c03fa4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">123</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c288c2cb-1878-465f-9547-1f482e82e117" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">139</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rates</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-037e8ee1-ebe7-4f5a-a57f-7c91575adbe0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">1.98</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ced9831c-e09b-4b4d-ba66-015f45fe289c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">3.69</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-069f93c7-5959-4d7a-ab15-9acb90a6ed5b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">1.12</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-faa367c5-ef9c-41ac-9687-d5bf7ded7bf8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">1.42</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ba91c2b6-2f7e-4643-9682-28fe2c1b78a5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">0.46</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1f4f6dff-2b6d-467b-a8ba-b6f4e6ab9996" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">0.78</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected life of option</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-1c6168b5-34e9-48b4-b157-f44bad1aba73" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.0</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-f78c36f0-cff4-401f-a7aa-cc7785fbfd88" contextRef="Duration_1_1_2021_To_12_31_2021" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.0</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ct-nonNumeric-144576a7-246c-480b-b616-21b917fc3d8a" contextRef="Duration_1_1_2020_To_12_31_2020" format="ixt-sec:duryear"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ea05144a-3b48-4e01-ae7e-7c848b16f1dd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-85841b41-71dc-43db-bd8f-fbd7288d5723" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a2166f1d-e011-455a-b51b-02a1eed5f816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Forfeiture rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-124314ad-9a65-4306-bb81-1c679be346db" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-93785624-a98c-4863-ace9-4243b76afe20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-98ecec7e-3925-4e8b-8f66-578ed9359a3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average fair value of stock options granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8b9a0f01-1c22-40f2-bd3f-b024743a2579" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">35.16</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-25d4dd4c-3d1f-4483-b434-141c5322e098" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">65.83</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ec0923f8-e589-4e5c-8a89-679c1fc83446" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2" format="ixt:numdotdecimal">6.69</ix:nonFraction></span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Volatility</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> is based on reviews of the historical volatility of the Company&#8217;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-91538564-2898-474b-8eb4-53270662e6d1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> because the Company does not anticipate paying cash dividends in the foreseeable future. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2022, the Company expects to recognize compensation expense of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2b48f971-bf6c-411b-a62e-c47585db6035" name="sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">7.7</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of </span><ix:nonNumeric name="sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" id="ct-nonNumeric-429736d4-9597-4457-8e33-6dcd88d5b105" contextRef="Duration_1_1_2022_To_12_31_2022" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.4</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">99</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-fe191c47-3d57-4462-ab29-41a8de586fec-continuation-3"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Performance Awards</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following summarizes information about performance award activity during 2022:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="ct-nonNumeric-187aff0a-8746-44d8-a385-c7f81a8bdcdc" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Performance Awards</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-325f6f2d-ab8c-47de-9bad-05d03f583253" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">138,055</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0a18ef04-da81-4da9-b08e-4f541d5d87fe;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a9cc683b-ce22-4d24-8a07-e6387b6743b3;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Forfeited/canceled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3b80978d-9ed8-4227-8c3e-217af6375c7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">130,913</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-28ffea1b-7d01-400a-82d3-fae1727d92f6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">7,142</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the year ended December 31, 2022, a total of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ed67067e-941a-440a-83f8-15000ef9af9c" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">57,143</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of restricted stock awards expired as performance criteria related to these Performance Awards were not attained. These shares of restricted stock were returned to the 2008 Equity Incentive Plan, which expired in December 2017, and thus were retired.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If and when outstanding performance awards vest, the Company would recognize $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b1582fa5-e049-4755-8e94-a916169286e3" name="sava:ShareBasedCompensationAdditionalExpenseExpectedOnVesting" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">101,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in stock-based compensation expense. These performance awards expire in </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-11a67b5d-6030-4b4a-89e9-be45bb42951d;">2026</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock-Based Compensation Expense</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following summarizes information about stock-based compensation expense, in thousands:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ct-nonNumeric-1fe6736b-1805-4676-9fb3-f11a9454bb96" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1befe707-ef22-4754-9682-cb9e151737d0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,631</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9764814d-630e-4be0-abec-2d5bab33940a" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,302</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3a2b282f-ee32-457c-8c58-5028a44c697c" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">453</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c6ada0a0-2a4a-41d4-a33d-5c27a485e70f" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">435</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a381da7a-3543-4dc7-b9d0-6b260bc97edb" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">457</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0f7cce0e-abfc-4b54-86e5-f6d0b91c79c3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">535</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-583abf75-2fa4-40ca-96cc-e8b0229d30f4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,066</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d8531b16-08b8-4dfa-b965-0ae8ead360f8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,759</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4cc65d1b-cbf2-4357-8b4b-2c19419b9dc0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">988</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ct-nonNumeric-eb462ad9-e21b-49ea-9aa0-95ab9b310389" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-eb462ad9-e21b-49ea-9aa0-95ab9b310389-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">8.  Employee 401(k) Benefit Plan</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-eb462ad9-e21b-49ea-9aa0-95ab9b310389-continuation-0" continuedAt="ct-nonNumeric-eb462ad9-e21b-49ea-9aa0-95ab9b310389-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the first day of the month after hire and may contribute up to the current statutory limits under Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through December&#160;31, 2022, the Company has not made any matching contributions to the 401(k) plan.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-eb462ad9-e21b-49ea-9aa0-95ab9b310389-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="ct-nonNumeric-4970a9c1-6a35-40d2-a23c-48fc4d996827" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-4970a9c1-6a35-40d2-a23c-48fc4d996827-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">9.  Income Taxes</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-4970a9c1-6a35-40d2-a23c-48fc4d996827-continuation-0" continuedAt="ct-nonNumeric-4970a9c1-6a35-40d2-a23c-48fc4d996827-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company did not provide for income taxes during the periods presented because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">100</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <ix:continuation id="ct-nonNumeric-4970a9c1-6a35-40d2-a23c-48fc4d996827-continuation-1" continuedAt="ct-nonNumeric-4970a9c1-6a35-40d2-a23c-48fc4d996827-continuation-2"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate for periods presented was as follows:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ct-nonNumeric-6db2ddf8-4661-44cf-8708-4db62a59cba7" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="7" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Year ended December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tax at federal statutory rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-05828735-d665-4be7-9707-acf998869f00" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">21.0</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-770bf994-aa31-4613-a9aa-5effd3084853" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">21.0</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eace7967-552e-490d-9681-9f9acbff5d83" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">21.0</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">State tax, net of federal benefit</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-2bbe3c9f-b94d-448f-b6dc-323b380f9a96;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-372e6af5-4c00-48eb-bae0-4471ae3a22e5;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Share-based compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5dc16046-dcfa-405e-a1f9-3904123016a5" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2" sign="-">0.5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5b347b1d-4b05-473d-9dda-626b790874f5" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">1.2</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-23b04828-08cb-4bdc-aa99-8167f826bde4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2" sign="-">42.8</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development credits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4c5a648b-d1d2-4854-a994-76f04784346f" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">4.9</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ec2b8eb6-129b-4184-b120-184411908a71" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">2.3</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d6652729-fc34-4bd2-917d-1d3410ff0bba" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">1.6</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Section 162(m) limitation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ccfb138b-82fc-4cf6-a5f5-0abc844150f2" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2" sign="-">0.2</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9a302206-62a3-4969-9111-84160872802e" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2" sign="-">0.5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c5477bfe-2785-4f75-a69d-a809395650e8;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6bb28270-be33-48fc-8a0a-7da9516fab68" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2" sign="-">1.8</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f2502e2f-8b46-4d2d-b187-f46c15e854c4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2" sign="-">0.2</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-6454e79f-5eac-4ce6-b83d-d54ce1ad34ec;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in valuation allowance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c74b22be-823d-4645-b96d-a6f7011dc0b8" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2" sign="-">23.4</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-238c73cb-f21f-439d-8fb7-4ddb630d6010" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2" sign="-">23.8</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d224b327-41a7-4056-a6f6-2f398e342d31" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit15" decimals="3" format="ixt:numdotdecimal" scale="-2">20.2</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Effective income tax rate</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eedb89d9-ad7e-4f41-a736-d7fd924e0c16;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eb885844-bf4c-4fb5-ba17-aadb840ba669;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Deferred tax assets and valuation allowance</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.21in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred taxes assets at December&#160;31, 2022 and 2021 were valued at the corporate tax rate of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-512360f3-a0e9-412e-8caf-88d84d0091bf" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2"><ix:nonFraction id="ct-nonFraction-86138e63-b258-4566-9182-d5e0b4d536d6" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">21</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ct-nonNumeric-7bab1450-6747-4e5c-bddc-1839bb13385a" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net operating loss carryforwards</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2c400d71-1d73-4f72-aba8-128736a65bab" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">28,017</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c7b59538-d88a-475c-a0c4-7d3041b314da" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,777</ix:nonFraction></span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Share-based compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a89b4086-5d13-4765-9082-706305607fe9" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,706</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-92a5f4c5-b255-4434-8a87-6d35626fd7b8" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,870</ix:nonFraction></span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development credit carryforwards</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-28b0fba5-aede-449e-9aa3-6d2ac08812aa" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,681</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2cc5ed68-b7e1-4cc7-9a11-7fdb68f6c8b0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,439</ix:nonFraction></span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Capitalized research and development expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cb474522-9f3a-4fea-a592-ad287b2e0661" name="sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">12,690</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-de6cc757-c8de-42c3-99b4-15243e637ef0;">&#8212;</span></span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d9add9a6-ca18-4013-bd2a-597851bcc818" name="us-gaap:DeferredTaxAssetsOther" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">934</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ea4b0b2d-6229-4528-a368-30e2cf68ea35" name="us-gaap:DeferredTaxAssetsOther" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,130</ix:nonFraction></span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a0bc4198-e96f-4759-9566-1b736b88d8f4" name="us-gaap:DeferredTaxAssetsGross" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">54,028</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a77341f7-2752-45a3-8dd1-321a9b12f5a7" name="us-gaap:DeferredTaxAssetsGross" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">36,216</ix:nonFraction></span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Valuation allowance</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fd428678-627c-4036-b813-0117bd660799" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">54,002</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-84df3fa3-44ce-4b23-b77b-41d491212598" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">36,166</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net deferred tax assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-096789b9-2ee9-4fc0-b482-3ae19eaf74e2" name="us-gaap:DeferredTaxAssetsNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">26</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4eb5ce08-9d3a-406a-b72c-716b4261c4e9" name="us-gaap:DeferredTaxAssetsNet" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">50</ix:nonFraction></span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax liabilities:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use assets</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a8db1f78-d191-447e-8ecf-5e7493d90a61" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">26</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1a73e784-49c5-43d8-a4d9-39266596296f" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">50</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax liabilities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f3069435-b6cd-4462-afef-ca003bf23ee7" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">26</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fdc0a5f9-cec7-4afe-81b5-763c5cf6b5b2" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">50</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net deferred tax asset (liability)</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-1da80672-2d90-4cfe-a52c-83cd81fc610f;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c36d2911-beed-46e5-a06d-8fb8d4dd3d41;">&#8212;</span></span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The valuation allowance increased by $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-08732002-8220-487c-bbe0-f0aadaa41240" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">17.8</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c477692f-65b9-495f-9ba4-b012b9960dec" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">7.7</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in 2022 and 2021, respectively, due primarily to continuing operations.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s net operating loss carryforwards of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3ab76bf4-d2e8-41b0-bd3b-08392eb1a230" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">133.4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million are federal, of which $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9aceb2d6-b2d0-484c-b360-638be7944dbd" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">74.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million expires between </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-ab3e4de0-d223-4a28-a263-17c41929c12c;">2029</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-c9c2841b-7ede-4662-83a9-7a4f7dcefb27;">2037</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-31de5752-836b-4ade-8f6f-dfb4016e442c" name="us-gaap:OperatingLossCarryforwards" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_IndefinitelyMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">43.9</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million carries forward indefinitely. As of December&#160;31, 2022, the Company had federal research and development tax credits of approximately $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f0862a77-8211-4e43-9446-94e6016e95a2" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">16.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million, which expire in the years </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-8869304f-1756-4722-a383-48272eaadb6a;">2024</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> through </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-16a796f0-25d3-4e27-b50c-84d331cdfb35;">2042</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">101</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><ix:continuation id="ct-nonNumeric-4970a9c1-6a35-40d2-a23c-48fc4d996827-continuation-2" continuedAt="ct-nonNumeric-4970a9c1-6a35-40d2-a23c-48fc4d996827-continuation-3"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Unrecognized tax benefits</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2022, 2021 and 2020, the Company has unrecognized tax benefits related to tax credits of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6f0ba0cd-99a7-4b6d-afc5-a66c326af4df" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">6.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">million, $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f48c473d-f16b-4c48-89ce-2fd620763edd" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">5.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c65eb66c-076d-4d91-8def-41c6f21f17ca" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">4.5</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million, respectively. None of the unrecognized tax benefits as of December&#160;31, 2022, if recognized, would impact the effective tax rate due to the valuation allowance and no interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="ct-nonNumeric-ae9616d1-9300-4506-9fdc-e39e0e2ccc80" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Beginning balance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f2c5ed6b-c2b5-4b7d-8d38-4a3ae55e2a5e" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,001</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-99636fce-9848-4b06-bec1-e2aa62effd50" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,500</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-83316d41-4267-4504-8516-78ca2beca4c2" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,400</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additions based on tax positions related to the current year</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6c35c35-a4b1-4225-a201-525648bb2fe9" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,495</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-59380b4a-b222-4a18-864d-35d6740fd554" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">501</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-16d12c67-c6a0-44b6-b7b0-9677e66c959a" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">100</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ending balance</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-273a62d6-8ae7-4b28-b4c0-043cf5f089f1" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,496</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-557d0091-698a-4f1b-b216-803d684cb88d" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,001</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f84dc899-c278-4dc6-9c5d-e6731bb78de4" name="us-gaap:UnrecognizedTaxBenefits" contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,500</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2022, there were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c785dbcf-8fab-4b4f-a8da-a0e33e40b80e" name="sava:UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> unrecognized tax benefits that we expect would change significantly over the next 12 months.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after 2018&#160;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2019 tax year and make adjustments to these net operating loss carryforwards.&#160;We are not under audit in any taxing jurisdiction at this time.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:continuation id="ct-nonNumeric-4970a9c1-6a35-40d2-a23c-48fc4d996827-continuation-3"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="sava:LeasesAndCommitmentsDisclosureTextBlock" id="ct-nonNumeric-70637d9d-7131-4edb-a4ae-5292f4805fcf" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-70637d9d-7131-4edb-a4ae-5292f4805fcf-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">10.  Leases and Commitments</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-70637d9d-7131-4edb-a4ae-5292f4805fcf-continuation-0" continuedAt="ct-nonNumeric-70637d9d-7131-4edb-a4ae-5292f4805fcf-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Right-of-use Asset and Liability</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company had an operating lease for approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-51413079-b865-4116-9b06-b1ae6279291f" name="us-gaap:NetRentableArea" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember" unitRef="Unit16" decimals="0" format="ixt:numdotdecimal">6,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> square feet of office space in Austin, Texas expiring </span><ix:nonNumeric name="us-gaap:LeaseExpirationDate1" id="ct-nonNumeric-db7161e2-6717-4f81-bdaa-c8e4e20d9cc7" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember" format="ixt:datemonthdayyearen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">April 30, 2024</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company terminated this lease on February 22, 2023 with no continuing obligations. The Company also had a short-term lease agreement for an additional </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f825b0dc-b233-442e-80d2-9b66d9754821" name="us-gaap:NetRentableArea" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_ShortTermOperatingLeaseMember" unitRef="Unit16" decimals="0" format="ixt:numdotdecimal">3,600</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> square feet of office space in Austin, Texas that expired on </span><ix:nonNumeric name="us-gaap:LeaseExpirationDate1" id="ct-nonNumeric-2f6597e9-62b7-4a05-bdfd-0519c3125615" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_ShortTermOperatingLeaseMember" format="ixt:datemonthdayyearen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">October 31, 2022</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Future expected minimum lease payments as of </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 31, 2022 are as follows (in thousands).</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ct-nonNumeric-bb85bf59-c283-4c6b-b84a-3610832a7bee" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2024</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total future lease payments</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: imputed interest</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating leases</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f1fb7a40-051a-41b0-a070-59834be44be3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">107</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-004842da-4eca-415f-a4f1-4555207a8157" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">36</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-88874d70-ae89-4455-952d-67bf8d97072d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">143</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-65e6ffbb-343c-41a8-937d-c6f8e164710b" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d3f2104f-f154-4734-a8d6-ca96f74c68b8" name="us-gaap:OperatingLeaseLiability" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">139</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Rent expense was $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e59e2aba-c27d-496a-b0c6-59474873565c" name="us-gaap:OperatingLeaseExpense" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6"><ix:nonFraction id="ct-nonFraction-a4860d12-7173-44c7-a72b-42429832a6cf" name="us-gaap:OperatingLeaseExpense" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6"><ix:nonFraction id="ct-nonFraction-ffc18f3f-320e-4a0a-8b63-bf58759f32e6" name="us-gaap:OperatingLeaseExpense" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million for the years ended December&#160;31, 2022, 2021 and 2020.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cf37052b-4902-4d9d-b130-7033ea4678b9" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction id="ct-nonFraction-01cb266d-9f03-473e-8be8-6deb5f7dd63a" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> right-of-use assets exchanged for operating lease liabilities during the years ended December&#160;31, 2022 and 2021. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recorded a&#160;right-of-use asset and lease liability&#160;of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d8e67df-ba3a-4c70-813f-963f8998f422" name="us-gaap:OperatingLeaseLiability" contextRef="As_Of_9_30_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-3e290909-3b9e-40ff-85f2-417ba55a2ab2" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="As_Of_9_30_2020" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">316,000</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;as a result of the lease&#160;modification in September 2020. The Company utilized a discount rate of&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37ee9d93-5237-437b-ae66-24f424f0a637" name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="As_Of_9_30_2020" unitRef="Unit15" decimals="4" format="ixt:numdotdecimal" scale="-2">3.25</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%&#160;for the modified lease&#160;to determine the present value of the future lease payments, which&#160;approximated the Company&#8217;s incremental borrowing rate&#160;in September 2020. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash paid for operating lease liabilities totaled $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ca03f64d-5f2f-4ff7-88b4-2b6efdbc1379" name="us-gaap:OperatingLeasePayments" contextRef="Duration_1_1_2022_To_12_31_2022" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">155,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7a734641-b2ff-4bf0-b20f-c9d767e04831" name="us-gaap:OperatingLeasePayments" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">109,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f5bbdb59-efa5-4d76-86cd-a1da0e227acd" name="us-gaap:OperatingLeasePayments" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">99,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Other Commitments</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations that are generally cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-70637d9d-7131-4edb-a4ae-5292f4805fcf-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">102</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="sava:CashIncentiveBonusPlanTextBlock" id="ct-nonNumeric-e2bc515a-4a20-446c-8360-0d5b4f55036d" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-e2bc515a-4a20-446c-8360-0d5b4f55036d-continuation-0"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 11.&#160; 2020 Cash Incentive Bonus Plan</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-e2bc515a-4a20-446c-8360-0d5b4f55036d-continuation-0" continuedAt="ct-nonNumeric-e2bc515a-4a20-446c-8360-0d5b4f55036d-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2020, the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has not occurred&#160;as of December&#160;31, 2022.&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (1) the Company&#8217;s closing price&#160;of one share&#160;on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (2) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;This constitutes a market condition under applicable accounting guidance.&#160; &#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-09852ce1-8342-4a24-9c8c-a2b6bf42d642" name="sava:PerformancePlanValuationAmount" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-9" format="ixt:numdotdecimal" scale="9">5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion in market capitalization. The Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af5b6656-ff6e-49a7-af5e-255b4be29a80" name="sava:PerformancePlanValuationAmount" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">200</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million and&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-13e3ccb1-6188-40c1-b35f-d78ad0d4af72" name="sava:PerformancePlanValuationAmount" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-9" format="ixt:numdotdecimal" scale="9">5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for no less than 20 consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f2cfa301-0013-4806-b589-fb22da11fe6f" name="sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" scale="-2">58</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;not awarded by the Compensation Committee&#160;are&#160;no longer available for distribution.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the Company were to exceed a $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dbc6feeb-e30b-4979-80e3-0bf5b1731979" name="sava:PerformancePlanValuationAmount" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" unitRef="Unit12" decimals="-9" format="ixt:numdotdecimal" scale="9">5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a679747e-4d03-47bc-9506-b907b63cab91" name="sava:CashIncentiveBonusAward" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">139.1</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-65ab2afb-b52c-4b5c-a2d9-7f4883ff97db" name="sava:CashIncentiveBonusAward" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">322.3</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(1)&#160;the Company completes a Merger Transaction, or&#160;(2)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which may ever occur. Accordingly, there can be no assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2020, the Company&#160;achieved&#160;the first&#160;Valuation&#160;Milestone.&#160;Subsequently, the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-76631a41-9484-40d3-a12c-a86eacbcb6d9" name="sava:CashIncentiveBonusAward" contextRef="As_Of_10_13_2020_srt_StatementScenarioAxis_sava_FirstValuationMilestoneMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">7.3</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million&#160;in total&#160;for&#160;all Plan participants, subject to future satisfaction of a Performance Condition.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the year ended December&#160;31, 2021, the Company achieved 11 additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ad89e709-c03e-4f15-9a5c-3c09a2a8eafc" name="sava:CashIncentiveBonusAward" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">93.7</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million up to a hypothetical maximum of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d39829e5-9ac6-4216-8f2d-46317fab5f1e" name="sava:CashIncentiveBonusAward" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">225.0</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million, to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b50cd431-73df-440c-9ee4-787ea34cef34" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;compensation expense has been recorded&#160;since no&#160;grant date has occurred and no&#160;Performance Conditions are considered probable of being met.&#160;There is no continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award. No Valuation Milestones were achieved during the year ended December 31, 2022.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-e2bc515a-4a20-446c-8360-0d5b4f55036d-continuation-1"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-12408f97-4b91-44f7-aab3-2952ff9c7b6b" name="sava:PaymentsForCashIncentiveBonus" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt-sec:numwordsen" scale="6">No</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> actual cash payments were authorized or made to participants under the Plan through December&#160;31, 2022.</span></ix:continuation></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">103</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:LossContingencyDisclosures" id="ct-nonNumeric-c127bef2-8f16-4e01-97e3-69add10db656" contextRef="Duration_1_1_2022_To_12_31_2022" escape="true" continuedAt="ct-nonNumeric-c127bef2-8f16-4e01-97e3-69add10db656-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">12. Contingencies</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-c127bef2-8f16-4e01-97e3-69add10db656-continuation-0" continuedAt="ct-nonNumeric-c127bef2-8f16-4e01-97e3-69add10db656-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Securities Class Actions and Shareholder Derivative Actions</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Between August 27, 2021 and October 26, 2021, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-97ad0bc8-198a-4b40-aa58-75a44ebba487" name="us-gaap:LossContingencyNewClaimsFiledNumber" contextRef="Duration_8_27_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember" unitRef="Unit14" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA, and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On June 30, 2022, a federal judge consolidated the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a6851846-5f29-47d7-b706-a1ccf752d79f" name="us-gaap:LossContingencyNewClaimsFiledNumber" contextRef="Duration_8_27_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember" unitRef="Unit14" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> class action lawsuits into </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-448ff494-24d5-4521-9728-140dafab8bfa" name="sava:NumberOfClassActionsConvertedToCase" contextRef="Duration_6_30_2022_To_6_30_2022_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember" unitRef="Unit14" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on August 18, 2022 on behalf of a putative class of purchasers of our securities between September 14, 2020 and July 26, 2022. Briefing on defendants&#8217; motion to dismiss was completed on January 23, 2023.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> The Company believes the claims are without merit and intend to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 4, 2021, a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s board of directors. This complaint relies on allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiff in this derivative case does not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since November 4, 2021, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f7bf8a1c-6f90-40d5-b17d-5121c71fb128" name="us-gaap:LossContingencyNewClaimsFiledNumber" contextRef="Duration_11_4_2021_To_11_4_2021_srt_LitigationCaseAxis_sava_ShareholderDerivativeActionsMember" unitRef="Unit14" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, and one in Texas state court (Travis County District Court). </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All four actions have</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> been stayed pending the resolution of the motions to dismiss in the securities class actions. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On July 5, 2022, the three federal court actions were consolidated into a single action.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s board of directors. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the 2020 Cash Incentive Bonus Plan in August 2020. The complaints seek unspecified compensatory damages and other relief. On January 6, 2023, the plaintiffs filed an amended complaint. Although the plaintiffs in this derivative case do not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-c127bef2-8f16-4e01-97e3-69add10db656-continuation-1"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">104</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 9.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span><span id="Changes_And_Disagreements" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 9A.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Controls and Procedures</span><span id="Controls_And_Procedures" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Evaluation of disclosure controls and procedures.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission, or SEC, rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosures.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Management&#8217;s annual report on internal control over financial reporting.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Our management has assessed the effectiveness of internal control over financial reporting as of December&#160;31, 2022. Our assessment was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-Integrated Framework (2013 Framework). </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(1)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(2)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and board of directors; and </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(3)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Based on the COSO </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">criteria, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">we believe our internal control over financial reporting as of December&#160;31, 2022 was effective.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Changes in internal control over financial reporting.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There was no change in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2022&#160;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The effectiveness of our internal control over financial reporting as of December 31, 2022 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">105</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Report of Independent Registered Public Accounting Firm</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">To the Stockholders and the Board of Directors of Cassava Sciences, Inc.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Opinion on Internal Control Over Financial Reporting</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have audited Cassava Sciences, Inc.&#8217;s internal control over financial reporting&#160;as of December 31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our&#160;opinion, Cassava Sciences, Inc. (the Company) maintained, in all material respects, effective&#160;internal control over financial reporting&#160;as of December 31, 2022, based on the COSO criteria.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">consolidated balance sheets of Cassava Sciences, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, stockholders&apos; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and our report dated February 28, 2023 expressed an unqualified opinion thereon.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Basis for Opinion</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s management is responsible for maintaining effective&#160;internal control over financial reporting&#160;and for its assessment of the effectiveness of&#160;internal control over financial reporting&#160;included in the accompanying </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Management&apos;s Annual Report on Internal Controls over Financial Reporting</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective&#160;internal control over financial reporting&#160;was maintained in all material respects. </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our audit included obtaining an understanding of&#160;internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our&#160;opinion.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Definition and Limitations of&#160;Internal Control Over Financial Reporting</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 12pt;text-align: justify;vertical-align: baseline;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;vertical-align: baseline;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;vertical-align: baseline;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;vertical-align: baseline;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;vertical-align: baseline;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ Ernst &amp; Young LLP </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">106</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Austin, Texas</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2023</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="_DV_C126" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">107</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Item 9B.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Other Information</span><span id="Other_Information" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 9C.    </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspecti</span><span id="ForeignJurisdictions" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">on</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART III</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 10.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Directors and Executive Officers and Corporate Governance </span><span id="_DV_M860" style="text-decoration: none;"></span><span id="Directors_And_Executive_Officers" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The information regarding our directors (other than the biographies below), executive officers, director nomination process and the audit committee of the Board is incorporated by reference from &quot;Directors and Executive Officers&quot; in our Proxy Statement for our 2023 Annual Meeting of Stockholders.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Biographies of Directors and Executive Officers</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Remi Barbier</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Company&#8217;s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company&#8217;s inception in 1998. </span><span style="white-space:pre-wrap; color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc., a publicly-traded drug development company, ArQule, Inc., a drug development company acquired by Merck &amp; Co., and EnzyMed, Inc., a chemistry company acquired by Albany Molecular Research, Inc. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington, the Santa Fe Institute, the Advisory Board of the University of California Institute for Quantitative Biosciences</span><span style="white-space:pre-wrap; color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and a life science incubator at the University of Arkansas for Medical Sciences</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">R. Christopher Cook</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> has served as Senior Vice President and General Counsel since October 2022. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">He previously served, since 2017, as the Global Head of Litigation and Government Investigations for Alcon, a publicly traded medical device and pharmaceutical company, as well as the Vice President and division General Counsel for Walmart Central America in San Jose, Costa Rica. Chris also spent seventeen years at Jones Day, where he was a litigation partner in the firm&apos;s Washington, DC and Chicago offices. Chris served as an Assistant United States Attorney in Chicago and graduated from Harvard Law School.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">James W. Kupiec, M.D.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> has joined the Company in January 2021 as Chief Clinical Development Officer and has served as our Chief Medical Officer since December 2022. Dr. Kupiec joined the Company </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">after three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy. Dr. Kupiec previously served as Vice President, Global Clinical Leader for Parkinson&#8217;s Disease and Clinical Head of the Neuroscience Research Unit for Pfizer, Inc., in Cambridge, MA. He joined Pfizer in 2000 after seven years with Sanofi, and two years with Ciba-Geigy Pharmaceuticals. During his 17-year career at Pfizer, Dr. Kupiec had extensive governance, business development, alliance and leadership responsibilities. Dr. Kupiec earned his BS with Honors in Biochemistry at Stony Brook University and his MD from the Albert Einstein College of Medicine. He completed his residency training at the Strong Memorial Hospital, University of Rochester School of Medicine, and is certified by the American Board of Internal Medicine. He served as an investigator on many clinical trials before transitioning to the pharmaceutical industry.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Eric Schoen</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> has served as Chief Financial Officer since 2018. Prior to joining the Company, Mr. Schoen served in numerous financial leadership roles. Most recently, he served as Vice President, Senior Vice President, Finance and Chief Accounting Officer of Aspira Women&#8217;s Health Inc. (formerly Vermillion, Inc.), a publicly-held women&#8217;s health company, from 2011 to 2017. Mr. Schoen also began his career and spent nine years with PricewaterhouseCoopers in the audit and assurance, transaction services and global capital markets practices. Mr. Schoen received his B.S. in Finance from Santa Clara University.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Richard J. Barry</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> has served as a director since June 2021. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Since June 2015, Mr. Barry has also served as a director of Sarepta Therapeutics, Inc., (Nasdaq: SRPT). Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC, and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. Mr. Barry holds a Bachelor of Arts from Pennsylvania State</span><span style="white-space:pre-wrap; color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">University.</span><span style="white-space:pre-wrap; font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">108</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Robert Z. Gussin, Ph.D</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. has served as a director since 2003. Dr. Gussin worked at </span><span style="white-space:pre-wrap; color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Johnson &amp; Johnson</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for 26 years, most recently as Chief Scientific Officer and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Corporate</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Vice President, Science and Technology from 1986 through his retirement in 2000. Dr. Gussin served on the board of directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Michael J. O&#8217;Donnell, Esq</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. has served as a director since 1998. Mr. O&#8217;Donnell has been a partner in the law firm of </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Orrick, Herrington &amp; Sutcliffe LLP since June 2021. Orrick, Herrington &amp; Sutcliffe LLP is </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the Company&#8217;s corporate counsel and provides legal services to the Company. Previously, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Mr. O&#8217;Donnell was a member of Morrison &amp; Foerster LLP from 2011 to 2021. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Mr. O&#8217;Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. </span><span style="white-space:pre-wrap; color: #0A0A0A;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Previously, Mr. O&#8217;Donnell was a member of Wilson Sonsini Goodrich &amp; Rosati.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Mr. O&#8217;Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Sanford R. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Robertson</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> has served as a director since 1998. Mr. Robertson has been a partner of Francisco Partners, a technology buyout fund, since 1999. Prior to founding Francisco Partners, Mr. Robertson was the founder and chairman of Robertson, Stephens &amp; Company, a technology investment bank sold to BankBoston in 1998. Mr. Robertson is the lead director of Salesforce.com, a publicly-held provider of enterprise cloud computing applications. Mr. Robertson received his B.A. and M.B.A. degrees with distinction from the University of Michigan.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.01in;margin-top: 0;text-align: justify;text-indent: 0.19in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Patrick J. Scannon, M.D., Ph.D.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> has served as a director since 2007. Dr. Scannon is one of the founders of XOMA. From 2006 to 2016, Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006, Dr. Scannon served as Chief Scientific and Medical Officer of XOMA.&#160;Dr. Scannon retired from XOMA and resigned from XOMA&#8217;s board of directors in 2016.&#160;Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Section 16(a) Beneficial Ownership Reporting Compliance</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Section 16(a) of the Exchange Act requires our executive officers and directors and persons who own more than ten percent (10%) of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Executive officers, directors and greater than ten percent (10%) stockholders are required to furnish us with copies of all Section 16(a) forms they file. We believe all of our executive officers and directors complied with all applicable filing requirements during 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Code of Ethics </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have adopted a Code of Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. We publicize the Code of Ethics through posting the policy on our website, </span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">http://www.cassavasciences.com</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. We will disclose on our website any waivers of, or amendments to, our Code of Ethics.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 11.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Executive Compensation</span><span id="Executive_Compensation" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading &quot;Executive Compensation and Other Matters.&quot;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-indent: 0;width: 0.674in;">Item 12.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span><span id="Security_Ownership" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The information required by this Item regarding security ownership of certain beneficial owners and management is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading &quot;Security Ownership of Certain Beneficial Owners and Management.&quot;</span><span id="_DV_M872" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">109</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table summarizes the securities authorized for issuance under our equity compensation plans as of&#160;December&#160;31, 2022:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 46.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 46.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Securities to be</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Issued Upon</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exercise of</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Outstanding</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options, Warrants</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">and Rights</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exercise Price of</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Outstanding</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options,</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Warrants</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">and Rights</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Securities</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Remaining Available</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">for Future Issuance</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Under Equity</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Compensation</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Plans</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 46.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Equity compensation plans approved by stockholders</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 2,536,590</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>(1)</sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 12.10</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>(2)</sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 4,128,705</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>(3)</sup></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 46.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Equity compensation plans not approved by stockholders</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 46.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 2,536,590</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 12.10</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 4,128,705</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 46.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 16.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(1)</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Includes outstanding stock options and awards for 1,692,798 shares of our common stock under the 2008 Plan and 843,792 shares of our common stock under the 2018 Plan.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: left;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(2)</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Includes the weighted average stock price for outstanding stock options of $11.31 under the 2008 Plan and $13.78 for the 2018 Plan.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">(3)</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Represents 4,070,688 shares of our common stock for the 2018 Plan and 58,017 for the Employee Stock Purchase Plan. No future awards shall occur under the 2008 Plan.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 13.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Certain Relationships and Related Transactions</span><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;"> and Director Independence</span><span id="Certain_Relationships" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading &quot;Certain Relationships and Related Transactions.&quot;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 14.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Principal Accountant Fees and Services</span><span id="Principal_Accountant_Fees" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#8220;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Principal Accountant Fees and Services.&#8221;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="_Hlk505686828" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">110</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART IV</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 15.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Exhibits and Financial Statement Schedules</span><span id="Exhibits" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.21in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.21in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.213in;">(a)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following documents are filed as part of this Form 10-K:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.13in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.13in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.375in;">(1)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Consolidated Financial Statements (included in Part II of this report):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.13in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Report of Independent Registered Public Accounting Firm</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.13in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consolidated Balance Sheets</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.13in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consolidated Statements of Operations</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.13in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consolidated Statements of Stockholders&apos; Equity</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.13in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consolidated Statements of Cash Flows</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.13in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Notes to Consolidated Financial Statements</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.13in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.13in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.375in;">(2)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Consolidated Financial Statement Schedules:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.63in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All consolidated financial statement schedules are omitted because the information is inapplicable or presented in the notes to the consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.375in;">(3)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Management Contracts, Compensatory Plans and Arrangements</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.63in;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Management contracts, compensatory plans and arrangements are indicated by the symbol &#8220;*&#8221; in the applicable exhibits listed in Item 15(b), below.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.63in;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.21in;margin-right: 1.00in;margin-top: 0;text-align: justify;text-indent: -0.21in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.500in;">(b)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Exhibits </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The exhibits listed below are filed as part of this Form 10-K other than Exhibit 32.1, which shall be deemed furnished.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Incorporated by Reference</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">No.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Description</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Form</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filing</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Date</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">No.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filed</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Herewith</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">3.1</span><span style="white-space:pre-wrap; color: #0000FF;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Certificate of Incorporation.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7/29/2005</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">3.2</span><span style="white-space:pre-wrap; color: #0000FF;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certificate of Amendment of Restated Certificate of Incorporation</span></a><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/8/2017</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">3.3</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certificate of Amendment of Restated Certificate of Incorporation.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3/29/2019</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.3</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="sava-20221231xex3_4.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">3.4</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="sava-20221231xex3_4.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Bylaws of Cassava Sciences, Inc.</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000032/sava-20190630xex4_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">4.1</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000032/sava-20190630xex4_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Specimen Common Stock Certificate.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/12/2019</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000009/sava-20191231xex4_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">4.2</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000009/sava-20191231xex4_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Description of Registrant&#8217;s Securities.</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3/26/2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.2</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000011/sava-20211231xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.1</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000011/sava-20211231xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Form of Indemnification Agreement between Registrant and each of its directors and officers.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3/1/2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312509027574/dex1012.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.5</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>*</sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312509027574/dex1012.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Employment Agreement, dated July&#160;1, 1998 and amended December&#160;17, 2008, between Registrant and Remi Barbier.</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2/13/2009</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.12</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312510170701/dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.6</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>*</sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312510170701/dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">2000 Employee Stock Purchase Plan, as amended and restated.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7/29/2010</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="https://www.sec.gov/Archives/edgar/data/1069530/000119312508124661/dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.7</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>*</sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312508124661/dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">2008 Equity Incentive Plan.</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/29/2008</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.8</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>*</sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex101.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amendment Number 1 to the 2008 Equity Incentive Plan.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/1/2013</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex102.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.9</span><span style="white-space:pre-wrap; color: #0000FF;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>*</sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex102.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amendment No. 2 to Employment Agreement between Registrant and Remi Barbier.</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/1/2013</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.2</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000025/ptie-20180511xex10_1.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.10</span><span style="white-space:pre-wrap; color: #0000FF;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>*</sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000025/ptie-20180511xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">2018 Omnibus Incentive Plan.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/11/2018</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000015/sava-20200327xex1_1.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.11</span><span style="white-space:pre-wrap; color: #0000FF;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000015/sava-20200327xex1_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Sales Agreement, Dated March&#160;27, 2020, between Registrant and SVB Leerink LLC.</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">S-3</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3/27/2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000048/sava-20200901xex10_1.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.12</span><span style="white-space:pre-wrap; color: #0000FF;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>*</sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953020000048/sava-20200901xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Cassava Sciences, Inc. 2020 Cash Incentive Bonus Plan</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9/1/2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000058/ptie-20181011xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.13</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>*</sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000058/ptie-20181011xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Employment Agreement, executed on October&#160;9, 2018, by and between Registrant and Eric Schoen.</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10/11/2018</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000002/sava-20210106xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.14</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>*</sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000002/sava-20210106xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Employment Agreement, executed on January&#160;1, 2021, by and between Registrant and Dr. James Kupiec.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1/6/2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000011/sava-20210311xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-variant: small-caps;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.15</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000011/sava-20210311xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Master Services Agreement between Cassava Sciences, Inc. and Evonik Corporation, dated February 22, 2021.</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3/11/2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000045/sava-20210630xex10_3.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.16</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000045/sava-20210630xex10_3.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Master Services Agreement between Cassava Sciences, Inc. and Premier Research International LLC, dated June 11, 2021</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/4/2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.3</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">111</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; "></span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000050/sava-20210930xex10_4.htm"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.17</span><span style="white-space:pre-wrap; color: #0000FF;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000050/sava-20210930xex10_4.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Agreement of Sale and Purchase Between DWF IV Lakewood, LP and Cassava Sciences, Inc. dated July 2, 2021</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11/15/2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.4</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000033/sava-20220630xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.18</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000033/sava-20220630xex10_1.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amendment 1 to 2018 Omnibus Incentive Plan</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8/4/2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000051/sava-20221013xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">10.19</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">*</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000051/sava-20221013xex10_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Employment Agreement, executed on October 13, 2022, by and between Registrant and R. Christopher Cook</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10/27/2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.1</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="sava-20221231xex21_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">21.1</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="sava-20221231xex21_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Subsidiaries of the Registrant.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="sava-20221231xex23_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">23.1</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="sava-20221231xex23_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="sava-20221231xex31_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">31.1</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="sava-20221231xex31_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="sava-20221231xex31_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">31.2</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="sava-20221231xex31_2.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><a href="sava-20221231xex32_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">32.1</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><a href="sava-20221231xex32_1.htm"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.INS</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Instance Document.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.SCH</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Schema Document.</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.CAL</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Calculation Linkbase Document.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.DEF</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Definition Linkbase Document.</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.LAB</span></p></td><td style="background: white;border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Labels Linkbase Document.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.PRE</span></p></td><td style="background: #CCEEFF;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">XBRL Taxonomy Extension Presentation Linkbase Document.</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">104</span></p></td><td style="background: white;border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup> </sup></span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 56.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The cover page from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, formatted in Inline XBRL (included in Exhibit 101).</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 8.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td colspan="4" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 64.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">* Management contract, compensatory plan or arrangement.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+Confidential portions of this document have been redacted as permitted by applicable regulations.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="4" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 64.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 4.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 6.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 0.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.22in;margin-right: 1.00in;margin-top: 0;text-align: justify;text-indent: -0.22in;"><span style="white-space:pre-wrap; display: inline-block;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.221in;">(c)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Consolidated Financial Statement Schedules </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All consolidated financial statement schedules are omitted because the information is inapplicable or presented in the notes to the consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 16.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;&#160;&#160;&#160;</span><span id="Form10KSummary" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Form 10-K Summary</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has elected not to include summary information.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">112</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.07in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SIGNATURES</span><span id="Signatures" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 212.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Principal Executive</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 166.6pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 90.3pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 212.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 166.6pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cassava Sciences, Inc.</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 90.3pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 212.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 256.9pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Registrant)</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 212.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 256.9pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 212.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 166.6pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ REMI BARBIER</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 90.3pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 212.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 256.9pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Remi Barbier,</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 212.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 256.9pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Chairman of the Board of Directors,</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 212.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 256.9pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">President and Chief Executive Officer</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 212.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 256.9pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 93.8%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dated: February&#160;28, 2023</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.07in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 42.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Signature</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Title </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Date</span></p></td></tr><tr style="height: 0.14in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/  REMI BARBIER</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">President, Chief Executive Officer and </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2023</span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Remi Barbier</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Chairman of the Board of Directors</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.35in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Principal Executive Officer)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/  ERIC J. SCHOEN</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Chief Financial Officer</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2023</span></p></td></tr><tr style="height: 0.33in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Eric J. Schoen</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/  RICHARD J. BARRY</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2023</span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Richard J. Barry</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/  ROBERT Z. GUSSIN, PH.D. </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2023</span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Robert Z. Gussin, Ph.D.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/  MICHAEL J. O&apos;DONNELL, ESQ. </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2023</span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Michael J. O&apos;Donnell, Esq.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/  SANFORD R. ROBERTSON</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2023</span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Sanford R. Robertson</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/  PATRICK SCANNON, M.D., PH.D. </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Director</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2023</span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patrick Scannon, M.D., Ph.D.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.04in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 42.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 35.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 19.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">113</span></p></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>2
<FILENAME>sava-20221231xex3_4.htm
<DESCRIPTION>EX-3.4
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.4.0.1-->
<!--Created on: 2/28/2023 2:51:35 PM-->
<html>
	<head>
		<title>
			Exhibit 34
		</title>
	</head>
	<body><div style="margin-left:54pt;margin-right:54pt;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;font-weight:bold;">Exhibit 3.</font><font style="display: inline;font-weight:bold;">4</font>

		</p>

		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-weight:bold;font-size:9pt;">AMENDED AND RESTATED BYLAWS OF </font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-weight:bold;font-size:9pt;text-decoration:underline;">CASSA</font><font style="display: inline;font-weight:bold;font-size:9pt;text-decoration:underline;">V</font><font style="display: inline;font-weight:bold;font-size:9pt;text-decoration:underline;">A SCIENCES, INC</font><font style="display: inline;font-weight:bold;font-size:9pt;text-decoration:underline;">.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-weight:bold;font-size:9pt;">a Delaware corporation </font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-weight:bold;font-size:9pt;">TABLE OF CONTENTS </font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font><font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:03.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;font-size:7pt;">Page</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="6" valign="top" style="width:94.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ARTICLE I STOCKHOLDERS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">1.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ANNUAL MEETINGS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">SPECIAL MEETINGS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">3.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">NOTICE OF MEETINGS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">4.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ADVANCE NOTICE OF STOCKHOLDER NOMINEES AND STOCKHOLDER BUSINESS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">5.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ADJOURNMENTS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">6.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">QUORUM</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">7.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ORGANIZATION</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">8.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">VOTING; PROXIES</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">9.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">FIXING DATE FOR DETERMINATION OF STOCKHOLDERS OF RECORD</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">10.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">LIST OF STOCKHOLDERS ENTITLED TO VOTE</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">11.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">NO ACTION BY CONSENT OF STOCKHOLDERS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="6" valign="top" style="width:94.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ARTICLE II BOARD OF DIRECTORS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">1.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">NUMBER; QUALIFICATIONS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ELECTION; RESIGNATION; REMOVAL; VACANCIES</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">3.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">REGULAR MEETINGS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">4.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">SPECIAL MEETINGS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">5.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">TELEPHONIC MEETINGS PERMITTED</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">6.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">QUORUM; VOTE REQUIRED FOR ACTION</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">7.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ORGANIZATION</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">8.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">INFORMAL ACTION BY DIRECTORS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="6" valign="top" style="width:94.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ARTICLE III COMMITTEES</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">1.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">COMMITTEES</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">COMMITTEE RULES</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="6" valign="top" style="width:94.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ARTICLE IV OFFICERS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">1.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">EXECUTIVE OFFICERS; ELECTION; QUALIFICATIONS; TERM OF OFFICE; RESIGNATION; REMOVAL; VACANCIES</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">POWERS AND DUTIES OF EXECUTIVE OFFICERS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="6" valign="top" style="width:94.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ARTICLE V STOCK</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">1.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">CERTIFICATES</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">LOST, STOLEN OR DESTROYED STOCK CERTIFICATES; ISSUANCE OF NEW CERTIFICATES</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="6" valign="top" style="width:94.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ARTICLE VI INDEMNIFICATION</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">1.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">THIRD PARTY ACTIONS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:87.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ACTIONS BY OR IN THE RIGHT OF THE CORPORATION</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">3.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">SUCCESSFUL DEFENSE</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">4.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">DETERMINATION OF CONDUCT</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">5.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">PAYMENT OF EXPENSES IN ADVANCE</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">6.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">INDEMNITY NOT EXCLUSIVE</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">7.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">INSURANCE INDEMNIFICATION</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">8.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">THE CORPORATION</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">9.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">EMPLOYEE BENEFIT PLANS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">10.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">INDEMNITY FUND</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">11.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">INDEMNIFICATION OF OTHER PERSONS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">12.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">SAVINGS CLAUSE</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">13.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">CONTINUATION OF INDEMNIFICATION AND ADVANCEMENT OF EXPENSES</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="5" valign="top" style="width:93.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ARTICLE VII MISCELLANEOUS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">1.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">FISCAL YEAR</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">2.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">SEAL</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">8&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">3.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">WAIVER OF NOTICE OF MEETINGS OF STOCKHOLDERS, DIRECTORS AND COMMITTEES</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">4.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">INTERESTED DIRECTORS; QUORUM</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">5.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">FORM OF RECORDS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">6.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">AMENDMENT OF BY-LAWS</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="5" valign="top" style="width:93.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">ARTICLE VIII EXCLUSIVE FORUM</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">1.</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:87.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-size:9pt;">EXCLUSIVE FORUM</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8&nbsp;
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;;font-size: 9pt"><font style="display: inline;font-weight:bold;font-size:9pt;">AMENDED AND RESTATED BYLAWS OF </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-weight:bold;font-size:9pt;text-decoration:underline;">CASSAVA</font><font style="display: inline;font-weight:bold;font-size:9pt;text-decoration:underline;"> SCIENCES, INC</font><font style="display: inline;font-weight:bold;font-size:9pt;text-decoration:underline;">.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">a Delaware corporation </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">ARTICLE I </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">STOCKHOLDERS </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">1.</font></p>
				</td>
				<td valign="top" style="width:468.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">ANNUAL MEETINGS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">An annual meeting of stockholders shall be held for the election of directors at such date, time and place, either within or without the state of Delaware, as may be designated by resolution of the Board of Directors from time to time. Any other proper business may be transacted at the annual meeting. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">2.</font></p>
				</td>
				<td valign="top" style="width:468.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">SPECIAL MEETINGS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Special meetings of stockholders for any purpose or purposes may be called at any time by the Board of Directors, Chairman of the Board, President or the Chief Executive Officer of the corporation and such special meetings may not be called by any other person or persons. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">3.</font></p>
				</td>
				<td valign="top" style="width:468.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">NOTICE OF MEETINGS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, date and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise provided by law, the certificate of incorporation or these by-laws, the written notice of any meeting shall be given not less than ten nor more than sixty days before the date of the meeting to each stockholder entitled to vote at such meeting. If mailed, such notice shall be deemed to be given when deposited in the mail, postage prepaid, directed to the stockholder at his address as it appears on the records of the corporation. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">4.</font></p>
				</td>
				<td valign="top" style="width:469.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">ADVANCE NOTICE OF STOCKHOLDER NOMINEES AND STOCKHOLDER BUSINESS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The stockholders&#x2019; nominees for the election of directors and other business proposed by a stockholder to be voted on at an annual or special meeting of stockholders must be received by the company&#x2019;s secretary not less than 120 days prior to the date the Company&#x2019;s proxy statement was released to the stockholders in connection with the previous year&#x2019;s annual meeting of stockholders. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:16.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">5.</font></p>
				</td>
				<td valign="top" style="width:470.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">ADJOURNMENTS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Any meeting of stockholders, annual or special, may adjourn from time to time to reconvene at the same or some other place, and notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;font-family:Arial;font-size:14pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">6.</font></p>
				</td>
				<td valign="top" style="width:467.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">QUORUM</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Except as otherwise provided by law, the certificate of incorporation or these by-laws, at each meeting of stockholders the presence in person or by proxy of the holders of shares of stock having a majority of the votes which could be cast by the holders of all outstanding shares of stock entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum. In the absence of a quorum, the stockholders so present may, by majority vote, adjourn the meeting from time to time in the manner provided in Section 1.5 of these by-laws until a quorum shall attend. Shares of its own stock belonging to the corporation or to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation is held, directly or indirectly, by the corporation, shall neither be entitled to vote nor be counted for quorum purposes; provided, however, that the foregoing shall not limit the right of the corporation to vote stock, including but not limited to its own stock, held by it in a fiduciary capacity. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">7.</font></p>
				</td>
				<td valign="top" style="width:469.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">ORGANIZATION</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Meetings of stockholders shall be presided over by the Chairman of the Board, if any, or in his absence by the Vice Chairman of the Board, if any, or in his absence by the President, or in his absence by a Vice President, or in the absence of the foregoing persons by a chairman designated by the Board of Directors, or in the absence of such designation by a chairman chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his absence the chairman of the meeting may appoint any person to act as secretary of the meeting. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:10pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">8.</font></p>
				</td>
				<td valign="top" style="width:467.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">VOTING; PROXIES</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Except as otherwise provided by the certificate of incorporation, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of stock held by him which has voting power upon the matter in question. Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for him by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A duly executed proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by filing an instrument in writing revoking the proxy or another duly executed proxy bearing a later date with the Secretary of the corporation. Voting at meetings of stockholders need not be by written ballot and need not be conducted by inspectors of election unless so determined by the holders of shares of stock having a majority of the votes which could be cast by the holders of all outstanding shares of stock entitled to vote thereon which are present in person or by proxy at such meeting. At all meetings of stockholders for the election of directors a plurality of the votes cast shall be sufficient to elect. Stockholders shall not be entitled to cumulative voting rights for the election of directors. All other elections and questions shall, unless otherwise provided by law, the certificate of incorporation or these by-laws, be decided by the vote of the holders of shares of stock having a majority of the votes which could be cast by the holders of all shares of stock entitled to vote thereon which are present in person or represented by proxy at the meeting. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;font-family:Arial;font-size:14pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">9.</font></p>
				</td>
				<td valign="top" style="width:470.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">FIXING DATE FOR DETERMINATION OF STOCKHOLDERS OF RECORD</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or if applicable, to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and which record date: (1) in the case of determination of stockholders entitled to vote at any meeting of stockholders or adjournment thereof, shall, unless otherwise required by law, not be more than sixty nor less than ten days before the date of such meeting; (2) if applicable, in the case of determination of stockholders entitled to express consent to corporate action in writing without a meeting, shall not be more than ten days from the date upon which the resolution fixing the record date is adopted by the Board of Directors; and (3) in the case of any other action, shall not be more than sixty days prior to such other action. If no record date is fixed: (1) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; (2) if applicable, the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting when no prior action of the Board of Directors is required by law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the corporation in accordance with applicable law, or, if prior action by the Board of Directors is required by law, shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action; and (3) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">10.</font></p>
				</td>
				<td valign="top" style="width:469.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">LIST OF STOCKHOLDERS ENTITLED TO VOTE</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The Secretary shall prepare and make, at least ten days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof and may be inspected by any stockholder who is present. Upon the willful neglect or refusal of the directors to produce such a list at any meeting for the election of directors, they shall be ineligible for election to any office at such meeting. The stock ledger shall be the only evidence as to who are the stockholders entitled to examine the stock ledger, the list of stockholders or the books of the corporation, or to vote in person or by proxy at any meeting of stockholders. </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;font-family:Arial;font-size:14pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">11.</font></p>
				</td>
				<td valign="top" style="width:469.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">NO ACTION BY CONSENT OF STOCKHOLDERS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Stockholders may not take action by written consent without a meeting and may act only at a duly called special or annual meeting of the corporation. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:10pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:18pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;;font-size: 9pt"><font style="display: inline;font-size:9pt;">ARTICLE II </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">BOARD OF DIRECTORS </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:470.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">1.</font></p>
				</td>
				<td valign="top" style="width:470.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">NUMBER; QUALIFICATIONS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The Board of Directors shall consist of one or more members, and is currently set at s</font><font style="display: inline;font-size:9pt;">ix</font><font style="display: inline;font-size:9pt;"> members. The number of directors may be changed by an amendment to this bylaw, duly adopted by the board of directors or by the stockholders, or by a duly adopted amendment to the certificate of incorporation. Directors need not be stockholders. </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;font-family:Arial;font-size:5pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden">
						&nbsp;</p>
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:470.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">2.</font></p>
				</td>
				<td valign="top" style="width:470.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">ELECTION; RESIGNATION; REMOVAL; VACANCIES</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The Board of Directors shall be divided into three classes designated as Class I, Class II, and Class III, respectively. Directors shall be assigned to each class in accordance with a resolution or resolutions adopted by the Board of Directors. At the first annual meeting of stockholders following the closing of the first sale of the corporation&#x2019;s common stock pursuant to a firmly underwritten registered public offering (the &#x201C;IPO&#x201D;), the term of office of the Class I directors shall expire, and Class I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following the date hereof, the term of office of the Class II directors shall expire, and Class II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following the date hereof, the term of office of the Class III directors shall expire, and Class III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Notwithstanding the foregoing provisions of this Article, each director shall serve until his or her successor is duly elected and qualified or until his or her death, resignation, or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. Any director, or the entire Board of Directors, may be removed from office at any time (i) with cause by the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares of the Voting Stock, voting together as a single class; or (ii) without cause by the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of the Voting Stock. Any director may resign at any time upon written notice to the corporation. Unless otherwise provided in the certificate of incorporation, any newly created directorship or any vacancy occurring in the Board of Directors for any cause may be filled by a majority of the remaining members of the Board of Directors, and each director so elected shall hold office until the expiration of the term of office of the director whom he has replaced or until his successor is elected and qualified. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">3.</font></p>
				</td>
				<td valign="top" style="width:468.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">REGULAR MEETINGS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Regular meetings of the Board of Directors may be held at such places within or without the State of Delaware and at such times as the Board of Directors may from time to time determine, and if so determined notices thereof need not be given. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">4.</font></p>
				</td>
				<td valign="top" style="width:468.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">SPECIAL MEETINGS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Special meetings of the Board of Directors may be held at any time or place within or without the State of Delaware whenever called by the Board of Directors, Chairman of the Board, President or Chief Executive Officer of the Corporation. Notice of a special meeting of the Board of Directors shall be given by the person or persons calling the meeting at least twenty-four hours before the special meeting. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">5.</font></p>
				</td>
				<td valign="top" style="width:468.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">TELEPHONIC MEETINGS PERMITTED</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Members of the Board of Directors, or any committee designated by the Board of Directors, may participate in a meeting thereof by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this by-law shall constitute presence in person at such meeting. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">6.</font></p>
				</td>
				<td valign="top" style="width:468.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">QUORUM; VOTE REQUIRED FOR ACTION</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">At all meetings of the Board of Directors a majority of the whole Board of Directors shall constitute a quorum for the transaction of business. Except in cases in which the certificate of incorporation or these by-laws otherwise provide, the vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">7.</font></p>
				</td>
				<td valign="top" style="width:469.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">ORGANIZATION</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Meetings of the Board of Directors shall be presided over by the Chairman of the Board, if any, or in his absence by the Vice Chairman of the Board, if any, or in his absence by the President, or in their absence by a chairman chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his absence the chairman of the meeting may appoint any person to act as secretary of the meeting. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:10pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">8.</font></p>
				</td>
				<td valign="top" style="width:468.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">INFORMAL ACTION BY DIRECTORS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Unless otherwise restricted by the certificate of incorporation or these by-laws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board of Directors or such committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board of Directors or such committee. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">ARTICLE III </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">COMMITTEES </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">1.</font></p>
				</td>
				<td valign="top" style="width:469.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">COMMITTEES</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The Board of Directors may, by resolution passed by a majority of the whole Board of Directors, designate one or more committees, each committee to consist of one or more of the directors of the corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent permitted by law and to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">2.</font></p>
				</td>
				<td valign="top" style="width:468.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">COMMITTEE RULES</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Unless the Board of Directors otherwise provides, each committee designated by the Board of Directors may make, alter and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board of Directors conducts its business pursuant to Article III of these by-laws. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">ARTICLE IV </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">OFFICERS </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:16.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">1.</font></p>
				</td>
				<td valign="top" style="width:470.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">EXECUTIVE OFFICERS; ELECTION; QUALIFICATIONS; TERM OF OFFICE; RESIGNATION; REMOVAL; VACANCIES</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The Board of Directors shall elect a President and Secretary, and it may, if it so determines, choose a Chairman of the Board and a Vice Chairman of the Board from among its members. The Board of Directors may also choose one or more Vice Presidents, one or more Assistant Secretaries, a Treasurer and one or more Assistant Treasurers. Each such officer shall hold office until the first meeting of the Board of Directors after the annual meeting of stockholders next succeeding his election, and until his successor is elected and qualified or until his earlier resignation or removal. Any officer may resign at any time upon written notice to the corporation. The Board of Directors may remove any officer with or without cause at any time, but such removal shall be without prejudice to the contractual rights of such officer, if any, with the corporation. Any number of offices may be held by the same person. Any vacancy occurring in any office of the corporation by death, resignation, removal or otherwise may be filled for the unexpired portion of the term by the Board of Directors at any regular or special meeting. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">2.</font></p>
				</td>
				<td valign="top" style="width:468.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">POWERS AND DUTIES OF EXECUTIVE OFFICERS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The officers of the corporation shall have such powers and duties in the management of the corporation as may be prescribed by the Board of Directors and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board of Directors. The Board of Directors may require any officer, agent or employee to give security for the faithful performance of his duties. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">ARTICLE V </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">STOCK </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">1.</font></p>
				</td>
				<td valign="top" style="width:469.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">CERTIFICATES</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Every holder of stock shall be entitled to have a certificate signed by or in the name of the corporation by the Chairman or Vice Chairman of the Board of Directors, if any, or the President or Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the corporation, certifying the number of shares owned by him in the corporation. Any of or all the signatures on the certificate may be a facsimile. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued by the corporation with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:10pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">2.</font></p>
				</td>
				<td valign="top" style="width:469.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">LOST, STOLEN OR DESTROYED STOCK CERTIFICATES; ISSUANCE OF NEW CERTIFICATES</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The corporation may issue a new certificate of stock in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the corporation may require the owner of the lost, stolen or destroyed certificate, or his legal representative, to give the corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">ARTICLE VI </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">INDEMNIFICATION </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">1.</font></p>
				</td>
				<td valign="top" style="width:467.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">THIRD PARTY ACTIONS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that he is or was a director or officer of the corporation, or that such director or officer is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture trust or other enterprise (collectively &#x201C;Agent&#x201D;), against expenses (including attorneys&#x2019; fees), judgments, fines and amounts paid in settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld) actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of </font><font style="display: inline;font-size:9pt;text-decoration:underline;">nolo contendere</font><font style="display: inline;font-size:9pt;"> or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interest of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">2.</font></p>
				</td>
				<td valign="top" style="width:469.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">ACTIONS BY OR IN THE RIGHT OF THE CORPORATION</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was an Agent (as defined in Section 6.1) against expenses (including attorneys&#x2019; fees) actually and reasonably incurred by him in connection with the defense or settlement of such action or suit if he acted in good faith and in manner he reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">3.</font></p>
				</td>
				<td valign="top" style="width:468.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">SUCCESSFUL DEFENSE</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">To the extent that an Agent of the corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Sections 6.1 and 6.2, or in defense of any claim, issue or matter therein, he shall be indemnified against expenses (including attorneys&#x2019; fees) actually and reasonably incurred by him in connection therewith. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">4.</font></p>
				</td>
				<td valign="top" style="width:470.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">DETERMINATION OF CONDUCT</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Any indemnification under Sections 6.1 and 6.2 (unless ordered by a court) shall be made by the corporation only as authorized in the specific case upon a determination that the indemnification of the Agent is proper in the circumstances because he has met the applicable standard of conduct set forth in Sections 6.1 and 6.2. Such determination shall be made (1) by the Board of Directors or an executive committee by a majority vote of a quorum consisting of directors who were not parties to such action, suit or proceeding, or (2) or if such quorum is not obtainable or, even if obtainable, a quorum of disinterested directors so directs, by independent legal counsel in a written opinion, or (3) by the stockholders. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">5.</font></p>
				</td>
				<td valign="top" style="width:467.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">PAYMENT OF EXPENSES IN ADVANCE</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Expenses incurred in defending a civil or criminal action, suit or proceeding shall be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of the director, officer, employee or agent to repay such amount if it shall ultimately be determined that he is not entitled to be indemnified by the corporation as authorized in this Article VI. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">6.</font></p>
				</td>
				<td valign="top" style="width:468.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">INDEMNITY NOT EXCLUSIVE</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The indemnification and advancement of expenses provided or granted pursuant to the other subsections of this section shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any by-law, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:10pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;;font-size: 14pt"><font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:16.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">7.</font></p>
				</td>
				<td valign="top" style="width:470.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">INSURANCE INDEMNIFICATION</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was an Agent of the corporation, or is or was serving at the request of the corporation, as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify him against such liability under the provisions of this Article VI. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;font-family:Arial;font-size:14pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">8.</font></p>
				</td>
				<td valign="top" style="width:469.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">THE CORPORATION</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">For purposes of this Article VI, references to &#x201C;the corporation&#x201D; shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors and officers, so that any person who is or was a director or Agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under and subject to the provisions of this Article VI (including, without limitation the provisions of Section 6.4) with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">9.</font></p>
				</td>
				<td valign="top" style="width:468.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">EMPLOYEE BENEFIT PLANS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">For purposes of this Article VI, references to &#x201C;other enterprises&#x201D; shall include employee benefit plans; references to &#x201C;fines&#x201D; shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to &#x201C;serving at the request of the corporation&#x201D; shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#x201C;not opposed to the best interests of the corporation&#x201D; as referred to in this Article VI. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">10.</font></p>
				</td>
				<td valign="top" style="width:468.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">INDEMNITY FUND</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Upon resolution passed by the Board, the corporation may establish a trust or other designated account, grant a security interest or use other means (including, without limitation, a letter of credit), to ensure the payment of certain of its obligations arising under this Article VI and/or agreements which may be entered into between the corporation and its officers and directors from time to time. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:16.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">11.</font></p>
				</td>
				<td valign="top" style="width:470.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">INDEMNIFICATION OF OTHER PERSONS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The provisions of this Article VI shall not be deemed to preclude the indemnification of any person who is not an Agent (as defined in Section 6.1), but whom the corporation has the power or obligation to indemnify under the provisions of the General Corporation Law of the State of Delaware or otherwise. The corporation may, in its sole discretion, indemnify an employee, trustee or other agent as permitted by the General Corporation Law of the State of Delaware. The corporation shall indemnify an employee, trustee or other agent where required by law. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">12.</font></p>
				</td>
				<td valign="top" style="width:467.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">SAVINGS CLAUSE</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">If this Article or any portion thereof shall be invalidated on any ground by any court of competent jurisdiction, then the corporation shall nevertheless indemnify each Agent against expenses (including attorney&#x2019;s fees), judgments, fines and amounts paid in settlement with respect to any action, suit, proceeding or investigation, whether civil, criminal or administrative, and whether internal or external, including a grand jury proceeding and an action or suit brought by or in the right of the corporation, to the full extent permitted by any applicable portion of this Article that shall not have been invalidated, or by any other applicable law. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:16.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">13.</font></p>
				</td>
				<td valign="top" style="width:470.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">CONTINUATION OF INDEMNIFICATION AND ADVANCEMENT OF EXPENSES</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The indemnification and advancement of expenses provided by, or granted pursuant to, this Article VI shall, unless otherwise prided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">ARTICLE VII </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">MISCELLANEOUS</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">1.</font></p>
				</td>
				<td valign="top" style="width:466.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">FISCAL YEAR</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The fiscal year of the corporation shall be determined by resolution of the Board of Directors. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:10pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:19.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:19.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">2.</font></p>
				</td>
				<td valign="top" style="width:466.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">SEAL</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">The corporate seal shall have the name of the corporation inscribed thereon and shall be in such form as may be approved from time to time by the Board of Directors. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:16.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:16.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">3.</font></p>
				</td>
				<td valign="top" style="width:470.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">WAIVER OF NOTICE OF MEETINGS OF STOCKHOLDERS, DIRECTORS AND COMMITTEES</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Any written waiver of notice, signed by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of any regular or special meeting of the stockholders, directors, or members of a committee of directors need be specified in any written waiver of notice. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">4.</font></p>
				</td>
				<td valign="top" style="width:468.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">INTERESTED DIRECTORS; QUORUM</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">No contract or transaction between the corporation and one or more of its directors or officers, or between the corporation and any other corporation, partnership, association, or other organization in which one or more of its directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or committee thereof which authorizes the contract or transaction, or solely because his or their votes are counted for such purpose, if: (1) the material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum: or (2) the material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or&nbsp;&nbsp;(3) the contract or transaction is fair as to the corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee thereof, or the stockholders. Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:18.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">5.</font></p>
				</td>
				<td valign="top" style="width:467.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">FORM OF RECORDS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">Any records maintained by the corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be kept on, or be in the form of, punch cards, magnetic tape, photographs, microphotographs, or any other information storage device, provided that the records so kept can be converted into clearly legible form within a reasonable time. The corporation shall so convert any records so kept upon the request of any person entitled to inspect the same. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:17.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:17.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;">6.</font></p>
				</td>
				<td valign="top" style="width:468.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;">AMENDMENT OF BY-LAWS</font><font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">These by-laws may be altered or repealed, and new by-laws made, by the Board of Directors, but except as otherwise provided in the Certificate of Incorporation, the stockholders may make additional by-laws and may alter and repeal any by-laws whether adopted by them or otherwise.</font><font style="display: inline;font-size:9pt;">&nbsp;</font><font style="display: inline;font-size:9pt;">. &nbsp;</font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ARTICLE VIII</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;text-indent:17.25pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">EXCLUSIVE FORUM</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:17pt;"><p style="width:17pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="line-height:100%;font-family:Times New Roman;font-size: 9pt;margin:4.5pt 0pt 0pt;">
				<font style="margin:4.5pt 0pt 0pt;font-weight:bold;font-style:italic;line-height:100%;font-family:Times New Roman;font-size:9pt;;"> 1.</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman;font-size: 9pt;margin:4.5pt 0pt 0pt;">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:9pt;text-decoration:underline;color:#000000;">EXCLUSIVE FORUM</font></p></td></tr></table></div>
		<p style="margin:4.5pt 0pt 0pt 17.25pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;color:#000000;">Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933. Any person or entity purchasing or otherwise acquiring any interest in any security of the Corporation shall be deemed to have notice of and consented to this Article </font><font style="display: inline;font-size:9pt;color:#000000;">V</font><font style="display: inline;font-size:9pt;color:#000000;">III</font><font style="display: inline;font-size:9pt;color:#000000;">.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;color:#000000;">***** </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:10pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>sava-20221231xex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.4.0.1-->
<!--Created on: 2/28/2023 2:51:43 PM-->
<html>
	<head>
		<title>
			Exhibit 211
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt 0pt 8pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;">Exhibit 21.</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;">1</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;">Cassava Sciences, Inc. </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;">S</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;">ubsidiaries</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;line-height:100%;margin-bottom:0pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;width:233.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
						<font style="display: inline;font-family:Times New Roman;text-decoration:underline;">Subsidiary</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;width:233.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
						<font style="display: inline;font-family:Times New Roman;text-decoration:underline;">State/Country of Incorporation/Formation</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:233.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
						<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:233.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:233.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
						<font style="display: inline;font-family:Times New Roman;">Austin Innovation Park, LLC</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:233.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
						<font style="display: inline;font-family:Times New Roman;">Texas</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>sava-20221231xex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.4.0.1-->
<!--Created on: 2/28/2023 2:51:50 PM-->
<html>
	<head>
		<title>
			Exhibit 231
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:right;text-decoration:none;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">EXHIBIT 23.1</font>
		</p>
		<p style="margin:0pt;text-align:center;text-decoration:none;line-height:93.75%;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:normal;font-size:10pt;text-decoration:none;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Consent of Independent</font><font style="display: inline;font-weight:bold;"> Registered Public Accounting Firm</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;background-color: #FFFFFF;line-height:normal;vertical-align:top;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-bottom:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-8 No. 333-265540) pertaining to the 2018 Omnibus Incentive Plan of Registrant,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-3 No. 333-252931) and related Prospectus of Cassava Sciences, Inc.,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-3 No. 333-237452) and related Prospectus of Cassava Sciences, Inc.,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 4)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-8 No. 333-168390) pertaining to the 2000 Employee Stock Purchase Plan of Registrant,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 5)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-8 No. 333-225708) pertaining to the 2018 Omnibus Incentive Plan of Registrant, and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
				<font style="margin:5pt 0pt;border-top:1pt none #D9D9D9;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size:10pt;;"> 6)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:106.67%;text-align:left;font-family:Calibri;text-justify:inter-ideograph;font-size: 10pt;margin:5pt 0pt 0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Statement (Form S-8 No. 333-147336) pertaining to the 2000 Employee Stock Purchase Plan of Registrant;</font></p></td></tr></table></div>
		<p style="margin:5pt 0pt 6pt;background-color: #FFFFFF;vertical-align:top;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Verdana;color:#000000;line-height:100%;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">of our reports dated February 28, 2023, with respect to the consolidated financial statements of Cassava Sciences, Inc. and the effectiveness of internal control over financial reporting of Cassava Sciences, Inc. included in this Annual Report (Form 10-K) of Cassava Sciences, Inc. for the year ended December 31, 2022.</font>
		</p>
		<p style="margin:5pt 0pt 6pt;background-color: #FFFFFF;vertical-align:top;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Verdana;color:#000000;line-height:100%;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">/s/ Ernst &amp;Young LLP</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Austin, Texas</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">February 28, 2023</font>
		</p>
		<p style="margin:0pt 0pt 6pt;background-color: #FFFFFF;line-height:normal;vertical-align:top;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>sava-20221231xex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.4.0.1-->
<!--Created on: 2/28/2023 2:51:58 PM-->
<html>
	<head>
		<title>
			Exhibit 311
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:5pt 0pt;text-align:right;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">EXHIBIT </font><font style="display: inline;">31.1</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">I, Remi Barbier, certify that: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">I have reviewed this </font><font style="display: inline;color:#000000;">Annual </font><font style="display: inline;color:#000000;">Report on Form 10-K of </font><font style="display: inline;color:#000000;">Cassava Sciences</font><font style="display: inline;color:#000000;">, Inc.;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e</font><font style="display: inline;color:#000000;">))</font><a name="_DV_C218"></a><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;"> and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))</font><font style="display: inline;color:#000000;"> for the registrant and have: </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-top:1pt none #D9D9D9;text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;color:#000000;font-size:6pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> c.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Evaluated the effectiveness of the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> d.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Disclosed in this report any change in the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s internal control over financial reporting that occurred during the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s most recent fiscal quarter (the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s auditors and the audit committee of the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s internal control over financial reporting.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:2.5pt;"><font style="display: inline;text-decoration:underline;color:#000000;">/s/ REMI BARBIER</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:20.5pt;text-align:left"><font style="display: inline;text-decoration:underline;color:#000000;"></font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;text-decoration:underline;color:#000000;"></font></font><font style="display: inline;text-decoration:underline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Remi Barbier,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Chairman of the Board of Directors,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">President and Chief Executive Officer</font>
		</p>
		<p style="margin:0pt 0pt 3pt 270pt;border-top:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">(Principal Executive Officer)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Date: </font><font style="display: inline;color:#000000;">February</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">, 20</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">3</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>sava-20221231xex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.4.0.1-->
<!--Created on: 2/28/2023 2:52:14 PM-->
<html>
	<head>
		<title>
			Exhibit 312
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:right;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">EXHIBIT </font><font style="display: inline;">31.2</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">I, </font><font style="display: inline;">Eric J. Schoen</font><font style="display: inline;">, certify that: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">I have reviewed this </font><font style="display: inline;color:#000000;">Annual </font><font style="display: inline;color:#000000;">Report on Form 10-K of </font><font style="display: inline;color:#000000;">Cassava Sciences</font><font style="display: inline;color:#000000;">, Inc.;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)</font><font style="display: inline;color:#000000;">)</font><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;"> and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) </font><font style="display: inline;color:#000000;">for the registrant and have: </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-decoration:none;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;color:#000000;font-size:6pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> c.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Evaluated the effectiveness of the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;font-size:6pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> d.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Disclosed in this report any change in the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s internal control over financial reporting that occurred during the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s most recent fiscal quarter (the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s internal control over financial reporting; and </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s auditors and the audit committee of the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s board of directors (or persons performing the equivalent functions): </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s ability to record, process, summarize and report financial information; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-top:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s internal control over financial reporting. </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:55.5pt;"><font style="display: inline;text-decoration:underline;color:#000000;">/s/ </font><font style="display: inline;text-decoration:underline;color:#000000;">ERIC J. SCHOEN</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:65.5pt;text-align:left"><font style="display: inline;text-decoration:underline;color:#000000;"></font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:center"><font style="display: inline;text-decoration:underline;color:#000000;"></font></font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Eric J. Schoen</font><font style="display: inline;color:#000000;">,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Chief Financial Officer</font>
		</p>
		<p style="margin:0pt 0pt 0pt 270pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">(Principal Financial Officer)</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Date: </font><font style="display: inline;color:#000000;">February</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">, 20</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">3</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>sava-20221231xex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.4.0.1-->
<!--Created on: 2/28/2023 2:52:22 PM-->
<html>
	<head>
		<title>
			Exhibit 321
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt 4.5pt 0pt 396pt;text-align:right;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">EXHIBIT </font><font style="display: inline;color:#000000;">32.1</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 72pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND THE </font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;text-align:center;text-decoration:none;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">CHIEF FINANCIAL OFFICER PURSUANT TO </font><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">18 U.S.C. SECTION 1350, </font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">AS ADOPTED PURSUANT TO </font><font style="display: inline;color:#000000;">SECTION 906 OF THE SARBANES-OXLEY ACT OF </font><font style="color:#0000FF;display: inline;color:#000000;text-decoration:none;">2002</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, </font><font style="display: inline;">each of the undersigned officers</font><font style="display: inline;"> of </font><font style="display: inline;">Cassava Sciences</font><font style="display: inline;">, Inc. (the &#x201C;Company&#x201D;), hereby certif</font><font style="display: inline;">ies</font><font style="display: inline;"> that to the best of </font><font style="display: inline;">such officer&#x2019;s </font><font style="display: inline;"> knowledge:</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 4.5pt 0pt 0pt;">
				<font style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 4.5pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">The Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, </font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">, and to which this certification is attached as Exhibit 32.1 (the &#x201C;Periodic Report&#x201D;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and</font></p></td></tr></table></div>
		<p style="margin:0pt 4.5pt 0pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 4.5pt 0pt 0pt;">
				<font style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 4.5pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">The information contained in this Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Date: </font><font style="display: inline;color:#000000;">February</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">20</font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">3</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;text-decoration:underline;color:#000000;">/s/ REMI BARBIER</font><font style="display: inline;text-decoration:underline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;text-decoration:underline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Remi Barbier,</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Chairman of the Board of Directors,</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;border-top:1pt none #D9D9D9 ;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">President and Chief Executive Officer</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;text-decoration:underline;color:#000000;">/s/ </font><font style="display: inline;text-decoration:underline;color:#000000;">ERIC J. SCHOEN</font><font style="display: inline;text-decoration:underline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;text-decoration:underline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;text-decoration:underline;color:#000000;"></font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Eric J. Schoen</font><font style="display: inline;color:#000000;">,</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Chief </font><font style="display: inline;color:#000000;">Financial</font><font style="display: inline;color:#000000;"> Officer</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 4.5pt 0pt 288pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>sava-20221231x10kg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20221231x10kg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@<_QEG.&_P"^,"A+H#VN>RBEH%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#(]>P44 >/_P#"/?'/_H<M#_[\K_\ (]'_  CWQS_Z'+0_^_*__(]>P44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA7F>DZ/>S>(=-MUAU>&STRYDG$-Y$!#""&&(Y!_K<EAC/09KTP4= ZBT444
M%%%% !1110!G:GJL>G-;1^6TL]S((XXD(R?4\] !UK%3QB6O8BVDW*:5-<?9
MHM0+KAI,D?<^\%R",].*EUS]QXOT&\E.+<":$L>@=@-OYX-85KJESK?B6-]8
MT;6;>WMK@BSMOL+>4&' FD?H<\X[#ZYH6X,Z;7M>ETA[2"UT]KZZNBVR(3)%
MPHR3N8@=Q4EQK@T[PY)K&JVQL_*C,DD/F+(1CH 5X)/MZUB>)8M)U*73[W5?
M#.H:E#%YJ(HMVD,;9 ^:+J0<<''\ZS+CP_XCGT"V%E]C6WA6=X[&]C<LN[/E
MC"GJ%) !Z9]J6J0UNCN-)U%-6TFUU!(WC6XC$@1_O*#V/O5*R\2V>H>)+[1;
M=7:6RC5Y9?X,G^$>XK)T%]4MO"ECHUQLMM9FLV,+"%_+BVX W9_B&X<=ZS/#
MFE>(M#\3W$U];V3V<6GJK26<4A:5@6/RY/+$]?J*?6Q.MCH-7\43:?>SP6>D
M7%^MI&);R2-U01*>1C=]\X!.!Z>]2:QXMT_1]%M=3D$DJ7;QI!&@^9RY';VZ
MGZ5@^)=9OKO4_P"RGTK6H](,2O//:V+2-<9'^J!'W1_>[]O6J?BO0?$-W;R7
M6E0V,EH8H([:UFAD$T"AE)  ./3/? J;NQ74[F+5HWUF337B:.7R1/$S$8D7
MH2/H2!^-:(KEF\Z;Q;I$3[#<VUH[W+1 [5S@ <\\GD#VKJ:HE"T444#"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE[+_DIFL?]
M@RU_]&35U%<O9?\ )3-8_P"P9:_^C)J .HHHHH **** "BBB@ HHHH ****
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M_P!\"C^SK+_GUA_[X% !_:5E_P _</\ WV*DBN8+C/DRI)MZ[6SBH_[.LO\
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MT6RU6/3+G4H([V3&V)CSSTSV'XT ;%)7/#QCI*:[-H]W<1VUTD@CC61O]:2
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MV#+7_P!&34 =11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!14$]Y;6I43S)&6Z!CUJ'^UM/_Y^XO\ OJ@"[15+^UM/_P"?N+_OJC^UM/\
M^?N+_OJ@"[15+^UM/_Y^XO\ OJC^UM/_ .?N+_OJ@"[16/J?B;2=*TNZU"XN
ME,%M&99/+&YL#T'K6)X7^)_AGQ=<7$.FW$RM;H'?SXM@P3CB@#LZ*I?VMI__
M #]Q?]]4?VMI_P#S]Q?]]4 7:*I?VMI__/W%_P!]4?VMI_\ S]Q?]]4 7:*I
M?VMI_P#S]Q?]]4HU6P9@HNXB2<  ]30!<HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**#2<T
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M16UW_A';<:4@:1G_ +0_>"-206V;,9P"<9K:U#Q3;6+Z9MB:1;W:Q.<&*-L
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MN/,)E,H)'S)C 4E6P<^E"U ZVBL+7=9O[*\L]/TJRBNKZY5Y )Y3'&J)C))
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ;,(;X3V=]=NT-A<I',R2N2K*S?+TQD'UK4T;PW>V6H^'9?LLJ0V\5VT_G7
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MYK_WS3Z* &>5'_SS7_OFCRH_^>:_]\T^B@!GE1_\\U_[YH\J/_GFO_?-/HH
M9Y4?_/-?^^:Y?QA\/="\;BT&KI./LF[R_(DV?>QG/'/W175T4 9>@Z!8>'=$
MM=)L4;[-;*5C\T[FP23R?QK1\J/_ )YK_P!\T^B@!GE1_P#/-?\ OFCRH_\
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MIEUI'A6RL+U EQ$&#JK!@,L2.1[$50=-#>HHHI %%%% !1110 4444 %%%%
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MH(M5E77AIEU$B^9;B:"1"2'Q@./P)&/:M:N3M[9_^$ETNR5S(-+LSY\O;<P
M5?J1D_A764"%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?"?B?5!IVG7<WV@HSCS82BX'7DT =Q15/^U+#_G[B_[ZI?[4L?\ G[B_[ZH
MMT54_M2Q_P"?N+_OJC^U+'_G[B_[ZH MT56CO[2:01QW$;.>BAN35F@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *,FKJ*Y>R_Y*9K'_8,M?_1DU '3]J**.] '.:QXPL=)U 6(M;V]N0H>5+.
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ME%ZZ]?/;[COQTI:0=*6MSR@HHHH **** "BBB@ HHHH *1E#*58 J1@@TM%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS%]N<G(P,=Z .SI*S="U>/7-'AOXXVCWY5XV/*,I(8>_(/-4=-\40:IXGO\
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M ("I_A5ZG-:GW?W?\$V<CU%)D>HK'_X1'P[_ - /3O\ P%3_  H_X1'P[_T
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MTRUVQQ(%49DF)X''6GJ*2C;1_@=?1113("BBB@ HHHH **** "BBB@ HHHH
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MX5U5,$:*[.% 9NI Z_6GT"%HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M])TJ[U"5'>.VB:5E098@#/%86DZ_K=Q=V/\ :&FVIL;]"T-Q8S-*$.,@294
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MY:?W%_*@"A_;FG?\_'_CIH_MS3O^?C_QTU?\M/[B_E1Y:?W%_*@"A_;FG?\
M/Q_XZ:/[<T[_ )^/_'35_P M/[B_E1Y:?W%_*@"A_;FG?\_'_CIH_MS3O^?C
M_P =-7_+3^XOY4>6G]Q?RH XOQC\3=%\&V=K<W,5S=+<2&-1;J,@@9R=Q%7O
M#/CO2?$^@P:M )K>*9F41S+\PVDCG&1V]:?XM\#:+XUM;:VU>*4QV[F2/R9-
MAR1CG%7?#?AK3?"VB0Z3IL;BUB+,HD;<WS$D\_4T 3_VYIW_ #\?^.FC^W-.
M_P"?C_QTU?\ +3^XOY4>6G]Q?RH H?VYIW_/Q_XZ:/[<T[_GX_\ '35_RT_N
M+^5'EI_<7\J *']N:=_S\?\ CIH_MS3O^?C_ ,=-7_+3^XOY4>6G]Q?RH H?
MVYIW_/Q_XZ:/[<T[_GX_\=-7_+3^XOY4>6G]Q?RH CMKF&[A\V!]R9(SC%34
M@ 48  ^E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 )0:** .6\%I"CZ_Y,K29U68ON3;M;Y<@<G/UX^E=
M3WKEO!<D<CZ_Y<"Q;=5F5MK$[R,98Y/!/M74U%/X3JQO\=_+\A:2JVI7]OI>
MG7%_=.4M[>,R2,!DA0,GBL+3O%5Q<:C:6NH:+<Z>MZI-I*\J2+*0-V#M)VG'
M/-6CEZ7.FHK,3Q!I<]Q=VUM?6\]U:*6F@CD!=,=<CM5.'Q?H_P#8FGZI?7<.
MGQ7T8>);F15/(SB@#H**RK[Q'HNF;/MVJVEOO4.GF2@;E/0CU%27^NZ5I<<$
ME_J-M;).<1-+(%#GV]: -&DK)N_$VAV%\EC=ZK:0W;XVPR2@,<]./>K0U73V
MCBD%[ 4EE,,;"08>0$C:/?@\4 7:*R#XGT);MK0ZO9"X52QB\Y=P"YSQ[8-/
M3Q#H\FDMJJ:G:M8*<-<B4; ?K0'6QIT5AW?BO2K?2H-4CNHKBQFF$7GQ2 HN
M<\D^@Q6C9:E9ZE9+>6-S%<V[9VR1,&4X]Z5P+E(0",$9!'0UR.E^+=7UB*&Z
MM/"MPUC*Y59VO(1\H;:6VYSV/%;YUG3%02&_MPIWX/F#^#EOR[TP+X  P!@#
ML**S[#6]+U5YDL-0MKEH<>8(I VS/KBC3M;TO5Q-_9^H6]UY)VR^5(&V'WQT
MH T**Y>3QWI#WDMM83PWICMWG=XYT"+M.-K$G@T0^-]-N=6O--@>)KBTFAB<
M&=5!\S'(YYP3C'<]*%J%CJ:*S_[;TL:M_97]H6_]H;=WV;S!OQC.<?2HX_$>
MBRZD-.CU2T>])($"R@N2.HQ0!IFBLK7M?L?#NGM>7TA"C(2-!N>1L?=4=S5"
MY\61Q>'=-U2&RFFDU$1BWMMZJQ9QD L?E''<T!8Z2BN=;Q7"WA^TU*WM)YY;
MQQ%!:K@,TF2"N3P "#\QXXJUHFN'5EN8Y[*6RO+5]D]O(RL5R,@AEX(((Z4,
M#8HKD;?Q]9S^%=4UX6=PL>G2R1O"2-[[#C(YQS5B?QC;V^FM?-;,R"&WE\M9
M4+XF8  KG(QGJ>O.*+!8Z:BL#7?%VD: K)<W437FU62T$@$CAF ! /\ GBMV
M-M\:N!]X9H ?10** $-%8NMZ\^F3Q6MI827][(AE%NDJQD(."VYB!U(&/>J]
M]XG>"*U2TTNYNKZ>+SOLC,L+I&."27.,YP,=Z .BHKGM0\17EM;V\EEH%_>&
M2'SY%)6+RE]"6/WO]D<UL:;?P:IIUO?6K%H)T$B$C!P: +5%%% !1110 444
M4 %%%(: "BN;MO%4KZM!:7FCW=C;W;M':W$S+^]<<X* [ER 2,CM5S6=8O=.
M:..QT:ZU*5E+L(V5%11U^9N,^W6@#9HJEI.I6^L:7;ZA:DF&==RY'(]JNT %
M%%% !1110 4444 (P### $>AHJAJ>JQZ<UM&8VEFN9!''$F,GU//0 =:Q4\9
M;KV+=I-RFES7!MHM0+KM:3)'W/O 9!&2,<4+4#J:*R=9U6\TX1)9:1<ZE-)D
M[(F5%51U)=N ?0=36;+XQ#Z?IMQIVFRWL]_OVP"5(BFSA\EB!P>/?M0!U&.<
M]Z*JV%Q<7-C'-=6C6DS#YH6D5ROXKP?PK/L?$MGJ'B2^T6W5VFLHU>63'R9/
M\(]Q1UL'2YM45S>K^*)=/O9[>TTBYU!;2,2WDD3JHA4\C&XC<< G ]/>H[GQ
M;.UY%;Z1H\NI;X$G9A<1P[%;[O#D9-(#IPJ@DA1D]3CK3JS8=6635WTV6%X9
MQ")DW$$.O1L8]"0#]:TJ8!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<O9?\E,UC_L&6O_ *,FKJ*Y>R_Y*9K'_8,M?_1D
MU '44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115=[ZTC<H]Q$
MK \@L* +%%5?[1LO^?J'_OL4?VC9?\_4/_?8H M455_M&R_Y^H?^^Q1_:-E_
MS]0_]]B@"U157^T;+_GZA_[[%(^I62HS?:H?E!/WQ0!;HKS#PE\:M(\6^(X]
M&BTV[M)'5V\V=UVC:,]J]%_M&R_Y^X?^^Q0!:HJK_:-E_P _4/\ WV*/[1LO
M^?J'_OL4 6J*J_VC9?\ /U#_ -]BC^T;+_GZA_[[% %JBJO]HV7_ #]0_P#?
M8I\=W;S/MBGC=L9PK T 3T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 E(:4]:* .?\+V^H0-K'
M]H!QOU"5X-[ _NCC;CT'6NAI**4596-*M1U)N312U=9WTFZ2WM8;J9HF"P3'
M"2''W2?0UQ.C0S_VO:KHUIKMC#AA=0:@KBWB3:<"(/QD-C&WM[5Z'109GF>F
M:=?.VD6']E7<-QI27 N[F2(JDQ*%1L;^/<>:KM!K%CH&BVJZ==VS_P!EK$]U
M;Z>+F97SS$RD':N.<^M>J44^EAW/,] T2]#6SWFERJ\7AM+;,L?24,V5^O3B
MJ%YI&L066A3.NJ1H=&2SDCM;%;EUD_B#*P.S(P-WM7K=%/<+Z'G9G:ROM+TZ
M^TC6I[738(MLB6)F\V7;@%G7CY1Z=\U0LH-0\O1=*_L;41)::V;J69K<B(1L
MTC!@W0\,,^AKU/M10G829Y\GA]WT>R272BT@UPW$@:/G;N;#GVQBHKNUU*P?
M6Y8=)DDC?5TD1A;>:T:>4 98X_XB#Q^=>C44AW/*;*RU$:%>27NEW]_G6TNM
MLMF(Y)H]@^;RQP,$=.^*[#PM!.1JM\]G+9P7ER98()4*/C: 69?X22.GM734
M4/41Y-X6MHM-MK2*]L_&45Y',V^.-9_LX)<D<#Y=N,>W6K%_87-O<>)=7ETZ
M:*TU"QN8XE93F A.78=%#XR3Z@5ZC4<T,=Q"\,R+)%(I5T89# \$$>E 'FFD
M6$^L:;$NF:5<Z;Y.AO9^;/%Y8=W VA3_ ! 8)W"HM#T/5;RUU!1)JL=R-*:R
MC-Y91VJ!CT VC+\C[W3!KU*.-(HUCC551 %55&  /2G4=0/)=6M+K5A,MCX:
MO[=H=%DM6>2VV;I,C"+_ 'NYS5N\TN__ +=N$32[HK)?Z;<+*L.4V(%#Y;U!
MSD>E>GT4)M#N><2:??&_?2AIMTUX=9%\+_RB(O)W[A^\]0OR[?:F0:'>Q:5:
ME=-E6X_X24W#D1X;RO-8[S[8Q^%>E44T[!<I:K$TVDW:(F^0PN%4#))*GI7G
MNK:/=77@OP]INIV.H/IBV:K=PV<3-/',$&S*KS@'.>WK7I]%(+Z6/,].UKQ7
MHWA22.YT.YENTE2"S2"SRL4&T 2,J\DCDE>H)Q73^$$A&GW#+!J(NI)-]S/J
M%LT+S.1UP>W0#' KI:*'J2>26^A:RFD?8?[-N1%<Q74TH(/#JTFQ2/5]XQ]*
MDN-$U5M/O%73;@NVGZ9&H\ODLDF7'U4<GTKU>BFG8JYYEXAL[J*'7=/?0[S4
M;C4+N.XMIHH"R",%."_\)7:QQ[UZ3 "MO&#U"@'\JDHI">KN+1110!Q'B[2K
M.37K74=3T>YU6R^RM;^3! 9MKE@P)0=N#SV-9$^A/!#I%SXDTJZU<)8-;/%!
M"9RDF_<"RCV&,]C7IM%):#N<'.;RU\*6.CZY8ZS<&2W EN-,WNX8'[C;.1QW
M/!KIO#,%Y;>'+&"^C6.XCB"LB@ +Z#CCI6M13$+1110 4444 %%%% !36SC@
M9XZ4ZB@#@I'N-5\5Z?=PZ7JUO?6TI6<72-]E2+!!*$_*6/RX*\XS6GKVJ+/I
MJP3Z7KAM+I"#)8QN)D8'[I5?F7///3'UKJ:*.E@ZW,7PE;7=GX:L[>\B$4J*
M0(\ %5S\H..^,9]ZVZ** 04444 %%%% !1110!S.MY@\7:!=RG%N!-"6/0.P
M&W\\&L*UU2XUSQ+&VKZ/K-O;VUP19VWV!_*##@32/T/? Z 5WMQ;PW,8CGB2
M1,@[77(R.AJ4=*2 YK7=5#Z<(Y-,UIK2Y#1O)91N)HR#C[J_, >>1_6N9_LB
MSCTC2#XA\,7NH16XF6W2. S&)68%?,B7JQ Y)'7KR:]+HH Y+2?MEIH4>CHS
MVU_<1326?FQL5A0'Y0WH0&''^%9'AS2_$6B>*+B6_MK)K./3U#26<<I:5@2?
MEW=6)ZCW%>A&-#(LA0%U! ;'(!Z_RIU/K<.EC@O$NLWMYJ?]E/I>LQ:0T2O<
M3VMB\C7.[K$"/N#'WCU[>M5M:TO1I+^65_"=_->3VL<=G<BW:18\*0H_Z9%2
M1DG'K7H])20')QQS'Q-HMO(WF75I9.US(.V<  GU)YQ[$UUE0I;0QSR3I$BR
MRX\QPN"V.F34PIAU%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "N7LO^2F:Q_V#+7_T9-745R]E_P E,UC_ +!EK_Z,FH Z
MBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K'3[-B2;:(DG))05
M9HH J_V=9?\ /K#_ -\"C^SK+_GUA_[X%6J* *O]G67_ #ZP_P#? H_LZR_Y
M]8?^^!5JB@"K_9UE_P ^L/\ WP*1],LF1E^RQ?,"/N"K=% 'F'A+X*Z1X2\1
MQZS%J5U=NBNOE3HNT[ACM7HO]G67_/I#_P!\"K5% %7^SK+_ )]8?^^!1_9U
ME_SZP_\ ? JU10!5_LZR_P"?6'_O@4?V=9?\^L/_ 'P*M44 5?[.LO\ GUA_
M[X%/CM+>!]T4$:,1C*J :GHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &FJT%];7%Q
M/!%)ND@8)(,'@E0P^O!!XJRPR"#TKF]'\'6>CZO+J$1C9G#!4\H 1Y)QLQ]T
M;>".^!4MNZLC6$:;C)S=GT.D) &:YC_A-+9M#UC4X[61UT[<0F\?OEQE6![!
MJUM>^UG1KB*R1C<RKY2%1G86XW?09S7 :SX2U?1M,NH+2XOM86[TY[/88XQY
M14;E/RA<YZ<^M-;F9U-IXHU);FU76=!;3[>[8)#.MTLR[ST#8 VY[>]-N?%=
M\]S=#1]!FU&VLW,<\XN%C&]?O! 1\^/;OQ6?-<WGB:+3=+BT74K**">*:XGO
MH!&%6,@X7DY8D8]NM26U]J/A47NG'0;Z]#W$DUI-9QAT=78D!SD;2"<'\ZK0
M70N3^,6FFM+;1=+DU"ZN+;[48I)1;[(R<<EA][/&*U-,UN/4=%;4'@EMC%O$
M\4@^:-DSN'O@@\]ZYO7([J8V<FN^'YKK= ,SZ,S^?#+GYDW!@VS'H>?2MGPY
M%J<?AR1+E9#(6<VJ7ARXC/W%D(YSC />ET8=BA9^-;B?['=W&B2P:1>MBWO1
M.KDY!*ET RH('<\=ZN^&_&FD^);='MIT29Y98UA+98^6<$C\"#^(KF;&UN?[
M5L_[.T35=)U!9E^U_.PL-@_U@0;BN#U&%!J'3;74](N=+NY=&U"5;&YOHI4A
MB#,?-?<CJ,\ICJ>U/2P['<W/B71K735U&;48$M'D,2REN"X)!'UR#^54M%\6
MVVN/;^0D:QS^=L+3#<PC(&0O<'/7M^-<SI-AJFE:=H>I7.E7<GV66\$UG$H>
M5?-DRK@9YP!Z]ZK:)H.JR36C-I4M@LEOJ"[6QB$R,-F<'OUI=0T.^T[Q#H^J
MRW,5AJ,$\EJ<3*C?<ZC^AYHTOQ%I&MRS1:;J$-R\!Q(J'E?\X-<'X;T34 Q6
M^M]:N#9Z=):&*[6*&)]V 40J-S XX8GC\:UO!T>IKJI$EMJ"V$-MY:G4[:..
M6(Y&$C9>73&<D^@]::L)FW#XGBE\977ATVSJ\%LMQYY8;6W'[N/7C-5-%\:0
MZS&DB6OD!KZ6S"RS ,Q0$[E'?..GXUBZ[I.K_P#"1ZQJ%E8R2EUMHHB#@.K!
MT?'/\._<?I46G^']1M=2LA]AF\J'6[B4O@8\LPE0_7H31%)K4JR.FMO&>E'P
M[8ZQ?SI817AQ&DS9.<GCCKTJWHWB"VU?P^NL[?(MBK,2S @*.^1VXKCM'L=2
MT&QT*_NM)O+E8;*6UDM84#R1NSY#8ST(&"?>KVFZ3?\ _"J;C3VL7M+N2WFV
MVO&5)R0OXU/<E]+%C4O&6K6-I:7L7AEYK6ZDCCB9KU(VW.<+E2..HJ9_'-MI
MFH167B&W329I+;S\O<"11\^W;D#D]Z9K*OK7A?19--C:X47EK*0G\*JX+$_3
M%27FF7$OCF6]^R,\ T=H5EP,;R^=OU(JAFOJ'B/1]*M[>XOM1@@AN/\ 4NS<
M/QGC':DU+Q+HVD!#J&I06^]0Z[FZJ3@$8[5Q5A9ZEHEEHMW<Z1>WG_$H^PO!
M!&'>&3.<L"> 1QFM+1O#][8W.GI=6JL;?1C;F0?,JN6.4!/M2"QTEIXCT:_O
MVL;74K>:Y5/,,:/D[<9S[]:;8>)M%U2]FL[+4[>>XA!\R-&Y&.#_ )%<K9Z)
M?6L7A%8=-V_8X+D31D *C-'P&QV)K-TVVUR\\1:;+=Z;J AM[>>*:U>VC@MH
M2R !8F')4XQDY]: MH=]IOB/1]8NI[73]1@N)X/];&C<KR1_3M5+6?$=W8WL
MEKIVCRZ@T$/G7+"81+&ISC!8?,W!X'MZUA>$(=2CUF)!9ZE'IUO;F/;J<$:M
M;?W4A=1EUXP2>P%3^+M2U.35$TD:5JQT@H'N+FP@\QIL_P#+('(VC'4_E0^@
MD7+OQH%2*73M,EO(_LJWERWF",P0G.#@YW-PWRCTI^N>.M,T:SLIE2:ZDO!&
M\442\['(&]CT4<_TK(OX;NRN+I[#1+U[;5-,2T@2-.;9U# "09^5<,.>>AJ]
MK>BWJ?#JVTFWA:XNH5MD*1\YVNFXCV&":>@U:Y?UCQ/)87XLK+3C?3HJR3J+
MA8BBMG&W=]\G!X'I5^+6$;6%T^6!X7DMQ/"7_C'\0QV*DC\ZY+Q1HJ'6KZYD
MT2?49;^T6&UECB$@M95W ,<_<Y8'</0UJ+'.=?T"SE?S;NRM&DNI <X^4+R?
M<G/O@TD)['6]J:[!5+,< #)IW:FR-LC9@K-M!.U>I]J0'+V7B^>YOK1;C1I[
M;3[YREI=O*"7(!(W1XRF0#UI=%\4WNM7G[O2(TL/F(N!?([D#.#Y8&1D^]8V
MBW]]K&OK>ZWH6L0W"ETM('MPMO;#!&XOGEB/XNV>*31M*MXM3L4TCPM<:--9
MNS7,TD8 E7!&T2Y)DR3W^M"!F[9^*;E]5AM-2T:;3HKI7:UEDE5C)M&2&4<H
M<<\U'I7C%]0O[2&XTJ:SM=0#&PN'D5O."C/S*.4..>:S8DN=5\6VM]'HNI65
MQ&K1WK7AS 4VD;8CDC)..5 XJCH&BWDGB/33]FU:WM=+:4B.^V^7$&7:$B8<
MN/=NU./2X/9V/2A2T@Z4M !1110 4444 %9NL7]U86RM9:;+?W#OM2)&" >[
M,>%'O6C65KUY+9V.Y=.N[Z%R4F6T;]ZJD=5'!/X$$=:3&A-"UG^V;*65[=K6
MXMYF@N(&8-Y<B]1N'!X(YK+L?&7VR_@C;39(K*\=X[&Z:4?OW4'(*XRO1L$^
ME1>%(9].T^6!K"]BL[JZ;[-',N98D*\F4YR,D'DDGD5E:5IVIRS:'H\^G7$
MT:[>>:Z=?W4JX<+L;/).\9],&JZBZ&Q#XHUC_A(+/2KSPWY!N=S>8E^DA1%Z
MNR@9QG ^IKK!TKG=%LK@^(M:U2[AD1GD6WM]X_Y9(.J^S$_I714N@=1:***
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M6?VSIW_/W'0!?HJA_;.G?\_<=']LZ=_S]QT 7Z*H?VSIW_/W'1_;.G?\_<=
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M<NK+@D'H%'/%=M]F@_YX1_\ ? J6B@"+[-!_SPB_[X%'V:#_ )X1?]\"I:*
M(OLT'_/"+_O@4?9H/^>$7_? J6B@"+[-!_SPB_[X%'V:#_GA%_WP*EHH B^S
M0?\ /"+_ +X%'V:#_GA%_P!\"I:* (OLT'_/"+_O@4?9H/\ GA%_WP*EHH C
M6&*-LI&BGU"@5)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN2Y\@L"8PP "DCC/'.#3Z#5B.T\7I+X-M=?GL;@-<)E;6!3*Y;) 7@8'3J<
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MKQ/X]T;PMHK:I=--/$KK&4@7+9/3J1QQ4'A+XCZ'XOTZ>]L_M%O'#+Y16Y0
MDX!R,$\<UI^*/"6E^+=&;2M2206S.LA\E@C9'3G%0>$O!&C>"].FLM*24PS2
M^:WGOO.[ '!QTX% &G_;>F_\_2_D:7^V]-_Y^E_(U<\F+_GDG_?(H\F+_GDG
M_?(H I_VWIO_ #]+^1I5UG3V956Y4L3@#!ZU;\F+_GDG_?(I?)C!R(T'_ 10
M \4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI:XS3?%VHW%[I\MY86\6EZI(\5F\<I:56&2/,&, $*>A-=D* %HHHH ****
M"BBB@!#30BABP4;CU..M9NK:JUE<V5I!$LMU>2;45C@!1RS'V _G62^OZS9Z
MU:1ZAIUK#I][<&W@"3%IU/.&88V[3@G@\9%"U!G545D:U<ZU"L2:/:6LKD%I
M);N8I&@';@$Y/TQQS61<>-3!X-BUN/3+FXN)8WVV\2$@,F=Q9^BK\I.3VH Z
MZ@  8 P*IZ5>-J&D6=ZR!&N(4E*@Y"[@#C]:R-*\4KJWBG4-*@MS]GM(E87)
M/$C$D$ >@QC/KFBVM@\SHZ:RJZE6 *D8(/0U@>+?$Z>&;".5(#<W,LBI'"#C
M@L 6/H!G^54-;\5ZA97=X+&SM)+?38$GO#/,4=E;)Q$ ,$X!ZXYQ26H'8# &
M!2UC6NM&;64LI8?+2XMA<VS\Y8<;@?0C(XK8%,!:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE[+_DIFL?]@RU_P#1DU=1
M7+V7_)3-8_[!EK_Z,FH ZBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BJUW?6UGM\^3:6Z#&35;^W=/\ ^>Q_[X-
M&E16;_;NG_\ /8_]\&C^W=/_ .>Q_P"^#0!I45YQXQ^,>B>#]4AL9[*]NFEA
M$P>$*  21CYB.>*Z'PYXWTOQ%H%KJT0F@CN Q$<J_,N&(YQQVH Z:BLW^W=/
M_P">Q_[X-']NZ?\ \]C_ -\&@#2HK-_MW3_^>Q_[X-7+6ZANXO-A;<F2,XQ0
M!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6([O1;*[L5@M-$,FV[\U6^T@J5&U1RO7)R*I_P#"QO$'_0BZA^<G_P ;I?\
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M:R?^%C>(/^A%U#\Y/_C='_"QO$'_ $(NH?G)_P#&Z'7A_28?V5BK[+_P*/\
MF6TT?Q#HIL+N"T34[C[ ;*=!.$*'=N5MS=0.A[TZ71;[3_#=AH,F@1:[9) J
MR 3K&5D!SDAR!CTQS5+_ (6-X@_Z$74/SD_^-T?\+&\0?]"+J'YR?_&Z'7@_
M^&8?V5BNR_\  H_YG:Z!9W>GZ%9VM]-YUS%&%=\YR?J>M:5><?\ "QO$'_0B
MZA^<G_QNE_X6-X@_Z$74/SD_^-T_;P_I,%E.)[+_ ,"C_F>C45YS_P +&\0?
M]"+J'YR?_&Z/^%C>(/\ H1=0_.3_ .-T>WA_28?V5BNR_P# H_YGHU%><_\
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M&9(OL,H&"^TGU(;Y<_=I_P#PL;Q!_P!"+J'YR?\ QND_X6-X@_Z$;4/SD_\
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M7Z*EQ'$%9%  7T'''3TIBU-; ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH
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M )^X?^^J=]@L_P#GUA_[X%'V"S_Y]8?^^!0 W^T['_G[A_[ZH_M.Q_Y^X?\
MOJG?8+/_ )]8?^^!1]@L_P#GUA_[X% #?[3L?^?N'_OJC^T['_G[A_[ZIWV"
MS_Y]8?\ O@4?8+/_ )]8?^^!0 W^T['_ )^X?^^JP_$WC[P[X3MH+C5+MA'.
MY1/)0R'(&><5O?8+/_GUA_[X%<KXX^'&E^.+*TM;F:6S6VD,@:V506)&,'(H
M UM"\7Z+XBTB/4["[!MI&95,@*-D'!X-:7]IV/\ S]P_]]5C>$O!FG>$_#L&
MCP9NHXF=A+.B[CN8GG ]ZV_L%G_SZP_]\"@!O]IV/_/W#_WU1_:=C_S]P_\
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M_BJ/^%8^$?\ H%M_X$R__%47K=D'+EW\T_N7^9J_\)=X=_Z#FG?^!2?XT?\
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M?[1'N /;.:D_X2[P[_T'-._\"D_QK+_X5CX1_P"@6W_@3+_\51_PK'PC_P!
MMO\ P)E_^*HO6[(.7+OYI_<O\S5_X2[P[_T'-._\"D_QH_X2[P[_ -!S3O\
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M_P#GZ\.?^ T__P 71Y?CO_GZ\.?^ T__ ,77444 <OY?CO\ Y^O#G_@-/_\
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M8=#T6TTNW=WAMHQ&K28W$>^*OT <OY?CO_GZ\.?^ T__ ,71Y?CO_GZ\.?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M??)M"*3@M[GVK70[E!]:K:C8Q:C:-;3%@C$$[3@\'-65&U0/2DNH/<=1113
M**** "D-+2&@#G/M^M0^*(K:9K![*?<4@C5O.10!\[-G&,YXQ_(UT=<_8^&#
M8:_=:JFL:C(;E]TEO(R-'TP /EW #L,XY/K704= ZBT444 %%%% !69KMQ>V
MNDS36+V\<J#<9+A69$4<DE5Y/'85IU1U33_[2M#"MU<6D@.Y)[=@'4^V01^8
M-)WMH->9%X?U"35="M+V8())8PS; 0,_0\CZ5IU3TO3HM+L5MHG>3!+/)(1N
M=CU8XXR:N53\B5>VH4444AA1110 AKF$\6)<>-TT*V-N\*1OYTAD&\2KM(0+
M]#G-=.:RF\.Z6=;AUA+.&.\B5QYB1*"^[&2QQD]/UHZ@:HZ4M(*6@ HHHH *
M*** *&M7DNGZ->7<$1EFBB9HXPI8LP' P.3S5'PMJ=[J6EEM2PE\C8DB^SF$
MH#T!4LW;WK5O;87EK) 9)(]ZX#Q-M93V(/K5;2=*72H&0W,UU,[;I+B<C>Y[
M9P /TH74&: Z4M(*6@ HHHH *0TM)0!QVI^*-2MO%*6=O;#^SHG6.YE>$D L
M,_ZS< O4?PG-=B*Q;OPY#=ZHEX;NYCCR&EM4*^5,PZ%@1G/T(Z5M"A; ]Q:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** $HJCK-Y+I^EW%W#$DCQ)O
M*NY4$#KR ><=!CDUF^$]3U'4]+W:E (YX3Y3$M\[./O%E"@+[ 9X-3S*_*:J
MC)TW4Z(Z"BL>\U>Y&H&PTVS2ZN(T#S-)-Y<<8.< D*Q+''3'3J1QFG-XJ^RV
M4S7-D8[RWFBAFMS)P [!0ZMCYEY)Z \$$"CF01H5);(Z2BJ5EJMAJ,3R65[;
MW"H<.895<*??%-L=8TW4VD6QO[:Y:/EQ#,K[?K@\4[HAPDNA?HJC:ZOIU]-)
M#:WUM/+%_K$CE5BGU /%-MM:TN\N?LUMJ%K-/MW>5',K-CUP#TY'YT70<DNQ
MH451N-7TZUCEEN+ZVB2)_+D9Y5 1B,@')X."#5/4/$^F:>M@[W4#1WL@2*3S
M5"E<9W9SR.@X[D>M%T5&E.3LD;5%48M1A-K/<SRV\<4+NK.LVY5"G^(D#!]1
MV]:6+5M.GM/M<-];R6^[;YJRJ4R3C&<XSD@471/)+L7:.U4K75M.O8))[6^M
MYX8B1(\<JL%QSR0>*K2Z_8MHU]J-A<6]ZEK$[D0S @E5S@D9Q_\ 7HNMQJG.
M]K&M14-O*9[>.;&W>@;'ID55;6],2_\ L#:A:B\_YX&9=_3/W<YZ<T76XN25
M[6-"BL;2O$VFZL)#!=096X:!5\U26()P1CU"DCU J_)?V<*3O+=0HMO_ *XM
M( (^,_-Z<$'GUH4E:XY4YQ?*UJ6J*YV/Q5;75_/!:-:RPQQQ2+<FY C;>Y7&
M0",C;QZD@<=:U+O5M.L)HHKN^MX))?N)+*JEOH">:.9,<J,XNS1>HJC?:QIN
MF;/M]_;6OF9*>=*J;L>F35Q&5T#(0589!'>GH0XM*]API:04M @HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRWMXT>25%%GX@EDN26_U*L9 K-Z [AR:C>ZM[K6;C4=WFZ9#JL<DT@&5VBW
M5_\ =#;3GIT/09KT? ]!0 /05/LGW-_KJWY?Q_X!YAJ%S87FN:O<Z:R21/\
M8"\L?*NPGP2#T;L,CTQVJ[?.UGK>M+J&J:=91W04(+ZV,GFP[ ,*=Z@@'=\N
M"<GW%>A8'H*,9ZT>S\P>-V26GX]/+R. D\C1EM95\0P079T](F_M*V94N%7.
MT@,RL&Y.1DXR,CI77Z%)YFA6+_8Q9[H5/V=5VB/CIC Q^5:! ]*4=*J,;&%6
MO[2-FM?Z\D+10**LYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>sava-20221231x10kg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20221231x10kg002.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_X0!:17AI9@  34T *@    @  8=I  0
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /LN@ H
MRM5UB'1_L_GAV^UW,5JFP*<22[MI;++A!M.XC<W3"FMZ=*5;GY;+DA*;O?:-
MKVLGKKILO,SG-4^6]_>DHJW=_H:M8&@4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 95YK$-E>VNGR!S+?^=Y94+L'D()'WDL",@X7:K9/7 YK>-*4X3JJUJ?+
M?>_O.RMI]]VC-S491@[WE>W;17=S5K T"@ H * "@ H * "@ H * "@ H *
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M6_/3C/:UN:^F[O:V^GH8TY^TYM+<LG'UMU-VN4V"@ H X7QS_P PO_L,6?\
M[4KU,'_R_P#^P>I^AQU_^7?_ %]A^IW5>6=@4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 %  >1QQ0!PS^-H=*O3INM+]DEZQSC)MYD.=K@_>C/9E;<JL"/,( )]-825
M6'ML,^==8_;B^J[/R:LVNAQ^W4)>SJ^Z^C^RUW\OZU(M:E2?7]#DB971AJ!5
ME(92/LR\@C((^E523CA\2FK->RT>C7OL4VG5HM;>_P#^DG?5Y1VA0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M& ,DECQW))]Z\^4Y3DZDG>3=V_/\CI45%**V2LO0X_\ X5IX=_Y]/_(]S_\
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M>:9V>['_ &\R_P"-'UZKVA_X!$/JT.\O_ F'_"O=/'26\'_;U)1]>J?RT_\
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M#?\ E6?^0>SJ_P#/W_R2(?V!XB_Z#7_E/MO_ (JCVV&_Z!O_ "K/_(/9U?\
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M3+7J4/\ =L3_ -PO_2V<=3^+2_[?_P#23NJ\L[ H * "@ H * "@ H * "@
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M\BN9(Z<$,,CD'D$5!0M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MP==P!VL.C#/1AV(Y':J3<;V;5U9VZKMZ":3W]22I&% !0 4 % !0 4 % !0
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MWZNUK_<5%./IT6]CMZS+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!%<3I:Q/-*=J1*SL?15!)/X 4>0'SUI=YXB^*-U/<6E[)H^FP/L3R2P;
M/4*?+>-I'VX9RT@5<@*,'%=;4:22:NSG7-/9V1T/AJ/Q7X;UH:9?M+JNFRJ#
M]J;)$8.[#^8YW!@RXDB+N=I#*#E2T2Y)1NM'V*7-%V>J[E3Q?XIU?6M<7PKX
M=D^S,G^OG!P<[=[?/@E$C7 )3YV<[0>@+C%1CSS^2%)MOEB9VNZ)XJ\"VW]L
M6^K2ZC'!M,\4_F, &(4D)+)*'3) 8J8W .X 8)%)PF^5QMVL)J4=4[G>R_$2
M"/PR/$80%V4((<G'VC<4*9Z[0P+YZF,9')%9<GO<G]6-.;W>8X31/#WBOQI;
M#5[K5IM.2X!>&*$R*"O\)*120JBG^$Y=RN"1DUHY0@^51O8A*4M;V.G\"3>*
M+#4)])UQ)+JUC!\N\;IN&"-LC;6E213W#,CC:<88")\C2E'1]BH\R=I;=SS#
M5?'6H^'/%MQ(T\\UE#<LKVS2NT7E' 8+&6**5!W)@## =B:W4%*"T5[;F3DX
MR\NQW'Q3UZX@ET:73+J6*"[>1B8)7C65"UJ4+;&7<,.<!LX#'U-94XKWDUM_
MP2YO:S_K0G\?ZK>V7B?1K:VN)H89Y8!+''*Z)(#=*I#HK!7!7Y2&!R.#Q1!+
MEDVN_P"0Y-J22_K4U_&/A#5+Z:XU2TUBZL8DBWBVB\T(/*BYP5N8U&\J22(^
M">_>8R2M%Q3\_P"D.47NFUY?TSS+P'HVN>-K::Y_MR^M/(E$>WS)Y=V5#9S]
MICQUQC!^M;3<8.W*G]W^1G%.6O,_Z^9UVEZA?P^/)-+ENIYK:&WC'EM+)Y3,
M+* E_*+E0S.2YZG<Q))))K-I>SYK*]_U92;Y[7_JQ1U#Q!K?CS7)M&T&X-A9
M69823H2K-L;8S[EP_P S\1QJR@J-S'J0U&-.*E)7;Z VY.T=$BOKB>)_AF8]
M1_M!]6L6D$<JW&\D$\X*R/*R!@I"R1R##8##!PS7+4TM9^0GS0UO=&M\5/$L
M[:)I^I:5<36RW<@?=#(\3%6B+;6*,I.T\$'HPJ:<?>:DMAS>B:+_ (/\:/XA
M\,W8ED8:CI]K,KON(D;$3F*<'.X-QAFSGS%+9&X4I0Y9+LW_ $AQE>+[I&C\
M'M1NM3T1IKV:6YD%U(N^:1Y&VA(B%W.2< DD#..3ZTJJ2E9::#@[K7N3?%N_
MN=-T(SV<LMM+Y\0WQ.T;X.[(W(0<'N,X-*DDY6?8<W9:',_!OQ#>7QNM.U*>
M6XF58KF)II'E;RY% 8!G)(49C.T' 9FZ'.;JQ2LXJW0BFWJF>8:MXQU:]UHW
M5O>745G/>M'#&D\J)Y4;HH^17" ,I!( P6+9R<D[**4;-*]NQFY.]TW:Y]"?
M$SQ _AW0YIH',=Q.5@A93M96DSN92.0RQAV5AR& ((/-<M./-)+IN;S?*CS#
MX?:YJNCZ]'I>MW$]PNH6L<D7GS22!'DC$R8\QFP<;XF QE\#L!6TTG&\4E9]
M#.+:=GU1W7Q@U&ZTS1%FLII;:0W4:[X9'C;:4E)7<A!P2 2,X.!Z5G22<K/L
M7-V6G<X_XDZU?V&@Z//:W-Q!+-$AD>.:1'D)MXV)=E8%CDD_,3R2>M:4TG*2
M:7],F;:2LSH?#OC1_$/A*]E,C)J-A97"R,K$2;E@<Q3AAA@S;<[@<B16(QQ4
M2ARS79M?GL-2O%]TAO@);_Q1X4DA>]N(KJ6:15NR\DDL85XVX8R*^, K@2+@
M,?H2=H3V5NP1O*.^O<\X\6Z?KGA;4;33?[:OKC[=M_>>;/'LW2"/[OVE]V,Y
M^\OI[UM%QDF^5*WI_D9R3BTKO4[O6?#NK^#]$U&]EUB[OG,,:Q[FF1HF\^/+
MHQN)2"5)4[=IP2,XXK)24I)<J7_#>AHTXIN[,GPOX-USQ)ID&I_V_?0?:%8^
M7NG?;M=D^]]K3.=N?NCKCWJI2C%N/*M/3_(E1;5^9_U\SO4T2_\ "OA_4_M&
MHW&H3_9KF6*:0R+)$5MVVA&::5@0PW JRX/(&>:RNI2C9):K\S2SBGK<\X^$
M?CRYEO&TC5IY)_M7S6\L\C.PD4<Q;G8G:ZC*#. ZX )>M:L$ES15K;V,X2UL
MSI?">JWMQXVU2SFN)I+:**8QPO*[1(1-;@%(RQ12 S $ 8!([FIDDH1:6O\
MPY46^9HL?%O7KRT6RT?2I9(;R^F'S0NZ2!00B*&0A@))'[==A%*E%:REL@FV
MK);LB^%&NWKW%_H.K32W%U9REE:9VD<JK>5( SDMM5@C*,D?O#CW*B5E*.B8
M0;UB]T8OQIUO4-)NK(6%S<6H>.4L(99(PQ#)C<$8!L=L@^E522:=TA5&U:QN
MWWC-]?\ !5QJEK(UO>0I''*8G*/',)8@Q4J0RK(IW+@_=;;DX-2H<LU%[#YK
MQNMR?2_%\F@^"H-8NF>ZN2C*AE=F:25II%3>Y)8A0,GG.Q< CBAQO-Q6B_X
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M:5F6% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M4G=R_KH)JW*=I\7]2EU76;31;6&2\^RKYTD$09GD9_F9 %5VXA3.0IVAV)!
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MSGHE)^S3ZLQ27/;L?3]<1TA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M'25!1G:OJD6B6<U_.&:*V0R.$ +$+U"AF4$_5@/>FE=V0F[*X:/JD6M6<-_
M&6*Y02(' # -T#!68 _1B/>AKE=GT!.ZN:-(84 % !0 4 % !0!@7?B!(;EK
M&U@N+ZXB4/*L B A#8V>9)<2P1!G'*QJ[2;06*!<$THZ7;27G_P+DWZ+4N:5
MJT&L1&6#>IC<QRQR*4DBE4*6BD4]&4,.061@0R,RD,1KET&G?8TZD84 % &7
M+J\,5_'I9#^=/#).K #8%B9%8$[MVXF08 4C&<D<9JVE_D*^MB[=7"V<,EPX
M)6%&=@,9(12QQD@9P.,D#/<4EKH/8CT^]34K6&\B#+'<11RJ&P&"R*'4, 2
M0",X)&>A/6AJSMV$M=2W2&8VG:TFJV"ZE:12R+(K,D7[M96VLR[1ND$0)*G&
MZ0#&,D535GRL2=U=&9:^*7N[J2R33[U9;<Q>=N:QQ&)061B1>G<-H+'R][ #
M&,X!KELKW7X_Y$WZ6?X?YG65F6% %'4]2@TBVDO+HE8H1EB 6/)"@ #N6( [
M<Y) R0TKNR$W;4O4AA0 4 % %'3-2@U>VCO;4EH)@6C8@KN7) ;!P0&QD!@&
MP1N .0&URNS$G?5%ZD,* "@ H * "@ H * "@ H * "@#'US2!K-N(0_DS12
M1SP2A=WES1,'1BF5#KD;70D;D9ER"012?*Q-7,6ZTS5==6.TU(6MO:J\<D_V
M>669[@Q.DBQ@/#!]GC9UW.0\SE0(P1DO5)J.JO?I?2WYW)LWH[6.6L;#4M57
M6M/MOLZ6MYJ$\,DSLXFB5XH5FV1")DEW1'$>Z6$HY).X8%6VERMWNDO^ 39N
MZ6UR_-X(-M/<-;V>F7R73B1);],S6[E%1T(%O)]HB&P2(OFV[ LZ%L8>ES[7
M;5NW7\=/Q'RVV2?J:P\,W"#5 IA4:C;Q0PA R*ACM3 =R8;RTW$%55I"$]Q@
MSS+W?)_K<=M_/_(MQ^&56T1&>;[2EJL/%U="WWK (L^0)!"5R,\P\GYBN_FE
MS:^5^ROOW';3Y=V<NW@R_,-O;3BTOHH+"VMECN)9O(MKB*)XI+A+80M%=%MX
M93-Y,H"A5DC!R-.9:M76K>EKM=K]".5[:/1?+Y=271?#&L>'VLY(/L<YMK#[
M'*CS31ACYS2!TD%O(0 -O#1\Y8<8#%.497WWO_6HTFK6MM88/ 3V_P!GN&BL
MM3G19UN8KQ=L+-<3-<F2!O)N#$T<K,@!B821-R49?F.?=:I:6MY::["Y;=GZ
M_>;%AX:GM[JPN?+LK9;07GFPVD;11@W"Q!!&-N)"NPB21A%NX(C'W0G+1K76
MV_D4E:VVE]O,V?%.E2ZWILMC;E%DE,1!<D*-DL<AR55CT4@8!YQG YJ8OE=V
M-JZL@O\ 2I;K5+&_0H(K-+I9 2=Q,ZQ*FP!2" 4.[++CC&><"=DUWM^ 6U3[
M7.1'@AK>6=([/2;J.XN7G2YNXB\\2S2>9(C1"$^?L)<1$W4/RE0V-IS?/MK)
M66RV_P"!]Q/+;HOG_7ZE+Q'X&O\ 6_MD9%I.UR[&WNKJ6=Y+:(A6$$-MY+Q0
M8=2AFBE#,AWO&S?)3C-1MNK;I6U\[B<6[[>O8UM7\+7]^^HB,VZIJ:V;*S22
M!HY+9HMR%1"0R,JL5D#!MP53'ABRI22MOI?\?F-IZ^=C7NM N)K^]O%:,1WE
M@EK&"6W"13.26&W 3]XN""S<'Y>F94DDEV=_R';5ORL<XG@>2U,4IM=.U)_L
M5M;2I>9 BEMHQ&)()/LTY,<@)#QM'&<HC!QDJ*Y_-K5O3S[ZHGEMT3T6_E\C
MH=)\/3:??QWC"VCC2P%J8[:-H4$GGM*3'%\P6/#8'[PL6R2HS4N5U;7>^OH4
ME9W\K&3HWA2^TF33),P2&QANH)QOD7Y;B59 \1\H[RH7!1Q$"3P]4Y)WWUM;
MY"46K>5ST:L30* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \.\*:
MO9:3XGUTWUQ!:B2:,(9I4BW8,F=N]ESC(SCID9ZUTR3<8V5S&+2E*^AQT^KR
MV;^)-3\/'9:LUM&)8?E4,[E))(RN/FR92LB_=\P2*1N4UI;X(SWU(O;F<=C7
MO-+L_"+:)?\ AZ5S>7\T238E=_ML4@0R-(A8KM#X'RA0K/N/SHK+*;ES*6R_
M =E'E<=W^)+X<GCM]#\3^:P3$UZO)QS)$\:#'J[G:OJW YHE\4/D"VE\SG[.
MRM]1NO#5I>.T<$]G-&^UVC+AVG7R=RE6 G)$+ $%ED*CK5-V4VN_^7Y;BWY4
M^Q;U"!-$;Q%HFG.QTV*TBE6(N9%BF+0[E5F)(/S.K9)8[%#DE*2UY)/>_P"&
MH/3FBMK%28W6K3Z/I+VK:G:KI4,T=E]J^R)+)L<&8R$C<T:Y  (8 ''REPST
M7-*]GS/6UPWLK75MKV.P\+:]J_AO0W*63ZJ(KXP00V]U'=/# 8B^QI;9;CB
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M8?\ "]M"_P">%_\ ]^X/_DFCZA5[P^^7_P B'UF':7W+_,/^%[:%_P \+_\
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M+_(/^%M>%_\ G]_\E[K_ .,4?5ZG:/\ X'#_ .2#VL//_P !E_D'_"VO"_\
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MT_PYX3TIUELQ:PND4D(9;ELF.7=O#DS'S"=Q :3<ZKM56"HH#>,I/>M3_P#
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M*T+POH<WVBP%M!)Y)@)%P2&B9MS*ZM*5D).,LX9\!1NPH 'BZ3T=6GW^./\
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M G_D&NV/A'Q*ZRZG)9321C"N+I8WV_W6:*5&91U56)"DDJ!N.18NE'X:M/\
M\#C_ )@\)6>]&I_X!+_(=<VWA.ZM8+"26Q%M9.)((TNEC5'&?F_=RJ6)+,6W
M%MS$LV6)-'UNDFW[6G=_WX_YA]4K;>QJ:?W)?Y$\3>%X;JXOUGLC/?)Y=PS7
M2.LJ8"[6C>5H\%0 0$&1USDT?6J5DO:T[+;WX_YA]5K+7V537^Y+_(SM&TWP
M;X>N#>:?)8PSD%=YNQ(5#==GF3.$R."4"G:2N<$BF\73EHZL+?XX_P"8EA*L
M=51J?^ 2_P BM?:'X'U&YDO;EM/:>?<9&%X%#%AAFV).J!SDL7"A]Y\S=O\
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M  +@_P#CE'L:O_/N?_@,O\@]I#^:/WH/^$QT+_H(V'_@7!_\<H]C5_Y]S_\
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MWH/^$QT+_H(V'_@7!_\ '*/8U?\ GW/_ ,!E_D'M(?S1^]!_PF.A?]!&P_\
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M .@:A7KTO]TJ?XU_[8<$_P"/'_#_ /)'L&ZO-.L-U !NH -U !NH -U !NH
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MNHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL ;J+
M&ZBP!NHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL!\^_'8Y.F_P#;
MW_[;5ZN$^"M_A7Y2.*M\4/7]4> 5B6% 'J?@V1;S3)--AOKG3KK[5Y_^B6]S
M.\D7E*F'^S ':K<KEL [LJ<J1A+1WLFK6U:7YFL=K7L[]+_H<OXM3R;E8C?S
MZFZ*0YN(IXGB.?\ 5[;AF?D?-Q@<]*N.VR7I;]"9>MSE*T("@#Z*^ /74_\
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MJ>S]OR_N[VO==[;7OOY&*KT_:?5^;]Y:_+9]K[VMMYD5CI5UJ;%;6,R%>3R
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M75ON^\T6UKV90\7ZA%>/;0K<?VA-:V_E3W>''G/YLCA09 '=8D98UE8 N!G
M4+3BK7TM=Z(4GMUMU.0K0@* /5OAAXZL?!7VS[?'/)]J\C9Y"QMCRO.W;M\D
M>,^8N,9Z'..,Q4BYQBET<OQ4?\BX246[]4OPO_F=EJWQRVWD4NE0N]H$(GAN
M52-BV[(:*2)Y-IV\98,O^P3S7.J.GO;]+&KJ:Z;#OB!XMMO%WAN&ZM8YH=M]
M$&66-E&?(N<[)!F.09!^ZVX#!=$R ?G<UBX4HI_SK_TF1]%E,N:M)K_GV_\
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MM2="M%*</Y;VT=GNWW(/#UJ+J^B1AE5)<_\  06'Z@"L\)#VE:">R=W\E?\
M.Q>,J>SH3:W:LO\ MYV_*YLM:#7-5F1F*(F[..3B,A,+V&3S^9QFNYT_K>)G
M%MI*_P!T;1T]7J<*J?4\+"44FW;TO*\KOT6@7.CVB1.T;2PR1YPMQM7?C/W.
M%SG'&">V0,@T3P])1DXN<)1Z5++F_P .U[]/RU"&)JN<8R4)QEUI7?+_ (M[
M6Z[>N@+9_P#$J-QYDOWL>7O_ '?^L ^YCKWZ]>:%3_V;VG-+?X;^[\5MOQ]0
M=7_:E2Y8;?%R^_\ #?>_RVV+USHEC9R1I(\W[[ 4#:2#D#).T +R!T)KHGAJ
M-*48RE/WM$E;?NW;;5=+G-#%5ZL9RA&'N:MN^W9*^^CZV%;0[.&X%K))*7DY
M3:%  P<;B0<DD'H![XH>&I0FJ4I2YI:JUM%YNWD]@6*K2INM&,%&.CNWJ_)7
M7=;D-EH4<MU+;3,V(@""N 3G&,Y!['\ZBGA8RJ3I3;]W9JRW]4^C-*N*E&E"
MK!+WMT[NUO1KJ5=&TN+43()2R[ "-I ZYZY!]*RPU"-;FYVU9*UK>?=,UQ->
M5#EY$G=M.]_+LT;>E"W73I?]8%Y\W[N[.T9V=L8Z;O?-=U#D6'G\5M>;:][*
M_+Y=KG!B/:?6(?#?3DWM:[MS>?>QEO9K_9K3I)-M#D+&6&S'F8&5 QNQR<'&
M[FN1TU]7=2,IVOI%OW;<UE==_P!3K51K$JG*,+\NLDO>ORW=GVO^!9\01>:E
MFF0NY2-S$ #(BY)/0"M<7'F5"-TKIJ[T2TCJS+!RY'7E9NS3LM6]9Z(9#H-E
M=.T,3S,RKGS0%,)/' (')&>1GU&<BICA:-1N$)3;2^)6Y+^3MKZ7^94L76II
M5)Q@DW;D=U-+S5]/6WR*%CH<$]O--<.R&W=E)7!7" $G!7))YQR.W%<]+"PE
M"<ZDFG"33M:UE:^EK][:G15Q4X5*<*44U.*:3O>\KI:WLNE]![:+I[VHOUDF
M6$9W!@I<\[<+@  EL==PQUQUJGAJ#IK$*4U#JFDY;VLK:)W]4)8JNJKPSA!S
MZ--J*TO=WU:M?L[F;K.CPV=O%>6K.T4V!B3&X9!8= !T!R,<'N:Y<1AX4H0K
M4FW&725KZJZV2.K#8F=6I.A624X=8WMH[/=ONC#L9(8+A)+E#)$I)9!WX..I
M QNQGGIV/2N"DX0FI55S16Z[Z:=NMCT:L9SIRC1ERS>S[:J_?I<[C5KW^T-#
M,X41AG "#HH63:!V[#T'TKWJ]3VV#]I913:22Z)2LOR/GL/2]AC?9W<FHMMO
MJW"[_%E&WD?3_#IFMR8Y)'.67AN9-G!Z@[5 R.1VYYKG@W1P#G2?+*4M6M_B
MY='TT5CHG%5LP5.JN:,8Z)[?#S:KU=R]/&-3M-,FN/F<SQJS$9)&'+ _[WEK
MN]:Z)+V]+"SJ:R]I%-]U9M_?RJYSQ?U>KBZ=+2*IR:79WBE;TYG81]5N1XC%
MH'/D !-G.WF'S,D=-VX]>N..E)UZBQZH\SY+6Y>FL.:]N]^O;0:P]/\ LYU^
M5>TO?FZZ5.6U^UNG?4\X\2VZVVI7$:<+YA8#TW8;'X%J^9QD%3Q%2,=N9O[]
M?U/J<%-U,-2E+?E2^[3]#9M_#NGC28]5NY)DRS!U38=P#NBK&"HPQPI)9B,!
MN.01Z$,)0^K1Q=:4U=NZCRN_O2BE%-:/1.[;6_R\ZIC*_P!:G@Z,8.R7*Y<R
MM[L9-R:>JU:LDGMKWGU#PSH^GPQ7\L]S]EN NQ55#*2XW YVA0H7)8%<^A)P
M#M4P>&HPAB)3J>RFE9)1YKO6][)));JU_P C"EC<56G/#PIT_:P;YFW)123M
M:UVVV]G>W?N9NK^#/LNHV]C:R%H[P91GQN0+R^[ 4-A?F& N?N\8R<:^ ]G7
MIT*4KQJ;-[JWQ7M:]EJMNWF;T,P]I0J5ZL;2I;J.SO\ #:][7>CWMOY%Y?"V
MAOJ TD3W7VA?O'$>QB%+%$.S*L!\QW!EP"N=W3H6#PKK?55.ISK?X;-VNTG;
M1]=;KI>YS/&8M4?K;IT_9O;XN9*]DVKZI[:-/K:QP?B+3H])OYK.$LT<3 *7
M(+<JIY("CJ>P%>1B:2H59TH7M%V5]]D^B7Y'LX:K*O1A6FDI25W;;=K2[?YG
MI'@>UN+SP_=06;^3.]PX1]S)M/EP<[D!8<9Y S7T. C.>$J0I/EFYNSNU9\L
M.JU7R/G,PG"GC*4ZJYH*"NK)W7-/H]'\S=\/:3J^A">XU6Z:]B$1VPHTL[%A
M@Y!D4,#@%0JY#;LGH*[</1KX;GGB*CJ1Y=(IRF[^7,D_*RWOKL<&)K8?$\D,
M-35.7,KR:C!)>?*VK=;O56TW..\-MO\ #&J, $!>8[1T&8H^![#I7G8;7!XA
MVMK+3M[L3T\4K8W#J]](:]_>EJ&LWUQI_A'3Y+262!S*BEHG9&*E+@D$J0<$
M@''3(![4ZLY4\%1E3DXOF2O%M.UIZ:"HPA4Q]:-2,9+E;M))J]X:V?4G\$ZG
M/XHTR_TW4W:X6.,;'?YG =7QECR2C1AT9LMN/7@5I@ZDL52JT:[YDDK-ZO5/
MKY-)IO6YEC:4<)6HUZ"46Y.Z6BT:Z=$TVFE96,'P_"-9\(W]I+R;%VGB.!\F
MU!*0/KMD!/7#GMBN>@O;8.K"7_+MN4?*RYOTE]YTXA^PQM*I'_EXE&7G=\OZ
MQ^Y'CK5X)]"0M3)(&JA$+4".D\&.L>KVSN0JK<6Q))P !=0DDD\ #&2:Z*'\
M:C_U\A^9SU_X%;_KU/\ (^K[GQKHD$3RI?V4C(C,$%W!EBH)"C#DY8C P#UZ
M&OT/DEV?W,_-^9=U]YP[_$72?%EC'#;N8+LWFG'[/-A7.-0M2WED920 !C\I
MWA5+,BBNJG!PG=[<L]?^W)&$Y*4=-[QT_P"WD>D;JS&&Z@ W4 &Z@ W4 &Z@
M W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@#/\
M#?\ Q\:G_P!?Z?\ INL*=7:G_@?_ *7,=/[7^+_VV)U-<IN% 'AOB;CX@Z9_
MUX/_ .@W]>S1_P!UJ?X__D#SZG\:/^'_ .2/4=U<1J&Z@ W4 &Z@ W4 &Z@
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M/;(4C1SF,9;<2R='/L^Y<?PYYKB4G%66AT.*>K//_C2BQ:';H@"JM[$ H
M$%Q@ #@ =@*\+,_X,?\ &O\ TF1[^5_QI?\ 7M_^E1/F1:^2/L29:0R=:0R9
M:0SU'P'XCLK2WN=%U8E+.^SB09^1V4(VXC. 0%(;&%*Y;@Y'KX.O"$9X:OI"
M?7LVK._X:]+:GBXW#U)RAB</K4I].Z3NK?C==4]-3=MO"7A?36:YO=3BO(0"
M5AC= V,'&[RI'D=AD$;0F2.01D5T1PV$I-SJUE..MHIJ_P ^5MM^B1SRQ6,J
MI0I4)0EI>33M\N9))>K>A%X5US3/(O\ 1)':SMKUI#;RRD-M#+LQ(> " JL,
MG!^92^<%L\-6H\M7"MN$)M\DI:VNK6?W)]MU>^^F*H5N:CBHI5)TTN>,=+V=
M[Q7S:[[.UKVMZ?/9>"M,NT%W!>WE\NQ$MG\Q% #JK,PZ8\PLP.,X"KGDU4)4
M\#1J+VD:E2HK)0=TK)I-OYW=_1=R9QJ8^M2?LYTZ=-W;FN5N[3:2_P"W;*WJ
M[;$&MW]M+X6L;:.6)YXY4+Q*ZF10$G!+(#N49(Y('4>HK*O4A+!4J<91<E)7
MBFKK2>ZW6Z-</3G''5JDHR4'%VDTU%ZPV>SV?W$WB*_MI_#EA;Q2Q/-&8]\:
MNK.N(I =R@EEP2 <@<D"GB:D)82C",HN2<;I--KW7NMT&%ISCC*\Y1DHM2M)
MII/WH[.UF;?B>XL]5GLM3@N[8K"8@T9D E^:9"3LZJ%!8ONQM"]\\=.+E3K2
MI8B%6%HN-X\RYM9+IT25V[VM8Y<'&I0A6PTZ52\E.TN5\ND'UZMNR5KWN:S:
MM9'Q(MP+B#R19;/,\U-F[S"=N[=MW8YQG.*W=:E]=53GAR^RMS<RM?F>E[VO
MY',J%7ZBZ?LY\_MK\O++FMRK6UKV\SG/"U];V^OW<\LL<<3_ &C:[.JHVZ92
M,,2 <CD8/(Y%>=@ZD(8RK.4HJ+]I9MI)WFFK-NVJV/3QM*<\'2IPA)R7L[Q4
M6VK0:=TE=6>C+VA:C:21ZEI\TT<'VJ28QR.P"$/N7(;(4XX/49!XSS6F&JTY
M+$X><XP]I*;C)M<KYKK?;31[ZIZ&6)HU8RPN)A"4_9Q@I12?,N6SVWUU6VC6
MI8LA9Z3HMW9_:[>:>0.Q$<@QED"A4S@OPN20.IQCBJI^RP^$K4?:TY3:D[1D
MK7:22C>SEMT76Q-3VN(QE&O[&I"$7%7E%WLFVW*UU'?9OI<U%U*V-M:FPO(;
M*WB ,\1P)6 P2 N"Y8D,#C&[=N!;@'I]M3]G1^KUH4J<=:D=.=I6=DOB;NFG
MWO>[Z\WL*BJ5OK-"=6I+2G/7D3=U=OX4K--7VM:RZ4]4U*V37K:\66-X1&%9
MT=7"D^8IW;2=N-P//8Y[&L*]:FL;2K*<7!12;332^):V>FZW.BA0J/ UJ#A)
M3YFU&47%OX7I=*^SV+$3VUOKGVTW-NT4XD(*R+\F$0#><X!8YVC)R!^ TBZ<
M,9[?VM-QFI;27NVC%>\]DV[VUZ&4E4G@OJ_LJBG!QW@_>O*3]U;M)6OIU*VG
M:K;>??V,\@2*[EF*2C!7YBPSNZ8((*G[O!R>165&O3Y\10J22C4G/EGTU;6^
MVJLT]O,UK8>IR8;$4XMSI0AS0V>B3VWT=TUOY;C[![;PW;3GSXKF:<!46%MP
M&-P!8CI][+9QC&!DU5)T\#3J/VD:DYJT5!W6E[-]M[O[E<FJJF/J4U[.=.$'
M>3FK/6UTEUVLO6[L1:C<POHMM"CHTB.I9 P+ ;9>2H.1U'4=QZU%:<7A*4%)
M.2DKI-76DMUOU+HPG'&59N,E%Q=I--)ZPV>SV)=5N89-)M8D=&D0IN4,"RX1
M@<J#D<\<BKKSC+#4H1DG)6NDU=>Z]UNB,/"<<56G*,E%\UFTTG[RV>S*?AB4
M0W\>>C!E_$J<?F1C\:PP4N6O&_6Z^]?TCHQT>:A*W2S^YJ_X:FA$(K75)A/(
M\'SN5="!C<=P#95@00>>P/7CD=,>6GB9JI*4/>=I1:ZNZO=/1I^ARRYJF&@Z
M<8S]V-XR3Z*SM9K5->IT']H+'!(M[-!<KC""/!=O]Y1P">.@P.N:]'VJC"2K
MSIU%;11W?JEHOT[GF^Q<IQ>'IU*;OJY745Z/=K\^QD)/%_8YAWKYF[[FX;O]
M8#]W.>G/3I7&I1^J\EUS7VNK_%VW.UPE];4^5\MM[.WPM;[%O6;B*6>V9'1@
MA&XJP('S+UP>/QK;$3C*=)QDFD];-.VJW[&.&A*%.JI1:;6B::OH]B2ZN(FU
M2*570HJ@%@PVC[_4YP.H_.JJ3B\3":DN5+>ZM]KJ13A-8:<'%J3>BL[_ &>F
MY);WT,6I3,SKLD4 /G*Y 7N./7GU&*J%6$<1-MKEDE9WTNDNNW<F=*<L/!*+
MYHMW5M;-OIOV%TJ*WTUI T\3%QQAAC SU/3<<]!Z=^SH1A0<KU(N^UFMEY]]
M=A8B52NH6IS5M[I[OLNVFY1T^:./3IXV95=BV%+ $_*HX&<G\*YZ,HQH5(MI
M-WLKJ[T6R.FM&3Q%.23:5KM)V6KW8T31C2##N7S-WW-PW?ZP'[N<].>G2ES1
M^JN%US7VNK_%VW'RR^MJ=GRVWL[?#WV+5]=6S261=D=(PV\ AMORIC<!G'([
M^AK:K.FY4')IQ5[V:=M(VO;S_(QI4ZBC744XRE;ENFKZRO9OR_,T8[U$NB[W
M41@88CC#+P< DL1P,8.,GG..#@'I51*HY2JPY&K1BFM/5]-G:[Z]-CD=)NDH
MQHS4T[RDT]=>BZ[J]ETZ[F+#<0I9WL9D0,\DI4;ERP(&"O/(/8CK7#&<52KQ
M<HW<IV5UKHMN_P CT)0FZV'DHRLHPN^5Z6;O?32WF4_M$0T0P[T\S=]S<-W^
ML!^[G/3GITYK#GC]3<.9<U_ANK_$NFYOR2^NJIROEM\5G;X&M]B/5[F*32K:
M)'1G0IN4,"PPC#D Y'/'(J<1.,L-2A&2<E:Z35U[KW6Z+P\)QQ56<HR46I6;
M32?O+9[,XMA7AL]]'6O=0_V (-Z>;OSY>Y=_^M)^[G/3GITYKV'.'U%4^:/-
M?X;J_P ;>V^QXBIS^ONIRRY.7XK/E^!+?;<32+JUO]-?2KJ46S!MR.Q 7&X,
M.I )#9RI(R#P>N##SI5L/+"5IJFT[J3M;>_6RWW5UIMY&)IU:&(CC*,'435I
M15[[6Z)O5;.SUW\UUC6+;3UL[2S?SULW21W4@@[>, C@E@S9P<#(&>N#$8BG
M15"C0ESJE)2;3WMT[:W=^P8;#5*SKUZ\>1U8RC%-6M?6]M[*RMW-4OI+7PUS
M[4@(3)BR-Q;9LSMSOSMXV!>6 .>QZ[X5UOK_ +5?#?DNKWY>7:_-MI:VYQ6Q
M2H/+O8RMS6Y[.UN;FM>W+OKS-[=#RO5;PZA=2W/3S79@#U"Y^4?@N!7R5>I[
M:I.K_-)M>2Z+Y(^RP]/V%*%'^6*3]>K^;N=3=7D!\,PVPDC,RR$F/>N\#S93
MDIG<!@@].A![U[$JD/[/A24H\ZD[QNN9>_)[;['BPIS68SJN,N1Q5I<KY?@@
MM[6WTW&^)+VWGT2QABEC>2,1[T5U++B(@[E!)7!X.0.>*K%U(2PE"$91<DHW
M2:;7N=4M5KW)P=*<,9B)RA)1;E9N+2?OWT;5GIV-C7M>M+;4]/NTE2:.%9!(
M8F5]H=0A)"D] Q..IP<5VXG$TX5\/5C*,HQ4E+E:E;F5NE^]_D<&&PM6>'Q%
M&491E)Q<>9.-^5\VE[=K7\QMMIUE)KZZE%>02K,Y:.&-MTID9&!# <*BC+[B
M0>-I7N7"E2>+6(A5A)2=XQB[RYG%WNELEO=^EA3JU8X-X:=&<7%)2E)6CRJ2
MLTWNWM9>MSSSQK_R&+K_ 'U_] 6O$QW^\U/5?DCW<!_NU+T?_I3.J\)265QH
M-UIUU=0VCSSO@R.@8*4APP1G0D94CJ!D'GBO4P;IRPM2A4J1IN4W\32=K0UL
MVK['E8U5(8NG7ITIU%""^%.U^:>ETG9ZE_P]8:3X2E>];58;@;"/+C9!GODH
MDLK.>/E  P?6NC#TZ&"DZKQ$9*WPQ:_)2DV^QS8FIB,=%45AI0=_BDGI\W&*
M2[F1I>LVDFB:MODCADNIKB2.%Y$60B1%*A5)!;GCY0<D$"L*5:#P^(O*,7.4
MVHMI/5*UEU[:'16HU(XG#6C*480A&4DFU[K=[NUEWU+BP:;K_AVSTZ;4+:RD
MA*R-O>-F! E7:4,L94G?G)/;ISD;)4L1A:5&5:$'&S=W%O3F5K.2MN8.5;#8
MNK7A1G44KQ5E)+7E=TU%WV*OV[2? NEW$&GW27]]>#;OC*D#Y2JL=C.JK&'9
M@"Q9F..GW9YZ. HSA1J*I4GI=6[63T;22NWO=O\ "N2OF%:$ZU-TZ4-;2O?>
M[6J3;=DMDDOQS/"$@L_"^K7$A 20/",_WFB" ?B95%9X5\F$KS>SO'YN-O\
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M_P"ZU/\ '_\ ('G5?XT?\/\ \D>F;JY+&@;J+ &ZBP!NHL ;J+ &ZBP!NHL
M;J+ &ZBP!NHL!S/BVZCMK M<6IO[<NBSQCJD1/S2@!6+&,X.!M/?<H!--(#S
M72VL(=5M%\)37+1O+F[AS*;>.#'S%A,HVOU"Y+$'IAL9OIJ+T([\_P#$J\1_
M]?Y_]&Q4=4!T?CX_\2:Q_P"OJT_] :DMP-'Q@?\ B9:-_P!?C?\ H I+J!CZ
M5KUMX5U'4[?4R\+W%VUQ!B-W$R..!&44Y;H".!DXSPV':]K <S;.S>%-:+JT
M3'4)2R-PR$O:Y5A_>4\'W%/JO0#M-;/_ !,= _WY?_1"4EU YUKR^L;/79M-
MW><-2;+(,ND9*[W0=R%_[Y!+<;<T[;7[ <QXH_L>[TUI--EO=2N5*-)-,T[K
M"NY=QDWA(PS$A0 &.6SP,&FK^@CU9)!)XO#H05;1001T(-YD$?45'3YC*VA'
M_BJ]7_ZYV?\ Z(2A[("?P2<7>K_]A*7^0H?3T [_ '5-AANHL ;J+ &ZBP!N
MHL ;J+ &ZBP!NHL ;J+ &ZBP'@_QM.3I_P#V]?\ MO7I8;X*O^'])'-4^*'K
M^J/"JY38* /4/!?BJ/0;2.-II+8?V@'G"*_[ZW>$0MADZFV)\WRR03O5D!9:
MQG'F>W33R?\ P36+M]YE>.;_ .VO9K)=?VC/!;&.6Y7S/*?]]*4V&14+,(R@
ME8#!88)9E8TX*U]+*^PI/;6YPE:F84 ?17P!ZZG_ -N?_MU6-?X(?XI_E VI
M?%+TC^<CZ+KSSJ/'OC;_ ,@6#_K^C_\ 1%Q7BYE_!C_C7_I,CW<K_C2_Z]O_
M -*B?,*U\D?8DRTADRTADZTADRTADZTADRTADZU(R9:11,M(9.M(9,M(9.M(
M9,M(9,M(9,M R=:I$,G6M$9LF6K1FR=:T1FR9:T1FR9:M$,LQ.T3!T.&4@@^
MA!R#^=:Q;BU):-.Z]4922DG%[-6:\F:FHWPU&;SPGEL5 ;!SDCC=T&.,#'/3
MK776JJM/VG+RNROK>[779''0I/#P]GS<R3=M+63Z;OJ5%%8HV9,HJR&2 51!
M(%JK$C]M585PVT6%<0K2L.Y&14V*(R*DI$3"I+(B*AFB(&%9LM$3"H9HB!JS
M-$0M4,M$#5FS1$+5#-$0-69HB%JAFB(&I#(6H$/M;G[',DVQ)=ASLD4,C#N&
M4\$'].HYK:G+V<E.RE9[25T_)HQJ0]I!PO*-UO%VDO-,ZZ/Q?8VLXO+?3(HK
ME5(5UE(1<@C(B6-4S@X)&&()^;FO9CCJ4)>UIX:,:B5DU)I+_MU12^>_F>)+
M 5IP]C4Q,I4V[M.";?7XG)OY;>1PE]=R7\[W,QS)*Q9CVR3T'H!T [  5Y$Y
MRJR=2?Q2;;^?]:'LTX1I0C3AI&*27R_7N4&J"R!J8B%J8B!J8B%J8CH;OQ(T
MFCPZ)!'Y,<<C2S/OW&9R21D!%"JN>A+YVISE>>Z6(O1CAHJR3;D[WYG]RLE\
M]EV//CA[5Y8J4KMI1BK6Y5UZN[??3=]SD6KC.XA:F20-5"(6IB.F\$_\AJT_
MZ^;?_P!*(JWH_P :E_U\A_Z4CGK_ ,&M_P!>I_\ I+/M:OT _.3E_&'_ "#U
M_P"OW3O_ $XVM=-#X_\ MV?_ *1(QJ_#\X_^E(7=6I@&Z@ W4 &Z@ W4 ><Z
MEIOVS6)IM%O_ +%JB11"XA:/?'(F/W9(< 'Y< LF_;QPK')KIKL(Y#6=3FN]
M UBUNXK=+FTGMUFFM5VQSL]Q$=YX!,@P=Y/<XP,&J2LT!V[*K^,E9ADIH^5]
MC]K*Y_)B/QJ>GS K:'_R-FKGOY5G_P"B8Z'L@.+U4$Z/XC"C_F) X'_7Q"2?
MZD_C5=5Z =;\3[R&31X=KJ?/N(&CP1\Z\MN7U&""3T&1ZBE%:@R]='_BK[?_
M +!LG_HXTNGS XC4C_Q3OB#_ +#,W_I3:U75>@'::CJEW<ZW)IND1VD-S#;J
M\UU<(6D*,RD1QA,,RC*D[B5SG@$#,VTU&<YHKS_\)!J*W5Q'>3)IQ5Y(T6-0
M04.S:I/*9P226['&,!]%ZB)M.4)X#8*,9M;@GW)EDR:/M!T)?$2J/ D> !BT
ML"..A+V^2/<Y.3U.3ZT+XOO#H>M[J@8;J #=0 ;J #=0!#X7_P!=J?\ U_I_
MZ;["HK?\N_\ !_[?,UI?:_Q?^VQ.MKD.@* /"O%?'C_3?^O!OY7]>U0_W6?^
M/_Y \ZK_ !8_X?\ Y(]'W5RE!NH -U !NH -U !NH -U !NH -U !NH -U !
MNH -U !NH -U !NH -U !NH -U !NH -U !NH -U !NH -U !NH -U !NH -
MU !NH -U !NH -U 'A/QJ.3I_P#V\_\ MO7HX?X*O^'])'/4^*'K^J/#JY#<
M* /3] NWMM(.G2V,M^C7TIN;?R)=Z(8(522.54/E3HP;:,[MI(==K@UBUK>]
MM-'?S?X&JT5K7U*'C:UM]/M].M+5I62.&9@)XFAE027$D@21",;T#;69<HQ&
MY?E8"G#5MORV]!2TLD>?UJ9A0!]%? 'KJ?\ VY_^W58U_@A_BG^4#:E\4O2/
MYR/HNO/.H\J^+^G76IZ1#%90RW,BWD;%(8WD8*(9P6*H"0H) )QC) [BO(S"
M$JE**A%R?.G9)MVY9=CV<MG&G5DZDE%<C5Y-)7YHZ:GSHOA/6A_S#[W_ ,!9
M_P#XBOF/J];_ )]S_P# )?Y'U?UBC_S]I_\ @<?\R9?"FM#_ )<+W_P&F_\
MB*7U>M_S[G_X!+_(?UBC_P _:?\ X''_ #)E\*ZS_P ^%[_X#3?_ !%+ZO6_
MY]U/_ )?Y#^LT/\ G[3_ / X_P"9*OA;6!_RX7G_ (#3?_$4OJ];_GU4_P#
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M53_P"7^1'UJA_P _J?\ X''_ #)5T:_'_+M<?]^9/_B:M8:O_P ^JG_@$O\
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MQE_[X;_"H]C4_DE_X"_\BU6I_P \/_ E_F1-IUU_SQE_[]O_ (5/L:G\D_\
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M?U]T? '+>,?^0</^OS3O_3C:UTT/C_[=G_Z1(QJ_#\X_^E(CW5N<P;J #=0
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MW.BV5W8C2IH]UFJ1QB/>X^2(J8QO#!_E*+SNR<<DY.3S UMU( W4 &Z@ W4
M&Z@!/"O^MU+_ *_U_P#3?85E7^Q_@_\ ;YF]+:7^+_VV)UU<AT!0!X1XMX\?
M:;_UX-_*_KVZ'^[3_P ?_P @>;6_BQ_P_P#R1Z%NKG&&Z@ W4 &Z@ W4 &Z@
M W4 &Z@#'UO6DT2 3-').\CB***)2SO(RLRJ .@(4Y8]/0G )8#%\%:S>ZS!
M=2Z@ DT5[+"(P !$J)%^[R/O;6+98DDGOC !8#+M;W6/$[W%UIUTEC:P2O#
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M[.+#3[,[@WF6T,D<G&?EW-,XVG/(V^G-4HVUNWZB;OI9(]B^ /74_P#MS_\
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M^&+QMJYE%X7) ^8J'"YXYP ,9Z=J974B%O$/!& JC,'F=!]_S<[O][WZ]NE
M=30T<BYU]#<_,T6EP-;[NV[;YCKG^+)()'.,BD!;MHH8?%\IA 5GTW=+C _>
M&XC&3CN4"$^O7O0'0T?'Y_XD5W_NI_Z-CH$C,\5VMG%X898PJQ0Q1- < $-E
M-K+C.&;)R023N;).2:!K<[FPD=[:)I<^88T+9Z[BHSGWSFBPCC_!QQ=:K_V$
M)/Y"@&1^)<3:YI,-P ;8O<, <%3,L8,8;)Z@[=G'))'/8 A\2PPKK^DS*%$[
M/,K$?>**@V[O8$MM/N1]&,]$W4K$ANHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL ;
MJ+ >(_&0Y-A_V\_^V]=U#X*O^'])&4OBCZ_JCQ2N(Z0H ]2\&W(GTR33K>]O
M-/N_M)G'V*WN)GDC\I4(D-NRMM#9*@G"G)(.X%<):.[2:M;5I?F:QVLFT_(Y
MCQ:SBY6.2_N=3>-2&-U'/&\1SGR]L[NPS][C YZ5<=MDO2WZ$R]6_4LZ%X1U
MK4K5KNPM([F"X1H0[M!\I#C<4$DBM'("F V =K''#9H<HIV;M]X*+>J0S4O"
MNL>'K*1[ZUCCAE>,&5F@DD1EWX5"DC.@?)WX&&VKD\"A2C)Z/\P<7%:H]9^
M/74_^W/_ -NJFO\ !#_%/\H%TOBEZ1_.1]%UYYU&5J/^OL_^OEO_ $DNJY*W
MQT/^OC_],U3LH_!7_P"O2_\ 3U$U:ZSC"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,K5ONP_]?,/_H8%
M<E?:'_7R'_I1V8?>?_7JI_Z2:M=9QG*^-/\ D&_]OFG?^G"UKJP_\3_MV?\
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MM=MV23GD9YSD@]BWX @:T?4H7<RLE_("[?><X^\W^TW5O<F@&>B[J+"#=18
MW46 L^$/OZE_U_K_ .F^PKGQ'V/\'_M\SJH[2_Q?^VQ.RKB.D* /!?&/'CS3
MO^O!OY7U>YA_]VG_ (__ ) \RO\ Q8_X?_DCN-U9V(#=18 W46 -U%@#=18
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M)I9?W)_^^4_^.4_[2H_RS^Z/_P D+^S*W\U/[Y?_ "([_A,[/^Y-_P!\I_\
M'*/[1I?RS^Z/_P D+^S*W\U/[Y?_ "(O_"8V?]R;_OE/_CE/^T:7\L_NC_\
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M;V0_@G_[Y3_XY2_M.C_+/[H__)#_ ++K?S4_OE_\@-/CFQ'_ "SG_P"^8_\
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M_P"U:'\M3[H__)A_9%?^:G]\O_D!I^*NE#_EE=_]\1?_ !^C^U:'\M3[H_\
MR8O[(K_S4_OE_P#(#3\6-*'_ "RN_P#OB+_X_3_M2C_+4^Z/_P F']DU_P":
MG]\O_D!A^+6DC_EE=_\ ?$/_ ,?H_M2C_+4^Z/\ \D']DU_YJ?WR_P#D!I^+
MND#_ )8WG_?$/_Q^C^U*/\M3[H__ "0O[)K_ ,U/[Y?_ " T_&#2!_RQO/\
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MLW?X'WBOS/7:]\^=.4\:_P#(,_[>]/\ _3A:UU8?^(O\,_\ TB1A6^!^L?\
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MX[T[_KP;_P!OJ]S#?[M/_'_\@>97_B+_  _YG9[JDR#=0 ;J #=0 ;J #=0
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M "';'_KYB_\ 0UK>C_%I?]?*?_I:.>O_  :O_7JI_P"D,^UZ_0#\Y.3\;?\
M(,_[>]/_ /3A:UU8?^(O\,__ $B1A6^!^L?_ $I&'NKT#S@W4 &Z@ W4 &Z@
M W4 &Z@ W4 &Z@ W4 &Z@#EY_!NCW$IGDME+LVYL-(JENN3&KA#SSRM*Q5V=
M,@6-0B *J@  #  '   X  X '2@0[=3$&Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4
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MW_Y!9_Z^]/\ _3A:UUX?^(O2?_I$CGK? _E_Z4CGMU>B>:&Z@ W4 &Z@ W4
M&Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@#
M7\%==1_Z_P ?^D%C7#B=X?X/_;YG?0^%_P"+]$=O7"=84 > ^-O^1ZT[_KP/
M_M]7NX;_ '>?^/\ ^0/+Q'\1?X?U9UM!@% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!XW\6NMC_ -O'
M_M"NJG\%3_#^DB?M1]?U1X_7G':% 'JO@35K33+9!(;5'DOU2Y:=(FD%M)#L
MB=/-5OW<<Q9Y2H^7Y=_RL<X33;Z[:6[_ /#&L6EVW,OQ_<2S/9I=-;_:XK8K
M/':^28D;SI=K9A^0-+'LD9,Y7(.%#!14-+VO:^EQ2Z=_(\^K4S"@#USX7^(K
MSP[%?26-A-JC2M:JR0[\Q@"Z(8[(9C@GCD#ZU%6*E"%W;WI_E N#<7*ROI'_
M -N.A\6_$[7XQ;RQV%SHACD;YIM[1S@KS&4EMXE..N1EEZKM/-81IQUU3_3\
M324WVL5?%_BZ_P#%7AR&6^L7M-MY$5G'$$W[FX_U:N?-'7C'FI@',H.%/SV:
MQ4:4;/[:TZ_#(^BRF3E6E=?\NW_Z5$\B6OC3[4F6D,G6D,F6D,F6D,G6D,F6
MD,F6D,F6D4=Q\/O^0Y;?]MO_ $1+7IY?_O-/_M[_ -(D>5F/^ZU/^W/_ $N)
M#XJ4OK-TJ@EFF(  R23C  '4GL*QQ:OB*B6_.S;!-+#4F]$H(]AU;C6])5C\
MX6XW>O\ JA_4']:^HK?[UA4][3O_ . _\.?)T/\ =<4UM>G;_P "_P"&,JSO
M+*TUW4/M3I!,^P02R 80[/GP6^4')0X)&0",UR0G2IXO$>UE&,WR\DI6LM-=
M7HNF^]CLJ4ZM3!X?V493@N9SC&]W[VFBUMOMM<E\2V5U+I3&?R=0,9WBZ3;%
M(B@@D^6JLK#&0VV1>"#M)7-/&4ZDL.W/DK..JJ*T9):?92::M>]I+3II<6"J
M4XXE*GST5+1TG>46]?M-IIWM:\7K?76Q7UB\D\(VEG!IH1/-4O*Y4,9"H3.<
M]FW'/<# 4J!6.(J2RZG1IX;E7,FY.R;DUR[^M_6UDFC?#4HYE5K5,5S/E:48
MW:44^:UK=K>C=VT[E+23:>*-765K=8%6-I'CW!ED=2 "1L3^\"PY#;>>K9YJ
M'LL?BE-TU!*+E*-[J335FURKOJNMM>M^K$*KEV$<(U'-N2C&5K.":;:3YGVT
M>EKZ=+:NG:[+J6J/IEPD;VCM+&L>P801AB#G&23MP<]SE=O2NNCBI5\3+"U8
MQ=)N<5&RM'E3L_G;7SVL<=;"0P^%CBZ4I*LE"3ES.\G)JZ[:7T\M[EW284TN
MTU)$ D2WEE*JW((5 55O4= WKS6V'BL/2Q44DU"4[)ZIVC=)]^S.?$2EB*N%
MDVXRG"%VM&KRLVNW=%:WNWUO1;F2\"N\);8P4*1M567&T #&2. ,KP<\YSA4
M>+P=65>S<&^5V2M9)K;UMINM&:SIQP>-I1P]XQFES*[=[MI[][7UV>J+6H:O
M=1:-;W*/B65@CMM0Y!63(QMVC[HZ 'CZUK5Q%2.$IU8R]Z32;LM5:5U:UNBV
M1E1P]*6,JT91]R*;BKRT=X6=[WZO=BW7_'GI?_72W_\ 013G_"PG^*G^2%3_
M (V,_P -7\V6]2U26TU6&WB"A)3&)/E&6WMLY;KA1C:!CG.<BMJU>5/$PI0L
MHRY>;17?,[;[Z+:WXF-##QJX6=6=^:/,XZNT>5<VVVKWOTVL.M($@UR41@*&
MAW$#@9)3)_$\GW)ITXJ&,FHJR<+_ #?+?_,FI-SP4.9W:G;Y+FM]VWH9_AP?
M\32X_P!V7_T:E<V#_P!YJ>D__2T=6-_W:EZP_P#2)$FDQR11SS((X<R,/M$C
M?=&>BH5(//<L 21UVXJL.I1C4G%1C>37M)/97V2MK]Z5[;V)Q#C*5.G)RE:*
M?LHK=VW<KZ?)-V3VO<N:U*8;>WNXV5IE8 2A0-V4;)P01@XSCIZ5OB6XTZ=:
M+3FG\:2UNGT\S#"Q4JE6A)-0:?N-O2TE;7R'>(;F1)8H%.(WVEEP.2'!'.,C
MIV-/%SDI0II^Z[-K3I+[R<'3BX3J->]&Z3UTO'738L7=I'=ZHBRC<J0;MIZ$
MAV !]N<X[XP>*TJ4XU,3%3U2A>W?WG_F9TZDJ6%DX:-U+7[7BO\ (JVNHO=W
MK6<JJT#%U";1A0H;!]><<Y[GC%90K.I5=&:3@^9)6VM?_+_*QK4H1I457@VJ
MB46W=ZWM_G_G<GL8UL8+M5 98G? /(.%R ?7T/K5TDJ4*R6JC*5D_):)_J15
M;JSH-Z.48W:TW>K7Z%:.=M3TV9KG#-&6VG &, ,.F,8SCCJ.#GFLU)U\/-U;
M-QO9VMLDUM_5C64%A\335*Z4DKJ[>[:>_P!_J<C;QB25$;HSJ#]"0#7C0BG*
M*>S:7WL]N;<8R:W2;_ Z7723J4([+Y>/^^R:]3%?[Q!=N7_TIGDX33#U'WY_
M_247=8U26QO8XX@H5@I?(!+@L5P3U  '&._7/2M\17E2K1C"UFES:;W;5K^7
M2QSX;#PK493G>Z;Y==(V2=[;:WUOT)([6.VUG]T HD@+D#@9+8.![[<GW)-4
MH1IXOW%:].[2[WM^A,JDJF#]]WY:BBF^UK_J9FFQR)->3QK&I$LB^?(P C^8
MDX7:<GD$Y*CH,^O+1C)3K5(J*]Z2]I)V4=7LK._=ZI;'77E%PH4Y.3]R+]G%
M7<M%N[JRZ*R;W)=<C6[TV*1G2>3S HF5=H.693P.W&#V)&0!Q58F*J8>,G)3
MES)<Z5NK3^7?H[7)PLG2Q$X1BX1Y6^1N]M$U\^W57L0:SJ;^'I8;2S55A5%=
MQ@?O/F92"2"03MR6'.3D^AC$UG@I0HT4E!13:LO>U:LW;RWWNR\-06.C4K5V
MW-R:B[OW=$[I7\]MK(@\/I;:K>S7HA6+RU4K&2&0.V<O]U<?=STX))ZXQGA%
M3Q%:==04>5)J+=XJ3O[VRMMVTNWVMIC'4PU&GA^=RYFTY)6DXJWN[N^_?5)+
MO>>=TO;.>+4[FRE?!:!HI$W*P!('13@' &,E@6#$U<FJM*I#%5:,I6;@XR5T
M[/3IY6W;5TR()T:U.>$I5X1NE44HNS5UKN^EV]DG9HBO]1ETS1+26#:)#L56
M90Q3Y&)*A@1NP,9(/!/K4U:TL/@Z,Z=N;W4FTGR^Z]5?2_3T;*HT8XC&UX5+
M\JYFTFUS>\M':SMK?U2*VLVT>LVEA>2JJ37,T4,C*,95]P/Y%<C.=N2*RQ$(
MXJEAZTTE.<X0DUII*]_RNK[7-L-.6$JXFA!MPITYSBGK9QM;\[.UKV0:OK<N
MAZA%IUFD<=JHC#1[!\^\\Y/7@=".2V2Q;.*,1B982O##4(QC27+>-E[W-OKO
M_P '5W%AL+'%T)XJO*3JOFM+F?N\JTLMO^!9*QFZM91:1XBM?LH$:RO"Q4<
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MS\Q_SK>E_%I_]?*?_I<3"M_"J_\ 7NI_Z1(^V*_03\X.2\;_ /(+/_7WI_\
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M##?\_/\ R6?_ ,B2CX9^(A_RZ?\ D>V_^/4?4,3_ "?^30_^2'_:&&_Y^?\
MDL__ )$E'PU\0C_ET_\ (]O_ /'J7U#$_P#/O_R:'_R0_P"T,-_S\_\ )9__
M ")(/AOX@'_+I_Y&M_\ X[2^H8G_ )]_^30_^2#^T<+_ ,_/_)9__(DH^'.O
MC_EU_P#(UO\ _':7]GXG_GW_ .30_P#DA_VCA?\ GY_Y+/\ ^1)1\.]>'_+K
M_P"1K?\ ^.TO[/Q/_/O_ ,FA_P#)#_M'"_\ /S_R6?\ \B2K\/M>'_+K_P"1
MK?\ ^.TO[/Q/_/O_ ,FA_P#)#_M'"_\ /S_R2?\ \B2CX?ZZ/^7;_P C0?\
MQVC^S\3_ ,^__)H?_)#_ +1PO_/S_P DG_\ (DH\!:X/^7;_ ,C0?_':7]GX
MG_GW_P"30_\ DA_VEA?^?G_DD_\ Y$D'@36Q_P NW_D6#_X[2_L[%?\ /O\
M\FA_\D']I87_ )^?^23_ /D24>!M:'_+O_Y%@_\ CE+^SL5_S[_\FA_\D/\
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M#?\ /S_R6?\ \B1'PCJO_/#_ ,B1?_%U']GXG_GW_P"30_\ DBUF.%_Y^?\
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MOU'_ *!EY_W]T_\ ^3J.:'_/R/W3_P#D Y)_RO[X_P"8;]1_Z!EY_P!_=/\
M_DZCFA_S\C]T_P#Y .2?\K^^/^8;]1_Z!EY_W]T__P"3J.:'_/R/W3_^0#DG
M_*_OC_F&_4?^@9>?]_=/_P#DZCFA_P _(_=/_P"0#DG_ "O[X_YFWX3M+FW%
MY+=PO:FYNQ*D<C1,^P6EK#N/DR2H,O$^!OS@ D#-<M>49.*@[VC9M76O-)]4
MGLUT.FE%Q3YE:[OT[)=+]CK*Y3<* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#*U'_7V?_7RW_I)=5R5OCH?]?'_ .F:IV4?@K_]>E_Z>HFK76<8
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!E:U_P >I]I(?_1T=<F)_AO_ !0_]+B=F%_BK_#4_P#3<C5K
MK.,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H RM1_U]G_ -?+?^DE
MU7)6^.A_U\?_ *9JG91^"O\ ]>E_Z>HFK76<84 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'C7B#QKXBBU^;0M"M;6Z,,22@2[E?:4C9B6:YA3AG
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MI--:-6!.^Q3@\1:7<SBUAO+62X)*B))XFD++G< @<MD8.1C(P<]*?*UK9V]
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M@ H * "@ H * "@ H * ,K6O^/1O]Z+_ -&I7)B?X3]8_P#I<3LPO\5>D_\
MTB1JUUG&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 96H_P"OL_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M76<84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MI>5FM5W#5)73T9T.J7-QXUFM+*WL[RVMH+J*ZN9KN%K<;(#N6*-7^=WD; )
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M;T_,[KQEI$NO:-=6%N0)IH_W>3@%T99%7)X&XJ%R>!G)K*#Y9)LN2NFD<4D
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % %#5-,AUBUDLKD$Q3+AMK%6&"&5E8
M<AE8!E/8@<$<4T^5W0FKZ&/I_A6*RNDOI[BZOIX5=(6NI$<1!P ^Q8XXUW,
M SL&<CC=5.5U9))>0E&VNIT]04% !0 4 % !0 4 % !0 4 % !0 4 9.LZ-#
MK< @F:2,QR++')"^R2.1/NNC8(R 2/F5@02"*I/EV$U?0I:9X9@TZ:2ZDEN+
MRYFC$+37$@9Q$"6\M/+2)$7<2QV*"6P2<TW*^FB7D)*QMVEI%80I;6ZB.*%0
MB*.BJHP!SR>.Y))ZDDU+UU96VB+%( H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
@@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>sava-20221231x10kg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20221231x10kg003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #_!7(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/[F?JK17Y5?\/\?B%_T)?@S\[G_XY1_P_P ?B%_T)?@S\[G_ ..4?\0ZSO\
MD7_@2#_6K+OYG]S/U5HK\JO^'^/Q"_Z$OP9^=S_\<H_X?X_$+_H2_!GYW/\
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M*/\ A_C\0O\ H2_!GYW/_P <H_XAUG?\B_\  D'^M67?S/[F?JK17Y5?\/\
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MYSF=L]O2A^'&=)?#'_P)!_K9E_=_<?K!17Y5?\/\?B%_T)?@S\[G_P".4?\
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M/SN?_CE'_$.L[_D7_@2#_6K+OYG]S/U5HK\JO^'^/Q"_Z$OP9^=S_P#'*/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_0W7XMXK_P ;#>DOS1^@\%?PZOJOU"BBBOR0^W"BBB@ HHHH **** "BBB@
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M4U[U^CVM<^S/VGM?@E_X)]?LZ:CK\CWEFFLZ7+?M-F0RPK;S;]V?O?(#5_\
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M)494R>3M YKG?C+\?O&/[0>OQ:GXQUZ\UR[MT,<)E"I' IY(2- J)GC.U1G
MSTJLNX)Q^&SM9A"<84U.<FHRFU+F3_Y=R3497>LHS](HG$Y]AJN >&DG*7+%
M)M1NK?WDTVNR<?5LX^BBBOU(^0"BBB@ HHHH **** "BBB@#J?@?_P EJ\(?
M]ANR_P#1Z5_0W7\\GP/_ .2U>$/^PW9?^CTK^ANOQ;Q7_C8;TE^:/T'@K^'5
M]5^H4445^2'VX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 45X3_P4RU*XTC]A;XAW%K/-;7$5E$4EB<HZ'[3".".17XG_ /"TO$W_ $,6
MN_\ @?+_ /%5]QPQP5/.<-+$1J\G++EM:_1/NNY\[G'$$<!55)PYKJ^]NOH?
MT345_.S_ ,+2\3?]#%KO_@?+_P#%4?\ "TO$W_0Q:[_X'R__ !5?2_\ $**G
M_02O_ ?_ +8\G_76'_/I_?\ \ _HFHK^=G_A:7B;_H8M=_\  ^7_ .*H_P"%
MI>)O^ABUW_P/E_\ BJ/^(45/^@E?^ __ &P?ZZP_Y]/[_P#@']$U%?SL_P#"
MTO$W_0Q:[_X'R_\ Q5'_  M+Q-_T,6N_^!\O_P 51_Q"BI_T$K_P'_[8/]=8
M?\^G]_\ P#^B:BOYV?\ A:7B;_H8M=_\#Y?_ (JC_A:7B;_H8M=_\#Y?_BJ/
M^(45/^@E?^ __;!_KK#_ )]/[_\ @']$U%?SL_\ "TO$W_0Q:[_X'R__ !5'
M_"TO$W_0Q:[_ .!\O_Q5'_$**G_02O\ P'_[8/\ 76'_ #Z?W_\  /Z)J*_G
M9_X6EXF_Z&+7?_ ^7_XJC_A:7B;_ *&+7?\ P/E_^*H_XA14_P"@E?\ @/\
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M_P#BJ/\ B%%3_H)7_@/_ -L'^NL/^?3^_P#X!_1-17\[/_"TO$W_ $,6N_\
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M_MC+_76'_/I_?_P#^B:BOYV?^%I>)O\ H8M=_P# ^7_XJC_A:7B;_H8M=_\
M ^7_ .*H_P"(45/^@E?^ _\ VP?ZZP_Y]/[_ /@']$U%?SL_\+2\3?\ 0Q:[
M_P"!\O\ \51_PM+Q-_T,6N_^!\O_ ,51_P 0HJ?]!*_\!_\ M@_UUA_SZ?W_
M / /Z)J*_G9_X6EXF_Z&+7?_  /E_P#BJ/\ A:7B;_H8M=_\#Y?_ (JC_B%%
M3_H)7_@/_P!L'^NL/^?3^_\ X!_1-17\[/\ PM+Q-_T,6N_^!\O_ ,51_P +
M2\3?]#%KO_@?+_\ %4?\0HJ?]!*_\!_^V#_76'_/I_?_ , _HFHK^=G_ (6E
MXF_Z&+7?_ ^7_P"*H_X6EXF_Z&+7?_ ^7_XJC_B%%3_H)7_@/_VP?ZZP_P"?
M3^__ (!_1-17\[/_  M+Q-_T,6N_^!\O_P 51_PM+Q-_T,6N_P#@?+_\51_Q
M"BI_T$K_ ,!_^V#_ %UA_P ^G]__  #^B:BOYV?^%I>)O^ABUW_P/E_^*H_X
M6EXF_P"ABUW_ ,#Y?_BJ/^(45/\ H)7_ (#_ /;!_KK#_GT_O_X!_1-17\[/
M_"TO$W_0Q:[_ .!\O_Q5'_"TO$W_ $,6N_\ @?+_ /%4?\0HJ?\ 02O_  '_
M .V#_76'_/I_?_P#^B:BOYV?^%I>)O\ H8M=_P# ^7_XJOU&_P""%/B'4/$?
M[/'B^74+Z\OY$\1E%>XF:5E'V:$X!8GBO#XAX"GE6">,E64K-*W+;=^K/1RO
MB6.-Q"H*G:]];]OD?<%%%%?GQ].>5?ME_LQ)^UY\#;OP5)K+Z"MU=07/VM;7
M[25\I]V-F].OUKX[_P"(?>S_ .BJW/\ X3J__)->Y_\ !8W6;S0?V']6N+&Z
MN;.X&IV0$L$K1N 9>1D$&OQ__P"%I>)O^ABUW_P/E_\ BJ_6^!\NS:OESG@<
M7[*',].12ULM;L^(XBQ6!IXI1Q%'GE9:\S7?L?H;_P 0^]G_ -%5N?\ PG5_
M^2:/^(?>S_Z*K<_^$ZO_ ,DU^>7_  M+Q-_T,6N_^!\O_P 51_PM+Q-_T,6N
M_P#@?+_\57V/]B\1?]#'_P I1/!_M#*O^@7_ ,G9^AO_ !#[V?\ T56Y_P#"
M=7_Y)H_XA][/_HJMS_X3J_\ R37YY?\ "TO$W_0Q:[_X'R__ !5'_"TO$W_0
MQ:[_ .!\O_Q5']B\1?\ 0Q_\I1#^T,J_Z!?_ "=GZ&_\0^]G_P!%5N?_  G5
M_P#DFC_B'WL_^BJW/_A.K_\ )-?GE_PM+Q-_T,6N_P#@?+_\51_PM+Q-_P!#
M%KO_ ('R_P#Q5']B\1?]#'_RE$/[0RK_ *!?_)V?H;_Q#[V?_15;G_PG5_\
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M_P#@?+_\51_8O$7_ $,?_*40_M#*O^@7_P G9^AO_$/O9_\ 15;G_P )U?\
MY)JY%_P;^Z&-"FC?XEZJVIF9&BN%T>,0)$ VY6B\TLS$[2&$@  (VG.1^<W_
M  M+Q-_T,6N_^!\O_P 57L_A'XAZ^_[ ?C:Y.N:P;F/QII$:2F\DWJIM+XE0
MV<@$@<>PKEQ66<0THQ;S"]Y17\./5I&U'&97-M+"]&_B?1'U-_Q#[V?_ $56
MY_\ "=7_ .2:/^(?>S_Z*K<_^$ZO_P DU^>7_"TO$W_0Q:[_ .!\O_Q5'_"T
MO$W_ $,6N_\ @?+_ /%5U?V+Q%_T,?\ RE$Q_M#*O^@7_P G9^AO_$/O9_\
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M  M+Q-_T,6N_^!\O_P 51_8O$7_0Q_\ *40_M#*O^@7_ ,G9^AO_ !#[V?\
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M;G_PG5_^2:/^(?>S_P"BJW/_ (3J_P#R37YY?\+2\3?]#%KO_@?+_P#%4?\
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MS6RJG4PF,]G#WK1Y(NWO.^K[O4^ SS&8"GC91KT.:6FO,UT70_0W_B'WL_\
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M=_\  ^7_ .*H_L7B+_H8_P#E*(?VAE7_ $"_^3L_0W_B'WL_^BJW/_A.K_\
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M=_\  ^7_ .*H_L7B+_H8_P#E*(?VAE7_ $"_^3L_0W_B'WL_^BJW/_A.K_\
M)-'_ !#[V?\ T56Y_P#"=7_Y)K\\O^%I>)O^ABUW_P #Y?\ XJC_ (6EXF_Z
M&+7?_ ^7_P"*H_L7B+_H8_\ E*(?VAE7_0+_ .3L_2'P3_P0;M/!OC/2-7'Q
M/N;@Z5>PW@B.@*OF^6ZOMS]H.,XQG%?H+7\__P %/B9XDN/C)X21_$&MNCZU
M9JRM?2D,#.F01NK^@"OS3C[!YAAZE%8_$>U;4K>ZHVVOMO<^NX9KX6K"H\-2
MY-KZMWW[A1117Y\?3A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#3A<U^(U?MS_P2;_Y1]?#S_KG??^G"YK\T\4O^173_ .OB_P#29'UW!O\
MOLO\+_.)]%T445^#'Z4?G?\ \' G_(H?#'_K\U#_ - MZ_,NOTT_X.!/^10^
M&/\ U^:A_P"@6]?F77]'^'W_ "(J/K+_ -*9^3\4?\C*?R_)!1117VI\^;OP
MU^&FO?&'QO8>'/#.F7&KZWJDGEVUK#C=(0"2220J@ $EF(  )) %>VP_\$V/
M$FK:M<Z-I'CWX2:]XLMA(/\ A'-/\1[]2DDC!+PJ&C6,R#:01YG&#GH:Z'_@
MF?(FF>#/CYJ6G2/'XNT_X?7C:48G*SQQD'SY(\<[E(AP1R"1ZU\T^!=>U;PM
MXUTC4M DGBURPO8;C3W@C\R1;A7#1[5P=QW 8&#GI@UX%3$8NOB:U'#S4%3M
MNKW;5]==([+37?4].%.A3I4ZE6+ESWV=K).VGGZ^12U?2;K0-5N;&]MYK2]L
MI7@N()D*20R*2K(RGD$$$$'TJO7UM\)]#GL/!/QH^-WQ3\+P^*?&WAJZLK.#
M1]?T_P"SVWVZ\8*UQ=6P1 =JLC!" &R<X)5A/H7ASP[^W5^S1K^L'PCX2\">
M-/!GB'1M/%]X<TP6%G?6NI7(M0LD"MM9T?+Y&#A5'&6RGGJ@VYP]R+C&4D[I
M2DH[+=KWDK^>PUEKDO=E[S3:3WLK[]$]'H?(5%?=OB#XB^ _A)^W%I/P7@^#
M_P /=0\%:=K-CH$UW?Z2)M:NY)#$IN6NF.3^\<-L(V,@*XPW$8TKP?\ "/P#
M^TUXH;X?^#-?O/!_Q&>RT.VU'3(WM;!'NIH5C"*!^Y53D1 A"53C@5S_ .LC
MM%NB_?47'5:J<E%>CU39K_9*NU[1>[=/1Z<JN_78^(_#FC?\)%XAL-/^U6=C
M]NN([?[3>2^5;V^]@N^1\':BYRQQP 37>Q_LM:]J-S\0FTS4O#>MZ9\-;876
MIZKI]_Y]E<HSA$^SOMS+N.<':!\IR1QGZ#\3:#X5^-_P;^!GQ'/@SPIX<US5
M/'B^&]8M-%TU+33=2@$JLI:W&4SM 4_WMS9R, >IZ!XUL_@MJ'[7^EZ-X1\#
M_P!F^&9XKVUM)]#A>&57D6/[/(F &MU\O<L6 %9W(Y:N7%\15DOW,+26C3M:
MZJQ@]?GIZW?8UH953;_>2TW37^!R6GRU/@'Q%\/?^$=^'_AS7_[<\/7W_"1M
M=+_9MI>>;J&E^0ZIFZBP/*$F[='R=RJQXQ7.U]G?##]G+PU^T%X5_97TV\TS
M3=+;QOJWBB36[G3[1+>>^AMKA)5B9U 8@(K1IDG8'XJQ\#?BUX&_:D_:<'PH
MO_A!\/=&\&^(9KK3=.NM-TDV>N:9Y:2/#,USGS'?]V-X8#.3G@%3U_ZP<D9O
MV;ER<[ELK1C.<=.[]QV79:ZLQ_LOF<5S)<W*EOJW&+^7Q+[SXIHK[,0>'_V7
M/V&=-UUO ?@+Q=XNA\<:GX>&H:UI4=Y%Y48RS%<_O/\ 5 )N)"AVQUKA/V^?
M"?ARY\$?"'Q[H7A[2O"]W\0/#TESJNGZ5 +>P6YAD"-)%$"1&&W'@'&%7ODG
MIPV>*M75+V;492E%2NM7%-[;V:3,JN7.%-SYM4DVO)Z?J?-U%>B? 7X=?#_Q
M]_:O_"=?$>7X??9/)^P[/#L^K_;]V_S/]4Z^7LVIUSN\SC[IKZ%_X*R?#OX?
MQ?M$_$#7H_B/+)XY:>RW^%?^$=G54_<6Z'_3=_EG]U^\^[_L]>:WJYQ3IXZ.
M"<97DF[\LK:.-M>6S7O:RO:-K/<RA@9RP[Q":LFM+J_7SO?316N^FQ\;4445
MZYPA7MW_  3A_P"3VO '_7[+_P"D\M>(U[=_P3A_Y/:\ ?\ 7[+_ .D\M>9G
M/_(OK_X)?^DL[,O_ -ZI_P")?F>(T445Z9QA1110!ZQ^S/\ LA:U^T_H_BK4
M=/\ $/A#PUIO@Z*WGU*\\07LMK!&DQ=5(=(G'!C.=V.HZUUNJ?\ !.#Q3<^$
MM6U7PGXQ^&7Q(?0X#=WFG^%-=-]?Q0CJXB:-"P'H,DXP 3Q70?L1?\F8?M/?
M]@/2_P#T?/7*_P#!,'4]2TS]N[X=_P!F-()9[]X9E0GYX&AD\T'U 3<?^ @]
MJ^3Q6-QJGBZM*HDJ.T7'1^Y&;N]];M7Z'MT</AVJ$)Q;=3K?;WG'1;'@E%?H
M%\./V=?#'@_P)\3/']K8?"6?5]1\?ZCH&@?\)W>Q0Z'IUE#*[$I%)A))FP0J
M]E4,. RMS_Q9^%/@#7?%'P3UOS_@ZWC&^\9V6B^(]"\$W]O>:5J%H]PK).;9
M6(C&T&-QMVMO&>PJX<4T95'!0=M5?S4;[=NE^_2VI,LFJ*',Y*_Z7M]_6W8^
M':*_1;X7W/P\^-/[97Q1^$MU\)/A]:>#/#L.J^3+:Z6+?5S/:3*K.+M#O16?
MS"%3:%4JH&!SXW)XLT#]J#]A[XO:[=_#OX?^%=:^'%WHMQI=YX<TK[!(T=Y=
M- \4I#$R@*IQO)Y.>H!JJ7$;E)*5%I?N[ZK157:/X[KIYBGE22O&HG\71Z\B
MO+\-NY\FT5^E7Q#^"/AC]FOQAI/@K1=,_9@NM(T.UM5UP^.=6ME\0ZG,ZK),
MY:0[[<,K@H ,#((!4A:\]\$?"OX6?"SQ5^TW<Z-I7A;XD>%_!>G:;JGAR2XD
M34+>-W83"-9T)9D21A&X5\NL;(Y.6K&EQ;2J0=2%-M636VJ<HQU[/WD[/IZ,
MTGDDX2Y9275/RLF_FM&CX7KU+6/V2M>\(_&_1O 7B36/"?A74]7L8K]KS5M2
M\C3M/22 S*L\X4A6P-OR[AN90"<YKVCQ'XJT+XN_L4CXJO\ #_X?:%XL\!^.
M+6S2/2-$2UT[5;5HUE\FZMP=DJEN#GJHQ_$V?=_BMJ^G?%O_ (*M_#+P;KWA
M/P9?Z0NFQW<YDT6%Y;[?I4KB*9F!\R)&4%$(PI''05GB^(J\9-1AR\L:KEJF
MTX*+5NC^+\?(JAE5-I-RO=PMZ2;6OW'YG45]A?L5_"V2Y_9JOO$.C?#SP9JF
MN2ZRT5UXG^(:6P\/6=FD8_<VZRRY>;>2S/Y> ,C.5%:O[;G[))^(VN?!6/X?
M^'O!4OC/XA:7?_;+?PA/%;Z)?RV@60RVY=DC4>69"3D9V@#)QGN?$F'CC/JL
M]%>2O=:<L7)M]E9/5_=8Y_[)JNA[:.NVEGK=V5N[NSXHHK[>_8@_88UOX._M
M0OI/QD\!Z9+8ZEX4U.]M;*^EM-02;R3"&=?+>01N-^ W##=Q3?V2XO#O[4Q^
M(/Q"\0>#/A!H)^&^EVMMI.G2VT>B^'I;J\FE6*:^);$FSRPH#'YMP&-Q!J:_
M$U"#G*DN>$%%\T6FFYMQBEW]Y6;Z#IY14ERJ;Y92;T:=_=5VW\OO/B.NW_:+
M^ VL?LQ_&36/ ^O7.FW>K:)Y'GRV$CR6[^;!'.NUG1&/RR*#E1R#UZU],?M.
M>!/!_B7]E?7]9UJ\_9_TSQ_X;O;:71H_ASJUJO\ ;%M-*D4\,UK&?F:,$2!U
M&< ] &+>A_&3X;VWQ _X*L?&!Y/ K^/;_3-%LYM,M+KRET>RNCIUF$N-0>26
M-?(0;OD&XMDX4E:Y_P#65.:FXVBHU&UIO%TK6D[*UI[_ .1K_9'N\M[MN-M]
MFIWNN_N_U<_.VNL^*OP:UKX-CPW_ &T+9&\5:%;>(K)89?,(M;C?Y6_C 8A-
MV!G 89YR!]I?'7X8:<W[&/BKQCK?A[X$?\)CX#US39;4^!+>$P*DDZ(]M?I'
M^[?.X_(<Y _/1^)VFV/[7O[37[.'P\USP_X7T[1_$7@K2?$%Y-I>F):781;*
MZF:QCF7YH[3$9"Q+]W.000*S7%/,U44+0CS\^M_@BI>[WT97]C6]QR]Y\O+_
M -O-K7MJC\\**_1FV\!_#_XG>(]:\/>+&_9/\-^ ]1@N(=.O_#FOV4&O:,X!
M:VE,P;]\V54.&X;<3T!5O%;B\T+]C?\ 9)^&&MP> _!'C#Q9\3A>ZE?7WB73
MO[2@L[:"41Q001OA5)5PS,.<Y'(VD=5#B2-9JG"D^=M)*ZL[J4M]M%%W7IO<
MQJ92X>]*:Y4FV_FEMYW5OGV/#OC1^SKK?P+\.>"M3U:ZTNX@\=Z+'KM@MG)(
M[PP28PLH9% ?GD*6'O7 U];_ /!4;Q/8^-/"7P(U73=+AT2QO_!$4T.GPL6B
ML5+_ .J0GDJO09[ 5\D5Z62XNKB<'&M6TDW*_P I-?H<F84(4:[IT]M/Q284
M445ZIQ'4_ __ )+5X0_[#=E_Z/2OZ&Z_GD^!_P#R6KPA_P!ANR_]'I7]#=?B
MWBO_ !L-Z2_-'Z#P5_#J^J_4****_)#[<**** "BBB@ HHHH **** "BBB@
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MY?\ 5[!Y>SR\?>;=G/&,5RWC/X=:W\/$T@ZUIT^G?V]IL6KV EQFYM)2PCF
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MVT-1\-?#CXS:/J^F'7=4^,8MWN]2-V+?[%+%+/(S^4(R'#&;A04"A>..!F?
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MGZH?*'_!:/\ Y,4U?_L*6/\ Z-K\:J_97_@M'_R8IJ__ &%+'_T;7XU5^_\
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M:=IUI>*(]+UJ5$DFLK9^ 'P%9=I 3#@;0,#YV^!O[//Q@L_A'XELKB[_ .$
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M9Y=2P\+TVVT[===-_A2^YRWW/(*]M\'_ /*/;QS_ -COHW_I)?UXE7MO@_\
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MZ5_0W7XMXK_QL-Z2_-'Z#P5_#J^J_4****_)#[<**** "BBB@ HHHH ****
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MB'PU:^%O$VF6,X1X_P#1T),$G3S(2Q49(&2X.",CP3QK\5?@GX)^#/B'P_\
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M)%%(K*DFW<QP>/*)P#7%?'ZP\?\ Q%^'/P7\"_$#P[\,OA;X9\9>++=[30]
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M&'![5YRS3%RA]=56U25*CTC:\JCBW9KY[]?2W4\'0C+ZNX7BIU.]](IK6_\
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M'_!_]G?P1XKC^$.C_$2]\5>+])FT&75?%<UK%'I=G-CS?)BMB0\C;5P7(VD
M@\%6K67[2/PN^-7P0\&>&/BSIOCFVU;X?P/I^FZKX7%H[7MD2"L,R3LH4I@
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M9<U^62AO>_NRE?6Z5K:.6#]A->[=J6RMK=VM=.7IJE;2USZ%^+_[)-A^TO\
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MGT:6.A*'MJ<E)*GRJF^6"M\2:OR^MT]+*#OJ=52>&:E[.2:O*[DKR?9IVO\
M<UK\1]$?#3]B#P)XN^(>F>']/^ GBK5? ER(K=O'VK:]>:3>3;HQFY6RE\L8
M\S(">7\PY&017GNG_#=O!O\ P3R^._A"P:2^?2OB9!H]LS85K@QSPPJ3T +8
M'MS4FN?MV_!K5/VF]-^+<]E\8]9UVUOXKQ-%O[NT&EZ82%20P$.SL$7<R)A
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M/_Y+5X0_[#=E_P"CTK^ANOQ;Q7_C8;TE^:/T'@K^'5]5^H4445^2'VX4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X'_P5"_Y,*^(__7C#
M_P"E,-?AO7]"WQW^&NC?&'X2ZUX:\00376C:K$L=U%%,87=0ZL,..1RHKY7_
M .'4/P*_Z%S7?_![+_A7ZAP/Q7@\KP<Z&)4FW*^B3Z)=6NQ\?Q%DF(QM>-2D
MU9*VOJ_(_)&BOUN_X=0_ K_H7-=_\'LO^%'_  ZA^!7_ $+FN_\ @]E_PK[3
M_B(^5_RS^Y?_ "1\_P#ZI8WO'[W_ )'Y(T5^MW_#J'X%?]"YKO\ X/9?\*/^
M'4/P*_Z%S7?_  >R_P"%'_$1\K_EG]R_^2#_ %2QO>/WO_(_)&BOUN_X=0_
MK_H7-=_\'LO^%'_#J'X%?]"YKO\ X/9?\*/^(CY7_+/[E_\ )!_JEC>\?O?^
M1^2-=?X0_:"\>_#[0/[)T'QOXOT32\L?L>GZQ<6UO\Q)/[M'"\DG/'>OT_\
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M35&BVB)IPS$2E-B;2^=NQ<8P*S(/'6MVW@^;P]'K&J1Z!<W(O)M,6[D%G+.
M%$K19V%P !N(S@#FOU9_X=0_ K_H7-=_\'LO^%'_  ZA^!7_ $+FN_\ @]E_
MPJH^(&315HTY6_PQZ;?:)?"V8-W<U][_ ,C\J+OX@:]?^#+7PY/K>KS>'K*<
MW5MI<EY(UE;RG=F1(2=BN=S98#/S'UK8\'_M!^/?A[H']E:!XW\7Z'I>2?L>
MGZS<6UODDD_(CA>23GCO7Z?_ /#J'X%?]"YKO_@]E_PH_P"'4/P*_P"A<UW_
M ,'LO^%*7'^32CRRI2:O?X8[]_BW&N%\P3NIJ_J_\C\K/"OQ+\1^!?$,VKZ)
MK^MZ/JURKI->V-]+;W$JN<N&D1@Q#$ D$\]ZC\%?$#7OAMJ[:AX=UO5] OWB
M:!KG3;R2UF:-L;D+H0=IP,C.#@5^J_\ PZA^!7_0N:[_ .#V7_"C_AU#\"O^
MA<UW_P 'LO\ A5/Q!R=WO3EKO[L=?_)A+A7'JUI1T\W_ )'Y9^ _B_XL^%B7
M:^&/%'B+PXM^ MT-+U*:S%R!G ?RV&[&3C/J:YVOUN_X=0_ K_H7-=_\'LO^
M%'_#J'X%?]"YKO\ X/9?\*:\1,H4G)0G=[^['7_R83X4QS23E&R\W_D?E?\
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M2:'3XSC*0HQ(C4[5X4 ?*/2OU7_X=0_ K_H7-=_\'LO^%'_#J'X%?]"YKO\
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M9:QHGA[4](L]5U*TTG6_*_M&RAN7CM[_ ,IB\7G1@[9-C$LNX':3D8-2VGQ
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M .2#_5+&]X_>_P#(_)&BOUN_X=0_ K_H7-=_\'LO^%'_  ZA^!7_ $+FN_\
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MO_@]E_PH_P"(CY7_ "S^Y?\ R0?ZI8WO'[W_ )'Y(T5^MW_#J'X%?]"YKO\
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MN7_R0?ZI8WO'[W_D?DC17ZW?\.H?@5_T+FN_^#V7_"C_ (=0_ K_ *%S7?\
MP>R_X4?\1'RO^6?W+_Y(/]4L;WC][_R/RZ^!_P#R6KPA_P!ANR_]'I7]#=?'
M'A;_ ()<_!+P[XGT[4+3P]K:75C=17$+-K<K!71PRDC'/('%?8]?G/'?$.&S
M6I1EADURIWNDM[=FSZOAS*JV"A-5FM;;?\,%%%%? GTH4444 %%%% !1110
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M;PJN,C[Q%=UX _:/^)$?QY\%>"O&F@^'M(N?$-C=7E[';!GDB\L7!CV.L[H
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M2K/2K/4K:34?#<D4<B/=V\<TD;!RS$.V%/S*%&8I..@'9?\ "^M8_P"&Q_\
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MAG_@K9IQOW6V7Q)\+CI^FO(<"ZN(-4>:2%?5A&X?'H#71:.C2Z&%Y:IOJ/\
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M ,$V?@/XHTC0]+LO$K:CX8U9]62V07TES<(DLTC38WL6=B3DGH/08]:_9Q\
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M?P/OM3LO@+\-[U/%%O:6$GA634OMVM69&+FQ")9A&C:(_>E*HK;<LN\YY_\
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M%^,$FC:3\"/[:\)K>Q0)XC_X36QMM\#;=\_V5D\P;,M\F<G;QUKP%_B=X_\
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MBY;_ / O_0C7#5W/@_\ Y%RW_P"!?^A&N?$?"7#<TZ***XS4YOXA_P"HM?\
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M?1;U9% ^X")F8#H0<?\ +/CNOBI\ =/_ &C?^"@VOZ'JE[>6=A;>'8KZ46V
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MN?!__(N6_P#P+_T(UPU=SX/_ .1<M_\ @7_H1KGQ'PEPW-.BBBN,U.;^(?\
MJ+7_ 'F_I7+UU'Q#_P!1:_[S?TKEZ[J'P&,MPHHHK8D**** "O!/C9\'X?B+
MXZ\07NK?"R7Q!]MT7_A']4OK;Q'):OJVBF<SK;6T:R(!.)6=G#^6"J[1*PD
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M  H_X6IX@_Z"4G_?"?X5?U2IY?U\B?:Q.XHKA_\ A:GB#_H)2?\ ?"?X4?\
M"U/$'_02D_[X3_"CZI4\OZ^0>UB=Q17#_P#"U/$'_02D_P"^$_PH_P"%J>(/
M^@E)_P!\)_A1]4J>7]?(/:Q.XHKA_P#A:GB#_H)2?]\)_A1_PM3Q!_T$I/\
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M*,D_5-=8I,[*BOD#_@H7XIL_BG\0=!^'W]NZ=I%G9:?=:Y=W-U=)% \_D/\
M9(B7(7+$8ZDXFR!QST-A\73\9_\ @FQK>HSR>9J%CHTNFWQ/4S0A5W'W9-CG
MW>G_ *W4?KF)P<87]E&4D[_$XI.4;6TM=*^M]>PEP;6^I87&RG;VTHQ:Y?@4
MVU&5[ZWY6[:6T[GT]17FW['O_)L'@?\ [!45?-G[?W[//@KPYX@DU6VNO$FI
M?$'QO?J+#28+B$Q%F(4N4\K?LSA0-V69A@X#8WS3B"MA<KAF=*DI)I-ISY;7
M5TD^5\SNTDK*YSY3PY1Q>;3RNK6<6FXIJ'-?E=FVN9<JLFV[NQ]N45Y7^Q[^
MSR/V</@_;Z5/)YVKW\GV[4F#9C69E V)_LJJJN>Y!/< >J5[N K5JV&A5Q$.
M2<E=QO>WE>R^>AX&84*-#$SHX:I[2$792M;F\[7>G;4YSXM_\DZU3_KFO_H:
MU\_5] _%O_DG6J?]<U_]#6OGZOJ,K_AOU/'Q'Q!1117IG.%%>*^+_P!N/0=#
M\<:OH&A^%/B%X[N_#\WV;4Y?#6C?;+>PF'6)Y&=!O'=5ST(Z@UVGP+_:!\.?
MM#^%[C4_#\UTK6-PUG?65[ ;>\T^=>L<T1Y4_F#Z\' +F5[';5Q_Q.^"FE?%
M?Q'X2U/4;C4(9_!NJ#5K);9T5)90C)MD#*Q*X8\*5/O785Q.A_'C2/$'QVUS
MX>PV^I+K.@:?#J5Q,\:"U>.4@*$8.6+<\Y4#W- .W4SOBYX#\1>*OC%\-]1T
M?4=;L-+T.\NYM96VU'R;*Z@: !(YX 0T[F4)L.=L8\TD$LM97Q+_ &.-#^('
MQ"OO%%CXB\:>#-9UBV2UU2;PYJ2V@U1$&$\T,CC<%X#+M;'>N^^)GCK_ (5I
MX&U#7/['UW7_ + JM_9^C6GVJ^N<NJXBBR-Q&[)YZ GM6QIUY_:&GP3^5-!Y
M\:R>7,NV2/(SM8=B.XH%9' 77[*G@BZ^ "_#,Z3M\*QP"*.)9")HW#;Q,)/O
M>;YGS[O4G/!Q69\+?V0]%^&WC^V\47?B'QEXQUS3K1K+3[GQ%J2W9TV)AAQ"
M%1 "PX+$%B.]>L44#LCQGX@?L0^'?&WC'7-9LO$7C?PD_BE5&MVN@:H+6VU8
M@%=TJ%&^8J2"4*D@GU.?4/ G@;2OAGX.T[0-$M([#2=)@6WM8$R1&@]SR3W)
M/)))-9O@KXOZ-\0/&GBC0M,>XEO?"%Q%:ZBSQ%(UED3S JD\MA<9.,<\$UU%
M )+=!1110,*W_&O_ "#?#_\ V#5_]&R5@5O^-?\ D&^'_P#L&K_Z-DK*?QQ_
MKH4MF8%%%%:DE;6=+CUS1[JRE+K%>0O Y0X8*RE3C.>>:YCX8_!#1/A;\%['
MP';_ &G4M!L;)]/VW[+))<0ONW+(555.0Q'"CBNPHH \,\*?L ^$_#&I:*)=
M=\;ZSH'AN[%[I7AW4M6$^DV,JY,;+%L#-L))4.[ ?0D5TWQC_98T3XO^--/\
M3+J_B;PIXFTVV:R35M O5M;F6W8Y,,FY'5TR21E<@G@UT?QM^+^E_ 3X6:QX
MOUI+N73-$B66=+5%:9]SJ@"!F522S <L*XOP!^UI-X\\8V&D-\*_B]H8OI"A
MO]5T**"SMN"=TCB9BHXQT/)%/7<GW5H==\$O@?H?P"\(2:1H@O)1=74E]>WE
M[.;B\U&YD.7FFD/WG.!S@=!Q1\1/@II7Q,\;^#]>O[C4(KSP3>RWUBENZ+'*
M\D9C(E!4DK@\;2ISWKBOB!^VWX>\$>+M;TBR\.^-_%C>& /[;NM TH75KI)(
MW%979U^8+R0@8@ YZ&O3_ GCG2OB7X.T[7]$NX[_ $G5H%N+6=,@2(?8\@]B
M#R""#1J&CT,#3O@1I&F?'W4/B,EQJ1UO4M(3198&D3[*L*2"0,J[-^_(ZER,
M=J\R^,G[-6D> OA#\1SI_A36OB(OCS6/[9U72/M\<%Q&S,I:2T81@[H\!U0D
ML2OWNQ^@J*5Q\J/A[PW\%+_XL?'3X;3Z78_&NZM_!^KQZK?:O\0U:W33[>$9
M%K;*53S'D?;N;:Q^1?GQG'VUJ>FV^LZ=<6=W#'<6MU&T,T4B[DE1@0RL#U!!
M((J>BFW<2C8\#B_X)W>#QID>BR^(?'USX,BG$Z>%9=;)TA</O$>S8)3&&YV&
M3&>>M>CV_P "-&L_CTGQ#BDO8M7B\.#PNEJC(MDEJ+C[0"$";@X;C.[;MXVY
MYKM:*5V/E04444#+&C_\A:U_Z[)_,5>\??\ (\:O_P!?DO\ Z&:HZ/\ \A:U
M_P"NR?S%7O'W_(\:O_U^2_\ H9K+_EXO3_(K[)DT445J2%</\:?@>GQJM]/C
M?Q7XX\+_ -GM(P;PYK#Z<UQOV\2E0=X&WCTR?6NXKSS]K/XE3?"#]FKQMXCM
MG,=YIVDS&U<-M,<[CRXFS[.RG\*!/;4\'_94\$:GKG[37B7Q#IOQ"^(FI_#;
MP#)-I*_V]XDFO8=;U 1LL[X)$?D0AN"0<N%8'L//M+_:)T?XR^"M1\7>)/C;
MXH\&^*=8EGET/3-)N;F/2?#T0D9+5+Q88GC)?8&<S'E7X KZK_96^$%I\.OV
M4?"GA?:P631D:](&UY)KA/,F;ZEY&Z^U?-GP$^+W@_\ 97_92\0_"7QO97%A
MXSTYM2M)-*.G22R>)FF>3R98 %*R*Z-&@.> @R0.:HRM9(^Q/A1/K%U\,]!D
M\07FDZCK3V,37MWICE[.[D*C,L1*KE&^\. .>.*\C^ GC34?"?[47QH\)Z_K
M6H7EG:RVOB326OKIY5MK.>-C,D>XG9%'(N JX ["NK_8I\ ZU\+_ -E7P1H7
MB%'BUBPTX"XB<Y:WW,SK$?=%95/^[7A/_!3&ZUCX8>.M$\1Z KM>>/?#][\/
MIMJ]&G=)+?GL=S38(&1CCK2ZE-V2D1_L3?&7Q=JO[0D5_P")]:U>[T+XR:9?
MZWH%A=W$DD.EM;7T@6"%6.$'V9E<[>HVYKL?A/\ M!0^'-?^-_Q+\7>(;]?!
MNG>(5T#2+9KB2:WC^R((G^S0 D%YI6'*CYB,YQDU3_;1\(+^S9\#?AEXNT2$
MS'X,ZA9Q?*F/,L9(A:3 @<_,3%GGUSUS7$_$[]GS6M'_ ."<OPSBM;?5;JZT
M+6;#Q=X@72E4ZA+'(9IKAXPRD-*AN 1E6 \H<$+3T)U6G8]_\!?MC:+XO\;Z
M7X?U3PUXW\$WVO([:2WB/3%M(M390&,<3K(X\S:<[&VG';) ,?C/]M'0_#GC
MK5_#^D>&?'/C6]\.E5U>3P[I:W4&F.1G9([2("^,G:FX\'C((KY[TVX\&_&3
MXS_#2Q\+^/\ XM?%B?3]?M];G2[U"**R\/K;_.)[C-B"3R4\H,C,"PW*<9Q_
M"UKHWP%^(_Q)TCXB?%#XF?#G4;OQ+>:Q8G2Y%CLM?MIV#)/&3;2EYNS+OR.
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MJFD_VMKVFQ)?Z3>O:S/;S,<[9$(.&4@^G2H_'7[&?B7PCX7O-5\#_%WXM?\
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M7..]'[47_!/[PS\/_#-KXY^&'@_1(_$?@Z3[?+I,]O\ :[36[9>9(C%+N7S
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MBQ-JOQ4^(J?\*NUW6- T-[+53;32BS!E6:Z=1NN&;>JX<XVICOD?3&B_ O\
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M_P"3$7_Q5'_"E?$O_0-_\F(O_BJ][HK?^U*O9?U\R/J\3P3_ (4KXE_Z!O\
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M4KXE_P"@;_Y,1?\ Q5'_  I7Q+_T#?\ R8B_^*KWNBC^U*O9?U\P^KQ/!/\
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M_%4?\*5\2_\ 0-_\F(O_ (JO>Z*/[4J]E_7S#ZO$\$_X4KXE_P"@;_Y,1?\
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M_%5[W16O]J5>R_KYD_5XG@G_  I7Q+_T#?\ R8B_^*H_X4KXE_Z!O_DQ%_\
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M^*KWNBC^U*O9?U\P^KQ/!/\ A2OB7_H&_P#DQ%_\51_PI7Q+_P! W_R8B_\
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,#2$%'8****YRS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>sava-20221231x10kg004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20221231x10kg004.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MJS10!6_L^U_YY?\ CQ_QH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\
MGE_X\?\ &K-% %;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\
M?\:/[/M?^>7_ (\?\:LT4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^
MU_YY?^/'_&C^S[7_ )Y?^/'_ !JS10!6_L^U_P">7_CQ_P :/[/M?^>7_CQ_
MQJS10!6_L^U_YY?^/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C^S[7
M_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\ GE_X
M\?\ &C^S[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QJS10!6_L
M^U_YY?\ CQ_QH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\ GE_X\?\
M&K-% %;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?
M^>7_ (\?\:LT4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'
M_&C^S[7_ )Y?^/'_ !JS10!6_L^U_P">7_CQ_P :/[/M?^>7_CQ_QJS10!6_
ML^U_YY?^/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C^S[7_GE_X\?\
M:LT4 5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\ GE_X\?\ &C^S
M[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QJS10!6_L^U_YY?\
MCQ_QH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\ GE_X\?\ &K-% %;^
MS[7_ )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?^>7_ (\?
M\:LT4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'_&C^S[7_
M )Y?^/'_ !JS10!6_L^U_P">7_CQ_P :/[/M?^>7_CQ_QJS10!6_L^U_YY?^
M/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C^S[7_GE_X\?\:LT4 5O[
M/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\ GE_X\?\ &C^S[7_GE_X\
M?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QJS10!6_L^U_YY?\ CQ_QH_L^
MU_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\ GE_X\?\ &K-% %;^S[7_ )Y?
M^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?^>7_ (\?\:LT4 5O
M[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'_&C^S[7_ )Y?^/'_
M !JS10!6_L^U_P">7_CQ_P :/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'_&C^S[
M7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C^S[7_GE_X\?\:LT4 5O[/M?^>7_C
MQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\ GE_X\?\ &C^S[7_GE_X\?\:LT4 9
M>H6L,$"M&FUBV,Y/H:*FU7_CU7_?'\C10!+I_P#QXQ_C_,U9JKI__'C'^/\
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M/_[]O_\ %UQ-%>C]4H_RG)[>IW.V_P"%HZW_ ,^NG_\ ?M__ (NC_A:.M_\
M/KI__?M__BZXFBCZI1_E#V]3N=M_PM'6_P#GUT__ +]O_P#%T?\ "T=;_P"?
M73_^_;__ !=<311]4H_RA[>IW.V_X6CK?_/KI_\ W[?_ .+H_P"%HZW_ ,^N
MG_\ ?M__ (NN)HH^J4?Y0]O4[G;?\+1UO_GUT_\ []O_ /%T?\+1UO\ Y]=/
M_P"_;_\ Q=<311]4H_RA[>IW.V_X6CK?_/KI_P#W[?\ ^+H_X6CK?_/KI_\
MW[?_ .+KB:*/JE'^4/;U.YVW_"T=;_Y]=/\ ^_;_ /Q='_"T=;_Y]=/_ ._;
M_P#Q=<311]4H_P H>WJ=SMO^%HZW_P ^NG_]^W_^+H_X6CK?_/KI_P#W[?\
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M )]=/_[]O_\ %T?\+1UO_GUT_P#[]O\ _%UQ-%'U2C_*'MZG<[;_ (6CK?\
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M&: %KG?&6O77AW1X;NTCA>1[@1$3*2,%6/8CG@5T.:XGXHG_ (IFV_Z_%_\
M0'K?#14JL4]C.JVH-HYO_A:.M_\ /KI__?M__BZ/^%HZW_SZZ?\ ]^W_ /BZ
MXBBO<^J4/Y3S?;5.YV__  M'6_\ GUT__OV__P 71_PM'6_^?73_ /OV_P#\
M77$44?5*'\H>VJ=SM_\ A:.M_P#/KI__ '[?_P"+H_X6CK?_ #ZZ?_W[?_XN
MN(HH^J4/Y0]M4[G;_P#"T=;_ .?73_\ OV__ ,71_P +1UO_ )]=/_[]O_\
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M /OV_P#\77$T57U2A_*3[>IW.V_X6CK?_/KI_P#W[?\ ^+H_X6CK?_/KI_\
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M\C-<_P#7FW_H:5CB<-2C2DU'4TI59N:39ZY129HS7A'HBT4F:,T +129HS0
MM%)FC- "T4F:,T +129HS0!2U7_CU7_?'\C12:K_ ,>J_P"^/Y&B@"73_P#C
MQC_'^9JS5;3_ /CQC_'^9JS0 4444 %%%% !1110 4444 %%%% !1110 444
M4 <WX]_Y$K4/^V?_ *,6O$Z]L\>_\B5J'_;/_P!&+7B=>WEO\)^OZ(\[%_&O
M0****]$Y0HHHH **** "BBB@ HHHH **** "BBB@ K2\/?\ (S:5_P!?D/\
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MXT3*M_#9Y)1245]&>4+1244 +1244 +1244 +1244 +1244 +1244 +1244
M:?AW_D9M)_Z_(?\ T,5] U\_>'?^1GTG_K\A_P#0Q7T#7CYG\<3OPGPL****
M\PZPHHHH *S?$7_(LZK_ -><W_H!K2K,\1?\BSJW_7G-_P"@&KI_&B9?"SP"
MBBBOJ#QPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^@/#O_ "+.E?\
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M579F9HS4>:,UJ029HS4>:,T 29KN/A6?^*HN?^O)O_0TK@\UW7PI/_%47/\
MUY-_Z&E<^*_@R-:/\1'L-%%%?/'J!1110 4444 %%%% !1110 4444 4=5_X
M]5_WQ_(T4:I_QZK_ +X_D:* )+#_ (\H_P ?YFK-5K#_ (\H_P ?YFK- !11
M10 4444 %%%% !1110 4444 %%%% !1110!S?CW_ )$K4/\ MG_Z,6O$Z]L\
M>_\ (E:A_P!L_P#T8M>)U[>6_P )^OZ(\_%_&O0****]$Y0HHHH **** "BB
MB@ HHHH **** "BBB@ K2\/?\C-I7_7Y#_Z&*S:TO#W_ ",VE?\ 7Y#_ .AB
MHJ? RH_$CWZBBBOECV HHHH **** "OFZOI&OFZO6RO[?R_4XL9]D****]4X
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]_\/?\BSI7_7G#_P"@"M*L
MWP]_R+.E?]></_H K2KY>I\;/8C\*"BBBH*"BBB@ KQ+Q]_R.VH?]L__ $6M
M>VUXEX^_Y';4/^V?_HM:]#+?XK]/U1RXOX%ZG-T445[9YX4444 %%%% !111
M0 4444 %%%% !1110 4444 >M_"[_D6;G_K\;_T!*[:N(^%W_(LW/_7XW_H"
M5V]?.8O^-(]6C_#04445SFH4444 %>;_ !7_ .81_P!MO_9*](KS?XK_ /,(
M_P"VW_LE=>!_WB/S_(QQ'\)GF]%%%?0GEA1110 4444 %%%% !1110 4444
M%%%% !1110!VWPO_ .1FN?\ KS;_ -#2O6J\E^%__(S7/_7FW_H:5ZU7@YA_
M'/2PO\,****X3H"BBB@ KB/BG_R+%M_U^+_Z ]=O7#_%/_D6+;_K]7_T!ZZ,
M+_&B95OX;/(\T9IN:,U]$>4.S1FFYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS
M0 [-&:;FC- #LT9IN:,T .S1FFYHS0!J>'?^1GTG_K\A_P#0Q7T%7SYX</\
MQ4^D_P#7[#_Z&*^@Z\?,OCB=^$^%A1117FG6%%%% !6;XB_Y%G5O^O.;_P!
M-:59OB+_ )%G5O\ KSF_] -73^-$R^%GS_1117U!XX4444 %%%% !1110 44
M44 %%%% !1110 4444 %?0'AW_D6=)_Z\X?_ $ 5\_U] >'?^19TG_KSA_\
M0!7F9G\$3KPGQ,TJ***\<[PHHHH **** /G[Q%_R,VK?]?DW_H9K-K2\1?\
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M;7B7C[_D=M0_[9_^BUKT,M_BOT_5'+B_@7J<W1117MGGA1110 4444 %%%%
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M!7CG>,2/:*EHHH **** "BBB@ HHHH **** *6J?\>R_[X_D:*-3_P"/9?\
M?'\C10!)8?\ 'E'^/\S5G-5;'_CRC_'^9JS0 N:,TE% "YHS244 +FC-)10
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M/^V?_HM:]LKQ+Q]_R.VH?]L__1:UZ&6_Q7Z?JCEQ?P+U.<HI**]L\\6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH ];^%Q_XIFY_Z_&_] 2NWS7$?
M"[_D6;G_ *_&_P#0$KMJ^<Q?\:1ZM'^&A<T9I**YS47-&:2B@!<UYO\ %?\
MYA'_ &V_]DKT>O./BM_S"/\ MM_[)77@?X\?G^1AB/X3/-Z***^@/,"BBB@
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MTZS/#W_(LZ5_UYP_^@"M*OEZGQL]B/PH6BDHJ"A:*2B@!:\2\?'_ (K;4/\
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M/_7FW_H:5ZS7DOPO_P"1EN?^O-O_ $-*]9KP<P_C'I87^&+1245Q'0+1244
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MQ_(T4 /L?^/./\?YFK%5[+_CSC_'^9JQ0 4444 %%%% !1110 4444 %%%%
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MZHY<7\"]3FZ*2BO:. 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
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M^CZ^;Z]7+/M?+]3BQGV1<T9I**]4XQ<T9I** %S1FDHH 7-&:2B@!<T9I**
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MH 6BDHH 6BDHH 6BDHH 6BDHH 6OH3PY_P BQI/_ %Y0_P#H KYZKZ$\.?\
M(KZ3_P!>4/\ Z *\[,OAB=>$^)FI1245Y!W"T4E% "T4E% 'SQXD_P"1IU?_
M *_9O_0S696EXD_Y&G5_^OV;_P!#-9E?2P^%'D2W8M%)15B)8()KF9(8(GEE
M<X5(U+,Q]@.M79O#^M6\+S3:1?QQ(-SN]LX51ZDD<5#I>HS:3J=O?P*C2P/O
M42 E2??!%=1J/Q-UK4]-N+&:UL%BN(S&Y2-PP!&.,O64Y5%)<JT+BH6]YFWX
M1\9@SZ'X?L+-88^%N9B!F1MI)P![CJ>3[5D_$*6*'XA++.F^%%A9TP#N4=1@
M^U9'@3_D=M+_ .NI_P#036A\3_\ D=)O^N,?\JYE3C'$675?J:N3=+7N=_X.
M\72>)M4OHX[9;:RMHD\F(<GDGDG\.@Z>]>7Z/J<.C^.8[ZXSY,5T^\@9P"2"
M?PSFNI^#_P#Q_P"J?]<H_P"9KS[4?^0G=_\ 79__ $(T4J455G!;603FW",G
MN>FW]]I>EV'B6:#5+2^FUE]MM!;2;W&X$?,!TY8_EZG%97B*WGTKP]IW@_3X
M9+B]D'VJ]6%"[%NH&!Z?R45E^ =+AN-5FU:]XL=+C^T2$CJPR5'Z$_A71Z%J
MLVH^'O%^N(S)J,F2&0_/&@7Y0#U '//M427LY::VM]^R^XI/F7:_],\UN;:X
MLYV@NH)8)5ZQRH58?@:BKT#XA?OO#_ABYN"3?26O[QF^\PVJ>?Q)_,UY]792
MJ<\.8YYQY96%HI**U)%KT/P&V-#G_P"OEO\ T%:\[KT+P)_R YO^OEO_ $%:
MXL?_  3?#?Q#J_,/K1YA]:92A<UXAZ(_>:>NXTL<)8]*OP6GJ* (886-:,,!
M%2Q0!>U6 N* !%P*?244 +1244 +1244 +1244 +1244 +1244 +1244 +12
M44 +1244 +1244 +1244 +1244 +1244 +1244 +1244 5-1_P"/=?\ ?_H:
M*-1_X]U_W_Z&B@!]G_QZ)^/\ZGJO9_\ 'HGX_P ZL4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '.>//^1+U#_MG_Z,6O%J]I\>?\B7J'_;/_T8M>+5
M[>6_PGZ_HCS\7\:] HHHKT#E"BBB@ HHHH **** "BBB@ HHHH **** "M+P
M_P#\C+I7_7Y%_P"ABLVM+P__ ,C)I?\ U^1?^ABHJ? RH_$CWJBBBOESV HH
MHH **** "OF^OI"OFZO5RS[7R_4X\7T%HI**]0XA:*2B@!:*2B@!:*2B@!:*
M2B@!:*2B@!:*2B@!:*2B@#W_ ,/?\BSI7_7G#_Z *TJS?#W_ "+.E?\ 7G#_
M .@"M*OF:GQL]>/PH****@H**** "O$O'W_([:A_VS_]%K7MM>(^/O\ D=M0
M_P"V?_HM:[\N_BOT_P CFQ7P+U.<HI**]H\\6BDHH 6BDHH 6BDHH 6BDHH
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MTC2XI%DCTVT1U(966!001T(.*NT %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-0_P"/=?\
M>_H:*-0_U"_[W]#10 ^S_P"/5/Q_G4]5[3_CU3\?YU/0 M%)10 M%)10 M%)
M10 M%)10 M%)10 M%)10 M%)10!SOCS_ )$O4/\ MG_Z,6O%J]H\=_\ (F:A
M_P!L_P#T8M>+U[>6_P )^OZ(\_%_&O0****[SE"BBB@ HHHH **** "BBB@
MHHHH **** "M'P__ ,C+I?\ U^1?^ABLZM'P_P#\C)I?_7Y%_P"ABIJ? RH_
M$CWNBDHKY<]@6BDHH 6BDHH 6OFZOI"OF_->IEGVOE^IQXOH%%&:,UZIQ!11
MFC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- 'O_A[_ )%G2O\
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MI** %HI** %HI** %HI** %HI** %HI** .U^&7_ ",EQ_UYM_Z&E>KUY/\
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M%)10 M%)10 M?-]?1]?-]>IEOVOE^IQXOH+1245ZIQ"T4E% "T4E% "T4E%
M"T4E% "T4E% "T4E% "T4E% 'O\ X>_Y%G2O^O.'_P! %:59GA[_ )%G2O\
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M_P"AI7JU>4?#+_D9+C_KS;_T-*]6KPLP_C'I87^&+1245Q'0+1244 +1244
M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
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M[^*7_,)_[;?^R5UX+^/'Y_D8XC^$SSNBBBO?/+"BBB@ HHHH **** "BBB@
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M:,TE% "YHS244 +FC-)10 N:,TE% "YHS244 +FC-)10 N:,TE% "YHS244
M+FC-)10 N:,TE% "YHS244 +FC-)10 N:,TE% "YHS244 +FC-)10 N:,TE%
M "YHS244 +FC-)10 N:,TE% "YHS244 +FC-)10 N:,TE% %>]_U*_[W^-%)
M>_ZD?[U% #[;_CW7\?YU+4-M_P >Z_C_ #J6@!:*2B@!:*2B@!:*2B@!:*2B
M@!:*2B@!:*2B@!:*2B@#GO'7_(F7_P#VS_\ 1BUXQ7LWCK_D3;__ +9_^C%K
MQFO:R[^$_7_(\_%_&O0****] Y@HHHH **** "BBB@ HHHH **** "BBB@ K
M1\/_ /(R:7_U]Q?^ABLZM'0/^1DTO_K[B_\ 0Q45/@8X_$CWBBDHKY@]@6BD
MHH 6BDHH 6OG#-?1U?.%>IEOVOE^IQXOH+FC-)17J'$+FC-)10 N:,TE% "Y
MHS244 +FC-)10 N:,TE% "YHS244 +FC-)10![]X>_Y%K2O^O.'_ - %:59G
MA[_D6M*_Z\X?_0!6E7S,_B9Z\?A0M%)14E"T4E% "UXEX^_Y';4/^V?_ *+6
MO;*\3\??\CKJ'_;/_P!%K7?EW\5^G^1S8KX%ZG-T445[)P!1110 4444 %%%
M% !1110 4444 %%%% !1110!ZU\+S_Q3-S_U^-_Z E=MFO/OAQ<"+P]<+G_E
M[8_^.)78?;!ZU\_BOXTCU*/\-&CFC-9WVP>M'VP>M<YH:.:,UG?;!ZT?;!ZT
M :.:\\^*)_Y!/_;;_P!DKLOM@]:X3XCS"7^S.>GF_P#LE=6"_CQ^?Y&.(_AL
MX2BBBOH#S HHHH **** "BBB@ HHHH **** "BBB@ HHHH [/X9_\C'<?]>C
M?^AI7JM>5?#3_D8[C_KT;_T-*]4KPL?_ !CT<-_#%HI**XCH%HI** %HI**
M%HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI**
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ME% "T4E% "T4E% "T4E% "T4E% '/>.O^1-O_P#MG_Z,6O&:]E\=?\B;?_\
M;/\ ]&+7C5>UEW\)^O\ D>?BOC7H%%%%=YS!1110 4444 %%%% !1110 444
M4 %%%% !6CH'_(QZ7_U]Q?\ H8K.K1T#_D8]+_Z^XO\ T,5%3X&5'XD>[T4E
M%?,GKBT4E% "T4E% "U\X5]'5\XUZF6_:^7ZG'B^@4445ZAQA1110 4444 %
M%%% !1110 4444 %%%% !1110![[X>_Y%K2O^O.'_P! %:58N@3@>'-+&>EI
M%_Z *T/M"^M?,S^)GK1^%%JBJOVA?6C[0OK4E%JBJOVA?6C[0OK0!:KQ/Q[_
M ,CKJ'_;/_T6M>Q?:%]:\;\<MN\97[>OE_\ HM:[\N_BOT_R.;%? O4YVBBB
MO9. **** "BBB@ IZPRLNY8W(/<*:95NTD<+,N]L+$Q ST-9U9N,;Q*@DW9E
M9D9#AU*GT(Q3:<SLYR[%CZDYIM6KVU)=KZ!1113 **** "BBB@#O_ [E=%F
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M_7W%_P"ABLZM'0/^1CTO_K[B_P#0Q45/@94?B1[M1245\R>N+1244 +1244
M+7SC7T;7SE7J9;]KY?J<>+Z!1117J'&%%%% !1110 4444 %%%% !1110 44
M44 %%%% 'KFCW!&B6 STMHQ_XZ*N_:3ZUD:3_P @:Q_Z]X__ $$5<S7S,_B9
MZT?A1;^TGUH^TGUJIFC-246_M)]:/M)]:J9HS0!;^TGUKS#Q:Q?Q/>-Z[/\
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M* (KG_5CZT4EQ_JQ]:* %A_U2U)4<7^J%/H 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH Y_QS_R)U__ -L__1BUXW7L?CC_ )$Z_P#^V?\ Z,6O
M'*]G+OX3]?\ (\_%?&O0****] Y@HHHH **** "BBB@ HHHH **** "BBB@
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M!W_PH_L35O\ H%WO_@._^%'/'N'++L4**O\ ]B:M_P! N]_\!W_PH_L35O\
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M)ON#ZT42_='UHH $^X*=34^X*=0 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3/X6./Q(]RHI**^9/7%HI*3=0 ZBF[J-U #J*;NHW4 .HINZC=0 ZBF[J-U
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MBN/^O1O_ $-*]1KR[X<?\C#<?]>C?^AI7J%>'C_XQZ.&_ABT4E%<9T"T4E%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
M"T4E% "T4E% #9/N_C10_P!W\:* !?NBES2+]VEH ,T9HHH ,T9HHH ,T9HH
MH ,T9HHH ,T9HHH ,T9HHH ,T9HHH Y_QN?^*/OO^V?_ *,6O'Z]@\;_ /(G
MWW_;/_T8M>/5[.7?PGZ_Y'!BOC7H+1245WG,+1244 +1244 +1244 +1244
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MT44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
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M_P"87_VU_P#9*ZL%_'C\_P C'$?PV>?T445[QYH4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M30 P+FIXX2QZ5/%;$]JOQ6P':@"M#:^U7HX O:I50"I,4 -"XIU%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7G_Q-_P"87_VU_P#9*] KS_XF_P#,
M+_[:_P#LE=6"_CQ^?Y&.(_ALX"BBBO>/-"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#L/AQ_R,-Q_P!>C?\ H:5Z?7E_PY_Y&&X_Z]&_]#2O36<"O#Q_
M\8]##?PQQ.*B>4+4$MP!WJA-<Y[UQG069KKWJC)<$GK4+R$U'F@"0RGUH\T^
MM144 2^:?6CS3ZU%10!+YI]:/-/K45% $OFGUH\T^M144 2^:?6CS3ZU%10!
M+YI]:/-/K45% $OFGUH\QJ8JDU9BMR3TH 1-QJW#&QJ6&UQVJXD044 -B3 J
M<4 4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C=**
M&Z44  Z44@Z4M !1110 4444 %%%% !1110 4444 %%%% !1110!S_C;_D4+
M[_MG_P"C%KR"O7_&W_(H7W_;/_T8M>05[.7_ ,)^O^1P8KXUZ!1117<<P444
M4 %%%% !1110 4444 %%%% !1110 5:TS_D+6?\ UW3_ -"%5:M:9_R%K/\
MZ[I_Z$*F?PLJ/Q(])HHHKYH]8**** "BBB@ HHI0,T )3@I-/2(FKD-MGM0!
M!' 6J]#;>U6(K<#M5E4 H CCB"U,!BEHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K@/B9_S"_\ MK_[)7?UP'Q,_P"87_VU_P#9*ZL%
M_'C\_P C'$?PV<!1117NGF!1110 4444 %%%% !1110 4444 %%%% !1110!
MU?P_?9KUP?\ IU;_ -"2N^FNO>O./!C[-7F(_P"?<_\ H2UVC.37B8_^,>CA
MOX9+).6[U 6)I,TE<9T!1110 4444 %%%% !1110 4444 %%%/5": &@$U,D
M1:IHK<GM6A#; =J *T-M[5>C@"U*D8%28H 0+BG444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 AZ44'I10 #I2TE% "T4E%
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M3DC>3.Q&;'7 S2;2U86N-HI[12(,O&RCU(Q3*$T]@::W"BBBF 4444 %%%%
M&_X1_P"0M+_UP/\ Z$M=IFN+\(_\A67_ *X'_P!"6NSKP\?_ !CT,-_#%HI*
M*XSH%HI** %HI** %HI** %HI*4#- !2@9IZ1DU;BMB>U $$<);M5Z&V]JL1
M6X':K2H!0!%'"%'2IP *6B@ I:2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@
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M8;BI%C)J6.$GM5Z&U]J *T5N3VJ_%; =JGCA"CI4P7% #5C J3%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10
M!@>-C_Q2%]_VS_\ 1BUY!7LOBFRN-1\.W5K:Q^9-)LVKN SAP3R>.@->;GP=
MKXZV'_D9/_BJ]7 U(1IM2:6O^1Q8F$G/1&%16W_PB&N_\^/_ )%3_&C_ (1'
M7?\ GQ/_ ']3_&NWV]+^9?><_LY]F8E%;?\ PB.N_P#/B?\ OZG^-'_"(Z[_
M ,^)_P"_J?XT>WI?S+[P]G/LS$HK;_X1'7?^?$_]_4_QH_X1'7?^?$_]_4_Q
MH]O2_F7WA[.?9F)5F;_CRM?^!_SK2_X1'7?^?$_]_4_QIQ\.:M,BVT=IF:WS
MYJ^8OR[N1W]*SG6IN4?>6_?R9<:<[/3^KHPJ*V_^$1UW_GQ/_?U/\:/^$1UW
M_GQ/_?U/\:T]O2_F7WD>SGV9B45M_P#"(Z[_ ,^)_P"_J?XT?\(CKO\ SXG_
M +^I_C1[>E_,OO#V<^S,2BMO_A$==_Y\3_W]3_&C_A$==_Y\3_W]3_&CV]+^
M9?>'LY]F8E6]+_Y"UG_UW3_T(5H?\(CKO_/B?^_J?XU:T[PKK4.IVDLMEMC2
M9&<^8AP PSWJ9UJ7*_>7WCC3G=:'9I&2:MPVV>U68K7':KB1!17SYZA#%;@=
MJLJ@%. Q2T %+244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +
M1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +
M1244 +1244 +1244 +1244 +1244 +1244 +1244 +7 ?$S_ )A?_;7_ -DK
MOJX#XE_\PO\ [:_^R5U8+^/'Y_D8XC^&S@:***]T\T**** "BBO0_"GA/1%\
M-MX@\2R$6SDB-"S* ,XS\OS$D] *SJU8TU=E0@YNR//*DM_^/F+_ 'Q_.N]\
M9>$-(M] B\0:!(1:,5#1[BRD$X!!;D'/!!_3%<;HVGW&J:Q:V=LFZ620 >@'
M4D^P'-2JL:E-R7F5R.,TF5+C_CYE_P!\_P ZCKTKX@^%-(T'P_;7%E;E;IIU
M228R,2_RL3P3@9(["F:7X;T"RTG03JME)>76L2;0XF9!""., =>J]?4_2LX8
MF/LU*S_X8J5*7.T><45U7_"(,WC]O#T3LT*RY,AZB+ ;)]\''UK-\3C3$\07
M4.D6XALX6\M1O9MQ'5LL3W_3%;1JQDTEVN9N#2NS'HHHK0D**** -_PC_P A
M67_K@?\ T):[.N,\(_\ (5E_ZX'_ -"6NSKQ,=_&/0PW\,****XSH"BBE )H
M 2GJF:DCA)J[#:^U %>* GM5^&V [5/' %'2IPN* &I&!4@ HHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!"*:4!I]% $7ECTH\H>E2T4 1>
M4/2CRAZ5+10!%Y0]*/*'I4M% $7E#TK*L$!\0:N/3R?_ $$UM5D:?_R,.L?]
ML/\ T T :7E#TH\H>E2T4 1>4/2CRAZ5+10!%Y0]*/*'I4M% $7E#TI1&/2I
M** &A0*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7 ?$S_F%_]M?_ &2N_K@/B9_S"_\
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MTWW\= W'(H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFG5T._#IJ&I6AM<]JOQ6X Z5,D0 J4"N0W&J@%/Q110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%%  .E+0.E+0 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
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MH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 8W2BE?I10
MY/NBEH3[@IU #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG
M44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44
M-HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HI
MU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU%
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M* &XHQ3L48H ;BC%.Q1B@!N*,4[%&* &XHQ3L48H ;BC%.Q1B@!N*,4[%&*
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MY_U8^M% #[?_ %"_C_.I:9;#]POX_P ZEQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0
MVBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8
MHQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0 VBG8HQ0!6NO]4/\
M>HIUV/W0_P!ZB@"2V'^CK^/\ZEQ4=K_Q[)^/\ZFH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC
M%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH
M ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH ;BC%.HH JW@
M_<C_ 'J*6^_U*_[W^-% $MI_QZI^/\ZFJ*S_ ./5/Q_G4^* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&*
M&T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[%&* &T4[
M%&* *=__ *A?][^AHIVH?ZA?][^AHH ELO\ CT3\?YU/4-E_QYQ_C_,U/B@!
M**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H
M 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&
M* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ
M1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI
M<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!*
M*7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H
M2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&*
M $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1
MB@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<
M48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**
M7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2
MBEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&*
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MBC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M%
M"8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+1
M0 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2
MT4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,
M4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )B
MC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "
M8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
M F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T
M4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4
MM% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC
M%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8
MHQ2T4 )BC%+10 F*,4M% %+4O^/9?]\?R-%&I_\ 'LO^^/Y&B@"6P_X\H_Q_
MF:LU7L/^/*/\?YFK- "44M% "44M% "44M% "44M% "44M% "44M% "44M%
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MFXOQ!,_FBW$_[J)R<EE7&,]>N>M;EMID-KJ-Y?(TAENP@<,1M&P8&./>KM%
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MZ5<TCP_9Z+/=36SSL]SL\TS2;RQ4'YLGDDY).3^5:U% !1110 4444 %%%%
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MT 7J*H_VK!_<D_(?XT?VK!_<D_(?XT 7J*H_VK!_<D_(?XT?VK!_<D_(?XT
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FJP?W)/R'^- !JO\ QZK_ +X_D:*K7M['<PJB*X(;/('O10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>sava-20221231x10kg005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20221231x10kg005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF6WB^33O$EQ976EZA;O^\*?(+C _/;[^F1SUKMZ $551%1%"JHP !@ 4M%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11534M2
MM-(L);V]F$4$0RS'] !W- %NBN7T'QYI6OZD;"&.YM[@KOC6X0+Y@QGC!/;G
MZ5U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%4KW5].TUXTOKZWMVE.$$L@4M^= %VBCJ,BB@ HHHH **** "BBB@
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M** "BBB@ HHHH ***C,\0F$)E3S2,A-PW8]<4 24444 %%%% !1110 4444
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M^BZ;IDLD]GI]O;33?ZQHD SWQGTS570/"VE>'1(UA;;)90-[LY<X] 3VK:H
M**** "BBB@ HHHH ***K:A=FPT^XNQ!+/Y*%_*B&6;'84 6:HZRVHII%RVDQ
MQ/?!/W2RG@G_ !QG';-8L7BR+6/!M]JND_\ 'U!;NS0MRT3@$\^O3(]:X'2K
M?[<8=9TZ_P!26>TB-SJNH-(.N"3$BMPQX/4XYYZT ;SWVD^/?#TT&J,FG:U8
M*S,7.TQL.K#/53CD=OR-6O#=A<>+_#4,7BFP,BP%'M;HO\\JD9Y(YZ8!/?OR
M,U=B\/:!XVM+37[O3GBEG7+*LA4N 2!NQC/3K_\ 6KKXXTBC6.-0B( JJHP
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ME;GA(ZXVGW%AXAM0S6S^4EPS!A<+CKCOCCGO]0:Z-$2*-8XT5$4855& ![4
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M9R5' R 2.F:?6Q-]+G6T4BLKJ&4AE(R"#P12T#"BBB@ HHHH **** $P-P;
MR!@&EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P">$7_? H^RV_\ SPB_[X%2T4 1?9;?_GA%_P!\"C[+;_\ /"+_ +X%2T4
M1?9;?_GA%_WP*/LMO_SPB_[X%2T4 1?9;?\ YX1?]\"C[+;_ //"+_O@5+10
M!%]EM_\ GA%_WP*/LMO_ ,\(O^^!4M% $7V6W_YX1?\ ? H^RV__ #PB_P"^
M!4M% $7V6W_YX1?]\"C[+;_\\(O^^!4M% $7V6W_ .>$7_? H^RV_P#SPB_[
MX%2T4 1?9;?_ )X1?]\"C[+;_P#/"+_O@5+10!%]EM_^>$7_ 'P*/LMO_P \
M(O\ O@5+10!%]EM_^>$7_? H^RV__/"+_O@5+10!%]EM_P#GA%_WP*/LMO\
M\\(O^^!4M% $7V6W_P">$7_? H^RV_\ SPB_[X%2T4 1?9;?_GA%_P!\"C[+
M;_\ /"+_ +X%2T4 1?9;?_GA%_WP*/LMO_SPB_[X%2T4 1?9;?\ YX1?]\"C
M[+;_ //"+_O@5+10!%]EM_\ GA%_WP*/LMO_ ,\(O^^!4M% $7V6W_YX1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%8$6O7'VW5Q=6?V:WLK9)XPY!D<'?DG!(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^VG_ *+:MZ>;3G.$.5>];\[$U<GA"G.?,_=O^5SUS[+;_P#/"+_O@4?9;?\
MYX1?]\"I:*]T\ B^RV__ #PB_P"^!1]EM_\ GA%_WP*EHH B^RV__/"+_O@4
M?9;?_GA%_P!\"I:* (OLMO\ \\(O^^!1]EM_^>$7_? J6B@"+[+;_P#/"+_O
M@4?9;?\ YX1?]\"I:* (OLMO_P \(O\ O@4?9;?_ )X1?]\"I:* (OLMO_SP
MB_[X%'V6W_YX1?\ ? J6B@"+[+;_ //"+_O@4?9;?_GA%_WP*EHH B^RV_\
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M;_\ /"+_ +X%'V6W_P">$7_? J6B@"+[+;_\\(O^^!1]EM_^>$7_ 'P*EHH
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M:* (OLMO_P \(O\ O@4?9;?_ )X1?]\"I:* (OLMO_SPB_[X%'V6W_YX1?\
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M122QE)RTD@7./E* #(&?O'J*2TU^6XQ UFBWGVH0-$D^Y -JNSAMHX"L.W7
M[YH6H/0W**** "BBB@ HHHH JZG_ ,@F\_ZX/_Z":\VKTC4_^03>?]<'_P#0
M37F]?.YU_$CZ'O91\$O4*Z/XD?\ (NV__7VO_H#USE='\2/^1=M_^OM?_0'K
MGP?^[5_1?J=-?_>J/J_T/+JZ#P1_R.%C_P!M/_1;5S]=!X(_Y'"Q_P"VG_HM
MJXL)_O$/5?F>KC/]WJ?X7^1[#1117VY\&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 450N=<TFRG:"
MZU2R@F7&8Y;A%89Z<$YJ['(DL:R1NKQN RLIR&!Z$'TH =1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9D_O2_\ ?UO\:/LR?WI?^_K?XU+10!%]F3^]+_W];_&C[,G]Z7_OZW^-2T4
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MV9/[TO\ W];_ !J6B@"+[,G]Z7_OZW^-'V9/[TO_ '];_&I:* (OLR?WI?\
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M^D\U:M<=?W4XO=+'F/\ -=,"2<D?N9>GH?<=N.F:TH9I7GC5II<,P!'F'O\
MY/\ GH ;]%<EXCO;JQU".*VN)8T:(,1O)YRWK61_;>I?\_DOYUYM;-:-*;A)
M.Z]/\ST*66U:D%--6?K_ )'HE%<EX=O;J_U"2*YN)701%@-Y'.1Z?4USWBGQ
M#JVG>)+NTM+Z6."/9M7@XR@)Y//4FJEF5)456L[-VZ?YA#+:LZSHIJZ5^O\
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MGZL 2/R-9NAV^IVD4D%[!:)&TTTP>&X9SF25GVX*+P-V,Y[=.:UZ* "BBB@
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M-6K0!Q?B[_D+1?\ 7 ?^A-6!6_XN_P"0M%_UP'_H35@5\=C_ />9^I]7@O\
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M,^)'_(Q6_P#UZ+_Z&]:?AS_D/VW_  +_ -!-9GQ(_P"1BM_^O1?_ $-ZN/\
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M^5PO\>'JOS/I,3_!GZ/\C,^)'_(Q6_\ UZ+_ .AO7'UV'Q(_Y&*W_P"O1?\
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M?R7_  H\E_\ GYE_)?\ "I:* (O)?_GYE_)?\*/)?_GYE_)?\*EHH B\E_\
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M_/R+R7_Y^9?R7_"CR7_Y^9?R7_"I:* (O)?_ )^9?R7_  H\E_\ GYE_)?\
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MWB'J<76IX>!;7;8!BOWN1C^Z:RZU?#G_ "'[;_@7_H)KY7"_QX>J_,^DQ/\
M!GZ/\C*^(JE?$%N"[/\ Z*O+8_O/Z"N1KL/B1_R,5O\ ]>B_^AO7'U68?[S/
MU.K+O]UAZ'7?#I2_B"X"NR'[*W*X_OIZBO3O*?/_ !\2_DO^%>9_#?\ Y&*X
M_P"O1O\ T-*]1KW\H_W9>K/G,Y_WI^B(O)?_ )^9?R7_  H\E_\ GYE_)?\
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MW&> !TWAJ2\ET"V>^,IF.X!IEP[)N.PL/[Q7!/O56]VY-];&M1114E!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q?B[_D+1?\
M7 ?^A-7:5Q?B[_D+1?\ 7 ?^A-7F9M_NS]4>AEG^\?)F!75>#?\ E]_[9_\
MLU<K75>#?^7W_MG_ .S5XN6?[W#Y_DSU\Q_W:7R_-'F^O?\ (Q:G_P!?<O\
MZ&:SZT->_P"1BU/_ *^Y?_0S6?7#5_B2]6>S1_AQ]$>H_#?_ )%VX_Z^V_\
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MM6_Y"6A?]?S?^D\U:M4+K0](O9VGN]+LIYFQNDEMT9CCW(J['&D4:QQHJ1H
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M7_7I<?\ L]>?E?\ $G_A?Z'=F'PP_P 2_4\CHHHKRCWSZ!HHHK[\_.PHHHH
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M ,B[IG_7I%_Z *Z\D_B3]#ES[^'#U-"BBBOI#YD**** "BBB@ HHHH ****
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MS+^2_P"%2T4 1>2__/S+^2_X4>2__/S+^2_X5+10!GZG;2R:3>HLLTC- ZA
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MHQZ>]2:M_P A+0O^OYO_ $GFK5K!8.@FFHK0V>*K--.6YY9\15*^(+<%V?\
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M]GKS^O0/AC_S%/\ ME_[/665_P"]P^?Y,ZLV_P!SG\OS1Z#1117UY\8%%%%
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M'_/6+_OV?_BJ-MQ_SUB_[]G_ .*J6B@"+;<?\]8O^_9_^*HVW'_/6+_OV?\
MXJI:* .)\5AQJD7F,K'R!RJX[M[FL*M_Q=_R%HO^N _]":L"OCL?_O,_4^KP
M7^[P]#=\*!SJDOELJGR#RRY[K[BN3\:[AXNOMY!;]WR!C_EFM==X1_Y"TO\
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M^+]$5#_D8Q_P_P"9Q]=]\-1(?[4\ME7_ %7WES_?]Q7 UZ!\,?\ F*?]LO\
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MG_XJEVW'_/6+_OV?_BJEHK[\_.R+;<?\]8O^_9_^*HVW'_/6+_OV?_BJEHH
MBVW'_/6+_OV?_BJ-MQ_SUB_[]G_XJI:* (MMQ_SUB_[]G_XJC;<?\]8O^_9_
M^*J6B@"+;<?\]8O^_9_^*HVW':6+_OV?_BJEHH \L^(N\>(+?>5)^RKRHQ_&
M]<2L,0NGQ$@PJD?*.#DUW'Q(_P"1BM_^O1?_ $-ZXI?^/J3_ '%_FU?(XN4E
MB*MG_5T?98.,98>C=?U9G9_#H.?$%QL95/V5OO+G^)/<5Z;MN,?ZV+_OV?\
MXJO-/AO_ ,C%<?\ 7HW_ *&E>HU[64?[LO5GA9S_ +T_1$6VXS_K8L?]<S_\
M52;;C_GK%_W[/_Q5345ZAY1%MN/^>L7_ '[/_P 51MN/^>L7_?L__%5+10!#
MMN,?ZV+_ +]G_P"*I=MQG_6Q8_ZYG_XJI:* /-M1S_:EWN()\Y\D#_:-9>G_
M /'L_P#UWF_]&-6IJ6?[5O,]?/?_ -"-9>G_ /'L_P#UWF_]&-7Q53[?K_F?
M74_L^G^1U=@)/^$+U<JZA?+FR"I)_P!6.^:\N=%D&'4,/0C->J:=_P B1K'_
M %SF_P#18KRVM\8VJ5%KM^I67I.=9/O^A#:HB6T9554E!D@=>*]RT-9_^$?T
MW$D8'V6+@QG^Z/>O#K;_ (]8?]P?RKW;0?\ D7=,_P"O2+_T 5WY4V\14;_K
M4X,W26&I)?UH6]MQ_P ]8O\ OV?_ (JG()!GS&5O3:N/ZFGT5[Y\\%%%% !1
M110 4444 %17,KP6[21V\MPZ](HBH9OIN('YFI:Q_%,]Q;>&KR6VD>-PJ[I$
M^\B%@'8>A"Y.>V* ,W1I-3TU]1$GAZ_=;B[>X1UDM]Q#8X8&7J.@P>@'2NDM
MIGGMUDDMI;9SG,4I4LOUVDC\C5;^RM-?1ET[[/&UAL "9R,=<YZYSSNZYYSF
MJOA6YFN_#EM+-(\IRZI+)]Z1%<A6)[DJ <]ZI_D(V:***D84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%^+O\ D+1?
M]<!_Z$U8%;_B[_D+1?\ 7 ?^A-7+MJ%DCE'O+=7!P5,J@@_G7Q^-C*6)G9=3
MZG!R4</"[Z'4>$?^0M+_ -<#_P"A+7)>-_\ D<+[_MG_ .BUKK?"/_(6E_ZX
M'_T):Y+QO_R.%]_VS_\ 1:UK4_Y%T?\ %^C'AO\ D82_P_JCGZ]1^&__ "+M
MQ_U]M_Z E>75ZC\-_P#D7;C_ *^V_P#0$HRC_>5Z,USG_=7ZH["BBBOJSY *
M*** "BBB@ K _P"$1L/^>US_ -]+_A6_16-7#TJUO:*]C6G7J4K\CM<X_P /
M^%[*X\-Z7.\MP&DM(G(##&2@/I5SQA"MOX'NH4)*QI$@)ZX#J*O^&?\ D5-'
M_P"O&'_T 54\;_\ (GWW_;/_ -&+7/7H4J=&I*"LVG^1T8:M4J5Z<9NZ4E^9
MX]6AH/\ R,6F?]?<7_H8K/K0T'_D8M,_Z^XO_0Q7R5'^)'U1]G6_AR]&>XT4
M45]V?GX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC67I_P#Q[/\ ]=YO_1C5UUYX7OI[V>9)(-LDC.-S'.">_%9>D^%[Z>SD99(
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M=I)7MY$C 0X;#E0IQ@]">E+!K5A<6XGCF?:9A!M:)U<.<8!4C<."#TZ<].:
M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!?<7_H8KY&F](>O^1]G46L_3_,]QHHHK[8^$"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .5
M\9=;+_@?_LM<M74^,NME_P #_P#9:Y:ODLS_ -[G\OR1]/EW^[1^?YLU/#G_
M "'K;_@7_H)K-^)'_(Q6_P#UZ+_Z&]:7AS_D/6W_  +_ -!-9OQ(_P"1BM_^
MO1?_ $-ZN/\ R+I?XOT14/\ D8Q_P_YG'UZ!\,?^8I_VR_\ 9Z\_KT#X8_\
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M\8?_ $ 5JT %%%% !1110 4444 %%%% !7,>,9M1BBM?LK:DEHQ;SWTV$23
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MC_GE%_W\/_Q-&ZX_YY1?]_#_ /$U+10!%NN/^>47_?P__$T;KC_GE%_W\/\
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MVRLK?3K*&SM8_+MX5"1IN)P/J>:L54Y<SN3%65C%\0-/_9T.8XP/MUITD/\
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MN/\ GE%_W\/_ ,34M% $6ZX_YY1?]_#_ /$UE>'VG_LZ7$<?_']=_P#+0_\
M/Q)GM6K<3I;0--()"J]1'&TC?@J@D_@*R/#=VKVTUN8+N*3[3<S?OK26(%6G
M=E.64#)# XZT :VZXQ_JHO\ OX?_ (FH+N&\N8=D4[6K;L^9"ZEB/3YXV'Z=
MJNT4 96DZ=<Z39QVBW$ES#&BQQ+.Z?NU48 !6-<\>N>E:&ZX_P">47_?P_\
MQ-2T4 1;KC_GE%_W\/\ \33D,ASYB*OIM;/]!3Z* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *RKC_D:]/_Z\;K_T."M6LJX_Y&O3_P#KQNO_ $."@#5K
MQ[QQG_A+K_& ?W>,C_IFM>PUX]XW_P"1POO^V?\ Z+6O(SK_ '>/K^C/9R/_
M 'B7^%_FCF8C*TCAF0JIQPI&> ?7WKU?X;_\B[<?]?;?^@)7E,7^LG_W_P#V
M45ZM\-_^1=N/^OMO_0$KS\M_WM>GZ'HYI_N;]?U9V%%%%?3GRH4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*+_OX?\ XFC=<?\ /*+_ +^'_P")J6B@"+=<?\\HO^_A_P#B:-UQ_P \HO\
MOX?_ (FI:* (MUQ_SRB_[^'_ .)HW7'_ #RB_P"_A_\ B:EHH BW7'_/*+_O
MX?\ XFC=<?\ /*+_ +^'_P")J6B@"+=<?\\HO^_A_P#B:-UQ_P \HO\ OX?_
M (FI:* (MUQ_SRB_[^'_ .)HW7'_ #RB_P"_A_\ B:EHH BW7'_/*+_OX?\
MXFC=<?\ /*+_ +^'_P")J6B@"+=<?\\HO^_A_P#B:-UQ_P \HO\ OX?_ (FI
M:* (MUQ_SRB_[^'_ .)HW7'_ #RB_P"_A_\ B:EHH BW7'_/*+_OX?\ XFC=
M<?\ /*+_ +^'_P")J6B@"+=<?\\HO^_A_P#B:-UQ_P \HO\ OX?_ (FI:* (
MMUQ_SRB_[^'_ .)HW7'_ #RB_P"_A_\ B:EHH BW7'_/*+_OX?\ XFC=<?\
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M/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\
M$T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC
M_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\
M/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\
M$T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC
M_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\
M/_Q-2T4 1;KC_GE%_P!_#_\ $T;KC_GE%_W\/_Q-2T4 1;KC_GE%_P!_#_\
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M>ZD%O?B.:VMX4=["=5+*\Q.24P -Z\GCFNAHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJD&J:
M?=74EK;WUM-<1YWQ1S*SK@X.0#D8/% %NBJ<6K:;//+!#J%K)-""98TF4L@!
MP<@'(P?6GQ:C8SVRW,-[;R6[,$65)5*EB< 9!QG)QB@"S1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8FN0
M>'+4"_UFQLF,CK%YLMJ)&9CPH^Z3VK;KS_XE6>IM:07":MLLVN846U^S*=KY
M.'W]?PZ4XJ\DA-V39WT<:11K'&BI&@"JJC 4#H /2G52TJVOK2Q6+4-0^WW
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M\U_QH\Y_^?:7\U_QJ6JUQ>QVT@1U<L1GY1]?\* )/.?_ )]I?S7_ !H\Y_\
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M#=\Y_P#GVE_-?\:/.?\ Y]I?S7_&J&E^(]'UFVFN+"^CEB@_UI(*;!UR0P!
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MY_\ GVE_-?\ &I:* (O.?_GVE_-?\:/.?_GVE_-?\:EHH B\Y_\ GVE_-?\
M&CSG_P"?:7\U_P :EHH B\Y_^?:7\U_QH\Y_^?:7\U_QJ6B@"+SG_P"?:7\U
M_P :/.?_ )]I?S7_ !J6B@"+SG_Y]I?S7_&CSG_Y]I?S7_&I:* (O.?_ )]I
M?S7_ !H\Y_\ GVE_-?\ &I:* (O.?_GVE_-?\:/.?_GVE_-?\:EHH B\Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>sava-20221231x10kg006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20221231x10kg006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M*\^\7^+KN#Q/8Z'IFK6E@C\W-VX1_*.3\K;N!@#H<'D5VVF"4:9;^??+?2%
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M0RD,I&00>"*+/<=^@M%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2?EP >_<FL6Y^%OANYU)KPI<QJS;FMXI (R>_&,@>P(H4E:S[)#:UOYW//\
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MPO91>*YO$2RW'VR6/RV0LOEXP!P,9[#O3H?#-E!XIN/$*RW!NYXO*9"P\L#
M' QG/RCO0I)6]+#:W^7Z'%>%[F"S\1^.KFZW?9XI'>3:>=H9\X]ZQ+^YN[OX
M?79TO0+33O#WF!]\L[22NV\#*Y.<YXY[9Q7I=CX1TVQO-6N 9IO[5)-Q'*P*
MX))(& "!\Q[FLE?AEHHM9;1KO5'M&)9+=KK]W$Q_B50.H]\TE)?@OP!IWOYL
MXSQ2HE\ >#T?)#84\]L"KGCOP]I5KXH\,VEK916\%S((I5B4+O7>HYQU.">>
MM=G=^!--O='TW3)KF],.GL3"P=-Q]F^7'Y 5=UCPO9:WJFG:A<RW"2V#[XA&
MRA2<@_-D'^Z.F*OG7.GYMD<CY;>21Q.IZ?9Z3\7M!33[:*UCDA!9(4"J3\X/
M ]A7HVJ//'I%[); F=8',>/[P4X_6L^]\+V5_P")+/799;@75HFR-%9=A'/4
M8S_$>];=92=X)>IHM)W]#R[X;:1X>U+PW=7%_!:W5X9&^T-< ,T:]CS]WN=W
MUYXJEX1=AX/\96\+L^GQK)]G)/JK9_0+75:E\+O#NHWS706YM2YW-';R (3]
M"IQ^&*WHO#FFVWA^71+6(P6<L;1MY9^8[A@G)SD^YJY233\T3&-FO)G >'/#
MFDS?"F[OY[&"2[D@GD$S+EU*[MN">GW>U=%\+6)\#6P))Q+(!GM\QK;L?#=G
MI_AEM!BDG:U:.2,N[#?A\YYQC/S'M4N@:%:^'-*33K.29X49F#3$%LDY[ ?R
MHE--R\P4;)?,X/QZW]G?$+PYJEQQ9J55G/1=KDD_DP/X5Z%?:OIVG:?]ON[R
M*.UP")=V0V>F,=?PI-6TBQURP:RU&W6:!CG!."I[$$<@UR5O\)?#<-RLKO?3
MJ#GRI)5VG_OE0?UI)IQY7T&T^;F1:\8ZUX;ET2S358I;S3KY_P!U/;8*QL/X
MLY&.IZ9Z&N5UCP>WA/29=:T'Q//!"H#K&SC]]ST#*0&^FVO2K_0M-U/21I=U
M:(UFH 2-?E"8Z;<=,5RL'PD\-Q7 D=[Z9 ?]5), I_[Y4']:(M+9V!INU]3#
M\::I/K/PJTG4+I L\URN_ P"0'&1]<9_&M*S\!Z\]O;RCQQJ2J45@@#X QT_
MUE=5KOA;3]?T>#2IS+;VL#JT:VQ5=NT$ <@C&#6Q#$L,$<2DE44*,]< 4^>U
M[=Q<K=K]AXZ5Y5X[LI]1^)FC6EM>26<TML MQ'G=&=S\C!'\Z]5KE_$G@32_
M%%_'>7T]Y')'$(@('4#&2>ZGGFIB[23935XM'">+O#FI>&K:SU6_U\ZTD-P-
MMK?!]I/L"YSTYZ5J^-;P:C=>![T1F,7$RR["?N[C$<5IVOPE\.6]PDKR7UPJ
MG/ERRKM;Z[5!_6N@UGPO8ZW<Z;/<//&=/D\R%82H4G*G!!!X^4=,5:FDU?HR
M.5Z^AQ.LQ6FH?&&"TUO:UFL"_9XY6PC';D#\6S]< 4FOVECI'Q/\/KHD45O<
M2,HN(;<!5"DXY X&5W?E7;>(O"6D^)XT&H1.)8QA)XFVNH],\@CZ@U6\.^!=
M%\,SM<6B2RW)&!-<,&91W P !^6:49)6\OQ'*+=_,Y'0M*L=4^*OB$7]K%<I
M%N9$E4,N=RC.#P:K^ ?#VE7OB#Q)'=644\=M*8H4E4,$!9QP#W^4<UZ!I_A>
MRTWQ!?:U#+<-<WH(D5V4H.0> !GMZFC1/"]EH-[J-W:RW#R7\GF2B5E(!RQ^
M7 ']X]<TN;W;>5OF#CJWYW/.O!=]8Z?\/?$#ZE%)/9+<;6A1RI?< ,9!!&>,
MUG^*IM2N/!6G.=&L],T595-H@E,DQW*QSG/0C).1GI7I6G^!=(T_1K[2LW%Q
M:WC[Y!,XR#VP5 QT!J@_PPT:6P%I/?:K-&G^I\RY!\@=P@QM&>_!JG--W] Y
M7T\SG_&UM%?>)/!]M<#?%,J)(,]067-3?%:SMM.T'2X;&UAMXQ=EA'#&%7.W
MT%=?>^$+&_OM)O)[BZ,NF!1"0RX?!!^;Y>>G;%3>(_#%EXG@MX;V6XC6"3S%
M,+*"3C'.0:.9:>OZ@HO7T_0X7P)YNG^-[ZV\10_\3NZB66&>0Y)!&64=NGI_
M=(K+TNRU#5_''B );Z+<W:S.#'JR.V%#$90#T 49[#&*]-UCPO8ZSJ%C?R2W
M%O=V39BFMV4'KG!R""/\35#Q!\/M$\17WVVX%Q!<,,.]NX7?CID$$9]Z7.KI
M^5@Y79KYG(:?I,VD^"_%B'4=+NH98]XCT^X,BPMSD$$<<8]^*U_!6B:5_P *
M[%U*EO;SW,$RRWSJH:,$LI.X] ![XKI+?PAI5IX;N-"MDDBM;A2)75LR,3U;
M)'7CTQ[5<TG1+32-$CTB+?-:HK+^^PQ8,22#@ =SVHE*Z:] 4;-?,\D>T\1:
M)X;DMGM=/UOPV&WEX7#IPV20R$.#GJ>0/I7JGA.\MK_PMI]Q9V[6]N8MJ0LY
M?9M.W&X\D#'6L<_#?2 KP17NJPV+MN:QCNR(3]01G]:ZJSM+>PLXK2UB6*"%
M0B(O0 42DF@46F3T445F6%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOYTZB@!OF)_?7\Z/,3^^OYTZHHO]9/\ [_\ [** '^8G]]?SH\Q/[Z_G3J*
M&^8G]]?SH\Q/[Z_G3J* &^8G]]?SH\Q/[Z_G3J* &^8G]]?SH\Q/[Z_G3J*
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M WS$_OK^=.J*Y_X]9O\ </\ *I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"*?_5C_ 'T_]"%2U%/_ *L?[Z?^A"I: "BB
MB@ HHHH **** "BBB@")?^/J3_<7^;5+42_\?4G^XO\ -JEH **** "BBB@
MHHHH **** (K;_CUA_W!_*I:BMO^/6'_ '!_*I: "BBB@ HHHH **** "HI?
M]9!_O_\ LIJ6HI?]9!_O_P#LIH EHHHH **** "BBB@ HHHH *BB_P!9/_O_
M /LHJ6HHO]9/_O\ _LHH EHHHH **** "BBB@ HHHH BN?\ CUF_W#_*I:BN
M?^/6;_</\JEH **** "BBB@ HHHH **** (E_P"/J3_<7^;5+42_\?4G^XO\
MVJ6@ HHHH **** "BBB@ HHHH BMO^/6'_<'\JEJ*V_X]8?]P?RJ6@ HHHH
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MS_\ 84?\)G>_] 3_ ,F?_L*.5A='845Q_P#PF=[_ - 3_P F?_L*/^$SO?\
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M,[W_ * G_DS_ /84<K"Z.PHKC_\ A,[W_H"?^3/_ -A1_P )G>_] 3_R9_\
ML*.5A='845Q__"9WO_0$_P#)G_["C_A,[W_H"?\ DS_]A1RL+H["BN/_ .$S
MO?\ H"?^3/\ ]A1_PF=[_P! 3_R9_P#L*.5A='5VW_'K#_N#^52UQL?C"]CB
M1/[%SM4#/VG_ .PIW_"9WO\ T!/_ "9_^PHY6%T=A17'_P#"9WO_ $!/_)G_
M .PH_P"$SO?^@)_Y,_\ V%'*PNCL**X__A,[W_H"?^3/_P!A1_PF=[_T!/\
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M"3Z#-:*>)O%&H^(M8TG2;+3"MBX"S7&\ #G@X/+'MT P:.1_U\O\QM_U]_\
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M2/\ NBK-% %;[)'_ '11]DC_ +HJS10!6^R1_P!T4?9(_P"Z*LT4 5OLD?\
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M)"AFX&<=LFN+L/!OB6SB"&YTXX])7_\ B*] G_U8_P!]/_0A4M-.PFKG$_\
M".>(_P#GXL/^_K__ !%'_".>(_\ GXL/^_K_ /Q%=M13YF'*CB?^$<\1_P#/
MQ8?]_7_^(H_X1SQ'_P _%A_W]?\ ^(KMJ*.9ARHXG_A'/$?_ #\6'_?U_P#X
MBC_A'/$?_/Q8?]_7_P#B*[:BCF8<J.)_X1SQ'_S\6'_?U_\ XBC_ (1SQ'_S
M\6'_ ']?_P"(KMJ*.9ARHX<>'_$1D*?:+'( /^L?OG_8]J=_PCGB/_GXL/\
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M_P"$<\1_\_%A_P!_7_\ B*/^$<\1_P#/Q8?]_7_^(KMJ*.9ARHXG_A'/$?\
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MV*_\?4G^XO\ -JEHYF'*CB?^$<\1_P#/Q8?]_7_^(H_X1SQ'_P _%A_W]?\
M^(KMJ*.9ARHXG_A'/$?_ #\6'_?U_P#XBC_A'/$?_/Q8?]_7_P#B*[:BCF8<
MJ.)_X1SQ'_S\6'_?U_\ XBC_ (1SQ'_S\6'_ ']?_P"(KMJ*.9ARHXG_ (1S
MQ'_S\6'_ ']?_P"(H_X1SQ'_ ,_%A_W]?_XBNVHHYF'*CAT\/^(I(U<7%CA@
M",R/_P#$4[_A'/$?_/Q8?]_7_P#B*[&V_P"/6'_<'\JEHYF'*CB?^$<\1_\
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M #\6'_?U_P#XBC_A'/$?_/Q8?]_7_P#B*[:BCF8<J.)_X1SQ'_S\6'_?U_\
MXBD/ASQ'C_CXL/\ OZ__ ,17;T4<S#E1YIJ?@?Q+?Q,BW6G#/K*__P 17I=%
M%)NX)6(KG_CUF_W#_*I:BN?^/6;_ '#_ "J6D,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** (I_\ 5C_?3_T(5+44_P#JQ_OI
M_P"A"I: "BBB@ HHHH **** "BBB@")?^/J3_<7^;5+42_\ 'U)_N+_-JEH
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M **** "BBB@ HHHH *BB_P!9/_O_ /LHJ6HHO]9/_O\ _LHH EHHHH ****
M"BBB@ HHHH BN?\ CUF_W#_*I:BN?^/6;_</\JEH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** (I_P#5C_?3_P!"%2U7FB55
M5@7SO7JY(^\/>K% !1110 4444 %%%% !1110!$O_'U)_N+_ #:I:B7_ (^I
M/]Q?YM4M !1110 4444 %%%% !1110!%;?\ 'K#_ +@_E4M16W_'K#_N#^52
MT %%%% !1110 4444 %12_ZR#_?_ /934M12_P"L@_W_ /V4T 2T444 %%%%
M !1110 4444 %11?ZR?_ '__ &45+447^LG_ -__ -E% $M%%% !1110 444
M4 %%%% $5S_QZS?[A_E4M17/_'K-_N'^52T %%%% !1110 4444 %%%% $2_
M\?4G^XO\VJ6HE_X^I/\ <7^;5+0 4444 %%%% !1110 4444 16W_'K#_N#^
M52U%;?\ 'K#_ +@_E4M !1110 4444 %%%% !44O^L@_W_\ V4U+44O^L@_W
M_P#V4T 2T444 %%%% !1110 4444 %11?ZR?_?\ _914M11?ZR?_ '__ &44
M 2T444 %%%% !1110 4444 17/\ QZS?[A_E4M17/_'K-_N'^52T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4_P#JQ_OI
M_P"A"I:BG_U8_P!]/_0A4M !1110 4444 %%%% !1110!$O_ !]2?[B_S:I:
MB7_CZD_W%_FU2T %%%% !1110 4444 %%%% $5M_QZP_[@_E4M16W_'K#_N#
M^52T %%%% !1110 4444 %12_P"L@_W_ /V4U+44O^L@_P!__P!E- $M%%%
M!1110 4444 %%%% !447^LG_ -__ -E%2U%%_K)_]_\ ]E% $M%%% !1110
M4444 %%%% $5S_QZS?[A_E4M17/_ !ZS?[A_E4M !1110 4444 %%%% !111
M0!$O_'U)_N+_ #:I:B7_ (^I/]Q?YM4M !1110 4444 %%%% !1110!%;?\
M'K#_ +@_E4M16W_'K#_N#^52T %%%% !1110 4444 %12_ZR#_?_ /934M12
M_P"L@_W_ /V4T 2T444 %%%% !1110 4444 %11?ZR?_ '__ &45+447^LG_
M -__ -E% $M%%% !1110 4444 %%%% $5S_QZS?[A_E4M17/_'K-_N'^52T
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MK3O_  *3_&C_ (2/0_\ H-:=_P"!2?XT6871IU%+_K(/]_\ ]E-4?^$CT/\
MZ#6G?^!2?XU')XBT0R0D:SI_#Y/^E)Q\I]Z+,+HUZ*S/^$CT/_H-:=_X%)_C
M1_PD>A_]!K3O_ I/\:+,+HTZ*S/^$CT/_H-:=_X%)_C1_P )'H?_ $&M._\
M I/\:+,+HTZ*S/\ A(]#_P"@UIW_ (%)_C1_PD>A_P#0:T[_ ,"D_P :+,+H
MTZ*S/^$CT/\ Z#6G?^!2?XT?\)'H?_0:T[_P*3_&BS"Z-.HHO]9/_O\ _LHJ
MC_PD>A_]!K3O_ I/\:CC\1:())B=9T_E\C_2DY^4>]%F%T:]%9G_  D>A_\
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M_0:T[_P*3_&C_A(]#_Z#6G?^!2?XT6871IU%%_K)_P#?_P#915'_ (2/0_\
MH-:=_P"!2?XU''XBT023$ZSI_+Y'^E)S\H]Z+,+HUZ*S/^$CT/\ Z#6G?^!2
M?XT?\)'H?_0:T[_P*3_&BS"Z-.BLS_A(]#_Z#6G?^!2?XT?\)'H?_0:T[_P*
M3_&BS"Z-.BLS_A(]#_Z#6G?^!2?XT?\ "1Z'_P!!K3O_  *3_&BS"Z-.BLIO
M%'A]!E]=TQ?K=QC^M:M(9%<_\>LW^X?Y5+45S_QZS?[A_E4M !1110 4444
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MO]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\
M<%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/
M]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,
M4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8
MO]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\
M<%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/
M]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,
M4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8
MO]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\
M<%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/
M]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,
M4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8
MO]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\
M<%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/
M]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8O]B0_P!P4?V)#_<%;6*,
M4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\ <%']B0_W!6UBC%'*@YF8
MO]B0_P!P4?V)#_<%;6*,4<J#F9B_V)#_ '!1_8D/]P5M8HQ1RH.9F+_8D/\
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MOS#YC@$@CGW%>HRZ?9362V4MG;R6B@ 0/$I0 =!MQCBB?3K&ZM5M;BSMYK=
M L4D2L@QTP",5?M/S_S_ ,R5#\O\O\CS-+"'_A%O%]Q::Z-6:9 9VCLS#&'4
MDDC'RMD?W?KWJOK>MZ?=>"?"MA;W<,MRDUOYD2,"R;5VG<.W)[UZQ;VMO:6Z
MP6T$4,*C CC0*H_ <5370=&1"BZ38*I<2$"V3&X=&Z=?>DIJ_P!WX XZ??\
MB<IX7AC?XC>+)&12ZF-58CD CG^0K)\-ZAI.EZ%XDLM>E@CU W$OVB.?&^8$
M?+C/+<YQC/7/>O2XK*T@N)KB&UACGFQYLB1@-)CIN(Y/XU%<:3IMY<+<76GV
MD\Z?=DEA5F'T)&:F^EGVL5;6_G<\JMH;J#2? *W88,;YF0-U"%U*_I^E=)X:
M@BE^(?BUI(U9AL4$CH"#D?C@5VT]E:74D,EQ:PS20MNB:2,,8SZJ3T/THBLK
M2"XFN(;6&.>;'FR)& TF.FXCD_C3E.]_._XV)4;)+T_"YXKIW_(L>'AV&OX
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MC<* %HI-PHW"@!:*3<*-PH 6BDW"C<* %HI-PHW"@!:*3<*-PH 6BDW"C<*
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M9[BR\':+JMS?Q7FDB]\Q-)'&WYFX#]6(YX/3->LV>AZ9HFEW%MIMG'!$RL6
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M>0;M:_Z NI?^ DG^%&[6O^@+J7_@))_A7K]%:?6)&?L(GD&[6O\ H"ZE_P"
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M^L2#V$3R7=K7_0%U+_P$D_PHW:U_T!=2_P# 23_"O7Z*/K$@]A$\@W:U_P!
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M%>OT4?6)![")Y!NUK_H"ZE_X"2?X4;M:_P"@+J7_ ("2?X5Z_11]8D'L(GD
M?62 1HVI$'D$6LG^%&[6O^@+J7_@))_A7K5M_P >L/\ N#^52T?6)![")Y!N
MUK_H"ZE_X"2?X4;M:_Z NI?^ DG^%>OT4?6)![")Y!NUK_H"ZE_X"2?X4;M:
M_P"@+J7_ ("2?X5Z_11]8D'L(GD&[6O^@+J7_@))_A1NUK_H"ZE_X"2?X5Z_
M11]8D'L(GD&[6O\ H"ZE_P" DG^%!?600#HVI<\#_19.?TKU^HI?]9!_O_\
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MBB@ HHHH **** "BBB@"*V_X]8?]P?RJ6HK;_CUA_P!P?RJ6@ HHHH ****
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M[B_S:I: "BBB@ HHHH **** "BBB@"*V_P"/6'_<'\JEJ*V_X]8?]P?RJ6@
MHHHH **** "BBB@ J*7_ %D'^_\ ^RFI:BE_UD'^_P#^RF@"6BBB@ HHHH *
M*** "BBB@ J*+_63_P"__P"RBI:BB_UD_P#O_P#LHH EHHHH **** "BBB@
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M_P#LHH EHHHH **** "BBB@ HHHH BN?^/6;_</\JEJ*Y_X]9O\ </\ *I:
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MPZO_ .!LO_Q5']L^(_\ H8=7_P# V7_XJC%&*/80[![>?<!K'B,  >(=6 '
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M / V7_XJC^V?$?\ T,.K_P#@;+_\51BC%'L(=@]O/N']L^(_^AAU?_P-E_\
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M##J__@;+_P#%4?VSXC_Z&'5__ V7_P"*HQ1BCV$.P>WGW :QXC  'B'5@!P
M+V3_ .*H_MGQ'_T,.K_^!LO_ ,51BC%'L(=@]O/N']L^(_\ H8=7_P# V7_X
MJC^V?$?_ $,.K_\ @;+_ /%48HQ1["'8/;S[A_;/B/\ Z&'5_P#P-E_^*H_M
MGQ'_ -##J_\ X&R__%48HQ1["'8/;S[A_;/B/_H8=7_\#9?_ (JC^V?$?_0P
MZO\ ^!LO_P 51BC%'L(=@]O/N']L^(_^AAU?_P #9?\ XJ@ZQXC)!/B'5N.1
M_ILG'_CU&*,4>PAV#V\^X?VSXC_Z&'5__ V7_P"*H_MGQ'_T,.K_ /@;+_\
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M_P#BJ/[9\2?]##J__@;+_P#%48H(XH]A#L'MY]RE>^(/$T2$KXCU@?2^E_\
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M3W-_>W)A,*37D_F-$A&,+P .M)R33\_\BE%Z7Z?Y[G$>&?"7]I?#[^T; O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M71_:$>P?4)=SPW[6GJ*/M:>HKVZ#X7^#G@C9M())4$G[5-Z?[]2?\*M\&_\
M0'/_ (%S?_%T?VA'L'U"7<\-^UIZBC[6GJ*]R_X5;X-_Z Y_\"YO_BZ/^%6^
M#?\ H#G_ ,"YO_BZ/[0CV#ZA+N>&_:T]11]K3U%>Y?\ "K?!O_0'/_@7-_\
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MM\&_] <_^!<W_P 71_:$>P?4)=SPW[6GJ*/M:>HKW+_A5O@W_H#G_P "YO\
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M (%S?_%T?VA'L'U"7<\-^UIZBC[6GJ*]R_X5;X-_Z Y_\"YO_BZ/^%6^#?\
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M!]0EW/$?M:>HH^UIZBO<O^%6^#?^@.?_  +F_P#BZ/\ A5O@W_H#G_P+F_\
MBZ/[0CV#ZA+N>&_:T]11]K3U%>Y?\*M\&_\ 0'/_ (%S?_%T?\*M\&_] <_^
M!<W_ ,71_:$>P?4)=SPW[6GJ*/M:>HKW+_A5O@W_ * Y_P# N;_XNC_A5O@S
M_H#G_P "YO\ XNC^T(]@^H2[GSWJ-RIC/-?6E<8_PH\$R##:*3_V]S__ !==
MG7%B*RJM-'7AZ+I)ID5S_P >LW^X?Y5+45S_ ,>LW^X?Y5+7.= 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 13_ZL?[Z?^A"
MI:BG_P!6/]]/_0A4M !1110 4444 %%%% !1110!$O\ Q]2?[B_S:I:B7_CZ
MD_W%_FU2T %%%% !1110 4444 %%%% $5M_QZP_[@_E4M16W_'K#_N#^52T
M%%%% !1110 4444 %12_ZR#_ '__ &4U+44O^L@_W_\ V4T 2T444 %%%% !
M1110 4444 %11?ZR?_?_ /914M11?ZR?_?\ _910!+1110 4444 %%%% !11
M10!%<_\ 'K-_N'^52U%<_P#'K-_N'^52T %%%% !1110 4444 %%%% $2_\
M'U)_N+_-JEJ)?^/J3_<7^;5+0 4444 %%%% !1110 4444 16W_'K#_N#^52
MU%;?\>L/^X/Y5+0 4444 %%%% !1110 5%+_ *R#_?\ _934M12_ZR#_ '__
M &4T 2T444 %%%% !1110 4444 %11?ZR?\ W_\ V45+447^LG_W_P#V44 2
MT444 %%%% !1110 4444 17/_'K-_N'^52U%<_\ 'K-_N'^52T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4_^K'^^G_H0
MJ6J\TJLJJ ^=Z]4('WA[58H **** "BBB@ HHHH **** (E_X^I/]Q?YM4M1
M+_Q]2?[B_P VJ6@ HHHH **** "BBB@ HHHH BMO^/6'_<'\JEJ*V_X]8?\
M<'\JEH **** "BBB@ HHHH *BE_UD'^__P"RFI:BE_UD'^__ .RF@"6BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (I
M_P#5C_?3_P!"%2U%/_JQ_OI_Z$*EH **** "BBB@ HHHH **** (E_X^I/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,SQ%J/]C^'=0U/RO.^QPM<>7NV[]GS8S@XSCK@UY.G[0#N,_P#"+?\
ME0_^U5Z7XZ_Y$+7_ /KPF_\ 0#7RS:H-@KHH4U/<PK5'#8]>_P"%^2?]"M_Y
M/_\ VNC_ (7Y)_T*W_D__P#:Z\J\L>E'ECTKI^K0.;ZQ,]5_X7Y)_P!"M_Y/
M_P#VNC_A?DG_ $*W_D__ /:Z\J\L>E'ECTH^K0#ZS,]5_P"%^2?]"M_Y/_\
MVNC_ (7Y)_T*W_D__P#:Z\J\L>E'ECTH^K0#ZS,]5_X7Y)_T*W_D_P#_ &NC
M_A?DG_0K?^3_ /\ :Z\J\L>E'ECTH^K0#ZS,]3'QYD$K/_PB_50,?;_3/_3/
MWIW_  OR3_H5O_)__P"UUY5Y8]*/+'I1]6@'UF9ZK_POR3_H5O\ R?\ _M='
M_"_)/^A6_P#)_P#^UUY5Y8]*/+'I1]6@'UF9ZK_POR3_ *%;_P G_P#[71_P
MOR3_ *%;_P G_P#[77E7ECTH\L>E'U: ?69GJO\ POR3_H5O_)__ .UT?\+\
MD_Z%;_R?_P#M=>5>6/2CRQZ4?5H!]9F>J_\ "_)/^A6_\G__ +71_P +\D_Z
M%;_R?_\ M=>5>6/2CRQZ4?5H!]9F>IQ_'F2.)$_X1?.U0,_;_P#[73O^%^2?
M]"M_Y/\ _P!KKRKRQZ4>6/2CZM /K,SU7_A?DG_0K?\ D_\ _:Z/^%^2?]"M
M_P"3_P#]KKRKRQZ4>6/2CZM /K,SU7_A?DG_ $*W_D__ /:Z/^%^2?\ 0K?^
M3_\ ]KKRKRQZ4>6/2CZM /K,SU7_ (7Y)_T*W_D__P#:Z/\ A?DG_0K?^3__
M -KKRKRQZ4>6/2CZM /K,SU7_A?DG_0K?^3_ /\ :Z:WQYD9D/\ PB^-K9_X
M_P#KP1_SS]Z\L\L>E'ECTH^K0#ZS,]5_X7Y)_P!"M_Y/_P#VNC_A?DG_ $*W
M_D__ /:Z\J\L>E'ECTH^K0#ZS,]5_P"%^2?]"M_Y/_\ VNC_ (7Y)_T*W_D_
M_P#:Z\J\L>E'ECTH^K0#ZS,]5_X7Y)_T*W_D_P#_ &NC_A?DG_0K?^3_ /\
M:Z\J\L>E'ECTH^K0#ZS,]5_X7Y)_T*W_ )/_ /VNC_A?DG_0K?\ D_\ _:Z\
MJ\L>E'ECTH^K0#ZS,]5_X7Y)_P!"M_Y/_P#VNFK\>9%9S_PB^=S9_P"/_IP!
M_P \_:O+/+'I1Y8]*/JT ^LS/5?^%^2?]"M_Y/\ _P!KH_X7Y)_T*W_D_P#_
M &NO*O+'I1Y8]*/JT ^LS/5?^%^2?]"M_P"3_P#]KH_X7Y)_T*W_ )/_ /VN
MO*O+'I1Y8]*/JT ^LS/5?^%^2?\ 0K?^3_\ ]KH_X7Y)_P!"M_Y/_P#VNO*O
M+'I1Y8]*/JT ^LS/5?\ A?DG_0K?^3__ -KH_P"%^2?]"M_Y/_\ VNO*O+'I
M1Y8]*/JT ^LS/4Y/CS))$Z?\(OC<I&?M_P#]KIW_  OR3_H5O_)__P"UUY5Y
M8]*/+'I1]6@'UF9ZK_POR3_H5O\ R?\ _M='_"_)/^A6_P#)_P#^UUY5Y8]*
M/+'I1]6@'UF9ZK_POR3_ *%;_P G_P#[71_POR3_ *%;_P G_P#[77E7ECTH
M\L>E'U: ?69GJO\ POR3_H5O_)__ .UT?\+\D_Z%;_R?_P#M=>5>6/2CRQZ4
M?5H!]9F>J_\ "_)/^A6_\G__ +71_P +\D_Z%;_R?_\ M=>5>6/2CRQZ4?5H
M!]9F>ICX\R"5G_X1?JH&/M_IG_IG[T[_ (7Y)_T*W_D__P#:Z\J\L>E'ECTH
M^K0#ZS,]5_X7Y)_T*W_D_P#_ &NC_A?DG_0K?^3_ /\ :Z\J\L>E'ECTH^K0
M#ZS,]5_X7Y)_T*W_ )/_ /VNC_A?DG_0K?\ D_\ _:Z\J\L>E'ECTH^K0#ZS
M,]5_X7Y)_P!"M_Y/_P#VNC_A?DG_ $*W_D__ /:Z\J\L>E'ECTH^K0#ZS,]5
M_P"%^2?]"M_Y/_\ VNC_ (7Y)_T*W_D__P#:Z\J\L>E'ECTH^K0#ZS,]3C^/
M,D<2)_PB^=J@9^W_ /VNG?\ "_)/^A6_\G__ +77E7ECTH\L>E'U: ?69GJO
M_"_)/^A6_P#)_P#^UT?\+\D_Z%;_ ,G_ /[77E7ECTH\L>E'U: ?69GJO_"_
M)/\ H5O_ "?_ /M='_"_)/\ H5O_ "?_ /M=>5>6/2CRQZ4?5H!]9F>J_P#"
M_)/^A6_\G_\ [71_POR3_H5O_)__ .UUY5Y8]*/+'I1]6@'UF9ZK_P +\D_Z
M%;_R?_\ M=-;X\R,R'_A%\;6S_Q_]>"/^>?O7EGECTH\L>E'U: ?69GJO_"_
M)/\ H5O_ "?_ /M='_"_)/\ H5O_ "?_ /M=>5>6/2CRQZ4?5H!]9F>J_P#"
M_)/^A6_\G_\ [71_POR3_H5O_)__ .UUY5Y8]*/+'I1]6@'UF9ZK_P +\D_Z
M%;_R?_\ M='_  OR3_H5O_)__P"UUY5Y8]*/+'I1]6@'UF9ZK_POR3_H5O\
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MF)SE\CYLXZ>]$K6?I^K"-[KU_1$?A3Q->:F=)T?1HX#;V=G%]ON9U)P=H^5
M".>",G^G)J?CR^.JZC!I;Z-#!I[%'_M&XV27##J(QD>A'/M]*33O"5_X>N]!
MU/2K+]Z(%M]4MEE4%LC+/DG!(/OV&*AG\+ZEI6M:K):^&]-UJWOI3-#)<F,&
MW8]00W)7)Z#TJI<KE?U^^XHW4;>GW%B?Q[J-Y-H*Z)9VLAU2-\I<%LQNIP?F
M!Z @GIR!45UXS\06^L/HTC:!:WMO'OFENI)$AD)Y CR<]".O?-7#X<U-?$GA
MF[%A9QPV<<GVK[$JQQ1LP/"J3D]>H^M/\5:5J5_J+>9X7T_6K-D B=9_L\\7
MJ&<GD9STQ4^[T\QZ_D=-HEW?7VDPSZC9K:73#YHTE613Z%2I/!%8NK^(M4;Q
M(N@:!;6DEXD/GSS7C,(XU[#"\D\C\Q[XE\#:%>>'_#WV6]9?->5I1$K;A"#C
MY >_3/U-4]4TG6-+\7MXBT6RCU!;F 0W-JTPB;(QA@QX[#]?7A.W/Y#5^4Y?
MQ9XGU74_"NHV$\,%I=V5PD5\B.QWJ3\I0^A(.0>V/6N\\(Z2VC>'H;62"UAD
M),C+:L[)ST.7).<8S7&:EX-UV_T/6;R:WC;5M3N(G^S1RKB*-3TW$@$_CV%>
MF0*4MXU8894 (_"FVE&W];(6KDNW_!/#O$7_  C_ /PG.N?V[_:>/.7R?L/E
M^G.[?^&,>]6-"DA;P]XM33;J?^R5M1Y5O=2*90W=MJ\ =>1ZCTKI9K/QIH_B
MO6K[1='MKFWOI%(>>5>BCC \Q2.IZU /"_B;53KFKZI:6\%_=61MHK6!E&\\
M<D[B.PZG\L4T_<MY?IV!KW[^9P(;PDNE!D.NC5!$"#F(0B7'_?6W/XUV'C!M
M_@3PJVJW+7*F5?/EMW#LR[><$\%@.,GN*O0_\+&CT--''A_3OLRVXM]SR(6V
M[=N3^\P3CV_"I=0\(ZYI_A7P]::9#'>WNGW7VEP754!R6Q\Q&1GBKE)?BB8I
M_@SBK2308]8TW_A&;K5;:]-R@:74)(DC"=_N_P CUZ5ZS\0?^1%U7_KFO_H:
MURVJ:=X\\6Q0Z9JVE:?96AE5WG1E)3'I\['\A^-=CXMTVZU+PA?:?91F:XDC
M544L!NPP[G [5G4=XHJ"M(PK_P 1W_A[PIX8-A;0W$ETL,)CESR"@X!!X/N<
MTRX\4>);34[O1KVWTV.\DLGN;26 N47 )PV>IP#V'(]ZEUGP_JEWI'A2""UW
M26$T#7*^8HV!5 /4\].V:L:QH%_?^/;6_CA_T$:=);O-O7Y68. ,9S_$.U$K
M-OY_EI^(0NDOE^>OX&#H/BK5-$\ +JFH?9[I9YC'9YD82/(SON,K'C QD8[>
ME;&A>,[J;Q!#I&J2Z1</<QEX9]+G,B!ADE&!)(.!U_G6-#X1UV[\$)HESIT-
MO<Z=.)[61YDD2YRS$J0/NC#=^OM6]H&F:@VKQW%SX3T71[>)/O1HDDS/C&49
M,!1]>?SXJ7+=_P!=!+FM_7<JQ^+O$.I#5-1TK3K&32;!WCQ*[":4J,DKCCT.
M#CTSFJ5OX\U^\BT!+6RL)+G4UEW*P=54JQ4$'<<# R>M5[!=5T;3?$&EZ6-.
MO-,+2RB^6]0BV!4Y#(,G.!TX&>^*B\(:)J-RG@_48K?=:6JW'G2;U&W<[XX)
MR?P%**CUVT_)CDVEIOJ6H+S5XO%>NB6UTN/6HM,,AN83+M.-N!AF(Z?[(YIN
M@ZYXEL/AS)K/^A721N9$\SS&E=3(PD+G(&<X(QV!S6Z- OY/'FLWSP[+&[T_
M[/'-O7EL*.F<]CVI/!VDZE:^%I] UK35@A1'C683JXF5RQ/ ^[C/?]*5_=^[
M\V.VOS_1%G5?%,ZWWA^TTA(9GU1A(QD4MLAP"6X(YP3^1KJ:\O\ ACIMQ-JE
MY?74XGCTY3I]JX.5P&).#Z8Q_P!]5ZA2FDM%_7;\ BV]_P"NYS_CK_D0M?\
M^O";_P! -?+=K]P5]2>.O^1"U_\ Z\)O_0#7RW:_<%=.$ZG-BNA:HHHKN.(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMU]PU:JK=?
M<-3+8J.Y]4^#?^1&\/\ _8-M_P#T6M<;/<:OK]SXGOH]:O+'^QW9+6W@?:AV
M9)+C^+.WOZ^G%=EX-_Y$;P__ -@VW_\ 1:UQ/B?2WDUW5!'X?UL2W2!4>QFS
M;7;8X,PP-N#CC/8_4^2OB9ZGV5<?K7BJ^O\ P#H=Q'-<0WE_<".5K/*R$*2&
MVX[D@<>]6]"O8OLNM?V;J7B*75H+5]MCK$FYU.,JRIZYQ^?3FKMO#KG@WPII
M$%G8+J"PD_;HHP6E 8[CY>#S@DCO2Z#;WVK^-[KQ)-IUQI]HMJ+6&.Z39+(<
M@EBO8=?T]ZMV]Y+;4E723?E^9E:-X@DL[6_NGO9[RPCTJ*25I96DQ=MP4!)^
M4G/W1T]!7:^';6\M-%A&H3R37DN9IB[EMK-SM&>@'0 <<5C:XW]N>(HM(4;K
M73H_MMWZ&3!\I#^K?@*R/"NIZC<:[I\<EY<SW$L=R=4@ED)$#!_D^0\1]@
M,BE\7]>O]?</X?Z_K^FST6BBBLRPHHHH **** "BBB@ HHHH **** "BBB@
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M_DA_]LH_X4')_P!#3_Y(?_;*/K, ^K3/*O,'K1Y@]:]5_P"%!R?]#3_Y(?\
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M*/K, ^K3/*O,'K1Y@]:]3D^ TD<3O_PE&=JDX^P?_;*=_P *#D_Z&G_R0_\
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M:?\ R0_^V4?\*#D_Z&G_ ,D/_ME'UF ?5IGE7F#UH\P>M>J_\*#D_P"AI_\
M)#_[91_PH.3_ *&G_P D/_ME'UF ?5IGE7F#UH\P>M>J_P#"@Y/^AI_\D/\
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MB@ HHHH **** "BBB@")?^/J3_<7^;5+42_\?4G^XO\ -JEH **** "BBB@
MHHHH **** (K;_CUA_W!_*I:BMO^/6'_ '!_*I: "BBB@ HHHH **** "HI?
M]9!_O_\ LIJ6HI?]9!_O_P#LIH EHHHH **** "BBB@ HHHH *BB_P!9/_O_
M /LHJ6HHO]9/_O\ _LHH EHHHH **** "BBB@ HHHH BN?\ CUF_W#_*I:BN
M?^/6;_</\JEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEH **** "BBB@ HHHH **** (E_X^I/]Q?YM4M1+_P ?4G^XO\VJ6@ HHHH
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M>S4/%O\ )4(2P"2GA@YRHZ]*N:1XKE:\L[?5;F6 I%Y4FZV(\Z9F4*7PI$>
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M@7VK&"\G,,CJL4, A.QI &WMY@! )*N%4MDB,L 0<UU=1*+B[,:=QNP>K?\
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/5MT44G)O<$D@HHHI#/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>sava-20221231x10kg007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20221231x10kg007.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_X0!:17AI9@  34T *@    @  8=I  0
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /LN@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M=VTNATU04% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M<#*MB1STW*2#M0(N02,@D'!HG+FE=;= BN56.WK,L* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M<L%;H?ND]#19[)._H%UO<OV]S%=QK/;NDL3C*O&P9&'JK*2"/<&IVT8_0FH
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MD-M )(XV40W=V-^YF\PR/$2"@2(*C8F>VFUW][^2*CIOO9?UNST>L30* "@
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M@"C?:I9Z6%-[/#;"0[4,TB1[CZ+O9=Q]ADTTF]D*Z6Y>I#"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * &O&LJE' 96!#*0""",
M$$'@@C@@\$4 4;#2++20PL+>"U$F"XAB2+=C.-VQ5SC)QGIDXZTVV]V))+;0
MT*0PH * "@ H * "@ H * "@ H * "@ H * ,R+1;""Y-]';6Z73$DSK#&)2
M6X8F0*');OD\]Z=W:UW;L*RWL:=(84 % !0 4 4-5ADN;*XA@_ULD,J)SCYV
M1@O/;DCGMUIK1JXGL><^"+*=;V&;[/-:Q6VCVME*)H7AW7,<C,P7>JF4*,GS
M5W(=X^;)-;3>EK_:;^1G'?MHE\SU6L#4@*S=F3_O@_\ QR@ VS?WD_[X;_XY
M0 ;9O[R?]\-_\<H -LW]Y/\ OAO_ (Y0 ;9O[R?]\-_\<H H7UY-9;?N-NS_
M  L,8Q_MGUH S_[9F_NI^3?_ !5 !_;,W]U/R;_XJ@ _MF;^ZGY-_P#%4 ']
MLS?W4_)O_BJ -"QO)KS=]Q=N/X6.<Y_VQZ4 7]LW]Y/^^&_^.4 &V;^\G_?#
M?_'* #;-_>3_ +X;_P".4 &V;^\G_?#?_'* #;-_>3_OAO\ XY0 ;9O[R?\
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MBVKVMIIKJCJP]-5JU*C*ZC.I"+MO:4DG:]U>STT9XI_PM?5?^>5I_P!\2_\
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M%KWIQB[V@GLWUW/7-LW]Y/\ OAO_ (Y7VI\*3T % !0 4 % !0 4 % !0 4
M% !0!@ZW_P L_P#@7_LM &#0 4 % !0!O:'_ ,M/^ _^S4 ;U !0 4 % !0
M4 % !0 4 % 'EGCC_C^3_K@O_H<E?G>>_P"\P_Z]1_\ 2YGW>3?[O+_KZ_\
MTF!QM?+'T@4 % !0!ZGX'_X\7_Z[M_Z!'7Z)D7^[3_Z^R_\ 2('PF<_[Q'_K
MTO\ TJ9V5?4GS84 % !0 4 % !0 4 % !0!\R?$+_D/77_;'_P!)XJ_*LW_W
MVK_VY_Z;@?KN3?[C1_[B?^G9G%UX1[X4 % !0!].?#W_ ) -K_VV_P#2B6OU
M;*/]RI?]O_\ IR9^19S_ +]6_P"X?_IJ!V=>X> % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 07?^ID_P!QO_030!Q5 !0 4 % %_3/^/E/^!?^@F@#K: "
M@ H * "@ H * "@ H * /+/''_'\G_7!?_0Y*_.\]_WF'_7J/_I<S[O)O]WE
M_P!?7_Z3 XVOECZ0* "@ H ]D\*?\@R'_MI_Z->OU+*?]RI?]O\ _IR9^<9G
M_O=3_MS_ -(B=#7MGCA0 4 % !0 4 % !0 4 8OB3_D%7O\ UZ7'_HIZX<9_
MNU?_ *]5/_2)'?@O]ZP__7ZE_P"EQ/DJOQL_;0H * "@#M/A[_R'K7_MM_Z3
MRU[N4?[[2_[?_P#3<SP,Y_W&M_W#_P#3L#Z;K]5/R(* .'\8G4F>V@TB5([B
M87"A)'>,',:KYV44AS;[BXC?ABP8!BF*TC;5RVT_X;YD2OI8N^$]'N]$AFMK
MF66>,2@P--)YLFWRXP[%NRR2B1UCR2@;DY. I-/5:>@XJVAU=04% !0 4 %
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M):_5LH_W*E_V_P#^G)GY%G/^_5O^X?\ Z:@=G7N'@!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % $%W_ *F3_<;_ -!- '%4 % !0 4 7],_X^4_X%_Z": .
MMH * "@ H * "@ H * "@ H \L\<?\?R?]<%_P#0Y*_.\]_WF'_7J/\ Z7,^
M[R;_ '>7_7U_^DP.-KY8^D"@ H * /9/"G_(,A_[:?\ HUZ_4LI_W*E_V_\
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MK\[SW_>8?]>H_P#I<S[O)O\ =Y?]?7_Z3 XVOECZ0* "@ H ]3\#_P#'B_\
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M?_'* #;-_>3_ +X;_P".4 &V;^\G_?#?_'* #;-_>3_OAO\ XY0 ;9O[R?\
M?#?_ !R@ VS?WD_[X;_XY0!\T_$ ,-=N=Q!/[GD# _U$78D_SK\JS?\ WVK_
M -N?^FX'Z[DW^XT?^XG_ *=F<;7A'OA0 4 % 'TM\/UE_L*VVLH'[[@H2?\
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M '*E_P!O_P#IR9^<9G_O=3_MS_TB)T->V>.% !0 4 % !0 4 % !0!B^)/\
MD%7O_7I<?^BGKAQG^[5_^O53_P!(D=^"_P!ZP_\ U^I?^EQ/DJOQL_;0H *
M"@#M/A[_ ,AZU_[;?^D\M>[E'^^TO^W_ /TW,\#.?]QK?]P__3L#Z;K]5/R(
M* /+M?TKPGJ5[+-J-[#%<DJLJ?V@L.&C 4;HQ*NUE"@<@$$>M;1<TK):>ADU
M%O5_B=+X2T_1["&4:),MS&\@,KK<?:?G"J "^]\84#"Y'!SZ5$FW\2M\K%Q2
M7PG65!04 % !0 4 % !0 4 % &#K?_+/_@7_ ++0!@T % !0 4 ;VA_\M/\
M@/\ [-0!O4 % !0 4 % !0 4 % !0 4 >6>./^/Y/^N"_P#H<E?G>>_[S#_K
MU'_TN9]WDW^[R_Z^O_TF!QM?+'T@4 % !0!ZGX'_ ./%_P#KNW_H$=?HF1?[
MM/\ Z^R_](@?"9S_ +Q'_KTO_2IG95]2?-A0 4 % !0 4 % !0 4 % 'S)\0
MO^0]=?\ ;'_TGBK\JS?_ 'VK_P!N?^FX'Z[DW^XT?^XG_IV9Q=>$>^% !0 4
M ?3GP]_Y -K_ -MO_2B6OU;*/]RI?]O_ /IR9^19S_OU;_N'_P"FH'9U[AX
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 >6>./^/Y/^N"_P#H<E?G>>_[S#_KU'_TN9]WDW^[R_Z^O_TF
M!QM?+'T@4 % !0![)X4_Y!D/_;3_ -&O7ZEE/^Y4O^W_ /TY,_.,S_WNI_VY
M_P"D1.AKVSQPH * "@ H * "@ H * ,7Q)_R"KW_ *]+C_T4]<.,_P!VK_\
M7JI_Z1([\%_O6'_Z_4O_ $N)\E5^-G[:% !0 4 =I\/?^0]:_P#;;_TGEKW<
MH_WVE_V__P"FYG@9S_N-;_N'_P"G8'TW7ZJ?D04 >6>.M%4-&VG65A]HN/M$
MDDTUE%.SR11&58N4_P!9/A\,Q.2F!R<'>#[MV5M+V,I+LE]Q8^&,XN+.X9/L
MYC$X"O;6BVD;_N8V8% JEI$=FC<D'&T88] JFC6^W5W'#;_)6/2ZQ- H * "
M@ H * "@ H * ,'6_P#EG_P+_P!EH P: "@ H * -[0_^6G_  '_ -FH WJ
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MU.PB#JBB4JT@4;F52JEL?,54LY4$Y(4NQ X+-U.99)0 4 % !0 4 % !0 4
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MG>>_[S#_ *]1_P#2YGW>3?[O+_KZ_P#TF!QM?+'T@4 % !0!ZGX'_P"/%_\
MKNW_ *!'7Z)D7^[3_P"OLO\ TB!\)G/^\1_Z]+_TJ9V5?4GS84 % !0 4 %
M!0 4 % !0!\R?$+_ )#UU_VQ_P#2>*ORK-_]]J_]N?\ IN!^NY-_N-'_ +B?
M^G9G%UX1[X4 % !0!].?#W_D VO_ &V_]*):_5LH_P!RI?\ ;_\ Z<F?D6<_
M[]6_[A_^FH'9U[AX 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 >6>./\ C^3_ *X+_P"AR5^=Y[_O,/\
MKU'_ -+F?=Y-_N\O^OK_ /28'&U\L?2!0 4 % 'LGA3_ )!D/_;3_P!&O7ZE
ME/\ N5+_ +?_ /3DS\XS/_>ZG_;G_I$3H:]L\<* "@ H * "@ H * "@#%\2
M?\@J]_Z]+C_T4]<.,_W:O_UZJ?\ I$COP7^]8?\ Z_4O_2XGR57XV?MH4 %
M!0!VGP]_Y#UK_P!MO_2>6O=RC_?:7_;_ /Z;F>!G/^XUO^X?_IV!]-U^JGY$
M% '/7U[IGAAI;Z]F2V^V2(6:1OO.D:QJ$7KPB G /<FK2<M$MB=(ZLMZ/KUA
MKT;3:=,EPD;;&*9X; .#D ]"#2<7'1JPTT]C6J1F?=WCV\BQ^1+)$X.^9&@6
M.$=S)YD\<N .<Q1N0/>FEY_G_D(\Z\"R:;>:I>WVE20QV\D<<4=LDJF:40,0
M][/%O,BEW<HCRCS74^9)@RC.T[I)2W[^O1&<;7;7]>9ZK6!J0%INRI_WV?\
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M/^05>_\ 7I<?^BGKAQG^[5_^O53_ -(D=^"_WK#_ /7ZE_Z7$^2J_&S]M"@
MH * .T^'O_(>M?\ MM_Z3RU[N4?[[2_[?_\ 3<SP,Y_W&M_W#_\ 3L#Z;K]5
M/R(* /&OB!K]OYEO-9W$<4UE/<0.9;.:<!]D>] #'MP,J=X!!(&Q\!P>B$=T
MUND][&,GVZ>1T?PZU635K.:266*<I-M!BMFM@!L4X*LJ[CSU XZ'M435GII\
M[E1=U_P+'H59&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MUL-.YL5(PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MBU,4GV=69C"+FZ$+%I#*WF1"81RYD).)%88PN-H I\SWZ^B#E6W^9TX 48'
M'  [5!0M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >6>.
M/^/Y/^N"_P#H<E?G>>_[S#_KU'_TN9]WDW^[R_Z^O_TF!QM?+'T@4 % !0![
M)X4_Y!D/_;3_ -&O7ZEE/^Y4O^W_ /TY,_.,S_WNI_VY_P"D1.AKVSQPH *
M"@ H * "@ H * ,7Q)_R"KW_ *]+C_T4]<.,_P!VK_\ 7JI_Z1([\%_O6'_Z
M_4O_ $N)\E5^-G[:% !0 4 =I\/?^0]:_P#;;_TGEKW<H_WVE_V__P"FYG@9
MS_N-;_N'_P"G8'TW7ZJ?D04 >;?$=([J&WL6MX)WN'DV27%P;9(MB9;$JD-N
M=20$!PRJVX$+BMJ>EW=JW97,Y=O^ 7_ %HUA8O 8[6("4G_1;A[D.2B O)(Y
M+>8< 8SC:%P  !2GJ^OS5AQT73Y'=5D6% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 >6>./^/Y/^N"_P#H<E?G>>_[S#_KU'_T
MN9]WDW^[R_Z^O_TF!QM?+'T@4 % !0!ZGX'_ ./%_P#KNW_H$=?HF1?[M/\
MZ^R_](@?"9S_ +Q'_KTO_2IG95]2?-A0 4 % !0 4 % !0 4 % 'S)\0O^0]
M=?\ ;'_TGBK\JS?_ 'VK_P!N?^FX'Z[DW^XT?^XG_IV9Q=>$>^% !0 4 ?3G
MP]_Y -K_ -MO_2B6OU;*/]RI?]O_ /IR9^19S_OU;_N'_P"FH'9U[AX 4 %
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M> )^?[/6Z6/.Q?O_ &H!]_\ N_+MQWS6=3=7O\[?H7#;2WRO^IZ;6)H% !0
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M -TW]U/^^V_^-T &Z;^ZG_?;?_&Z #=-_=3_ +[;_P"-T &Z;^ZG_?;?_&Z
M#=-_=3_OMO\ XW0 ;IO[J?\ ?;?_ !N@ W3?W4_[[;_XW0 ;IO[J?]]M_P#&
MZ #=-_=3_OMO_C= !NF_NI_WVW_QN@ W3?W4_P"^V_\ C= !NF_NI_WVW_QN
M@ W3?W4_[[;_ .-T &Z;^ZG_ 'VW_P ;H -TW]U/^^V_^-T &Z;^ZG_?;?\
MQN@ W3?W4_[[;_XW0 ;IO[J?]]M_\;H \P\:%C>IO !\A>A)_CD[E5_E^-?G
M>>_[S#_KU'_TN9]WDW^[R_Z^O_TF!R%?+'T@4 % !0!Z?X+,@LGV*I'GMU8C
M^"/L$;^?X5^B9%_NT_\ K[+_ -(@?"9S_O$?^O2_]*F=?NF_NI_WVW_QNOJ3
MYL-TW]U/^^V_^-T &Z;^ZG_?;?\ QN@ W3?W4_[[;_XW0 ;IO[J?]]M_\;H
M-TW]U/\ OMO_ (W0 ;IO[J?]]M_\;H -TW]U/^^V_P#C= !NF_NI_P!]M_\
M&Z #=-_=3_OMO_C= 'S3\0-W]NW.X ']SP#D?ZB+N0/Y5^59O_OM7_MS_P!-
MP/UW)O\ <:/_ '$_].S.-KPCWPH * "@#Z6^'YE&A6VU5(_?<ER#_KY>P0_S
MK]6RC_<J7_;_ /Z<F?D6<_[]6_[A_P#IJ!V6Z;^ZG_?;?_&Z]P\ -TW]U/\
MOMO_ (W0 ;IO[J?]]M_\;H -TW]U/^^V_P#C= #D,F?G50/9B3^11?YT 2T
M% !0 UV*J2 6(!(48R<=AD@9/09('J0* /*/'M]8WUDEIJ$*VE]>%X;9;Z6!
M4MQE#)>,R3RP)Y:_ZM@QG=OW*+M=ZW@FG=:I;VOKY;7_ $,I6M9Z/I?\ST^Q
MV_9HMDGVA?+3;+NW>8-HQ)N!(;>/FW G.<Y-8O<T1.Y<?< /U8K_ "5J0R/=
M-_=3_OMO_C= !NF_NI_WVW_QN@ W3?W4_P"^V_\ C= !NF_NI_WVW_QN@ W3
M?W4_[[;_ .-T &Z;^ZG_ 'VW_P ;H -TW]U/^^V_^-T &Z;^ZG_?;?\ QN@
MW3?W4_[[;_XW0 ;IO[J?]]M_\;H -TW]U/\ OMO_ (W0 ;IO[J?]]M_\;H -
MTW]U/^^V_P#C= !NF_NI_P!]M_\ &Z #=-_=3_OMO_C= !NF_NI_WVW_ ,;H
M -TW]U/^^V_^-T &Z;^ZG_?;?_&Z #=-_=3_ +[;_P"-T &Z;^ZG_?;?_&Z
M/,/&A8WJ;P ?(7H2?XY.Y5?Y?C7YWGO^\P_Z]1_]+F?=Y-_N\O\ KZ__ $F!
MR%?+'T@4 % !0!Z]X7,HTV':JD?O.2Y!_P!:_8(?YU^I93_N5+_M_P#].3/S
MC,_][J?]N?\ I$3H-TW]U/\ OMO_ (W7MGCANF_NI_WVW_QN@ W3?W4_[[;_
M .-T &Z;^ZG_ 'VW_P ;H -TW]U/^^V_^-T &Z;^ZG_?;?\ QN@ W3?W4_[[
M;_XW0 ;IO[J?]]M_\;H -TW]U/\ OMO_ (W0!C>(VE_LN\RJ ?9;C.')_P"6
M3]O+'\Q]:X<9_NU?_KU4_P#2)'?@O]ZP_P#U^I?^EQ/E"OQL_;0H * "@#LO
MA_N&NVVT G]]P3@?ZB7N ?Y5[N4?[[2_[?\ _3<SP,Y_W&M_W#_].P/I;=-_
M=3_OMO\ XW7ZJ?D1/0!YW\0[VXTZ&">WO(+#<98CY\DL8)E3:)5$0)D> ;G5
M&!3<P8_,JUK!)W35_3^NIG+39V'_  \-N+6XCLKLWULD^(B7>1E'E1ABS. 0
M99 \OEC<L8888DD GNKJSL$?)W/0:R- H * "@ H * "@ H * "@ H * "@
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M_=Y?]?7_ .DP.-KY8^D"@ H * /9/"G_ "#(?^VG_HUZ_4LI_P!RI?\ ;_\
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M".OT3(O]VG_U]E_Z1 ^$SG_>(_\ 7I?^E3.RKZD^;"@ H * "@ H * "@ H
M* /F3XA?\AZZ_P"V/_I/%7Y5F_\ OM7_ +<_]-P/UW)O]QH_]Q/_ $[,XNO"
M/?"@ H * /ISX>_\@&U_[;?^E$M?JV4?[E2_[?\ _3DS\BSG_?JW_</_ --0
M.SKW#P H * "@ H * "@ H Q;OQ%86%S'93RE)IG2)?W<C)YLF3'&TJH8HY'
M RD;NKL,$ @@FE%M71-TM!;_ %^STV=+28RM/(AD6.&WN+AO+5@K.1!%)M4,
MR@EL#)'K0HMZK\TOS'=+0V:D84 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?Y%^8,3\JCIC'7)R>RF]=T_16''3I8[JLBPH * "@ H * "@ H * "@ H *
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M_P"4?_Q% !Y+_P#/1_RC_P#B* #R7_YZ/^4?_P 10 >2_P#ST?\ */\ ^(H
M/)?_ )Z/^4?_ ,10 >2__/1_RC_^(H /)?\ YZ/^4?\ \10 >2__ #T?\H__
M (B@#F-=NKW3XIYY+8WMK J21)"WG74LRO&8U%J+(JNV7YA*LSF,()=@P=H!
MS?A/_B6VBV[17L\^I7%W/=;;)X((YW0S.A%Y# 5B<;8(G8>7++PQ3+!0#$LK
M!O-U>XEBO+FSEMK58Y;BP9;AYH@1%#':I:Q[H[=RCI+%:KL;YFE81!T .T^'
M\,J:#9PR_:+>6WA2*2.:%H65U49 6:%69>>'&Y3SAC@X .R\E_\ GH_Y1_\
MQ% !Y+_\]'_*/_XB@ \E_P#GH_Y1_P#Q% !Y+_\ /1_RC_\ B* #R7_YZ/\
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M_N\O^OK_ /28'(5\L?2!0 4 % 'I_@N1DLG 1F_?MR-O]R/CYF!_2OT3(O\
M=I_]?9?^D0/A,Y_WB/\ UZ7_ *5,Z_SG_P">;_G'_P#%U]2?-AYS_P#/-_SC
M_P#BZ #SG_YYO^<?_P 70 ><_P#SS?\ ./\ ^+H /.?_ )YO^<?_ ,70 ><_
M_/-_SC_^+H /.?\ YYO^<?\ \70 ><__ #S?\X__ (N@ \Y_^>;_ )Q__%T
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M>.R>*UT^XTF-)2?*N 0\C,JDR;F9G?/"EF)/RXSZ3/?5I^@X[:*QV59EA0!
MMK"DK7"QH)G4(T@50[*N2JL^-Q5220"<#)QUI^0$]( H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#RSQQ_P ?R?\ 7!?_ $.2OSO/?]YA
M_P!>H_\ I<S[O)O]WE_U]?\ Z3 XVOECZ0* "@ H ]3\#_\ 'B__ %W;_P!
MCK]$R+_=I_\ 7V7_ *1 ^$SG_>(_]>E_Z5,[*OJ3YL* "@ H * "@ H * "@
M H ^9/B%_P AZZ_[8_\ I/%7Y5F_^^U?^W/_ $W _7<F_P!QH_\ <3_T[,XN
MO"/?"@ H * /ISX>_P#(!M?^VW_I1+7ZME'^Y4O^W_\ TY,_(LY_WZM_W#_]
M-0.SKW#P H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M5NK^9N5)04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!Y9XX_X_D_ZX+_Z')7YWGO\ O,/^O4?_ $N9]WDW^[R_Z^O_ -)@<;7R
MQ](% !0 4 >I^!_^/%_^N[?^@1U^B9%_NT_^OLO_ $B!\)G/^\1_Z]+_ -*F
M=E7U)\V% !0 4 % !0 4 % !0 4 ?,GQ"_Y#UU_VQ_\ 2>*ORK-_]]J_]N?^
MFX'Z[DW^XT?^XG_IV9Q=>$>^% !0 4 ?3GP]_P"0#:_]MO\ THEK]6RC_<J7
M_;__ *<F?D6<_P"_5O\ N'_Z:@=G7N'@!0 4 % !0 4 % !0 4 8/B#7T\/0
M&ZE@N+B-$>20P+&1&B;=S,998EYW#:BEI&^8JA",148\VB:1+?+J;4,R7$:R
MQG*2*&4X(RK#(." 1P>A ([BIV*)* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Q?$G_(*O
M?^O2X_\ 13UPXS_=J_\ UZJ?^D2._!?[UA_^OU+_ -+B?)5?C9^VA0 4 % '
M:?#W_D/6O_;;_P!)Y:]W*/\ ?:7_ &__ .FYG@9S_N-;_N'_ .G8'TW7ZJ?D
M04 >6?%"VBNH;:-WM?,;SUCANW,4<C2(L8D1_N": L&0284AF(.16]/2^_3;
M^NIE/Y?,M>#=4AAN[BPOI[==6F9"UK"S-Y:06\<07>RJKR;4+R!"< \#"DTI
M+1-)\O?U8XNSL]^QZ36)H% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 >6>./\ C^3_ *X+_P"AR5^=Y[_O,/\ KU'_ -+F?=Y-
M_N\O^OK_ /28'&U\L?2!0 4 % 'J?@?_ (\7_P"N[?\ H$=?HF1?[M/_ *^R
M_P#2('PF<_[Q'_KTO_2IG95]2?-A0 4 % !0 4 % !0 4 % &9<:)I]W(9KB
MUMY9&QN=X8V8X  RS*2<  #)X  Z5R3PU"I)SJ4J<I/=RA%MV5E=M7VT]#LA
MBL12BJ=*M4A%;1C.44KN[LDTE=MOU(/^$;TK_GRM/_ >+_XBH^IX;_GQ2_\
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MKHGVL>QUSFP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % &+XD_Y!5[_UZ7'_ **>N'&?[M7_ .O53_TB1WX+_>L/_P!?J7_I
M<3Y*K\;/VT* "@ H [3X>_\ (>M?^VW_ *3RU[N4?[[2_P"W_P#TW,\#.?\
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M2*00VPDC5%VHL;@[D5%^50I 5>  * -CSG_YYO\ G'_\70 ><_\ SS?\X_\
MXN@ \Y_^>;_G'_\ %T 'G/\ \\W_ #C_ /BZ #SG_P">;_G'_P#%T 'G/_SS
M?\X__BZ ')(S'!1E]R4Q^C$_I0!+0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % &9K=O)=Z?<V\(W22V\R(N0,LT;*HR2 ,D@9) '<XKDQ,)5*%6G!7E*G
M.,5HKMQ:2N]-^^AV86<:6(HU9NT8U*<I/5V49)MV5WHETU/G?_A7NO?\^O\
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MU$F"XAB2+=C.-VQ5SC)QGIDXZTVV]V))+;0T*0PH * "@ H * "@ H * "@
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M\7_Z[M_Z!'7Z)D7^[3_Z^R_](@?"9S_O$?\ KTO_ $J9V5?4GS84 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 5[NT@OHFM[J-)X7QNC
MD571L$$;E8%3@@$9'! /44T[:H/(P+WPG:WK1*SRQVEN\4JV<9C6VWP\1G'E
MF5%7"_NHI8X25W&,LTC/2DUZ]^NI/+]W8@NO""WMJ=/GO;Z2V<MYJ.\+F4-(
M9"CRM;M,%&?+41R1XC 4'.26I6=TE?Y_YBY>EW8ZR-%B4(@PJ@ #T & /RK,
ML=0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MPFD]T:%E86^FPK;6D:00I]U(U"J/P ')[GJ3R232;OJP2MHBU2&% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >6>./^/Y/^N"_
M^AR5^=Y[_O,/^O4?_2YGW>3?[O+_ *^O_P!)@<;7RQ](% !0 4 >I^!_^/%_
M^N[?^@1U^B9%_NT_^OLO_2('PF<_[Q'_ *]+_P!*F=E7U)\V% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9M]K%GIK".YFBCE=2T<
M32(LDF.T:,P+GL,=^*:3>R%=(X?P-XEN-99/M[W(N+JV:[2)TM%M1%YVS-N8
M=UQ\FY$(N7WM][;SQK./+M:R=NM_GT^XB+OOZ]+?UZGI58FA 9F'_+-_SC_^
M+H /.?\ YYO^<?\ \70 ><__ #S?\X__ (N@ \Y_^>;_ )Q__%T 'G/_ ,\W
M_./_ .+H /.?_GF_YQ__ != !YS_ //-_P X_P#XN@ \Y_\ GF_YQ_\ Q= !
MYS_\\W_./_XN@ \Y_P#GF_YQ_P#Q= !YS_\ /-_SC_\ BZ #SG_YYO\ G'_\
M70 ><_\ SS?\X_\ XN@ \Y_^>;_G'_\ %T 'G/\ \\W_ #C_ /BZ #SG_P">
M;_G'_P#%T 'G/_SS?\X__BZ #SG_ .>;_G'_ /%T 'G/_P \W_./_P"+H /.
M?_GF_P"<?_Q= !YS_P#/-_SC_P#BZ #SG_YYO^<?_P 70!7NKR6WC,D=M-<,
MN,1QM;AVR0.#+/''P#N.YUX!QDX! /(]0EAL?$D5Y'':7=[J%S:1RV4L4$FH
M6*"V8M,DL5U+Y0C4+))F+RBIXG *LP!/XQETSQG;64%I;QW$VK3^1%<O#'YL
M5M;R%[QXVDQ(FP(Z#[H+/D$;@U 'K4;&%1&D3JJ *H!CP !@ ?/V% #_ #G_
M .>;_G'_ /%T 'G/_P \W_./_P"+H /.?_GF_P"<?_Q= !YS_P#/-_SC_P#B
MZ #SG_YYO^<?_P 70 ><_P#SS?\ ./\ ^+H /.?_ )YO^<?_ ,70 ><__/-_
MSC_^+H /.?\ YYO^<?\ \70 ><__ #S?\X__ (N@ \Y_^>;_ )Q__%T 'G/_
M ,\W_./_ .+H /.?_GF_YQ__ != !YS_ //-_P X_P#XN@ \Y_\ GF_YQ_\
MQ= !YS_\\W_./_XN@ \Y_P#GF_YQ_P#Q= !YS_\ /-_SC_\ BZ #SG_YYO\
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M?_GF_P"<?_Q= !YS_P#/-_SC_P#BZ #SG_YYO^<?_P 70 ><_P#SS?\ ./\
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M&78L8X@B%L$J=JXIR;W)22V-VI*"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@"&XMXKN-H9T66)QM='4,C ]0RL""#Z$8
MHVV E50@"J  !@ <  = !V H 6@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
) "@ H * /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>sava-20221231x10kg008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20221231x10kg008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG.&#8P,'.C;^)-2?4X)Y5M3I5UJ$^GQ0K$PG1H_,_>%BV&!,3_*%! 8')P:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV*RZ?<N\DL+.WS,[EV.<Y!W$G@\=L5K44 47TBPDTZZT]X,VUUO\Y-[9;?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>O6:K:?86^EZ;;:?:1B.WMHEBC4=E P*LT5ZOM:CETZ>G0$K(****Q&%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9GB+68?#WAS4-7
MGP4M(&D"G^)L?*OXG _&G%.3L@/,K@?\)O\ 'V&#[^F^&8=[?W3-G/Y[RO\
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M7ZH1?\A^\_Z]8/\ T*6K] !1110 4444 %%%% !1110 4444 %%%% !1110
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M.BTC1['3(&=H;.WCMXVD(+%44*"<8&<"K=%5S2Y>6^@!1114@%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15#5-<TO1%@;5-0MK
M,7$@BB\Z0+O8]AG_ "*D;5=.74UTQK^U&H,F];4S+YI7U"9SCWQ0!;HK/CU[
M1Y;6ZNH]6L'M[1BMS*MRA2$CJ'.<*1[U;MKJWO;:.YM)XI[>5=T<L3AE<>H(
MX(H JQ?\A^\_Z]8/_0I:OU0B_P"0_>?]>L'_ *%+5^@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!0B_P"0_>?]>L'_ *%+5^J$
M7_(?O/\ KU@_]"EJ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% ')_$O7_ /A'/ &JWJ/MG>+[/!@\[W^4$?0$M^%0_"S0/^$=^'FF6SIM
MN+A/M4_'.Y^1GW"[1^%<E\3B?%?Q!\+^"8SN@$GVV] Z;1G@^AVJ_P#WT*]>
M  & , =!774_=X>,.LM?ELOU)6K%HHHKD*"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^EZU=L4)[1J3G'MN)'_ !77AO<A.MVT7J_\ @$O70]6HHHKD*"BBB@ HHHH
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M+_D/WG_7K!_Z%+5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1WI:T- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK^H7;#^_*J_^A9/ZU>@\$^!+'EHK>5O6:Z+?IG'Z5YZ-:\5^'F_XJ;P'<SQ
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M#_(/K,/^?<?Q_P SGO[4U]?O:0A_W3_]>C^V-;7EM&)'L370T4?4ZRVK2_\
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M+)_Z$#5ZBFFT[H#CKKX4^!KLDR>';9<_\\F>/_T%A53_ (4SX _Z '_DY/\
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ML32?^@79?^ Z?X4?V)I/_0+LO_ =/\* +]0-<A;Z*UVG,D;R!L]-I48_\?\
MTJO_ &)I/_0+LO\ P'3_  H_L32?^@79?^ Z?X4 7Z*H?V)I/_0+LO\ P'3_
M  H_L32?^@79?^ Z?X4 7Z*H?V)I/_0+LO\ P'3_  H_L32?^@79?^ Z?X4
M7Z*H?V)I/_0+LO\ P'3_  H_L32?^@79?^ Z?X4 7Z*H?V)I/_0+LO\ P'3_
M  H_L32?^@79?^ Z?X4 7Z*H?V)I/_0+LO\ P'3_  H_L32?^@79?^ Z?X4
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MX4?V)I/_ $"[+_P'3_"@"_4%G<B\L;>Z"E1-&L@4GID9Q5?^Q-)_Z!=E_P"
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M.C7-BUC/I-A+:-*9F@DMD:,N3DL5(QN)).>O-:"JJ(J(H55& H& !0 M%%%
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M>"*U1$E&,?,H&&X]: +.FLSZ7:.[%F:%"6)R2=HJU2*JHBHBA548"@8 %+0
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M(;5$D.>N6 SSWK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M >[T5E>&M)&A>&-,TH=;6V2-CG.6 ^8_B<FM6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &"*-96E$:"1P%9PHR0,X!/MD_G3Z** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ J!;*U6]>]6VA%VZ"-YQ&/,9 <A
M2W4@$GCWJ>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** (;NTMK^UDM;RWBN+>4;9(ID#HX]"#P:J)
MX?T6."U@32+!8;23S;:-;9 L+_WD&,*?<5HT4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>sava-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.4.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2023 2:50:35 PM-->
<!--Modified on: 2/28/2023 2:50:35 PM-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" targetNamespace="http://www.cassavasciences.com/20221231" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sava="http://www.cassavasciences.com/20221231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022">
  <annotation>
    <appinfo><link:roleType roleURI="http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets"><link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations"><link:definition>00200 - Statement - Consolidated Statements Of Operations</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows"><link:definition>00500 - Statement - Consolidated Statements Of Cash Flows</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"><link:definition>40301 - Disclosure - Prepaid And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails" id="DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"><link:definition>40402 - Disclosure - Real Property Acquisition (Summary Of Acquisition) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails" id="DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails"><link:definition>40403 - Disclosure - Real Property Acquisition (Components Of Other Income, Net) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"><link:definition>40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" id="DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"><link:definition>40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails" id="DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"><link:definition>40603 - Disclosure - Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"><link:definition>40902 - Disclosure - Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"><link:definition>40903 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" id="DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails"><link:definition>41002 - Disclosure - Leases And Commitments (Future Minimum Lease Payments) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation"><link:definition>00090 - Document - Document And Entity Information</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical"><link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity"><link:definition>00400 - Statement - Consolidated Statements Of Stockholders&apos; Equity</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentation" id="DisclosureGeneralLiquidityAndBasisOfPresentation"><link:definition>10101 - Disclosure - General, Liquidity And Basis of Presentation</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies"><link:definition>10201 - Disclosure - Summary Of Significant Accounting Policies</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssets" id="DisclosurePrepaidAndOtherCurrentAssets"><link:definition>10301 - Disclosure - Prepaid And Other Current Assets</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisition" id="DisclosureRealPropertyAcquisition"><link:definition>10401 - Disclosure - Real Property Acquisition</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment"><link:definition>10501 - Disclosure - Property And Equipment</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets"><link:definition>10601 - Disclosure - Intangible Assets</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation" id="DisclosureStockholdersEquityAndStockBasedCompensation"><link:definition>10701 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureEmployee401KBenefitPlan" id="DisclosureEmployee401KBenefitPlan"><link:definition>10801 - Disclosure - Employee 401(k) Benefit Plan</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes"><link:definition>10901 - Disclosure - Income Taxes</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments" id="DisclosureLeasesAndCommitments"><link:definition>11001 - Disclosure - Leases And Commitments</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan" id="Disclosure2020CashIncentiveBonusPlan"><link:definition>11101 - Disclosure - 2020 Cash Incentive Bonus Plan</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureContingencies" id="DisclosureContingencies"><link:definition>11201 - Disclosure - Contingencies</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicy"><link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policy)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables"><link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsTables" id="DisclosurePrepaidAndOtherCurrentAssetsTables"><link:definition>30303 - Disclosure - Prepaid And Other Current Assets (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionTables" id="DisclosureRealPropertyAcquisitionTables"><link:definition>30403 - Disclosure - Real Property Acquisition (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables"><link:definition>30503 - Disclosure - Property And Equipment (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables"><link:definition>30603 - Disclosure - Intangible Assets (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables" id="DisclosureStockholdersEquityAndStockBasedCompensationTables"><link:definition>30703 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables"><link:definition>30903 - Disclosure - Income Taxes (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables" id="DisclosureLeasesAndCommitmentsTables"><link:definition>31003 - Disclosure - Leases And Commitments (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentationNarrativeDetails" id="DisclosureGeneralLiquidityAndBasisOfPresentationNarrativeDetails"><link:definition>40101 - Disclosure - General, Liquidity and Basis of Presentation (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"><link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"><link:definition>40202 - Disclosure - Summary of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails" id="DisclosureRealPropertyAcquisitionNarrativeDetails"><link:definition>40401 - Disclosure - Real Property Acquisition (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" id="DisclosurePropertyAndEquipmentNarrativeDetails"><link:definition>40501 - Disclosure - Property And Equipment (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails" id="DisclosureIntangibleAssetsNarrativeDetails"><link:definition>40601 - Disclosure - Intangible Assets (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"><link:definition>40701 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"><link:definition>40702 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Stock Option Activity) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"><link:definition>40703 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails"><link:definition>40704 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails"><link:definition>40705 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails"><link:definition>40706 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Stock-Based Compensation Expenses) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails"><link:definition>40901 - Disclosure - Income Taxes (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"><link:definition>40904 - Disclosure - Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails" id="DisclosureLeasesAndCommitmentsNarrativeDetails"><link:definition>41001 - Disclosure - Leases And Commitments (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" id="Disclosure2020CashIncentiveBonusPlanNarrativeDetails"><link:definition>41101 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails" id="DisclosureContingenciesNarrativeDetails"><link:definition>41201 - Disclosure - Contingencies (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="sava-20221231_cal.xml" xlink:title="Calculation Links, all"></link:linkbaseRef><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="sava-20221231_def.xml" xlink:title="Definition Links, all"></link:linkbaseRef><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="sava-20221231_lab.xml" xlink:title="Label Links, all"></link:linkbaseRef><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="sava-20221231_pre.xml" xlink:title="Presentation Links, all"></link:linkbaseRef></appinfo></annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"></import>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"></import>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"></import>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"></import>
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"></import>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"></import>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"></import>
  <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"></import>
  <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"></import>
  <element name="AustinMember" id="sava_AustinMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"></element>
  <element id="sava_TwoThousandEightEquityIncentivePlanMember" name="TwoThousandEightEquityIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" name="ShareBasedCompensationAdditionalExpenseExpectedOnVesting" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="sava_RangeOneMember" name="RangeOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_RangeTwoMember" name="RangeTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_RangeThreeMember" name="RangeThreeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_RangeFourMember" name="RangeFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_RangeFiveMember" name="RangeFiveMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_LeasesAndCommitmentsAbstract" name="LeasesAndCommitmentsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_LeasesAndCommitmentsDisclosureTextBlock" name="LeasesAndCommitmentsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_LeasesAndCommitmentsTable" name="LeasesAndCommitmentsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_LeasesAndCommitmentsLineItems" name="LeasesAndCommitmentsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_AtMarketEquityProgramMember" name="AtMarketEquityProgramMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_WarrantsMember" name="WarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ReductionToResearchAndDevelopmentExpense" name="ReductionToResearchAndDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="sava_TwoThousandEighteenEquityIncentivePlanMember" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" name="ResearchAndDevelopmentExpenseNetOfGrantReimbursement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="sava_ProceedsFromGrantsPolicyPolicyTextBlock" name="ProceedsFromGrantsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" name="ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_IndefinitelyMember" name="IndefinitelyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PercentageOfCommissionAtmOffering" name="PercentageOfCommissionAtmOffering" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant"></element>
  <element id="sava_CashIncentiveBonusPlanTextBlock" name="CashIncentiveBonusPlanTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_CashIncentiveBonusPlanAbstract" name="CashIncentiveBonusPlanAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_PerformancePlanValuationAmount" name="PerformancePlanValuationAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="sava_CashIncentiveBonusAward" name="CashIncentiveBonusAward" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"></element>
  <element id="sava_CashIncentiveBonusPlanTable" name="CashIncentiveBonusPlanTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_CashIncentiveBonusPlanLineItems" name="CashIncentiveBonusPlanLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_CashIncentiveBonusPlanMember" name="CashIncentiveBonusPlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_Exceeds5BillionMarketCapitalizationMember" name="Exceeds5BillionMarketCapitalizationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" name="PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PublicOfferingMember" name="PublicOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_RegisteredDirectOffering2021Member" name="RegisteredDirectOffering2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_FirstValuationMilestoneMember" name="FirstValuationMilestoneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PaymentsForCashIncentiveBonus" name="PaymentsForCashIncentiveBonus" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="sava_SecondThroughEighthValuationMilestonesMember" name="SecondThroughEighthValuationMilestonesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" name="StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PrepaidAndOtherAssetsDisclosureTextBlock" name="PrepaidAndOtherAssetsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_LeasingCommissionsAndOtherMember" name="LeasingCommissionsAndOtherMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ShortTermOperatingLeaseMember" name="ShortTermOperatingLeaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ExpirationResearchAndDevelopmentTaxCreditsMember" name="ExpirationResearchAndDevelopmentTaxCreditsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ExpirationOperatingLossCarryforwardsMember" name="ExpirationOperatingLossCarryforwardsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_NetLossPerShareBasicAndDiluted" name="NetLossPerShareBasicAndDiluted" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted" name="SharesUsedInComputingNetLossPerShareBasicAndDiluted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PercentageOfCurrentlyLeased" name="PercentageOfCurrentlyLeased" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PercentageOfOccupancy" name="PercentageOfOccupancy" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" name="ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ViolationsOfFederalSecuritiesLawsMember" name="ViolationsOfFederalSecuritiesLawsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_NumberOfClassActionsConvertedToCase" name="NumberOfClassActionsConvertedToCase" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ShareholderDerivativeActionsMember" name="ShareholderDerivativeActionsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_RegisteredDirectOffering2022Member" name="RegisteredDirectOffering2022Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"></element>
  <element id="sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months" name="UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"></element></schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>sava-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.4.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2023 2:50:35 PM-->
<!--Modified on: 2/28/2023 2:50:35 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails"></roleRef>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638131926339727721"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638131926339727721" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638131926339737697"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638131926339727721" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638131926339737697" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638131926339737697"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638131926339727721" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638131926339737697" order="2" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638131926339737697"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638131926339737697" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638131926339737697"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638131926339737697" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638131926339737697"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638131926339737697" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638131926339737697"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638131926339737697" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638131926339797538" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638131926339797538" xlink:to="us-gaap_LiabilitiesCurrent_638131926339797538" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638131926339797538" xlink:to="us-gaap_AccountsPayableCurrent_638131926339797538" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638131926339797538" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638131926339797538" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638131926339797538" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638131926339797538" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638131926339797538" xlink:to="us-gaap_OtherLiabilitiesCurrent_638131926339797538" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638131926339797538" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638131926339797538" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638131926339797538" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638131926339797538" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638131926339797538" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638131926339797538" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638131926339797538" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638131926339797538" xlink:to="us-gaap_PreferredStockValue_638131926339797538" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638131926339797538" xlink:to="us-gaap_CommonStockValue_638131926339797538" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638131926339797538" xlink:to="us-gaap_AdditionalPaidInCapital_638131926339797538" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638131926339797538"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638131926339797538" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638131926339797538" order="4" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements Of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638131926339807513" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome_638131926339807513" order="2" use="optional" weight="1" priority="9"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638131926339807513" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638131926339807513" xlink:to="us-gaap_OperatingExpenses_638131926339807513" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638131926339807513" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638131926339807513" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638131926339807513" xlink:to="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_638131926339807513" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638131926339807513" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131926339807513" order="3" use="optional" weight="-1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements Of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" order="1" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="us-gaap_NetIncomeLoss_638131926339807513" order="1" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="us-gaap_ShareBasedCompensation_638131926339807513" order="2" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638131926339807513" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="us-gaap_Depreciation_638131926339807513" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638131926339807513" order="5" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638131926339807513" order="6" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638131926339807513" order="7" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638131926339807513" order="8" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638131926339807513" order="9" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131926339807513" order="10" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926339807513" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_638131926339807513" order="11" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131926339807513" order="2" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131926339807513" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638131926339807513" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131926339807513" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638131926339807513" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131926339807513" order="3" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131926339807513" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638131926339807513" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638131926339807513"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131926339807513" xlink:to="us-gaap_ProceedsFromWarrantExercises_638131926339807513" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131926339807513" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638131926339817485" order="3" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638131926339817485" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_638131926339817485" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositContractsAssets_638131926339817485" order="3" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Real Property Acquisition (Summary Of Acquisition) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_638131926339817485" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_638131926339817485" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Real Property Acquisition (Components Of Other Income, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense_638131926339817485" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome_638131926339817485" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638131926339817485" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638131926339817485" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638131926339817485" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638131926339817485" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638131926339817485" order="1" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638131926339817485" order="2" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638131926339817485"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638131926339817485" order="3" use="optional" weight="1" priority="3"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638131926339827456" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638131926339827456" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638131926339827456" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638131926339827456" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638131926339827456" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_638131926339827456" order="6" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638131926339827456" order="7" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638131926339827456" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638131926339827456" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131926339827456" xlink:to="us-gaap_DeferredTaxAssetsOther_638131926339827456" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131926339827456" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638131926339827456" order="2" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131926339827456" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638131926339827456" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131926339827456" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638131926339827456" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638131926339827456" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638131926339827456" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638131926339827456" order="1" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Leases And Commitments (Future Minimum Lease Payments) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637472758052522425"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637472758052522425" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638131926339827456" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638131926339827456"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637472758052522425" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638131926339827456" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>sava-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.4.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2023 2:50:35 PM-->
<!--Modified on: 2/28/2023 2:50:35 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureRealPropertyAcquisitionNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePropertyAndEquipmentNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureLeasesAndCommitmentsNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#Disclosure2020CashIncentiveBonusPlanNarrativeDetails" roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureContingenciesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"></roleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"></arcroleRef>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements Of Stockholders&apos; Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638131926340116685"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_638131926340116685" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SignificantAccountingPoliciesTable" xlink:label="sava_SignificantAccountingPoliciesTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="sava_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340156581"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340156581" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="sava_SignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340156581"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340156581" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="sava_SignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340156581"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340156581" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SignificantAccountingPoliciesLineItems" xlink:label="sava_SignificantAccountingPoliciesLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="sava_SignificantAccountingPoliciesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ReductionToResearchAndDevelopmentExpense" xlink:label="sava_ReductionToResearchAndDevelopmentExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="sava_ReductionToResearchAndDevelopmentExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638131926340166551"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638131926340166551" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted" xlink:label="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_NetLossPerShareBasicAndDiluted" xlink:label="sava_NetLossPerShareBasicAndDiluted"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="sava_NetLossPerShareBasicAndDiluted" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Real Property Acquisition (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638131926340176525"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_638131926340176525" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AustinMember" xlink:label="sava_AustinMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sava_AustinMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sava_PercentageOfOccupancy" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageOfCurrentlyLeased" xlink:label="sava_PercentageOfCurrentlyLeased"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sava_PercentageOfCurrentlyLeased" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Real Property Acquisition (Summary Of Acquisition) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AustinMember" xlink:label="sava_AustinMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sava_AustinMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sava_LeasingCommissionsAndOtherMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Real Property Acquisition (Components Of Other Income, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AustinMember" xlink:label="sava_AustinMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sava_AustinMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property And Equipment (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_638131926340206733"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_638131926340206733" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sava_LeasingCommissionsAndOtherMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638131926340246629"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638131926340246629" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_WarrantsMember" xlink:label="sava_WarrantsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638131926340246629"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638131926340246629" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638131926340246629"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_638131926340246629" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RegisteredDirectOffering2022Member" xlink:label="sava_RegisteredDirectOffering2022Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_RegisteredDirectOffering2022Member" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RegisteredDirectOffering2021Member" xlink:label="sava_RegisteredDirectOffering2021Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_RegisteredDirectOffering2021Member" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PublicOfferingMember" xlink:label="sava_PublicOfferingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_PublicOfferingMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CommonStockWarrantsMember" xlink:label="sava_CommonStockWarrantsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CommonStockWarrantsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AtMarketEquityProgramMember" xlink:label="sava_AtMarketEquityProgramMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_AtMarketEquityProgramMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_TwoThousandEightEquityIncentivePlanMember" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_TwoThousandEightEquityIncentivePlanMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_TwoThousandEighteenEquityIncentivePlanMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638131926340256603"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638131926340256603" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageOfCommissionAtmOffering" xlink:label="sava_PercentageOfCommissionAtmOffering"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_PercentageOfCommissionAtmOffering" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssued" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638131926340286550"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638131926340286550" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeOneMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeTwoMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeThreeMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeFourMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeFiveMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Stock-Based Compensation Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638131926340296494"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_638131926340296494" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638131926340306471"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638131926340306471" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementScenarioAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638131926340306471"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_638131926340306471" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ExpirationOperatingLossCarryforwardsMember" xlink:label="sava_ExpirationOperatingLossCarryforwardsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_ExpirationOperatingLossCarryforwardsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_IndefinitelyMember" xlink:label="sava_IndefinitelyMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_IndefinitelyMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ExpirationResearchAndDevelopmentTaxCreditsMember" xlink:label="sava_ExpirationResearchAndDevelopmentTaxCreditsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_ExpirationResearchAndDevelopmentTaxCreditsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638131926340306471"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638131926340306471" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months" xlink:label="sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Leases And Commitments (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsTable" xlink:label="sava_LeasesAndCommitmentsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="sava_LeasesAndCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AustinMember" xlink:label="sava_AustinMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sava_AustinMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="sava_LeasesAndCommitmentsTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638131926340316444"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_638131926340316444" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShortTermOperatingLeaseMember" xlink:label="sava_ShortTermOperatingLeaseMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sava_ShortTermOperatingLeaseMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsLineItems" xlink:label="sava_LeasesAndCommitmentsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="sava_LeasesAndCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanTable" xlink:label="sava_CashIncentiveBonusPlanTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="us-gaap_PlanNameAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="srt_StatementScenarioAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_Exceeds5BillionMarketCapitalizationMember" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_Exceeds5BillionMarketCapitalizationMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_FirstValuationMilestoneMember" xlink:label="sava_FirstValuationMilestoneMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_FirstValuationMilestoneMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SecondThroughEighthValuationMilestonesMember" xlink:label="sava_SecondThroughEighthValuationMilestonesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_SecondThroughEighthValuationMilestonesMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanLineItems" xlink:label="sava_CashIncentiveBonusPlanLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_CashIncentiveBonusPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PerformancePlanValuationAmount" xlink:label="sava_PerformancePlanValuationAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_PerformancePlanValuationAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_CashIncentiveBonusAward" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_LitigationCaseAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638131926340336442"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain_638131926340336442" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_NumberOfClassActionsConvertedToCase" xlink:label="sava_NumberOfClassActionsConvertedToCase"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="sava_NumberOfClassActionsConvertedToCase" priority="1" use="optional"></definitionArc></definitionLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>sava-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.4.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2023 2:50:35 PM-->
<!--Modified on: 2/28/2023 2:50:35 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"></roleRef>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"></roleRef>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"></roleRef>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"></roleRef>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Development Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee Related Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Notes 9, 10 and 11)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&apos; equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 120,000,000 shares authorized; 41,735,557 and 40,016,792 shares issued and outstanding at December 31, 2022 and 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&apos; equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&apos; equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Par value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Offering of common stock shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:to="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl" xml:lang="en-US">Research and Development Expense, Net Of Grant Reimbursement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl" xml:lang="en-US">Research and Development Expense, Net Of Grant Reimbursement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl" xml:lang="en-US">Research and development, net of grant reimbursement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest And Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_NetLossPerShareBasicAndDiluted" xlink:label="sava_NetLossPerShareBasicAndDiluted"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NetLossPerShareBasicAndDiluted" xlink:to="sava_NetLossPerShareBasicAndDiluted_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_NetLossPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net Loss Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_NetLossPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted" xlink:label="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted" xlink:to="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted_lbl" xml:lang="en-US">Shares used in computing net loss per share, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted_lbl" xml:lang="en-US">Shares used in computing net loss per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Stockholders&apos; Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Ownership Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock options for employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock options for employees, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock options for non-employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US">Expiration of restricted stock Performance Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Expiration of restricted stock Performance Awards,shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Expiration of restricted stock Performance Awards,shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock pursuant to exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock pursuant to exercise of warrants, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued in conjunction with follow-on public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued in conjunction with follow-on public offering, net of issuance costs, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense for intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid and other assets</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl" xml:lang="en-US">Operating lease right-of-use assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase Decrease In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase Decrease In Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase Decrease In Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Increase Decrease In Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from common stock offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchases of property and equipment included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">General, Liquidity And Basis Of Presentation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">General, Liquidity and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Prepaid And Other Current Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="sava_PrepaidAndOtherAssetsDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="sava_PrepaidAndOtherAssetsDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid And Other Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid And Other Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Real Property Acquisition [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Real Property Acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property And Equipment [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property And Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity And Stock-Based Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Shareholders&apos; Equity and Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity And Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee 401(k) Benefit Plan [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee 401(k) Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsAbstract" xlink:label="sava_LeasesAndCommitmentsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="sava_LeasesAndCommitmentsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_LeasesAndCommitmentsAbstract_lbl" xml:lang="en-US">Leases And Commitments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_LeasesAndCommitmentsAbstract_lbl" xml:lang="en-US">Leases And Commitments [Abstract]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Leases and commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Leases And Commitments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Leases And Commitments</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanAbstract" xlink:label="sava_CashIncentiveBonusPlanAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanAbstract" xlink:to="sava_CashIncentiveBonusPlanAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanAbstract_lbl" xml:lang="en-US">2020 Cash Incentive Bonus Plan [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanAbstract_lbl" xml:lang="en-US">2020 Cash Incentive Bonus Plan [Abstract]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanTextBlock" xlink:to="sava_CashIncentiveBonusPlanTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanTextBlock_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanTextBlock_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CashIncentiveBonusPlanTextBlock_lbl" xml:lang="en-US">2020 Cash Incentive Bonus Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAbstract" xlink:label="us-gaap_LossContingencyAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAbstract" xlink:to="us-gaap_LossContingencyAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAbstract_lbl" xml:lang="en-US">Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDisclosures" xlink:to="us-gaap_LossContingencyDisclosures_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xml:lang="en-US">Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xml:lang="en-US">Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use Of Estimates</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:to="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Proceeds From Grants Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Proceeds From Grants Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Proceeds From Grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash And Cash Equivalents And Concentration Of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Business Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Compensation Related Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value Of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:to="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Research Contract Costs And Accruals Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Research Contract Costs And Accruals Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Research Contract Costs And Accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Incentive Bonus Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property And Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule Of Prepaid And Other Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Summary Of Acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Components Of Other Income, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Components Of Property And Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Components Of Intangible Assets, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Amortization Expense For Finite-Lived Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Information About Stock Options Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Weighted Average Fair Value Of Options Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Summary Of Performance Award Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule Of Effective Income Tax Rate Reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule Of Deferred Tax Assets And Valuation Allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future Minimum Lease Payments</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SignificantAccountingPoliciesTable" xlink:label="sava_SignificantAccountingPoliciesTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_SignificantAccountingPoliciesTable" xlink:to="sava_SignificantAccountingPoliciesTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SignificantAccountingPoliciesLineItems" xlink:label="sava_SignificantAccountingPoliciesLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="sava_SignificantAccountingPoliciesLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ReductionToResearchAndDevelopmentExpense" xlink:label="sava_ReductionToResearchAndDevelopmentExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ReductionToResearchAndDevelopmentExpense" xlink:to="sava_ReductionToResearchAndDevelopmentExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Reduction To Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Reduction To Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Reimbursement from National Institutes of Health research grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of business segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Award expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible assets, Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Common stock excluded from net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Shares expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income Loss [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsAssets" xlink:to="us-gaap_DepositContractsAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsAssets_lbl" xml:lang="en-US">Deposit Contracts, Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositContractsAssets_lbl" xml:lang="en-US">Contract research organization and other deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US">Asset Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business Combination, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Purchase price</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfOccupancy" xlink:to="sava_PercentageOfOccupancy_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PercentageOfOccupancy_lbl" xml:lang="en-US">Percentage Of Occupancy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PercentageOfOccupancy_lbl" xml:lang="en-US">Percentage Of Occupancy</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageOfCurrentlyLeased" xlink:label="sava_PercentageOfCurrentlyLeased"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfCurrentlyLeased" xlink:to="sava_PercentageOfCurrentlyLeased_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PercentageOfCurrentlyLeased_lbl" xml:lang="en-US">Percentage Of Currently Leased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PercentageOfCurrentlyLeased_lbl" xml:lang="en-US">Percentage Of Currently Leased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Net Rentable Area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Office space</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US">Accrued property taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Total tangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Total intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Consideration paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Lease revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Property operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Gross property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_WarrantsMember" xlink:label="sava_WarrantsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WarrantsMember" xlink:to="sava_WarrantsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_WarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Award [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RegisteredDirectOffering2022Member" xlink:label="sava_RegisteredDirectOffering2022Member"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RegisteredDirectOffering2022Member" xlink:to="sava_RegisteredDirectOffering2022Member_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RegisteredDirectOffering2022Member_lbl" xml:lang="en-US">Registered Direct Offering 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RegisteredDirectOffering2022Member_lbl" xml:lang="en-US">Registered Direct Offering2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RegisteredDirectOffering2022Member_lbl" xml:lang="en-US">Registered Direct Offering 2022 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RegisteredDirectOffering2021Member" xlink:label="sava_RegisteredDirectOffering2021Member"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RegisteredDirectOffering2021Member" xlink:to="sava_RegisteredDirectOffering2021Member_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RegisteredDirectOffering2021Member_lbl" xml:lang="en-US">Registered Direct Offering 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RegisteredDirectOffering2021Member_lbl" xml:lang="en-US">Registered Direct Offering2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RegisteredDirectOffering2021Member_lbl" xml:lang="en-US">2021 Registered Direct Offering [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PublicOfferingMember" xlink:label="sava_PublicOfferingMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PublicOfferingMember" xlink:to="sava_PublicOfferingMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CommonStockWarrantsMember" xlink:label="sava_CommonStockWarrantsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CommonStockWarrantsMember" xlink:to="sava_CommonStockWarrantsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_TwoThousandEightEquityIncentivePlanMember" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_TwoThousandEightEquityIncentivePlanMember" xlink:to="sava_TwoThousandEightEquityIncentivePlanMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember_lbl" xml:lang="en-US">2008 Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Eight Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember_lbl" xml:lang="en-US">2008 Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2018 Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl" xml:lang="en-US">Stock Options Exercised Net Settled Satisfaction Of Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl" xml:lang="en-US">Stock Options Exercised Net Settled Satisfaction Of Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl" xml:lang="en-US">Stock options exercised, net settled in satisfaction of the exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of shares exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageOfCommissionAtmOffering" xlink:label="sava_PercentageOfCommissionAtmOffering"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfCommissionAtmOffering" xlink:to="sava_PercentageOfCommissionAtmOffering_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PercentageOfCommissionAtmOffering_lbl" xml:lang="en-US">Percentage Of Commission ATM Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PercentageOfCommissionAtmOffering_lbl" xml:lang="en-US">Percentage Of Commission ATM Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PercentageOfCommissionAtmOffering_lbl" xml:lang="en-US">Percentage of commission in ATM offering</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award options grant in period weighted average remaining contractual term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Expiration period of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_lbl" xml:lang="en-US">Compensation costs prior to forfeiture</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award options nonvested forfeitures in period weighted average contractual term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeitures In Period Weighted Average Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_lbl" xml:lang="en-US">Weighted average remaining recognition period</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" xlink:to="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_lbl" xml:lang="en-US">Share Based Compensation Additional Expense Expected On Vesting.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_lbl" xml:lang="en-US">Share Based Compensation Additional Expense Expected On Vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_lbl" xml:lang="en-US">Additional stock compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Performance awards vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Performance awards expiration date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding as of, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding as of, Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options forfeited/canceled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and expected to vest at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding as of, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding as of, Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options forfeited/cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and expected to vest at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Vested and expected to vest at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeOneMember" xlink:to="sava_RangeOneMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RangeOneMember_lbl" xml:lang="en-US">$0.95 - $1.88 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeTwoMember" xlink:to="sava_RangeTwoMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RangeTwoMember_lbl" xml:lang="en-US">$3.24 - $3.24 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeThreeMember" xlink:to="sava_RangeThreeMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RangeThreeMember_lbl" xml:lang="en-US">$4.09 - $12.04 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeFourMember" xlink:to="sava_RangeFourMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RangeFourMember_lbl" xml:lang="en-US">Range Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RangeFourMember_lbl" xml:lang="en-US">Range Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RangeFourMember_lbl" xml:lang="en-US">$12.39 - $35.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeFiveMember" xlink:to="sava_RangeFiveMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RangeFiveMember_lbl" xml:lang="en-US">Range Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RangeFiveMember_lbl" xml:lang="en-US">Range Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RangeFiveMember_lbl" xml:lang="en-US">$36.40 - $77.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of outstanding options, Options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), Options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average exercise price, Options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of vested options, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rates, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rates, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Forfeiture rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding as of, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding as of, Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited/canceled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ExpirationOperatingLossCarryforwardsMember" xlink:label="sava_ExpirationOperatingLossCarryforwardsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ExpirationOperatingLossCarryforwardsMember" xlink:to="sava_ExpirationOperatingLossCarryforwardsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ExpirationOperatingLossCarryforwardsMember_lbl" xml:lang="en-US">Expiration Operating Loss Carryforwards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ExpirationOperatingLossCarryforwardsMember_lbl" xml:lang="en-US">Expiration Operating Loss Carryforwards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ExpirationOperatingLossCarryforwardsMember_lbl" xml:lang="en-US">Expires Between 2029 And 2037 [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_IndefinitelyMember" xlink:label="sava_IndefinitelyMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IndefinitelyMember" xlink:to="sava_IndefinitelyMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_IndefinitelyMember_lbl" xml:lang="en-US">Indefinitely [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_IndefinitelyMember_lbl" xml:lang="en-US">Indefinitely [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_IndefinitelyMember_lbl" xml:lang="en-US">Indefinitely [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ExpirationResearchAndDevelopmentTaxCreditsMember" xlink:label="sava_ExpirationResearchAndDevelopmentTaxCreditsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ExpirationResearchAndDevelopmentTaxCreditsMember" xlink:to="sava_ExpirationResearchAndDevelopmentTaxCreditsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ExpirationResearchAndDevelopmentTaxCreditsMember_lbl" xml:lang="en-US">Expiration Research And Development Tax Credits [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ExpirationResearchAndDevelopmentTaxCreditsMember_lbl" xml:lang="en-US">Expiration Research And Development Tax Credits [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ExpirationResearchAndDevelopmentTaxCreditsMember_lbl" xml:lang="en-US">Expires Between 2024 And 2042 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax at federal statutory rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S federal corporate tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change in Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance increase (decrease)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xml:lang="en-US">Expiration date of pre-tax net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xml:lang="en-US">Tax Credit Carryforward, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xml:lang="en-US">Expiration date of federal research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months" xlink:label="sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months" xlink:to="sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months_lbl" xml:lang="en-US">Unrecognized tax benefits no significant change over the next 12 months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months_lbl" xml:lang="en-US">Unrecognized tax benefits no significant change over next 12 months</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US">Section 162(m) limitation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Deferred Tax Assets Capitalized Research and Development Expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Deferred Tax Assets Capitalized Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Capitalized research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax asset (liability)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Additions based on tax positions related to the current year</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsTable" xlink:label="sava_LeasesAndCommitmentsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsTable" xlink:to="sava_LeasesAndCommitmentsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_LeasesAndCommitmentsTable_lbl" xml:lang="en-US">Leases And Commitments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_LeasesAndCommitmentsTable_lbl" xml:lang="en-US">Leases And Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AustinMember" xlink:label="sava_AustinMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AustinMember" xlink:to="sava_AustinMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_AustinMember_lbl" xml:lang="en-US">Austin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_AustinMember_lbl" xml:lang="en-US">Austin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_AustinMember_lbl" xml:lang="en-US">Austin, Texas [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsLineItems" xlink:label="sava_LeasesAndCommitmentsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsLineItems" xlink:to="sava_LeasesAndCommitmentsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_LeasesAndCommitmentsLineItems_lbl" xml:lang="en-US">Leases And Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_LeasesAndCommitmentsLineItems_lbl" xml:lang="en-US">Leases And Commitments [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Rent expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Leases, discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets exchange for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">For the year ending December 31,</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanTable" xlink:label="sava_CashIncentiveBonusPlanTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="sava_CashIncentiveBonusPlanTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanTable_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanTable_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanLineItems" xlink:label="sava_CashIncentiveBonusPlanLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_CashIncentiveBonusPlanLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanLineItems_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanLineItems_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Line Items]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PerformancePlanValuationAmount" xlink:label="sava_PerformancePlanValuationAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanValuationAmount" xlink:to="sava_PerformancePlanValuationAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PerformancePlanValuationAmount_lbl" xml:lang="en-US">Performance Plan Valuation Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PerformancePlanValuationAmount_lbl" xml:lang="en-US">Performance Plan Valuation Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PerformancePlanValuationAmount_lbl" xml:lang="en-US">Valuation milestone amount in market capitalization</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl" xml:lang="en-US">Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl" xml:lang="en-US">Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl" xml:lang="en-US">Percentage of each cash bonus award associated with Valuation Milestone subject to adjustment and approval</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAward" xlink:to="sava_CashIncentiveBonusAward_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusAward_lbl" xml:lang="en-US">Cash Incentive Bonus Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusAward_lbl" xml:lang="en-US">Cash Incentive Bonus Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CashIncentiveBonusAward_lbl" xml:lang="en-US">Cash bonus award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xml:lang="en-US">Compensation expense</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PaymentsForCashIncentiveBonus" xlink:to="sava_PaymentsForCashIncentiveBonus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PaymentsForCashIncentiveBonus_lbl" xml:lang="en-US">Payments For Cash Incentive Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PaymentsForCashIncentiveBonus_lbl" xml:lang="en-US">Payments For Cash Incentive Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PaymentsForCashIncentiveBonus_lbl" xml:lang="en-US">Payments authorized or made to participants under the Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xml:lang="en-US">Putative class action lawsuits</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_NumberOfClassActionsConvertedToCase" xlink:label="sava_NumberOfClassActionsConvertedToCase"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NumberOfClassActionsConvertedToCase" xlink:to="sava_NumberOfClassActionsConvertedToCase_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_NumberOfClassActionsConvertedToCase_lbl" xml:lang="en-US">Number of class actions converted to case</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_NumberOfClassActionsConvertedToCase_lbl" xml:lang="en-US">Number of class actions converted to case</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Building And Building Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Site Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Tenant Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAcquiredInPlaceMember" xlink:to="us-gaap_LeasesAcquiredInPlaceMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAcquiredInPlaceMember_lbl" xml:lang="en-US">Leases Acquired In Place [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesAcquiredInPlaceMember_lbl" xml:lang="en-US">Lease-In-Place Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasingCommissionsAndOtherMember" xlink:to="sava_LeasingCommissionsAndOtherMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_LeasingCommissionsAndOtherMember_lbl" xml:lang="en-US">Leasing Commissions And Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_LeasingCommissionsAndOtherMember_lbl" xml:lang="en-US">Leasing Commissions And Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_LeasingCommissionsAndOtherMember_lbl" xml:lang="en-US">Leasing Commissions And Other [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Manufacturing Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xml:lang="en-US">Disposal Group Classification [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xml:lang="en-US">Disposal Group Classification [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xml:lang="en-US">Disposal Group Classification [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_lbl" xml:lang="en-US">Disposal Group Disposed Of By Sale Not Discontinued Operations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_lbl" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture And Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction In Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction In Progress [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AtMarketEquityProgramMember" xlink:label="sava_AtMarketEquityProgramMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AtMarketEquityProgramMember" xlink:to="sava_AtMarketEquityProgramMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_AtMarketEquityProgramMember_lbl" xml:lang="en-US">At-The-Market Equity Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_AtMarketEquityProgramMember_lbl" xml:lang="en-US">At Market Equity Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_AtMarketEquityProgramMember_lbl" xml:lang="en-US">ATM [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research And Development Tax Credit Carryforward [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShortTermOperatingLeaseMember" xlink:label="sava_ShortTermOperatingLeaseMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShortTermOperatingLeaseMember" xlink:to="sava_ShortTermOperatingLeaseMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShortTermOperatingLeaseMember_lbl" xml:lang="en-US">Short Term Operating Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShortTermOperatingLeaseMember_lbl" xml:lang="en-US">Short Term Operating Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShortTermOperatingLeaseMember_lbl" xml:lang="en-US">Short-Term Operating Lease [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanMember" xlink:to="sava_CashIncentiveBonusPlanMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanMember_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanMember_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CashIncentiveBonusPlanMember_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" xlink:to="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_lbl" xml:lang="en-US">Exceeding Performance Milestones Minimum 20 Consecutive Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_lbl" xml:lang="en-US">Exceeding Performance Milestones Minimum20 Consecutive Days [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_lbl" xml:lang="en-US">Exceeding Performance Milestones Minimum 20 Consecutive Days [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_Exceeds5BillionMarketCapitalizationMember" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_Exceeds5BillionMarketCapitalizationMember" xlink:to="sava_Exceeds5BillionMarketCapitalizationMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_lbl" xml:lang="en-US">Exceeds 5 Billion Market Capitalization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_lbl" xml:lang="en-US">Exceeds5 Billion Market Capitalization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_lbl" xml:lang="en-US">Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_FirstValuationMilestoneMember" xlink:label="sava_FirstValuationMilestoneMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_FirstValuationMilestoneMember" xlink:to="sava_FirstValuationMilestoneMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_FirstValuationMilestoneMember_lbl" xml:lang="en-US">First Valuation Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_FirstValuationMilestoneMember_lbl" xml:lang="en-US">First Valuation Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_FirstValuationMilestoneMember_lbl" xml:lang="en-US">First Valuation Milestone [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SecondThroughEighthValuationMilestonesMember" xlink:label="sava_SecondThroughEighthValuationMilestonesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_SecondThroughEighthValuationMilestonesMember" xlink:to="sava_SecondThroughEighthValuationMilestonesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_lbl" xml:lang="en-US">Second Through Eighth Valuation Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_lbl" xml:lang="en-US">Second Through Eighth Valuation Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_lbl" xml:lang="en-US">Second Through Eighth Valuation Milestones [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US">Litigation Case Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US">Litigation Case [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember_lbl" xml:lang="en-US">violations of the federal securities laws</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember_lbl" xml:lang="en-US">Violations Of Federal Securities Laws [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember_lbl" xml:lang="en-US">Violations of the federal securities laws [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsMember" xlink:to="sava_ShareholderDerivativeActionsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShareholderDerivativeActionsMember_lbl" xml:lang="en-US">Shareholder derivative actions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShareholderDerivativeActionsMember_lbl" xml:lang="en-US">Shareholder Derivative Actions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShareholderDerivativeActionsMember_lbl" xml:lang="en-US">Shareholder derivative actions [Member]</label></labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>sava-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.4.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/28/2023 2:50:35 PM-->
<!--Modified on: 2/28/2023 2:50:35 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureGeneralLiquidityAndBasisOfPresentation" roleURI="http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentation"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePrepaidAndOtherCurrentAssets" roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssets"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureRealPropertyAcquisition" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisition"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIntangibleAssets" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssets"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensation" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureEmployee401KBenefitPlan" roleURI="http://www.cassavasciences.com/role/DisclosureEmployee401KBenefitPlan"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxes"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureLeasesAndCommitments" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#Disclosure2020CashIncentiveBonusPlan" roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureContingencies" roleURI="http://www.cassavasciences.com/role/DisclosureContingencies"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicy" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePrepaidAndOtherCurrentAssetsTables" roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureRealPropertyAcquisitionTables" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIntangibleAssetsTables" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationTables" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureLeasesAndCommitmentsTables" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureGeneralLiquidityAndBasisOfPresentationNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentationNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureRealPropertyAcquisitionNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePropertyAndEquipmentNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIntangibleAssetsNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureLeasesAndCommitmentsNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" roleURI="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#Disclosure2020CashIncentiveBonusPlanNarrativeDetails" roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20221231.xsd#DisclosureContingenciesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"></roleRef>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638131926340525884"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638131926340525884" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638131926340545847" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638131926340545847" order="3" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638131926340545847" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638131926340545847" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638131926340545847" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638131926340545847" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638131926340545847" order="8" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638131926340545847" order="9" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638131926340545847" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638131926340545847" order="11" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638131926340545847" order="12" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638131926340545847" order="13" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638131926340545847" order="14" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638131926340545847" order="15" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638131926340545847" order="16" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638131926340545847" order="17" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638131926340545847" order="18" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638131926340545847" order="19" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638131926340545847" order="20" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638131926340545847" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638131926340545847" order="22" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638131926340545847" order="23" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638131926340545847" order="24" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638131926340545847" order="25" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638131926340545847" order="26" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638131926340545847"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638131926340545847" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638131926340555812" order="28" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638131926340555812" order="29" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638131926340555812" order="30" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638131926340555812" order="31" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638131926340555812" order="32" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638131926340555812" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_638131926340555812" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638131926340555812" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638131926340555812" order="36" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638131926340555812" order="37" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638131926340555812" order="38" use="optional"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_638131926340555812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638131926340555812" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638131926340555812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638131926340555812" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638131926340555812" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638131926340555812" xlink:to="us-gaap_AssetsCurrent_638131926340555812" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638131926340555812" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638131926340555812" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638131926340555812"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638131926340555812" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638131926340565780"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent_638131926340565780" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638131926340565780"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets_638131926340565780" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638131926340565780"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638131926340565780" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638131926340565780"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638131926340565780" xlink:to="us-gaap_AccountsPayableCurrent_638131926340565780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638131926340565780"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638131926340565780" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638131926340565780" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638131926340565780"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638131926340565780" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638131926340565780" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638131926340565780"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638131926340565780" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638131926340565780" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638131926340565780"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638131926340565780" xlink:to="us-gaap_OtherLiabilitiesCurrent_638131926340565780" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638131926340575752"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638131926340565780" xlink:to="us-gaap_LiabilitiesCurrent_638131926340575752" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638131926340575752"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638131926340565780" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638131926340575752" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638131926340575752"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638131926340565780" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638131926340575752" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638131926340575752"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities_638131926340575752" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638131926340575752"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies_638131926340575752" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638131926340575752"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_638131926340575752" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638131926340575752"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638131926340575752" xlink:to="us-gaap_PreferredStockValue_638131926340575752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638131926340575752" xlink:to="us-gaap_CommonStockValue_638131926340585728" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638131926340575752" xlink:to="us-gaap_AdditionalPaidInCapital_638131926340585728" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638131926340575752" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638131926340585728" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638131926340575752" xlink:to="us-gaap_StockholdersEquity_638131926340585728" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638131926340585728" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638131926340585728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638131926340585728" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638131926340585728" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638131926340585728" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638131926340585728" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638131926340585728" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638131926340585728" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638131926340585728" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements Of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638131926340585728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638131926340585728" xlink:to="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_638131926340585728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638131926340585728" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638131926340585728" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638131926340585728" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131926340585728" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638131926340585728" xlink:to="us-gaap_OperatingExpenses_638131926340585728" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638131926340585728" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome_638131926340585728" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638131926340585728" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638131926340585728" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_NetLossPerShareBasicAndDiluted" xlink:label="sava_NetLossPerShareBasicAndDiluted_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="sava_NetLossPerShareBasicAndDiluted_638131926340585728" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted" xlink:label="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted_638131926340585728"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted_638131926340585728" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements Of Stockholders&apos; Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638131926340595703" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638131926340595703" xlink:to="us-gaap_StatementEquityComponentsAxis_638131926340595703" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638131926340595703" xlink:to="us-gaap_CommonStockMember_638131926340595703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638131926340595703" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638131926340595703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638131926340595703" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638131926340595703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638131926340595703" xlink:to="us-gaap_RetainedEarningsMember_638131926340595703" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638131926340595703" xlink:to="us-gaap_EquityComponentDomain_638131926340595703" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638131926340595703" xlink:to="us-gaap_StatementLineItems_638131926340595703" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockholdersEquity_638131926340595703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_SharesIssued_638131926340595703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_638131926340595703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_638131926340595703" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638131926340595703" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_638131926340595703" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_638131926340595703" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638131926340595703" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638131926340595703" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_638131926340595703" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_638131926340595703" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638131926340595703" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638131926340595703" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_NetIncomeLoss_638131926340595703" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6381319263405957031"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_StockholdersEquity_6381319263405957031" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_6381319263405957031"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638131926340595703" xlink:to="us-gaap_SharesIssued_6381319263405957031" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements Of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703" xlink:to="us-gaap_NetIncomeLoss_638131926340595703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638131926340595703"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703" xlink:to="us-gaap_ShareBasedCompensation_638131926340595703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703" xlink:to="us-gaap_Depreciation_638131926340605653" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638131926340605653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131926340605653" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638131926340605653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638131926340605653" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638131926340605653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638131926340605653" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_638131926340605653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638131926340605653" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638131926340605653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638131926340605653" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638131926340605653" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638131926340605653" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638131926340605653" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638131926340605653" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638131926340605653" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638131926340595703" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638131926340605653" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638131926340605653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638131926340605653" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638131926340605653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638131926340605653" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638131926340605653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638131926340605653" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638131926340605653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638131926340605653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638131926340605653" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638131926340605653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638131926340605653" xlink:to="us-gaap_ProceedsFromWarrantExercises_638131926340605653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638131926340605653" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638131926340605653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638131926340605653" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638131926340605653" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638131926340605653" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638131926340605653" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381319263406056531"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381319263406056531" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638131926340605653" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638131926340605653"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638131926340605653" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638131926340605653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - General, Liquidity And Basis of Presentation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary Of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssets" xlink:type="extended" xlink:title="10301 - Disclosure - Prepaid And Other Current Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="sava_PrepaidAndOtherAssetsDisclosureTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="sava_PrepaidAndOtherAssetsDisclosureTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisition" xlink:type="extended" xlink:title="10401 - Disclosure - Real Property Acquisition">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10501 - Disclosure - Property And Equipment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssets" xlink:type="extended" xlink:title="10601 - Disclosure - Intangible Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation" xlink:type="extended" xlink:title="10701 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureEmployee401KBenefitPlan" xlink:type="extended" xlink:title="10801 - Disclosure - Employee 401(k) Benefit Plan">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10901 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments" xlink:type="extended" xlink:title="11001 - Disclosure - Leases And Commitments">
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsAbstract" xlink:label="sava_LeasesAndCommitmentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan" xlink:type="extended" xlink:title="11101 - Disclosure - 2020 Cash Incentive Bonus Plan">
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanAbstract" xlink:label="sava_CashIncentiveBonusPlanAbstract"></loc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureContingencies" xlink:type="extended" xlink:title="11201 - Disclosure - Contingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAbstract" xlink:label="us-gaap_LossContingencyAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures_638131926340615643"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyAbstract" xlink:to="us-gaap_LossContingencyDisclosures_638131926340615643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policy)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638131926340625625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_ProceedsFromGrantsPolicyPolicyTextBlock_638131926340625625" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638131926340625625" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638131926340625625" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638131926340625625" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638131926340625625" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638131926340625625" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638131926340625625" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_638131926340625625" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638131926340625625" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638131926340625625" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638131926340625625" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_638131926340625625" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638131926340625625" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638131926340625625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Prepaid And Other Current Assets (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390404728571071"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390404728571071" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638131926340625625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionTables" xlink:type="extended" xlink:title="30403 - Disclosure - Real Property Acquisition (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_637709203959354913"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_637709203959354913" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_638131926340625625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_637709203959354913" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_638131926340625625" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30503 - Disclosure - Property And Equipment (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637708885067040668"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637708885067040668" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638131926340625625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Intangible Assets (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637709277228814078"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637709277228814078" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638131926340625625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638131926340625625"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637709277228814078" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638131926340625625" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638131926340635300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_638131926340635300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_638131926340635300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638131926340635300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638131926340635300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_638131926340635300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables" xlink:type="extended" xlink:title="31003 - Disclosure - Leases And Commitments (Tables)">
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsAbstract" xlink:label="sava_LeasesAndCommitmentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentationNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - General, Liquidity and Basis of Presentation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SignificantAccountingPoliciesTable" xlink:label="sava_SignificantAccountingPoliciesTable_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_SignificantAccountingPoliciesTable_638131926340635300" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesTable_638131926340635300" xlink:to="us-gaap_AwardTypeAxis_638131926340635300" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638131926340635300" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340635300" xlink:to="us-gaap_RestrictedStockMember_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesTable_638131926340635300" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340635300" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340635300" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340635300" xlink:to="us-gaap_BuildingMember_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340635300" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638131926340635300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340635300" xlink:to="us-gaap_LeaseholdImprovementsMember_638131926340635300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesTable_638131926340635300" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638131926340635300" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638131926340635300" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340635300" xlink:to="us-gaap_LeasesAcquiredInPlaceMember_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SignificantAccountingPoliciesLineItems" xlink:label="sava_SignificantAccountingPoliciesLineItems_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesTable_638131926340635300" xlink:to="sava_SignificantAccountingPoliciesLineItems_638131926340635300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ReductionToResearchAndDevelopmentExpense" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638131926340635300" xlink:to="sava_ReductionToResearchAndDevelopmentExpense_638131926340635300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638131926340635300" xlink:to="us-gaap_NumberOfOperatingSegments_638131926340635300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638131926340635300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638131926340635300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638131926340635300"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638131926340635300" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638131926340635300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638131926340635300" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638131926340645571" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638131926340635300" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638131926340645571" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638131926340635300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638131926340645571" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_635240128367044116"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635240128367044116" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638131926340645571" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638131926340645571" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638131926340645571" order="1" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638131926340645571" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638131926340645571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638131926340645571" xlink:to="us-gaap_EmployeeStockOptionMember_638131926340645571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638131926340645571" xlink:to="us-gaap_WarrantMember_638131926340645571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638131926340645571" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638131926340645571" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638131926340645571" xlink:to="us-gaap_NetIncomeLossAbstract_638131926340645571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638131926340645571" xlink:to="us-gaap_NetIncomeLoss_638131926340645571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted" xlink:label="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638131926340645571" xlink:to="sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted_638131926340645571" order="2" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_NetLossPerShareBasicAndDiluted" xlink:label="sava_NetLossPerShareBasicAndDiluted_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638131926340645571" xlink:to="sava_NetLossPerShareBasicAndDiluted_638131926340645571" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638131926340645571" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638131926340645571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390406778822622"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390406778822622" xlink:to="us-gaap_PrepaidInsurance_638131926340645571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390406778822622" xlink:to="us-gaap_DepositContractsAssets_638131926340645571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390406778822622" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638131926340645571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390406778822622" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638131926340645571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Real Property Acquisition (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_637709232385376924"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_637709232385376924" xlink:to="us-gaap_AssetAcquisitionTable_638131926340645571" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638131926340645571" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340645571" order="1" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340645571" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340645571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340645571" xlink:to="us-gaap_BuildingMember_638131926340645571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638131926340645571" xlink:to="srt_StatementGeographicalAxis_638131926340645571" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638131926340645571"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638131926340645571" xlink:to="srt_SegmentGeographicalDomain_638131926340645571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AustinMember" xlink:label="sava_AustinMember_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638131926340645571" xlink:to="sava_AustinMember_638131926340655537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638131926340645571" xlink:to="us-gaap_AssetAcquisitionLineItems_638131926340655537" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638131926340655537" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_638131926340655537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638131926340655537" xlink:to="sava_PercentageOfOccupancy_638131926340655537" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageOfCurrentlyLeased" xlink:label="sava_PercentageOfCurrentlyLeased_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638131926340655537" xlink:to="sava_PercentageOfCurrentlyLeased_638131926340655537" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638131926340655537" xlink:to="us-gaap_NetRentableArea_638131926340655537" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638131926340655537" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_638131926340655537" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Real Property Acquisition (Summary Of Acquisition) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_637709261316440186"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_637709261316440186" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638131926340655537" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638131926340655537" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340655537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340655537" xlink:to="us-gaap_LeasesAcquiredInPlaceMember_638131926340655537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340655537" xlink:to="sava_LeasingCommissionsAndOtherMember_638131926340655537" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340655537" order="2" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340655537" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340655537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340655537" xlink:to="us-gaap_LandMember_638131926340655537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340655537" xlink:to="us-gaap_BuildingMember_638131926340655537" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340655537" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638131926340655537" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340655537" xlink:to="us-gaap_LeaseholdImprovementsMember_638131926340655537" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537" xlink:to="srt_StatementGeographicalAxis_638131926340655537" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638131926340655537" xlink:to="srt_SegmentGeographicalDomain_638131926340655537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AustinMember" xlink:label="sava_AustinMember_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638131926340655537" xlink:to="sava_AustinMember_638131926340655537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537" xlink:to="us-gaap_BusinessAcquisitionLineItems_638131926340655537" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638131926340655537" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_638131926340655537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638131926340655537" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_638131926340655537" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638131926340655537" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638131926340655537" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Real Property Acquisition (Components Of Other Income, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_637709261558608168"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_637709261558608168" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340655537" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340655537"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340655537" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340655537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340655537" xlink:to="us-gaap_BuildingMember_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537" xlink:to="srt_StatementGeographicalAxis_638131926340665515" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638131926340665515" xlink:to="srt_SegmentGeographicalDomain_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AustinMember" xlink:label="sava_AustinMember_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638131926340665515" xlink:to="sava_AustinMember_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638131926340655537" xlink:to="us-gaap_BusinessAcquisitionLineItems_638131926340665515" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638131926340665515" xlink:to="us-gaap_OtherNonoperatingIncome_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638131926340665515" xlink:to="us-gaap_OtherNonoperatingExpense_638131926340665515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638131926340665515" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638131926340665515" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property And Equipment (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638131926340665515" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638131926340665515" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340665515" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340665515" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515" xlink:to="us-gaap_EquipmentMember_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638131926340665515" xlink:to="us-gaap_DisposalGroupClassificationAxis_638131926340665515" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis_638131926340665515" xlink:to="us-gaap_DisposalGroupClassificationDomain_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain_638131926340665515" xlink:to="us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638131926340665515" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515" order="3" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515" xlink:to="us-gaap_Depreciation_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_638131926340665515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638131926340665515" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638131926340665515" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638131926340665515" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637708886452535935"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637708886452535935" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638131926340665515" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638131926340665515" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340665515" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638131926340665515" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515" xlink:to="us-gaap_LandMember_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515" xlink:to="us-gaap_BuildingMember_638131926340665515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638131926340665515" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515" xlink:to="us-gaap_LeaseholdImprovementsMember_638131926340665515" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515" xlink:to="us-gaap_FurnitureAndFixturesMember_638131926340665515" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638131926340665515" xlink:to="us-gaap_ConstructionInProgressMember_638131926340665515" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638131926340665515" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638131926340665515"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638131926340665515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638131926340675482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638131926340665515" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638131926340675482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Intangible Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638131926340675482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637709278730154570"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637709278730154570" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638131926340675482" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638131926340675482" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638131926340675482" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638131926340675482" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340675482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340675482" xlink:to="us-gaap_LeasesAcquiredInPlaceMember_638131926340675482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638131926340675482" xlink:to="sava_LeasingCommissionsAndOtherMember_638131926340675482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638131926340675482" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638131926340675482" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638131926340675482" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638131926340675482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638131926340675482" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638131926340675482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638131926340675482" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638131926340675482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637720627070870562"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637720627070870562" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638131926340675482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637720627070870562" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638131926340675482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637720627070870562" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638131926340675482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637720627070870562" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638131926340675482" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340675482" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340675482" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638131926340675482" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638131926340675482" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638131926340675482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_WarrantsMember" xlink:label="sava_WarrantsMember_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638131926340675482" xlink:to="sava_WarrantsMember_638131926340675482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340675482" xlink:to="us-gaap_StatementClassOfStockAxis_638131926340675482" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638131926340675482" xlink:to="us-gaap_ClassOfStockDomain_638131926340675482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638131926340675482" xlink:to="us-gaap_CommonStockMember_638131926340675482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340675482" xlink:to="us-gaap_AwardTypeAxis_638131926340675482" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340675482"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638131926340675482" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340675482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340675482" xlink:to="us-gaap_PerformanceSharesMember_638131926340685174" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340675482" xlink:to="us-gaap_EmployeeStockOptionMember_638131926340685174" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340675482" xlink:to="us-gaap_PlanNameAxis_638131926340685174" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638131926340685174" xlink:to="us-gaap_PlanNameDomain_638131926340685174" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RegisteredDirectOffering2022Member" xlink:label="sava_RegisteredDirectOffering2022Member_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638131926340685174" xlink:to="sava_RegisteredDirectOffering2022Member_638131926340685174" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RegisteredDirectOffering2021Member" xlink:label="sava_RegisteredDirectOffering2021Member_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638131926340685174" xlink:to="sava_RegisteredDirectOffering2021Member_638131926340685174" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PublicOfferingMember" xlink:label="sava_PublicOfferingMember_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638131926340685174" xlink:to="sava_PublicOfferingMember_638131926340685174" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CommonStockWarrantsMember" xlink:label="sava_CommonStockWarrantsMember_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638131926340685174" xlink:to="sava_CommonStockWarrantsMember_638131926340685174" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AtMarketEquityProgramMember" xlink:label="sava_AtMarketEquityProgramMember_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638131926340685174" xlink:to="sava_AtMarketEquityProgramMember_638131926340685174" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_TwoThousandEightEquityIncentivePlanMember" xlink:label="sava_TwoThousandEightEquityIncentivePlanMember_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638131926340685174" xlink:to="sava_TwoThousandEightEquityIncentivePlanMember_638131926340685174" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638131926340685174" xlink:to="sava_TwoThousandEighteenEquityIncentivePlanMember_638131926340685174" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340675482" xlink:to="srt_RangeAxis_638131926340685174" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638131926340685174" xlink:to="srt_RangeMember_638131926340685174" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638131926340685174" xlink:to="srt_MaximumMember_638131926340685174" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340675482" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" order="6" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_638131926340685174" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_638131926340685174" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638131926340685174" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_SaleOfStockPricePerShare_638131926340685174" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638131926340685174" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_ProceedsFromWarrantExercises_638131926340685174" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638131926340685174" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_638131926340685174"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_638131926340685174" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageOfCommissionAtmOffering" xlink:label="sava_PercentageOfCommissionAtmOffering_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="sava_PercentageOfCommissionAtmOffering_638131926340695434" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638131926340695434" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm_638131926340695434" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638131926340695434" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod_638131926340695434" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm" xlink:label="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm_638131926340695434" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting" xlink:label="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting_638131926340695434" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638131926340695434" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_638131926340695434" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_CommonStockSharesAuthorized_638131926340695434" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638131926340695434" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638131926340695434"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340685174" xlink:to="us-gaap_SharesIssued_638131926340695434" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Stock Option Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638131926340705402"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638131926340705402" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638131926340705402"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638131926340705402" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638131926340705402"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638131926340705402" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638131926340705402"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638131926340705402" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381319263407054021"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381319263407054021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638131926340705402"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638131926340705402" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638131926340715381"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638131926340715381" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638131926340715381"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638131926340715381" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638131926340715381"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638131926340715381" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638131926340715381"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638131926340715381" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638131926340715381"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638131926340715381" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381319263407153811"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381319263407153811" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638131926340725354" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638131926340725354" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638131926340725354" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638131926340725354" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638131926340725354" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638131926340725354" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638131926340725354" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638131926340725354" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638131926340725354" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638131926340725354" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638131926340725354" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638131926340725354" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638131926340725354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638131926340725354" xlink:to="sava_RangeOneMember_638131926340725354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638131926340725354" xlink:to="sava_RangeTwoMember_638131926340725354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638131926340725354" xlink:to="sava_RangeThreeMember_638131926340725354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638131926340725354" xlink:to="sava_RangeFourMember_638131926340725354" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638131926340725354" xlink:to="sava_RangeFiveMember_638131926340725354" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638131926340725354" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638131926340725354" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638131926340725354" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638131926340725354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638131926340725354" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638131926340725354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638131926340725354" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638131926340725354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638131926340725354" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638131926340725354" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638131926340725354" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638131926340725354" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638131926340725354" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638131926340725354" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_638131926340725354"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638131926340725354" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_638131926340725354" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638131926340735326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638131926340735326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638131926340735326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638131926340735326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638131926340735326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638131926340735326" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_638131926340735326" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638131926340735326" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637176597182574833"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637176597182574833" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340735326" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340735326" xlink:to="us-gaap_AwardTypeAxis_638131926340735326" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638131926340735326" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340735326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638131926340735326" xlink:to="us-gaap_PerformanceSharesMember_638131926340735326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638131926340735326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340735326" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340735326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638131926340735326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340735326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638131926340735326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340735326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638131926340735326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340735326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638131926340735326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381319263407353261"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638131926340735326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381319263407353261" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation (Stock-Based Compensation Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638131926340735326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638131926340735326" xlink:to="us-gaap_IncomeStatementLocationAxis_638131926340735326" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638131926340735326" xlink:to="us-gaap_IncomeStatementLocationDomain_638131926340735326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638131926340735326" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638131926340735326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638131926340735326" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638131926340735326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638131926340735326" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638131926340735326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638131926340735326"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638131926340735326" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638131926340735326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638131926340745301" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638131926340745301" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638131926340745301" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638131926340745301" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638131926340745301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638131926340745301" xlink:to="us-gaap_DomesticCountryMember_638131926340745301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638131926340745301" xlink:to="srt_RangeAxis_638131926340745301" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638131926340745301" xlink:to="srt_RangeMember_638131926340745301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638131926340745301" xlink:to="srt_MinimumMember_638131926340745301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638131926340745301" xlink:to="srt_MaximumMember_638131926340745301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638131926340745301" xlink:to="srt_StatementScenarioAxis_638131926340745301" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638131926340745301" xlink:to="srt_ScenarioUnspecifiedDomain_638131926340745301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ExpirationOperatingLossCarryforwardsMember" xlink:label="sava_ExpirationOperatingLossCarryforwardsMember_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638131926340745301" xlink:to="sava_ExpirationOperatingLossCarryforwardsMember_638131926340745301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_IndefinitelyMember" xlink:label="sava_IndefinitelyMember_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638131926340745301" xlink:to="sava_IndefinitelyMember_638131926340745301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ExpirationResearchAndDevelopmentTaxCreditsMember" xlink:label="sava_ExpirationResearchAndDevelopmentTaxCreditsMember_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638131926340745301" xlink:to="sava_ExpirationResearchAndDevelopmentTaxCreditsMember_638131926340745301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638131926340745301" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638131926340745301" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638131926340745301" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638131926340745301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638131926340745301" xlink:to="us-gaap_ResearchMember_638131926340745301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638131926340745301" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638131926340745301" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638131926340745301" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638131926340745301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638131926340745301" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638131926340745301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638131926340745301" xlink:to="us-gaap_OperatingLossCarryforwards_638131926340745301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638131926340745301" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_638131926340745301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638131926340745301" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_638131926340745301" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638131926340745301" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638131926340745301" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638131926340745301" xlink:to="us-gaap_UnrecognizedTaxBenefits_638131926340745301" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months" xlink:label="sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638131926340745301" xlink:to="sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months_638131926340745301" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638131926340745301"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638131926340745301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638131926340755277" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638131926340755277" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638131926340755277" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_638131926340755277" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638131926340755277" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638131926340755277" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638131926340755277" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_638131926340755277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638131926340755277" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638131926340755277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638131926340755277" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638131926340755277" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638131926340755277" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther_638131926340755277" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross_638131926340755277" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638131926340755277" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_638131926340755277" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_638131926340755277" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638131926340755277" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638131926340755277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638131926340755277" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638131926340755277" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638131926340755277" xlink:to="us-gaap_DeferredTaxLiabilities_638131926340755277" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_638131926340755277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638131926340755277" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6381319263407552771"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_6381319263407552771" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Leases And Commitments (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsAbstract" xlink:label="sava_LeasesAndCommitmentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsTable" xlink:label="sava_LeasesAndCommitmentsTable_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="sava_LeasesAndCommitmentsTable_638131926340755277" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsTable_638131926340755277" xlink:to="srt_StatementGeographicalAxis_638131926340755277" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638131926340755277" xlink:to="srt_SegmentGeographicalDomain_638131926340755277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_AustinMember" xlink:label="sava_AustinMember_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638131926340755277" xlink:to="sava_AustinMember_638131926340755277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638131926340755277"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsTable_638131926340755277" xlink:to="us-gaap_LeaseContractualTermAxis_638131926340755277" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638131926340755277" xlink:to="us-gaap_LeaseContractualTermDomain_638131926340765247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShortTermOperatingLeaseMember" xlink:label="sava_ShortTermOperatingLeaseMember_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638131926340765247" xlink:to="sava_ShortTermOperatingLeaseMember_638131926340765247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsLineItems" xlink:label="sava_LeasesAndCommitmentsLineItems_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsTable_638131926340755277" xlink:to="sava_LeasesAndCommitmentsLineItems_638131926340765247" order="3" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_638131926340765247" xlink:to="us-gaap_NetRentableArea_638131926340765247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_638131926340765247" xlink:to="us-gaap_LeaseExpirationDate1_638131926340765247" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_638131926340765247" xlink:to="us-gaap_OperatingLeaseExpense_638131926340765247" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_638131926340765247" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638131926340765247" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_638131926340765247" xlink:to="us-gaap_OperatingLeaseLiability_638131926340765247" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_638131926340765247" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_638131926340765247" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_638131926340765247" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638131926340765247" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsLineItems_638131926340765247" xlink:to="us-gaap_OperatingLeasePayments_638131926340765247" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Leases And Commitments (Future Minimum Lease Payments) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_LeasesAndCommitmentsAbstract" xlink:label="sava_LeasesAndCommitmentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638131926340765247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638131926340765247" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638131926340765247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638131926340765247" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638131926340765247" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638131926340765247" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_LeasesAndCommitmentsAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638131926340765247" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanAbstract" xlink:label="sava_CashIncentiveBonusPlanAbstract_637399223356820786"></loc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanTable" xlink:label="sava_CashIncentiveBonusPlanTable_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanAbstract_637399223356820786" xlink:to="sava_CashIncentiveBonusPlanTable_638131926340765247" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_638131926340765247" xlink:to="srt_RangeAxis_638131926340765247" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638131926340765247" xlink:to="srt_RangeMember_638131926340765247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638131926340765247" xlink:to="srt_MinimumMember_638131926340765247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638131926340765247" xlink:to="srt_MaximumMember_638131926340765247" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_638131926340765247" xlink:to="us-gaap_PlanNameAxis_638131926340765247" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638131926340765247" xlink:to="us-gaap_PlanNameDomain_638131926340765247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember_638131926340765247"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638131926340765247" xlink:to="sava_CashIncentiveBonusPlanMember_638131926340765247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_638131926340765247" xlink:to="srt_StatementScenarioAxis_638131926340775216" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638131926340775216" xlink:to="srt_ScenarioUnspecifiedDomain_638131926340775216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638131926340775216" xlink:to="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_638131926340775216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_Exceeds5BillionMarketCapitalizationMember" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638131926340775216" xlink:to="sava_Exceeds5BillionMarketCapitalizationMember_638131926340775216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_FirstValuationMilestoneMember" xlink:label="sava_FirstValuationMilestoneMember_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638131926340775216" xlink:to="sava_FirstValuationMilestoneMember_638131926340775216" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_SecondThroughEighthValuationMilestonesMember" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638131926340775216" xlink:to="sava_SecondThroughEighthValuationMilestonesMember_638131926340775216" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusPlanLineItems" xlink:label="sava_CashIncentiveBonusPlanLineItems_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_638131926340765247" xlink:to="sava_CashIncentiveBonusPlanLineItems_638131926340775216" order="4" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PerformancePlanValuationAmount" xlink:label="sava_PerformancePlanValuationAmount_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638131926340775216" xlink:to="sava_PerformancePlanValuationAmount_638131926340775216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638131926340775216" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_638131926340775216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638131926340775216" xlink:to="sava_CashIncentiveBonusAward_638131926340775216" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638131926340775216" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_638131926340775216" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638131926340775216" xlink:to="sava_PaymentsForCashIncentiveBonus_638131926340775216" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAbstract" xlink:label="us-gaap_LossContingencyAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyAbstract" xlink:to="us-gaap_LossContingenciesTable_638131926340775216" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638131926340775216" xlink:to="srt_LitigationCaseAxis_638131926340775216" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638131926340775216" xlink:to="srt_LitigationCaseTypeDomain_638131926340775216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638131926340775216" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember_638131926340775216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638131926340775216" xlink:to="sava_ShareholderDerivativeActionsMember_638131926340775216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638131926340775216" xlink:to="us-gaap_LossContingenciesLineItems_638131926340775216" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638131926340775216" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_638131926340775216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20221231.xsd#sava_NumberOfClassActionsConvertedToCase" xlink:label="sava_NumberOfClassActionsConvertedToCase_638131926340775216"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638131926340775216" xlink:to="sava_NumberOfClassActionsConvertedToCase_638131926340775216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2"></presentationArc></presentationLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847554272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-29959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cassava Sciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1911336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6801 N. Capital of Texas Highway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 1; Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">501-2444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SAVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Portions of the Registrant's proxy statement for its 2023 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), to be filed with the U.S. Securities and Exchange Commission, no later than 120 days after the Registrant</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8217;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s fiscal year ended December 31, 2022, are incorporated by reference to Part III of this Annual Report on Form 10-K.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001069530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Austin, Texas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847353568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 201,015<span></span>
</td>
<td class="nump">$ 233,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,211<span></span>
</td>
<td class="nump">11,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">211,226<span></span>
</td>
<td class="nump">244,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">22,864<span></span>
</td>
<td class="nump">20,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">234,834<span></span>
</td>
<td class="nump">266,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,017<span></span>
</td>
<td class="nump">7,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued development expense</a></td>
<td class="nump">2,280<span></span>
</td>
<td class="nump">2,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,063<span></span>
</td>
<td class="nump">12,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,295<span></span>
</td>
<td class="nump">12,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 9, 10 and 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 120,000,000 shares authorized; 41,735,557 and 40,016,792 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">511,049<span></span>
</td>
<td class="nump">461,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(283,552)<span></span>
</td>
<td class="num">(207,306)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">227,539<span></span>
</td>
<td class="nump">253,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 234,834<span></span>
</td>
<td class="nump">$ 266,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847519296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">41,735,557<span></span>
</td>
<td class="nump">40,016,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">41,735,557<span></span>
</td>
<td class="nump">40,016,792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847571696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement', window );">Research and development, net of grant reimbursement</a></td>
<td class="nump">$ 68,032<span></span>
</td>
<td class="nump">$ 24,813<span></span>
</td>
<td class="nump">$ 3,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,988<span></span>
</td>
<td class="nump">8,055<span></span>
</td>
<td class="nump">3,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(346)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">80,020<span></span>
</td>
<td class="nump">32,868<span></span>
</td>
<td class="nump">6,446<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(80,020)<span></span>
</td>
<td class="num">(32,868)<span></span>
</td>
<td class="num">(6,446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">2,777<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (76,246)<span></span>
</td>
<td class="num">$ (32,385)<span></span>
</td>
<td class="num">$ (6,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_NetLossPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (1.90)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted', window );">Shares used in computing net loss per share, basic and diluted</a></td>
<td class="nump">40,202<span></span>
</td>
<td class="nump">39,405<span></span>
</td>
<td class="nump">26,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_NetLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Loss Per Share Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_NetLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Net Of Grant Reimbursement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares used in computing net loss per share, basic and diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766845562960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements Of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 190,664<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (168,587)<span></span>
</td>
<td class="nump">$ 22,099<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">21,841,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Stock options for employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Stock options for employees, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock options for non-employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options, shares</a></td>
<td class="nump">71,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock pursuant to exercise of warrants</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">4,936<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock pursuant to exercise of warrants, shares</a></td>
<td class="nump">3,950,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued in conjunction with follow-on public offering, net of issuance costs</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">70,242<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">70,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in conjunction with follow-on public offering, net of issuance costs, shares</a></td>
<td class="nump">9,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,334)<span></span>
</td>
<td class="num">(6,334)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">267,086<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(174,921)<span></span>
</td>
<td class="nump">92,200<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">35,237,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Stock options for employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,706<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Stock options for employees, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock options for non-employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,824<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options, shares</a></td>
<td class="nump">143,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock pursuant to exercise of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock pursuant to exercise of warrants, shares</a></td>
<td class="nump">554,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued in conjunction with follow-on public offering, net of issuance costs</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">189,821<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">189,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in conjunction with follow-on public offering, net of issuance costs, shares</a></td>
<td class="nump">4,081,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(32,385)<span></span>
</td>
<td class="num">(32,385)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">461,181<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(207,306)<span></span>
</td>
<td class="nump">253,915<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="nump">40,016,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Stock options for employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock options for non-employees</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Expiration of restricted stock Performance Awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Expiration of restricted stock Performance Awards,shares</a></td>
<td class="num">(57,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options, shares</a></td>
<td class="nump">109,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued in conjunction with follow-on public offering, net of issuance costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">47,327<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 47,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in conjunction with follow-on public offering, net of issuance costs, shares</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(76,246)<span></span>
</td>
<td class="num">(76,246)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 511,049<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (283,552)<span></span>
</td>
<td class="nump">$ 227,539<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="nump">41,735,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766852435312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (76,246,000)<span></span>
</td>
<td class="num">$ (32,385,000)<span></span>
</td>
<td class="num">$ (6,334,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,066,000<span></span>
</td>
<td class="nump">1,759,000<span></span>
</td>
<td class="nump">988,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">804,000<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">497,000<span></span>
</td>
<td class="nump">224,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(346,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">1,189,000<span></span>
</td>
<td class="num">(10,956,000)<span></span>
</td>
<td class="num">(220,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="num">(9,000)<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,449,000)<span></span>
</td>
<td class="nump">6,215,000<span></span>
</td>
<td class="nump">458,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued development expense</a></td>
<td class="num">(523,000)<span></span>
</td>
<td class="nump">2,084,000<span></span>
</td>
<td class="num">(58,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="num">(1,707,000)<span></span>
</td>
<td class="nump">1,794,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="num">(136,000)<span></span>
</td>
<td class="nump">731,000<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(77,514,000)<span></span>
</td>
<td class="num">(30,196,000)<span></span>
</td>
<td class="num">(5,382,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,712,000)<span></span>
</td>
<td class="num">(22,214,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(2,712,000)<span></span>
</td>
<td class="num">(22,214,000)<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">475,000<span></span>
</td>
<td class="nump">1,824,000<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of common stock upon exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,000<span></span>
</td>
<td class="nump">4,940,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering, net of issuance costs</a></td>
<td class="nump">47,329,000<span></span>
</td>
<td class="nump">189,825,000<span></span>
</td>
<td class="nump">70,251,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">47,804,000<span></span>
</td>
<td class="nump">192,341,000<span></span>
</td>
<td class="nump">75,447,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(32,422,000)<span></span>
</td>
<td class="nump">139,931,000<span></span>
</td>
<td class="nump">70,425,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">233,437,000<span></span>
</td>
<td class="nump">93,506,000<span></span>
</td>
<td class="nump">23,081,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">201,015,000<span></span>
</td>
<td class="nump">$ 233,437,000<span></span>
</td>
<td class="nump">$ 93,506,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable</a></td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766848792176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General, Liquidity And Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General, Liquidity And Basis Of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">General, Liquidity and Basis of Presentation</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">1.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">General, Liquidity and Basis of Presentation</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discovers and develops proprietary pharmaceutical product candidates that may offer significant improvements to patients and healthcare professionals. The Company generally focuses its product discovery and development efforts on disorders of the nervous system. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Coronavirus Disease 2019 (COVID-19)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The widespread outbreak of COVID-19 has not significantly impacted the Company&#8217;s operations or financial condition as of February&#160;28, 2023. However, this pandemic has created a dynamic and uncertain situation in the national economy. The Company continues to closely monitor the latest information to make timely, informed business decisions and public disclosures regarding the potential impact of pandemic on its operations and financial condition. The scope of pandemic is unprecedented and its long-term impact on the Company&#8217;s operations and financial condition cannot be reasonably estimated at this time.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Basis of Consolidation</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">&#65279;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Liquidity  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">283.6</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million at December&#160;31, 2022. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company may seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are no assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next 12 months.</span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847425472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2.  Summary of Significant Accounting Policies</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and assumptions</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Proceeds from Grants</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2022, 2021, and 2020, the Company received $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.9</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.9</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.2</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of reimbursement from the National Institutes of Health and National Institute on Drug Abuse, respectively. The Company records the proceeds from these grants as reductions to its research and development expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cash and Cash Equivalents and Concentration of Credit Risk</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at one financial institution.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value Measurements </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 1 includes quoted prices in active markets.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 2 includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does not have any financial instruments where the fair value is based on Level 2 inputs.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">financial instruments</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> where the fair value is based on Level 3 inputs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 inputs at December&#160;31, 2022 and 2021.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Business Segments</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">one</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> business segment: the development of novel drugs and diagnostics.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(&#8220;Black-Scholes&#8221;) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each </span><span id="_cp_text_1_372" style="text-decoration: none;"/><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For all options granted, it</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has granted share-based awards that vest upon achievement of certain performance criteria</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (&#8220;Performance Awards&#8221;)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Net Loss per Share</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company computes </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options and warrants. There is no difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Numerator:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">76,246</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">32,385</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,334</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Denominator:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares used in computing net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">40,202</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,405</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26,105</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.90</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.82</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.24</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Dilutive common stock options excluded from net loss per share, diluted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,055</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,211</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,145</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock warrants excluded from net loss per share, diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">554</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company excluded common stock options and warrants outstanding , along with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">57,143</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted stock awards, from the calculation of net loss per share, diluted, because the effect of including outstanding options and warrants would have been anti-dilutive. The </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">57,143</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted stock awards expired during the year ended December 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Tahoma', 'sans-serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value of Financial Instruments</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments may be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Research Contracts, Prepaids and Accruals</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have not been materially different from actual costs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Incentive Bonus Plan</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants.  Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718 &#8220;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met.  See Note 11 for further discussion of the Plan.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Leases</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;consolidated balance sheets.&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize right-of-use assets or lease liabilities</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#160;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Property and equipment</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years and approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Intangible assets</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which approximates </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.3</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years at December 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Income Taxes</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for uncertain tax positions in accordance with ASC 740, &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766852800848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid And Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid and Other Current Assets</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">3.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Prepaid and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Other Current Assets</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid and other current assets at December 31, 2022 and 2021 consisted of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid insurance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">874</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">662</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contract research organization and other deposits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,177</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,330</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">160</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">53</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total prepaid expenses and other current assets</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,211</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,045</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid And Other Assets Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847430432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Real Property Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Real Property Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Real Property Acquisition</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">4.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Real Property Acquisition</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On August 4, 2021, the Company completed the all-cash purchase of a two-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#8217;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are being outsourced to professional real-estate managers. The purchase price of the property was $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, including transaction costs. The office complex measures approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> rentable square feet. At December 31, 2022, the property was over </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">60</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% leased. The Company also occupied approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the property as of December 31, 2022. The seller was a third party not affiliated with the Company.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The purchase was accounted for as an asset acquisition under ASC 805, Business Combinations. As substantially all of the fair value of the gross assets acquired were concentrated into a single identifiable asset, the Company concluded that the screen was met, and the transaction is considered an asset acquisition rather than an acquisition of a business. Pursuant to the cost accumulation method as prescribed in ASC 805, the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values. The value of acquired in-place leases is measured as the sum of lost revenues that would be incurred during a&#160;prospective lease-up period that would be necessary to achieve occupancy similar to that at the time of&#160;acquisition. The value is calculated as the average number of months of lease-up multiplied by the gross monthly market rental rate (base rent plus reimbursements) for each particular suite.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The assets acquired are summarized as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.07in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.06in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Land</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,734</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Buildings</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,980</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Site improvements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">453</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tenant improvements</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">567</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total tangible assets</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20,734</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.16in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease-in-place agreements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,053</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasing commissions and other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">246</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,299</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consideration paid</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22,033</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.06in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company records the net income from building operations and leases as other income, net, as leasing is not core to the Company&#8217;s operations. Building depreciation and amortization for space not occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> were as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,459</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">911</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property operating expenses</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,462</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">477</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Other income, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">997</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">434</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">      The Company had accrued property taxes related to the building totaling $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">433,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">450,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> at December 31, 2022 and 2021, respectively, included in other current liabilities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766851155808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property And Equipment</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">5.  Property and Equipment</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The components of property and equipment, net, as of December 31, 2022 and 2021 were as follows (in thousands): </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.06in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Land</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,734</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,734</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Buildings</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,980</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,980</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Site improvements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">470</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">470</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tenant improvements</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,016</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">567</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">851</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">178</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Construction in progress</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">83</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross property and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,064</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21,012</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated depreciation</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,200</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">396</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Property and equipment, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22,864</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20,616</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.05in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation expense for property and equipment was&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">804,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">310,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;and&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;for the years ended&#160;December&#160;31, 2022, 2021&#160;and 2020, respectively.&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> sales of property and equipment during the years ended December 31, 2022 and 2021.</span></p><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the&#160;year ended&#160;December&#160;31, 2020, the Company sold surplus manufacturing equipment to an independent third party and received proceeds totaling $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">360,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#160;The original&#160;cost of the property and equipment was </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">892,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;and accumulated depreciation was $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">878,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">,&#160;resulting a gain on sale&#160;of property and equipment of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">346,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;during the&#160;year ended&#160;December&#160;31, 2020.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766850343616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">6.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Intangible assets</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The components of intangible assets, net, as of December 31, 2022&#160;and 2021&#160;were as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.07in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr style="height: 0.20in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease-in-place agreements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,053</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,053</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasing commissions and other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">290</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">246</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,343</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,299</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated amortization</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">721</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">224</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Intangible assets, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">622</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,075</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization expense for intangible assets was&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">497,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">224,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the years ended&#160;December&#160;31, 2022 and 2021, respectively. There was </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> amortization expense for the year ended December 31, 2020.&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization expense for finite-lived intangible assets is expected to be as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.15in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.19in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">For the year ending December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">451</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">167</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total amortization</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">622</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766853676336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders&#8217; Equity And Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stockholders' Equity And Stock-Based Compensation</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">7.  Stockholders' Equity and Stock-Based Compensation</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Preferred Stock</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2022 Registered Direct Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November&#160;22, 2022, the Company completed a common stock offering pursuant to which certain investors purchased </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,666,667</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock at a price of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">30.00</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share. Net proceeds of the offering were approximately $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">47.3</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million after deducting offering expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2021 Registered Direct Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On February&#160;12, 2021, the Company completed a common stock offering pursuant to which certain investors purchased </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,081,633</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock at a price of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49.00</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share. Net proceeds of the offering were approximately $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">189.8</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million after deducting offering expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2020 Follow-on Public Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November&#160;13, 2020, the Company completed the sale of&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,375,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;shares of Cassava common stock in an underwritten public offering at a price of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8.00</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;per share. The Company received net proceeds from the offering of&#160;approximately $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">70.3</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million&#160;after deducting underwriting discounts and offering expenses.</span></p><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 106.7%;margin-bottom: 10pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Common Stock Warrants</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2018, the Company issued warrants to&#160;purchase up to an aggregate of&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9.1</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million shares of its common stock in conjunction with an offering of its common stock.&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During 2021, the Company received proceeds of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.7</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million from the exercise of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.6</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million shares pursuant to common stock warrants. There were no common stock warrants outstanding following the 2021 exercises.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During 2020, the Company received proceeds of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.9</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million from the exercise of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million shares pursuant to common stock warrants.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">At the Market (ATM) Common Stock Issuance </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On March&#160;27, 2020, the Company established an at-the-market offering program (ATM) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million&#160;in transactions pursuant to a shelf registration statement that was declared effective by the&#160;U.S. Securities and Exchange Commission (the SEC)&#160;on May&#160;5, 2020. The Company is obligated to pay a commission of&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%&#160;of the gross proceeds from the sale of shares of common stock in the offering. The Company is not obligated to sell any shares in the offering.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;common stock sales under the ATM during the years ended December&#160;31, 2022, 2021 and 2020.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2008 Equity Incentive Plan </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Under the Company&#8217;s </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2008 Equity Incentive Plan, or 2008 Equity Plan,</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2008 Equity Plan</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> expired in December 2017. Share-based awards generally expire </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ten years</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> from the date of grant.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2018 Equity Incentive Plan </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s Board or a designated Committee of the Board is responsible for administration of the Company&#8217;s 2018 Omnibus Incentive Plan (the 2018 Plan) and determines the terms and conditions of each option granted, consistent with the terms of the 2018 Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the 2018 Plan, including grants of stock options and performance awards. Share-based awards generally expire </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ten years</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> from the date of grant. The 2018 Plan, as amended on May 5, 2022, provides for issuance of up to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,000,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock, par value $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.001</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share, subject to adjustment as provided in the 2018 Plan. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company may then use its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock Options</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following summarizes information about stock option activity during 2022:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Exercise Price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Remaining Contractual Term in Years</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Aggregate Intrinsic Value in Millions</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,663,727</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11.56</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">104,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">36.50</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">203,640</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15.56</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options forfeited/canceled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34,639</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.59</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,529,448</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.13</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.94</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49.6</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested and expected to vest at December 31, 2022</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,529,448</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.13</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.94</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49.6</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exercisable at December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,270,464</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.02</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.43</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">46.9</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Of the stock options exercised </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">during the year ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 31, 2022</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">94,399</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stock options were net settled in satisfaction of the exercise price, with no cash proceeds received.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following summarizes information about stock options at December&#160;31, 2022 by a range of exercise prices:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.20in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="6" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options outstanding</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options exercisable</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">remaining</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td></tr><tr><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Range of exercise prices</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">outstanding</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">contractual</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">exercise</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> vested</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">exercise</span></p></td></tr><tr><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">From</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">To</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">life (in years)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">price</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.95</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.88</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">585,833</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.6</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.51</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">505,833</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.46</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.24</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.24</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">550,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.0</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.24</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">550,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.24</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.09</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.04</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">536,951</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.09</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">512,888</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.07</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.39</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">35.00</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">655,874</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.6</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.82</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">653,290</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.79</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">36.40</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77.00</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">200,790</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8.8</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">52.64</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,453</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">62.61</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,529,448</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.9</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.13</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,270,464</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.02</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#8217;s common stock. Factors utilized in Black-Scholes to value each stock option granted, and the weighted average fair value of options granted during the years ended December 31, 2022, 2021 and 2020 were as follows:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Volatility</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">151</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">154</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">147</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">151</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">123</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">139</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rates</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.98</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.69</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.12</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.42</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.46</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.78</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected life of option</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Forfeiture rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average fair value of stock options granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">35.16</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">65.83</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.69</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Volatility</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> is based on reviews of the historical volatility of the Company&#8217;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;">zero</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> because the Company does not anticipate paying cash dividends in the foreseeable future. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2022, the Company expects to recognize compensation expense of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.7</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Performance Awards</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following summarizes information about performance award activity during 2022:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Performance Awards</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">138,055</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0a18ef04-da81-4da9-b08e-4f541d5d87fe;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a9cc683b-ce22-4d24-8a07-e6387b6743b3;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Forfeited/canceled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">130,913</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,142</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the year ended December 31, 2022, a total of </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">57,143</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of restricted stock awards expired as performance criteria related to these Performance Awards were not attained. These shares of restricted stock were returned to the 2008 Equity Incentive Plan, which expired in December 2017, and thus were retired.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If and when outstanding performance awards vest, the Company would recognize $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in stock-based compensation expense. These performance awards expire in </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-11a67b5d-6030-4b4a-89e9-be45bb42951d;">2026</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock-Based Compensation Expense</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following summarizes information about stock-based compensation expense, in thousands:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,631</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,302</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">453</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">435</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">457</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">535</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,066</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,759</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">988</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766853676336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(k) Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee 401(k) Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee 401(k) Benefit Plan</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">8.  Employee 401(k) Benefit Plan</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the first day of the month after hire and may contribute up to the current statutory limits under Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through December&#160;31, 2022, the Company has not made any matching contributions to the 401(k) plan.</span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766849817216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">9.  Income Taxes</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company did not provide for income taxes during the periods presented because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate for periods presented was as follows:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="7" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Year ended December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tax at federal statutory rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.0</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.0</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.0</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">State tax, net of federal benefit</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-2bbe3c9f-b94d-448f-b6dc-323b380f9a96;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-372e6af5-4c00-48eb-bae0-4471ae3a22e5;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Share-based compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.2</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">42.8</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development credits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.9</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.3</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.6</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Section 162(m) limitation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.2</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c5477bfe-2785-4f75-a69d-a809395650e8;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.8</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.2</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-6454e79f-5eac-4ce6-b83d-d54ce1ad34ec;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in valuation allowance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23.4</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23.8</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.2</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Effective income tax rate</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eedb89d9-ad7e-4f41-a736-d7fd924e0c16;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eb885844-bf4c-4fb5-ba17-aadb840ba669;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Deferred tax assets and valuation allowance</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.21in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred taxes assets at December&#160;31, 2022 and 2021 were valued at the corporate tax rate of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net operating loss carryforwards</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">28,017</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,777</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Share-based compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,706</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,870</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development credit carryforwards</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,681</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,439</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Capitalized research and development expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12,690</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-de6cc757-c8de-42c3-99b4-15243e637ef0;">&#8212;</span></span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">934</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,130</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">54,028</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">36,216</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Valuation allowance</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">54,002</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">36,166</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net deferred tax assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax liabilities:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use assets</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax liabilities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net deferred tax asset (liability)</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-1da80672-2d90-4cfe-a52c-83cd81fc610f;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c36d2911-beed-46e5-a06d-8fb8d4dd3d41;">&#8212;</span></span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The valuation allowance increased by $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17.8</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.7</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in 2022 and 2021, respectively, due primarily to continuing operations.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s net operating loss carryforwards of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">133.4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million are federal, of which $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74.1</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million expires between </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-ab3e4de0-d223-4a28-a263-17c41929c12c;">2029</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-c9c2841b-7ede-4662-83a9-7a4f7dcefb27;">2037</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43.9</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million carries forward indefinitely. As of December&#160;31, 2022, the Company had federal research and development tax credits of approximately $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">16.1</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million, which expire in the years </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-8869304f-1756-4722-a383-48272eaadb6a;">2024</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> through </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-16a796f0-25d3-4e27-b50c-84d331cdfb35;">2042</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Unrecognized tax benefits</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2022, 2021 and 2020, the Company has unrecognized tax benefits related to tax credits of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.5</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">million, $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.5</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million, respectively. None of the unrecognized tax benefits as of December&#160;31, 2022, if recognized, would impact the effective tax rate due to the valuation allowance and no interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Beginning balance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,001</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,500</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,400</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additions based on tax positions related to the current year</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,495</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">501</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ending balance</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,496</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,001</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,500</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December&#160;31, 2022, there were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> unrecognized tax benefits that we expect would change significantly over the next 12 months.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after 2018&#160;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2019 tax year and make adjustments to these net operating loss carryforwards.&#160;We are not under audit in any taxing jurisdiction at this time.</span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847350704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases And Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_LeasesAndCommitmentsAbstract', window );"><strong>Leases And Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_LeasesAndCommitmentsDisclosureTextBlock', window );">Leases And Commitments</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">10.  Leases and Commitments</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Right-of-use Asset and Liability</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company had an operating lease for approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> square feet of office space in Austin, Texas expiring </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">April 30, 2024</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company terminated this lease on February 22, 2023 with no continuing obligations. The Company also had a short-term lease agreement for an additional </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,600</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> square feet of office space in Austin, Texas that expired on </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">October 31, 2022</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. Future expected minimum lease payments as of </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 31, 2022 are as follows (in thousands).</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2024</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total future lease payments</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: imputed interest</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating leases</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">107</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">36</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">143</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">139</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Rent expense was $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.1</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million for the years ended December&#160;31, 2022, 2021 and 2020.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> right-of-use assets exchanged for operating lease liabilities during the years ended December&#160;31, 2022 and 2021. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recorded a&#160;right-of-use asset and lease liability&#160;of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">316,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;as a result of the lease&#160;modification in September 2020. The Company utilized a discount rate of&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.25</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%&#160;for the modified lease&#160;to determine the present value of the future lease payments, which&#160;approximated the Company&#8217;s incremental borrowing rate&#160;in September 2020. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash paid for operating lease liabilities totaled $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">155,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">109,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">99,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Other Commitments</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations that are generally cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases And Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847350704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2020 Cash Incentive Bonus Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanAbstract', window );"><strong>2020 Cash Incentive Bonus Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanTextBlock', window );">2020 Cash Incentive Bonus Plan</a></td>
<td class="text"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 11.&#160; 2020 Cash Incentive Bonus Plan</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2020, the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has not occurred&#160;as of December&#160;31, 2022.&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (1) the Company&#8217;s closing price&#160;of one share&#160;on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (2) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;This constitutes a market condition under applicable accounting guidance.&#160; &#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion in market capitalization. The Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">200</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million and&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for no less than 20 consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">58</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;not awarded by the Compensation Committee&#160;are&#160;no longer available for distribution.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the Company were to exceed a $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">139.1</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">322.3</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(1)&#160;the Company completes a Merger Transaction, or&#160;(2)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which may ever occur. Accordingly, there can be no assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2020, the Company&#160;achieved&#160;the first&#160;Valuation&#160;Milestone.&#160;Subsequently, the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.3</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million&#160;in total&#160;for&#160;all Plan participants, subject to future satisfaction of a Performance Condition.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the year ended December&#160;31, 2021, the Company achieved 11 additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">93.7</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million up to a hypothetical maximum of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">225.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million, to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;compensation expense has been recorded&#160;since no&#160;grant date has occurred and no&#160;Performance Conditions are considered probable of being met.&#160;There is no continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award. No Valuation Milestones were achieved during the year ended December 31, 2022.</span></p><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> actual cash payments were authorized or made to participants under the Plan through December&#160;31, 2022.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2020 Cash Incentive Bonus Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Incentive Bonus Plan [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766850091488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">12. Contingencies</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Securities Class Actions and Shareholder Derivative Actions</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Between August 27, 2021 and October 26, 2021, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA, and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On June 30, 2022, a federal judge consolidated the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> class action lawsuits into </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">one</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on August 18, 2022 on behalf of a putative class of purchasers of our securities between September 14, 2020 and July 26, 2022. Briefing on defendants&#8217; motion to dismiss was completed on January 23, 2023.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> The Company believes the claims are without merit and intend to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 4, 2021, a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s board of directors. This complaint relies on allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiff in this derivative case does not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since November 4, 2021, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, and one in Texas state court (Travis County District Court). </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All four actions have</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> been stayed pending the resolution of the motions to dismiss in the securities class actions. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On July 5, 2022, the three federal court actions were consolidated into a single action.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s board of directors. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the 2020 Cash Incentive Bonus Plan in August 2020. The complaints seek unspecified compensatory damages and other relief. On January 6, 2023, the plaintiffs filed an amended complaint. Although the plaintiffs in this derivative case do not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2127163<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2127197<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847396960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use Of Estimates</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and assumptions</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ProceedsFromGrantsPolicyPolicyTextBlock', window );">Proceeds From Grants</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Proceeds from Grants</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2022, 2021, and 2020, the Company received $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.9</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.9</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.2</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of reimbursement from the National Institutes of Health and National Institute on Drug Abuse, respectively. The Company records the proceeds from these grants as reductions to its research and development expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash And Cash Equivalents And Concentration Of Credit Risk</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cash and Cash Equivalents and Concentration of Credit Risk</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at one financial institution.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value Measurements </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 1 includes quoted prices in active markets.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 2 includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does not have any financial instruments where the fair value is based on Level 2 inputs.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">financial instruments</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> where the fair value is based on Level 3 inputs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 inputs at December&#160;31, 2022 and 2021.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Business Segments</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Business Segments</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">one</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> business segment: the development of novel drugs and diagnostics.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(&#8220;Black-Scholes&#8221;) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each </span><span id="_cp_text_1_372" style="text-decoration: none;"/><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For all options granted, it</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has granted share-based awards that vest upon achievement of certain performance criteria</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (&#8220;Performance Awards&#8221;)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Net Loss per Share</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company computes </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options and warrants. There is no difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Numerator:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">76,246</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">32,385</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,334</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Denominator:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares used in computing net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">40,202</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,405</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26,105</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.90</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.82</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.24</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Dilutive common stock options excluded from net loss per share, diluted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,055</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,211</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,145</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock warrants excluded from net loss per share, diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">554</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company excluded common stock options and warrants outstanding , along with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">57,143</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted stock awards, from the calculation of net loss per share, diluted, because the effect of including outstanding options and warrants would have been anti-dilutive. The </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">57,143</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted stock awards expired during the year ended December 31, 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Of Financial Instruments</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value of Financial Instruments</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments may be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock', window );">Research Contract Costs And Accruals</a></td>
<td class="text"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Research Contracts, Prepaids and Accruals</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have not been materially different from actual costs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Incentive Bonus Plan</a></td>
<td class="text"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Incentive Bonus Plan</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants.  Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718 &#8220;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met.  See Note 11 for further discussion of the Plan.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Leases</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;consolidated balance sheets.&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize right-of-use assets or lease liabilities</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#160;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property And Equipment</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Property and equipment</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years and approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Intangible assets</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which approximates </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.3</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years at December 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Income Taxes</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for uncertain tax positions in accordance with ASC 740, &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ProceedsFromGrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Grants Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ProceedsFromGrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Contract Costs And Accruals Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766850088704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Numerator:</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">76,246</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">32,385</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,334</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Denominator:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares used in computing net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">40,202</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,405</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26,105</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.90</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.82</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.24</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Dilutive common stock options excluded from net loss per share, diluted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,055</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,211</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,145</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock warrants excluded from net loss per share, diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> -</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">554</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766853676336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid And Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule Of Prepaid And Other Assets</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid insurance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">874</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">662</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contract research organization and other deposits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,177</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,330</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">160</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">53</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total prepaid expenses and other current assets</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,211</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11,045</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766848864432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Real Property Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Real Property Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary Of Acquisition</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.07in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.06in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Land</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,734</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Buildings</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,980</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Site improvements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">453</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tenant improvements</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">567</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total tangible assets</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20,734</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.16in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease-in-place agreements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,053</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasing commissions and other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">246</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,299</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Consideration paid</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22,033</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.06in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Components Of Other Income, Net</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,459</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">911</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property operating expenses</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,462</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">477</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Other income, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">997</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">434</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766853548848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components Of Property And Equipment, Net</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.06in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Land</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,734</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,734</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Buildings</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,980</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,980</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Site improvements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">470</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">470</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tenant improvements</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,016</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">567</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">851</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">178</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Construction in progress</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">83</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross property and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,064</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21,012</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated depreciation</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,200</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">396</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Property and equipment, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22,864</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20,616</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.05in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766848888576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Components Of Intangible Assets, Net</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.07in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span></p></td></tr><tr style="height: 0.20in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease-in-place agreements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,053</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,053</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasing commissions and other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">290</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">246</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,343</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,299</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated amortization</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">721</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">224</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Intangible assets, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">622</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,075</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Amortization Expense For Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.15in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.19in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">For the year ending December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">451</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">167</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total amortization</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">622</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766843118096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders&#8217; Equity And Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Exercise Price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted Average Remaining Contractual Term in Years</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Aggregate Intrinsic Value in Millions</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,663,727</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11.56</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">104,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">36.50</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">203,640</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15.56</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options forfeited/canceled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34,639</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.59</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,529,448</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.13</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.94</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49.6</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested and expected to vest at December 31, 2022</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,529,448</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.13</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.94</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">49.6</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exercisable at December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,270,464</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.02</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.43</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">46.9</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Information About Stock Options Outstanding</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="6" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options outstanding</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Options exercisable</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Weighted</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">remaining</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">average</span></p></td></tr><tr><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Range of exercise prices</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">outstanding</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">contractual</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">exercise</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> vested</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">exercise</span></p></td></tr><tr><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">From</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">To</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">life (in years)</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">price</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">price</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.95</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.88</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">585,833</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5.6</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.51</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">505,833</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.46</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.24</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.24</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">550,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.0</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.24</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">550,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.24</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.09</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.04</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">536,951</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.09</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">512,888</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.07</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.39</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">35.00</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">655,874</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.6</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.82</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">653,290</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.79</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">36.40</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">77.00</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">200,790</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8.8</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">52.64</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">48,453</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">62.61</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,529,448</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.9</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.13</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,270,464</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10.02</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Weighted Average Fair Value Of Options Granted</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Volatility</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">151</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">154</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">147</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">151</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">123</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">139</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Risk-free interest rates</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.98</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.69</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.12</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.42</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.46</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.78</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Expected life of option</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.0</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Dividend yield</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Forfeiture rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">zero</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Weighted average fair value of stock options granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">35.16</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">65.83</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.69</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Summary Of Performance Award Activity</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Number of Performance Awards</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">138,055</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0a18ef04-da81-4da9-b08e-4f541d5d87fe;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Vested</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a9cc683b-ce22-4d24-8a07-e6387b6743b3;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Forfeited/canceled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">130,913</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,142</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #FF0000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,631</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,302</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">453</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">435</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">457</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">535</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,066</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,759</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">988</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766843237696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule Of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="7" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Year ended December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tax at federal statutory rate</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.0</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.0</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.0</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">State tax, net of federal benefit</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-2bbe3c9f-b94d-448f-b6dc-323b380f9a96;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-372e6af5-4c00-48eb-bae0-4471ae3a22e5;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Share-based compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.2</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">42.8</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development credits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.9</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.3</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.6</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Section 162(m) limitation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.2</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c5477bfe-2785-4f75-a69d-a809395650e8;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.8</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.2</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-6454e79f-5eac-4ce6-b83d-d54ce1ad34ec;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Change in valuation allowance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23.4</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23.8</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.2</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Effective income tax rate</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eedb89d9-ad7e-4f41-a736-d7fd924e0c16;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eb885844-bf4c-4fb5-ba17-aadb840ba669;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule Of Deferred Tax Assets And Valuation Allowance</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, </span></p></td></tr><tr style="height: 0.17in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net operating loss carryforwards</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">28,017</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,777</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Share-based compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,706</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,870</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development credit carryforwards</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,681</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,439</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Capitalized research and development expenses</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12,690</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-de6cc757-c8de-42c3-99b4-15243e637ef0;">&#8212;</span></span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">934</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,130</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">54,028</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">36,216</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Valuation allowance</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">54,002</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">36,166</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net deferred tax assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Deferred tax liabilities:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use assets</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total deferred tax liabilities</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">26</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">50</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net deferred tax asset (liability)</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-1da80672-2d90-4cfe-a52c-83cd81fc610f;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c36d2911-beed-46e5-a06d-8fb8d4dd3d41;">&#8212;</span></span></p></td></tr><tr style="height: 0.07in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule Of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Year ended December 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2021</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2020</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Beginning balance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,001</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,500</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,400</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additions based on tax positions related to the current year</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,495</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">501</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Ending balance</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,496</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,001</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,500</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766849690272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases And Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_LeasesAndCommitmentsAbstract', window );"><strong>Leases And Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2024</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total future lease payments</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: imputed interest</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating leases</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">107</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">36</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">143</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">139</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases And Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766848963408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General, Liquidity and Basis of Presentation (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General, Liquidity And Basis Of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 283,552<span></span>
</td>
<td class="nump">$ 207,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766845442784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ReductionToResearchAndDevelopmentExpense', window );">Reimbursement from National Institutes of Health research grants | $</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Lease-In-Place Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, Estimated useful lives</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, Estimated useful lives</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Site Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Tenant Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, Estimated useful lives</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock excluded from net loss per share, diluted</a></td>
<td class="nump">57,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares expired</a></td>
<td class="nump">57,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ReductionToResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction To Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ReductionToResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847442608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (76,246)<span></span>
</td>
<td class="num">$ (32,385)<span></span>
</td>
<td class="num">$ (6,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted', window );">Shares used in computing net loss per share, basic and diluted</a></td>
<td class="nump">40,202<span></span>
</td>
<td class="nump">39,405<span></span>
</td>
<td class="nump">26,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_NetLossPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (1.90)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock excluded from net loss per share, diluted</a></td>
<td class="nump">2,055<span></span>
</td>
<td class="nump">2,211<span></span>
</td>
<td class="nump">2,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock excluded from net loss per share, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_NetLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Loss Per Share Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_NetLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares used in computing net loss per share, basic and diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847223840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 874<span></span>
</td>
<td class="nump">$ 662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsAssets', window );">Contract research organization and other deposits</a></td>
<td class="nump">9,177<span></span>
</td>
<td class="nump">10,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 10,211<span></span>
</td>
<td class="nump">$ 11,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99397363&amp;loc=d3e9420-108338<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99383045&amp;loc=d3e9351-108337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847316624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Real Property Acquisition (Narrative) (Details) - Austin, Texas [Member]<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 04, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price | $</a></td>
<td class="nump">$ 22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageOfOccupancy', window );">Percentage Of Occupancy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageOfCurrentlyLeased', window );">Percentage Of Currently Leased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued property taxes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433,000<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfCurrentlyLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Currently Leased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfCurrentlyLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfOccupancy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Occupancy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfOccupancy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6419918&amp;loc=d3e35281-107843<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sava_AustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sava_AustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766845580176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Real Property Acquisition (Summary Of Acquisition) (Details) - Austin, Texas [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 04, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Total tangible assets</a></td>
<td class="nump">$ 20,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total intangible assets</a></td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Consideration paid</a></td>
<td class="nump">22,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Total tangible assets</a></td>
<td class="nump">3,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Total tangible assets</a></td>
<td class="nump">15,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Site Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Total tangible assets</a></td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Tenant Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Total tangible assets</a></td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Lease-In-Place Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total intangible assets</a></td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember', window );">Leasing Commissions And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total intangible assets</a></td>
<td class="nump">$ 246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sava_AustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sava_AustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766852464640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Real Property Acquisition (Components Of Other Income, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member] | Austin, Texas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Lease revenue</a></td>
<td class="nump">2,459<span></span>
</td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Property operating expenses</a></td>
<td class="num">(1,462)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sava_AustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sava_AustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847571968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 804,000<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">24,064,000<span></span>
</td>
<td class="nump">21,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing Equipment [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766852536944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property And Equipment (Components Of Property And Equipment, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 24,064<span></span>
</td>
<td class="nump">$ 21,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="num">(396)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">22,864<span></span>
</td>
<td class="nump">20,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,734<span></span>
</td>
<td class="nump">3,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">15,980<span></span>
</td>
<td class="nump">15,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Site Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Tenant Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,016<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture And Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction In Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847404064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">$ 497,000<span></span>
</td>
<td class="nump">$ 224,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766852486368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Components Of Intangible Assets, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 1,343<span></span>
</td>
<td class="nump">$ 1,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(721)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Lease-In-Place Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember', window );">Leasing Commissions And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847334032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 1,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766843091008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Nov. 13, 2020</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,329,000<span></span>
</td>
<td class="nump">$ 189,825,000<span></span>
</td>
<td class="nump">$ 70,251,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692,000<span></span>
</td>
<td class="nump">$ 4,940,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod', window );">Compensation costs prior to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm', window );">Weighted average remaining recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Offering of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember', window );">ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageOfCommissionAtmOffering', window );">Percentage of commission in ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember', window );">ATM [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_TwoThousandEightEquityIncentivePlanMember', window );">2008 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Expiration period of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Offering of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Expiration of restricted stock Performance Awards,shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting', window );">Additional stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Performance awards expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice', window );">Stock options exercised, net settled in satisfaction of the exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Registered Direct Offering 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offering</a></td>
<td class="nump">$ 47,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 2021 Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,081,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember', window );">Common Stock Warrants [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfCommissionAtmOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Commission ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfCommissionAtmOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Additional Expense Expected On Vesting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grant in period weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options nonvested forfeitures in period weighted average contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options Exercised Net Settled Satisfaction Of Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_TwoThousandEightEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_TwoThousandEightEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_RegisteredDirectOffering2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_RegisteredDirectOffering2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_RegisteredDirectOffering2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_RegisteredDirectOffering2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847588656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders&#8217; Equity And Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of, Beginning | shares</a></td>
<td class="nump">2,663,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted | shares</a></td>
<td class="nump">104,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised | shares</a></td>
<td class="num">(203,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited/canceled | shares</a></td>
<td class="num">(34,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of, Ending | shares</a></td>
<td class="nump">2,529,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at December 31, 2022 | shares</a></td>
<td class="nump">2,529,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2022 | shares</a></td>
<td class="nump">2,270,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding as of, Beginning | $ / shares</a></td>
<td class="nump">$ 11.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options granted | $ / shares</a></td>
<td class="nump">36.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercised | $ / shares</a></td>
<td class="nump">15.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options forfeited/cancelled | $ / shares</a></td>
<td class="nump">20.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding as of, Ending | $ / shares</a></td>
<td class="nump">12.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest at December 31, 2022 | $ / shares</a></td>
<td class="nump">12.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2022 | $ / shares</a></td>
<td class="nump">$ 10.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest at December 31, 2022</a></td>
<td class="text">3 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2022</a></td>
<td class="text">3 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 49.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2022 | $</a></td>
<td class="nump">49.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2022 | $</a></td>
<td class="nump">$ 46.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766852361456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">2,529,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 12.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">2,270,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 10.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember', window );">$0.95 - $1.88 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Minimum</a></td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Maximum</a></td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">585,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 1.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">505,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember', window );">$3.24 - $3.24 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Minimum</a></td>
<td class="nump">3.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Maximum</a></td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember', window );">$4.09 - $12.04 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Minimum</a></td>
<td class="nump">4.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Maximum</a></td>
<td class="nump">$ 12.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">536,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 7.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">512,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 7.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember', window );">$12.39 - $35.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Minimum</a></td>
<td class="nump">12.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Maximum</a></td>
<td class="nump">$ 35.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">655,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 20.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">653,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 20.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember', window );">$36.40 - $77.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Minimum</a></td>
<td class="nump">36.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Maximum</a></td>
<td class="nump">$ 77.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding options, Options outstanding | shares</a></td>
<td class="nump">200,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Options outstanding</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, Options outstanding</a></td>
<td class="nump">$ 52.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of vested options, Options exercisable | shares</a></td>
<td class="nump">48,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 62.61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766845537120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders&#8217; Equity And Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, Minimum</a></td>
<td class="nump">151.00%<span></span>
</td>
<td class="nump">147.00%<span></span>
</td>
<td class="nump">123.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, Maximum</a></td>
<td class="nump">154.00%<span></span>
</td>
<td class="nump">151.00%<span></span>
</td>
<td class="nump">139.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rates, Minimum</a></td>
<td class="nump">1.98%<span></span>
</td>
<td class="nump">1.12%<span></span>
</td>
<td class="nump">0.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rates, Maximum</a></td>
<td class="nump">3.69%<span></span>
</td>
<td class="nump">1.42%<span></span>
</td>
<td class="nump">0.78%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted</a></td>
<td class="nump">$ 35.16<span></span>
</td>
<td class="nump">$ 65.83<span></span>
</td>
<td class="nump">$ 6.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766852421920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details) - Performance Award [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of, Beginning</a></td>
<td class="nump">138,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/canceled</a></td>
<td class="num">(130,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of, Ending</a></td>
<td class="nump">7,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766845414208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation (Stock-Based Compensation Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,066<span></span>
</td>
<td class="nump">$ 1,759<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,631<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 435<span></span>
</td>
<td class="nump">$ 457<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766846901856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S federal corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">$ 17,800,000<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">6,496,000<span></span>
</td>
<td class="nump">$ 5,001,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months', window );">Unrecognized tax benefits no significant change over next 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">133,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Expires Between 2029 And 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">74,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Indefinitely [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">43,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Expires Between 2024 And 2042 [Member] | Research And Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Minimum [Member] | Expires Between 2029 And 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Expiration date of pre-tax net operating loss carryforwards</a></td>
<td class="text">Jan.  01,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Minimum [Member] | Expires Between 2024 And 2042 [Member] | Research And Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Expiration date of federal research and development tax credits</a></td>
<td class="text">Jan.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Maximum [Member] | Expires Between 2029 And 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Expiration date of pre-tax net operating loss carryforwards</a></td>
<td class="text">Dec. 31,  2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Maximum [Member] | Expires Between 2024 And 2042 [Member] | Research And Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Expiration date of federal research and development tax credits</a></td>
<td class="text">Dec. 31,  2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits no significant change over the next 12 months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_ExpirationOperatingLossCarryforwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_ExpirationOperatingLossCarryforwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_IndefinitelyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_IndefinitelyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_ExpirationResearchAndDevelopmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_ExpirationResearchAndDevelopmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766845415424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="num">(42.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Section 162(m) limitation</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.40%)<span></span>
</td>
<td class="num">(23.80%)<span></span>
</td>
<td class="nump">20.20%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766852829536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 28,017<span></span>
</td>
<td class="nump">$ 24,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">2,706<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">9,681<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses', window );">Capitalized research and development expenses</a></td>
<td class="nump">12,690<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">1,130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">54,028<span></span>
</td>
<td class="nump">36,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(54,002)<span></span>
</td>
<td class="num">(36,166)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax asset (liability)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized Research and Development Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766849948528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 5,001<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">1,495<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 6,496<span></span>
</td>
<td class="nump">$ 5,001<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766845944432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases And Commitments (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_LeasesAndCommitmentsLineItems', window );"><strong>Leases And Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">122,000<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Leases, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets exchange for operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sava_AustinMember', window );">Austin, Texas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_LeasesAndCommitmentsLineItems', window );"><strong>Leases And Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Office space | ft&#178;</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Apr. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sava_AustinMember', window );">Austin, Texas [Member] | Short-Term Operating Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_LeasesAndCommitmentsLineItems', window );"><strong>Leases And Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Office space | ft&#178;</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Oct. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases And Commitments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sava_AustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sava_AustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=sava_ShortTermOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=sava_ShortTermOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766847586448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases And Commitments (Future Minimum Lease Payments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>For the year ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766846935024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2020 Cash Incentive Bonus Plan (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 13, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember', window );">Exceeding Performance Milestones Minimum 20 Consecutive Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationAmount', window );">Valuation milestone amount in market capitalization</a></td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Cash Incentive Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment', window );">Percentage of each cash bonus award associated with Valuation Milestone subject to adjustment and approval</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PaymentsForCashIncentiveBonus', window );">Payments authorized or made to participants under the Plan</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Cash Incentive Bonus Plan [Member] | First Valuation Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Cash Incentive Bonus Plan [Member] | Second Through Eighth Valuation Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Cash Incentive Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationAmount', window );">Valuation milestone amount in market capitalization</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Cash Incentive Bonus Plan [Member] | Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="nump">139.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Cash Incentive Bonus Plan [Member] | Second Through Eighth Valuation Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Cash Incentive Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationAmount', window );">Valuation milestone amount in market capitalization</a></td>
<td class="nump">5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Cash Incentive Bonus Plan [Member] | Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="nump">$ 322.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Cash Incentive Bonus Plan [Member] | Second Through Eighth Valuation Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Incentive Bonus Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Incentive Bonus Plan [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PaymentsForCashIncentiveBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Cash Incentive Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PaymentsForCashIncentiveBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanValuationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance Plan Valuation Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanValuationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_FirstValuationMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_FirstValuationMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_SecondThroughEighthValuationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_SecondThroughEighthValuationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_Exceeds5BillionMarketCapitalizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_Exceeds5BillionMarketCapitalizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139766852289168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Narrative) (Details) - item<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 04, 2021</div></th>
<th class="th"><div>Oct. 26, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember', window );">Violations of the federal securities laws [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Putative class action lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_NumberOfClassActionsConvertedToCase', window );">Number of class actions converted to case</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember', window );">Shareholder derivative actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Putative class action lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_NumberOfClassActionsConvertedToCase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of class actions converted to case</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_NumberOfClassActionsConvertedToCase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>sava-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sava="http://www.cassavasciences.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sava-20221231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationResearchAndDevelopmentTaxCreditsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationResearchAndDevelopmentTaxCreditsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationResearchAndDevelopmentTaxCreditsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEightEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="As_Of_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="As_Of_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:PublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-13</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2018_To_8_31_2018_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2020_To_3_27_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="Duration_2_12_2021_To_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="Duration_11_13_2020_To_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:PublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-13</startDate>
            <endDate>2020-11-13</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationOperatingLossCarryforwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationOperatingLossCarryforwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_IndefinitelyMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:IndefinitelyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExpirationOperatingLossCarryforwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_ShortTermOperatingLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:ShortTermOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_4_2021_To_11_4_2021_srt_LitigationCaseAxis_sava_ShareholderDerivativeActionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="Duration_8_27_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-27</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_ShortTermOperatingLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:ShortTermOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="Duration_8_4_2021_To_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_27_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2022_To_6_30_2022_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:Exceeds5BillionMarketCapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:Exceeds5BillionMarketCapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_13_2020_srt_StatementScenarioAxis_sava_FirstValuationMilestoneMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:FirstValuationMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-13</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_23_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit17">
        <measure>sava:segment</measure>
    </unit>
    <unit id="Unit16">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit15">
        <measure>pure</measure>
    </unit>
    <unit id="Unit14">
        <measure>sava:item</measure>
    </unit>
    <unit id="Unit13">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit12">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit1">
        <measure>shares</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-0e304a11-bbcc-4ad5-b368-a6d07b61420a">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-c0ad6956-b080-4e1f-9d5c-c9773583c40c">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-32324d6b-f2e3-4a0f-9ae2-4e97aa53f39e">0001069530</dei:EntityCentralIndexKey>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-17afd52e-4a19-4dbd-b019-91148f64b848">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-5dd58f08-72e3-49a8-bbc9-2abf4a5c73a8">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-0fd78f32-8b4b-4615-82ac-704df8a8ec92">No</dei:EntityVoluntaryFilers>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-426b8df1-d620-47b0-b66f-3739456c5617">Yes</dei:EntityWellKnownSeasonedIssuer>
    <sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2021"
      id="ct-nonFraction-de6cc757-c8de-42c3-99b4-15243e637ef0"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-df8c0a4a-fcf8-445d-a1bd-210c9fac8742"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-d8c20985-8ceb-42dd-996f-4a0a47c0e08e"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-7580528a-87fd-452f-94c7-806f4337e589"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-a109bcc7-7b2b-4ca9-b816-fa1fa8e5a4b9"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-afdfdc90-7985-4059-ac0e-4428e6895644"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-5bcdce4c-9682-486d-b80b-c542fbc7e4b0"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-9273aa42-9a73-4159-90cd-fce2d9937049"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-c9a5eb2b-dc7d-4861-bb84-a923cff12f6a"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-8d886509-becc-4809-98f7-33fa6d1e2229"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-c6fa6d0d-7a6f-4f1a-86b9-487d2fc5526e"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-d3752495-f9b1-4d21-9b8b-e7a3f1bfd9f6"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-ec90904b-e73c-4265-b905-29b18c11c1e7"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021"
      id="ct-nonFraction-2482011d-65b9-477a-825f-eea0d38abc1d"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022"
      id="ct-nonFraction-c85d098c-43ef-4402-ad21-3eab6b4c27b8"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2021"
      id="ct-nonFraction-c36d2911-beed-46e5-a06d-8fb8d4dd3d41"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022"
      id="ct-nonFraction-1da80672-2d90-4cfe-a52c-83cd81fc610f"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020"
      id="ct-nonFraction-eb885844-bf4c-4fb5-ba17-aadb840ba669"
      unitRef="Unit15"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonFraction-eedb89d9-ad7e-4f41-a736-d7fd924e0c16"
      unitRef="Unit15"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="Duration_1_1_2020_To_12_31_2020"
      id="ct-nonFraction-c5477bfe-2785-4f75-a69d-a809395650e8"
      unitRef="Unit15"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2020_To_12_31_2020"
      id="ct-nonFraction-6454e79f-5eac-4ce6-b83d-d54ce1ad34ec"
      unitRef="Unit15"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020"
      id="ct-nonFraction-372e6af5-4c00-48eb-bae0-4471ae3a22e5"
      unitRef="Unit15"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonFraction-2bbe3c9f-b94d-448f-b6dc-323b380f9a96"
      unitRef="Unit15"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-f679e88d-5156-4cf8-ac0b-88135755453e"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      id="ct-nonFraction-4e0ecb2c-bd96-4ebb-bced-daa182b0ed24"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-edb04fec-6821-4e71-b08a-24673be2beb4"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-d4c3c33b-3414-43d4-982a-455cfcd1d850"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-5793b5c3-1cbb-486a-b34d-eb398efe6a99"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      id="ct-nonFraction-0e0796a2-6853-4ce7-b9dd-66419cd567a2"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-0db0de42-f4bd-4029-b4ac-4141a7fa729c"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-60c0c054-0845-4646-97f5-4ee1a9062712"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-6a872f17-c446-49cb-b5c0-521df86f5620"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      id="ct-nonFraction-d329d997-53ed-4249-8a3e-3c0e4ed13b4e"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-5ec1ab38-faae-43c7-9586-d76cf41a362f"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-96f181e2-9fe8-4966-8d28-9554ea90c3ec"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      id="ct-nonNumeric-c9c2841b-7ede-4662-83a9-7a4f7dcefb27">2037-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      id="ct-nonNumeric-ab3e4de0-d223-4a28-a263-17c41929c12c">2029-01-01</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021"
      id="ct-nonFraction-59321846-f327-4f04-bbc4-4fc6ff45a6d5"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022"
      id="ct-nonFraction-2be3e229-c641-48c7-81d3-b5714626c15b"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="ct-nonFraction-0a18ef04-da81-4da9-b08e-4f541d5d87fe"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="ct-nonFraction-a9cc683b-ce22-4d24-8a07-e6387b6743b3"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="ct-nonNumeric-11a67b5d-6030-4b4a-89e9-be45bb42951d">2026-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-f72a1e5d-aec7-4a71-a833-c2f28f7c3aa7"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-b3474d5b-40e6-4751-af80-757d598097ba"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-b9904651-ff3f-47a5-b170-f86d82d7e2fc"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-eff39773-9f57-43b6-b38b-6e48c8992dac"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-127faa7e-439c-4f35-a3cb-ac23fc2037ad"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-68a04647-00b0-4839-9b0a-b55ed1d8a1f4"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-d6b508b8-e5f6-4fe3-bc4b-333dafca92c3"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-8f3d3aee-e688-4a58-8c82-2dcaecba5338"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-42361762-5433-4b01-ab66-912546a855b8"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-f94615b8-ca86-4b50-bf26-783b381cf0ce"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-54c7ab99-4813-4b1d-b474-b37c9a524dcc"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-710cf88c-85ca-4d71-9477-12fb47d6f033"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-066675fe-3f2a-440e-946b-8efc90ddb585"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-81530414-bf2f-4aaa-b26e-077e1df6e132"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-23845146-836d-4a7b-8df9-875e29e06cb0"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-aea819c2-5b65-4213-bc0e-bb07a6069a77"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-f8301e49-4c2c-48ac-8f2f-9428fb07e149"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-ed009123-4af1-44d6-8158-b2dbd107c848"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-474b8871-4327-4d19-9f77-fb3abc9b7840"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-6d603b54-7185-48ca-b5ed-9fc404d6c467"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-8a742db3-f945-4ab7-8e73-11b06c08c252"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-1dafedde-6946-46d3-ac0a-4c7e0c43d181"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-973e7776-7e8a-4f63-b1e9-ffd2515ee290"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-73e54030-2cd6-4c79-a8e1-8c37360ff959"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-0987ba20-66f7-4bf9-b131-7ab51e4f204f"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-9588f41e-4c12-4cd8-a47f-0b8a2f1e1a6c"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-11ab857d-4a58-4fa0-adba-79c7330d2414"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      id="ct-nonFraction-27e5a001-2996-4703-ae33-f911acb2c051"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-3c6cc885-b3d3-4198-9eb0-166e06c19899"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-76ef54f7-3e1c-4b2f-a533-2721893b12a5"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-864a6697-b067-4537-bbe4-cc70a3df80eb"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-955b4d43-5e21-4308-8bea-88e35c283798"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-ab248c3f-9fd0-4817-9180-ea9ab4b4557d"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-919cbe35-3e67-4ee3-829c-05770b6d8549"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-9267357c-efdf-4dea-8df4-bf960417e97f"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-0d5dde46-8f93-44ec-a3a8-40b8d2a7bf84"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="ct-nonFraction-f2dbc5ec-044c-49d1-9f0d-50a8037a6db2"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      id="ct-nonFraction-0f5134fe-cbd1-471e-8931-4e1628ea7e4e"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      id="ct-nonFraction-645041b0-469c-42d6-b90e-61c9bd3dbb17"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"
      id="ct-nonNumeric-16a796f0-25d3-4e27-b50c-84d331cdfb35">2042-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"
      id="ct-nonNumeric-8869304f-1756-4722-a383-48272eaadb6a">2024-01-01</us-gaap:TaxCreditCarryforwardExpirationDate>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-0c5fe495-2496-42af-a3a8-aa9104feb034">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-1a6aa34c-b496-481d-8ded-cc678eea403b">true</dei:DocumentAnnualReport>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-11df01cd-472c-4bdf-8d62-6875a3c467db">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-83eb4d07-bd42-4a9f-92af-9bae4db4057a">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-e5ed7c20-7435-447d-a003-d3248845a5c1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-7610ff56-b855-484d-a2d0-e9a8b1563732">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-f451a28e-5ae5-4139-9ff5-d4c6ccf0f119">000-29959</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-713f19e3-653e-4f20-bf35-8f93c871dcba">Cassava Sciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-1e58b247-270f-4102-a985-6f0110555f96">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-47ad67a3-798d-471f-8fdd-77d8fc3c6639">91-1911336</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-9afa33d4-2c80-48a4-9bc5-3814c8fc0700">6801 N. Capital of Texas Highway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-5ef44b32-b157-434e-a129-9ba788df5752">Building 1; Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-3de8d719-5ca0-4ce4-8a76-37b2837c4bea">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-a31b818f-14c7-4336-b30b-96aac7f8a28c">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-19d24242-1053-4897-a2d6-2eb5b812d0c2">78731</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-abf9d838-2e9a-431c-a686-a13a28e78bfb">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-f81255ca-4ea0-4435-b762-bf0d79580dcb">501-2444</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-a4291b4f-63e7-4a36-b48e-2f5bbddef721">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-d4e6f5b4-a8dc-4b66-880a-858541a9f5f6">SAVA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-604e7b84-6500-423c-8c43-f00ec82fdb05">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-d33fbec7-a83f-4500-be76-207de00ab116">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-68a2f873-3736-42c3-87e5-7cf59c678ad2">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-2ec7c5b4-2e3c-4060-9167-a1bc6640f65f">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-bc3fdf7e-e4a1-4025-b981-98a4bd4fe60d">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-958f990e-4a37-420e-945d-2572f1f90a3e">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022"
      decimals="-8"
      id="ct-nonFraction-70e38567-b98d-4817-877b-1ec9fe389f96"
      unitRef="Unit12">1100000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_23_2023"
      decimals="INF"
      id="ct-nonFraction-16a4e665-6dc1-4f8e-9a09-676e06da9a0c"
      unitRef="Unit1">41735557</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-d05d6a2c-57d9-40e6-93f0-17c7e37ab55e">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Portions of the Registrant's proxy statement for its 2023 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x201d;), to be filed with the U.S. Securities and Exchange Commission, no later than 120 days after the Registrant&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x2019;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;s fiscal year ended December 31, 2022, are incorporated by reference to Part III of this Annual Report on Form 10-K.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-dd3e3ef8-66c0-4881-b751-1e58a81b8c32">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-1ea9acc9-5848-43a8-aefc-7f709fb14d7d">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-09c25620-29bd-4b74-91b7-845d44be1737">Austin, Texas</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-81476662-9405-416e-9311-977caca6c97b"
      unitRef="Unit12">201015000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b54c9479-bb75-454d-850f-da8866b1ed2c"
      unitRef="Unit12">233437000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-49ae83e7-6c53-4c10-90d1-4257c974fafd"
      unitRef="Unit12">10211000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-cc932389-46aa-45b1-b265-dc72af95472d"
      unitRef="Unit12">11045000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-854b19af-ac93-4cfc-a833-14f348a98919"
      unitRef="Unit12">211226000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-8b18780a-a908-4e2a-9909-f932a87ec4e9"
      unitRef="Unit12">244482000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-baec01e8-a159-4e4e-ba7f-bb6a16e703c8"
      unitRef="Unit12">122000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-11c36bab-e436-4f25-938c-1d707fd0c3b6"
      unitRef="Unit12">210000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-1e7be90f-33c7-4959-8b02-5bcbca03de38"
      unitRef="Unit12">22864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-5aee8551-74d5-40c7-abbd-58b4c5ab35a2"
      unitRef="Unit12">20616000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-5557985a-8029-4409-90b0-fe4a2b703c58"
      unitRef="Unit12">622000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-bad59371-a202-4637-8076-2d3ec212f30f"
      unitRef="Unit12">1075000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c5ee752e-4f5b-4b58-b3e8-37616594d952"
      unitRef="Unit12">399000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-00091c28-aff0-4b26-91fe-3bf0a0fcbb35"
      unitRef="Unit12">234834000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-b91e792a-7f21-4e42-b7ec-0811efdfc93a"
      unitRef="Unit12">266782000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-58efd822-46ba-40db-a454-344857888008"
      unitRef="Unit12">4017000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-75ff5715-25ae-40dc-981e-3f58f29527cd"
      unitRef="Unit12">7126000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-882a1274-3736-4f16-98e0-caf7297fd819"
      unitRef="Unit12">2280000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-e05693fb-446a-4cb4-ad34-af74d826a44e"
      unitRef="Unit12">2803000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-541b498b-2f32-4a12-bb9a-1cc56349015f"
      unitRef="Unit12">170000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-fb317e33-201c-4ef6-abd7-1838440cc51c"
      unitRef="Unit12">1877000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-6746de89-dc94-40cc-ae06-a7e6b10e062e"
      unitRef="Unit12">104000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-dd466847-0580-4e98-a804-c6b80ce13cfb"
      unitRef="Unit12">97000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a4dfacf4-d89c-4875-880d-e3362f9b0f2c"
      unitRef="Unit12">492000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-188fb8d5-d0ae-4448-87db-d0a06a8ecf9c"
      unitRef="Unit12">631000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-107eb91b-1fd0-49e6-857e-e288feaa6de7"
      unitRef="Unit12">7063000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c8cd4fff-185c-4b10-bcbc-10e4691e8f30"
      unitRef="Unit12">12534000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-035e1b2f-eaca-4b0a-86a8-fb2e5f646caa"
      unitRef="Unit12">35000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-91434a00-e271-4172-88b6-1beb0ced2d04"
      unitRef="Unit12">139000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a2132bd6-7203-46da-89a0-6c3af3ac61c3"
      unitRef="Unit12">197000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c1fb24c8-efba-4de5-9561-117c3ad78e58"
      unitRef="Unit12">194000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-8b756573-450e-46fe-afa4-4e2be516e4e4"
      unitRef="Unit12">7295000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0f328b47-b630-4625-a888-ac77b7246576"
      unitRef="Unit12">12867000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021"
      decimals="3"
      id="ct-nonFraction-c2caca6a-b3d1-4ab0-a373-f7208602487d"
      unitRef="Unit13">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022"
      decimals="3"
      id="ct-nonFraction-5d1aa434-57f3-427b-8fd6-e0e3beb04a89"
      unitRef="Unit13">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-1839e692-c74c-4b1d-b22d-59f14d003087"
      unitRef="Unit1">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-d4447d5b-712b-45af-aa07-ce03308d6f5f"
      unitRef="Unit1">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-37fdca10-68ba-442e-a07e-79e7bac33417"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-b193d2a3-9ad2-4727-bf61-5dc52069ef0a"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-6aaddbcc-ea24-4c63-ac28-966dba2523e2"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-0b33955e-dcf0-4f31-af0b-f1f3ecbdfa2d"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021"
      decimals="3"
      id="ct-nonFraction-9ca2019c-184e-42e9-bc97-89e700d739ab"
      unitRef="Unit13">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022"
      decimals="3"
      id="ct-nonFraction-81cd21e4-57c5-4e73-bc30-1a9a5d46e616"
      unitRef="Unit13">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-5401e40a-4bc5-4956-bf54-a79b8dfbd9fd"
      unitRef="Unit1">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-6ff34702-9fe9-439b-b614-61c29dded341"
      unitRef="Unit1">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-930f2b18-9c78-4b53-af8d-78f585c8bda9"
      unitRef="Unit1">41735557</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-01db6178-39ec-4617-94a1-4a12fc20072c"
      unitRef="Unit1">41735557</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-4b612c29-822d-4ef9-bf03-a7219849db33"
      unitRef="Unit1">40016792</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-fe138c09-553b-4a28-a489-14b18cdfb0aa"
      unitRef="Unit1">40016792</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-01bdda67-0f4e-4501-b0de-9fde0a852e20"
      unitRef="Unit12">42000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-076e0cb6-e510-4ef3-bd32-5437192ea3fe"
      unitRef="Unit12">40000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-74d4a0c1-a267-4e7a-8396-4c6e0508b1bd"
      unitRef="Unit12">511049000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-3d7c4d33-37d5-482a-9521-46a4543ce1b4"
      unitRef="Unit12">461181000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-98c00456-cd2e-41fa-a6c7-8edfaea41b5f"
      unitRef="Unit12">-283552000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-484a3fc2-7590-45d6-a481-65052c31c200"
      unitRef="Unit12">-207306000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-dc6f55d7-c697-41cc-be92-cf760e1aa0f3"
      unitRef="Unit12">227539000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-eddcf17b-521b-41c0-a284-8161e4a70989"
      unitRef="Unit12">253915000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-937c1f23-c787-4f52-aa2b-ada70f86bbca"
      unitRef="Unit12">234834000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-9e9be844-5e80-4168-8623-b34256d1c637"
      unitRef="Unit12">266782000</us-gaap:LiabilitiesAndStockholdersEquity>
    <sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d02475b9-c59f-49ea-9470-12907b9d731b"
      unitRef="Unit12">68032000</sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement>
    <sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c738d885-8214-45df-81a1-f19271ef7a1f"
      unitRef="Unit12">24813000</sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement>
    <sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-173c86fb-6af7-4e77-a28f-5611237e5671"
      unitRef="Unit12">3053000</sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-ba26d6bf-3c22-43ca-bda6-8ef44fc98d35"
      unitRef="Unit12">11988000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ef3aff21-b006-4fad-99f1-53844c624bc1"
      unitRef="Unit12">8055000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-89ca0e25-7fb3-4f8f-8ef4-eb0ea9034f14"
      unitRef="Unit12">3739000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-263267bc-2542-4e4d-83e1-378864808664"
      unitRef="Unit12">346000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-c18d5f71-12f9-4119-a8c3-c745538ef709"
      unitRef="Unit12">80020000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0113d379-99fc-497e-be12-9742a52799ce"
      unitRef="Unit12">32868000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-932f2270-7f35-4f7e-92a8-5cbd2bec6085"
      unitRef="Unit12">6446000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-5c7b0461-1a70-4e29-87b3-721fde6ae2a5"
      unitRef="Unit12">-80020000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-81cdb769-7c23-4f57-b3db-83a682cf08a2"
      unitRef="Unit12">-32868000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-cb855186-aeef-4aaa-b0f5-3ec7d81529d3"
      unitRef="Unit12">-6446000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-f1e9dbf7-ce4e-48a6-8cbb-f94f1badc41b"
      unitRef="Unit12">2777000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-9a747ee5-784c-4489-92e7-5e3980b164a7"
      unitRef="Unit12">49000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-964aef9e-a005-4920-887a-671fb2c539fe"
      unitRef="Unit12">112000</us-gaap:InterestAndOtherIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-25b29c8c-cc6d-4354-8a1e-a00a53e637df"
      unitRef="Unit12">997000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ad1ae878-ff70-4355-9c4b-d8866cfb4168"
      unitRef="Unit12">434000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-10333e9f-e73d-497e-b026-f9aafc692f6d"
      unitRef="Unit12">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-428486f2-f747-4a15-ab07-5b4a98d930af"
      unitRef="Unit12">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-5e120bbb-02af-4cf5-9547-db04448bd8f0"
      unitRef="Unit12">-6334000</us-gaap:NetIncomeLoss>
    <sava:NetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-f9f0a55a-c8f8-4748-b46a-161bb2bb87fa"
      unitRef="Unit13">-1.90</sava:NetLossPerShareBasicAndDiluted>
    <sava:NetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-c2f4fe6c-ab34-4f7c-ad60-a210d210ad86"
      unitRef="Unit13">-0.82</sava:NetLossPerShareBasicAndDiluted>
    <sava:NetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-17b0ad83-8c42-428f-8431-bbd3d92a3b99"
      unitRef="Unit13">-0.24</sava:NetLossPerShareBasicAndDiluted>
    <sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-cd342426-a51c-47ac-b805-3796e491f51c"
      unitRef="Unit1">40202000</sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted>
    <sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-85f62dba-777d-4e90-83e9-b164d0ce64b6"
      unitRef="Unit1">39405000</sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted>
    <sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-db33be43-1882-4190-b385-053ed71b8f78"
      unitRef="Unit1">26105000</sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-e3cdf0de-8fe1-449d-9423-cb8b42fc0230"
      unitRef="Unit1">21841810</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-38db4701-6909-4b99-9bbe-af265a5a6959"
      unitRef="Unit12">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-bff70054-ec98-45c9-8ddb-e0b3184f8682"
      unitRef="Unit12">190664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-f9c1694c-227f-4288-b90e-85fb3e98cd2c"
      unitRef="Unit12">-168587000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-bb27fdaa-2e16-40c0-a079-276cec583a07"
      unitRef="Unit12">22099000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-bc0a07b6-638c-4cdb-874e-4a29d34cd920"
      unitRef="Unit12">961000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-46e61d79-36ea-42c3-bfc4-37254b419246"
      unitRef="Unit12">961000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-6393f07c-97aa-4528-97fb-af9417f754c2"
      unitRef="Unit12">27000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-21779b89-29d5-4b3f-8242-f2227f20fc93"
      unitRef="Unit12">27000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-22258803-6f73-478b-a88d-c16ae2e59ce1"
      unitRef="Unit1">71105</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-13757ea4-6d91-4621-8eab-14b7eae7eae0"
      unitRef="Unit12">256000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-c9b49a2c-3f70-4cdc-a84d-03a3482add77"
      unitRef="Unit12">256000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-adcc66fb-3f9a-4f13-965f-0a1bc91b7f02"
      unitRef="Unit1">3950072</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-a1ec60d2-73bd-4b43-b52d-35d89a77b402"
      unitRef="Unit12">4000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-4e5c1168-dbf0-467f-88eb-47bdf3eb4121"
      unitRef="Unit12">4936000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-3c0e9c35-8c10-4456-8aeb-83c1c5022d1d"
      unitRef="Unit12">4940000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-8a25d3ab-8bde-4c80-9f7f-aef12ff7951e"
      unitRef="Unit1">9375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-84690ecc-c0f9-40c3-8064-c74440620031"
      unitRef="Unit12">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-c5c4c553-b0af-4134-a341-18c8d7652ac1"
      unitRef="Unit12">70242000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-da4d2483-6504-4676-95dd-857fadc1a7cf"
      unitRef="Unit12">70251000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-9414f9ac-1192-424a-a7e7-ba322eb96c45"
      unitRef="Unit12">-6334000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-ada7d970-69af-4173-8197-651259246042"
      unitRef="Unit12">-6334000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-e6da0348-d5a2-4c11-94b7-c6439d56698c"
      unitRef="Unit1">35237987</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-f07e645e-a469-42f5-b49a-7420da3e7064"
      unitRef="Unit12">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-4f33d49b-1136-4ecf-a89e-125b66f6994d"
      unitRef="Unit12">267086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-7ba1c231-8925-468b-93ac-f262bcfb682f"
      unitRef="Unit12">-174921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-dc62ce4f-e725-460f-882f-5ed8ab3ed38a"
      unitRef="Unit12">92200000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-f7cfe373-ad18-4877-92a2-40ee5b3eb05a"
      unitRef="Unit12">1706000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-dcd29bf5-fdb7-421b-bd48-ccf15a09c133"
      unitRef="Unit12">1706000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-b2312527-21f7-499c-b00f-a4fd3a09c660"
      unitRef="Unit12">53000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ed88ad26-730c-4ae5-b12b-1eb343a97bfe"
      unitRef="Unit12">53000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-e63d892b-8d39-4142-88b3-9c451902b922"
      unitRef="Unit1">143153</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-1c479fbf-d09a-46ad-a228-e5cc1ddc7b25"
      unitRef="Unit12">1824000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d98e28cb-f7e2-4182-9c87-cfcf4bd29fa9"
      unitRef="Unit12">1824000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-47163b09-f2f6-4938-8338-aadf97952d4e"
      unitRef="Unit1">554019</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-1dc63614-051a-418b-97ba-7d35c6874a42"
      unitRef="Unit12">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-3e42f9ec-d937-4075-afed-29634e5dddd9"
      unitRef="Unit12">691000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-318ea7ce-01f7-473b-864a-010f50a993a6"
      unitRef="Unit12">692000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-e91e9a19-a55c-46fd-8158-377a09831c62"
      unitRef="Unit1">4081633</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-000fa3ee-33c4-4077-9dd6-e1de51f614ed"
      unitRef="Unit12">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-9a9478dc-72c6-4ca5-9978-f837bafcf5b3"
      unitRef="Unit12">189821000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-18a9cd3c-4d3a-4083-bbac-bf93af2f1584"
      unitRef="Unit12">189825000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-771e6692-5b16-4083-b4d3-f80f1041a81b"
      unitRef="Unit12">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2a138d40-8aa3-4b8f-a08d-3e63bda51bfa"
      unitRef="Unit12">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-96410f80-6339-427a-a0f9-1c28662a9fab"
      unitRef="Unit1">40016792</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-698c239b-6232-4aeb-b12f-2f5f35c542d6"
      unitRef="Unit12">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-943f93a8-9d8f-4c52-b5e4-65dc9aad6c73"
      unitRef="Unit12">461181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-2fd52861-10f5-4ecc-b913-c335f96aa984"
      unitRef="Unit12">-207306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-20922f82-df9a-441e-b2c1-e3396913d0c6"
      unitRef="Unit12">253915000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-cbf3c599-df62-4f2b-abf1-beb6cefbfabf"
      unitRef="Unit12">1972000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-f76d7243-5653-41f6-b868-d9ae3ed16456"
      unitRef="Unit12">1972000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-f335b414-0e86-466d-b458-bbff3e320dc2"
      unitRef="Unit12">-94000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-8255c392-41b3-43d9-965f-48ba5d47272d"
      unitRef="Unit12">-94000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-dafe5b85-e62c-416c-ae93-97da9705d7d0"
      unitRef="Unit1">57143</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-feb6d510-5526-4531-8fa3-950db57b5669"
      unitRef="Unit1">109241</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-0b4b6c27-0464-4554-9e4a-eac09f6915d1"
      unitRef="Unit12">475000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-f8cb5ba2-d637-49dd-863b-99740c941e60"
      unitRef="Unit12">475000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-25f49f74-496b-47c2-b0a7-0a15f1b8ef05"
      unitRef="Unit1">1666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-aff7f90b-e464-424e-9a47-77d8d30305c8"
      unitRef="Unit12">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-32c9295f-b529-4e2f-bc0c-5d03d7262983"
      unitRef="Unit12">47327000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b3493439-331d-4689-be74-eda1991069a4"
      unitRef="Unit12">47329000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-2aa423f7-a3ca-4ef3-ab0a-1380f9d5a1d0"
      unitRef="Unit12">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-7ffd6a1c-0193-4402-98a4-09c47d25b75a"
      unitRef="Unit12">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-33e8e328-64b5-441e-9943-be4f99df27d0"
      unitRef="Unit1">41735557</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-f1695a02-d6e4-408c-ac54-f909550c363e"
      unitRef="Unit12">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-b2df147b-d5a9-47b1-bb33-5475bbfdcd76"
      unitRef="Unit12">511049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-72211e0f-8f36-49cf-beb0-d391275e7e07"
      unitRef="Unit12">-283552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-77028949-5b06-4ebf-b94c-bbedbcef30c1"
      unitRef="Unit12">227539000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-5154526c-af88-4575-b065-0c1e49afefd0"
      unitRef="Unit12">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-51c342b9-28b8-47fb-b323-bde884d640ef"
      unitRef="Unit12">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-8909ecb2-2f98-4b19-a33d-55653b6b9edd"
      unitRef="Unit12">-6334000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-516b1268-6ce7-48f0-8fcd-04c04b27e07c"
      unitRef="Unit12">2066000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-dec6c3ab-8be4-423f-ae1c-6bc71f1589f2"
      unitRef="Unit12">1759000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-cce08b5b-828e-4e58-840e-dc01ba716133"
      unitRef="Unit12">988000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-434bf574-7190-4c9e-a44d-0f6dd88ced11"
      unitRef="Unit12">804000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ae6821b6-0572-4c04-b926-c3a701dc8a66"
      unitRef="Unit12">310000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-9e2ce832-7eec-4967-80b2-84ebc8bed99e"
      unitRef="Unit12">22000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d82b7404-dc93-406a-bfe3-5b4ef8c3a4dd"
      unitRef="Unit12">497000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-3c993d19-9e69-411f-a90a-875c5e7f6c39"
      unitRef="Unit12">224000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-d9631add-ee72-4ad4-a5b4-4c13c62cd4ff"
      unitRef="Unit12">346000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-3e2c52b7-416f-427b-8bee-c94f33640cb1"
      unitRef="Unit12">-1189000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2f151b5d-7913-42d7-a0af-3750a14fab45"
      unitRef="Unit12">10956000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-8018909e-8873-46aa-9cf8-bedc0419998d"
      unitRef="Unit12">220000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-0a4e0fd0-7ca4-4c14-864d-7e1fa8bc9320"
      unitRef="Unit12">9000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ad5705e6-c2e4-4621-9c0c-ba9823280555"
      unitRef="Unit12">-28000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-e149c7ae-c277-4270-b0cd-1ec6f2da9ad9"
      unitRef="Unit12">2000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-bf7c6a89-dbd7-44e4-a472-f791060d0824"
      unitRef="Unit12">-3449000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-73be590f-3399-4424-bfe5-bbb295fc7907"
      unitRef="Unit12">6215000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-f76571e6-fb47-4e11-be56-5068456eec90"
      unitRef="Unit12">458000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-e8b13cd5-d624-464b-8c50-a8e2046014e4"
      unitRef="Unit12">-523000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-73a9e004-4ca9-4ba0-a208-1517d3facb2c"
      unitRef="Unit12">2084000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-ff32304c-cdbe-47e9-ae3d-322e79e0967b"
      unitRef="Unit12">-58000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b246ab6b-951d-441b-8845-00917387d2b4"
      unitRef="Unit12">-1707000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-34f79c5b-3434-41d8-b43e-222e3ebb4483"
      unitRef="Unit12">1794000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-124bbc1f-c70e-446f-90e6-090fdf7325fc"
      unitRef="Unit12">25000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-4cc1f2dd-308c-4169-9b7e-d0e8834c711b"
      unitRef="Unit12">-136000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-7cee2f7b-9d66-449f-932b-e1a2755c81b7"
      unitRef="Unit12">731000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-47380f5a-a70c-4f6a-b501-33fca24d1e0e"
      unitRef="Unit12">85000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-3f734f7a-bd6c-4bda-b1ae-0ce5b3e9b71f"
      unitRef="Unit12">-77514000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c6e64ac8-df97-4e82-b84a-9ec36ddec4d6"
      unitRef="Unit12">-30196000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-785f6e62-85e4-4e6a-b420-7461dbeffbfe"
      unitRef="Unit12">-5382000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-7d870bf0-a036-4093-b53c-7d045d81294c"
      unitRef="Unit12">2712000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2cdff020-2699-47d2-bc40-3f9be508592b"
      unitRef="Unit12">22214000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-dc6aae91-9929-4a9f-a20b-6df3b849ad28"
      unitRef="Unit12">360000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-11e54dab-05a3-41f4-986a-e55bc37bcff5"
      unitRef="Unit12">-2712000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-e85033f2-acff-487f-81f9-0f6b2a7ed84a"
      unitRef="Unit12">-22214000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-931e4591-a80f-421e-a616-7aa21881410f"
      unitRef="Unit12">360000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-c1bdcd1a-4419-4448-81d1-b14d152f0c02"
      unitRef="Unit12">475000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-771240d3-9fec-4854-94e6-67a1c09a214b"
      unitRef="Unit12">1824000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-bcd9406c-388c-434c-beae-c23811786026"
      unitRef="Unit12">256000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-e0b48985-4c0e-41bf-bf32-09be870e0912"
      unitRef="Unit12">692000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-466d7ed5-1540-42ed-8551-32e8d61cb477"
      unitRef="Unit12">4940000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-121365fb-4e36-4722-bfb4-c3f282a24e20"
      unitRef="Unit12">47329000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0626b5a1-2c77-4028-8bee-36f80806af28"
      unitRef="Unit12">189825000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-4a940cdf-f035-4765-bb71-37ccb2db10a3"
      unitRef="Unit12">70251000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-7aeada19-8cc8-448e-8f6d-8c8f424a346e"
      unitRef="Unit12">47804000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-6d97f12a-d0dc-4713-a397-79ba924f2599"
      unitRef="Unit12">192341000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-9782095f-8386-4534-a7cc-65a551309686"
      unitRef="Unit12">75447000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-597bac15-f572-43c0-baba-7d65929019e8"
      unitRef="Unit12">-32422000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a2b7923d-17ea-4ee5-9254-eda4271c9bfc"
      unitRef="Unit12">139931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-76cb60ef-df23-4a8b-a8b2-42b3fd0b2c5a"
      unitRef="Unit12">70425000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-14582589-ad3b-409a-b130-6f0bc2fc1cbf"
      unitRef="Unit12">233437000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-9fd42c4e-9293-4fbe-83da-ece28a28a0df"
      unitRef="Unit12">93506000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-73a2b1ff-b7c7-4e7f-b1c2-34321f8e128c"
      unitRef="Unit12">23081000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-8ed4d72f-568c-4e92-ac20-f85131190f83"
      unitRef="Unit12">201015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-0db68a3c-07e0-4ba5-8386-3681a434f776"
      unitRef="Unit12">233437000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-3e3887d9-4eeb-47f1-a330-c2db656be715"
      unitRef="Unit12">93506000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-c7bb5e07-abc2-40f2-915a-904f9c9c55e3"
      unitRef="Unit12">340000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-a760b771-6a87-4195-85d0-d6b0f2ff130a">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;1.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;General, Liquidity and Basis of Presentation&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#x201c;Company&#x201d;) discovers and develops proprietary pharmaceutical product candidates that may offer significant improvements to patients and healthcare professionals. The Company generally focuses its product discovery and development efforts on disorders of the nervous system. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Coronavirus Disease 2019 (COVID-19)&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The widespread outbreak of COVID-19 has not significantly impacted the Company&#x2019;s operations or financial condition as of February&#160;28, 2023. However, this pandemic has created a dynamic and uncertain situation in the national economy. The Company continues to closely monitor the latest information to make timely, informed business decisions and public disclosures regarding the potential impact of pandemic on its operations and financial condition. The scope of pandemic is unprecedented and its long-term impact on the Company&#x2019;s operations and financial condition cannot be reasonably estimated at this time.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Basis of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Liquidity  &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;283.6&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million at December&#160;31, 2022. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#x2019;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company may seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are no assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#x2019;s working capital needs for at least the next 12 months.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022"
      decimals="-5"
      id="ct-nonFraction-80bbec2b-2ffb-48b1-bcf7-ab37c1e1fd45"
      unitRef="Unit12">-283600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-c2e05d1f-031b-49c7-a5a9-e722e8cc862f">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2.  Summary of Significant Accounting Policies&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and assumptions&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Proceeds from Grants&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In 2022, 2021, and 2020, the Company received $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.9&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.9&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.2&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million of reimbursement from the National Institutes of Health and National Institute on Drug Abuse, respectively. The Company records the proceeds from these grants as reductions to its research and development expenses.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at one financial institution.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value Measurements &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 1 includes quoted prices in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 2 includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does not have any financial instruments where the fair value is based on Level 2 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;financial instruments&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; where the fair value is based on Level 3 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 inputs at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Business Segments&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;one&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; business segment: the development of novel drugs and diagnostics.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;(&#x201c;Black-Scholes&#x201d;) &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each &lt;/span&gt;&lt;span id="_cp_text_1_372" style="text-decoration: none;"/&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s judgment. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;For all options granted, it&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;four years&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&#x201c;Performance Awards&#x201d;)&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company computes &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options and warrants. There is no difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;76,246&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;32,385&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,334&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;40,202&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,405&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26,105&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.90&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.82&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.24&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; Dilutive common stock options excluded from net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,055&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,211&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,145&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Common stock warrants excluded from net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; -&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; -&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;554&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company excluded common stock options and warrants outstanding , along with &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;57,143&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; restricted stock awards, from the calculation of net loss per share, diluted, because the effect of including outstanding options and warrants would have been anti-dilutive. The &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;57,143&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; restricted stock awards expired during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Tahoma', 'sans-serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments may be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Research Contracts, Prepaids and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have not been materially different from actual costs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Incentive Bonus Plan&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#x201c;Plan&#x201d;) to incentivize Plan participants.  Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718 &#x201c;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x201d;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met.  See Note 11 for further discussion of the Plan.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;consolidated balance sheets.&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize right-of-use assets or lease liabilities&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;.&#160;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years and approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which approximates &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.3&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years at December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740, &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-026e378d-f468-47f1-9e4d-ad4a50014632">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Use of Estimates&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and assumptions&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <sava:ProceedsFromGrantsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-db2ea440-c1c9-4425-aa14-8ac4214abab3">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Proceeds from Grants&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In 2022, 2021, and 2020, the Company received $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.9&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.9&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.2&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million of reimbursement from the National Institutes of Health and National Institute on Drug Abuse, respectively. The Company records the proceeds from these grants as reductions to its research and development expenses.&lt;/span&gt;&lt;/p&gt;</sava:ProceedsFromGrantsPolicyPolicyTextBlock>
    <sava:ReductionToResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-5"
      id="ct-nonFraction-50454448-d7bf-4b09-9d65-51d00529aae5"
      unitRef="Unit12">900000</sava:ReductionToResearchAndDevelopmentExpense>
    <sava:ReductionToResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-01ddae7b-9237-430f-b01e-3b2ab431fa8e"
      unitRef="Unit12">3900000</sava:ReductionToResearchAndDevelopmentExpense>
    <sava:ReductionToResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-2e18fb2f-24e5-4eba-984c-bebd14edceae"
      unitRef="Unit12">4200000</sava:ReductionToResearchAndDevelopmentExpense>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-f733ac84-abb6-46d2-a8e9-6e853bfdc0ce">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at one financial institution.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-97ca764b-b17e-4af5-abc8-1ee8a08dc486">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value Measurements &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 1 includes quoted prices in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 2 includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does not have any financial instruments where the fair value is based on Level 2 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;financial instruments&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; where the fair value is based on Level 3 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 inputs at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-11586f83-f908-4e76-900e-41f89c180b09">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Business Segments&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;one&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; business segment: the development of novel drugs and diagnostics.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-645a6f7e-ca16-4b3c-a101-e2fb0ecdec60"
      unitRef="Unit17">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-eaaf6494-97e0-4778-bda5-e9347336e2ff">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;(&#x201c;Black-Scholes&#x201d;) &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each &lt;/span&gt;&lt;span id="_cp_text_1_372" style="text-decoration: none;"/&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s judgment. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;For all options granted, it&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;four years&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&#x201c;Performance Awards&#x201d;)&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-ace1e61c-55a6-4cf4-a4fe-f85c4f2b9ed6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-cbcfad27-c70a-49e2-b5ef-a9fdb85c9ce7">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Net Loss per Share&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company computes &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options and warrants. There is no difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;76,246&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;32,385&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,334&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;40,202&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,405&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26,105&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.90&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.82&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.24&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; Dilutive common stock options excluded from net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,055&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,211&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,145&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Common stock warrants excluded from net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; -&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; -&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;554&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company excluded common stock options and warrants outstanding , along with &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;57,143&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; restricted stock awards, from the calculation of net loss per share, diluted, because the effect of including outstanding options and warrants would have been anti-dilutive. The &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;57,143&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; restricted stock awards expired during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-e50e6e4a-2cd6-4108-9ae6-5eaa63ea58fc">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;76,246&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;32,385&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,334&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;40,202&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,405&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26,105&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.90&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.82&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.24&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; Dilutive common stock options excluded from net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,055&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,211&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,145&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Common stock warrants excluded from net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; -&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; -&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;554&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 63.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a890b622-99b7-4fb0-a06d-df898fd7e963"
      unitRef="Unit12">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c105cf41-720f-448f-9641-8a8e3f252e57"
      unitRef="Unit12">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-49611192-2fcd-433f-b6e2-5e53c6f9e90e"
      unitRef="Unit12">-6334000</us-gaap:NetIncomeLoss>
    <sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-145be4b7-01de-434b-b966-87ed86f2824d"
      unitRef="Unit1">40202000</sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted>
    <sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-5440c773-5581-41c5-bd13-a537eedb9863"
      unitRef="Unit1">39405000</sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted>
    <sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-fd64f1aa-a9c1-432f-9f57-c6f6a341657e"
      unitRef="Unit1">26105000</sava:SharesUsedInComputingNetLossPerShareBasicAndDiluted>
    <sava:NetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-2bfbcd1c-2f63-48b3-b88e-90aa8705666b"
      unitRef="Unit13">-1.90</sava:NetLossPerShareBasicAndDiluted>
    <sava:NetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-d9c15bbc-b3bd-462c-8c44-9f6d87567042"
      unitRef="Unit13">-0.82</sava:NetLossPerShareBasicAndDiluted>
    <sava:NetLossPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-02b1a8c5-2f14-48ee-991f-de114645c481"
      unitRef="Unit13">-0.24</sava:NetLossPerShareBasicAndDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="ct-nonFraction-0dad55dc-9c87-4e12-8009-5386dc659f7c"
      unitRef="Unit1">2055000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="ct-nonFraction-aba3e800-fbda-4fec-ac33-0dbe615d5168"
      unitRef="Unit1">2211000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="ct-nonFraction-08822609-3cac-4ccf-900e-2fdeb916f82a"
      unitRef="Unit1">2145000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"
      decimals="-3"
      id="ct-nonFraction-92b96fe9-e0a3-4dab-87cc-6b648bbf8d1c"
      unitRef="Unit1">554000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="ct-nonFraction-df9e723b-9f80-454e-aac5-0e3afa227468"
      unitRef="Unit1">57143</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="ct-nonFraction-ee4c0b80-c90b-4ea1-bc08-75ba8ada4b11"
      unitRef="Unit1">57143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-34ce1393-af1b-4eda-ba40-b583535b889a">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments may be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <sava:ResearchContractCostsAndAccrualsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-35edde5f-8323-4313-84d1-cbeeddfeab0d">&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Research Contracts, Prepaids and Accruals&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have not been materially different from actual costs.&lt;/span&gt;&lt;/p&gt;</sava:ResearchContractCostsAndAccrualsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-35d51175-3ae9-432d-a69c-9b69a9ce3dcf">&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Incentive Bonus Plan&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#x201c;Plan&#x201d;) to incentivize Plan participants.  Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718 &#x201c;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x201d;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met.  See Note 11 for further discussion of the Plan.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-e6bd170a-9a56-4433-a2e3-26a6a3fb2749">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Leases&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;consolidated balance sheets.&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize right-of-use assets or lease liabilities&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;.&#160;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-dbac76ca-823c-4fe4-9717-07aaf2a90a64">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Property and equipment&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years and approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      id="ct-nonNumeric-50f57131-a555-4102-a968-3a39d40b2fd0">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      id="ct-nonNumeric-69707852-7b4e-424d-8916-9b8a934869ab">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      id="ct-nonNumeric-f5933e12-7aeb-4a50-8d8e-22f779235b55">P1Y4M24D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-0397d26a-6461-4e33-abde-a548573525e2">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Intangible assets&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which approximates &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.3&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years at December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"
      id="ct-nonNumeric-3ca93393-ec7f-4491-809c-925be227881f">P1Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-6ed6180a-9ae3-48ec-b684-969120cf603d">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Income Taxes&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740, &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <sava:PrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-18a25781-5d13-4485-b049-a01adbb5021d">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;3.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;  &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;"&gt;Prepaid and &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Other Current Assets&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Prepaid and other current assets at December 31, 2022 and 2021 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;874&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;662&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Contract research organization and other deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,330&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;160&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;53&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,045&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</sava:PrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-8ad92adf-333a-44bb-9112-a117d05b7f35">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;874&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;662&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Contract research organization and other deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,330&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;160&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;53&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11,045&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-86176a02-fa62-4add-9632-410654d5ec12"
      unitRef="Unit12">874000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-e02913c5-fe54-4306-95af-4c0bb5c7c186"
      unitRef="Unit12">662000</us-gaap:PrepaidInsurance>
    <us-gaap:DepositContractsAssets
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-00cc27f4-dc7b-4563-9f16-1feb9b2b85ff"
      unitRef="Unit12">9177000</us-gaap:DepositContractsAssets>
    <us-gaap:DepositContractsAssets
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-de2637a3-1ada-41a0-8f6f-8bb20dbc7af9"
      unitRef="Unit12">10330000</us-gaap:DepositContractsAssets>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-edf3fb1c-b91e-45e4-a032-8f4ae1a6e695"
      unitRef="Unit12">160000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-be70dda5-ccb4-41a2-86e2-fb6cd88a7b4d"
      unitRef="Unit12">53000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-20e2932f-73f8-47fe-9156-a92faf5bb4ba"
      unitRef="Unit12">10211000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-3342a5ed-8cb2-4981-a4eb-9adaca2550ca"
      unitRef="Unit12">11045000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-b31f6ca2-63b2-4990-9937-ffa4c8e0b1dc">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;4.  &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;"&gt;Real Property Acquisition&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On August 4, 2021, the Company completed the all-cash purchase of a two-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#x2019;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are being outsourced to professional real-estate managers. The purchase price of the property was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million, including transaction costs. The office complex measures approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;90,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; rentable square feet. At December 31, 2022, the property was over &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;60&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% leased. The Company also occupied approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;25&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the property as of December 31, 2022. The seller was a third party not affiliated with the Company.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The purchase was accounted for as an asset acquisition under ASC 805, Business Combinations. As substantially all of the fair value of the gross assets acquired were concentrated into a single identifiable asset, the Company concluded that the screen was met, and the transaction is considered an asset acquisition rather than an acquisition of a business. Pursuant to the cost accumulation method as prescribed in ASC 805, the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values. The value of acquired in-place leases is measured as the sum of lost revenues that would be incurred during a&#160;prospective lease-up period that would be necessary to achieve occupancy similar to that at the time of&#160;acquisition. The value is calculated as the average number of months of lease-up multiplied by the gross monthly market rental rate (base rent plus reimbursements) for each particular suite.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The assets acquired are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.07in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.06in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Land&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,980&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Site improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;453&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Tenant improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;567&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Total tangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.16in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Lease-in-place agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,053&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Leasing commissions and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;246&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,299&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.07in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Consideration paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22,033&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.06in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company records the net income from building operations and leases as other income, net, as leasing is not core to the Company&#x2019;s operations. Building depreciation and amortization for space not occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Lease revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,459&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;911&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,462&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;477&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;997&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;434&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;      The Company had accrued property taxes related to the building totaling $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;433,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;450,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; at December 31, 2022 and 2021, respectively, included in other current liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="Duration_8_4_2021_To_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-5"
      id="ct-nonFraction-e768600e-cfe4-4a35-9186-e8059e43dea8"
      unitRef="Unit12">22000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:NetRentableArea
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="0"
      id="ct-nonFraction-50a9d6be-f489-494b-ae69-3289f6899eec"
      unitRef="Unit16">90000</us-gaap:NetRentableArea>
    <sava:PercentageOfCurrentlyLeased
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="2"
      id="ct-nonFraction-171e4bb4-6cf4-4159-98e6-1ec68e14268f"
      unitRef="Unit15">0.60</sava:PercentageOfCurrentlyLeased>
    <sava:PercentageOfOccupancy
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="2"
      id="ct-nonFraction-f0e60cc9-5622-47d9-a53a-4e24045106d6"
      unitRef="Unit15">0.25</sava:PercentageOfOccupancy>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-0de8c33e-4c7f-41fa-8da0-b51529716c20">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.07in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.06in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Land&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,980&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Site improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;453&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Tenant improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;567&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Total tangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.16in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Lease-in-place agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,053&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Leasing commissions and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;246&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,299&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.07in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Consideration paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22,033&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.06in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 69.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 26.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"
      decimals="-3"
      id="ct-nonFraction-85b85c05-85f5-4014-a78c-d203061e7e2d"
      unitRef="Unit12">3734000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-7b95ea96-bb03-4033-876f-129c9e17ca06"
      unitRef="Unit12">15980000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-d6696bdc-3414-4070-9496-9c22979979c1"
      unitRef="Unit12">453000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-af65a15b-8d48-4f90-8dcb-85d562f70195"
      unitRef="Unit12">567000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember"
      decimals="-3"
      id="ct-nonFraction-a001de5e-b8e6-42f6-a822-1eda26123841"
      unitRef="Unit12">20734000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="ct-nonFraction-7476b078-a628-40f0-a841-bd699bb762b3"
      unitRef="Unit12">1053000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-54f563c8-756b-4152-902c-b6e5ef9baa6e"
      unitRef="Unit12">246000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember"
      decimals="-3"
      id="ct-nonFraction-bd5992b5-dc16-404d-950b-0b1f39e9b30a"
      unitRef="Unit12">1299000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember"
      decimals="-3"
      id="ct-nonFraction-73e09a75-d37b-4e80-abf8-7780e5184e3c"
      unitRef="Unit12">22033000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-6b0151ed-0135-4fc0-8671-80dd94a81713">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Lease revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,459&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;911&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,462&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;477&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;997&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;434&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-f1c498fa-cfa0-4d20-9e00-f7410db7291a"
      unitRef="Unit12">2459000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-a673b6e4-8679-4126-bed8-6aeb7025db61"
      unitRef="Unit12">911000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-b566d1d3-20b3-4ff8-adb8-0b6a5bcff1b2"
      unitRef="Unit12">1462000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-5705f9d8-6bb0-40bb-88f4-809dc16b2865"
      unitRef="Unit12">477000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-5b84c109-74ad-47f5-ba66-8952ce4e5cb3"
      unitRef="Unit12">997000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-7ef69bd8-57ad-4f04-8aa8-469ae0d89a15"
      unitRef="Unit12">434000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="0"
      id="ct-nonFraction-1b4aafa5-cfd2-4dc2-bc71-39e9524ffd2a"
      unitRef="Unit12">433000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="0"
      id="ct-nonFraction-c23af27c-63d5-4079-a970-6017d60523aa"
      unitRef="Unit12">450000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-6c57fc52-32c9-49d9-81c2-1bbd4abd1cd9">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;5.  Property and Equipment&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The components of property and equipment, net, as of December 31, 2022 and 2021 were as follows (in thousands): &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.06in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Land&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,980&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,980&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Site improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;470&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;470&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Tenant improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,016&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;567&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;851&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;178&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;83&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Gross property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,064&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21,012&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,200&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;396&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22,864&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20,616&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.05in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Depreciation expense for property and equipment was&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;804,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;310,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;and&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;for the years ended&#160;December&#160;31, 2022, 2021&#160;and 2020, respectively.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;There were &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; sales of property and equipment during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the&#160;year ended&#160;December&#160;31, 2020, the Company sold surplus manufacturing equipment to an independent third party and received proceeds totaling $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;360,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;.&#160;The original&#160;cost of the property and equipment was &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;892,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;and accumulated depreciation was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;878,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;,&#160;resulting a gain on sale&#160;of property and equipment of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;346,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;during the&#160;year ended&#160;December&#160;31, 2020.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-13525d58-dc28-4dad-9915-07b9882742f2">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.06in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Land&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,980&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,980&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Site improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;470&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;470&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Tenant improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,016&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;567&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;851&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;178&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;83&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Gross property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,064&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21,012&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,200&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;396&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22,864&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20,616&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.05in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"
      decimals="-3"
      id="ct-nonFraction-101c5c73-3b1e-45d8-b01d-0e3c20347264"
      unitRef="Unit12">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"
      decimals="-3"
      id="ct-nonFraction-a9773c33-26dd-4014-b3cd-090c1e81d9bd"
      unitRef="Unit12">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-ddfc58c7-c287-491f-9d72-0ddc0fd6aad3"
      unitRef="Unit12">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-c5dd5f80-89ce-4b07-9680-7b58a629f161"
      unitRef="Unit12">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-83a68623-8e1d-46ff-8734-f1762cafe510"
      unitRef="Unit12">470000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-e7c3b7f4-5d3b-4713-aa00-f1090e970bc8"
      unitRef="Unit12">470000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-abe6a0b6-57bd-4bc2-bcda-d441957703c1"
      unitRef="Unit12">3016000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-6f4c16b9-1a43-4078-a74e-41c26d7e7ceb"
      unitRef="Unit12">567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="ct-nonFraction-859d9d94-de3e-49f9-9ef3-9e31eca33800"
      unitRef="Unit12">851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="ct-nonFraction-c162dc3c-010f-48ef-ab8c-ee99031c685c"
      unitRef="Unit12">178000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="ct-nonFraction-7ee05ae1-6540-42fd-acf4-5003e8294c47"
      unitRef="Unit12">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="ct-nonFraction-e0afd582-cdce-40ba-a682-e2de4542f1bc"
      unitRef="Unit12">83000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-9d1bc58d-7a48-4e09-89d3-273fba42cd42"
      unitRef="Unit12">24064000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-950bbea4-f9ee-46b4-939d-d000b6659d8e"
      unitRef="Unit12">21012000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d3d0f58d-c7fb-4cdf-be1b-27f23dc2d3db"
      unitRef="Unit12">1200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-39a6cace-929d-4cdf-a8d2-30c3d65ad843"
      unitRef="Unit12">396000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-55a63b32-5ae2-4e0f-baca-c8b4e69e57dd"
      unitRef="Unit12">22864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-fdeea608-5224-422c-a64e-01115895c43d"
      unitRef="Unit12">20616000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="0"
      id="ct-nonFraction-c74a19d8-fcb4-458e-95fd-de3d2d0fb1f2"
      unitRef="Unit12">804000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-d119fb45-fc30-4532-8e99-a428d8d1ebca"
      unitRef="Unit12">310000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="0"
      id="ct-nonFraction-96ac4af8-b0d4-416a-9f3b-283f4f307b65"
      unitRef="Unit12">22000</us-gaap:Depreciation>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-32a0cf2d-df3c-463b-be14-626e135b68ad"
      unitRef="Unit12">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-08660c5f-4f57-4185-a1cc-1cfaa61725d6"
      unitRef="Unit12">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      decimals="0"
      id="ct-nonFraction-10127f1f-8cf9-48f5-96f7-ae6e996f7b99"
      unitRef="Unit12">360000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      decimals="0"
      id="ct-nonFraction-9e28f4f4-46cf-41ff-99a2-47a88e8df2ac"
      unitRef="Unit12">892000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      decimals="0"
      id="ct-nonFraction-1d6f715f-ff63-47cc-9b54-1b40b9b094e1"
      unitRef="Unit12">878000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      decimals="0"
      id="ct-nonFraction-16222dee-fff0-4e7b-be6e-46ad3633c00d"
      unitRef="Unit12">346000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-f84b82a4-e30c-43e6-a632-fbb05b1d0722">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;6.  &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;"&gt;Intangible assets&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The components of intangible assets, net, as of December 31, 2022&#160;and 2021&#160;were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.07in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.20in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Lease-in-place agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,053&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,053&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Leasing commissions and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;290&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;246&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Gross intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,343&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,299&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;721&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;224&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;622&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,075&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.07in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Amortization expense for intangible assets was&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;497,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;224,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; for the years ended&#160;December&#160;31, 2022 and 2021, respectively. There was &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; amortization expense for the year ended December 31, 2020.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Amortization expense for finite-lived intangible assets is expected to be as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.15in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;"&gt;For the year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;451&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;167&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;622&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-dd70f45a-ff01-4cc2-a5fb-2cde74438461">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.07in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.18in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.20in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Lease-in-place agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,053&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,053&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Leasing commissions and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;290&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;246&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Gross intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,343&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,299&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;721&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;224&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;622&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,075&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.07in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="ct-nonFraction-ba09da73-b75c-43cc-8a02-b91190bd59cf"
      unitRef="Unit12">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="ct-nonFraction-252584d4-0acc-4215-9aad-f3bd556fb636"
      unitRef="Unit12">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-395041a7-a9ca-4564-abab-e7b72464f3ac"
      unitRef="Unit12">290000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-14bb2bff-48c0-45f5-bfe1-2e87175ec85a"
      unitRef="Unit12">246000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-10902f56-c5ee-4505-8bf2-535c5a48270b"
      unitRef="Unit12">1343000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a077a338-be8a-4582-a358-ad1d20b4b64d"
      unitRef="Unit12">1299000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-968e1a65-327a-4951-9942-1ee306384319"
      unitRef="Unit12">721000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-969b16a9-ccc5-4d31-90f6-084aa271e6aa"
      unitRef="Unit12">224000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d13e9f80-55ec-49fc-a70d-bb3a1b7097df"
      unitRef="Unit12">622000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-196554f0-e17f-4e6a-86b0-3cee5d81ef99"
      unitRef="Unit12">1075000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="0"
      id="ct-nonFraction-487eafaa-2d6d-405a-8baf-95dd875bc787"
      unitRef="Unit12">497000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-3cd31542-86e8-41e2-b7f8-d1ed717188e9"
      unitRef="Unit12">224000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="INF"
      id="ct-nonFraction-153fc9d8-76d0-413e-9ef3-02215c3a10f3"
      unitRef="Unit12">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-f7d84405-3f49-4940-a1e6-0adbd7fa8f5c">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.15in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.19in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;"&gt;For the year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;451&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;167&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;622&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.21in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a2925334-75cd-4fde-aa1d-1ab1307b68b9"
      unitRef="Unit12">451000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-1c666267-c616-4f3a-9827-6daa76816e2a"
      unitRef="Unit12">167000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-6375cc47-a267-4c0e-ae57-7c2886301626"
      unitRef="Unit12">4000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-175aec1b-3bcc-4492-8be7-f9afc2b9318f"
      unitRef="Unit12">622000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-fe191c47-3d57-4462-ab29-41a8de586fec">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;7.  Stockholders' Equity and Stock-Based Compensation&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;2022 Registered Direct Offering&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On November&#160;22, 2022, the Company completed a common stock offering pursuant to which certain investors purchased &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,666,667&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;30.00&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; per share. Net proceeds of the offering were approximately $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;47.3&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million after deducting offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;2021 Registered Direct Offering&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On February&#160;12, 2021, the Company completed a common stock offering pursuant to which certain investors purchased &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,081,633&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49.00&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; per share. Net proceeds of the offering were approximately $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;189.8&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million after deducting offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;2020 Follow-on Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On November&#160;13, 2020, the Company completed the sale of&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,375,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;shares of Cassava common stock in an underwritten public offering at a price of&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8.00&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;per share. The Company received net proceeds from the offering of&#160;approximately $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;70.3&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million&#160;after deducting underwriting discounts and offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 10pt;line-height: 106.7%;margin-bottom: 10pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Common Stock Warrants&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In August 2018, the Company issued warrants to&#160;purchase up to an aggregate of&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million shares of its common stock in conjunction with an offering of its common stock.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During 2021, the Company received proceeds of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.7&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million from the exercise of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.6&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million shares pursuant to common stock warrants. There were no common stock warrants outstanding following the 2021 exercises.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During 2020, the Company received proceeds of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.9&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million from the exercise of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million shares pursuant to common stock warrants.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;At the Market (ATM) Common Stock Issuance &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On March&#160;27, 2020, the Company established an at-the-market offering program (ATM) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;100&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million&#160;in transactions pursuant to a shelf registration statement that was declared effective by the&#160;U.S. Securities and Exchange Commission (the SEC)&#160;on May&#160;5, 2020. The Company is obligated to pay a commission of&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&#160;of the gross proceeds from the sale of shares of common stock in the offering. The Company is not obligated to sell any shares in the offering.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;There were&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;common stock sales under the ATM during the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;2008 Equity Incentive Plan &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Under the Company&#x2019;s &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2008 Equity Incentive Plan, or 2008 Equity Plan,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2008 Equity Plan&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; expired in December 2017. Share-based awards generally expire &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;ten years&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; from the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;2018 Equity Incentive Plan &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s Board or a designated Committee of the Board is responsible for administration of the Company&#x2019;s 2018 Omnibus Incentive Plan (the 2018 Plan) and determines the terms and conditions of each option granted, consistent with the terms of the 2018 Plan. The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the 2018 Plan, including grants of stock options and performance awards. Share-based awards generally expire &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;ten years&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; from the date of grant. The 2018 Plan, as amended on May 5, 2022, provides for issuance of up to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of common stock, par value $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.001&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; per share, subject to adjustment as provided in the 2018 Plan. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company may then use its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following summarizes information about stock option activity during 2022:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Remaining Contractual Term in Years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Aggregate Intrinsic Value in Millions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,663,727&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11.56&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;104,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;36.50&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;203,640&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15.56&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;34,639&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20.59&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,529,448&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.13&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,529,448&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.13&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,270,464&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10.02&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;46.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Of the stock options exercised &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;during the year ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;December&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; 31, 2022&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;94,399&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; stock options were net settled in satisfaction of the exercise price, with no cash proceeds received.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following summarizes information about stock options at December&#160;31, 2022 by a range of exercise prices:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.20in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Options exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Range of exercise prices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt; vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;From&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;To&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;585,833&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;505,833&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;550,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;550,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;536,951&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;512,888&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;35.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;655,874&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;653,290&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;36.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;77.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;200,790&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;52.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,453&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;62.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,529,448&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,270,464&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#x2019;s common stock. Factors utilized in Black-Scholes to value each stock option granted, and the weighted average fair value of options granted during the years ended December 31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;151&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;154&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;147&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;151&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;123&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;139&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Risk-free interest rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.98&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.69&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.12&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.42&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.46&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.78&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected life of option&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Forfeiture rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Weighted average fair value of stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;35.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;65.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Volatility&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt; is based on reviews of the historical volatility of the Company&#x2019;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt; because the Company does not anticipate paying cash dividends in the foreseeable future. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December&#160;31, 2022, the Company expects to recognize compensation expense of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.7&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Performance Awards&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following summarizes information about performance award activity during 2022:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Performance Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;138,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0a18ef04-da81-4da9-b08e-4f541d5d87fe;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a9cc683b-ce22-4d24-8a07-e6387b6743b3;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;130,913&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the year ended December 31, 2022, a total of &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;57,143&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of restricted stock awards expired as performance criteria related to these Performance Awards were not attained. These shares of restricted stock were returned to the 2008 Equity Incentive Plan, which expired in December 2017, and thus were retired.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;If and when outstanding performance awards vest, the Company would recognize $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;101,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; in stock-based compensation expense. These performance awards expire in &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-11a67b5d-6030-4b4a-89e9-be45bb42951d;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The following summarizes information about stock-based compensation expense, in thousands:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,631&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,302&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;453&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;435&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;457&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;535&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,066&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,759&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;988&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-85b96dc5-164b-431f-bc60-31ed41848a4a"
      unitRef="Unit1">1666667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="ct-nonFraction-d898e7c0-b889-471d-8fab-c97c119ca19c"
      unitRef="Unit13">30.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="ct-nonFraction-a1965f39-ebae-4d44-b75e-d197e15b3401"
      unitRef="Unit12">47300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-4337d88b-019c-4b0e-918d-d86d5fba3554"
      unitRef="Unit1">4081633</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="ct-nonFraction-7761cb21-b883-4a80-9435-07511dabb2f3"
      unitRef="Unit13">49.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="ct-nonFraction-46e59d54-f4eb-46af-af27-316d418cb3b2"
      unitRef="Unit12">189800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_11_13_2020_To_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-fa8543b0-b350-4d47-860c-ecd81432b78c"
      unitRef="Unit1">9375000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="ct-nonFraction-34301cf6-0003-46c2-928a-dd639023be5e"
      unitRef="Unit13">8.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_11_13_2020_To_11_13_2020_us-gaap_PlanNameAxis_sava_PublicOfferingMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="ct-nonFraction-30a21f3d-ecb6-47f6-8b05-662773804681"
      unitRef="Unit12">70300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_8_1_2018_To_8_31_2018_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember"
      decimals="-5"
      id="ct-nonFraction-f97acd70-45c2-44af-bdb9-65fd3df52931"
      unitRef="Unit1">9100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember"
      decimals="-5"
      id="ct-nonFraction-e3228323-a347-47b9-add8-55e9296e6494"
      unitRef="Unit12">700000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember"
      decimals="-5"
      id="ct-nonFraction-691217d4-2c32-41b6-aaba-755698f4a7c7"
      unitRef="Unit1">600000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember"
      decimals="-5"
      id="ct-nonFraction-114eb582-e529-40ff-9199-5ab0cb1da877"
      unitRef="Unit12">4900000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_sava_WarrantsMember_us-gaap_PlanNameAxis_sava_CommonStockWarrantsMember"
      decimals="-5"
      id="ct-nonFraction-2e4fb523-cbac-40ac-b7e9-81767737facf"
      unitRef="Unit1">4000000.0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="Duration_3_27_2020_To_3_27_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"
      decimals="-6"
      id="ct-nonFraction-7a3c28eb-d792-4a8c-9b65-5e95abd3a656"
      unitRef="Unit12">100000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <sava:PercentageOfCommissionAtmOffering
      contextRef="As_Of_3_27_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"
      decimals="3"
      id="ct-nonFraction-85d08b6e-743d-4cab-8171-4f47f9c100ff"
      unitRef="Unit15">0.030</sava:PercentageOfCommissionAtmOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"
      decimals="INF"
      id="ct-nonFraction-e6e41dd4-9232-4ea3-838a-b1199197311f"
      unitRef="Unit1">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"
      decimals="INF"
      id="ct-nonFraction-4dbf876c-1344-4eea-a7c6-0c56e3366ba5"
      unitRef="Unit1">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"
      decimals="INF"
      id="ct-nonFraction-66017c5f-781d-4fe9-b8c9-b0dbd6ecd62f"
      unitRef="Unit1">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEightEquityIncentivePlanMember"
      id="ct-nonNumeric-5d2cbf90-ec89-4cda-96dc-d9668e601cf1">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"
      id="ct-nonNumeric-27c969f4-d975-4fef-8ed9-3dca57894823">P10Y</sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="ct-nonFraction-4f3fc0ac-e6ec-47b2-a351-fa2c047923c1"
      unitRef="Unit1">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="3"
      id="ct-nonFraction-6f0054dd-4fa1-4107-b4f0-f88a3bcec055"
      unitRef="Unit13">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-63efec09-be0f-477a-bd79-75354121fe7f">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted Average Remaining Contractual Term in Years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Aggregate Intrinsic Value in Millions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,663,727&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11.56&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;104,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;36.50&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;203,640&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15.56&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;34,639&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20.59&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,529,448&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.13&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,529,448&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.13&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;49.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,270,464&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10.02&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;46.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 44.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-614db9c0-a736-4850-a3d8-971dc2934f5e"
      unitRef="Unit1">2663727</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021"
      decimals="2"
      id="ct-nonFraction-9fea8806-fa49-42fb-8ad9-d24960ddbcce"
      unitRef="Unit13">11.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-1e9c8125-38f1-458b-a39d-98e61f97e701"
      unitRef="Unit1">104000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-5ba35cad-856d-4024-b794-e877ae04b93c"
      unitRef="Unit13">36.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-e2b0f4f4-3bcd-4465-94e4-5100f9944044"
      unitRef="Unit1">203640</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-545f09eb-4f87-4a5d-b5b3-f307d9fe9e8e"
      unitRef="Unit13">15.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-74d22dbd-2b80-4747-ba09-2a833de81c50"
      unitRef="Unit1">34639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-23f5b4c1-0223-426e-b1b8-1414f9c822ea"
      unitRef="Unit13">20.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-3e79f5a9-15eb-4da8-b22b-2f4169f2bf47"
      unitRef="Unit1">2529448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022"
      decimals="2"
      id="ct-nonFraction-610ef7d9-33d5-4d19-b194-e8bcb033774a"
      unitRef="Unit13">12.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-389c86fb-5523-4b97-a715-c651918e708f">P3Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022"
      decimals="-5"
      id="ct-nonFraction-bea41aeb-f3c7-4633-893d-7c9644cb4540"
      unitRef="Unit12">49600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-f07a707c-5d7c-48e5-9f3c-2cdde068c025"
      unitRef="Unit1">2529448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022"
      decimals="2"
      id="ct-nonFraction-cdf6b801-4490-46c8-93e1-8b7bf4109fd5"
      unitRef="Unit13">12.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-d4237110-ab31-47bd-829d-fc2d8f387a14">P3Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2022"
      decimals="-5"
      id="ct-nonFraction-9bba3571-8d5d-44ec-9f97-2a18107f66f7"
      unitRef="Unit12">49600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-7a64947c-96e2-40a2-9a6e-016be21ac4c3"
      unitRef="Unit1">2270464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022"
      decimals="2"
      id="ct-nonFraction-b9f3fead-4a2c-4af7-9e8b-c726e67f2424"
      unitRef="Unit13">10.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-8063abac-646b-4b60-bf8b-cf65f07f4224">P3Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022"
      decimals="-5"
      id="ct-nonFraction-55911beb-dd3e-41c1-937a-f880090909c2"
      unitRef="Unit12">46900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-db912761-56ae-46df-a405-f132120861d3"
      unitRef="Unit1">94399</sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-5c5ac3a3-396b-4357-8059-bd8b6eb0ffae">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Options exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Range of exercise prices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt; vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;From&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;To&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;585,833&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;505,833&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;550,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;550,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;536,951&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;512,888&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;35.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;655,874&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;653,290&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;36.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;77.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;200,790&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;8.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;52.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;48,453&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;62.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,529,448&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,270,464&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember"
      decimals="2"
      id="ct-nonFraction-b4a2b64b-cd9a-4d03-ad87-0f5a7bc3f630"
      unitRef="Unit13">0.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember"
      decimals="2"
      id="ct-nonFraction-a5238fda-2a2a-4845-9350-b251609a7363"
      unitRef="Unit13">1.88</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember"
      decimals="INF"
      id="ct-nonFraction-fd7af10c-7aba-499b-87ef-1f6202403111"
      unitRef="Unit1">585833</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember"
      id="ct-nonNumeric-f07c81b3-41e3-4a10-8661-d533108bffa5">P5Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember"
      decimals="2"
      id="ct-nonFraction-a82fe05a-1a9b-4dcf-b7fa-74006b8a93c2"
      unitRef="Unit13">1.51</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember"
      decimals="INF"
      id="ct-nonFraction-dcdd1a90-24d2-4251-b824-0f72386bd195"
      unitRef="Unit1">505833</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeOneMember"
      decimals="2"
      id="ct-nonFraction-c1f671f8-b9a6-49e0-a51b-9fb31da6383f"
      unitRef="Unit13">1.46</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember"
      decimals="2"
      id="ct-nonFraction-ca3ed199-e0b7-4ac3-b18d-7ca6c1318742"
      unitRef="Unit13">3.24</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember"
      decimals="2"
      id="ct-nonFraction-953f8fd3-73e5-43ce-8d3a-0ec5992a6d16"
      unitRef="Unit13">3.24</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember"
      decimals="INF"
      id="ct-nonFraction-3e022fa7-c680-44bc-9b66-ab5dcfdd491c"
      unitRef="Unit1">550000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember"
      id="ct-nonNumeric-957a03eb-5e97-4dea-8f16-1941f1df09a7">P3Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember"
      decimals="2"
      id="ct-nonFraction-6b49feeb-1b76-464c-92a3-11e98a8ca8f5"
      unitRef="Unit13">3.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember"
      decimals="INF"
      id="ct-nonFraction-a6ab502c-3f5f-427b-a2fe-902cf557f2d9"
      unitRef="Unit1">550000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeTwoMember"
      decimals="2"
      id="ct-nonFraction-91c0302f-4aa0-4f6c-a324-f0810149c9d0"
      unitRef="Unit13">3.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember"
      decimals="2"
      id="ct-nonFraction-e25fcced-62e3-4469-8da0-f42955169cc5"
      unitRef="Unit13">4.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember"
      decimals="2"
      id="ct-nonFraction-2c240e1d-2fd9-4adf-b8b7-c5e5c649ec4c"
      unitRef="Unit13">12.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember"
      decimals="INF"
      id="ct-nonFraction-86bd5fe4-84f8-4223-9926-66173b60f2a3"
      unitRef="Unit1">536951</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember"
      id="ct-nonNumeric-36ef09a2-bef3-4bb9-8861-216cbb079008">P4Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember"
      decimals="2"
      id="ct-nonFraction-99f9729f-a144-4552-a888-d128ca7c904c"
      unitRef="Unit13">7.09</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember"
      decimals="INF"
      id="ct-nonFraction-a8eec33f-987e-4140-b8d4-cbdb1a203e77"
      unitRef="Unit1">512888</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeThreeMember"
      decimals="2"
      id="ct-nonFraction-721e97d1-766f-4639-b360-1cf408a5ab88"
      unitRef="Unit13">7.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember"
      decimals="2"
      id="ct-nonFraction-485b8914-1f35-454d-858a-1205515a3d7f"
      unitRef="Unit13">12.39</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember"
      decimals="2"
      id="ct-nonFraction-8a9eba69-f398-4b79-9412-767bbbae378d"
      unitRef="Unit13">35.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember"
      decimals="INF"
      id="ct-nonFraction-c385d4f8-28d2-4efb-b412-38a237774108"
      unitRef="Unit1">655874</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember"
      id="ct-nonNumeric-020c166b-6ec5-4998-99ee-f90657dc2510">P1Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember"
      decimals="2"
      id="ct-nonFraction-bcda7541-3abf-49bb-bfc4-6d673021fedd"
      unitRef="Unit13">20.82</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember"
      decimals="INF"
      id="ct-nonFraction-533360fa-0e4c-46ac-864f-e06d9ed6b246"
      unitRef="Unit1">653290</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFourMember"
      decimals="2"
      id="ct-nonFraction-cfeb4888-813f-41c1-a383-8b80271f32f4"
      unitRef="Unit13">20.79</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember"
      decimals="2"
      id="ct-nonFraction-73caf96b-a770-483b-bc03-e13ebc9b6775"
      unitRef="Unit13">36.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember"
      decimals="2"
      id="ct-nonFraction-08484b4c-b816-48cc-ab69-25fe7e925997"
      unitRef="Unit13">77.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember"
      decimals="INF"
      id="ct-nonFraction-f398eda0-be55-4a38-9f11-0c5e90b29179"
      unitRef="Unit1">200790</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember"
      id="ct-nonNumeric-24180801-3b27-4956-bdc0-3c0c860f750a">P8Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember"
      decimals="2"
      id="ct-nonFraction-e43e0098-b7a2-4254-b152-471ec33e443d"
      unitRef="Unit13">52.64</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember"
      decimals="INF"
      id="ct-nonFraction-bd8e0392-a957-4750-84a0-08eb68dc31ef"
      unitRef="Unit1">48453</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sava_RangeFiveMember"
      decimals="2"
      id="ct-nonFraction-96385b58-c4c0-47e7-b277-bd8e78b0ce0a"
      unitRef="Unit13">62.61</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-76a8ea2a-c0be-428b-8f86-b87117e70667"
      unitRef="Unit1">2529448</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-dea42c07-e3a1-4bc4-a231-2bf20f1deb6b">P3Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022"
      decimals="2"
      id="ct-nonFraction-d956d13c-aa3c-46f9-aab2-2dad396449ba"
      unitRef="Unit13">12.13</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-8b259ad0-eff4-480c-96c9-bb21656691fc"
      unitRef="Unit1">2270464</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2022"
      decimals="2"
      id="ct-nonFraction-15665781-2619-4f88-bd8c-e63dd21b035d"
      unitRef="Unit13">10.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-0f4343df-3399-4923-9c67-6364769d50fd">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;151&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;154&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;147&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;151&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;123&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;139&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Risk-free interest rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.98&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.69&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.12&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.42&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.46&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.78&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Expected life of option&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Forfeiture rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;zero&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 54.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Weighted average fair value of stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;35.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 13.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;65.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 14.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-4f4e7e34-5770-40c1-a5e9-0d67dabcd1b1"
      unitRef="Unit15">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-1ca82d12-3cc9-416b-a44f-1cac61291460"
      unitRef="Unit15">1.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-6b7008e3-3dcf-4904-bf88-97e08fd13648"
      unitRef="Unit15">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-5cc4ba6f-c49e-4f1d-9f04-73a12de124ac"
      unitRef="Unit15">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-02c2cdda-671b-4273-babd-61a0f3c03fa4"
      unitRef="Unit15">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-c288c2cb-1878-465f-9547-1f482e82e117"
      unitRef="Unit15">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="4"
      id="ct-nonFraction-037e8ee1-ebe7-4f5a-a57f-7c91575adbe0"
      unitRef="Unit15">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="4"
      id="ct-nonFraction-ced9831c-e09b-4b4d-ba66-015f45fe289c"
      unitRef="Unit15">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="4"
      id="ct-nonFraction-069f93c7-5959-4d7a-ab15-9acb90a6ed5b"
      unitRef="Unit15">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="4"
      id="ct-nonFraction-faa367c5-ef9c-41ac-9687-d5bf7ded7bf8"
      unitRef="Unit15">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="4"
      id="ct-nonFraction-ba91c2b6-2f7e-4643-9682-28fe2c1b78a5"
      unitRef="Unit15">0.0046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="4"
      id="ct-nonFraction-1f4f6dff-2b6d-467b-a8ba-b6f4e6ab9996"
      unitRef="Unit15">0.0078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-1c6168b5-34e9-48b4-b157-f44bad1aba73">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021"
      id="ct-nonNumeric-f78c36f0-cff4-401f-a7aa-cc7785fbfd88">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020"
      id="ct-nonNumeric-144576a7-246c-480b-b616-21b917fc3d8a">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-ea05144a-3b48-4e01-ae7e-7c848b16f1dd"
      unitRef="Unit15">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-85841b41-71dc-43db-bd8f-fbd7288d5723"
      unitRef="Unit15">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-a2166f1d-e011-455a-b51b-02a1eed5f816"
      unitRef="Unit15">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-124314ad-9a65-4306-bb81-1c679be346db"
      unitRef="Unit15">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-93785624-a98c-4863-ace9-4243b76afe20"
      unitRef="Unit15">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-98ecec7e-3925-4e8b-8f66-578ed9359a3b"
      unitRef="Unit15">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-8b9a0f01-1c22-40f2-bd3f-b024743a2579"
      unitRef="Unit13">35.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-25d4dd4c-3d1f-4483-b434-141c5322e098"
      unitRef="Unit13">65.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="2"
      id="ct-nonFraction-ec0923f8-e589-4e5c-8a89-679c1fc83446"
      unitRef="Unit13">6.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-91538564-2898-474b-8eb4-53270662e6d1"
      unitRef="Unit15">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-5"
      id="ct-nonFraction-2b48f971-bf6c-411b-a62e-c47585db6035"
      unitRef="Unit12">7700000</sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod>
    <sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-429736d4-9597-4457-8e33-6dcd88d5b105">P2Y4M24D</sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-187aff0a-8746-44d8-a385-c7f81a8bdcdc">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Number of Performance Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;138,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-0a18ef04-da81-4da9-b08e-4f541d5d87fe;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a9cc683b-ce22-4d24-8a07-e6387b6743b3;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.42in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;130,913&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 78.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-325f6f2d-ab8c-47de-9bad-05d03f583253"
      unitRef="Unit1">138055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-3b80978d-9ed8-4227-8c3e-217af6375c7c"
      unitRef="Unit1">130913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-28ffea1b-7d01-400a-82d3-fae1727d92f6"
      unitRef="Unit1">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-ed67067e-941a-440a-83f8-15000ef9af9c"
      unitRef="Unit1">57143</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <sava:ShareBasedCompensationAdditionalExpenseExpectedOnVesting
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="0"
      id="ct-nonFraction-b1582fa5-e049-4755-8e94-a916169286e3"
      unitRef="Unit12">101000</sava:ShareBasedCompensationAdditionalExpenseExpectedOnVesting>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-1fe6736b-1805-4676-9fb3-f11a9454bb96">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,631&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,302&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;453&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;435&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;457&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;535&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,066&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,759&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;988&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 59.2%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-1befe707-ef22-4754-9682-cb9e151737d0"
      unitRef="Unit12">1631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-9764814d-630e-4be0-abec-2d5bab33940a"
      unitRef="Unit12">1302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-3a2b282f-ee32-457c-8c58-5028a44c697c"
      unitRef="Unit12">453000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="ct-nonFraction-c6ada0a0-2a4a-41d4-a33d-5c27a485e70f"
      unitRef="Unit12">435000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="ct-nonFraction-a381da7a-3543-4dc7-b9d0-6b260bc97edb"
      unitRef="Unit12">457000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="ct-nonFraction-0f7cce0e-abfc-4b54-86e5-f6d0b91c79c3"
      unitRef="Unit12">535000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-583abf75-2fa4-40ca-96cc-e8b0229d30f4"
      unitRef="Unit12">2066000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-d8531b16-08b8-4dfa-b965-0ae8ead360f8"
      unitRef="Unit12">1759000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-4cc65d1b-cbf2-4357-8b4b-2c19419b9dc0"
      unitRef="Unit12">988000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-eb462ad9-e21b-49ea-9aa0-95ab9b310389">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;8.  Employee 401(k) Benefit Plan&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the first day of the month after hire and may contribute up to the current statutory limits under Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through December&#160;31, 2022, the Company has not made any matching contributions to the 401(k) plan.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-4970a9c1-6a35-40d2-a23c-48fc4d996827">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;9.  Income Taxes&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company did not provide for income taxes during the periods presented because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective tax rate for periods presented was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-2bbe3c9f-b94d-448f-b6dc-323b380f9a96;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-372e6af5-4c00-48eb-bae0-4471ae3a22e5;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;42.8&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.2&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c5477bfe-2785-4f75-a69d-a809395650e8;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.8&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.2&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-6454e79f-5eac-4ce6-b83d-d54ce1ad34ec;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;23.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;23.8&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eedb89d9-ad7e-4f41-a736-d7fd924e0c16;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eb885844-bf4c-4fb5-ba17-aadb840ba669;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred tax assets and valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.21in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#x2019;s deferred taxes assets at December&#160;31, 2022 and 2021 were valued at the corporate tax rate of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;28,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-de6cc757-c8de-42c3-99b4-15243e637ef0;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;54,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;36,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;54,002&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;36,166&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-1da80672-2d90-4cfe-a52c-83cd81fc610f;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c36d2911-beed-46e5-a06d-8fb8d4dd3d41;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.07in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The valuation allowance increased by $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17.8&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.7&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million in 2022 and 2021, respectively, due primarily to continuing operations.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s net operating loss carryforwards of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;133.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million are federal, of which $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;74.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million expires between &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-ab3e4de0-d223-4a28-a263-17c41929c12c;"&gt;2029&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-c9c2841b-7ede-4662-83a9-7a4f7dcefb27;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;43.9&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million carries forward indefinitely. As of December&#160;31, 2022, the Company had federal research and development tax credits of approximately $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;16.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million, which expire in the years &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-8869304f-1756-4722-a383-48272eaadb6a;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; through &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-16a796f0-25d3-4e27-b50c-84d331cdfb35;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December&#160;31, 2022, 2021 and 2020, the Company has unrecognized tax benefits related to tax credits of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;million, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million, respectively. None of the unrecognized tax benefits as of December&#160;31, 2022, if recognized, would impact the effective tax rate due to the valuation allowance and no interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December&#160;31, 2022, there were &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; unrecognized tax benefits that we expect would change significantly over the next 12 months.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after 2018&#160;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2019 tax year and make adjustments to these net operating loss carryforwards.&#160;We are not under audit in any taxing jurisdiction at this time.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-6db2ddf8-4661-44cf-8708-4db62a59cba7">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-2bbe3c9f-b94d-448f-b6dc-323b380f9a96;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-372e6af5-4c00-48eb-bae0-4471ae3a22e5;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;42.8&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.2&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c5477bfe-2785-4f75-a69d-a809395650e8;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.8&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.2&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-6454e79f-5eac-4ce6-b83d-d54ce1ad34ec;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;23.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;23.8&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eedb89d9-ad7e-4f41-a736-d7fd924e0c16;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-eb885844-bf4c-4fb5-ba17-aadb840ba669;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 41.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="3"
      id="ct-nonFraction-05828735-d665-4be7-9707-acf998869f00"
      unitRef="Unit15">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="3"
      id="ct-nonFraction-770bf994-aa31-4613-a9aa-5effd3084853"
      unitRef="Unit15">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="3"
      id="ct-nonFraction-eace7967-552e-490d-9681-9f9acbff5d83"
      unitRef="Unit15">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="3"
      id="ct-nonFraction-5dc16046-dcfa-405e-a1f9-3904123016a5"
      unitRef="Unit15">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="3"
      id="ct-nonFraction-5b347b1d-4b05-473d-9dda-626b790874f5"
      unitRef="Unit15">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="3"
      id="ct-nonFraction-23b04828-08cb-4bdc-aa99-8167f826bde4"
      unitRef="Unit15">-0.428</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="3"
      id="ct-nonFraction-4c5a648b-d1d2-4854-a994-76f04784346f"
      unitRef="Unit15">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="3"
      id="ct-nonFraction-ec2b8eb6-129b-4184-b120-184411908a71"
      unitRef="Unit15">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="3"
      id="ct-nonFraction-d6652729-fc34-4bd2-917d-1d3410ff0bba"
      unitRef="Unit15">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="3"
      id="ct-nonFraction-ccfb138b-82fc-4cf6-a5f5-0abc844150f2"
      unitRef="Unit15">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="3"
      id="ct-nonFraction-9a302206-62a3-4969-9111-84160872802e"
      unitRef="Unit15">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="3"
      id="ct-nonFraction-6bb28270-be33-48fc-8a0a-7da9516fab68"
      unitRef="Unit15">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="3"
      id="ct-nonFraction-f2502e2f-8b46-4d2d-b187-f46c15e854c4"
      unitRef="Unit15">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="3"
      id="ct-nonFraction-c74b22be-823d-4645-b96d-a6f7011dc0b8"
      unitRef="Unit15">-0.234</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="3"
      id="ct-nonFraction-238c73cb-f21f-439d-8fb7-4ddb630d6010"
      unitRef="Unit15">-0.238</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="3"
      id="ct-nonFraction-d224b327-41a7-4056-a6f6-2f398e342d31"
      unitRef="Unit15">0.202</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="2"
      id="ct-nonFraction-512360f3-a0e9-412e-8caf-88d84d0091bf"
      unitRef="Unit15">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="2"
      id="ct-nonFraction-86138e63-b258-4566-9182-d5e0b4d536d6"
      unitRef="Unit15">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-7bab1450-6747-4e5c-bddc-1839bb13385a">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr style="height: 0.01in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31, &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;28,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-de6cc757-c8de-42c3-99b4-15243e637ef0;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;54,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;36,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;54,002&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;36,166&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;26&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;50&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.17in;"&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-1da80672-2d90-4cfe-a52c-83cd81fc610f;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-c36d2911-beed-46e5-a06d-8fb8d4dd3d41;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 0.07in;"&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 66.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 14.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-2c400d71-1d73-4f72-aba8-128736a65bab"
      unitRef="Unit12">28017000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-c7b59538-d88a-475c-a0c4-7d3041b314da"
      unitRef="Unit12">24777000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a89b4086-5d13-4765-9082-706305607fe9"
      unitRef="Unit12">2706000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-92a5f4c5-b255-4434-8a87-6d35626fd7b8"
      unitRef="Unit12">2870000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-28b0fba5-aede-449e-9aa3-6d2ac08812aa"
      unitRef="Unit12">9681000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-2cc5ed68-b7e1-4cc7-9a11-7fdb68f6c8b0"
      unitRef="Unit12">7439000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-cb474522-9f3a-4fea-a592-ad287b2e0661"
      unitRef="Unit12">12690000</sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d9add9a6-ca18-4013-bd2a-597851bcc818"
      unitRef="Unit12">934000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-ea4b0b2d-6229-4528-a368-30e2cf68ea35"
      unitRef="Unit12">1130000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a0bc4198-e96f-4759-9566-1b736b88d8f4"
      unitRef="Unit12">54028000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-a77341f7-2752-45a3-8dd1-321a9b12f5a7"
      unitRef="Unit12">36216000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-fd428678-627c-4036-b813-0117bd660799"
      unitRef="Unit12">54002000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-84df3fa3-44ce-4b23-b77b-41d491212598"
      unitRef="Unit12">36166000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-096789b9-2ee9-4fc0-b482-3ae19eaf74e2"
      unitRef="Unit12">26000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4eb5ce08-9d3a-406a-b72c-716b4261c4e9"
      unitRef="Unit12">50000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a8db1f78-d191-447e-8ecf-5e7493d90a61"
      unitRef="Unit12">26000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1a73e784-49c5-43d8-a4d9-39266596296f"
      unitRef="Unit12">50000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-f3069435-b6cd-4462-afef-ca003bf23ee7"
      unitRef="Unit12">26000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-fdc0a5f9-cec7-4afe-81b5-763c5cf6b5b2"
      unitRef="Unit12">50000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-5"
      id="ct-nonFraction-08732002-8220-487c-bbe0-f0aadaa41240"
      unitRef="Unit12">17800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-c477692f-65b9-495f-9ba4-b012b9960dec"
      unitRef="Unit12">7700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="ct-nonFraction-3ab76bf4-d2e8-41b0-bd3b-08392eb1a230"
      unitRef="Unit12">133400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_ExpirationOperatingLossCarryforwardsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="ct-nonFraction-9aceb2d6-b2d0-484c-b360-638be7944dbd"
      unitRef="Unit12">74100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_IndefinitelyMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="ct-nonFraction-31de5752-836b-4ade-8f6f-dfb4016e442c"
      unitRef="Unit12">43900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_sava_ExpirationResearchAndDevelopmentTaxCreditsMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember"
      decimals="-5"
      id="ct-nonFraction-f0862a77-8211-4e43-9446-94e6016e95a2"
      unitRef="Unit12">16100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022"
      decimals="-5"
      id="ct-nonFraction-6f0ba0cd-99a7-4b6d-afc5-a66c326af4df"
      unitRef="Unit12">6500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-f48c473d-f16b-4c48-89ce-2fd620763edd"
      unitRef="Unit12">5000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-c65eb66c-076d-4d91-8def-41c6f21f17ca"
      unitRef="Unit12">4500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-ae9616d1-9300-4506-9fdc-e39e0e2ccc80">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: left;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 56.3%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-f2c5ed6b-c2b5-4b7d-8d38-4a3ae55e2a5e"
      unitRef="Unit12">5001000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-99636fce-9848-4b06-bec1-e2aa62effd50"
      unitRef="Unit12">4500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2019"
      decimals="-3"
      id="ct-nonFraction-83316d41-4267-4504-8516-78ca2beca4c2"
      unitRef="Unit12">4400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a6c35c35-a4b1-4225-a201-525648bb2fe9"
      unitRef="Unit12">1495000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-59380b4a-b222-4a18-864d-35d6740fd554"
      unitRef="Unit12">501000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-16d12c67-c6a0-44b6-b7b0-9677e66c959a"
      unitRef="Unit12">100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-273a62d6-8ae7-4b28-b4c0-043cf5f089f1"
      unitRef="Unit12">6496000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-557d0091-698a-4f1b-b216-803d684cb88d"
      unitRef="Unit12">5001000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020"
      decimals="-3"
      id="ct-nonFraction-f84dc899-c278-4dc6-9c5d-e6731bb78de4"
      unitRef="Unit12">4500000</us-gaap:UnrecognizedTaxBenefits>
    <sava:UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-c785dbcf-8fab-4b4f-a8da-a0e33e40b80e"
      unitRef="Unit12">0</sava:UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months>
    <sava:LeasesAndCommitmentsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-70637d9d-7131-4edb-a4ae-5292f4805fcf">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;10.  Leases and Commitments&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Right-of-use Asset and Liability&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company had an operating lease for approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; square feet of office space in Austin, Texas expiring &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;April 30, 2024&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The Company terminated this lease on February 22, 2023 with no continuing obligations. The Company also had a short-term lease agreement for an additional &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,600&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; square feet of office space in Austin, Texas that expired on &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;October 31, 2022&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. Future expected minimum lease payments as of &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;December&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; 31, 2022 are as follows (in thousands).&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total future lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;107&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;36&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;143&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;139&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Rent expense was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million for the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;There were &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; right-of-use assets exchanged for operating lease liabilities during the years ended December&#160;31, 2022 and 2021. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recorded a&#160;right-of-use asset and lease liability&#160;of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;316,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;as a result of the lease&#160;modification in September 2020. The Company utilized a discount rate of&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3.25&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;%&#160;for the modified lease&#160;to determine the present value of the future lease payments, which&#160;approximated the Company&#x2019;s incremental borrowing rate&#160;in September 2020. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cash paid for operating lease liabilities totaled $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;155,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;109,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;99,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; during the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Other Commitments&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations that are generally cancelable. The Company&#x2019;s obligations under these contracts are largely based on services performed.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.&lt;/span&gt;</sava:LeasesAndCommitmentsDisclosureTextBlock>
    <us-gaap:NetRentableArea
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember"
      decimals="0"
      id="ct-nonFraction-51413079-b865-4116-9b06-b1ae6279291f"
      unitRef="Unit16">6000</us-gaap:NetRentableArea>
    <us-gaap:LeaseExpirationDate1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember"
      id="ct-nonNumeric-db7161e2-6717-4f81-bdaa-c8e4e20d9cc7">2024-04-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:NetRentableArea
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_ShortTermOperatingLeaseMember"
      decimals="0"
      id="ct-nonFraction-f825b0dc-b233-442e-80d2-9b66d9754821"
      unitRef="Unit16">3600</us-gaap:NetRentableArea>
    <us-gaap:LeaseExpirationDate1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_ShortTermOperatingLeaseMember"
      id="ct-nonNumeric-2f6597e9-62b7-4a05-bdfd-0519c3125615">2022-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-bb85bf59-c283-4c6b-b84a-3610832a7bee">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total future lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"&gt;&lt;p dir="ltr" style="font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 32.8%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;107&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.2%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;36&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;143&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.4%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;139&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-f1fb7a40-051a-41b0-a070-59834be44be3"
      unitRef="Unit12">107000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-004842da-4eca-415f-a4f1-4555207a8157"
      unitRef="Unit12">36000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-88874d70-ae89-4455-952d-67bf8d97072d"
      unitRef="Unit12">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-65e6ffbb-343c-41a8-937d-c6f8e164710b"
      unitRef="Unit12">4000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-d3f2104f-f154-4734-a8d6-ca96f74c68b8"
      unitRef="Unit12">139000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="-5"
      id="ct-nonFraction-e59e2aba-c27d-496a-b0c6-59474873565c"
      unitRef="Unit12">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-5"
      id="ct-nonFraction-a4860d12-7173-44c7-a72b-42429832a6cf"
      unitRef="Unit12">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-5"
      id="ct-nonFraction-ffc18f3f-320e-4a0a-8b63-bf58759f32e6"
      unitRef="Unit12">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-cf37052b-4902-4d9d-b130-7033ea4678b9"
      unitRef="Unit12">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-01cb266d-9f03-473e-8be8-6deb5f7dd63a"
      unitRef="Unit12">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2020"
      decimals="-3"
      id="ct-nonFraction-9d8e67df-ba3a-4c70-813f-963f8998f422"
      unitRef="Unit12">316000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2020"
      decimals="-3"
      id="ct-nonFraction-3e290909-3b9e-40ff-85f2-417ba55a2ab2"
      unitRef="Unit12">316000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_9_30_2020"
      decimals="4"
      id="ct-nonFraction-37ee9d93-5237-437b-ae66-24f424f0a637"
      unitRef="Unit15">0.0325</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022"
      decimals="0"
      id="ct-nonFraction-ca03f64d-5f2f-4ff7-88b4-2b6efdbc1379"
      unitRef="Unit12">155000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="0"
      id="ct-nonFraction-7a734641-b2ff-4bf0-b20f-c9d767e04831"
      unitRef="Unit12">109000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020"
      decimals="0"
      id="ct-nonFraction-f5bbdb59-efa5-4d76-86cd-a1da0e227acd"
      unitRef="Unit12">99000</us-gaap:OperatingLeasePayments>
    <sava:CashIncentiveBonusPlanTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-e2bc515a-4a20-446c-8360-0d5b4f55036d">&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Note 11.&#160; 2020 Cash Incentive Bonus Plan&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In August 2020, the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#x201c;at-risk&#x201d; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s market capitalization. The Plan is considered &#x201c;at-risk&#x201d; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#x2019;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has not occurred&#160;as of December&#160;31, 2022.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (1) the Company&#x2019;s closing price&#160;of one share&#160;on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (2) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;This constitutes a market condition under applicable accounting guidance.&#160; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#x2019;s market capitalization increases significantly, up to a maximum&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;billion in market capitalization. The Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;200&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million and&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;billion&#160;(each increment,&#160;a &#x201c;Valuation Milestone&#x201d;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for no less than 20 consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;58&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;not awarded by the Compensation Committee&#160;are&#160;no longer available for distribution.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;If the Company were to exceed a $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;139.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;322.3&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(1)&#160;the Company completes a Merger Transaction, or&#160;(2)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#x201c;Performance Condition&#x201d;),&#160;neither&#160;of which may ever occur. Accordingly, there can be no assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#x2019;s market capitalization increases&#160;significantly.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In October 2020, the Company&#160;achieved&#160;the first&#160;Valuation&#160;Milestone.&#160;Subsequently, the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.3&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million&#160;in total&#160;for&#160;all Plan participants, subject to future satisfaction of a Performance Condition.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the year ended December&#160;31, 2021, the Company achieved 11 additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;93.7&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million up to a hypothetical maximum of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;225.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million, to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;compensation expense has been recorded&#160;since no&#160;grant date has occurred and no&#160;Performance Conditions are considered probable of being met.&#160;There is no continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award. No Valuation Milestones were achieved during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;No&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; actual cash payments were authorized or made to participants under the Plan through December&#160;31, 2022.&lt;/span&gt;</sava:CashIncentiveBonusPlanTextBlock>
    <sava:PerformancePlanValuationAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-9"
      id="ct-nonFraction-09852ce1-8342-4a24-9c8c-a2b6bf42d642"
      unitRef="Unit12">5000000000</sava:PerformancePlanValuationAmount>
    <sava:PerformancePlanValuationAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-6"
      id="ct-nonFraction-af5b6656-ff6e-49a7-af5e-255b4be29a80"
      unitRef="Unit12">200000000</sava:PerformancePlanValuationAmount>
    <sava:PerformancePlanValuationAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-9"
      id="ct-nonFraction-13e3ccb1-6188-40c1-b35f-d78ad0d4af72"
      unitRef="Unit12">5000000000</sava:PerformancePlanValuationAmount>
    <sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="2"
      id="ct-nonFraction-f2cfa301-0013-4806-b589-fb22da11fe6f"
      unitRef="Unit15">0.58</sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment>
    <sava:PerformancePlanValuationAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember"
      decimals="-9"
      id="ct-nonFraction-dbc6feeb-e30b-4979-80e3-0bf5b1731979"
      unitRef="Unit12">5000000000</sava:PerformancePlanValuationAmount>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-a679747e-4d03-47bc-9506-b907b63cab91"
      unitRef="Unit12">139100000</sava:CashIncentiveBonusAward>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-65ab2afb-b52c-4b5c-a2d9-7f4883ff97db"
      unitRef="Unit12">322300000</sava:CashIncentiveBonusAward>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_10_13_2020_srt_StatementScenarioAxis_sava_FirstValuationMilestoneMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-76631a41-9484-40d3-a12c-a86eacbcb6d9"
      unitRef="Unit12">7300000</sava:CashIncentiveBonusAward>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-ad89e709-c03e-4f15-9a5c-3c09a2a8eafc"
      unitRef="Unit12">93700000</sava:CashIncentiveBonusAward>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-d39829e5-9ac6-4216-8f2d-46317fab5f1e"
      unitRef="Unit12">225000000.0</sava:CashIncentiveBonusAward>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-6"
      id="ct-nonFraction-b50cd431-73df-440c-9ee4-787ea34cef34"
      unitRef="Unit12">0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <sava:PaymentsForCashIncentiveBonus
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-12408f97-4b91-44f7-aab3-2952ff9c7b6b"
      unitRef="Unit12">0</sava:PaymentsForCashIncentiveBonus>
    <us-gaap:LossContingencyDisclosures
      contextRef="Duration_1_1_2022_To_12_31_2022"
      id="ct-nonNumeric-c127bef2-8f16-4e01-97e3-69add10db656">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;12. Contingencies&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Securities Class Actions and Shareholder Derivative Actions&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Between August 27, 2021 and October 26, 2021, &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;four&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA, and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On June 30, 2022, a federal judge consolidated the &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;four&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; class action lawsuits into &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;one&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on August 18, 2022 on behalf of a putative class of purchasers of our securities between September 14, 2020 and July 26, 2022. Briefing on defendants&#x2019; motion to dismiss was completed on January 23, 2023.&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; The Company believes the claims are without merit and intend to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On November 4, 2021, a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#x2019;s board of directors. This complaint relies on allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#x2019;s alleged wrongful conduct. Although the plaintiff in this derivative case does not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since November 4, 2021, &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, and one in Texas state court (Travis County District Court). &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;All four actions have&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; been stayed pending the resolution of the motions to dismiss in the securities class actions. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On July 5, 2022, the three federal court actions were consolidated into a single action.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#x2019;s board of directors. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the 2020 Cash Incentive Bonus Plan in August 2020. The complaints seek unspecified compensatory damages and other relief. On January 6, 2023, the plaintiffs filed an amended complaint. Although the plaintiffs in this derivative case do not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.&lt;/span&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="Duration_8_27_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="ct-nonFraction-97ad0bc8-198a-4b40-aa58-75a44ebba487"
      unitRef="Unit14">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="Duration_8_27_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="ct-nonFraction-a6851846-5f29-47d7-b706-a1ccf752d79f"
      unitRef="Unit14">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <sava:NumberOfClassActionsConvertedToCase
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="ct-nonFraction-448ff494-24d5-4521-9728-140dafab8bfa"
      unitRef="Unit14">1</sava:NumberOfClassActionsConvertedToCase>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="Duration_11_4_2021_To_11_4_2021_srt_LitigationCaseAxis_sava_ShareholderDerivativeActionsMember"
      decimals="INF"
      id="ct-nonFraction-f7bf8a1c-6f90-40d5-b17d-5121c71fb128"
      unitRef="Unit14">3</us-gaap:LossContingencyNewClaimsFiledNumber>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MQ=G')<$P!*H3X/<Y8W+[15U@][[2[?\!4$L#!!0    ( -N 7%;+P=N5J@4
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M=TSS*UG^+0JSNAQ-1ZC@2]:4YJ-\_(UO'4JLO5R6VOU'CUM9/$)YHXVLMLJ
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MR'00Y)]KKI@1]3TJ.50]I&QY.Y/+LP9N^C&G?L H[0#V92C!8;39'FWV3"H
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M&T,@<*E6'TA]A4@Z HZYDWWGE'WGVNS?D+*IJ#X70-$1+ERA,UQ?F&(AIIA
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M],8U(3$QM5LCJ>4'H1>:98F$N.B(9#$')7;/A0:59A425*^>,"S7><V]"_-
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M;LT?5T8C3M$"O%\XE._A"QV0?FCV[G\ 4$L#!!0    ( -N 7%:';>(AP0(
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M&W>R[+2IM%WC9*5+U0L^"$WZ0]0V$Y_5@PP9[K?.LVT(;VI=UH*3%X0,0L<
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M27?8C\ T/;\QG*Y#GYUK1UT[3"MZ)M%X!]I?:.VVAC^@?7BG?P%02P,$%
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M*!4E>$T^"-OW=D(J)QA\Q%PL5*EJ6:"TV&V"2ILU=>\DN<OE+)W/9>&,:>]
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MO';D)S0>CVD/P*$WQOS$)[)IY",LDHF7I*3&",-P$&P(,\L4(7<<1</*@((
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M!VE/:ST9P<'BW-4(YU8WPFRA%AY$./P,+M[DO.5.KMIXS;Q82U-Y:()/RZ?
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M%+I@P-]+:VDW"0&&7][B%U!+ P04    " #;@%Q6]M-4<IL'  ")$P  &0
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M6)-X?CH*([^[<7KM/[8LM'.Z\I<K*> ($^!]H;7K;EA!__7M^O]02P,$%
M  @ VX!<5LM/RNPO!0  ,PP  !D   !X;"]W;W)K<VAE971S+W-H965T,38N
M>&ULE5=M;Q,Y$/XKH\ AD$*RV:0%2ALI+:!# H& N_MPN@_.[B1KX;7W;"]I
M^/7WC#=9DE+*(;7)>CWSS#.O=LXWSG\.%7.DZ]K8<#&H8FS.QN-05%RK,'(-
M6^RLG*]5Q-*OQZ'QK,JD5)MQGF6GXUII.YB?IW?O_?S<M=%HR^\]A;:NE=]>
MLG&;B\%DL'_Q0:^K*"_&\_-&K?DCQS^:]QZK<8]2ZIIMT,Z2Y]7%8#$YNYR)
M?!+X4_,F'#R3>+)T[K,L7I<7@TP(L>$B"H+"UQ>^8F,$"#3^W6$.>I.B>/B\
M1W^5?(<O2Q7XRIF_=!FKB\'3 96\4JV)']SF=][Y<R)XA3,A?=*FDYW.!E2T
M(;IZIPP&M;;=M[K>Q>% X6GV X5\IY GWIVAQ/*%BFI^[MV&O$@#31Z2JTD;
MY+25I'R,'KL:>G'^AN%2H(4MZ<K5M8X(> SGXPALD1@7.YS+#B?_ <XDI[?.
MQBK02UMR>0PP!JF>6;YG=IG?B?B"BQ%-)T/*LSR_ V_:>SI->--?\I3^7BQ#
M]"B.?VYSNH.<W0XI#7,6&E7PQ0 =$=A_X<'\P;W):?;\#L*SGO#L+O1?2,W=
M.)-L1#LL=</YU(./W>IQ&Y@6(6 (B,@;K9;:Z+BE3Q6+0J/LEBI58I<P#[R*
MVJ[)""AA,)!J&N^N-9J$S99.AUF6H;]:Y;$MD\6M\+?2!5,*%VE+"]2VMD/Z
MQ-<J$%\WV@OFHO':T#1+:9_1Z(A!9(\6@)&28J7#C@!Z^Q4O/:QM*<^3XA1=
M%"NRC@H4I;:M0+NET6LELR <PRH37.<=A<KY^%CL[,#5VC-+L#H_,4;*4@N&
M LOAZ:_Z&2L5.V?A XB_*Z);LN_K' Z_:F,+/ AA<$$*'NNZW?-IU+9+'<!@
M#4W"]1& <,'>RAG,VT /02%6K@W(:W@TZH*30OO)1?BPZJS= '_#(9R1KIM6
M&&B+@'"(.Y5WQP40Z#Y-LB<T/:7);$H/:4:/Y-7T&7V0N(DC%N ;)9+9: */
MC)&)+!&-R,.6E4<)R-SXWJ'T.4EEB8<L90Z$-_*!_/K#"E92P5),1:7L&FAB
MX6:]FEUQ:S OVU1T/R6Q-S\Y+AS/A?.BH&[AD72.36XE9?>!VG4( @)%#CA
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MI2&9I3EAU$O-[+SZ$]>*@)7L3WC-:0K>QI$(EJ12'J=^F(4JZD#!I!D,V#'
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M<9+NBY]WCS3 WO4!P&1.W*:*0VXZ:G24PKB;A9TNVDD"OW%(G>:8-7UZ10L
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MT;VT')DW<M@.03^)X>PEP:<;%NR833S.::LLMT*DI% B?5B+-C@>97*U1';
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MG:5O)=OCZ8O3.^E D[@HJ8#HL/_B64^X]!4GO02[B%].9C8$6\7'$I<Q.3Z
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M-,6+/%@R(C#*L&!Q05G,Q:.&-#DGOLP-8MA:@F?#B-,]0HB1GLGQNF.LDDK
M')$X 0A6'ZN0N0BI),(A_2BJ)1M::&5;4<P.3SH*=8S:  ^$=.)5^+Z^5* 7
M'&U%K?N]S5F=QNH#)(KD)T@.)Y,F'Y$)2"112AQ4-=B)!F$O@W 2[W98Q14-
M!?44L:7DI2N11$IUJ6]/1D9)'6INVUIMD<HZU9??I8XX#\BZN LZ5OP*3BM@
M.X+A\ 3L&;(,D0[0TU'6[Y*7-PPU"OQ. D3469>%)U?5LJ? ,?L0R-7O*XA4
M\5;(U0(=JEY1B^_Y+2U+90]!5%K*4<5J36751E$P0O+M&4%F14BS:]8C-6C)
MCE@/6:Q'R4D0AT/H(&2I2/Z@ CZ DF I8LB5D"$L(6PP&S,)^G![ 4C1<TEH
M/E"7@;6E7>="%">6!NI.Y-RISLT/H2A !#_'>A.%ZQA^XR%18.D4< GK<9,"
M-B,$1#N">_" (^YN<MXU*<Z/NJE/,#\_6SA=8*ON2:D&FQ"/!+(.0';**:LU
MU\G(1&2JPNHRK&8]#L+O38C<><-M'Y.?(N:M8=02)0O4H[U8CX"M 5%9"KW3
MW"_1OB_*E@S'P.F%"RCF_W^8K"$M:HT,#QD=0NN<CB>K=WA'YR0;7W\Y%?D(
MCN_N6] 2;Y,"[MN9)&R 4'(]D55<"(%4)$3XD+69:3;&5&E)-?J52$@OS^O:
M+*FG^&#XL9@-4(IB/EO[:,U4=H5T@Q_X-D,2OQ/B(B,2VAWDV(930$J:2Z0.
M3CUA6+9UF@M<YBMU,H8V4K[[]*7Z%WL70RVS@3B?8GRN):M/ ?V7ZE, ]KUZ
MHIY=CZ:7U^HI?[F8CBZ>7_DOUZ.+BTM\?M_=]*6H1%>?$&$CSNQC.!H@P.7Y
M"-BHBQ>CR_,K-;T>3?#GTZ.V$DJ3\8MSC]WY^/DT?IPRGKN2U!,2$)*,LD_?
MA[ -!TU'YU? ;32=@'2CR>45R4L',$C:7X!XBO^NKB[[O96P^YLBW5, A$FE
MQ5\N8%T] WH7Y+D06B91H$01HZ[2OR.81W %Y4VF6R<^VD@CC-/8$'&FV RB
MN^'V#.?W,](X/"Q.@YJ++AU'G%QNL=.HHB#JD)0?=1])CWORV+KIKW/U(582
M/G95B4%_\FBH]@#4Y&F_!"LU\%CV7NMMK(KA8=V:O:JI28/[?NW QXS#U9:5
MWE)9(S=PQRM.9,6"QUI45POK4N]8P4M#D23U8E-O2[M@Y'ZR&T0"]2C6_1EL
MB.C)7OL,B.T*I_$PPVQ:T@(?PDB?1N]D(?&VK]*<HEGVVH(PFU1[JB!!SNFZ
M**FE0H$6VPWO(T.GEZ,WZ37.R WKDNL]N/8F/%QK[FX@@>#6*N[A<85V+W6U
M\.+>J9&0M2L\A5I9VGRN\C.*6@7K/4H&7M&-:N*C+R,-,MY?1;#(H*!;YFK2
MRGZD<#'IF!RNB8D=L?VK)VUR:-Z:@)1;(G0)?:2M$)AZPXGL'57>::>\TZ-J
M]CDT#&]MQ7,7^.!\)^^&KJ/+8>W]BV!A5.]H?*'PL72 O9?<&1)@EF60X@&B
M!H]^N*V9!?!BU^.ZI,>45D?2XO,#C**MXU!#VE('R[I4-*.(V]>5/_N&/)C>
M+95^+>6@C^B_TJ(P3S#<]EVG9-*!3/-.LCE"E0F"I/'O2%K_29F4+]\%!Z!S
MF >=;:.6[@MIOU^N*UUN*;F#E((H+L; KH$C,VD1A?,2<(TKV!32E":X2IJG
M:'BZX<%R<R.VX7TJQ7QC-\ZHIX-!P;BY7ME%J+W"?;@&[4UN1$/(UM/#F2Z)
M>7%:Q%1<A.A*HVER\)A9B;T ..(V7.U<(A*W-7=S]O##L^YF[/3)PK+C#R8*
MTM=9/,9!"Y)"LV,&H!O-FAP=FGK[D3OH9,7?V0JJ=@>2#2K\7P?CQS-VQC&Z
M;I\,XW"0S=W]01A/:$THS>!!6GTL_ :X%UE,FHWT?2T)C4^X6P0_DA'R&C;(
M8KV-+X6XJ S;$$G)IF1"[9Y"-WYU:W/IG).D/[FYOWVJGDV>!QS5P:*OQWRH
M0<&5EBY1%#RY+AH:)TF$8;EQZJM#4BO*8%!\,.G74[N5NZYYJ+GMRGL/MU"K
M@3^U6<$V)O:N&9L.KJ_]Y%U=)U9*TZI%4FIB!+H[C:3@HWO%D=M0_E1/P YI
M7%.D@-3NJ23G<>@A5'PX4S0<YY@&!L08]0DD5,@^N%G>UFSSJ37=.N?-4KC0
M4>7I1@(GQR?Z?@:-AR<!'[7Q4%7MP,R;;R$6U!@@8U R$*GI=ET:>=K7N31(
MA-[$H\"$FJNW=G[:"ON-%*>TP.D4@RQYT8A1BJ+E[2I/6X+G49ZYG\?[HZ=,
M4A)Y0_(\B@6 =';/FVW%<[<[_0L>./:6@X.D4X+C0?I[>8DV$AB*BD-ZA3!"
M17C$LIAO0R/!:"J[2^&(PJR!I7V"QFYL1\I]0OIIGY2,Q$88)I<"^S\7SLLM
MP_1M\5X%E_KW7*27IJRD.3)3 8,QHR;_AB,"L@>QMR<MD2[SZ-(2SSG*H:G*
MPRK+MF38M?;9VV?M6+$T]YI6.\QG^>L,QS<;!YV$'-73;@)Q\LWA0>@'K#N%
MM31$QD'9H-X^$A ')@&0.O#87UN"PY #4 U!$HAVU4HXF1N0F,PN]Z_?)]]Z
M()(.6H]XDN8D]CC&B1"6>0O)AT^-49R(YEC]NF$+VQ8EA7)AD%00@MA!!GTX
MS+')89@7+WRCALU&E]K 3DS.Y=7>M*.IR'?U3DEF79G[N>)1;G'7*_)=?_X%
M$@Q=O'=<K!'3&!O#)#,2)XEK0MA*K2885$[>*!7G>02R/:86X_1X*#RGTJ?1
M^%*(-#XD19)C4"_#QRNX"*('F:N0@#]<27)G&7,L:@@8%9QD=HF3=>.+6KU\
M5D)B;_LI298XE.7N0<H-/"6R/HQ>XIUEL%%0I*J8&+& +Q?/>M;@J()W$ZF3
MXV.B'V$&JT5!ENV&Y7M0MQ\-PYOOFRP65G9?]1._WKC;SFBZ)B!.G!)1;EV#
M]5Q!24KU+!VG176Z+EGH^_/=]#84\0L.96AN9Q"G3E4&S %WLE/W/'3B8)5B
M,KX(6CXP%7,(F4-2*V/PNJHHE_%3\!R\+J7/(&T(:H"0#R.!*BFN%'^,]X'4
M+BF6Y@5Y+,XJXF&48G^<'^#>?TMFN[G5R?%Y4Z0[=F74W_77 R'DX[?W0J18
MFF*JRZJ&5W694!?H=9E/:#&]-\@XF2SZZ\&?7]2]5""TW)):F@PW$ @B-,R%
M\9FX#'-P$-*DC2;7ZS0-_'YCL YGOA8R8W#DMR4B,<G4 6$UD]BY=]FN7D":
ME/_>NB8$S/.2IRNPJ-:^C2F1C*]?TMA4)04-6E3J352DD#K!*/MZI@]Z1:'P
M1=9QUP]!JZWIMU(I80B=F&0Q.M!M9_8G(]*@(IV8RP=8RLH4+[84J@B"+O0Z
MDJPB=/F8HS)ES_P@,^/?#.*>,G6PD#K,M_ZX<Y*]MO7:NHZQ$10WUOH2'Q=3
MX8Z*T+&/$XKZ0W0I*/U<4\>D\E,D7I;IIT$4*?7)7KAN,L>//C,QR1S)>&SJ
M9;?[P&YXN)I&HG9R##N?>T91?7((5?E)5](ZT-0*)1$>'[8(';9,(BNN:7!R
M_>;^5CV[/!^%VD9J<GPU(PAY5L*GS<,L3/(SL]Z1S5;MGAOJKYSTR&R%3U5[
MZ5P7PVEI".@>F*!2NP6XP9^!V8K:%W/1@ X"#935E*I]H;@,+RN.A&*5P<$<
MR" S2X7YJKFYR\.46\*&&>X'_;FJVLO#&I,M*RX%KDQ=-#$L#0A $OB'*E3^
M]A,BD$)=LCHDT?$A_G45FKG/D<D@<%765GZ.)-$-GZT-NK*SY!>O0';!O^OE
MDFC5R(]?X]/XV^$;^<5LMUQ^>/R+KA?T&Y'2S+'U?/P,^54MO^65+XU=\^]G
M9[9I[(H_+HV&GZ(%>#^WM@E?Z(#XB^JW_P902P,$%     @ VX!<5C_>LB_\
M @  SP8  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULE55_C]LV#/TJ
MA#<,+>#%/Y->LR1 <K=A!=9KT'0;AF%_*#(3"R=+KB0WMV]?2G:\#,C2#@%L
M428?WR,E9G'2YLG6B Z>&ZGL,JJ=:^=)8GF-#;,3W:*B+P=M&N;(-,?$M@99
M%8(:F>1I.DL:)E2T6H2]K5DM=.>D4+@U8+NF8>;O#4I]6D99=-YX+XZU\QO)
M:M&R(^[0_=IN#5G)B%*)!I456H'!PS):9_--Z?V#PV\"3_9B#5[)7NLG;[RI
MEE'J":%$[CP"H]<GO$<I/1#1^#A@1F-*'WBY/J/_%+23ECVS>*_E[Z)R]3*Z
MBZ#" ^ND>Z]//^.@9^KQN)8V/.$T^*81\,XZW0S!Q* 1JG^SYZ$.7Q.0#P%Y
MX-TG"BP?F&.KA=$G,-Z;T/PB2 W11$XHWY2=,_154)Q;[?IF@#[ 3AR5. C.
ME(,UY[I33J@C;+447*"%%Q_87J)]N4@<)?;A"1^2;/HD^7\DR7)XJY6K+?RH
M*JS^#9 0XY%V?J:]R6\B/B"?0)'%D*=Y?@.O&,M0!+SB"V5X]^4R_+G>6V?H
M-/UUK1!]FO)Z&G_#YK9E')<172&+YA-&J^^^R6;I#S=$E*.(\A;ZZK%KT#"G
MC86UJN !E:83TV^\4?"A1KAGDG>2A0M!6C?,"MX["]DYK."1YL OVEK8HH%=
MS0Q>4WF3QW65\ <RXH'^ ! UCLV>,IQ;Z!^9?Z0PJI@',M*3^19>P*M9G)<S
M>!F,(H^+N^E@S.*B*&E](7C><[?064HG%'#=M%UHI#J#MI3?>J_8WVNJ Z,Z
M5$,=RC0F-E"\CLMT"ODLSNCU^%6AGE(V>9T.[-+)73XN\\#3.](L\J0::@1=
M<OX$NO5=H0H]<]GY(AV,;JZR/2?*XW1*W.(\H]+%63F%^TO $S.&#O'_0?R>
M?M-I"=<.8W(Q9*A#QS!*+80+TL^;<7><UNM^2/WCWH_ZM\P<!4F5>*#0=/)J
M&H'IQV=O.-V&D;77C@9@6-;TCX/&.]#W@];N;/@$XW_8ZC-02P,$%     @
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MUA8:C2[. M!=>W8&J<:WQ$J1;3"_K>Q$0^T"[/E:*=H9+L$P(_,_4$L#!!0
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M"PP&XR%&JNG7)C"R\E=^(XUM(#\M[!,'RB78_5Q*<PA<%W6/9O('4$L#!!0
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M(]4F6& )K$%PKR*X9T(?/0*)9QD7D&?1G+,8/6 ]<V&*[A(AB<RD(E>5T1?
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M49\@O&PHRX%D>]-BW3.I&C9SF:HF'',=H.YO&9// _V NJU?_@!02P,$%
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MTP?"!.CY%>=JUS'5M7U,DS]02P,$%     @ VX!<5CV,\1N! P  ^0X  !D
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MA:QC].->UJ; 5 ?Y?4NI>&HH!TVU&_X&4$L#!!0    ( -N 7%:/+00WEP,
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MAH-B(UF:]]<)DZI;Y\M(S5/ M8&ZGS(F5QO]@FI"\_\ 4$L#!!0    ( -N
M7%;C#C":#00  -X4   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;+58
M46^C.!#^*Q9W.K52KV"2DK271&K+[MU*V]UHJ[U[.-V# Y,$+6#6-DTKW8^_
M,1!""G&;'ON28)CY/-\WQAYFLN'BFUP#*/*8Q*F<6FNELBO;EL$:$B;/>08I
M/EERD3"%0[&R92: A853$MNNXWAVPJ+4FDV*>W,QF_!<Q5$*<T%DGB1,/-U
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M$>=RC02X6- TIYD\Y.#C"O1778%_B+@$%_=$X#CAE^ M^/)X#R[>7((W(,[
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M4P7R^Q6EXG"B=BOKW>G@?U!+ P04    " #;@%Q6:M;\<6\"  "6!@  &0
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M86D?#M NP.[/E<+MQ"7HGJ+T/U!+ P04    " #;@%Q6A(8E,!\#  #<"P
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M=</77R%+J&GX(IY(^XO66:SGH&@I%:<96"N@A&W^\6-FQ!; ;SP#"#) \%I
M/0/4;:(;93:M$58X[ F^1L)$:S8SL-Y8M,Z&,+.-MTKHMT3C5#AF"K,%F2:
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M;P0X98!S:H!;!KBG!GAE@'=JP* ,&+P.&+P1,"P#AJ\"G+<"1F7 Z-0FC<N
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MI5 :@](XE!9 :0)%TV5:>SR<T;8Y97YG)G26I]=,QB>OE0DU_* T!J5Q*"V
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M_Q4KN]KK2BR)G1] %Y"@[>KVH=JJO78?3O=@D@&B)C%K&VBE^^//3B"A2^)
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MTJY*:= @S87@)DOYBH'K=$$7NP9&(LXJ6+@-]@I:+;ZG\R% [CF #H3@#(P
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MZ9)O<0(+2QX['-@.K.CM&S=T/IKJ^2?)XC]$=E3KH*MU,,0>W=-"%J^0M?V
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M!:WC=]>:; ER9H>5(JF8<UTWI=;:SL.1'0-;]C'.R7JL_:>IA^PME?B.*E+
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MOON=U0U:&+V0I[+\BW;UL]X$A5NI>%8'ZQID25[]I[>U$9T O'P@@-0!Y'[
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MG6%-,U6?)<#U!'5]Q9C<=_0"]8=.^ =02P,$%     @ VX!<5G;ZGT-* P
MRA0   T   !X;"]S='EL97,N>&ULW5A=3]LP%/TK41@32!-I&TB;T5;:*B%-
MVB8D>-@;<ANGM>0XF>.REE\_7]M-/_#M.AY&62J(?8_/N<?V36/HUVK)Z=V,
M4A4L"B[J03A3JOH81?5D1@M27Y05%1K)2UD0I;MR&M65I"2K@53PJ--J)5%!
MF B'?3$O;@I5!Y-R+M0@[#:AP-Z^9(.PG5R&@94;E1D=A ]G[W_.2W7]+K#W
MDP\G)ZV+UL/Y]2YRYJ#S,/(*7QT@C,IBHLE!;EO[_+90\>YAXONT,>G>MK09
M?JJ%+/$4HZ4>FMF,/RQ^M^4E;J2$CB%'KDR&_;P4ZVJ)0QO0ZJ2@P2/A@W!$
M.!M+!JR<%(PO;;@#@4G)2QDH7:8Z71LB]9.%V[8'%>QT"B9*:7+;#/;WV W?
M 58],,@X;PQV0AL8]BNB%)7B1G?,8!-\!@6N?;^LM,.I),MVYRI<$\Q-)QF7
M,J.R2=,.5Z%AG],<[$@VG<%=E54$H%)EH1L9(]-2$.-AQ7 -+3NAG-_!X_TC
MW])>Y!O[9G9--$UMR#6MC.V _J::U=Z4O7R1;E"QQU)]GNOI"-.'RJ:WDN9L
M8?J+O#& J;=Q=5)5?/F)LZDHJ)W\P0F'?;+B!;-2LB>=#4IEH@-4AL$CE8I-
M-B._)*GNZ4*MRFF1XYX[;]#SOUWG*154$KYI6M?^,:_RBQV[]^%K>#9?*[N.
MO2;C[O%[=.__8S>9O 63;V*[>\=O,DZ/WZ,[\QVYR>ZK?;/O-1FYD]#&<6OK
ML-5$ SC4#L+O<$3FZZ3!>,ZX8L+U9BS+J'AVYM+RBHSU'VI;^GI\1G,RY^J^
M 0?ANOV-9FQ>I,VH6U@(-VK=_@K3:R?-B5KG8B*C"YJ-7%=.QZ89Z(;.ZBX@
M["(WYO(C&,=B?@0P+ _F .-8%I;G?YI/#YV/Q3!O/2_20SD]E&-9/F1D/E@>
M/R?5EW^F:1K'28*MZ&CD=3#"UBU)X,>OAGD#!I8',OW=6N.[C5?(_CK ]G1?
MA6 SQ2L1FRF^UH#XUPT8:>K?;2P/,+!=P&H'\OOS0$WY.7$,NXIYPYY@'$E3
M#(%:]-=HDB"KD\#'OS_84Q+':>I' /,[B&,,@:<11S 'X %#XMB\!W?>1]'J
M/16M_WLY_ U02P,$%     @ VX!<5I>*NQS     $P(   L   !?<F5L<R\N
M<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9
M>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:
M+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU
M1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*
MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #;@%Q6-W]I:6@$  "V(P  #P
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MZNKZ*I3-]:V1Y>:SD\TG,^_^!5!+ P04    " #;@%Q6?'[I&]0!  #&'P
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MN[B]I[4NFT,^Z_[)3SX!4$L! A0#%     @ VX!<5@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #;
M@%Q6]44'.^X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #;@%Q6F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -N 7%:H@B>L
MB @  +LT   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #;@%Q6R\';E:H%  #5%P  &
M@('+$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ VX!<
M5L_@C2?+ @  W0D  !@              ("!JQ8  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( -N 7%8X8.TS# 0  (<.   8
M      " @:P9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #;@%Q6>3Z3\3P(  !S0@  &               @('N'0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ VX!<5FK%SV/6!@  :2(  !@
M             ("!8"8  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( -N 7%;)KGEQ#08  ,0-   8              " @6PM  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #;@%Q67%(,:(,2  !T
M-@  &               @(&O,P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ VX!<5H=MXB'! @  F@8  !@              ("!:$8
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -N 7%9H4=Y'
M% <  'L0   9              " @5])  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ VX!<5L7A7XFK P  VP@  !D
M ("!JE   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #;
M@%Q6IV$_Z1H#  "$!P  &0              @(&,5   >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -N 7%9_*KYA>0P  +(C   9
M          " @=U7  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ VX!<5D30]I<" P  _@8  !D              ("!C60  'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #;@%Q6]M-4<IL'  ")
M$P  &0              @('&9P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    ( -N 7%;+3\KL+P4  #,,   9              " @9AO
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ VX!<5O]=
MR"M9"   7Q<  !D              ("!_G0  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    " #;@%Q6ZD+P$=(&  !6$P  &0
M    @(&.?0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M -N 7%8DF[]9AA,  %T]   9              " @9>$  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ VX!<5C_>LB_\ @  SP8  !D
M             ("!5)@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #;@%Q6EDWB5H$"  "@!0  &0              @(&'FP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -N 7%;<F*W $0,
M  ('   9              " @3^>  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ VX!<5IU)532Z @  $08  !D              ("!
MAZ$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #;@%Q6
MDL%18M,"  "Q!@  &0              @(%XI   >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( -N 7%8W3Y; D 4  ) .   9
M      " @8*G  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ VX!<5OO7J5U-!   T0H  !D              ("!2:T  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #;@%Q6NENB]5 "   O!0
M&0              @('-L0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( -N 7%;O?%H"/P(  $ %   9              " @52T  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ VX!<5K55/DD*
M!0  5AX  !D              ("!RK8  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #;@%Q6]S7=YM@#  #B#P  &0
M@($+O   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -N
M7%;* 2-_L0(  %@'   9              " @1K   !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ VX!<5CV,\1N! P  ^0X  !D
M         ("! L,  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " #;@%Q6CRT$-Y<#  "/$   &0              @(&ZQ@  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( -N 7%8O1&Q3# ,  *T)
M   9              " @8C*  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ VX!<5N,.,)H-!   WA0  !D              ("!R\T
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #;@%Q6(>'
M=1$$  "I%@  &0              @($/T@  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( -N 7%9JUOQQ;P(  )8&   9
M  " @5?6  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
MVX!<5H2&)3 ? P  W L  !D              ("!_=@  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #;@%Q6]LEE7'H"  !<!P  &0
M            @(%3W   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( -N 7%8A_#!Z$@P  -F8   9              " @03?  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ VX!<5BOY6(YW!
M$1(  !D              ("!3>L  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #;@%Q6:\X)C4T&  "D)@  &0              @('[
M[P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( -N 7%;X
MIJ-*KP,  -P,   9              " @7_V  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ VX!<5B4?#P7, @  5@<  !D
M     ("!9?H  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -N 7%:%QR^GXP(  $D(   9              "
M@48/ 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ VX!<
M5NOP"@]Y!   ?AH  !D              ("!8!(! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " #;@%Q6-*3+':D"   :"   &0
M        @($0%P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( -N 7%:2T4VA#@8  -<M   9              " @? 9 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ VX!<5F4L3(D= P  ] P
M !D              ("!-2 ! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " #;@%Q6=OJ?0TH#  #*%   #0              @ &)(P$
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -N 7%:7BKL<P    !,"   +
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4!08     /0 ] *(0  "#, $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>142</ContextCount>
  <ElementCount>275</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements Of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements Of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements Of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements Of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00500 - Statement - Consolidated Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - General, Liquidity And Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentation</Role>
      <ShortName>General, Liquidity And Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary Of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary Of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Prepaid And Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssets</Role>
      <ShortName>Prepaid And Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Real Property Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisition</Role>
      <ShortName>Real Property Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Property And Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property And Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stockholders' Equity And Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Employee 401(k) Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureEmployee401KBenefitPlan</Role>
      <ShortName>Employee 401(k) Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Leases And Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments</Role>
      <ShortName>Leases And Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - 2020 Cash Incentive Bonus Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan</Role>
      <ShortName>2020 Cash Incentive Bonus Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureContingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy</Role>
      <ShortName>Summary of Significant Accounting Policies (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Prepaid And Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid And Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Real Property Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionTables</Role>
      <ShortName>Real Property Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisition</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Property And Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property And Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Leases And Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables</Role>
      <ShortName>Leases And Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40101 - Disclosure - General, Liquidity and Basis of Presentation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentationNarrativeDetails</Role>
      <ShortName>General, Liquidity and Basis of Presentation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Prepaid And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Real Property Acquisition (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails</Role>
      <ShortName>Real Property Acquisition (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Real Property Acquisition (Summary Of Acquisition) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails</Role>
      <ShortName>Real Property Acquisition (Summary Of Acquisition) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Real Property Acquisition (Components Of Other Income, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails</Role>
      <ShortName>Real Property Acquisition (Components Of Other Income, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Property And Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property And Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property And Equipment (Components Of Property And Equipment, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets (Components Of Intangible Assets, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40705 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40706 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Stock-Based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation (Stock-Based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails</Role>
      <ShortName>Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Leases And Commitments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails</Role>
      <ShortName>Leases And Commitments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Leases And Commitments (Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases And Commitments (Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41101 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails</Role>
      <ShortName>2020 Cash Incentive Bonus Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="sava-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails</Role>
      <ShortName>Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureContingencies</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:OperatingLossCarryforwardsExpirationDate, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate, us-gaap:TaxCreditCarryforwardExpirationDate -  sava-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="sava-20221231x10k.htm">sava-20221231x10k.htm</File>
    <File>sava-20221231.xsd</File>
    <File>sava-20221231_cal.xml</File>
    <File>sava-20221231_def.xml</File>
    <File>sava-20221231_lab.xml</File>
    <File>sava-20221231_pre.xml</File>
    <File>sava-20221231xex21_1.htm</File>
    <File>sava-20221231xex23_1.htm</File>
    <File>sava-20221231xex31_1.htm</File>
    <File>sava-20221231xex31_2.htm</File>
    <File>sava-20221231xex32_1.htm</File>
    <File>sava-20221231xex3_4.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sava-20221231x10kg001.jpg</File>
    <File>sava-20221231x10kg002.jpg</File>
    <File>sava-20221231x10kg003.jpg</File>
    <File>sava-20221231x10kg004.jpg</File>
    <File>sava-20221231x10kg005.jpg</File>
    <File>sava-20221231x10kg006.jpg</File>
    <File>sava-20221231x10kg007.jpg</File>
    <File>sava-20221231x10kg008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="605">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sava-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 605,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 142,
   "dts": {
    "calculationLink": {
     "local": [
      "sava-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sava-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sava-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sava-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sava-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sava-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 419,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 82,
    "http://www.cassavasciences.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 7,
    "total": 90
   },
   "keyCustom": 25,
   "keyStandard": 250,
   "memberCustom": 26,
   "memberStandard": 23,
   "nsprefix": "sava",
   "nsuri": "http://www.cassavasciences.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Real Property Acquisition",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisition",
     "shortName": "Real Property Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Property And Equipment",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment",
     "shortName": "Property And Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cassavasciences.com/role/DisclosureIntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Stockholders' Equity And Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation",
     "shortName": "Stockholders' Equity And Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Employee 401(k) Benefit Plan",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cassavasciences.com/role/DisclosureEmployee401KBenefitPlan",
     "shortName": "Employee 401(k) Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cassavasciences.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:LeasesAndCommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Leases And Commitments",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments",
     "shortName": "Leases And Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:LeasesAndCommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - 2020 Cash Incentive Bonus Plan",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan",
     "shortName": "2020 Cash Incentive Bonus Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cassavasciences.com/role/DisclosureContingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policy)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy",
     "shortName": "Summary of Significant Accounting Policies (Policy)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Prepaid And Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsTables",
     "shortName": "Prepaid And Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Real Property Acquisition (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionTables",
     "shortName": "Real Property Acquisition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Property And Equipment (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property And Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables",
     "shortName": "Stockholders' Equity And Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Leases And Commitments (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables",
     "shortName": "Leases And Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - General, Liquidity and Basis of Presentation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentationNarrativeDetails",
     "shortName": "General, Liquidity and Basis of Presentation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sava:ReductionToResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sava:ReductionToResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit13",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit13",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Prepaid And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetRentableArea",
      "reportCount": 1,
      "unitRef": "Unit16",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Real Property Acquisition (Narrative) (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails",
     "shortName": "Real Property Acquisition (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_8_4_2021_To_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Real Property Acquisition (Summary Of Acquisition) (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails",
     "shortName": "Real Property Acquisition (Summary Of Acquisition) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Real Property Acquisition (Components Of Other Income, Net) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails",
     "shortName": "Real Property Acquisition (Components Of Other Income, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherNonoperatingIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Property And Equipment (Narrative) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
     "shortName": "Property And Equipment (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ProceedsFromSaleOfMachineryAndEquipment",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfMachineryAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
     "shortName": "Property And Equipment (Components Of Property And Equipment, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Intangible Assets (Narrative) (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails",
     "shortName": "Intangible Assets (Components Of Intangible Assets, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails",
     "shortName": "Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements Of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements Of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
     "shortName": "Stockholders' Equity And Stock-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-5",
      "lang": null,
      "name": "sava:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails",
     "shortName": "Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails",
     "shortName": "Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40705 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails",
     "shortName": "Stockholders' Equity And Stock-Based Compensation (Summary Of Performance Award Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40706 - Disclosure - Stockholders' Equity And Stock-Based Compensation (Stock-Based Compensation Expenses) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails",
     "shortName": "Stockholders' Equity And Stock-Based Compensation (Stock-Based Compensation Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit15",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit15",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails",
     "shortName": "Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements Of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements Of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "us-gaap:OperatingLeaseExpense",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Leases And Commitments (Narrative) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails",
     "shortName": "Leases And Commitments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "us-gaap:OperatingLeaseExpense",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Leases And Commitments (Future Minimum Lease Payments) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases And Commitments (Future Minimum Lease Payments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember",
      "decimals": "-9",
      "first": true,
      "lang": null,
      "name": "sava:PerformancePlanValuationAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
     "shortName": "2020 Cash Incentive Bonus Plan (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember",
      "decimals": "-9",
      "first": true,
      "lang": null,
      "name": "sava:PerformancePlanValuationAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_8_27_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit14",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Contingencies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails",
     "shortName": "Contingencies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_8_27_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit14",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Consolidated Statements Of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements Of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - General, Liquidity And Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentation",
     "shortName": "General, Liquidity And Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary Of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary Of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:PrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Prepaid And Other Current Assets",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssets",
     "shortName": "Prepaid And Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:PrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sava_AtMarketEquityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Equity Program [Member]",
        "label": "At Market Equity Program [Member]",
        "terseLabel": "ATM [Member]"
       }
      }
     },
     "localname": "AtMarketEquityProgramMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_AustinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Austin [Member]",
        "label": "Austin [Member]",
        "terseLabel": "Austin, Texas [Member]"
       }
      }
     },
     "localname": "AustinMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_CashIncentiveBonusAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Incentive Bonus Award",
        "label": "Cash Incentive Bonus Award",
        "terseLabel": "Cash bonus award"
       }
      }
     },
     "localname": "CashIncentiveBonusAward",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_CashIncentiveBonusPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Cash Incentive Bonus Plan [Abstract]",
        "label": "2020 Cash Incentive Bonus Plan [Abstract]"
       }
      }
     },
     "localname": "CashIncentiveBonusPlanAbstract",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sava_CashIncentiveBonusPlanLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Incentive Bonus Plan [Line Items]",
        "label": "Cash Incentive Bonus Plan [Line Items]"
       }
      }
     },
     "localname": "CashIncentiveBonusPlanLineItems",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sava_CashIncentiveBonusPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Incentive Bonus Plan [Member]",
        "label": "Cash Incentive Bonus Plan [Member]",
        "terseLabel": "Cash Incentive Bonus Plan [Member]"
       }
      }
     },
     "localname": "CashIncentiveBonusPlanMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_CashIncentiveBonusPlanTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Incentive Bonus Plan [Table]",
        "label": "Cash Incentive Bonus Plan [Table]"
       }
      }
     },
     "localname": "CashIncentiveBonusPlanTable",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sava_CashIncentiveBonusPlanTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Incentive Bonus Plan [Text Block]",
        "label": "Cash Incentive Bonus Plan [Text Block]",
        "terseLabel": "2020 Cash Incentive Bonus Plan"
       }
      }
     },
     "localname": "CashIncentiveBonusPlanTextBlock",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sava_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants [Member]",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Capitalized Research and Development Expenses.",
        "label": "Deferred Tax Assets Capitalized Research and Development Expenses",
        "terseLabel": "Capitalized research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exceeding Performance Milestones Minimum 20 Consecutive Days",
        "label": "Exceeding Performance Milestones Minimum20 Consecutive Days [Member]",
        "terseLabel": "Exceeding Performance Milestones Minimum 20 Consecutive Days [Member]"
       }
      }
     },
     "localname": "ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_Exceeds5BillionMarketCapitalizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exceeds 5 Billion Market Capitalization [Member]",
        "label": "Exceeds5 Billion Market Capitalization [Member]",
        "terseLabel": "Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]"
       }
      }
     },
     "localname": "Exceeds5BillionMarketCapitalizationMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_ExpirationOperatingLossCarryforwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Operating Loss Carryforwards [Member]",
        "label": "Expiration Operating Loss Carryforwards [Member]",
        "terseLabel": "Expires Between 2029 And 2037 [Member]"
       }
      }
     },
     "localname": "ExpirationOperatingLossCarryforwardsMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_ExpirationResearchAndDevelopmentTaxCreditsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Research And Development Tax Credits [Member]",
        "label": "Expiration Research And Development Tax Credits [Member]",
        "terseLabel": "Expires Between 2024 And 2042 [Member]"
       }
      }
     },
     "localname": "ExpirationResearchAndDevelopmentTaxCreditsMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_FirstValuationMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Valuation Milestone [Member]",
        "label": "First Valuation Milestone [Member]",
        "terseLabel": "First Valuation Milestone [Member]"
       }
      }
     },
     "localname": "FirstValuationMilestoneMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net",
        "negatedLabel": "Operating lease right-of-use assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_IndefinitelyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinitely [Member]",
        "label": "Indefinitely [Member]",
        "terseLabel": "Indefinitely [Member]"
       }
      }
     },
     "localname": "IndefinitelyMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_LeasesAndCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases And Commitments [Abstract]",
        "label": "Leases And Commitments [Abstract]"
       }
      }
     },
     "localname": "LeasesAndCommitmentsAbstract",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sava_LeasesAndCommitmentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases and commitments.",
        "label": "Leases And Commitments Disclosure [Text Block]",
        "terseLabel": "Leases And Commitments"
       }
      }
     },
     "localname": "LeasesAndCommitmentsDisclosureTextBlock",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sava_LeasesAndCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases And Commitments [Line Items]",
        "label": "Leases And Commitments [Line Items]"
       }
      }
     },
     "localname": "LeasesAndCommitmentsLineItems",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sava_LeasesAndCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases And Commitments [Table]",
        "label": "Leases And Commitments [Table]"
       }
      }
     },
     "localname": "LeasesAndCommitmentsTable",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sava_LeasingCommissionsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasing Commissions And Other [Member]",
        "label": "Leasing Commissions And Other [Member]",
        "terseLabel": "Leasing Commissions And Other [Member]"
       }
      }
     },
     "localname": "LeasingCommissionsAndOtherMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_NetLossPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Loss Per Share Basic And Diluted",
        "label": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "NetLossPerShareBasicAndDiluted",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "sava_NumberOfClassActionsConvertedToCase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of class actions converted to case",
        "label": "Number of class actions converted to case"
       }
      }
     },
     "localname": "NumberOfClassActionsConvertedToCase",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sava_PaymentsForCashIncentiveBonus": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Cash Incentive Bonus",
        "label": "Payments For Cash Incentive Bonus",
        "terseLabel": "Payments authorized or made to participants under the Plan"
       }
      }
     },
     "localname": "PaymentsForCashIncentiveBonus",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_PercentageOfCommissionAtmOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Commission ATM Offering",
        "label": "Percentage Of Commission ATM Offering",
        "terseLabel": "Percentage of commission in ATM offering"
       }
      }
     },
     "localname": "PercentageOfCommissionAtmOffering",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sava_PercentageOfCurrentlyLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Currently Leased",
        "label": "Percentage Of Currently Leased"
       }
      }
     },
     "localname": "PercentageOfCurrentlyLeased",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sava_PercentageOfOccupancy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Occupancy",
        "label": "Percentage Of Occupancy"
       }
      }
     },
     "localname": "PercentageOfOccupancy",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment",
        "label": "Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment",
        "terseLabel": "Percentage of each cash bonus award associated with Valuation Milestone subject to adjustment and approval"
       }
      }
     },
     "localname": "PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sava_PerformancePlanValuationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Plan Valuation Amount",
        "label": "Performance Plan Valuation Amount",
        "terseLabel": "Valuation milestone amount in market capitalization"
       }
      }
     },
     "localname": "PerformancePlanValuationAmount",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_PrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid And Other Assets Disclosure [Text Block]",
        "label": "Prepaid And Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sava_ProceedsFromGrantsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Grants Policy [Policy Text Block]",
        "label": "Proceeds From Grants Policy [Policy Text Block]",
        "terseLabel": "Proceeds From Grants"
       }
      }
     },
     "localname": "ProceedsFromGrantsPolicyPolicyTextBlock",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sava_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering [Member]",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering [Member]"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_RangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Five [Member]",
        "label": "Range Five [Member]",
        "terseLabel": "$36.40 - $77.00 [Member]"
       }
      }
     },
     "localname": "RangeFiveMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_RangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Four [Member]",
        "label": "Range Four [Member]",
        "terseLabel": "$12.39 - $35.00 [Member]"
       }
      }
     },
     "localname": "RangeFourMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_RangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range One [Member]",
        "label": "Range One [Member]",
        "terseLabel": "$0.95 - $1.88 [Member]"
       }
      }
     },
     "localname": "RangeOneMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_RangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Three [Member]",
        "label": "Range Three [Member]",
        "terseLabel": "$4.09 - $12.04 [Member]"
       }
      }
     },
     "localname": "RangeThreeMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_RangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Two [Member]",
        "label": "Range Two [Member]",
        "terseLabel": "$3.24 - $3.24 [Member]"
       }
      }
     },
     "localname": "RangeTwoMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_ReductionToResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction To Research And Development Expense",
        "label": "Reduction To Research And Development Expense",
        "verboseLabel": "Reimbursement from National Institutes of Health research grants"
       }
      }
     },
     "localname": "ReductionToResearchAndDevelopmentExpense",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_RegisteredDirectOffering2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered Direct Offering 2021 [Member]",
        "label": "Registered Direct Offering2021 [Member]",
        "terseLabel": "2021 Registered Direct Offering [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOffering2021Member",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_RegisteredDirectOffering2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered Direct Offering 2022 [Member]",
        "label": "Registered Direct Offering2022 [Member]",
        "terseLabel": "Registered Direct Offering 2022 [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOffering2022Member",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Expense, Net Of Grant Reimbursement",
        "label": "Research and Development Expense, Net Of Grant Reimbursement",
        "terseLabel": "Research and development, net of grant reimbursement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseNetOfGrantReimbursement",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Contract Costs And Accruals Policy [Policy Text Block]",
        "label": "Research Contract Costs And Accruals Policy [Policy Text Block]",
        "terseLabel": "Research Contract Costs And Accruals"
       }
      }
     },
     "localname": "ResearchContractCostsAndAccrualsPolicyPolicyTextBlock",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sava_SecondThroughEighthValuationMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Through Eighth Valuation Milestones [Member]",
        "label": "Second Through Eighth Valuation Milestones [Member]",
        "terseLabel": "Second Through Eighth Valuation Milestones [Member]"
       }
      }
     },
     "localname": "SecondThroughEighthValuationMilestonesMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_ShareBasedCompensationAdditionalExpenseExpectedOnVesting": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Additional Expense Expected On Vesting.",
        "label": "Share Based Compensation Additional Expense Expected On Vesting",
        "terseLabel": "Additional stock compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensationAdditionalExpenseExpectedOnVesting",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options grant in period weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Expiration period of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeitures In Period",
        "terseLabel": "Compensation costs prior to forfeiture"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriod",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options nonvested forfeitures in period weighted average contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeitures In Period Weighted Average Contractual Term",
        "terseLabel": "Weighted average remaining recognition period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeituresInPeriodWeightedAverageContractualTerm",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sava_ShareholderDerivativeActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder derivative actions",
        "label": "Shareholder Derivative Actions [Member]",
        "terseLabel": "Shareholder derivative actions [Member]"
       }
      }
     },
     "localname": "ShareholderDerivativeActionsMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_SharesUsedInComputingNetLossPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares used in computing net loss per share, basic and diluted",
        "label": "Shares used in computing net loss per share, basic and diluted"
       }
      }
     },
     "localname": "SharesUsedInComputingNetLossPerShareBasicAndDiluted",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "sava_ShortTermOperatingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short Term Operating Lease [Member]",
        "label": "Short Term Operating Lease [Member]",
        "terseLabel": "Short-Term Operating Lease [Member]"
       }
      }
     },
     "localname": "ShortTermOperatingLeaseMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Line Items]",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sava_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table]",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options Exercised Net Settled Satisfaction Of Exercise Price",
        "label": "Stock Options Exercised Net Settled Satisfaction Of Exercise Price",
        "terseLabel": "Stock options exercised, net settled in satisfaction of the exercise price"
       }
      }
     },
     "localname": "StockOptionsExercisedNetSettledSatisfactionOfExercisePrice",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sava_TwoThousandEightEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2008 Equity Incentive Plan [Member]",
        "label": "Two Thousand Eight Equity Incentive Plan [Member]",
        "terseLabel": "2008 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEightEquityIncentivePlanMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_TwoThousandEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits no significant change over the next 12 months",
        "label": "Unrecognized tax benefits no significant change over next 12 months"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNoSignificantChangeOverNext12Months",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_ViolationsOfFederalSecuritiesLawsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "violations of the federal securities laws",
        "label": "Violations Of Federal Securities Laws [Member]",
        "terseLabel": "Violations of the federal securities laws [Member]"
       }
      }
     },
     "localname": "ViolationsOfFederalSecuritiesLawsMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants [Member]",
        "label": "Warrants [Member]",
        "terseLabel": "Common Stock Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://www.cassavasciences.com/20221231",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case Type [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r207",
      "r227",
      "r314",
      "r322",
      "r341",
      "r342",
      "r351",
      "r353",
      "r359",
      "r396",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r207",
      "r227",
      "r314",
      "r322",
      "r341",
      "r342",
      "r351",
      "r353",
      "r359",
      "r396",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r207",
      "r226",
      "r227",
      "r256",
      "r257",
      "r258",
      "r313",
      "r314",
      "r322",
      "r341",
      "r342",
      "r351",
      "r353",
      "r359",
      "r391",
      "r396",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r207",
      "r226",
      "r227",
      "r256",
      "r257",
      "r258",
      "r313",
      "r314",
      "r322",
      "r341",
      "r342",
      "r351",
      "r353",
      "r359",
      "r391",
      "r396",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r162",
      "r228",
      "r371",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r352",
      "r358",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r328",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r352",
      "r358",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r162",
      "r228",
      "r371",
      "r372",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r357"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "auth_ref": [
      "r12",
      "r87",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "terseLabel": "Accrued property taxes"
       }
      }
     },
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Development Expense Current",
        "terseLabel": "Accrued development expense"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r55",
      "r131"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r17",
      "r18",
      "r107",
      "r312",
      "r323",
      "r324",
      "r375",
      "r376",
      "r377",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r5",
      "r357"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r382",
      "r383",
      "r384",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition",
        "verboseLabel": "Stock options for non-employees"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r29",
      "r45",
      "r50"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense for intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "verboseLabel": "Common stock excluded from net loss per share, diluted"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r118",
      "r134",
      "r148",
      "r176",
      "r184",
      "r186",
      "r190",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r292",
      "r294",
      "r298",
      "r357",
      "r394",
      "r395",
      "r435"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r127",
      "r138",
      "r148",
      "r190",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r292",
      "r294",
      "r298",
      "r357",
      "r394",
      "r395",
      "r435"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building And Building Improvements [Member]",
        "terseLabel": "Site Improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r103",
      "r104",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Real Property Acquisition"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Consideration paid"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Total intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Total tangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Property Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r31",
      "r129",
      "r344"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "verboseLabel": "Cash And Cash Equivalents And Concentration Of Credit Risk"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r26",
      "r31",
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r26",
      "r111"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r148",
      "r163",
      "r164",
      "r166",
      "r167",
      "r170",
      "r171",
      "r190",
      "r211",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r298",
      "r343",
      "r370",
      "r380",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r63",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Number of shares exercise"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r15",
      "r115",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Notes 9, 10 and 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r382",
      "r383",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Offering of common stock shares"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r4",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r4",
      "r357"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value; 120,000,000 shares authorized; 41,735,557 and 40,016,792 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee 401(k) Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureEmployee401KBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee 401(k) Benefit Plan [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction In Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid And Other Current Assets [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule Of Prepaid And Other Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r113",
      "r117",
      "r275"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r97",
      "r427"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r97",
      "r427"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r95",
      "r97",
      "r427"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r97",
      "r427"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r88",
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Net deferred tax asset (liability)"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r97",
      "r427"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositContractsAssets": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.",
        "label": "Deposit Contracts, Assets",
        "terseLabel": "Contract research organization and other deposits"
       }
      }
     },
     "localname": "DepositContractsAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r29",
      "r53"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity And Stock-Based Compensation [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r52",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group Disposed Of By Sale Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r149",
      "r269",
      "r285"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax at federal statutory rate",
        "verboseLabel": "U.S federal corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r425",
      "r428"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r425",
      "r428"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "terseLabel": "Section 162(m) limitation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r425",
      "r428"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r425",
      "r428"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r425",
      "r428"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Manufacturing Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r61",
      "r124",
      "r142",
      "r143",
      "r144",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r169",
      "r191",
      "r225",
      "r261",
      "r262",
      "r263",
      "r282",
      "r283",
      "r296",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r312",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value Of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Intangible assets, Estimated useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r132",
      "r196"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r49",
      "r320"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r46",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r49",
      "r319"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails",
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture And Equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of property and equipment",
        "terseLabel": "Gain on sale of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Operations [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r270",
      "r273",
      "r280",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r141",
      "r267",
      "r268",
      "r273",
      "r274",
      "r279",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued development expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase Decrease In Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase Decrease In Other Accrued Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r48",
      "r315",
      "r316",
      "r317",
      "r319",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r44",
      "r47"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest And Other Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Tenant Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAcquiredInPlaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired.",
        "label": "Leases Acquired In Place [Member]",
        "terseLabel": "Lease-In-Place Agreements [Member]"
       }
      }
     },
     "localname": "LeasesAcquiredInPlaceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Leases, discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r148",
      "r190",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r293",
      "r294",
      "r295",
      "r298",
      "r348",
      "r394",
      "r435",
      "r436"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r114",
      "r120",
      "r357",
      "r381",
      "r389",
      "r431"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r128",
      "r148",
      "r190",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r293",
      "r294",
      "r295",
      "r298",
      "r357",
      "r394",
      "r435",
      "r436"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r59",
      "r60",
      "r201",
      "r203",
      "r205",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies [Abstract]"
       }
      }
     },
     "localname": "LossContingencyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDisclosures": {
     "auth_ref": [
      "r201",
      "r202",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.",
        "label": "Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "LossContingencyDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Putative class action lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r26",
      "r27",
      "r30"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r19",
      "r30",
      "r116",
      "r123",
      "r126",
      "r139",
      "r140",
      "r144",
      "r148",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r165",
      "r176",
      "r183",
      "r185",
      "r187",
      "r190",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r297",
      "r298",
      "r349",
      "r394"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Office space"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r176",
      "r183",
      "r185",
      "r187",
      "r349"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "For the year ending December 31,"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsFutureMinimumLeasePaymentsDetails",
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r307",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.",
        "label": "Operating Loss Carryforwards, Expiration Date",
        "terseLabel": "Expiration date of pre-tax net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General, Liquidity And Basis Of Presentation [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]",
        "terseLabel": "General, Liquidity and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r357"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedTerseLabel": "Property operating expenses"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Lease revenue"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "totalLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r373",
      "r390"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Award [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r3",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r3",
      "r357"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "verboseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r345",
      "r350",
      "r390"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "netLabel": "Proceeds from offering",
        "verboseLabel": "Proceeds from common stock offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from sale of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "verboseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r83"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of common stock warrants",
        "verboseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r58",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r54",
      "r130"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Gross property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r56",
      "r121",
      "r321",
      "r357"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Components Of Property And Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Property and equipment, Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research And Development Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r6",
      "r62",
      "r119",
      "r326",
      "r327",
      "r357"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureGeneralLiquidityAndBasisOfPresentationNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r124",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r191",
      "r261",
      "r262",
      "r263",
      "r282",
      "r283",
      "r296",
      "r323",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r310",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureLeasesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionSummaryOfAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule Of Deferred Tax Assets And Valuation Allowance"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule Of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r81",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r46",
      "r48",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r46",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Components Of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Components Of Other Income, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Summary Of Performance Award Activity"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summary Of Acquisition"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]",
        "terseLabel": "Information About Stock Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r70",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted Average Fair Value Of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Amortization Expense For Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Business Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 1",
        "terseLabel": "Vesting period of stock options",
        "verboseLabel": "Award expiration period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding as of, Ending",
        "periodStartLabel": "Outstanding as of, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "terseLabel": "Performance awards vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date",
        "terseLabel": "Performance awards expiration date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "terseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rates, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rates, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Shares expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding as of, Ending",
        "periodStartLabel": "Outstanding as of, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding as of, Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding as of, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationSummaryOfPerformanceAwardActivityDetails",
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options forfeited/cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r234",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Incentive Bonus Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of exercise prices, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options",
        "terseLabel": "Number of vested options, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options",
        "verboseLabel": "Number of outstanding options, Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of exercise prices, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life of option"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationWeightedAverageFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest at December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life (in years), Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r64",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Stockholders' Equity And Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r37",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r148",
      "r163",
      "r164",
      "r166",
      "r167",
      "r170",
      "r171",
      "r190",
      "r211",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r298",
      "r343",
      "r370",
      "r380",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r61",
      "r124",
      "r142",
      "r143",
      "r144",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r169",
      "r191",
      "r225",
      "r261",
      "r262",
      "r263",
      "r282",
      "r283",
      "r296",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r312",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r169",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r62",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "verboseLabel": "Stock options for employees, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock issued in conjunction with follow-on public offering, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "verboseLabel": "Issuance of common stock pursuant to exercise of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Expiration of restricted stock Performance Awards,shares",
        "terseLabel": "Expiration of restricted stock Performance Awards,shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r62",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised",
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationStockOptionActivityDetails",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r62",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan",
        "verboseLabel": "Stock options for employees"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Common stock issued in conjunction with follow-on public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "verboseLabel": "Issuance of common stock pursuant to exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r3",
      "r4",
      "r61",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedLabel": "Expiration of restricted stock Performance Awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r61",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r4",
      "r7",
      "r8",
      "r43",
      "r357",
      "r381",
      "r389",
      "r431"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r90",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule Of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format.",
        "label": "Tax Credit Carryforward, Expiration Date",
        "terseLabel": "Expiration date of federal research and development tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r266",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r172",
      "r173",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use Of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Change in Amount",
        "terseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=99383045&loc=d3e9351-108337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=99397363&loc=d3e9420-108338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/subtopic&trid=2127163",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/subtopic&trid=2127197",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r361": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r362": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r363": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r364": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r365": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r366": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r367": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r368": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r369": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001069530-23-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001069530-23-000009-xbrl.zip
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M[-QS!L.87(VL/WTJ=/6/ONMBOIK,$L]R/&(+"2;(/_2'FY KR2@2C1)R .M
MNH(Z\7P/IA&*,7.7S LG/]4'KF'1Y)([(NM!6B['#.QA#6#7=>CI5??8H)KO
M$%34=H1C5#S[$JRV#&;5-2RF\GR<=Y1F0OLHVXW70,,8',O9A-I,M0<=;'@-
MC?'F=.J08,Y*0K19E@_VEE),('_,@KR6$,_':7PS!'MH#:",7,8E_4MK',8N
M5XQ?*:W(#7TF]B9#1;"WEFN&/S.B&^!/5AG%80@J14&M75UMEG'O$6JR>\*O
M)!%/7\YFQ))@L+CT 18]#\1BGD4=B@O"LYWEF3S@V#0 *$E(5Y2.Q>/*$C1(
MU8?2%>Z1-R!U068$UBLV/ Y[LF?_@AU?MV/DP$)7I87J8%]/HAE]0__/0S^J
M3J,>C@UJBH^K1'&=;7> &X*#Q3+,G"Z5.J=QY4LHN05-7-_5!/=XI4MR,-].
MB 'F03_;R0/A&K^$>/0NJ "%-01D**JCI;"&>T_1;Q5#>Y+*U;4W8]S5^H;8
M5:$T)<:@(RJ HDVNQ)\ZAM8R4$)(BZQ?GH2_QRH+M""20A.J9N[33.8T_E'U
M-#YZEQ+8INY1FA-^E,SZO&".3;A0RT&YJIA,-C":@/I0)ZN<E/EOO&3B/R@0
MW2+$UA/!3\0C'#LW%$Q@4YT>.,>"ZH3!NJF;$U-%KBQ6 ^A4F71P*.T[%,O3
M@YZ6B)A. ,<R6PE2G']]I'./SF!\@9G%TGO'U)O?@Z,#<R9ZJ,AE FF8!2F1
MI4W(0VN!*)+82HB*]E+J[+L8X=AB"Z65(.3DNBNFQ(VF_Y U?6[&NY4V-^65
MJ^2FC=8^,CFZ*9?<2E-OYO7*$H5&$W_,FCB3MVNE=;.Q)GB<?JB/#:H,./&$
M,1RJPVK"Y'O#=)L7I>I^H$O#XXQ)Z:T$[M)=.FQ%" S5_SV'4')&Y3VLS#9!
MRB,S ?)#%I"('0'_N\_O42@"*1FM-'LB(5F0JS2:]]@T!JV3CJTTIRG75R4?
M:#+PH)\UL#G=UTI3JS.ZZFP9^!RTBSZ3<^;YPC1F%%":S&Y8VRH)P4&V6 ;2
M0MH[<(R97B]"N6'1FBXT&=FP-DTQM=*FU=;Z^O=JNSQ!R)M%1'EX9G,ARA:P
MTFP!>A=(;E/"M*[MGS#$YEOF=T+>+&Z'@%MF[Z\.;H'D=N)6E,(QHU6!PX31
M81:C\M.S;48F)[EC!J68V(1'O1.0;0;"E/3)ZQJYE"8(CDQ=PGPLL<WVW\P&
MF6V?0V6R>[6C8FTV>8T\4,Z47EN ":CO#?/Z5NFD=J.9R&+D]9U- A,:I2>L
MVFQC4T;#;.P"2H/5!_VLU?,./+79_M4V\N\P5V]&/N>=3=Q2BN&@6L7C 3CO
M> !Z%]?2TJ-J-9>'9=!N*<4$;<&A@BK+S3VP]2#Q7?4Z,^-JS+P@'G.II_^]
M]L;K%DYFJAM9BH0ZOB3V'9$W3(A[PA\7F._H%6^J@MFE=LH\K174LT)219BC
MT=."H(2BZNB+5C4@#I15+[X@I2X"?9%6N.W^F;.H+AMIJK*9_*#.*8W]2%*X
M\"Z#J1*/":/*9SOV .6NSLO *:4W 5/E1,@>DVW6Z*7!U0ZB3$B^V3F2/=S;
M8*2?3I;JSY%Z20YH=P>^0*C9!;(1T98NH$M04#6*ZMZ[0V7D$F_KC*;,EPDD
MQ<27ZBHW==O=[BY2LR*SV[Q9RC"A#=+JH*0C"930:.],E3'^E=#Y M8;HV=8
ML<S)%:9<O75)U!58VJX_<5CF$'MW;ZI;D]F=/KR5.T7JH% ?I!32;YR2X-*N
MP*M"I?8>57UBB=;PL'#5/19DCEXPM]]P[JI:A=F'CMYL)EN_NY+0!&E5]C/;
MEC%)YFET/]<;Q3RE\LU.\_%-PQ]32:1'VQTFL?U5OB[-)S7!6') >+\\*;X6
MXF>/$XO-/?J7OAHB/*J>?[],?1%FT#*3?OY5$DGY^CJ)J(:V VK:YRSK7I5X
M#)!5/R>^[W$5SH27P52#TP16[=/E>]#,Q\K+<"HF-D%3=B;]_P@)]4-=*O]
M9DA?&7^B[NP^ZPCJ+AUUU;Q^AKFE^(HOF^\M@_P_&*@7B8T$9+C35]MK>#?:
M&FH525AP,@.UP#&ZT67NOP/'P:OK1"222E5+<H]/"1+?(>RH*T%ZFRUNG@W2
M %8P 3 83' 1B_G;6<#!4^)4;#S0&AI_HR3\[=J].3)4:#ZP&)J?.C]39H5>
M?/U^;^-J_E,P >,2><;O0>1]R"+X4,8-L[2@ A;U7S?BZZI'W<&P>S@X>!6V
M4C6HO;8F:\O7TR3BVU83\Q<U*NH0,:C*C[8W@/&C%2851 5._;^H;X/LERKR
M-#"2JS^T@^_D!\=!E_+(7%T85 T'A_,4EP+C6'G"X./;Z%+1'Q)ZR&UUR/E@
M1R$21IX><:2(GM3')98IN*RE0T0?U __Y=8=?GI&5W[6&?D"HK1;XDX)#\)
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MSU2@; Y@!0F.8>54R+"!#;L@H![7ET8$JX X?TKLPJW].+&PDX1OLSU2\11
MSJ4:=RQQW&.\T >KH3O>P4IH,+QEGES$MME)0E.VCDY[P4M=G_X'4$L#!!0
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MT0O[I<I.?%-7 YSU3']J$ND;HK$Z5H1TN[(&3-LP^N5D A;46Q3&_DYZ0U.
M7;:,!HAJ6>2V."R#1/IOTL>?C41HUK\:G9:R(%SS:'^T?V#LII,,[!I)?X8_
M-5(]&ILNC56?QD_K7O]N_)1T_/=RL9OY\';ZY7<IK[PH3=5:.L(VV5'XD70@
M"=/,E@$2EED2BHSI,<LSI,F,;_$<$TWVXO0:^/1M4^;.?*/?XMM7:Z8\.[[D
ML4#2H,%6NH(4%<I5[9PGLW%A#^K46%?9V,[CD^//![!"6+6H&$\JH+1NR]I:
M$./%*PLF\K7- 92-$..*#!*JJ_P"E)DPG63@]*U@_Z!24]>N8M38KD))/KT
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M('>732(-[%JIAT2^MF@RL$(F/W""JS:"=QHK^#?TP_'JC^]_7/WXXQ^9$?Q
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M 7F0Y06#V2K;;H6\VAI;;8D]V@I;;X%A0NQM\?*8^JRWZX759'Z@18W5))Y
MZ8,V]X%+]7E/YH%&=\#H=)J3(DH+K-8.H!,)VJ4*?V(R"F5=BYYC5I[A2HEA
MBWMJX'?*>4HH00MXJO!(RUHR8K;CX2D@.3W,*F48]EB*>+F<K5=9FK5-4W\$
M8&""SMUJ%*>7OU7) 9S#58]+E0-5Y*J=_K<5(U#AVA'2<., +&(]#_9%K/L*
ME\;%6)L&T':E8$53;1' 668?1O_ST[-M\.66+5#9$FL2A!;1=6,PCKC*(TW2
M#NOXW-.@B$-Z]!\GN[(7%6?# 74]9R=(<Q&G)P>^<K, )U<.RK4/9T>,D2T(
M*]9E+]$&BT%U?!\)OD+W3 YVBR278X0!\'"E+P6FZ;&RS79')S9WJQC2#)2I
MC!"YL9\!;0 ;U5#$DB0X/%9M1YI"-$=:W1B[UG36W7EMT%>I%\H?546%7:\'
MY*^VX07-,N4@7#OQE 4C9"XJ6WA.,8&2#-+&9-C+*BF'0XTT2UD"^>=8M571
M\_B@E#IAI,HH8_! "96P))5:N3KM:8EF$6H8K>K@/L\V0=R=%O6TD+5_=>!;
M]7YEA( U?I5PS-J"?N/D0 &FLT!?^E7+)Y;$62%AG\Z/]RMMT(I'*YS(BY<J
M A1#QO'?."F01D\*&3+1MU:K]3S^)?U6:[N6P;L$X%J54J<!![:)"80YLA!F
M&6O9)REF=PQT.LKQ(TZ+^ GSHU2]Y5CS0UJ1JY MB[)E!K0N)XCZ3-7\IJG5
M0GWU &QUL$*").O7FIZ"V*.D_&JCDE/ZDWQ?JTG]A/NPEN$$7E(; %;G+?)'
M^)(TPI0IPH_T$!8Y%>;/&FB7>MZ,M$KD7C_2!TT^[P=:<UE Z^\/F$6#;10Y
MQO,=S6YSPSX"2W/U8;--LA>,&<WUUY0(_!AO:62^\IQQ4&/0Q2T&B]\K@.'<
M$G"1C&%X%84T*C>&>'.(M[?B6>E6J&ZS.IIH6F4O;*#"5&88A&S+4S6LLQSA
MJ@F82&>%<-SG3&7;QM;\,V[; ;"P;E-3WIFW%6 W^ZZS]AR2@8\:!JF%KR"S
MP)U$?]L5O.KV7:8X%:MC(W!$M]MDK\U"2[CH7*!;^F*NB$O\&>=/<8CY4-WB
M,'M(8TD<RM*]@Q[_+CK [8/D1;J&/))>3D#9>7#3.RHSU#WKCIOCX<K1'=U3
M%$B$L:H]'D>R0@T65(&I?"42X$ Y1-C1[CO0-$N/O%PFL37@+2[*/ [+*D?X
MR=<@CSYF^1K'Y2Y7OND=TZ)_RR67@;#=$!F:\V[99 UZT-9HWW#E25C3*R0T
M#I5W8/KQ^/"\C7DZ._IB/]^+SG/IDO:)6]C0TQL^#%XY!;YNU BN/CH=WJ!_
M+L%A&*PW4=K6O',(MIB';:4,#F'JH^+1[F#X:#A[@Y5\F[70B:ZOXH,OE,3%
MX8=GG(=QX>H*->WXYP'-0MLNA:2->.?O#% '+7M:NR;4-.B5:3O+39M@]MHM
M$K#=Y?27DNXR<=4()2K$+9%/=LV]V@2&K6O(/\NV$-MZ37,8MFW"JKBVE)R$
MH),\)W3LJ0&Z?VF=F-P$+^R?JZ5,<UA2]U70LQ8.R,O5C<OXU#X->^G3W.49
MY]1 C\9U?IU%GPV8#SB??ZZK+Y3M(H0Q>>>8.M &+3(8NV>W3T:YG.V-^%2:
M?-@K$ZLJ9[C;F,CHGY%)Q+)>#_AI9EULP\XL?#0TLV2#+<W;2>T*?V6_#+F<
MV//Z9W=RX6PGN(;1.^N3P!LTT9$F. %8SI\Q HKEDZIP2)Z6(?W;+@W9WN)K
M7#ZB=98DV=<C\M?M[CZ)0V*2O"A?DX4_KBTZS H?)\2!]MEE]L] %>)93X[^
MFJ@,W[!)<F8C';<CA+)1X*FTR<]Q%A2/'PER4U4K+8L/V2HTHB@RI_3H/<A5
MH4+EE">%-H%8&]")4:YP2<'<Y-E3'.'H](5G,6HR(I\0"WJ*R]A85&U 0[#9
M'P>*W4D1Z=@*:![)(5CEN>.8_M9-H=,71!NC+[#WF;3W[8'7=9M,=";VFIDM
M52<A%7[0-#&H!-RTH;8TX"T-XP2WTEW>9=,8^BQ=^1)$._'0*2-F)^K'D_#8
M*:71Q\+>9:CI#'72WM(?#\LQ 0UBF:&\&<0FL2#Y5_KGD(Y@G7_0'P<G#_Y5
M+=;DQ-!/@Y7P>X^$>Y3 SX7E>!0WL.BT=P,+^-+5&CK=/U:7PJ$&^B+:?HZW
MQ$)CG8ZW2  U6P95U&?Q=S@M[J'H*X!( J.OCB#K^DLP"\Y-EI?Q/QB0Z_5%
M6A*4\7V"3XH"EZI#1 ,3Y"+02IS6<D[+ ;@P,^.2K X$)GH2MF=#G ]H?32%
M+/%>EF ^66S>.(V6IC)X]D+)*-9"9:O"'),Y\QSS_PI+T^K5EF$WZ=  :'DK
M5S';):]LN2'+8#EAE)67XHRH;J&]ZVJRV0%ON4;+>?9(0PF+SNZ(62!+Q9[$
MP7V< .Z4^A+>Y'@;Q-$Y7N,\QU%52J@N&J:=L0<VYI6INHBO-UN;EGPR86N\
M&G/^MF[N.Q8)RUNL"Y8RC>?9\N98)]C'R$XJ>RTD%2YCP@V?814%431NZ)+^
M_39^>"ROUU^*:G5 <%_N'<L5[DZG$S4*52QELN%H2J>,;A&XD,HT^)VG:=8V
M8HW3>TK2?&78S!B$'FC0P#P5\F0N[I]U2,P.<-:1$>KBLD'(:3M'V?IH5V#%
MFL>3)<])&&:[M"QN@I> ;)&L9XTNGU<+&850^C5+A\FGY8D,FJ5YUJRHXO5E
M,V$G4H-^*T</9S3Y#HNNP47N+JMOIJ,0S6@]'3[/#$B&SMZ&*+<XA7ED1G:"
MU3)$^ DGV98]Y8,\%N^+4F=SN\4LJ?(0X](TX961F475&YN:WR>C,Z"T-+XF
M+6'5C(]6Z"QI;8WB_2E;(-[C%*]C?\ZH68& 79X3=S'$(%7\7EFC04C# ;6<
MV2<[U$&TW>3QDRM_YT$W&;DXT)LQ^VA+Q3 X-' 0$<0RB[/G/H2(X:DBA><Q
M.XO"]>/E-(;-^62+%^D3+MJBG64I^8<=^;=*[BP=&/'OVKA_-CQP>"SLV[%E
M[VQ_"'Y'O]!T(0;J[CM!^U[ [Y)G':3N6X.X&1?H4-PJ90Y-U!O^?1?GF P
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M%ID>5XBS'C%>_^QJ,D%ATVK835I*<A_2:5A,2BI:#])HV+EA(86&-[<3@T4
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M*[U(BQA1*UD/7W!_PC0&03$":GI LS$*(=J+DAC.4/20^OK4R1Y59<[[C?,
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MEM%P)^PUU?X-$NDM2.M";#2N,6,EDR/>*DQT%4NB6IED]?;J;)?G6!DRI6$
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M#CA-'F.NA">B$E8Z")J&8KQD6ON"S$=QNHN3*$X?M*_Q.T2@BSX9W/:"3:2
M7&SU<,@62IP(^$G^-%B7>XISE:597>"%W\\J!%-10S_"40O0>X'3)P5^?J,
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M$NU82[G[FADL94\!:BD]H&U+:7[VP5+:8%1*2*@@+<43D!:68D+ZA_=OWOU
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MB9NN6T;"[1^E1^W65R@H47UETO3095K1J+J03!) P8>S#1,5D S NAJ HAD
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M*_$3/LW277%# "@?PNC(H6("+41H(@(UM,#Q@"9DBB/&A@4Q'D298-[$+"#
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M'1 R@1![3E2QPD:&S/)=>B)5_[TD_=,_D__0FIO_\?\ 4$L#!!0    ( -R
M7%;0T);<]D(  .,(!0 5    <V%V82TR,#(R,3(S,5]P<F4N>&UL[7WI;^LX
MLN_W![S_P>\\X&(&N*<[=N(L/<N%LQT$DQ,'24[/G?>EH4BTHVE9RM62I?_Z
M1U*R+%GB)I$211N])+&Y5=6/9+%85?SK?WVLO-$;"",W\/_V9?S3P9<1\.W
M<?WEW[XD\>+KZ9?_^OO__E]__3]?O_[W^</MR GL9 7\>&2'P(J!,WK^'%V
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MAP[:;_ ([L>%#(OH"W@(+W]0*)GFX]B^ZKGZL+W$@9R%O[Q8_A(\0$WY:K$
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M\L0\G!X>'/2_FBG(I:B$409OQD1&H4^C61*_!"$RS/V *U=8X![VJ3S_O/H
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MW6;#=3X*/-=)!>0[Q<$6DML\PD\ S^VEG+;[6(4>D#!\X*R#UF:VG:P2;""
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M2\OVM5S$Y*"HWOM% ;^&X1R#;];FBW^B1<*/Y^&#NWR)*:XPQ/):0D:M@*N
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MY=\N%-$3/AUK6BR&T"XD]5&TN%0DVIS21/I,:9 %2*9*ORV$8$U] $LW@KT
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M'MQH/;K]%5JA48CID_')\?3L9'PZF9X<G1X>:IF>B^<9L3:9N+C;-W!IK<-
MW6JKDH7#2$>4T@ [H"3+*I71$BUJ!5D%#I,CPQ!^<V9M&. [R-7GSEHU24;5
MKBLMH<B&1@.M3Q)S#+R8+RA%J4M:;58)1FDM@=09**IX%&"3@9!J? :[;918
M0J1A/8':\>:KAHT#RPW!06YZOKSQH4J<8.;/XQ<0/KU8?F8LN O\-YS&/O6(
MEXU:T?[U!+<:L$E$M0PVRUK%TV=T'V,KC'6-UU7"XK+9K?.)5.Y^/X_ZXK(L
MKS[-0]Z5<#=]4*6W*53N?C^%^N)R:]^_LW0*^?CI'6>GIM!U$"Z V^<LJHQ@
M/Y%Z9'1K5\'R7'JJ#9@[,WA"Z7] &N]G4T=\EN6$F!Z1KGS.K4FS>_+:3Y'W
MFA^!2/22_%C:)3GIF_7(]A?DO<>8YD;"J]6K%WP"\ C"-S<S,%=GM8>' 7^;
M+QZ '2Q]%&2>;G68/+Z;<8E]::G)J'R:2C'OU&8H[?]N]<:'2RU<6Z$<$--O
M,S91KMDI-;0$7W=0J<)4D%?#N(XG$$6]5Z?6T1(VHJ+C%GZG]]Y: ><!]@T%
M\ *UI$OP!KS@%?$E4WZH%^(<-8<$(J%;[H:TFPZF;\ 'H>5!KLR<E>N[2%>(
MW3?  R>NNL8"JC'U:I-/]P\I.?H!R[U"<B]:PK1/G:L#_IH^$3+N *>>>=E"
M07+#Y:JL)6R[@$Z-EVYCALG:XTD7N7UEF4MWN2?K T1W5ICN3F)6N[.#\;;5
M+FUTA%L=_2EOMS^;6T[E9I@,@QJM1A_6LODK0$STE[=!%%U CGXN@A"9LJEV
M+T:M,M"/IH<'&MP><,BJ.*4;D#BDLS_D0Y92,_YD6HJV"VLIWR8"(YWX>0@>
MJK0YC#S5XEI*7$!6/((F4VJ@ZSDD%H6UVQ<HT#W\I)ZU:\L.!!$4H58QP4WH
M4  1A7$!#/"O#1#@'[_EK]!O";[TG9:";K?8,^FCG0X5K^T\(JM_S[;\K59B
M8S.\1CC&3[\L,2%1FJ7O]90G149EB3)I,46F:3X]LDR+WP]=IBQ:AI)[EB'3
MW%;_: /?@AL 8<NL+:>5C.5MG]RTTMRL^]U*UR/_X4>OP'87+G!JST;4LEJ)
M5TPP6P(5H5"_Q1K9([%XQY/#<2IB](C]U<>K&Z:67B+DZ]=JL=KZP4!(G 4H
MM*=;[;7U6!%2;GP'+*"2$@.O_C1,*&66Y/GH4WMYIDK"&U37^V,\61\7<.1N
MS+4B\+5A%CID4*\@Y;I,[+0VK.4\**Z6% L[L;Q6T)%K9!>BF19;I(^=O98D
M9JXB1BTM(2 F/$[ATVG63]V4YDC)Y3.IX5[21II53+ )-1 "Y+7TEN%_QE%3
M2[#(V3T:4D\+J]-G'[E:+ #*M;IQH$$9VI&3DF^[GIL.*KX&#O+_1&?]!([A
MLU28Y+38ON6!@8H.ARJP%'&H%Q>O3D&+,CSGCG7O*)G;9488NHJ-(A!?O"#+
M\HT_6Z&K50)"19LQ'(XRV*'VI-X_\LC<%MXZ#4>3&.%J3^DZXV9CX[@D[Z6\
MU7<64VPV*'A=3"N$U1Z,N,#%4=-P7#7D@*S$&8."%%6CHM3810BQ]22)SUUI
M!9T??IC'N4#6G ,?+-R8I"012AL.&0&J%;SU)!,NA LP H%WP:,+/URXMN5G
M1XHY/&O>@8]X//D>^/%+Q=FE76N&XD@!5V2]D.1QW9-U&Q96"##EL+N(QHY-
MZ+%CZ\[1:T=Y]X4R(S2"47D(^S"SO5E3VW US6V7&EV[\' *.]'-? <E9_ *
M:U8+#)*:+'-].IV<G!@)/A'ZA^(W+!EU=P':S!)8[-E;I_*H#RA'0>HML"C6
MT:X@M#U7%%A-AX#;C=O7^AZ_!3:KC>T*_O@H5V W'0+&+M.927Y76ZR17<$4
MG6(%!M,A8 DG9<X_\I?X<'\/0AL0#:EMF]T5O(GR0('==0@(7%_<;U_H1]4[
M_Q: %.AE5_#9DB4*[+YZPO4B\&/73^ ,SNRBHAMO70/F@HR76FDOW@>QY1'Q
MTY<=MS*IX'&_SHE)S))[R&_)70\ 6W#3(>!\_OD@1ODH]L;<%KECMN7\+0PB
MYDL"U$HF+ WB%!IH7:TP0=A#3Z %+5'3  8<6!)C@MH0W*E^*$.3-/LLL]R5
M\GWZSOHB5MB>JJ(K+7';=K53Q!<#[P+J6%=U5F(94P5;,15S@B3K9Z(G..M4
M:+VP7EVH]2/'$NI[ K7..LU;&S)N%)!NH/F]JFL@(QZW=H8*#QDDXI09:#:O
M5UJ%CG)&8H!(F33#-=62TR\&N(W1.V)@[LMH7/?0M'9@N0/<)RA8U$@X$.CJ
MQNC;E_1O7>O9]=S8!0(6P)I*AB&"D\(U-LZ,5"4*3+@%5N3ZR\(;RAS:!;V^
MEHAI  %>''&RH+7MKVZ[T2J8:<V>?'86F,0 55T5\W'$2W5K6UL9.D^;#8OU
M^+@&*Y30<F0^9OC1TF&.@+YNM@E17:)7V4?\5]G%'O%U]KK/_<6U5E&PFDQ]
M0455@#195XFO^'6]Q]@*8SWT5 (/("=#J&@!=(N0>.C&]1IR^B()D0C2)P)A
MZ?L@<FE.47(:-QAJ$CAAX,V@J@5J>/&,(K3)4D32)>K*)YO8.M _;O&LF/GH
M<GSEQOB8U^P%S?%!]07-M'7L%%=H7\9;FH1KS#IR"%H#NWP#G4%@6'4/7M(+
M:[4^<[,[OQD5HJO'YPYYGV?Y!H)E:+V^N+;EL9YHV2X[#%&2I5,0K2B9/)(]
M[$>R8+E-!/F%%E)9O20K+)PMP8I0J=8+L/5D)RS-LR2"ZB#Y"8;B]_K)5D@^
M6^LQBS+-Y=E:^\4K'@JE0+M58GE/(%Q17DX@%=<+%&V6\B:4]OAT94M14U]*
M(%<H,^%X.CG2X) L)#$^@9.IU2^,@+"T/[X$88QHV7BS(T+):SVUPF $3Y'<
MU@X@3.]@1%^W!-X2GCE@5]!*].VT]4:T$BT>?:_K=R!^0)U#PF<AL B+^5:I
M84B3+I#J&LY!I%J%3M&93727+^?M'=/V]ZVB9N*"E]+=2=V?,03YW!/045O6
M3'APD[H[*?H1(Q[<Y4L\7_R( /:UY,+)5IU=P L'R:8GWB\S9.W#\LF%F+ST
M+F"%2NPP7LNZ!1#EH$P6NN]":=XI.6-9U<R4?A.J3<^+O[5>SI]C>%)'#I-7
M'S9.%70=A&(+2HL6S82=9(9HGGI?\O9U;WW2?.7K"YN)(WY:I07<:.686L?#
MZR2&WWQW?7>5K$I\$?44J>3+)WF*I%V.LC[38J-UKZ9YCRA21ET0Y7)*6$ZT
M(DT,8^;3_+[:4JN?05R)DIMOD06VH,=$GMZ!]P9J'VUIVYQ6V)(&%SXUN2E_
MU!IX:Q]QT1*:_P)6^/0>M$1DUHI60&RTR$D@V$#G9UZNM$31[L!'J=58GV!T
M*CM^^$YFXD!IR:!J'5$?3&S4EN&($B&[M7%9QUP7.V11%E?-A:W'\G:G#@[=
M$ L'%U;T<N.C#/;N&S@/_"2Z]RR_84S&N!J3@?H8H4Y&>2\CW,T(]:,P-J.>
M,-KYFEX#(N'D\.QL,CD\G!Z?3@Y.3H\EAFS4]TT,VJ 4UV\JBO-UVX5(D%Q]
M??X?D$F8$+V1?S<4"9+Y7Q ?BS!](V_PL.N]-\O?ZB4O)L-KA#,D%\Q&LLP,
MND1IEK[74YX4&94ERJ3%%)E:'W29%K\?NDQ9M!AH,4GUT%7==EE71"\)M]LU
M>>D;1CC,F@IJ"$RYD%;"Y)8&68 &A+?4HYD<W4(KK[5X^0-:1$G43];M0M(?
M(>D67&A8X>C%<F6^G$PGX^UC]'"6:2$B:;;IGE,,9"/_X4>OP'87+G#(@>BD
MLGK)54@P6P(5H5"_&4U8O9%I&SBNO[P'X2((5RB=\W?7 U$<^"#*C@R3@XO
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M#KQ?>):[BJY=#SAW2<WZ(%!S&! 0M<DT)%SS/+V$[2.E9[Z )$91MB)"XM]
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M1=3U(M-0O< *5,L!=N$9)%1=S:*11SP6^L:*\_R0K3C-?[ D^5N:W:77C!1
M8>AE450L7S1=RW "CT:Z2AT#CI@;:&K@.)%JNJ9OV4YH.\@NU@36=WRKL[0S
MC^:22ID3AJ[MJJ%' 2>-T%1]/[!4W38LDSFFRR(0H,1*D8R_.6<1 VRAG\FW
MTZ)@97%&QG%)DOA/1J]8P4@>#D]3>LYN69*-D>9<?!NSM&#%['I.BR\?H^D"
M@,]5:2Q^^@,^Z,BFBOA-&B= ]_,*R?7KV>4LM;S( VIF$34*(T^U+)NJ1(<C
M9^A:Z$<D]%S+:)97\\@WI_1?55'BS(O/V2FE,8X$1)/$]#*M5WL])#G[%<0H
M>I:-<'E\;Z[++/SZ<8P?BRMD945<LFN6W\8A$S3WBH793<I'?'Q[M9GMU;[4
MD_N"A(6+GQ<P/- =>#M@&DSU]%M<M'>=AD#NJP3%T8_ED.5X6\Z&,$\X\9<@
M#8_8>S8*$#<W G4O-#3?@R,8,CB,!J6 5(#=0*.)Y88:TSQV@%"'RZ-Z.IN$
MKFM[FFUX1/7<B*J6;0#?LT)7]30GLDPXL;;G2^A^+W2)KOD@OKFJ&QB NR'Q
MU<#3'34B>@1LQ"96<(C0O0(1''0O>D'R%.278J,@CFA$0U]37:01EF;[*@&B
M .39\)CC@>1I6;T$L3X#8GV_B+(=A#1D5JCZC@="LN> X.EI@1K:EA$%H<NL
M0#M J&^);/@&2,+$,D %<4%.U@&G?2VD('<P@_J^"7)H/\G&7D W](G-D![3
MT*6(NZAC>Y9*?,,,HT@W(H<<('2W290]ZGF.K0&W8VB\\."3[T6N:IH1<:C.
M#,/H)P+?4X3VBRB'#D)7HZI+4#Z.=)#JG, '^+O4B$+;-IQ^2LK/@_J6R 8U
M75!C?5N-_$!7+6KHJA]X@<I<8D9Z$%$_<B1TOQ>Z#$0X7[,0G":W:-AJX&NV
M:@"PO5#70YVY!PC=;1)EP_(,3=>IZMA(%%P7R(-A1RIC1*.F1X)0I_=!C+L?
M"Q"?IA0MZ3!+EH;Q;BPPH6=3S?< 04P&%,[2#)7@0309"9S "@TW\-:U!&-#
M2S =:OAHUV<,I ^'V2K10'SVHL"C%J4FM?3[2^B8R7Z/21 G@)>[V0"=$D]S
M7$,%.50#A39B*K&-4/7,D'IZ%#JZ%JUA]AN"/0L\S_8L2PTB4%VL*  B0W17
M)82" *@%Q''FQ)*+*&+<MBWX-RSB"@ZV0*,*,.GCF F"4*RD4=]?H+V>!3)8
MB$]!!:8NJ,"1I:N@03@J=8$]&1;30GV.1ZUK@7/NIDTL$/1+UPT ZPP7M?W(
MA=/C^%0%K/1-T/5MC<T1@,4+1 (/1"")^2+.&:W"ONRB8]D6<_U(M1D!- V9
M \JU255JPV>=4--BX?<LDLND[:7TYA(85 'L+N3NFITOVW0-YI (MC74@+9X
M+(#3R>"3Y>J$F<0PF/T]R^:<&$C_[UF(/L#ZOOL4:"=+-H* F2'L=.!;P PL
M#SXYE'LC ]/3(I_X2Y[7=2QY*R<X<ER?>1Y5;=UVD(-X:*\+5,_33=NU;<LV
MYY24#ZP4B_@]*U;;MOU2X(! LS  =AI0'V## C@!(4@)E!#=,P*-46/.EKD]
MV"P6L#>J%-! LP#;5<<#(0]HHHY1! 0D6<<U V8$+-@=/+:E=EJA&9IFH)J6
M;H'<2RW5]PRB6K8=1B'5J6?/65H/#0:VZYN!'9JJ'L*1L#R'J($)!),%IN^!
M=.D0?TYN6P$&>VV)UYCF^@XQX(S8)@H++C 3"DJ>8^E^2&W')7-.Z>W!9OLT
M0P.:09EEJ)$5 $O5#%\-+!2C=$LG;D1<PY\3GK8&CRV=%T<+X:]MJ9IG@3CE
M6([JNRA8,1 ??<TQ7'UW.+$M&!#/-2)0[D(+EF_Y(?!2.]14V]!IY#F1[1C/
MH9M[;2BFI@%*HN^J(&O!&3$L7_6(R50SU)C%J&X&UG-DL&?"9OLTPV:A3D#@
M5B-"0&TV0U?U;0_59B<$'9J8CC%GU=@:/+;E<W0BW=.9H?H1\^"\.([J4<,#
M0( R"D0C-.>5SGV$P6R\7;.2VLB1WN!*SDB>3Z(LOR,Y+2Z^C6.QE'.8Z<((
M5S\T/$L/5)=AU)OC&*IG$E]UB16Y-&118*P6?O>ER,LO5R2]81P(^.T]^1:/
MJI%8/+_2 NX:U'>2QYFXE]R2+],I/[RL>J0&P*V.>%J5PRR'G9B!_SG\6)1Q
M>)95:9E/FCWH!A13F,Z$D1SVJ1Q2,GGQBZ&9KJH;JJDO%?JXCJV 0\PLRC25
M&@9&\0+^$L,!N=$-01H"SJ\;JP4;+]J*.-W#K0 Q2-/A?]\1U6G[IJ%[P$0C
MTW!5*](LC-H%720*G2BR;.+0.;O,I[PV^O(S^W>25&P7YFK0$$UFP-I#D(9!
M<<# -IV:( FXNN483JC;P7.GOB%;M08J/T-84^*ANQ%#QS0/C;JVI5.;>FXT
MQZ,7.[M.\QP1&!'TU\GTED]D@I=.$0<%\;U,"Y@O]Y1PJ>3SD*2UD^RO,$19
M7*;".?9]I)Z_"9,P9O 91N2XFX:,S^T!%]AZ8L7\,'0\T*5#0 ITX5H@]VBN
MRAS3<P/'M<S W!Y,_P[GF-%]@.EB0OW]D'F2CNLZ<=S !BU6,S75 @5.]7R&
MX226'026X=OZ=@#V)%EU'N5PCQI"78/H#&/(&9 EB[BZ2CS35$,C,KS(#4U"
MYCS>G"0-LX2RO!#X]1AITOW]4DL"TW(M:@>@M3-0V5P;(!)YFNK:+K5]3_/=
M8"XP:S6([)M!./!]S7( #E%D1@ 18JN![FHJ*+#4,ZC+C&A.*%\1(GMF[F(
M"<P< S7%AE-C!@Z@C1>H#@/N[OF^0<ES(;)GRKQNN*"VHKO7]-&I;=HJ,<-
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M3!3+V$0@5T2!28+0#US/6HEF+0F@O19<'>IH9F!;()1A.+P7HB6#40!<:&F
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M_%V^"_E3 '_^&5IO__'GR\/]BYA^*F-'GI[MI@#)T].GTS,7&_7$<;A,*8N
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MS#+7("#(O*I5<(Q\.PH<ZRY3XMBF<>R1O-.+;R%C*)-W:'XGN5+0 D,[RU+
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M$P"3X]+G,$>*,7_P\)"2"4N78.:?>%C0(Q/V3!985'/5@%J&:A$?=A:MM'Y
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MT%6)9T:JA=%9 7,=U=!<RC2-!+K^W(Y)C,^$<\:PGLGF^B8]7Y#Y?3'7WVI
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M]&JD %*568ZF624B(5RK)P<PY>^?PSF2LT<F/E#^P>#!DO'M(J525.&P^\J
M*>,<Q.BPWC5<4D$BI@Q)'F0@08/TBS_A?%DP&2""/P2DG&>4*&6FL&]8DE0D
MG)S .Y*81? !WO0O4:H4OD056H&4<4+JO).B1-RY 0B>*-B'%^-^\=6\S"D
M!^ %^$3KFV/ $I+CFW+&^\]S4(4LYYLS$@F78LT(HC0KYV [4"X!_-F(*2$I
M\*V3K(*/>%KAC4"2'L,(A!7+1X6 *"D4-!@8VMOIS$_X%?UM\PL'P^W<Y3"K
M$GK_(@.2.%HPA@#L_:MB@^]?'9')_4L([+EKL/LP9Y+<_Z$8+IK979PDS27<
MB.8RWMM<QZT"/$K9#6^=7-1GI6 UR.!W<0#";#0F.1K ^2]QFB79S62P[YQ,
M<O\CX/Z/D5U.<@(@*A1E@JS*IS20%$4U&D^S[;JD$L\)WMR01I;S?@E U4Z4
MDO!WP%'/%")R(10"3"6>]E10@ ,!A2R3B4)N"9!'?JXRI2H>)=MQ>ILEMTS)
MX^*KF%.%=!2Y#F=G> 5G!203^0Z0VRJI@V[PE .AJMEA3:B![@#^1<#]@4K?
MI'$$%)=/*LJS$7^D&8+&15@51</;'F=DUTAG'P-Y/<V@*@!G"[$'114@QT$H
MI""GY%E5/+A.SBN0!0C"A^RDB#%[/T!^CFST%LDRWP3^)BQ40U+@B9\Y;:O'
MA3LI*\(\#F!=(WPPJA)8?;W$@M4UO.,R82WYQ![RRCO"J[4-&C***2^\"G@R
M.>E.#'D9\-J)4HVS1Z46X$IP3IH:ZKA%-6:)G1HH%]_(:)P( ET\ 5^0[Y**
M B8&U92E)K#Y7#S(9MX;9%7Y9E<423LZ8K2Z-?IZ,@*]?$W4?F!KTVB0[X6R
MN@J8@7" * /KB%,^Y2#)PJ]OEUGAL_V:+58T\1(X;XU/_"\_.+ICF"OXC+K.
M6DW;B;/VQ2]<5*M& 5 Z( ,@N<:=+JS)GX .0#B1)NGN6TZS&3 VY8[5K(O+
M^VF><5[$Z6*6JC<94H]/0[S3!!A4E(OU^"IQ+P_)1'F_0)I32X?M?0UO25AZ
M [- \1$F@6]"B3%AH&74\^P.AP/A^^MAVE'$/(%*H6)33E -B6)@C4*C("5_
M.."U7802!LI%!7>0$1]RS#)XY1/PZ+N2*ZG#_E&'W6 *GB"0+F(4.Q7>;"0&
M@0#4-#@Y:(S(A90B#F-**Z0 <,A" #57K<L<=$EQ^$;D*PA#>05R1#4>@\ "
MPQ$%U/8;6"S<R]HCVU"*=A0XHS<Y&9W4NF0,XF<0)UB9"=Y+0=K(D,QPJI!Q
MBA-4](:5$LTEFB^'YEQRK=4N GH!H"LE)>'&LAPF)WX3.DNCK]3J69)A("7+
M1THV9H  !)0[SG0FJ-[51@TA%#,LM4S"23L$'X_4*D'#S.@)L,*49B-8'!6'
M#'@:,BP<%-4)0!F)VA*UEQ?H&FH)*-O25$YR.>$FH'07B*F@GG,T!QHZ9"0!
M":>6X6HJ#H\_*/)(A)0(N:RS:-(U!2GAD*0W\&;0(=!8A&("9_13VSE>@\=/
M$%FYFXF30$1''*NFPZV>T0C\,Z([(/*2NHQ$9(G(R\O&'3DT1NJ)7II6$N9(
M3)+)GT"!X3FDK4!X6PJ,0G$*:#LER37F<@3%T4'NY0/!.:$\F1'H-<K+J+Z2
M\A%]G)L_N5,E914,PFY H<VY_Z6YIY"(+A%]>1$B!C%6N+!Q-BW*1K \N*]H
M/!M=O8S=LB0;/X#($OLD]JV ?;-Z&&#AC HE4*R#ED!Y&<E1J;I'6T]:#[TP
M,NB<5(K/1G.3Q$V)F\N+ ")F!0C>GEGZHRKG$D)#I_L.ZVMR2\Z_G?##7GM?
M;T@M4P'69E05/G8:DYLT@U_#VG60*>R6)!4J$H0+7*A9!!F=*&0,C(D(3Z<B
MQI=G7Y[]U<5_0!\,A8+?>+"!"'JK/4XP158!-BHH*H6UD1$1;JJ=9E6)P072
MP"(1<TT"DW!NGK0F9VY1:8/[9M"RZ^N4LKI$O36:1+AC/>)F$*ID 8^KSME-
ME9 RRVOV>XOBNL2\P\&\7@BW(O*#AY!/./9UL!(D1Q(D<0%J8(H1DSF!.P'O
M,!9.!)4 ^\5Z83$:[M+) KP\4>*H1E]&)9+N'Y+NCC-/F7 =?IEC_&7%'N&_
M,]C&L7D&1R4"[B$"]H)*\@PFDG]E)4:1LW$IPGP>QL.^'S!Y3N0YV13=SN,0
MW<N(5CEHZ$&5%Z*6J*3;1X2/NT- 4-:;()XZ23/.TB8D4BDJU/1CEG)=/ZJM
MI"5+$B8R=>"9,<O+B40ZB70K.#=::17#$UD9\VC?+&^_8D1!3?G:X/U.(+VT
M:$I,7 \FIDP$T>8$L >^W0&C'<<EZE$\D[!."9FFA@#:@EHE8L/&+&^2*O..
M=7[V-XF/$A^7Q\>JX)K2J$K*&#."NID1H-!3H),G=9HD%QN5LR84X8H!^<O#
MH?(QOR%I_*>(:7AY=O7QU4DWD6(N+JR).&>$SDN;$GLE]BZ'O3-)YCF[(3RM
M&)@VH3PC.6<E9N>Q<,@K,' 4C-,TNVU*>"1QR-*"8_5-SF8RKLL",#2L4\#K
M?.II$G94I:$DM1)95R2UB+!IP7C6.4B6'/."B5*EW<(P9(15$$"XK)B(QHU$
MCV.):A+5E@R(2M )5-/%.O,E:GO'9*VH"-A71Q]*W)*XM3P9FZ)/DA7%_<)6
MTU^YH;#6;3CIHS$OD<Y_2(!?)RU%E @H$?!Y0A\&5Q=%U3A^BB')A::!INH,
MEP)0/@'L;-5GD5?"_ETU[O31.,DFV(49?@0,9"(C?%SE.*RH""%NYC:CM!#Z
M#L'2,G &4L:M1&(4;C,JR3>)V1*S5[&-US',''U$K0%>!:_KSN0I!"F9K9%5
M3(J2C01EG8T$D?@G\6]UX^00R%\WUP]X>I&E*4NF==.F<4BDY.4S:H\BUY1Y
M<DK[D,1!B8/+<O>XJ!43'EW9%A3L1%MV:&31U)_[(^4%VWA?S**3-?JO*H^+
MME0<W R+!<R\8[68.DL>94>2GO7&D!U)=@'UQSJ26+(CR;JQ1-;7?2:SEC4L
MI?AS&.+/3!KN-/-.*40$/U6*$.26ME*,]/A+#/N>G+IIB%V#2G6-;?0'H-^3
M%3.A)Y@!5<DPDP- NEY$(<]ECG2\[[QD$ ]!43 $)>;.4L3$M*XP7M_ 9D*0
MVVH:,OON4#!U=^21A$ -R90V-EU+NNZ&QF]UTCJX<O0-Y *+1;T&M*6)4-*.
M(:WVPZ8W$B<E3BY99_!^;XT6'RLL$](4&\:V$TE6< ?K%%&YVZLN*-)U6TGT
MVS_TZP7S;DK/ _4[:;JDU"%S(3:=PJP.QFNIH1NU9O!)W-2XF3I>10  ,.L0
MZ"0OO<;C!1(2CV8"3O\87 ^4F^R6Y2EWB\4I$MIXVFF]K^>6=Y*2QVSOCMEN
ML&5Z1$[J0S ]*@LZ^F"%69)C!H&HO9TD[*9VEXPP_)7<P.U%"2Q"J?D#4(^$
M!-C)$+OQ],KP)XVELAG9/+S/L<7"_8"(>:VO:?1%E"&,"@^@,LDK*\;%5R&)
M9RDV#U.*$;86FS:%R9O\!;RG^Z*Z34-1AT<J#U1[X0:Y*BA \L>G%BJDI%%'
M!\I'/(1-*L1,V4<L\1BS'$!%;N9[3N!1QZY4 6LK;]VR3MNKF:&P5V4S$!Q\
MWI4B%S72%S:SH!D?&]BY&&INE0/EG[,]NH#&APQ($L8GSW;4$,UNIGT_<UYT
MI$!+4XE%LD4K@CO,LX-;4UY7>%SQ"B9[3X^>=[8DC=I3&O4/[+*:XK% +0U.
M$#:TXPSZCO%*>G!$1/V=;H? +)\-8IAVG9HM%Y_E)[RI':;?(Z$I"3>;)9-F
M5'HB7@:#3\3K2!3A.%.VWTD9K&,E[H">M&_D;?Z6:)#W4*/>F>;0V#^/2Q^"
MX#8=4O'<,P5;[681;]T+Q /EF:_8;4_)@ #4ND&9"7H0\BZ 5(  Z\K$A2A@
M]. \\66D(=?P5DRK[,3'G<RV"&PEJ[L8M1CV#4N&X!"U$8?W#$[(G:1*DBH]
M#XZ]4-DOT]8">5+W*NZ[-M04M]XSXTC3-IHI]]MB]QW@#W?7?KCU]^(>WPM[
M>7<;:9\T%['_;$B*)1M_+^[R711QD,S-;+[[]S0D\"[+ZV[K==ONJ&V[/F($
M^ZSO&=(!UXH2+CQ,.S*+]8Y!WN?)#FDM?B3L%C,9FO[!0G(0I08 9S$3G!^\
M>R!J6@$O[ 3-N_5V0]'O-6F^+P;PSS&R6I0?A'X&P$WX#.I3(V;1'10_"0Y/
MBBSEH\/KX[K^,-X]G=S)_..H0@6L[>N;811]TZ;LI UI[JROH^\$"#A"12XF
M5[]8*^$-R2UKTMQY9220)88$F<8MJPV5$][<^J019  ;LNB$][AND72FLW6[
M29WY/[ !<8HR%6]"W5J(^&)0",4;0E+AXTPL!+<#9LJEQZ;-\GVE;>\E'BG=
M'+S.]9&W\JQ--ZVI!E#_7HL@0&]^/NNZT.@JXQ:2++U!34JXQZ;&"3PXTRQ9
M;.V)^DW;W?U#4Z)_S[C#90J;7%9E__TER!I^$^WZ7GZX_.V54$TQ"$GH;-$B
M_1/)7)$E2-!$B]=BC WNZ^24CH4+^$UM=4)%$@DQ'Q)>U'>XB ;3YPSC89I:
M5#6<<'V_5?!RY9KEMW&( 0EUZ:K9C(BI_VR[J\70B#A<9;62 QTA!VI@%M.?
M7UR"*/)%__)K76NE701_CK(P$[0=89(R?'+GQS?($OH@^875*/I Q('/_[O[
MT_C8Y)L]F)DE[M'*F[/OB"D/\YZD8SR&SA]OD4FRN^,!L$3*970<I&A??DN^
MFH9IZ(:F[P'+>7RWSDA1D%NB7/,@?Q0*+]-PH,1H06F<P+6/.(BSMD":*&R!
MXK$P[8!*=8K@2T^4S^P;*80+>Q07!?>[%Z(Y9LGJU&]>+/61/JW3EH4/5E(5
M;TA!6$V$:A9B58]Z.KR(!T\[_Q-5-_ZL_E8)JK(6\$?9;?<'6&L>E]SAS>L,
MQVGC 0MR$J?B7;P&8;>+$,6H@S9T_&3:W.J$SX3QZ-^Z#1MM"\5B4>(,)[E<
MQ5@ VXC;?G!&HFFC.5<F<>\E8>E]Z@,<MV^? 38K#@4I2AA0F3""-42G]M)1
M$*-1DIL=U2Q2X685E%NE0XEXFH?PXA;XTJF!!R@6OZ/3F;<F&%E239O2/:^G
M]*#W#IN/W<9 @A8G (Z<!_Y@6=<T_G?%.@:NURU]&2>D1-MR%X1$B>*\0#13
M>:YU8UCCL.P[+#C11<+\7<RG[ZL;'#D!DXQ@3QD!!D>)O-)D(DA_>;=*=^'=
MS!KXRWA(X(Z0"X0K6?QW,V,@UPP8)(^JZ@:6O3ERA-\-X9!9'$><Q9$M4BGG
M$I(Q:S1)4 *>42Y)+<AF.8_1;A3)QZ791I,4(2X2426BKH:H]SO03[O./X*W
M30O[#M)B5/'4'B1L(NAO#1_O!EZG+]6Y&07!F!Q\ '8SHWMO >D[K^HCS/9,
MR.5Z>">*!--F"&B:J[604@K&OG(E'EE"4I*4954!8C/&H>38<F+WGL(GQ.:L
M'/:=Z"V($!*%&N J[[,P:N+M_C&-1;Q7[#0>\3:(TWXYMZ)W4],19,;&/(TZ
MX822W9W AD<1C]H3Z6QYQ<.-6K3!<JJ4\AU_Q$I^W&=<TLH]II6+FS[=][/P
MM,EQ'K.2Y)-:.!AE"0LK.'$O44!^Q3TU ^6Z>4Z!6V\8;^"CD*1DN7#/C-HL
M3.X!J@48_@3ZMY27[W[_</JJ.;7S9Z[V%7T2>8K<:BV:6'&#!DC?<.:Y&9:V
MJ5ASKY<U9N_C7Y^P4M:8W0'4'ZLQ:\L:L[M72+9^#)$.8\8"]L?B$AG71B=%
M(UF==*XN)\'Q%(C6 %VG:8@>AHW/O?%R<7=CRX*0&XQAG&E%.H %!;BJ(Y >
MD=@O89 9*$<N7D@Q;4_%M([RTSD20N^I!2)E* +0 TPFNF6Y.%:UV,-/<D#"
MKUQ?@B.4<E_L2?T0/XJ=U.QR6!5PJ4(^UK3RH=D=BE4,Q;KL&^C5C.>U\Y#]
M[FOX.>>26$T1ZO[TXU9<PWS$/,8C65?L:-W@[#:FC7VJ7AV=7=TL5>A_3,#E
M"',B")*[D]Y/MH5KWR>*^@@&F%&&A<VX)0?T"-!C.+:2T23)8CI-%*H5ANN^
M+RM&U)^>[R&OH%!'C8Q8."1I7 CEJ6:_G?Q,/-33*JY=7T=S3NN,2Y%W?LOK
M.!03.*$W,3<MUU5<,]%[6$3C=(>9UFY5B*@QARVQ%P48 J\_;O8@V>R>LMGK
MF;,W8TD@PKQ85E0D3+<VY.9X\43?& 974")-.%^L!=!N[40Q 1$OR\\-C)\6
M=03O";RS;4,[)T&?M*;G!8%5^+/HRE.4&2>#(YA^/JE+=-VDL1#"CQREY-'L
MA=[Y6$Z(4 0-HES#89OL.Y@ENO8!CKLH\&-HNL]%M*:L!6V<ZB?3R-[:IG$R
M30(!K2>+, 0;5#(L@H4-4AE CH"DI[1G TW>D[I0RM1"PK.,!]>#DUI/FA8H
MF\^>[[OWLLWN;]/E4<@_O5FI&LR.U).7'RY/7P$_AG-V&Q=UW4E>LN#RMX'R
MN94=[MFXT$%M> HEDP*N LN. ".XI:Q5AIN:(E_9!!.%8 )?65XL=F0#;@UY
M8/[)LEY6Y>6>E5(8_R4IWVI(8U[U'2E6L57T K:_3M&KD7'O6,[C(GC:%B^8
MTYADX3N&&R!^LB#/BG',6RLD%>CA+\^NW[T2-J"$  '<>^WPN^O,27:^+])G
ML%OI4]NAP'28B-LWB.Y"(KT&<9+Q4MN&9FC]MT??K2*E]@+(6'@8"[_1WL,6
MZVHE>P;=:;7FJ'48 Z46NM"\OWB):+V^[LYE7=EY)@%]PEO^B5+(M3)QLF"1
M?5];(S/V70'M/2"Y#1K0@6.^K2DCWM]'U\2GKFF@O(M#IE("\YM5,H?979WU
MS9U O/!E1_-47C8*EOVJT4';)N\@U=]30?L.L"8>9'7%^$2YA356$F>?NP7[
M2ZZ4NV&FE%GV5;3;"+*^X\*@[Y!59JJ@[R]F]!T1>@_(&48VY5HU=[K/=VYA
M_51$=[-""(-L'!<9C<.NS[/ [0')Z2[+OT[=H2=RLYZY68(13BU_P#)W0A"_
MQP)[)OS@&"[31:HPRW.6<)0:946)15RR]":I=8K:)2_:'F-!%^';_Z26I-(]
M_434&!\GHH_;1!2[<MZV]9"QACMV7ZGI&DPR50L2L9)7_>9O;<4HD;!05#<W
M'+5%Z!L&_L!WX;IY6*DY'I/@_ENC#MZ,^G'JL^2&5/A7%$8Z1OO?@2#MSD&X
M=8[Q'@M4U:Y;+##(F@;D'9>\L,R(<E^-D[V585HBC27N56S=H=2D']A/A"TV
M.GD-,SFNV)4O253*4!W'KF+M""<+W\Z9$/8Z+,28><7C8K'CH@H@(C><UP$+
MO-_N$ "'K\-04]!N$ES&D"7CNMD%%Z7$\QP*38,+/K!H2#+;"A6CWNYWB423
M0]-@3"1[\":()W778N3'<Q474;;#>^MTD)UQMYTC_?[3C>-C=I^SL8I@4:[$
M(=L5Y.W5P(ZW=P&/SWP_]F*ZR4V>P<%_H_SPCO]YVPLWPF6JO.>2N?""W2%5
M ZT )?%]<XB01]D"D/*F+J[(J.UD=+?59NY5UQ4WSF7;/:QVK%HUO[=H\1D=
M+AQP8DEWP!-KAPL'!_#U8"):6@K%#O@2UHS ]I="-Q/174-6@W_/D.F.A[P+
M<:.+.ISOS\DOO+QTEK"\*<211?=P3'RMW1'< Z%,/1"Z@;Z*48;M26&*PSTH
M[WJ:BJ28.O22]VM#T07AAC5"B@)+A'0M 2Q"-TH('U(ZSN)I(S1XHE'J4;]O
MHO-%!/_4IW*\0L\N>,)_D[3"TA; %4S.%:;._'%6"+-1V3#VVOD\[?0][>T[
M0X.[]("E><9+76#G'WB-]OT9S2_?O[^^4'1'-9Q7 ^6B02\1H#>"6RI,QR0E
MK]/.)_RRF4.93T0P'C]W<!!WAF7KD$YZ*Q/>%P';&OC8T5(I0J!\0 W:[0$"
MTNQ'[PGA"D'"N[&A)QF< ]$;H 2>U;:3QD.*!Z<'L<*/H<Z;;92,O$_B9;7(
M_:H6>7I^>JV>93>Z7A.36J*H1=$]DSUU?Z"ODGRPFUF"1.NZ*V!&+T#K#XQ7
MO6<IY2I%R'L!5L!81V+L9D!K#LQ7D@=*'OBD>P:5H /@?H8^L"4MV<BDS8$C
MN=\&,!:(A<38C4S:&5B2^4GF]W1^_*=+75O(_4P\FP+W+21_0%Z,@=^]]$S\
M,I;!+V?.NK<O&&9(#.,8]M?SZT.0KO2!)UG5IB KA:M-@-62"+LAR/HK\;X>
M>;OVU*\Z[\+DK006-01M BV;5M"\9RT\>C)UD(MH0"R =\LP/#_+"S;M[S'G
M/^7]M!\HCH-.^^'TW27YBL[X$EWY2;)WM5H:;T##KWD:@6#: !9>EA#@]3++
MF\2'5\()K?-.P+VGX?$*.5:]V ] \2'<!S#'B)J<!,FV"VZM/N>L*L-LQ/8-
MTEB)Z'Z>/)SXV="*OL-^^="/F6@-V;FD9STT9.>274#]L<XECNQ<LOMX_/W/
M85A#1&1O0]6N6#'.4A""3U.23(IX&JNV*#SM*'9@-PB[-E.^[J_%T,J'V4-3
MON[OEZ'UOO;65GL%V=9R?^R*LV]%72A,H!@K0\+KTF- ::WKP9VJ-7 ;6[^)
M!KHZ-/CEO:C(5RO%_4K4/$[4Q!(MTRHMH& 9Y@P^GB@M\E*&6AA@;8)Y$"4@
MI&+7R/<TUAH8 2&05A]8#=)N!447.*HDDNX5DGZ:T?5ACAW?*"+7GRS/L 4'
M+^-1.[$LXT>4:FSK1^S.0>.0\'3CG-$*,SZ:EG%J4Z*#EP0;%Y-P&),RCT.E
MF(S&@#^%PC6 QI*6I9WN5!L0E99RO>X\?6=-CE0I[V]$WF_%?#@:%TV*6IM#
M)/TCVR1=+?QKZVN=PD5PB_X4I3X)5EMO.YUAYFY9Q)1AGF"G<"-V\,-$(R1B
M49R/E$0\?5W]25+0X'Z#Q_/XVXGR:7@NDM)PZ<68A7$48XI;'H_(HIQ%GM]8
M,VJL\MZHA-B,H<U!P%X'85M<J8#Y,"#&%)TT52$$V7F+9FNT;3)J!\I%-WNR
MS6H3W9-X.V>FO(>'U/>B>>!UB;;2BV^P:VG=P(#G]W3R,1L'#_<%(4#";@TH
M I""H=Z*>JKW2?QE>@L_XEQ><HXR,V[-(*8UG-B0W,99_E:DQL)X?P6$$0.=
M,]&V"29XS6'S\J_GUZ_$-KRKDF2J>5^S4GGY[O0:):!QE=2+^O"SH3NO^$YP
M<&(B4\GS"J?[3SJG>C[Q=%^3_/;T6#_@]NRX+Z>UB*^Q6Z?(H&ZQ%<O)3,9U
M05:!<>(X3T.>!TI3))C[/$ZX^W/J]L!.N_QF0U<-YZW2>A;F[\ T4FT !RNA
M=6)HXS^M I7+[&VEV#0KN2^+QE&$=6!"Q@O =9*96W7@Z3S'.8WT2!+?[OG-
M^B7[[UN0VF6Z%]V,\'#V'933\][1ZN^9I$[V,P30'F@RI&I#X>JFC '< ,8:
M,KUP0Y-V!]Y6 N!W+VC(\/=CD"QJ:;WOX'Q,NA"!G/LJ71@V>MSZ#O^]I-6R
M>,%FLF(U66YC<\4+=)ECL%60=ZHF\Q+%T]+^,P:I;L [7)\UE]65B3O]PPI>
M@+FUMN/(6*XX1%MOWKBMAW%19FCAK5L@-$YP!3ER7;$_K48,V%ZA3,L'QJP8
M*._BFRIG,".T#0N+'#>])=V!2=(,670M[K@ 6 ?&E[<5X<XNE?^;KZHN[X;K
MV_?> *L$I*XJ5CWF(OLI'@$RY.'/+PIR2U1#,PS=,/5ONO;U!I8T^-?XI@5>
M+> Z ]?5;<.#LZ(T(#$&NN]X<'Q>*"0I?W[Q*0Y+W'.?QXD>^9[LD3?XN2#;
M;JG"59&](41O^J[J<']?X^]J2>649M>M:3JT4U<YN;]'G9\@I?>I9]_!LN5&
M7ZM/\*>B&O^BPRRK\<ZHWA&$#^\MN+8<_W(M*EB?DY)(07V;@OIU2ZD75 7'
MX :1%,R;D,(><4+,A7!1:+P4@23<Y[VPSC(P,1X]DV:\JGT;NX>+00&<4.00
M(,??BG8KGX<Y \D>N\^AMJ""SI#?H-HP>Z/R\O/%Z47Q2LG"L,IS,0L,RZX+
MF",/XFF'C3;Q1CG[^/?+<U7WE9>Z\>.K$Z7*XQ2C:\J<A*B51%@['",[=.U'
M(:YCIA )0<EXZ?_X:J!<,6PD Z_BK^:^^H '+V*'TB2Y]T+>FS)G(8MO1=GG
M!/A6"?<"<#.168T $0$G@%$ 0UPYQD-FJ2A>70^%/"^$'8W3BL>>U/%(&%A)
M<W)'.,<5K6'@31ASA ^]_/"S;L$R[\,-+IMB><WPV/PLS$;C)"8I;#W<X:X6
MB"Z)W')$[LLC?]8/;V\#1,]Y@.AM"N3>L^F;D'.464&GIW-MA7[E'9K@2Y"1
ML[+G<ZYE_F"B?,+XOYPH9UD^SD3CY@TWD'C^[%'>X%RNR*H\;.+0D2#F0"&S
M4?PG;\7-K4/*RWC !N@H^7 I".CT'JR'D99U*X$RCTFRX5:YSU\Z3)A6W'(&
M>U>;P3#E,,L+9:[53,_7(G3%>G\6&MUD[OY>9I'+W/U=0/VQW'U7YNZO&TND
M+>.PQ/Q?V\[1TIRQ]=R=3K+*M&G7O00>+N2%<"G(LV(<8PIME%0Q55Z>7;][
MA3[K1/@4^8V&/16&ZJIF<UW]4-<G-Z"_\RYMO*_J38:= *M1@+;N*A5.IF[W
M)Y1-R TV$Q?9BD[==8W77&OL'P,%IJ04!+3S^3PD&$9(;U6ND! HXR@.^>Q)
M(&" [SO#-(8_TABM '5& V[#/[/\ZP#$HH2_X#ZHGNB7?J),&Z:W%AVV$/2\
M@2Y@Q2U:>S!QHFW@U;3IXB7F,.$@SMI\&5Y BN?G8"X/]P!0_I+_KF ,PS_!
MCF"Z3*#9;K38)Y4W7!:9)RDZ^+.[U@S&<?H6]MM1139)@MV&"\1/3.G"DZ%B
M ^$C22B1&23/0;5[-*F3A06D>)@EV<WD!/&)5,*2B9]T3S]!;V*=46YZ/_+?
M=._'$Z0U8]$:$O5$P)*A,OY+4K[5!AB6M%IPD,1)B9,")WG]@6G95&P6RB]A
M$UKD8&E=HH#[5]#2GN![,#,OQ@32Z/=7781U#8&PMMT3A-W?:O$291]%V3B-
M "%'-<H6GZ\NWAL<]?[YM]]52^LBI6,+I+2L'Y^+AE( >^YV?A3%F+L*"2H>
M&%H98RI^(WEU5 80E"V,\B_8ORMX(,%<>_P!9>FF/$I'W1#6WJYZTQ9.440O
M[BI0"U;.5'-M2V.IUL!W1))Q726@&]/#E:FEDH[?]C[!@U!EF(5]/_[3^@-3
M8W^,%LD4_?FON&HV)+?HG"\[MT15SMT!4S2J!V(/*L#[X2[>MO?RV9:DW^-1
M7-8^?SAQ'Z=0O^9F!Z3,]YL:[ZK T<ZLH'M<T6A=,-LS/L:]KFV7=F0+]]NT
MBV@P85NC64.?8+%E5;(3CO?%,*L27OT"N(8@:[ NI%^D0/GY!BNU\)HUR!PQ
ML 5C@L3 63XMQX*!-IT4@T5%<=JR('TG^%?Q3<;3&MHUX^HPS*A9.4*N77J,
M)7-R'I\D=@%+"-4!5 F\ 2#==7'7$;MJQ]7=)DY\GF4*6&'_1FA N+C6QB=V
M=$0FN&&@.U4PQ;;D$&Y$)Y@XB$G!IP-WURH6:[&&-U/ 7W#_HRH1H<)8::F*
MBR'*$7>,I6+IL%Y0I8J.RUZY)5@&B$<HG-=E4V X5@XS6HC8L45%?-+I7"FB
M, <:K_D#ZEUG;0DCW Z<!?]J=3C:OH;GGC0UEG Q''IUC'.3C])]/9V^-@(Y
MK<I%_XS[9T9P!$IK">];+! ]Z? 0F!.?;@C/<:,*KJ(].C5 +J>U)4\:0W#9
M,!E\HCX7HGQ.48$BD4^:1B&S !KG,59%$F^M!4\,L8.;"=\UOKJ(6^ )8%*)
M$_YW!=2MG#1HMG#D@!_'?_!!1Q5>+[GIO3-+I<@$EA381V0(7!95("QTB0U,
MT!(=AKPH9C:_"@[+]OA'6(LPO2FFRZF*.K(/\Y/P ;$$?"T(QYA&U'SE^%!7
MZN+H$F.A*Y+,SG5O<X%63*+8?[_E00!,AKGT+.!"AKGT+<S%DV$NO5'P]IA=
M''*8RUG; >X]01DRY=D#W#"Q*QO$<9J%+W$')CPBXD2Y8[6(R35AY9%-4EZ>
MO6\*GL(G(<YW];U.@DFMB7.M#C2$L]_ZK@GSL']C"U'_ZZ!.E$4\ Y:KR.5D
MW$E?:A1I3 A*DNRN>--[VSCJ38;V%M7(#CIUL8D'R)^@+^%?7#&?ZE)$P1 1
M(0U-G1)HQ  =K:V+C H<CSL1PXMRK  F$7U5ITKQ0/P9MP8J:CA\Y[I0YYI4
MY#J ?#:QBG -'A\&F$Y>;1;Z]VV9WY&/C> WM;?U?P:]3T06FWV:3DTD(1.*
MNTC]*UIC#NZ?:%<Q19A%F]W4>J[OG:)@9ZOON/&0LA%:%;EEB1<3X9:BQ@K0
M['PS<-_IR!YL-5 &?6=JSLY;,&P=(QK6/L-+>'AEB97K^8E@&-/'*TLW1O#6
M\-483M'PV<H1=6)L@G[BIC[^0JOYC(^Z.:>"$G.S[/3 UC4B9AZ8YKRR>[>#
M_%'6'8NS*D@P)@1V9"E3]62V-L5<FM-H^9:?M0PU4[F[0VI>ZF]T7II^^K9L
M6O-"^!R^U0&_((+!-J0XSS:7NJX?W@X_ @04OMI.+&W'E6^TP</3!.B.<?@>
M)^QX]>N<0V,_/+@;;(QRW%IF[PC;$L5QC,&CZLTY)W='NR>]1NM-MTSZWGI8
MSX\E>+Q*F;&X2IEM:)YISE8ITW3'MMVY,F6ZN<LZ9;)BCXSO>!K>=>^W6J9I
M5?A.! "&I"59P>A .>7.['<LR"OTP.HNS^TQ3^K:D+HV%8*X_#,5>J;CP2A*
M,<(:+&DU"AB/:10O9_?:KP \X:Z <<<M"D5-_9H9Z0WKO-1^ZO^?O2]_;ANY
MUOU74,F=E)1+<B3:DNUQ<JMDV9Y1XD5E.6_JOE]>-8$FB0A$<[!(9O[Z=[YS
MNK%0E"S*6D"I)[$M<0$:W6=?OM.Z"7VU\:EVKCO3,Y1ULS&*Y_I<9L'$T+NQ
MY)AMWU.=^&V.6I)*&#M!"!:[FL\S\RV>T0+)T*-%9%'_#]H@-(IA>P8;3]->
M#CRB7,#](MO<U:9WLC[T.G'N8#/P;8ZD]MA.K3V$/(P3%GN_J8S\U_@_RHG=
MKSJ<BG3\HO\HXXRA@T5$'D_IP_0T)=='R6N_E;3LX%_ W#TZ_&V[AZK8. S>
M[>[T@L.IB:7Z[U"B <&O'!@D87WH1/!7AFS9V#(<+U,WIQ+G;Z.,#'C$DW;V
MUVT@\N5 3Z(PQ9<#/<2N7U4.],J7 WF=M8E[=L]^P+LTZIMQGTPT,L6&P=:[
MS\?#[>"CUCP#F7,/[]\>=#V1NO'T\8@CQQNTCP]1"/8/E7(8K2H&FVJ>(!Q8
MSIRW.7-F.;/=!%55R_QK<#((2 _*#.*W2,,>1#/RF;AF@L&2B9UM#=F\S.86
MV)B#9KA#=0-@;!8F8+@CBR@M@$E2L4$.&=W@5"\"G5A7CWM$YO&9P5!Q$2C/
M9%@SK1 M)8C>79Z@K8:!#R!Q E5PQELW!I=_,2.=%>1I(I[8"SZ^[6$F>%DL
M@D,V8(*WY':&0%'"[E2NXDD8<XD*=N1$I^@(.8C.XMQD+I#X&?U5V@$M8=?R
MU\&;&#U*;\LTM;>R%^^U/EYF)I?KOP[>88;-&\5-3?GRE][&=$OK*_/7!!*E
M:B':?%_6R[ N[.-#R+ J%U )L1HTC+NS2N[<&I?)4D\9.N*:4F<@O(5V*R>'
M2'B5F (5FG0<9S,I-#L7;F8Y 8"U1&H)Z:(7)9*31%7TWHFDE@@5H4,?K5#A
M<)]&%QR]Y(PD>X$>";6)YO8_EK]T/":=&*Z*M)C[?2D4C2Y=1$]R'"4_-00K
M"E"FYKS5 UM]Z48ML +IC_*;)#<-$5X]8"DJ(-=SQ24TU>UR^DM++B3/T7E7
MUQ1M,4@$_=YURW#5U)2NKE70C\> 'K1[?'C2/WC[H>OKWJ32[6T1&$C6S=%1
M#/[NTT\SB"\R.!P,RKAB-J0JVRPAK$-R8<1%X.U*.W=\J)8.IZ@#CP_>?CGI
M^K[P&3[;C#/LV49F#004/C<G%]T!DEA-C/-?(>,^'1]MO'WU.&RI:PVY^/%,
MX)T.BUM.K-W.,*^.+K7&@_H[>XT738VWUH$[8"N!C8L3EI/\B=W7KNCO3 <G
MY8A%: ]C.NE+I12^UB+4$]P=$MQ]Z.A;(3BQ>XC@+B>V0V/F#.)XYLI'';4=
MH N$J$E -][R7*P/W'RR1'6V*-YI[(TEO?N>Z7-#ZKL/Z^+'E\K6&E$>BI,G
M,B[M<B+\HMA'/7$B#;ZBR>E95@NW1B?&QA'=+>3B;X&.?C@5?POSDWPFOL,Y
M89^)[UHF?G?'I^*]2[B)>W;?$W71+H_4668*$YJDX4_=!4;H!N4T//%N;F[H
MH)R@$W9%9@BY;H6I,IC8&S4R$Z[J1,;RD%E]!6<$6R?'!]N<$&&P<Y=HJ7 N
MKV\ETH4-Z9$_[_!_KQ]FQP18DIZIWH\\B$Q8UCD;EZA"6[$^UY&=2\19JW)N
M)*6-/)AM'U^&H&QNT0*)*-[3O-UI[5I;&L@;XZ7>Z^M-:'Q27+:*A+SPVE#A
M=9"V^3  JBAP2SD9S4/,D: =+9A1P)55NH%,SC]*)"28-<-0SPLUBA,[S<OB
MXH1!F,4"&=O,6*.+#HUQCC$=&V_IP630"^ACV8*_2<^L>C*:/->)MEFG*H=%
M/Q;A8-MAU5:W0/ZKNC'@)%(.5+!H@7B8)R2B&REK-TQW&8CA\D*>4&'4%.,_
MQR3 (:%X/XIZ&/T*2&)<,R_GZ.1S<+/</]L AL[+T2S.<Q=*F6%*!@=@U'R>
MX&@ A_NTN<1+FPV5-E\9E#@C4ZE.-K<4M+6&(%X@EM"D&A?@'PO?U74LH0,G
M47K!EP;PRUN!A'DCD##'%@;FL!(/])J"/-1)G[O >L'>L/^[UJ<VZO].T' <
MKO-)C9K^SF6%,8@AU70G*70Y:4JQ$P=IQK+[HX63^7@YG(P-_78]1SYX8.BF
M;G"QEX8;+ VEOL.+P^^(PQ?[ZXO#K^>&Q6'NY>&&\;&7?8\HXNM<+.[3."'?
M)[D+(.8-TC.>9C=47U\V,OS<SJOCM*8,L\/T%AEPQ 2_'/=]=V;2^#0X2B/:
MB0QQ@8-?ETOU_U6I_NK+/?=%,@3TM[E,@T<QO=RDM J-AR3U;0F:LRSZDTQ%
M&F-LTJ*J&VK<KKXRSUL2K-ESDR51I07YNCG/O"HR%19!A%G:9E[!V]+FEV,%
M1#"H9I--E //$#R,>0LC@_:)'BSB8.L@^,P]!F>:K(0L=T^DOX7QG#_0<P-M
MXAQQ],CD:L)SI&8.'[F.VQ2*K(LBQQA;' '1SJF:<&64_(@Q4B/,>YPTAAM5
MT:*\T/-JHJ!=A\S&M3 ?+,T:AWL'P9C-*6]Y0E+K3HL?;TW-5AV!Q[8#Z/.9
MSI!#V=1M]TJW2_MX_].%&\D\U]3&0?=<,@D%>7EV*N#:P,NK(OXWA5YN=/;^
M1L_%,]7SJNOX0E^>=,1AO!N#]M&-+7SL,QYU]X^2E/!EC88N#X*K'V=Z%I/Z
M^J)I%5DX#=IH5IA52!MX^.4S[(2I3N9NHFXK2[J\/)]?\,*BF\+B&@#,Q$$G
M]>#$IOQ8UHU/^W0\E=\4C_D6.A&OQ&-^MAJ/^?G.R]WG+YIXS+N#W1=#^N\B
M'O/SA\1C]O3M]_$Q[F-G-=^7=U]_._KTS_[!A__+(8TO[]Y_/OS7"7[?]#WW
MM-N%?7P0P!44B%4^T(:5N-8NFYU[:/VUKJ<0X17"I5XNC.O\NAMN? _8]7,W
MX[[K*U^G>OMA5K@T"V'XTLU"4$'!.&BVH#/8[1'#+0U&&&%&7C7U($Y;<0<7
M;N">^P)1G,)]_>*8!GTA#H1DA=SWQ5Y]WT'P.T(F11S&<S="KXW(=,DMN+9^
M1?TXZ'^T"!9:99J4JPPZ.'9/6<T#*PP*0O,PHR>61ZW"*CQ:,D#/;)59 (A=
M+SA4J8I4+S@N=4;?_Q*'IA<<("E$XEL)<MJ)*6E=_S295CXNX[7Y)FKSNNZS
MU9?1"T+%8J%AOS+NC52#+TT"Y-AG7>JC&Z4^)F/V<F'<79)"Y%_'$#Q3E88R
MDK/9H)XGYKSQZIENP1IA>(H.>1P*RY>](5D@^I0DRTD%QV.XA(B^66$W2JZV
M;MIIJJ2EX84 <4N!CSC/%^&4K . *N:+V9R().>EA"1K)C%N/BHS.N8E+1%'
M?__3__LM.7VU_V+_U?[.3D6Y3!BT>"-(F#B85(,T.JYCOB)*W@S9MX/YETY.
M1"%_+A7^/*FP/:&FJ1;6GJ6XZ3+"R]4-\_"OWMNWNE!QDKO2C*;+WVYVL^+H
MEZ=S%@]#O[_3U_#5_):V:+"W0UK\!VV!_CK& $DZDI_T*''*2QXE)CQ]?<V'
M_)&=;ILOKVV$&TO?X;7_Y<_[N_M[:Z.?W+]G=&O:QGH/SE%:2_EX0GSRA%AY
MHT)&5X]\MN9Q8_)S<0ZL[P@H8@,/_=-E$!H/_?,0NWXE],^NA_YYJB;@G>_9
M355QA_V8]068MV^\?=.V;]R,9$3M=X?!C"XT76^VB*>I)T]37Z=M7/QE?'5!
M$7' T+O#KC_/)DV!$!Q9%WMW:-EI%/AQ$'>SV8W4!N_V:\EVRO!YA91&HPF]
M,(#*0J*2!Q CY'C%[!4O=KW872=F=M5,"R3__"B1.^#_U4Q^31Y?/0OF8M(T
M#PT@^,:9F=4#%?ZB9O3D3JY[<>'%Q7K]7]R=VQ 9E77FTNZTO_E,!:.8UI&=
MZHQIV5$N*/33\5'7GY+%R?/-$2=M*<+B02H?,$IMRGWR>36/,M=GM Z!!71=
M<OU,)^S"C?14G<4FV_ATNR]MZL(^/D2A\B=SIF<CDE(K&C;;U;^J\[6>%H]J
M=9E6UQ??:'OH=7ZQ*VO<NK[HM6OP\*D]23>BF.W%OJNDNYN"KZ4*9%_RY?7-
M!J=*+I1\5>+-EWSYDB_OCSY(^.H6]8TO^O*D>&=%7Y>4??7$'.LUR[_>'+WU
M<3E/?+>5D:^,?$]2GJ36(*GU$O)=?QJ?CO?I^)NDXXE]-8.Y:I^1]W+79^0?
M:T;^4C[W27DO,3I.O]]/RA^>O.^YS#P(DDRZ"1KN?9;>9^F_&V'>VQGL/-D8
M\Z;OV@/AGK_CD9&'=F1D<"1RB%Q&S!>"%#K(<[6P&/XFGT]-MA#:_JK*8&O>
MIW^V-SU_LF&U$[\#'BJ)2? X59%@H@2KACF.!7.P=)SF/&V3?CDCFPD32O5<
M\T,"?&D<TRU<@<5%:\GBK*AB:A(S60R"*[ 2*[2G$CJ)AVSM[K_.'+0V7C5I
MLK#7[@%;I6^SX4Y0ZF_S!-@KF.1YW"]4N?MRM]*#3(&%P1".A([K.IF"&M3J
MH&"9W?617[M[75\A:_%B^A!J?/W%+N&Y'Q*]:QG)2P1?X5E_M>["JH&U:\\N
MNP/\Q/6?N]TE^/U%CU1X.LE,F4:T\O?\W^M. $%N'7X]>+O==6L1I6M#F(QS
MDQ.]6<NP$+GJ1D)']/ZSG2"=_/PA",NB+_&!?&HPGWUW9^<GLB'3'$YH;.N#
M7K[\J1H$C=>@?5>(Z"A6DY1N'(?P?8?#0)4%H+'Z5KRC^$<!P"_O^CZR;-G;
M# ]!4!=;NNE<LY*+#"T@-06TV@)216&\QL'QYW?]B4ZY8Z@H<V00!5?Q6Z"2
MB2'3:SKC?)#3U I G&52>*_!>PW=\AH^DP'9YRE@P;MO!:064;D,%UT&&_6S
M(AY".!VEP>>P,+:J>KAB#,Y2937]79^IKLXTK\[T$MS9.'<U=&W822?#4M2@
MYD6@PE#G>;NB@B]+\A#(L'CG<O,].)\:P</-2[[0N$PP5TY@:5FSMBOZ6L/Y
MGC;M=5J@#J^SCSL/O84/DLJ_@A^7YE?"J&#_-S'II$_VYZQ99%Z8A-X=Q0DL
MR$@5BOEN"_7FVQ<+SAM05LO@K;2H3./>J0G,B/97I >NIBI,:/EENLC)8J6]
MA210684E;<&;+W^TP=U:?</;8X*NDLX[%4[KR'6<GFGB@(ES@(&A+:T'^)@[
MM'!J>-#W^51S9F+5J0$L_/)C<WC>%V''*P4QTA/5;O89/BG#]MXIX?]=]=_&
M#%W=IX_?VQC1Y?&L-XR.W4?9TH\OM4YG_YU=V4MC7XC].U3N$Y3;2&AW]W5P
M6&7-3\J1JWL*9O0E3-$B(ZR&#?<$=X<$=Q^E6[="<%(P001W.;$=&M(S@%\'
M5;'F<-1V$')LS(X=?<LVR@=Z!:.I6U0WU2HIIE45AR>].R2]^R@9N@72XQHL
MHKLX+?0DXVCLY23XA:@OG8BLD]K.V=RPZ;12M,&>\B1W?R1W'R4DMT!RGY8G
M5!R1,9YR:G/KT_'1'63+/8W<:Q)A>:DW\"9/3)G1,N[6J_SQ+44U 3+QMA;D
MC:M""XYU-L8WN0H*HU>D<H0]0UM,PAFP"S,7EDL';,4F??+Z_7^]X*.:S>"-
M%H%*, [JZ\%;=BPWAK5V?H2Q;HUA1EGP\_]@=W?6KIV\-4[PL.G+^]NE6(*'
M37^ 7;\2-GUX@6$\;+I/5C_52.A5R>H3=:;>?MM4V;6A&:S/978A^3#/3%2&
M!:I1HS@BTZY"QI(CXMF%6F7)@NY+DJ@:5#HV(??YD"D9Z0)S \D[;U7@7]GI
MP[T[*B#+-4EL)12^,$J,B0;!>XPN)8LUU7G>"^CJ4TF=P$*=ZRPW:4HF)LE$
M^BGG1'IS9.F<#%RR<VG;>$$1"G#-_,( PQ[GSU-#[P915DZ:>\!I-K<#C8_5
M55W5AP?V<]@HK@[BRMJ^JZS];DEMU3[RV'+BM@'HAN69&R;&O91IYLDS/2D3
M(6^4J9_;+@7+*#/Z52/L4BI4C+C^*G9:P>,J613,[F>T$Y%DM%T9.P\2=9E4
M]R*W >7E?&ZR@JX<1T[^-(HW>ZVJ35S&<%[U3)&7.TIDBC%^,65N(X?R,2NQ
MHBHS.S=S/!RM2N8R<PT,2@O1.E9R 4!>AM/6DB/#GY * <@H^]GV)U$IRI.8
M'QG)7E\2>-;?9-:O%6%89ADMFKB[*D"34!2&F(],M.B/F*>LZ0 &7^2%EOHS
MXCV= 7@%6IIXXB#8>O_AT\$V<9O)3F%G,"A5,8VS2(HBM!@!P!JPN)/.&FEJ
M6E;)8Q(_><["H" ;1*/%BOA1%A+@/F3R#/2@QS<QI;2HV*_:U=/]-EY9=YB,
M'HQM;Z&HK;,>U\$(M/S=7II'O>6;3Z%/5+%<[D>RT\4^*;F**$_@WLA(V_I+
MO$(?-5F$$CKN%N=I]7F=*NY5"6*VU*JV\." 2QH$ +O@.LMS_-5&Y]W;DS L
M;4B"2\RU@2M[;K(D AQ&D' QA&@LUX/.<#GQ!$GK9LTH&<*9PU#<??:J?>'1
M@I:RMX.B;7H:5F^&/-,BQTUR3EE)/2AJRLFP#B:)&=$_7.G=Z'^78M'S0(W(
MHPW^:Q=9'KY#KWWIRS/QK?8]3L5/R6PN8$0')INH-/X/O_E@*O+!:Y.]G.F\
M.D0L["2$/P>7,& (5)3?QJ#S,3>D%D]G\SW!;JAB_'RFI;4K423F"YURXXYX
M0QR7L,%/;L=):3D<026_)\XAY_.: Y3C -<LQO"7'#25* A'/F/6B2MU+'0#
MW9@#&N3K78'E=C1#H$;!/>2%VN!(KO4IAT82]!ZIV2(Q<005Y\#"1YF*TP$J
MP4@;\S?=5_*"FRG^@_[,$*'?4$+;0%IPE0[\;;$!IK0^.A5R3LUYFN-!9T )
M@UVP\7Z=UUQ=V,<'R>VLXN:8^_N8EY?95HS*@JZG.5R"Z(R+O-"]9+A+'I+!
M3'JTXB:;'4*@!.9F9LK)5(0.YV]43G=W21#;XAAQ!D6%BFQ09$Y,DI#UR4&9
M/$"P%FNVU^0P$6UP5H9%F7%\V"W*K8!96*<2M!6,R16/AMO:U^-TG*B9151Q
M\6@K%2Z**2ME7& 76 #VGOC\\@[QFFF3YSH[4^R 7'UA7E>92KB)369ZS86;
M[600^:0715X4;:0H^M>R:4&TC.\QZ1/GVWSN'Z6-VCJ\)&>RZ*0,.;,:2:N:
MX_MHD3M/O98\_ GRMD]KDT=2VI)EI>>#"4/60)46DBB 96-F7P GYDW+@7B0
M^?(*&^9WS#B@I]=\&7+G>9>YT8&>M4]"$\W<R#IQAGM&5PQ+""Q(8Q:YK@_O
M"DF'#2-92G*2EE/D=M]))*EY&Q/3=GW7BUBZ:\\FV7 PD,5D87''.5&)+EO9
M[%XS/WZN&@WD1*-34UID0[C\*D0I*;#Y28U<+N$?73;+R[&G(<<^KV*4%?4R
M#8;A:&2;]UQ7-U>8<!10V6*2&8E!E<:Y6%H5'VLG'YJU*GSEALSJ-5P:)RU6
M^4-+SA9)9I* ]56G;&V5+(Q7K:<EGR&!YG0K1!&3UJ98WXD3^R,2$+2)[!62
M)YDOR"*;Q%PR8[-V1G)IDGY?*81H4?',QB$O,5U9 B/?5V<:;4J=3=EE6 RY
M=V,[TYM/N'&15&^?>;GV8_O8682W7XE[;=0D-G/2]3-:>%E8^(*(GCM;5'Q!
M4H-<0AA#Q+!D%9R2S8)$0N=A&59:>"W?U8F^PL%L/ +T/EIX2?HEA5"5O!,)
M3F214!Q*FDD">BZ (!8K(-F5M5B;)K#;'W-)]($5 OT866K*5#IAX3\W>1[#
M^^TZC511T$=P\LU#K8! '-S=8YD7ZI7:AF7NUN^-JV*=(<MDJ23C&E&Q>L4"
MO#(/\'1.QU/TAKJ?QPXHG*L:\]SZ71#<H28'LZI:&>E0E3P\12^6,:+.XLQ6
M66,4 C<;)&;BV *H?>0ACBL6J:Z)"3FSN8HSC+$&UU@L!9@*FIQ%8CU!,!]Q
MBE$!/I563OXK8GO5/51TIOBCZ"'6$2TLU79V!L (V9'B-Y-XK'FG^&EGZK2*
M5)$QDC.(FLX&P9NRL#XTT%OA#<)OG)6"ZILWRKK'Y, BO8 %SV.4[4P04R_J
M6#OM8=ZS:*ZX6YPNQ]]H;TY0(<H'KF37\<Q9',$9ULF8/>4+7_K-G&.W>\#N
M2BNW$<[UQ$ZIN!C!PY6Z;@LYB=KU=59'T2/2H,-%058CTVL)7PMG.3)W6'I"
M?^FB[C) 7"$6^D*491H#I<TQ)S$?D<CJ,*XE=+H\'[J-WC9/W!)A$>=Y:3L%
MN(**7D/DR89 *HL;6.E$6$1YBYX-#+.N6Z) MD#Q1<NT%JO'9N[X4X88%LE\
M!^/#@:MS6DT?H*!SB;W7D1EZ/!(H$\Z:5?OB&'KC34:O3!^],D5#(??T 5+3
MELA8AS4G#<1Y(Y63@!L1Y;LNH,O+7"R:KG ;)Y1F<<YI<DX[9^B HKW)I&MH
MZO0AZ=HKDDH]$@=9T8CH-JII7#4,@X>JDL2#$8T?9U=EA4[P=;NTIH!@S8V6
M<I:+#! ZF61Z8JV&,"EG<Q%'G.>>)PH!8KB,I,-LKU2C(N>M%OEGI1KO&YI+
M/7Y$AY$,/'[$0^SZE?@1SSQ^Q,/K^'OGPWR1JCG73L+V2K0@X=$)D,)AGR/2
MI$-D>'&C!J)5%5EUOUJ+$BH(64@[D=/&:2,[V9R.#\UN+6<.C7$7%(7/W7M[
M;S/M/5N65Q<PPE&JPAP(SG/A'5W+#6AKFS0'5:!@U05&\+ORVKNL;4$ST5*=
M'!KNI:DZ4>.,<2XSE^BO@@0KRBZE*LF%+?-ZO5=6+"(LNKKD"36,^:K")U?3
MB;K#>%068ME>GOH>+?!C5LZK_MH53JV8?VT7=G5]IHBN9GFF/,75118JGMFD
M5(D-;95E"KC^-W)9VP6:C;-%/*O,&^[S)8\AV9&E(+*L3^HWOA>"=KXU[:N=
M/#0S9\TWOA.CWGB_VLO>#;-=;I"*2357-C4B;:X8Z.GLNJ?4#;423JIZL!$M
MFI5*2S]RJH'S)FPH;(WUC+;+)"K;#ER%KRV]Y?(^(7U7LILW-8M$9YP^8C6U
M6NV<ZH75BV2CZSF2&(WJW5^LMIM/5?]%D,:A*1"-)<]!TR:$4X.CKK[Y>LWQ
MJJLJ%Q[F9#[U9V1'+9+^V[[*D=,B(Z#S:8>M3Q_?'FPW=M\=<]=73I9KF=1)
M\:XNL]I9SM7D-9W; .X\/C.%+=]G>U[XB'WHO,S.XC/TJ[<QXF=DE&7$Q$]<
M]'H5MJ$J[ AD'$.)H'*9DXE5W^Y2S;.DNKF3@]25@L,57DC$"\N([UNG'T@C
M<D?-4AHBB#3/8("&DNM$%4\&:!NAO>7&PJA^'\V]J7O5<1^>(HHL',=2>7HJ
M"?T1N8X ;T/I>?6$5N%RI3QQ-;W/A>ZR7DGJ6]\2^$_AHC"GP)1<\O67]Y#A
M,EQ.YM+MG. -=R]^,#?G_>A#?Y\?#T$YX)+0NU\_O>^SVN8WZ!.[(UU4P^')
MKWZY_Y/,%][YB7.[@ 6)SSC3&R=)R1E8*6R:FW.=C<N$T:CZ[0Y'/*9LBA=I
M7J1MIDA[LV@$9RK3F&SSRL6L]3Z/S?NF,V:--F.LX(EVOR&WK+E*98B:1G.+
M"?+$G%L\6PLNU(ANM2)9C5X2&"9E"WW!-L_58L->NH=L:G5#J<^"R<_E'1:V
MEB<U9-4\V-J:\:W!GK4WDK67*G?GY2B)\ZF8)'4P7>NL3YP0ZW-ZY]_$IF1'
MY$M& IC7M6HP\XZTKK)@TI+ZZ>@W[K3/FH+#?F.2*0";G*LLHBOS?$YY"2VO
M_#*'XQ/B5 N-0.= U@Z,(EY?UWTEMW]=7V>%URDRKB634>K:["J!T5E!@<]H
M-06.&7-N@0;.WQ8X-,Z"%)69-XYU$@V"DR(S&$O7F,AKDZ8,1@YR88,3ATZG
M7TH\2"I8>6'%N;F8FI!6B@M:H6G&8N$5FGK*"#>VA*X!3;[Q(OTIB>\?0)B[
MTT%=MQ#1/ZSZ:6= I8<LY=BFE(/&EM[O5ZRL_Q27IS#9+DOB6;Q<XRHFXN.G
MJ,WGOB=J//W>ZD<-WK\]8'V%U#*KS#/.?R\8Y@TLZYK\FE!N5\[D$'2 X<[.
M,]*@\+ 0^A$C*/_EB9^VYYH-Y1KR&OY1IMKB^"HRWE1:SM0HV*KT&] *HW*J
MDUG7K64>H_F7/^^^>/[Z'F9IWL*")1L60S3)=K,WQ=(*>4_8W9!C:PJJ,G=U
M.\V*R>JR#N(-WQONK#L]\=YME:IXB*,^)+BKYW7A[11U;&27&2[0UVDT-^1'
M2$%7G-LY2&I$-EL2GZ+>D]L3T)Y3H,C(>1L20N?Q(RY@U7.0-)G^HXRY7\'D
MQ/)N*WD$*+YPAB=?U#AX;!/B0^1OY6[2@B!9+]^OZS0Z8#K!+/-:.""CK]%[
MB"TYBU4PH^M->5C-F">I#H*CH@(?GV>Q+E2VD%TATGT3&W(%>QB\.@!"]D44
M#;3=D[(>! =-T&WWO0N4D*@RY;:SF#0TQR@8SO^_]O9[.SL[0!^LQ]/0S^AP
M<=[OOP8G'#MY2XPX&]&;(@GE5E7V0B*=N#J<7KGX\&5O:"^."_)5/JH%3W.M
M+J#2U-#:$,.1Z$D[$Y.'D@/B/A/:O$RY5CD[JHNQVIS\#;CL(9^C,!EO.SL=
M">J,_? 073QJLOE-9]X<Z<(^/H@Y0C(&P@*CGE D2YRB+Q@D'_0?Q*UQUV6G
M-TB\07*K!DG7Z<?:"H.-0H)*=%'HC!<F#S)X5HG>"T_XH1)(%XR@44Q7UJ<K
MS*"N']MJ,^U=G*LX^/(7-9N_?DNF34J&!3/[H2&S[4,1#3AVW[3F'NVQMPW1
MKI\GGUSO\3+AU0Z XC*CIAW!KHBUVO=[>]=P"9ZLW7<[PV;7XZTGN]D/(QT.
MD@167+\1%B_B?EV\Z(8XLIEWN5570\LF %3Y"/N%(6>7?=!')WY(U3W>9V,)
MF')<X01]!7GOXM%"GE9)0F/3*=) F:$TB\P$UTQMC?K*YA4,CE0#8T@)3"J"
M2RL]BJK*E('649,0IU*\@H\>,L2!4&FU0C96[*]$S"<Z.XO1O[UU^/%DFP?+
M:2 8)X#(2L.%&V/W7H^RAM?)E_]XP@FD2,,@E^>Q$;T5&W+_6=\;=/V2YU;Q
M_,RD)DP8AZ3!\=+Z#I%@\<"<5%C/X]M8]7EWR>*KIJW];90%/[/OM+._KOM[
M-Z$N#T?3,6 4#T?S$+M^)1S-<P]'XXOENK-G&^:$7%)(1]:F!6*TW;HY0$$P
MR3B=QJ-8^GW')BSS(#<)8J<(Q,(HX:E*B]F<-A7(EB8O.!!W_4$6:F[RY@RC
MKY>CB6QBSS ;L^C:J#NQ[ "X(E-I3L8\T$+LYK<:I@?!8==-V\MH92.[N^?H
M<^'!HIUW*73ZG\5LC=;S[FSR$NB-T'W;R-JDQVDQK.6#WB8^B!P!9QK9#*JJ
M(]HBJ>N,$:S0;Y=J- M@ 1CF5,_U?^*DD>T>+201(QN#U(O\5.5?CL>TZ,R^
MBB0,5^PA$C[O?''1YB7(>T$6 ] ]GB 8U3ZG3^8,^/*T^[_B#-Y]TXGI/&S$
MYAT!4_U$)8I\GXN'\ \R9G*=8L19HZ(LE_PDCN6+^H^*%FGG 5,V[V#(4+Q4
MQ,GP.REHR($)7]GEW,>&SEY&&$B+*0 ZX?M:,/FBFOFGHV7L'QMOIO/.XP+#
M-BT.J(4;HI,/%QRL)G>@^SKCP((YU$%:CC-S]]_5N1AZQ)F>(9";(EQ.-TK[
MJ*'4A8P:!*M,3!KG'+<%$$]C#UOL\X%L@)$.3\$IG]1,IY'J^KYM(*,\[6##
MY@=M-J;#<=U4Q$ESI"JZ>H\;A4%O(58/76MOE1/Z>G5.Z.T#YX1\[^"FR8>'
MZ!WDQE?;H&Z1<FO\A=6XP43M%6Y3$Q@*:O3B^)D:,K$!UKMRVOB%)OI!T&++
M=K7>%?.4.2.?:8 LL:5%FP^T@ QA4[1!KII)>=5,X>-J0_*BY'RQA7$ALTUF
MX$1RSP:>"QMN^2H89U4#+$O0D7?(%<EV78<309 ;2+95UQ?Z76#L@R:!\JRT
MO)Y1TD#4[S5>78:J;L-LN0'432@AIG*FRDMF@PLGY2LXZ<P"&+4XR0UQPMCM
ME,?/].KA928%D5FD"<:SMFC8+IID9UT)%K:#Y&U,*\,MUBEB?IBC;0TO[_IB
MJ[/N^D(A?= U'NFY9@V&%%,(8#XF0E<0@PAE R7O/?].2T1V"?_VEL?^5N@Z
M-MHG?8&EC'LG#9, S,K(%$+VR)#J*A9SA"^XR([8"6*2^7?_M;M<GZ^0)F[B
MM$/_A&?,^#ZDB Q7+\TT _40DQ7QA)D#K!RK26KRAMYI5')9T5&M?,YCXU&9
M52.S,/^S'L"F,<X0<W)J"\"$N^R\>S) 3J642@7 \..-(3O!>;FVM.O]VP/O
M(GE3<A--262-:V0L6&L6E(O59J'B!.*DZS)P8X1U'0F#:=$42PQ,J&:/ .CS
M*4F-C0FLK-\W>/3I;9"7HUDL8)FD TG-/?Y]WGR:?**:[/.9G1XT5WD1%&30
MV<F@YQK(URC@'Y>P3#$!N.2J\1%YQ+6AVY,1VT5FJG@!AU4R7;6XNM<;(]K@
MA:7!T9*9BL?E\.,6L='V13Z2+%+#G70C(02Z(Z=MK1?!A0Y!KL:Z6 06>0)#
M2,F+8H_0_DP^KN'?8_H8#V2*C:+%+ H+L5A,323(F\.=W1?8%[H[!X\",#L'
M>RZLS<=!-X#E'[$:.K2\U_4V>\>?C%Y?13_16G_,7N@N\_/B\5/(YG/3$U6@
M[RLWD#NO>'*\LHD#Q(:@(V+1':Q4Z]",11P2#N@%D<G=2 BGK3"HP<9LH',N
M<(D+A7;=?YN6=/6N+S(X,PG"QSK+I2Q<@.O=.8[C+ ==]OEAVN*),9\JQ)!,
M3\I$@GQCK2/$L'LUW@?/Q&C$"ZWM(QV39I0CXX"7<@D^HDP8@]A;%EC3N.KZ
MMM)C=7V)%RQ8/_+7*Z.-5$9'%RRG)@8[I)2%FI=Q \/GE0H1J5:+0#'"H)$2
M@.(6N@6EQ[Z.U5N% =83)KY:!VI)>^5 G8>0)'?NWYR".]>8S!W-8I2JR<A:
M=R?DM:$)6=?M[?1H4W:04@ &WVS24H #<17Q4.<Z2?JR#OMDBL>=R?W(=VNF
MT.K]P$A@3!DW=<-S/].)E 9$,H7$I0TY_VEX:7UNBN=.)#%>Q\AMI!.ZT?&2
MXIYIE9>9G2QU108=U7SM%'^/'PQHXQ&)?C7*33;2$3TS%H#* 'H@5AS8=7Q4
M5 <TD//HX;?+7F8JG=@=A2<MF[E1N9=U4$U&0*JX;16QSF8=TJF,LKBUA*[U
MWSIPBA]H _GA3?V(5.7QUZ/^[G O.$X4<4!P:%(\AJTZ:/^VE4Y^GGW8#G8"
M@/M ,NSBAYW@>? RV!T&N_O!Q$D*/$*PM4DD_@C4SZ\Q9X0! 4C2R#I!@&.W
M=BV 0=H2U(G7AC.CHC(I\A5! !:2/+]DI0$M1>%=MS7=&)ZNKW-I A%7R876
M,<$^KYPBU!HMQK/C;7ZNK?O&ZHST/(B!WC;C/OU_GL5IR..)7+UI,\NW[/=>
M#DFR\0;G4S+2?R"Z=N]CX=<KL>:E1CJTD^M^D1H=; BM6(3:D'2=\^%/FC'.
M+C[/D_?D-I_9NK&/#^$1#W=V7[%F0J]4(N#2=3C/=J@U(G254@IA?<X+&^-K
M*J&'Y]7KE0.SLXZ!@RQS.K_JKB^09';7E\AS$;H?:S=S34((Q:X]F4S9%^>U
MYV(JJ](@%_D0@?HX*U".NK7[;/OZ,#!+=F,/2('D5?9?[O5J</1=&W1"3*K1
M[' .^-E(T8ZQL3I\2;\L\D%PX,ILX_QJI'2<$:K7XPP(BKS4CR1[^A^E]80!
M&8-WW]#V;!W?CQ]/WFVC)OCESMYK^+G8'O[U^6M$\?#K.K39'22(L.NDJC,]
MRDP^CU&@,D[*. JV#D_>;P=?^X4J?S[XRY]?/5\;S^\ANF='__-\"!*A'[J^
M6K::*W+?&3S;&00G(A=8ON6Y#)2__G/<+Q;K)8\%D(_#7_.&J4$2$'WP+M;,
M@$#D*,>NJXR%X"+GS^I:(.3=[UHA%N&SBC)UGMI4IA/.(TUR4[N$=UZHS#7C
M,2"IQ04@N4I"LHC3TI0YBUCN29 OM5OLUMF.3E "=B=7L$9M-H2,-?18J63Q
M'VF>NZ179+5BP6P-+F<+ME@J]8)C^6=MZ=2)W;'":EU9U8FU;[^^V%,9;'T:
M?["-=0B7Q2E]:F5#7;#UO__\T'^^TPN./O3W^>]=.4+^_-=/[_';WNMM-/0E
M <BH01M,25T7#$N-3<%28U./42VL$>B2<:MY80VHCTZ01G#0];.!P,UAC:>3
MKA<.K@OB]D :/S:DWHH8G7?Q.FY9-PBVKCC: )1"Q*1L+^=C(]Y.4 -;)]:W
MY02-*E20ZV*CZ@B>6&1X>$]IF!MO87<"$0?!J4:B^M^NCUG*/JMD35WH*4W6
MJ.MIH.PV390ELZR)0=IU(3H(_JD9UX1S\,SIQ/'R[ Z_<NOA'^*J3-7[>(*C
M>?[PJ_R.I[")X;I?[G97A[<K1?V BXZ-6O #+AYBUZ\<<+'G!USX6IX-J^5Y
MF.TZ6<S([K@E<AKL[9"-_(.6=G\=4SN*\WFBZ#GBE)<\2HPKD_[.$_[('K<]
M@]?G<51,Q478X87_Y<_[N_O#9YV/Y'PU2,T6JK0A]FV,C,.\.QT%PYV?@JWY
M7Y+B]0[.>ML3E2>J:Q'5\=3D\RFYC!+F9NHZ7J:N9\^;U.7)RY/7=<GK$])+
MG"!%7CG!5X)PB@PK$E(\*%-B%)QPO)"VZC5%W- 3H2?"&Q.A9#V7""XTDU2
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MQN6'7"\X(J^F3%VC&6Y!2GM<)FQ&5&["'%^+0WJ6HR*8T6$[S5^MN2&^Z"+
M(DA1/:B318_M]HN?=QZ"ZQQ^S7>/"SP_$<989^14+((_2I@/*)D\(P$V(4^$
M-B\G$\3MM@5WRFEG&,&$UBW!PN81')HD$= ,+ @;KT9Q@H_3'M JW7L7UUF=
M:*@@+MWV<.C,P%%J[GJ<LHO(:]H2>\A>L"&&M[%$1#(O_Q(]/]VW]2U\*:;=
M'9>%@#64M+O;WM'QHG<C1>^A<V]Z-5A !/ V02 A#V-J6/Q9[M)7A/-CQDTP
MY80$<DE;E+NNUXCLK:F3U?0I""+V=L(R83-IJI,Y<7,7BJ.NWJZ/O!]YP^?J
M^HHO/ZZHS"##(<Q$BK%H[?KSD.A'["G-60_%Z9F2GZSZXI])KYZRGOZ9A#5I
M53,CR<[ ' -4K>%G(?F1#I5UCD']<F%!#')73BWLCHT#='Y_N">]ZXOL=7V!
M(@CGVB E">L2(LMB2Y5D!R6@EP5C! 1F=,:AUAJW*=*PV/0] WP]H;D WFCI
MTCX^E-&"($EF5#BEF\)-LB8*E-H51HK-(5G/TF78U6R1F#CJ_^7/KY[OOPZV
M7(H%7F@O.)"7NRZU_D9*\'^>#VF9]&_7%[M-%J<I /RERF"+$?_%(YN:G/YD
M"\F'\[O'\JYMDK-M>?@L VJ]1E-?B8)=NEK*<)PS->&X.5=A_%$BJBX'SV!^
M1"8:'E^F<W*W$6-S7]CZ^.6(5^$P_.AI8?[.4.\R)R]YZ_#K]NM@3E2&/L*^
M!FP7',;F1X[??=VNKEC%&"V%!5L'L\7_B:.N'P_1TAQ]62^>@^S+>??I20(7
M@K882]"U5LD6>?%?$E=")R>=\"A.J[C%3.*O*N50$P>AX*GHD.P_)5D6%VA0
M%2RDDSA(GZ(1E*.R@@K$(&\5^;$-P:52A9EHI&O%WV(.X&C)6,#I;'3#I7NU
MA1(28<123LJ#7++IJOHJAHAS(:-> #RC,]SXZE6B0$66*LZ;Q*-=Y!DWC&=S
MQ5$Q"3[[N+/O4KVS<OLN21C?I?H NWY5E^IPQW>IWI5(?&CQMXE[MF%N5"-_
M#8M$2Y:<K)PQ(^FF&I4KJ&*1BFQ7Z+*4JEN- --(NOU1QN%I#S7,\X1#=E7\
M3BZ I/E(IWH<2Z)EAIR+ L[M;%:F,(Z  JQ2(*LOR-(ZB,Y4BLQ2SE]U#EUH
MTG&<S=:K0$>6/H9-Q#@>23S6O)O(T#$\.!=ONV0][Y*:ZY*3=K@W%\Q5<7/8
M16'1$_>A3KN1Y9B5J&POBRM6HFP%G=0-<.:,GO4S5_;5*[#[E%=/C:J'+)ZQ
M(7NEW\NU]E(HR#%/28VR_QNK_#6'X'GO&IG.*G]WZ65?NZ2=27FO=)J9)*F<
M:OCG\RPF1ZX)"82BP>7"1X!H$EG0H]"'.-.YU)5@\Y*".Q0PXU6W<1>O5E<9
MS)6!+L4<BMS)C.QOKA&ISM(;L%Z";Z8$/V(G]9P8%OT08:CGA2M_0K7A95S;
MJPJ>1-#6LQ JK*+ A&&902HE&K56NSO]W3VIMG+%2A4/=STRX'S7KJ_3%GTQ
M8#U);)S:D#Y"J[)/0%(NY%=W7S<.S2H"S4$I"7O8@I-9G(]-@EDW*%IP7CN)
MUD+'Z3(V5==WYW.9=7V)06+229_TTRR8F U@#-:)=:ESUY?;-$UL:HZ?H.OK
MODH.-PI!N_X8(.X+LK^."T)?#()W;+[6\4DQ[H,0O8WX//L3*:SV A,^TD*"
MYR2RE!5YNR3<(*\JU9,GYCR(,*JC>EM45*1FL$_MDJ1BK3 F2-;L<'P@W=TL
M1%#<"NAJ#@*RZ37Y(]@L/$QZE>/ G:/8PJ5 ;6C*).*]KYIYT+@0R!"RQ-;]
MV5M)<2"LH'8)8<&U%( BE/T)IG'.S5I0*,T/)IE6D23$X474@7=1.S#5R9N!
M/Z;<ROLS$Q$KL]/AL/!QA.Q]]JPC5%,2O9/$IS!TI%S2D53"<*6RE1?ICP/<
MU=5!C2K)6]_'<SBQPC6-7%E]U2)[7'@-*G;N,U(&TMG;KM>4831C%2=<Q'J5
M32;54[3A]6I1.YJ1UTC&K[B$&5MWEL*=^K:U.XW"5<R24J=:^(Q]4M_OX?V;
M3?1O/I)@-YRS.N^Z.(<ADFFRWXMF:4$N7?D%+:+7;!*I4XGTT\C50+<REK:(
M*.#"!B?JS83D"!+.).G0-Q*/W54CHVUA9>/2.J1O!FE)\D8\/9[PA"KUDKMH
M.Z\D+Q6775\XMR0Y]1"[(&>MJ2"DN_X,Y%J:; XP@LYOMR3/.<;I_!F$&5T_
M%?!%&G'K<:9F&CE\YH%T>3AKCZV&KC_R525.C>KJKC_&(#APP=ETT8C7UO9,
M3]I,K,?'D "S$?KJ4(BAFOVOEV_)U;Z+Q%VX0!UQ>H2&<RNFT?\BQ9\F.$W)
M$7$^2.6>2#FH6F'#=G[KG[8UL_E6X;T"U]U[=?+;6F WX9 L]M0FSK%]BKGU
MIS<A_!*ZC>+Q&'J%C13&[FJ^ZU+<M8%HD]T(V9#-7R9%KVG"-+]KNU1SGD^+
M[\:,\(;;(0.>V]&S:4I+[-F8A(!92'4AOZ"_:?(.-G1 M%<('=G"^P=J@6EH
MV[? ,1)#NX11OL>"DDGC6<<F23B2V9E1O(/GSV\TD:CKY._'-MU@CQ_+V*;?
MQ9_C2C,D@:8&'<9J!F]-<5U#%F2,=4TL?A$J3MI^N,KH3/&X=0=_&>FYMO@.
M:3!6(2,'.,P4Y)Y29,5+V^M)_Z(>'\5HQ6(NKZ$!)-'?',1:9I(FND(_1*E\
MA/@:T-/NH"AX_]Z98%U)L>\%A1<4]V530UF[6D$'#A-I+A2,Z3M(37(0B7%B
MQN,XE-H XMCW;P]ZP<@BH7T?;M(:TW03"VZ8LQ3BDE)#'JPM5IR101XC'C76
M$:=3!>ZD:-U"3<C^=L")LJINB0HO);R4>$12XE\I*@3$LK=A(D"E->8\,B1K
M50Z\G#IC.'-8#!J\JD)1_1:@F4R&N2'3@9SR+THZ^*SG[-YHBI+S.$GJZS70
M6X,M=)E(!VE\IO/M-IRKO)OJB7+OND\Z,"+\* F\K;G.T-5CB[1YTF58U%]P
MD"TLL!"\3NOW0@RXW.;G<S>[]@VJ+ZRX0?6>W&"3@PE=]YP>7T3^ 6%>:7WK
MS$B0, ,*=" W%KH(1BC8RO19K,]E;C+9'8/@T.6:X%Q(811)@MR6Z5HP-*2F
MT&!C1R"PQ%!!$L]B1F"FKW--#_LG8%@+)EVA3I8,>=! =PTP\J$!K,;?%'QF
M>P?QC_A.M24C;E)/ I&TO@:VGEX8F# E=[84Y P- LP[T-^4-/68>4%F6#7$
MP3T9SX6H[L2E9("(DP]%F@1T9#.NJ"J#F+'FE]1.<,^USE$HZ%8.1+N\:%S%
M?1$;0P]0 FR;=L#*,OB5L42(5)Z3>5<#<7O(-B^T-E)H.:#VNJYS#,:4>LD&
MT+QT^(MP$$G!@ #%--/$T4G,(9!&_Y5("<=FSC;BS#H/SW;X" K-(.@K(+-F
MKJ1D GU9YY" 5\R"9UN#GZS"G+3"I,*>#+8^_7WX;-A:RK9=-5HB9.TDC<VX
M3_^GKZ/EQ3U$8]$S$K-%Q@ BJ6S,[L[.3VB1*;/*KJO-+FZYL%=W.T*"*S$+
M5,T&U0 /""Q=(7]#4):0FF4F(A_@$64!AS$X(Z%G,M]9YH7,9@J9 Q8JY",U
M!<6B#K%R4;-$;6WA%$,J(<4(6-9F D85JH65+?D5OKC+15:<-E9DC2QJAJM8
M+:<OA!!U/#+J(I]UW34]-#,2BJ%T>M .Q@G@""\\* 0/(&"D>[FH.KGJ<5+C
M1)TW\+]C#.&=\_0/)_C1:CU)&;R*KC!213@EPNSS#S(DA"=^2 F_M4=Q+VM)
M]8*6^8?5_%L;$O01AE-)*IKU17,J2-V[FXME*/*ZFG;5]>,1Q$?:$H[U&6Q,
MQH5CU?Z$O"=_E S7T\.XIMA9V&QZRI'R"]U'-SRW)@2PDF;2,VIJ3.NFBZ$Z
M_RS28JX+E2VZ3V?CF&YJLOZ\S.8&I8UDJ)@PL:#?3M;5 T20H6J$JF"GD+.J
MQ\ S)1J<*?1Q"AX5*9>^*Q#WOHU'9'H"V$ >D>DA=OU*1*9=C\C4E<R;][HV
MSNLZ2H-_E.0@#'>&NS('+$U-F<+QJ3,W+J3,+2_-/!9C&%F02=>$9B%2'70J
MXJ 79I+9O@@V8QGRL1HWVVQJ6&,PTA&"1,=3V,_#$0IX(C,#D&K/!7S8<\Q0
MIIK/R< V-GX"S_"3"[\?I72$15E(<.HWZ5;>^G3TVW:OL<"&JY/ ;XS*D!U)
M^]@SGA.S^K%7=N-6S\A/;@&PAB]ILU&->[R\F7, T^Z^W)6NXHA,T3E\Y=:B
M8A>]RM6LQD':^.8++XX>O3A"4#31$VZ5JEP25,]Q=J<4F"YR_.$#9XP9UXC[
MS.RH#/)7IG2S9.%*ZJ3D+K6A#1?=#?XU.!DP,!''/1 ?RL5)!;CS9)(X)W6,
MIEA%8E"KC$-.PHCR/?+*)[%UR\<\+XKL@12%.(VE$2/_*B ( KT@R'1X%H#]
M(@]HDC-)UF4\EIG#)2["+:DZCE"[8 BCQ-F9JA96P4XYD?4DTFSKGBU1\2RO
M9D]P),?>6_!\7-.E0P!"Q ?/F/+4.@L - A^<WB^KM2_0%2,-EF["N?J==G.
M)@;V>UNV=!AG81ES;P'M,V8=\6?YD8YEO5]94..% _3))<$;H[*H+G[L5>D(
MGF8NE9PL/;&W&%+)Y'JF)J6VV'CC)):\IU!7NQ\3*0?@^#DDO^:9UB=M=[&!
M^]X@NJ6^B7,>;8+S .Z##:EA=(.+9<8.EXX!%2RZ/ ARY0+-"!? \L@1EYDC
M[54-@O<(;])3D&;K?E#BRJUTB-3,O)C!)0>L,2PKU!NOQ?Q@\NYOZT-D6.NQ
MOW8H-DGTO)39V1;&4K16RD4:)RC]M(8Q21TW&]M&[9[L:3X2KOB!8C)\XV%-
MO)%)HLMV]-TW6E9NYPB@B" /8P;-!9P48\76PQT?SF.YO^W??%+M!LL_%! J
M.2:V#I7K\RS2I</!M"!U$-W27,394"UF96-\;&V,\ZA7B6KDG,-&AP"\?RXY
MJQBF8*SAF#B)ELJJX0*FB*VTQ6P:LG[5;%:_JH!G'0JRETRWF1GRKP#>X<;2
M]@+\%$XQ;J9 GHOSE6[(C4'Z5=GZO L<7*\?Q]#@9[ND\XN=D(VY2GA@\=L$
M;9FW+^8.XZJZ^?)(T-/F B]--E2:'&>Z,7)9^@BX#E;2#L$9.[Z<<*[]VY@<
MS#-5S>PQ8XRG)\&"X >/K+:P]A7D9\.#'RVJH:M<OV%# O6-B<$3Q 2XJPCM
MB)AP.0AJ?#295[AJW2C48=^N(:K@Q+)PJ HT,O)SLRBQPRYY,//,E(*O;M/-
M)N.!6:C#L6W67!K, U\+ 64DB57.3=I^@)4%(23E'! E>>>1X6B)-&;*M-D\
M3- +"H&S\K$$=D=&&:'"5^4RDG&D$0$AN84I4(H'1/,UXKG,WD8$X0*VO!=4
M&RZH'JV%3C8'S)ESDR41FRR9V!B6K"_:&0X>YPD<Q>:3;3?8_R'B*R#JE9F$
M9I#:QEJJK #9I8FS7GM2$VG-XX(+LW,=9MK&X^$&]!'CC>OT@BAFF8$"Y99Q
ML\Q7GA9C&A/UJOL*2DYNKX]D8MZX1J/RK&)+J,5S>3R -\<A#Y0FWZ2"&[:<
M2YJ+LPT.:X"L" DD<YX7[2F_ZW;[L0,R;*^5E9N-2=5+6YVDJ67'B!5AI22E
MW<^VT-A1AXRH9[6V?(^3"N2^8&RX%D3G36<<+VR>@K#)M3YM4C5XII8>9'WW
M+.:(,(_-?/10*R"==3PT(V> +/J]$B4HFP"*5I/_K*CJ>LZG*4J[OM8+8?6E
M\[/G YO>3C0E-N#:62O=;:2B*2P#:0^B;_/0 *B.TM; H*B6,X3?$Z*-)7!:
MD%T5MKY6AH V,7[JY>23D9,G54W5N>((7@B# \54"(*R(:31)$%&E<--P@?#
MJ<*$83LI>[1@-E AS*4XY$9@-9+(!5VTA.G0:'H)&1,AUI7AE+7:&KG7!['(
M;S%,%2Z,VWG)\0$>\5&W;X\TCV.6&&9SF0(*8YN%6JMA PMVFOY&]B;&;O16
MNED<'57MVA:5Y\[.Y (1'=7"@!L1<5O,^\O,0J&AR8P2VUC.UT2'33&-LXB!
MFA?KM"]U(D'ZN9:C#6MT64S757H69(N[AJH7KQP<V;!EEP0IXTY(2+N1I<U*
M[.R4@U%$)<]>28A<(/UR$N^,EB\I7-;?5F=+L2(]FD3>7&/,.@_G^C3@:*#L
MA2N';)%)B,A^9LE[>8W/I5'?E2X)?-!8*D?JI:\P+IK*FV_OB!".!.JP\O;<
M$WK*0Y0RH=B2'2MGN(B!8^NL&,%@!C\*E]2*&-2& GG#[&=]J,RKM_M%CEXW
M9 :>>MO(9GW5Q*1/9[<]A6ZH ?99_ =.332SL07H%].OQ+[*.84B<QS',@Q&
M)=5\6T!A:B@B%9Z26@A-AE14E9S"'*W4)GRMA;>P!EYU0QYOQ:ETU8:4'@%+
M C$K[O8MXEQO?@#(:X,N[..#\-I[6$J8)4WD?SB-]3AX)QCH9 M]9K#&K!=\
M(3<F>*.R$4\)!^ 3#W0:[DGKH0S$E?*1.7E",WJXTHV5BTH4:]C>>"[*P*UP
M#2YFUTACBE&6US7BQ*):LYN4<YU)$ERXKF/E5D&W(N[4?:Z=YNIE\'C^6@J:
MJXZAAE1I8EC.E14*/&2[G<FV/<F-P(;8M*_;@7!)RM*[70\FL3=ABV2ZOM;&
M%K=&SRNDT0?!&^G;XEDS((%#0%R=J>!$G@Z%^1ISW2-,JB%*SZ?QG(&,\\I[
M'UL>X++\?O7;6""%DGBLJX(B^!8J9>]6@'):"&$8C3,OR<L-,: 1V1(>.JQ"
MAO.*O-?@^]'7V/4-[8SV_>@/L>M7]J,/?3^Z=TF[LV<;:":+:?S15B]6AO$_
M%);PSW(>Z[ 7?'PKQG%Q;NQ ZO=O#VSHW(YGL!%,0*2:,L= 8^!Z1ABD=SRF
M!=,UC])P *?S!M'P _SO@:+A_^>X%_R:F!':*9VI_8$YGTWZ8Y6=QBGY[%6,
M^VTCQEU] \++!5P_-8Q4<D%LN@2]1H/@;3:PVRY-YY<8>$5PHE(SCN4F\4CU
M?Z6'6: MO^%-R*%8  #)P?"0\#ER.G$(JY(-9N0U\B<\1GH5G7FIMJ%2[0,M
M%5C ;\H,/O3QE(37"9BXR7:<##R%%R/U8TN^<^6<7Z@EKG+_CG^O<N+LR%'B
M.]Q;?PNVG,>$4-^[A#9PB6$%L_U@--%IO/3Q@QF]^'"0Z]V@)L^5&\J5'^-P
MJG02_%\U2\B"9Y8$IWVMJVP^SVTI32[6QEA*;JXP-_ IR\<N[FVJBP@*<#F?
M YMBJF0$HY+21K#D&Z.G7.N8!1]5FB)1W6:X+VC)"NIYCQC7<$!,GJJV!K\F
M4S>T=.L;G^AY$&[WK.U9>Z-9^Z/*<KI/3\C_;<7B7^J120?CL8JSO.DGL(&;
MD[I#>-Q61[.!>S2;JV_!!U?1PZ')CW&2Z#2-R]DRCTG3Y,DBI<W#J&_4&B$^
M2E9W3I_441V+K_%CEF9&-4?-.0L _5T WAQ#D7,0?4"VO-CFC:=(^ ;UE>QS
MNL+!0XZN+NQ >D8L5X!803F&M#H-=W9?>0'@!< F"H!?M<DFI ??D'T:?)V:
M+"U,6EO>;37?JU)D#73LZ$)*G$7 /\P4GG7P%S6CAW._-?+71:;27(JC1BJ/
MPV9_="LWENN"*[?HHJ/8-$I[\X*4;[^<U_,C 1[%\1!&HF)<)',6*\^<GCDW
MD3D1Y&L8OEU/BH+WN[Y&E.NX0DXX&"8K;/%.W8.MHK,X1U7T^=1P"A4Q/ 85
MX^J:"F%H',/^85<%9HH=PC2;Q8++B6IB!I"06-UYH^J3C8G65L71W__T_WY+
M3E_M/W_V?.?5RXJGF&0CE NQ:X3G2S6(MN,;?7EM<*,VHNL/<164ZJ;+0J\_
M.EQ9&Q=TYW"]RMH3US?U=';94^8&6S83@YJYO#G@9$7,GB%'9)AIW3IQL86O
MGKMSA<C^IUX$.K$C#&W3854Z6[4=0F^'4SL0B=8WB[F4U_5]_/+$:>5A>,Y/
MC[[!'C^6Z=&C,DZDE!:F>&H+'A>2%@>>L\HR<YXLI)U8,H-6I.!;C:K9%0+F
MNLUNDA4$V/.R[.G4X/B;TK:?'N_YOZO\[R;H 0>"5':9QG^4NN6Q6UA$Z;5I
M@K8T!X16O9JHALZG[G*-Z_#@#LS3T#KK5R.C_TV?0B=/I_C<L[AG\4?$XFB<
M7CB.;"840C67X8VQ. ,6D]5A>EQP%VP3=Q.6<.5(8EM>A^GIGJ\]7WN^OAN^
MEB'G/ 7=M:8VQM*Z?)^;4(*?*_!BUP;KPN?+ ,D7N;]734?ED'X]^I;D "GS
MJ"KZNRJ@S^US7B)XB> EPMW,M!%>M_CH  !BX.(6EK#5T;U@^14'[C8K9?A3
M&QR]!BUJ3HQ626+. PS\ 5YRS-:^G6SN:H8AGRH$Y4T/[W4]E-?%/=NP\/GO
MMHK-(G+9 II+BW+0&EX!;%6021446*-=7&5%JH' ]5DX8O7UH#93H#PQ+-A_
M[;\<[ 2T PG'X?]K^'SP4MHM[6O\_?]Z-MAMO^JJ^-"I'^@4?<EO=:AG(X3A
M\,%GNSW,VQSRW[M\%?IAI^? GLB_3Q:,(Y@[4'3!9$^U= +4PQ[I*_%L5&:Y
M5%*0J-'QF0,R^W3TVR XT?J>"RQ6Y?B^U\3*4^>.,/#OQ0"ES[8TI-F_1-93
M[C;](%7)(H\Y;/D^3E&+@%8H8$U50RZ^V%%Y])&ZBKOK2L2.VF,:<AAA#*-0
MJ#C)+6:^LSPOI>-:8?@*,:\(NHV==>B"FB9].GOLZ7)##11@^UZ-956C\,0K
MH$IIZ7&$2ONJ@*Z-XLGS2')=A_K=Q":D\8$7W74%IF?S*1EMG5>T@0RNJ-#T
M'9HS8[2.%?PV-S6G=1AL6,V0I*UGW5K_JC5'H(V@Q#'95HUW ]NFLE=C.W]<
MVLTF(*_41GG('B)RT;:E1&!O;+ H/@.(9V4+-"\R($-IL3J:+$,#[$B <9DD
MBZI8Q<X'F.D,5A5M>%V#4D.0DGTB6+B]:F"7+BSXK?X6YX6=I0N"U_7@K_H5
M7@*^:L?GT,7HP@"E<D&K$K.'O0'C%<4F*HK?B 5,!N;'Q._"J8U*.:#A1!7D
M\,SM>&.I_[J\8&.T:)9^<->7\!!'Z?@.^2+%] QVBWK!<B5V!S<ITS,2<EU?
M9<!3JO.^FDS@?Q4D#T>D-,@S7R0FYD+YGH3AX'X#&QI2NL*IXWF05J:-,H%H
M3AB.3Y6#X%V>BY9Q9((&/B53("(3%ADZ?G*,@'.WVT)X097;P8PHB>=D8RX]
MBH/*PJ%Y\'T002!:6%5.P-1%;J9,KI1!9M4-IHNYL7349SIEF.9,SS%@'<8+
M)M'7R.M..Z*Q@!X.G4^TUYA6>2'(*4D3U1R"6<']C51X.C(I5)R>T]7F#/M&
M)Z(+GM^.([*:$:/M5'8*E&N!W.8+FA*UCG1?=OFKVLB/]<$L+_4BLU5:U(.>
M+?->ESC2@YX]P*Y?"7KVS(.>/7Q4X?Z+6S+=+$V=D9^12#F;U7MY6_&QO<+(
M_Q#[_6HN,=K3JP&A=NR-=79JG57IJG@V*T6]JOEB\_N5?APAJC&7P_L+&^HO
M'*5<+)*IO.@M5V]6+("I8KD;!9(4*M6"]!#/&(3]NC/ .<8QT@FW@LAWP;,5
M./,9,CCD?Z>A%*6T>)CL0%A)G)*"2]]K!$(X<I"5G(RI%LVU;5&&5A0_MMM[
M^7<K#$>)6BY9N3<6_M(::+V"?WN.45WRFG8/5=V3M [TDBF3T(N.^8C=,!P.
MO':J%SS2DY9ND\S,?RZN<#ESK8]M2;[AV]UW#[2-$!@VCQT@,-D+:"]<9I<$
M"[M^ ISAL'$X* L1]?[MP=I/^Y D0Q9.,"U!- )LWG.3QGKT13G9*FK+KOB,
MO&'I!8#37X]R33A@4,/NJT)MVK$SB"'#$ '258"(UD@C=. TO1;S6FP3;<_/
M2U$\9&782VL4&A%;3A"A!L)P57!3E1:RIX9Q<MR Q)."8".&53)'A':O42S-
MIF2C?J7K4>!&BK?K2T5*+BW'*BQX^F6O58+**L/]@D@N?\*,$#J149D7L.?<
MV,EFI9F,K;6:N"^?U%$CC2K5:TVR:N4(RUPH@-R%N' CCS/M5O%'22PUCNF*
M33MJ \B$4[S8VZXO-"!&S$V::C*P*LYM&1&(VB](!A2Z&@492Y$AD+FM@PD[
M]&)Y<P,.C4Y9D$6Y:BUK)K&:I0],'0)A@'1\83B!E6JDI_$"W:?7G'=,%'8R
M0QZ%)\FPW>"R#BZSSG+,@B+".Y8A],WBR09U]KA&- Z)]MD$<>U6=7DIHE99
MINP@>CO^+$&"0AH_&M*O6L(3CDYYDV"330+4.;'#V6@YAD*!'%?C,8J4I;[#
ME9"T!NU*E0J*9*J0[F45**[HI!$E6HFPQ5T/*+$9!T[9] 3#+#[%F&9A;AG#
MSMT0*EST@ER-=4'_DO]XIE.+LC[/8OR#Q2>X.Y;.-^/IT56I3Z\2>"S\IHL\
M)J,'T@SMELJU7''F5&I7!,25KM96E>R=UM4\+73V.(OZ/)"9;K8PKD"]KKX)
M#$.YE2FN')HR06]GYY5@INFX==3U9;+F2.(9V;/(9\?C"_GL2TNB*D-'"!F$
MZ!IQI("_)Q;T6)^+AN*P$ /X0@5%W3]#>9+.U_'UZKVOF+S@.7",;VA'AZ88
MMHZC2I<.[ERSE6#/V3OP7EMOHK9>=N#9Z 5=BUO'HPKJ8*FT)\59S0I2O&1+
MDYE++%_8[[>^2S*2U-1[R,YO"C8[ZEZ#?Y2IYG:FG@O$5GJ:%'M)FK^<J5&P
M-:5_D"E.39AP.-<5 +T.WL2&U+#,9-JNNJ@J<%$HULO+XVQID:CG!(8#;NS6
M39I\>JX6@^"@6DIU!;$1Q(:WAD/@P-5CYY=\LY,;1O\FH2C(;B.Z!3DA,4<Y
MD US-Z/=D(UH/#=BM\!]GY%ADQ>UQU069#3\Q[9\2I\XK@6$=[HS<H&(9_+@
M2U(:.1&:6N6)BSF1\9QF.IPC.@^Z,?PF6LFS%4>2Z/:)<'TZ*2?NL$)9%JVT
MS/7J@WH7YRH.#LV@%WPHHKLZJC=(CDB=(V1Y1)H:VI/KSN)T7.:<R7S:DL9+
M[ V5V$>IJTGD><X]"%PV&,W(#JG+2+;JJ%_.,4TFB<#^D$\&L Z*5LEC[!K!
ME%%B3-0?J9P'/2,(]4=I829U :'%$3N30D-<A25Y(\_/M0)<S^WKNDUYWOV2
MY(;;7*&(KL .O8ZW/*-S+S,>KDP"N<S$<78-'W,=(EH66PV9PY3FYM)%*\HG
MEVJ[V<Y[KOQEZWK?I=O<+._EHOMJ4A+C'/(>_'!O#G]E97O.FMTY;TFC$U&A
M;PBZNSE_0EB]U\!CAPDA9XMF':[)GD)&6)7H[ 34YX#MW$P984GDT#EC#/6*
M6KVI.0<5H/Z^?L@*F8:1)H!?L\).\3K7Z]Q-U;FNI9X%X/<4YJ5*LM=VMA#V
M(4]($E?@5QC.P%,U""X6)%#9WIUHA],8S]2DRG]4=YVIN<R'@8.E5P*RLF4_
MW-D=]MK6_,%L<19W/MSVM[R<HW3_Q7.4[I?SSH]Z"+;>)7'P(8:\71Z?UY."
M'7B(BFRU*#8,NM#6.!/68V1O2>FD.W=H6MMK,T\4G?_ GB LI2 K$\V]/%?T
M@M&[D:$]2(TTQ\39C/U&EW:'&<<0PCTN$IM(&#W'Y4G=DP8CU5#@-AGJC&01
M>!1;VOD:Z@&Q2GQ=!J"==3]BB<?K^AKK8W.IS1CUNX( IZ^RRQO2J]<@%UQJ
MQ"*'NP@E!7H%Y9#?#_&4H^5VK@W*?0MU*F U4EH,R\#6)(*<N7* ; 0T8"R1
MK;-"\YX=*BOF&?^=5_&D*H8N )?1%:M#2C7FZ% QS2^/K4#^V1VXX[A*JC7#
M<HD=S)%_(/5+D<(@>.(:W%M"G>C1N0I=Y6.S$.CI[+*GS VUT4\J@ G7W5R7
MLEE17!>O94B0EU)+R&'ZF+/R4A_]Z\=C5\LFSK84I#5>LI9[(=G!'A!6,'K9
M];%(W+]G*]T6;DP*78'G)$L14 W(!=/=9!.$TD7MD&YIE%BY40\6Z9%\ H%^
M[@6X')<5]J0#R'!! FYOTLIEX%+P*IYF;*-C;JOY# (X*&&2#[A> OJ5 W3V
MLESC%)Z*#<IHL0I-0"CYJCXP-78@!>Z)*J]X5(K)D;BAMXO&QS/,;XM<?2 J
M%2Q"2:;IP%*T!9+N5,D9627-XD [ + 63<&93B.N/<6Q2^J\VB/QCDYU WXD
M3OFXPN*R@V^<$=8#=\E(A$AEC#)"I$04F;;J'<MB:K*X6#1R0T6<8Y'L?&'5
MS=A3M6979X;RLCI%!)!>$TGLB&']0'/2H!]G#:R_YI."P&V01YZD\7BC19W'
MJ6)A[C'<VKGH3$C=][!WN)O:][ _Q*Y?V</^W/>P/[SE=N]\V!3.;36/*2FL
MQ:%&(VA8D;L5F*AXW3;38$OIK;E0V2RMNDBN<LQST<EMM84Y$6350#.UK);W
M*DYP&0:3IZ\LY./DYQ>E**VT->6]I?FL,D*(JK$D!H^>FSR/<;>$+)@$NK&I
M"$.;/JKPS,Y5QN'-1!<%UV%R E#'_^%'Q)<!:F-WBY4\OOUOUT+,IDTN^-1A
MIFDGYXF$1=M8MJ+315&F;#N4=#HI+Z%M+S1.@6V@^"RVO0T9%_0EI'[I;]&'
MX"K@\+5V ;J8;+] IR$0=G7&C<RH +=(VV<F.;-8!LZJ6B 30T_#[0E%90GQ
MC=UK=,!E)NFN1H(L)^U<@=/4W0V5A2A0;6(= /77[4(6Z#,^2RG^%/ $>@ZT
M@2(>0O8,/9=)5R;4*L(;=#YX!]L*<XN3&"?3]=4*;AV,K]#%W:HIC]Q/P^!?
M_,,TGL]MZX,3$0TSEL][018@F$?PFY8E0R,%VG)>D(TMZ&_R/YXZS._]AW']
M?M\W+GQD.&P.#!@NIY8AAHLEM5"[4@QR44]A:,Q66&J/LQHTD3*T>M0",/G@
M[$ECD+8UCYR/-TB3:'$C&:62ZW?.XR1I37S)4&K!HKEQ&3L61AQYG7%]Y2IU
M4JF1NDFO*4L@8!#JMT,>+I;:/'&1X%E]<UD]++.,<10K#C*IIJ^EY$*1WHR9
M4T-GT[6 [UO&M[!*(R2W=?CVX^=M"2?5%GJMCMT )XG?-%F9I$]N/$MYEKI]
MR*Z'X# '_F0NQ&&K:>$7M)E.N4PP+^M90PA*L]&^L'@TQU.HY6>N2;?I08Y<
M.3>\TESZY[;B@1[T ELY09_*=(0K;U^,>=N/&@1&T6BKB__/WKLVMXTDVZ)_
M!7'FQH[NN)3&CWZ.SXFX:GL\VWOOGO:UNG??\^E$$2B2-08!#AZ2.;_^YLK,
M*A1 4K:Z6Q)I57^8L202*!0JWYEKM5]R4?Q';I>3AGLRPIR7XJ@<L7:5&;JF
MU'/9F?[K55VY]Q00-AO/&0/O79Z!AWG/6HID[<#0=$8/4EB8Z*H3QP#HHN/G
MX KQ$&NAA38B@=>-@^< >/=EH]%9  76V^<K^ +(W4<MOV# X5AZ)RY 'G@(
M &)(K\9<APBQ]3,;X^TT#(IJ"G0?#,C;W')).M?Q3XKM</K]?DG%??9>PSA]
MP$6D.%UV>RRD!]70Z@"1$JFG_LP&/H\CL<R^0'WHRV//E)#VTRS)?#LI7<6]
MW=H_+36VT\D#F694\>LK-&3UW.4TY)69]\,G5\<L$;3\J+5I2$3+7LW&UF/+
M6OMPY?/8-VMXW\>^TAL2;4>_RZ<E0+\OD3IU:]H_+J'ZR UX<H1.U!'Z5><(
M 6O12?]-50^-15=6@H&@(;35)1(2!E[B[EA8:0LJ$18;AG%#<:Q#>90GC0X(
MCV)B\+ @W^W8M1!TR+&O\>@WT>O@8U\GA\K:.>_EHK"Y:[WG-9*/T5F6SJU0
M8&TX24(7KE#1GV0,-:@7RG>=@41436'YNF49PW7+\OS8]^N1:_"TCT?1Q'-3
MD_O?CBBPN&F=V;M@,1_184@"=**N)"+)N,UJG.OPE%L,H<=)\=%$O.\1C_O3
M8C*)7RIV3R\[X^%%D?OFO!"W8_$,^C4<4&3U91DVSIV\-)4IS"R[I"AOE?UG
MS=/]H 8'OQYMO&$[KQ1[T_8Y1(?2^#;JE].U^?*\UM8GK69TO;*FJ!4P-K#[
M0T;.(XJAU\T5TF<W!U1<CU>>]17_#C=P3=ZOI7C =Y59TN%!SZ4[^&]1AFSH
M[PY;>'YYGGVQL 6ZQ6?<$BC8"F6=F_++V;XMF@W[$V7BAAW7-X7>M37H9@/@
M0K74IC^/4#"+"Z^SH4DAJJSN],G-PB#?+ P?1$,),]_5X <+SMY;N^$_/+QB
M_ZCSNZYC#NMC72A0J:X8@IOW=3SCL:G;;DA(*EC,T"*#^0Y]QX&"02KF] >=
M;.=_^@K9*0 V#_/:Q[[2:'[F;QX'!%24:$>*N4"8KC(,H6/F>^X!V $#X[43
M1R,@BB!!IE<MB,[T2C$GJW([VPN.1C_\V8_$*C2,']82O#C<1?LN0B4V$P+'
M\"TN2UKP ^T;P $ S7SMNDYGOK09F_NB/.@!16H'O_]PZ;LG?[B;\/RK1Q:O
M_(XMQ#?NSZ4"39;+/]W_9X/]"B+Z*NI9.M5M?NS'])%&!6\&YU-0:+S+V"I8
MX^#FOJYKL@0X\#(4^K)NUQ8VZ0(-/:]?O;SX<@SSR$.GWG(IC.DD[-"IQP-.
MK\[%V)VP0YIR_$ L'/N/$UX(QMV\I0C!DP=/)G::>M.@&W&RGIDNAB=]=3[S
MT,)\ "(4S(Q57+@P."0=1J"'SCIZOW+%7?J5@V-"/!0R3!:Q AK/QG;<1,T7
M+Z3#0$BHI4TH[JW4S9M%4)U^.QOQ',7'X"DJ_\:$P+.4^1[&> =.DO@:5SPY
M] \*Y_AI6J/#0GY^-?Q"9U]T,FL<FA@_8$1',:)Q7O0M]JSV[D+FIXAT-?HE
M;%+1F&M3"A=U%)^88= <0]%@(>M<5TI)96<<RF^8S$'QENAN#+>(/J:34PBI
MZD[&K[@]'-O $T\>AS6:/1(6\LA;'\U7+1Q39^N33^+QT"S+GP@(=.S^+\E3
M&P!/9(X*D])[QJ@PH<2=&MO1B],.#[F&K'7_L!)''JT'24=>O'^X-O5D_I+Y
M^PW[_787T]0'/W%D L.HD1GW(VB?PXA#H!@E<G[VW: [ZG4 ?9291+45B[HL
MZVM>V*G*T!&_YR,<SS__^@G)QNFEZA/VQ)&A(!SCX?[\=_U&[(FO$_9$JE2>
MK-TX 05VN5W/Z_*!=W3DZY[=QMFE0&U3&GH.5_&2YV4]I3D^\(2_9Z/'OOF+
M:U=T*W'2G_#"_^U/WSS]YMGS%\=>.7G)6&X>E2U OHUX496[4O@J47S\&#9+
M7(SV7];*L;CVT\OP-$<$H^8+QW=@B+\Y8F4QK/ >E6P2_T<L_I>H);:M#GLR
M%" G^][\_96'\=88/@<L<N#P\Q&\<%;M: J)Z>F&1R7 27:3['Y&LGOALV%S
M-!X *=TBE8]<<\2EPL40;A&8UZ8ILB_>O/OA2P;/ZE:H)"'OAFZ"(-+<.2 $
MUYJ:<P \![)$DN8DS4F:[RA[;AON X)/#!M<V'_VOH +I+PS;11$F>V U;W9
M/R>3/O;1\UJ&E=CY#A?SKC>&J%^^_7*V"QBLC9$CK.DSCQ(5UV\QHNNIWZ5D
MO*=E2M$>7'6%ZMO2J,[RY<#0"X6*<BV@DH56*9,Z2NHHJ:/[#0S^_NHBB5T2
MNR1V=^33,\-:@_X2CX\!V5/VGV^>9(79<@>+8X:%W+I--T@F=_7P/*62(S*%
MP= EG"0W26Z2W#LRF)X/0VA XJRZ$9KY Y VW@/>B];*[601"8:,?05X-$:B
MF_NF1($).8"B#DBDB3,O'Q8(':,J(V)?6=MN52N#R3"SAH$*'YL +!U#3\W5
ML*;0:>CP2F5@H6MLM>Q6P]"3<,%B'"&II*22DDJZHY1"W5GID&9TL;YPG5<V
MT_)>&%V:_+9U@9I<N5:M='_S=!0 M_J-GVO#KU-XD"0Z2?2=2;0,E4P&_J1#
M7Z4O+KV'<<;8S<"76_%*%'6PN'*M.BU2"6 R^IIGM/&AH3,WFFX5\C([ FN-
M>G9?8'U)$21%D!3!W;7MQ!-7)*?C$?78TX^5 EO_X!A$GXK9%\:7TOK"R6.\
M/_IVQ]\KX,<_@_*S=TWU8!<>;TQ@&#A)AA!V<&9AM*YKGA\C(1G-]<G0Y-*V
M?QGYRT(L*C_(<,JQ:XMH]<>^U-'NCICC=H9_PGCH=!9TANJBQ]W8,Q,ZTZ)J
M1!+OZ68$TJZ*YUT9OI]^(W0V>^AD0A9FV= B, 4)G'HLI-QZD/H!T^YD)Y(>
M^U3?R4QTW19[X6VDVRZUE0 "@H:!4]WLQWY8'['YCTWU'F.^;V8TZCRWI/-[
M$PBI.:[-5W:-\?+M+.9*\\"^ GDZ9K14*4(#C%P/N?(/ @B$+IW*K7GH73IL
MO7\2(RI,+.!Y=D&7W="JZH;)7+@K5Y" //987W;MH?R>DX'ZI>7>'0X9QO4&
M5PD*$<^^F\J4VTYVD)RIF5C$P(4R;"\\+4 BTPF@_8-Y9$L]-.M$;45U5^?
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MQP%1G@>XO1.A1T  $L,K(@>BQE[F[/>)[6\CX_]<&ZOD4KZORE,-]56) QY
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M%9;K1[Y##W^M*SYK&.F.8O>A1C'XP8 &@!-.5\- VV(O=RK?<,RZI-X9.VH
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MSFM]E^:U3CY!=GLY_ \L,;<SCP/V$UJ' AG9&VE!H[_]36"_\0?QUU@K_SL
M^[)+T*+GD_%>BL314B%=()V3\7GNMD#+RT3E9XVIA-=]8\E99B^YD^8??%HJ
M(*,VA2C_3*X 681XMB$G%[B4-'7#O (EAHP] #FZ@)6!FSF?#=?E2TY$B)GR
M/6P58U-JK\ZU]=ZV<LE(TML><-=3)OP1INN.-A,.:.P_QL&][9WOV;V]=8G
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M#D 2(V/M-HO4FR!KC178/GH#YEI0<@,D<BK_]RE@"RF[5567]7)+7K&IV@6
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M4ON941TH\8VAO5DAC4OCUJFE*2F$I!#NV*V]EJXF$E^'<81R&[4+#24\"*:
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M6-T!UZ">MS5[ 77#C?N9Z;J&B_LV26^2WB2]=R*]B-KW"*.??O""[/UV6.4
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M]*)>9PKM_-<>+0>TM_1G;\Y=%3LBWOEB:)&&V3A(&;$]G]O2D1;#A1HK.%.
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MO6EI2:VTZ8%D,WH=\6N.Z41YQR$V3[.M-0W[P:1VP&+6J8W'/0'B[PKE,TL
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M3<'*( %8/<)UNS;MM^($@F8<W&I2_9-C):]3# MA@=ZT3 J''#3P#B!_D%V
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M%@T8@*;AQ%I=/)/#;%$^L0/5;'=5LS="KRUF 9O-I7[8JTWBM J-P/S!&YO
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M[1.48Z](3CQ%,22,,8,]*;\%5\R[',<92%[\EX-:9]-2B 3*H2?NZJ9@FXL
M2RW>EY!C#77Z*QL^"C)2U#W]34'[UZRT?T5<%2>PFH^>*QZ*R)F<^ !'U1GS
MUIW=IM)WBX:9LA[HY;+A'P[I<*/NM!T<ZB*13&$@$1 7?3FH2@R^ 6_%>2\7
M;QI'&UA! ;,#\(D;0J6<4M? FJ3!?BF2SF5@4IL;^Y#(Q&2.?A?FL!&AHXR;
M5H--]?/S?I,%3U[<#/M/04\N<]61PCZSX1A$!<(>NPY*#+*Q@PVC37+ZH>SK
M;[;F#JFKH>Y,W\-MMX8TIP24#3-=0$EIP.7>\0S7#)6<2B![WT0S5"S]V,Q[
M=6=$.9EK]3\^8R36FS2LV0/,6JVY.9(!C/VQ/!W</F,X>L)JI1^W@1*DCJ6X
ME4@G<V:16;^BY2;UM#5L@ID-N<$E[M#U"FQUJMUQ^DZDP'"\]7H"N!-#U*0]
MA90\ICUU[=]6R%5(Y.^"J:TCK7%OOQ0Y9$\NG1U)%VBW5**?A1BU=L*N"L/]
MU SVG%'\U&("^*BE)Y3?D:[4!#F^.B_LPG<&S2<?JCV;@SNW'X9:&_>82*&4
M^\4O_7F9?_)^R?.JW^!D%51F64O;EZ9/(X_ [P]9XU TY,$6_H#]@C3N$EEB
MW3&,!*A!7%7)"2.X4:-A#?/"/PNI!\[HWO@/$%M:&]%2M)^T7H=FJ0^'M*#'
MQ).1;@8X?%?FT!?@F4I%=?L(.'J%NC@4T.SD"NWG.(U\'2E/Y+=Y6>G\9&$,
M2$6KQF)K'P8-OU$L1 ^)+L:6NC%)-O]GJ&1:G^Y6PAYM$F;D8Z_EN8G29UXW
M;BJ\W?&35V(58E$N-LT=VF$R-^=!2KY5KN5H[NT5[>OC-\>7]A=P;UHK&0\;
MJS@S0J_DKP*)C:8NA+%>8MPB+)QP?\W2\]GP72TGO/ 3Z%( \9+$''>)<D]M
M\A:/"\@R%A-[F=K<ES6"1FKT .+KV&U:%NJ3I5[4QFXU%GK-MARV]-WL5+G?
MXD1!<(ZUA-*/+ \VCX>Y82E7$P?L3SJ<;RDIMV&?3DSQTDA\S[BAH]!HO%#G
M(VD^DL[]2/I9LG2.5QYF1D,/VH4'G5*[H>V&7'B373.SQD<1QD*K;,'LJ];%
M36NDTX@V><+<G=J!@&DM8%FL.1'19=F&P%\,9(WBG;<(BZ7P*MV3\"-==%LU
MJ"LO"CDT_ ->+YY'1];$! AOM/#4,Y!;NS!Z(GYVT#!&:S!K4KS#'*F,"*?,
M2Z9F(Z:JUNP&T0X>%75%>YJ\G)!-MD/A!-" #ZA+#KV==),=>X!N9%TCO65]
MAU%*V8TAX[&*JK=4/M.(/*GY9V*@W?2Z>J80.CL)@HXY%XVK0TSMN4]#W,UL
MJQ3NRRTS('Z:[!!LK."N$E(4/*Z6^TC]!.[4$BEI%C9]5&Z?AAJ634ATA[HM
MYDJ>1XX]-XF2C(U\F6FTG;S%PHA/A7]M2;38'($A2"E?$K%&/A=ACKJ\,A=_
MNIQCK#^W\9Q90\G<QO,Q9OU4&\^?G\QM/+/#?8ES]H%3G:^.(>^]S,0DS/A.
MO'%6P9O*,W1TWC^/H"Y-?4.:,T+,EI7W=L35EDQ($=^F-;>EN0O\T.%#"OP+
M# $Q"8!X+T='!@\RKSK*K7Q\,913[T3G[KP'2:A P'[BY>ZL#WVU=>K'R;MF
M*?,N;A2G>@J9\#QG]S0LW;S;L7#&# G1[7BWD^]87?'%:;?7@P6!/_@$ .ZS
M/?[D$R#/Z_V4'=;<YST&/#9\,0(1>\EM3Y<G15,:(E]*4ZT;AX(BEAAH'2V!
MR28'E*"E=4;BXT N."Z,:>UZ9"'6#024KH9=*/@G:0,;7 :D#Y.D^^.M8A+S
M$OZL:H.KM_F-"/K%L.YP>@#]WTCE@I_HRTZ^:</W)A)J7C5ML7AKS$XE <-T
M3)QV%![H1@=G/#?$G3&V9X]-+]T!9*:B;K0]_)JALY,UU!!A859K69FMXMS=
MO>.^ V"CD(_B*Y6<6#Y"LJ_MY4)"'^*N8!3M]R(S)MT^>Z^&&(8D38;IQ:(Q
M-DO(*Q@!WMF9<BD6R)GE+= J[2%X3XL1+7+356EN9<185F6-[/2J'W31U':W
M0FURL66;(K#NV%_VWGY6QO %CX6/UG5T)JVC"0R(>IE*,TH8^=?,?$ZXT.4?
M&>>8U?C\YO&#'R,P/-:@^HQE@FR0DI;LBLBQBSA 8YH?/0A,G5/*.4(JN29%
MHM&J?/+@.M7P^S.ZFVHV1K5HDI8>8HI0E9NF*3(/7&O%V#('[$S4Y'!#B3!O
MRT[1L$(J!(1<V>G'8'P*:X28ZF4WC21\,Z<E&S.XX\,*)'[%TC%*%!CV04D@
MFH# 8^;K>.GQL4:>&*%/!Z]7!Y6:I2E'(&3.K1&VQA.7,.6OBN_3OT%W4G+W
MC)PB.TE+V)9HT6(1 3S9DL9_+D>N]'&I_4_?\^!E,KR1#6^V\XZZ3]#+MU'X
M,.WE6]+9:GY"R9!OU)JQZ'%H'A2:(H 3<9-0O;..QUY]B:ZG?^@0[_=77"+D
M #6KJ0_34NY&+<H(3W&\%C/OI<]Q+UV8!_(/MYUN3<P<R*-1^ZVCS>=^)>5C
MU\XM?=@D$N[V'638CS@>X42ZW^_(_($8->P:"5C]M^$-W'I =%0=CQ).8'HI
MP=F"/AA BJ908W%L;?>Y[NW#\5[^GIXCC7.8QP^^SU\%1UGR,I[[^[7=9];5
M%%W6EXS#7VV9WY&F<&S_[YO".O$.?./9PI_\<?%%<JV#SWT9^)*$'2&Z;][V
M4J9]Z>5PE:$,NK2%;VO?<V\RE>(L3CU 4 "#8,HXXCA=*LQ',B"B*&D][)VQ
M[O-*JH'\C6%/H:1^C@\_X9*@H]WUXAGP$PX[<FL(6!F1+,602B=U*4T?;0R?
M=5G!-5M>?#[-@SB<XWYMWY0G6'?U$TG8A2?P-_61)*=4%>KC#".2^J9W,UJV
M$'V8&&:GF1S. .H PC@K4,A%K#_!F&.7#'&VEK.UO$AK":OP6ADRG'*"9I^?
MK^U&+1@$O%#IA(R:N5L P]E.A]W_G7#3O' PR6_L'A:S\B/4Z5;6/8FL3"-U
M,T/&D&HO%GKZ3A/"Y-+@C+:UN$PGL@F+M3'(N@9M34V]>.49 A^II;=8MCF?
M81<?"5.!S:M>"AA::N@29%PDW"50<::3IX?.?(VI(0RAFA1*ZN-1FYF+Q*2R
M@420)GUNVN:N9_ME+#N.-$W!JH&I-X1](LTOA"T*K(S\U9$.,NH.!0NCU-#9
MV8_4J_UA)67D]>+[XW&C=C-TY-66,U3;T*-,GGY%P>>ML5?>\L/[4(9U1&1P
MST$+:*0]PN7_U>.MDXP.,:@QCY@_+:-7XY)C>]-G@0RMKO8\D&H4AY9&,*!R
M%[LR,Q8VCJS-4=J_L.<)D)%<3!W7F5U+:(^U&QR',5<*VR_L'>Q;6TEA2GK]
M$T_!*\F[V)QK+^DTB<(6>W[9%:5Y+I]=(YQT/H_F\^ABSZ-C!\\=@]I.#6MD
ME<2@++9VDPRM,_S<YDMC:K^9V S6['KQF .[_V$;,JY9WC1M0V2Z.IKVG*!1
M<FP?D7V;- $^H7;4 1Y[OG%=4(N-UDZ0'0-;7U,3S#4,.)RD-A]\])%72S_5
MVQ8/U8[J%&IOQACWW'N_R=5/.\!X<R4:T?$9#S-G'*&')V_I7Y(?S\&+U*)0
M@]AL6ZK=B_(<-Z86C0:=B0SX=VW"8 )$R4_:XWG0V4#.!O*3,I!"YH FOVKO
MV3)VI5FQ"A>7$K1>*KA&X3XBHP/+GT4C=412\[ 22B\%'F\A3!514RSLI[7(
MZ(A1F=H <(,E4)YFKVH[->R10T>K(+\2B-REKZZ/O2/GAHTS:QV8&S8^QJR?
M;-CX:F[8^%3-WZ<]9Q^!FT;8"QI(/>\4%KJRXVZVC@914_83\-1(5Q5NQ-7;
M<O5VF:_>9H>YJ3@G%:M31*'"E )<EJ22$D8<#S'J\GJE'UZ5MV45DTN9=TI+
M+1%.%"A%-W8Q4^:YT)!\+/*MW?"LY;HF8.2]R)$V G9IVD8[7DO^;2-!X+KL
MDRJTR=L:Z</+CU9F0_#)1R;?)7L$E4UTDH]TT]4\0 H35*/:I-XVE>=>!>@=
M9#E%[BL1298>B,L' !O(RG(<W !;MAK:5E$;NM_RM@7L0[(<-&XZ7@9$WLY1
M'2>V+DSN5_O8Q(ULVL.-6$",ID6 .$1:6U-6BXI-/&*Y4FR@^TTKA$IA6C 7
MF0.(%$(N4"Z'_@C+T..F]9M;@]$Z$J<HG!3NI$9"3_N^D>LQ=O!5%^H:4M8P
M[2U1:/:V2WS);EQA!8ITO#/]5UF$/%*_*=OB2C@4Y;5E7A2<O)$D@KQO]G="
MT*$$/5-OT9$?_"&W*^#9@ANZ.V )B9:"2B2%HL6/,0!6R@#QRI$Q9Q%SI:/"
MOV_P+!E,8H.<K"F^D2Q=SSL$BI\(!?"WBS>?YW[DS(+&OV&./Q5!8V;/U#@]
MAS?\O]4;)ENXM<;.E[66=5,N2_883Y25T:=E_Z5$8# ^PA_7$14CK68-\.[\
MEQ0@")1O]9 60/YVJ)59)POVECQ![B>8!GLJ=!NE#WIK_Y0)#YXK6K>&-1!M
M6)"S7&R\'-J\FKTEB_4@QM7Z\FYH5YL<?G_3PA;R4HD3T*RE6'S3-(4R"N&,
MR**SR2%_?)M@8=2TGCP#? 7$=7S[>@G18'K(H,YL#6@G/1%(<5JK6C1&5'0<
M(Z#4KB4>P'NI3'%C7/*SD]?*T:,$O"Y7RJ%.*KZR(>BS%,IU3H.[(F:B[ D.
MU\_9*7DV2\[/%GJVT._90G_[XKFSPPYZY!,)# G&&80 HG2>MWS$7J/K*[,4
MGD5R6I:+'CA0EXQPD)U@(SMO:TKUPH.Q1T2$/]&\MY114(]U:=P?C=CG^*0)
M&0U/:<YV:;6=TG$+L)"]NY'^7.O_#I5&2=O\+=U]_3N-Z58M6'[;E$7F&;P4
MQ+0RG*F(D$'HP_9D%=L?']^H'9LHJ)".H9_;V=?NQJQD<S&&U2CSJ8\G KQ3
M)2F\,74V^N2!'/4$=WX*TBF207!&AU:6BU[9+J398L\6>[;8[S4!]>KU\X?8
MZ\#PN&8C+SM.:=>ZU<8:-)'Q<Z'_/G87EZ8VZ](#9R*C.#*)*<]O= 45/+Y>
MO%&(S<@$'@D&\G^7__FH9YL]U=GNS7;O0NS>46C^JQJH.O%T?C*K3=U4S8T8
MOV^L4]-L[0:'=?02//J]T/WT5\$\H@_&(?PD;W!0>A/ LMK>A(:K]MS'KFU)
M[=AFLF[@(.-5[DIET>=6E<F1T=@T9 N*L*'2X>-SY5Y+1]/JUH@2*NJ&XIU#
MD;5Q75>J%@\NFJKIE,H@>.;6 5<V^Y(96X^(]_,<1P(@LG44#*%@2&I^X0DF
MZ[P624$S=S-$+:>$6:(*"F($]HAA+E@@W99=Y]E\'SZVV2#/!GDVR._3(#M?
MCC4:::G!=E8:,]^/U';"^,V.I&B#>A)P"95#;4]3O]C[:WS;;OS;O!HTVXE/
MI\76@WIC9%]C//U=;7^U*7>2V@4O.*-L*D0;D)-O3,5#971],;;E%EU'E'KD
M1"^V!ETX238D]+JXN?EA9^K%:_=TOO$%+B1[<X2 3"SZXLV >F9]K!7@L%"F
M,R_'$VVPKU7Z1OIG_,9L"V=;.-O"]V<+#_<F[*$U6XX<T"E+BB1[<RNE[=AX
MN$M$F#&Y($-NS6/*EP*C:TZ=5WI4E8 )(ALP!DWH-8(3&-E,R22&HE,7NFQH
M$^NFO@JI2:H["O8@/(!KE7%R0\_TD6BE9,A.SW#4-Q@ULZH@_3YP,8X^JVV8
M>\$E=*I/G"?47XN;P=I_+&-OP7':F%MT3XX^)MHE;;,=JAL>1QI5'"9K/0;C
M#MTZGMX+3^X,O >U+,-I-74P/8O*= <&7>XX\HPUR:O.<>B1C0_4,@H^8KUE
M='[%/:A@54+%$/EA69>.>RWN,@6,5\[7=8_V,NTOW4&H9:<3I3%9OV$'F6N&
M8'NFGV2#?HA/H17IW)$6YSAG%P;N^T;6JDBE,R+V_+\AV#Y SQ&2)7(W1C'!
ML1&+0$_W(9OX7:\]&_7@:[OS_T"DQKJIHG3#=BAK!;N2^"N,-#'1CG E&I72
ML!X^U8[2.RL31.+B1SC$$&JBE5#@,'X6Z3H^7'3,G, +3K5'3LT,*2 QX*"-
M)"6\9J@=N:VU7TFM*X^9%7E1Q\@R:A EG>X$,M$?KD-WA$PRMI?,NF=I)GZ$
MB8Y*J!Y)K7R4Y=8:^J[1JN4(HNV5E)R9CPZE]<!<V"1T^R3:(_-'HWV[]M"H
MW!G'DVU [*:$ONF\7WRSVCFVE,X-;&?62C4WL'V,63_9P/9T;F";7=M+G+,/
MW,#VW,>N*WMR]XMVJ"0YN-<BC4G9A.QPHA+0 3>25Q>PW\SQ?Q1$0'9"9*8!
MAD*H&Y(2E=TJ$LEW"K#59C!H[(9;?2!/XL]/KI^<P2*8-\Z%QH0GMI-+9T%H
M:21^"H'MKDEJ'VZG>'6 ._O;S4B3Q+S3[,KH>MQ\1W&$BL9;.C(*U*%=G?LG
M,(QUU_;#1!L^??+T219(]E^62LK[@@_GR-#>- ."I#K\W0X3<_W_-NU;A';V
MG1:Y8&!LX,**BCT][8,$4IS_>?7=85RUR8OPC$Q+':B70)]]($WXTO1WH#9Z
M^N3)?S):>?KDJ_^4D&A:H<P9.)_%^Q90>GP31*B+YU$X!JH^X CD>\]7/4-,
M&\IWZ7ON\[=V3$K,AF#8S@PB0X/>)3SW6@/Q8<?Z45/[OY9.L<&M$^E%LO$C
M.$6!%[6.!,B71)F8H595C SN:>RHS* -N25"I>:+9#NY )D8D%XQO%FE%&*V
M&:%A<B<A@^/OY8WR]AKS>B)V"HTU=J&87*X>Z-B5\P\ #<>RI,$C9]S<E*M%
MMRG7/21V]PI/M0&Q#8/M7U@VC(6B2[SWK_YZO0B"T(NJJ6],ZV!8TF&'">&;
M\)R#F3[ :"*5GDI.J!MB"$8ZU[I1[;^P=A/V+#N,;^VJL'L"O%DN^3+4Q&C8
ML\](B0ZS=^I ]2F%LLZ5@F]M0V\1>LJ7=J7:-5$<3H:+Z:\7S]/IE>R&'8<D
M?B6YD.*(O;V)+)<=]2W7(WFP[%2NK>G OMDU7>FD.K#226[E<[E,!IUX/GE9
MFBVJ]N^3:&>\3\><B9_W*3E[&Q_<39^:VU-N^H]E][9;_!A $&C6?F5/4?+&
M CSUND76S=KNS^<=S.OV[,/+H,4TU"/M%*&@5%$F"!"!LARG5][K(>:8EQTW
MY)1.A*B.;G>F+ZDK*SZ4GH;*'1D3'GHE)$?G"*^,X$"<_=*6KN#*4;NX/:[A
M,D@O:7K1(RP!ZC^XP7B^3=+W5JXMW1277^V<SY]SF,</'NWB$-)M85<YN+?I
M(]IM=2.1A'.T8M:%B=U_N.5C:;< VULA\FFE0IEBA)7'U+KRAO".(]I.BA9T
M@._R8).2\;$SYJV*Q_2.-R*YN'-[;=RX+BL!=? )M'CI11:29Q!]NJ0)1JQ7
MW'.M(A@'=NX X)<\A.]2%"[WO/:3$A@V_JL4(I+C$K6\0 V&)4G$1<$VRH]4
MW AAAMC>,O9!=LX'P2#6354V!R_*84YR_J8[+@%$]DX@YW-&OS(H#N3:!NKH
M4<J!NV<DRQ!O[2(CX9T7^3Y&M(>OICD80!^: .30:,W$H)XM-LV=80Q)'1'\
M"3;=1IMYY[C?Y678(T'"XXG;2^7>?L'@?=H77S.:XB?MFTIC1[OSD0H-<7O\
MM#4;7Y77G4"KR8<],NNCASZR:2(T6F?NO5LI#5C&&K92#WRADB?; 9[9/:EU
M"7H4P:<X'.[D"6VX"2S9Z7MRC=F'^^HI.FC[C>\PU;W))+9#TP5TP>F+"I,T
MPFT".YK'#X=19V\M,4X/]4O0E.PR.U6CNG6'QG':!1)-:(AJ<:(UJ@[,W;ZQ
MH[CO)<T.Q^QP7*3#<8]E=&BDY8%0HQH>!;6RV\HA#_4P[S[2P:SZ('77HQ#&
M)S NP8ACN#[E8@C>:O10^6)K^@U88=8+)>CZ7\#Z^E_&^B]K8;UQ=L;^59*]
M38(-FGSP27^*I/?OYV"46X+?'GET>V>F#/GI++FD3HC&6T 8^^"27IT($R9
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MWXC=*_.CF50 IC/LUAV3LQY?!L^+]Q/$B+"G[T4NO;YRN\><YKJ*YZ6+AQ.
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M!F&1,!2FI:O^%LT>51%7IP:ZPJJ(GU@B8TWQ[J<=38&RT=IXYYGO!2WQ=#9
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M4S3.H9-U]9L6T'3R >83E1^]R_ABY_'6IFN*S+%M^F2#)]E\D6#83'),NLP
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M&/GMH-UJIR/P=@T[,\W[OGK]XUNFRX0_8RSD[$=;"&<!<;J/JNF>W>JW/KU
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M!'8P%?<T\D0'RE-^\#$8\TN7ILH<>/H /LE6760VILA0DZ^JNJ\RCK*Y9V
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M#%S@9Z<'[@(/A"$ZZ_$!]P*Q1V)"5A=E-0'LE!(^2E\57;&T]E#0^/> U@I
M:5G/'7.(U 'G:5NT,;[^[<Q7@"@N_"RUA[-BO\21FN9U4%%\CR29"K_<EI%Y
M<J-LG,C#(:RG<("=";AU8'VW_6"[#X@<Y85!CY'K%646CO6F;CW,K^!=Y:8L
M+DWC)SS9.[*]]):>;Q?G7/:,GW/(L4(O#HD \0@N4QFZA&-O65NR[1S;F/7
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MOQ=_AO3>%7-&0.XPBM.83CF^(1I\M 54#]/2W!=B+)O:IU5,MWVT@&)7X03
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MZ,SK%M9! Y);H<],&GK2T$>IH7^N%?NR8W=8\_X['HX+:?<G$!C>HKHT35=
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M\9/[?>@=L](S*F7:2*;PM^B)&).7CTL(-[A1Y*E@'9>NO2EJ?<O22ABK/-P
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M0R:RD#SY*BWE4VC&YXI#.-$H<+X]F<!T+1,,>=,O8=-R#J0X!GM9_DY'8!V
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M)H%!95F1\F]4WPOKZ1<_-^DEBM) Y=T.KOZE;S4ZU&#K95E*]&1W&-UQQZ8
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MV17#ICJ6:=GFC6E\NS0,=_COQ66]I-=14,Q>:6,08W 1BC*M6JC1T(Z29\!
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M.*)/F/BGV?7.P"S+(#J"D@(=\3DK5G/@ZF-7L@[6@F'3'4-;<I;E%/M+T3S
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M+,4B!5Y158M-+G/\2+"Z')[K(_?Z330#JX?BP23%7+%G-8MRWGX7#BD7W;5
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M^)N49 0?$0Q&&$^%SI'F[9FW;!;L,N.MU];0 :1ZS+Q4;)EX-V*:S??.HAR
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MP(Q_S7C29G8D@@)07YB_K.S?]$@>K.H>UXBU6;S\#^I8*8B>/*^NK^(QVGH
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M8!.I.$! >[JB,3;'JJ4[XL(A;=(PLTK;9'2ZJZH 6E408*A]2&L/+RYQ'2Y
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M!'9<V1]3]+#$OAMD)6K9D&(0*2T;+TU,2!RTXE)932%Q*FLP1>JEUPF:5+9
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M";C.6R:5@-LFX&QC8$['2L#=2EMG6<1B6G^6Y'I?N962;4JV=9<-G:1LZQW
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M@H706.:39*VP@U?FL*QY/FCE!;;<!^BE0 RID>,D!V00U;D1<$('PM@7PP-
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M+;><&+&6^>I:P)&,R"^]D*P5!LHD9]VVQL-C.&=BX7><,6U-'>W4N*+K\*B
M8X=G8%@5L6T2UQHM\35ZJI\NXRZ*L@ZZV"":LRT9"8-Z+A1&===D2.P1B6R,
MD1P?SZWAI&[FC$][;CH8<E#F\,N@"K^B/(]N.;[OEY=[,*0=7F2B.Z+R<JS'
MY>V\Z=DJ&MJR]UOXDW8-S*'E.=(\[K,RK\(0*[XL@T9JU].6 W+%2*RW5 #A
M=2IX(@(0:?@E<%0*:#P"!K-VZ'%U:U$@(TN %90%N<Z6O- \.'';)$TE SY_
M[+K8'VXW=&Y:&:RAZQZOE>')^: * #JB3LT/M[?\EEYC6-M9$,A$D\;B@A@<
MP_5(IBCS2Z?(2AW%XS5[P'$44<]5VA<F:V/X-(7CR"!6>5(#CI&P,K&8Y]7'
M,J$80!@/0X&_"3IA8$Y*F8.Y2$_<#A-37U[<SL=(LT<&D ,9#(QOVX(*,WX5
MP=I+1 B#O,RJ*:T\!T8&\Z6\E82 (\9YH:Z4 H(*+KF,?T( 2O@*H"F/$(G6
M<6"H,I\8D2ONT!?N\"6M68 (- OXGZ74A ZO] V:&/AM:04#U/?0SH0F(S0O
M8:Q^%8-WETZ'%XCZO%1/ [1!)H+_5Z+[<:R5-85+MK#;;(=:>QWO'0J^7R9&
MY ROK5(CKF$/7T0O&X:-918BV#_27@,JQ10O5U@+/O,;7ZYSK=J6B],1HT #
M:-24A:#Z$C"+H H^Y1DOTI4,A[LL2;A6,-D!C!<&S(![XMK4"RNS-F! ODQD
M:QG:VY9S.8W!W6-*@E_2K%Z[9GW:*T%#@;'X:9:E7IK54NUVYM[,+DHPPI9V
MJ#)8@M #1I_P&&-!2;[E?,,B)L;](KIZV9:R@10O6#RE]'(X4D@M=\L(7)_6
MT!]$?U@H!*_G25#16%,?0,0?=TL$]5#ZW&540 5<&154.((*1^BP/MQ+]'97
M.,+O*<@T# J#3WCB1UR%$!P@.ZAV*>=5+@M*;DSI+R/T>?HQB^:("^*87U:%
MTJ2*B'A5?M;*?LVC>1E&,9O391?LBKVY&6IGZ-I#=N&UPA7,A\0KY)B=VQJ&
M0($T/+B]C -9.(SR9@+"-_18@BL^O]7;U_;JHI>F%.FI&^@YCK[Q.)JE*8$2
MIL5 KZ"5APCS$&?F*0RY:!5C@/=7Z[AMQ61Y@XR#YL#7WERGR2[K!%[Y1LJ?
MHDH), C\H%M(Z,@=AULL+ZM6H,%:PC?LTD#LF]_F;&U]DFCK#CJYS7.X92Q5
M#G<CCU>)E@929]]566K=HJ!^IF_LU#:^?W!'P6;E55(HNM<IX!URF*R*IZ['
M8*P56D'[[H9LES!/9CAC$&+4*ANSNCC;L -5PVF7NUF5U](\B=5E:L@I<KA;
M97VVHD)"#1LHTJMRP,5F-Y8WN*M")*U\[&X! ^7GZ>S"'?QL?KS+KZ)=,BK6
MM,'NJD/6!(6FR66*7]R!OS%,D]5EG>:<"T4@2DHLJB2?Z%7])8*ZOP1KC-=U
M&8L[KF]>DY=SF'747$Q3Y/A=54VOJFJ>R4I6R"$&!.RE"RGFHN0"6>3KVKMX
M,^RS^ 7U:'2LE* AQX-Z8J2\[G 'Z<? *LH\;W.2!VDV17HIV!B]%'UEJ HG
M>>3CG$-.90!KKX208C3&#%<3ZYZUJU/E+?^#5.=%$'";05>UD5?EWKK,6BO8
M15-J?#ZMYZD&AT?*,Q^J;JR#70Q"E]U3U4H>>B4/+HY^R7^I%SVZ>04*U(=R
M#B_RM83-8:P!CUZ12I=F'^"#9]1.S"_TYD+=Y&P*:'.JCUS'U1V;N3KCH:]/
MPHDQ#3W3"2;!,T*4L&"?L2_QFU*T1?AJPO_0E(DMBDWKJRU^Z_!RO<V2O-!^
M9G,8P?^ .+G4?O_]4TVT*PO8W4F<_"G;7VO;O%S0<I:+O_=U47N F:N^/)@[
M(7( MT$?)MB4ED>H=5J&875+"U1@YE!K=H\@^ST5]>RV"3-CZENCL67HUM0+
M=,>;./K4]":ZZXP"Q_&X.;$GQR+,SG#%DH'VA=^P_#8AUF,RZ.JZ;_0#.8(C
M=W#)V[FF\CTJ@[:E0_"OHIG=UPMJ9K?OKL"/4T5-54OK5MTN52WM*5;]SFII
MXWY42^L3F1P9-N_:R7H\>=$JR=>5\GLRJ, TC+^(4GPKD1*MJ@:T5J_[&#LA
MGE1'Y1A#\R^JZ/(^BBX?(7680U<1AR*.6XC#&HX4=2CJN(UU.(HX%'$HN:*(
M0\F5P_<Q4)I+0R9GF(].Q,&27.\#A=S1,4VQD\>2-8I,3II,=I8ZBDY.FDYV
MU6L4F9PVF2BIH\A$29V#T4E;ZX$WX[=_>S9^=LS$8PR-?>K)5M<\CWO(>;5^
ML)#,^=G%Q=E_GVD7Y^_??CA_>S'0WG\XO[6B]K%SJWT["[L7'G"X5N6G(-SV
M:^55U'+<U+)GLZ\BE^,FE_WZ%Q6U'#FU*%&DJ$6)HB<B%Z6<*^7\$93SCQ\N
M/O[^_LW9E[=OM%_/?C\##5V[^.WMVR\7B@+W3H&=2_DX4$FTNRCPQ?ND[L&8
M#S1^X_-%H>4S[$R)=686+,,F>Z4HSO]24>5I4N6!ZX0>(=7LV?+H]@B0N8\#
MWVMV,U+LYLC8S8&%8+L.NN)/BC_MF3]9N_*G5QJ5_:_&J)E#I.R^4)!B5(_.
MJ+#ZRZE9LGIH)>\PVE9\Z20HZ/!\R53 20&G/OIEMC,WY<[KFU@[":KIHUM/
MD8V"SHI8^L-CE&125*,D4X>\8O?X57\Z/W_[]MV[(Q!82E-_=$W][.+BON"2
MBL1Z3TZGF>QQ\!*MY]25K:#^;47^ZL@:-?8?''4YK/*H:*./$$@1A]+%%6T\
M-6THH:)H0PF5+H2;'H\RW1WM9VBX1]Y6_)SE,PJ7]_$'_F<97;$8&\#N: X\
M'JH[25EV<'I[?GITU5DY.#1&#7?;0EUT78]HJQ:9/1FO;,WW+F,^M:5N&O!5
M'^FNZ4S&X[&E3QUCI#OFF.M3VS3UZ63B,Y^-_>G$>R:;^I6Y?LG8XA6R]+,D
MP'_>-OS\K#AG6;:$E_\W)D6MMNT[R[]^#-M]^K0RB<17_X0?3/@@X'X$<\G_
M]DRWGV&#[SDK_O8LNBE>)>4\2 OY/9 VG 08C8VQ5>; ,$=5%[UJ4G\_/1:@
M5.@#>":/B5X4%%%01$$1!44Z!$6\D>-/G<E4][P)0)&1$^CNR CU@+GN>.R9
M/+#\_4,1<T]0Q+8'CCVY'XHH=[(RJ/S02?J4\06+ HW?+'B2PRO1N)(6,YYI
M_HJ[>5?C;[]36#H#90Y.>8=W$_2<4A0X4>#D>\&),V7<M?E$'_LC6W=\T]"G
M1F#JCC6:^-.)$[(P6 <GDE._%8P:8,I'Y-)GQ)QE9- AK"2F,;!,\T%&DMX#
M$F4040)!00=%*0HZ*.CPU-#!]Z>V9;M3W1DSICLCS]0]:SS2 W]BL7 Z<B;6
MWJ'#GJP:ICDPG!W\*RIRY/ RPYP<N:'C2UJP^ $VC4,1W(GG'AZ<\([+SZ=R
M$!6 Z=)X=XD1&3F>.66AS@#)Z(X?^CIS;5LWG=!V7#9UI^9T'< <W,IA 5:Q
MK+&*!5&F#R4C%,)0U*,0AD(8G1CO+@C#,]V):S"=30U7=[C%].G4F.KAU+:8
M.^&^PW\ 8>PKQ,-Q!HYKJ1"/CIWOHS)Z?%SPC!7PJQ9SEG/!G/0TU$OXY6%Q
M';TD,P5"5-:GPAF=8$5'B#,\QGW#Y*[.S-$4<(;#X:-)J'O>F)EC/C%LWUW'
M&35'_AT9\F<<R<?PGSDG_'&0^ UK!\QQ5$=<63 4^U?X0!&(P@==EK='B ],
MT[?''O-T[MACW0FMD3ZU75\W@XDQ"0/#M[WQ_O#!ONP2IJ$B-)2=XM!9*"G0
M?;&D[!.LZK&8\Z08: DONF #5YCDB##)<1*-PBD*IWPW3N$3CT^-4+=M?Z([
MT]%4=SW#TD>>[_G,L -N;]@Q*H[]*69)<98$;RNF_>$P9@S+&KAC1\5G*.N&
M$A0*72BB4>A"H8MNHHL1X]P=C4Q]X@0CW3$ 8C#/"_21ZSG^B'GVB%E[0Q?[
M,H(8@[&Y0_2GBLTX&DQQ\*/S/BE8<AEY<16)<:^YH_>4I<"'<K<HH-$)[G.,
M0&,TFDS=$=-=PYKJCF-,]:GA&7K('69Y&(TQVC!C-$Q8!( "OGA[X\<EOOB_
MTC2XCN+X$.:,L8K*Z,A!5U*@ [2A8((B$ 43.B!VCQ F>"P83>V)J3,0W[HS
MMB< &"9CW0IL[ENF%=I&N'>8L*\*&@-CH@IH*%/%H=-(J!YH=VIFG"8:.3X@
M<ISTHL#)H<#)SS^Y(+!?GQZ)*>59L20EPA2]*!'6=Q%V?/JU/^)\,K*X[H0C
M3W>\D:M[-G=U>S(VQZ.I$TQ'&_[^5CW*#VGB'ZX*@SV=*B__J5E9GZCVY$/[
M: 1IB<$!5>$=X,D_5N/XQ.M '36%W=D<["C)2D$4!5&^%Z+ X*:F;[DZ"T,#
M((HUUJ=FR'7;"PUFA+[GV:/M!:(.DMI@.P/7?EAN0^_AB#)I',3=>S3L7Z$*
MA2H4JE"HHD.HPIN:?#*UF#X)+1/+05FZ-^&^;KBFR<,@]*<V^PY4L:^4AO%X
M,/G>>I-':>4\80O(<=G&;Y$^"H,HRNDHY7069CP>PC@NPE&ZL6(T?6 T2D0I
MRE$BZND)IZU4P:OQV[\]&S\['ONM,31Z1RX^!Z4[ZY31Q$OCX#:J^OW]V:_O
M?W__Y?W;"^WLPQOMXLO'\W_\]O'W-V\_7_S,%FG^6GO[?_[Y_LO_*)6^5V38
M/[NP;).BQ1'SHC@J(IZ_ZH*L5$&5"EMUEUX4HE+DHI1^12]*'"EZZ0"]*''T
M6 K^T2CUW5&GAH9[Y#'B9[X/+*;(M05;,B_F1Q[M=X+"JKOA6_VDH<X*,!6K
MU?E8K9'+P\"UL/Z+QW3'"#R=.2-'MQW''4U<US6,C5IQ%8?^)!CT+KV"]Q01
M[@P,<Z+BP3MQN/NOSAP!;2CTH-"#0@_]H*,C1 ^341B.)N9(MT:,(WKP]:EK
M<MT.1VYH34?6Q _V@![V%/D]&9C6=]:R/TK+E[)J'-2JD94\ +*]XG%*+1PT
M?K/@27ZG@>,HZ:XSL.7@9*?,] JG=)Y5'2%.<5V+F=;$T>T)-2 VQX!3N*'[
M+)Q8TTD8N.9T"TY!COU[$]IS0$.'-;#<'=H/'_VA5\8/)204LE!$HY"%0A:=
M1!;<&(VG=NCICC-FNN-[CLX"&_X*)T[@6F/F.'P_R&)?Z>\#U[!5J;]3DP]/
M9O#PTSE:.1@=()8$FL<3'D:[U__K):4I(*)<=PIT=((1'2'H&#FFYTQ=3[="
MV](=9EJZYTV9;OK^:&P[4\,<;73N>3M?Q.F2\\\\9L53F37,R<.,&OT_YLJ
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M&H\FMNZ,#*X[XY#K+&2.[G#+XR-SS!V^X;)I09##)*E84Q7"T8T3K01 %P6
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M-EL&.,8$QX:;1 #'F.!@#RC@ !S7F([-%G0!QYC@@*P #L@*X+@]'.:!!AR
M [("." K@ .R C@@*X #L@(X&H0#L@(X("N  [("." KK<#Q9G.83[0#<;0#
MW1H?VQP^UR^BLP@U]]H=!%;&S,IF#2U8&3,KF_6W8&7,K&RVE0BLC)D5:!!8
M@0:!E;93+F!ES*Q @\ *- BL0(/ "C0(K+3."C0(K$"#P HT"*Q @\!*ZZQ
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M1IB),<*[3&F_ -P[(H.O1H=32YAB)HGB8^!Q\VYG*W4?/J%68J%3$R,?JM
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MA2R9>R9+WL2VG=%QI4TQO,$+I_[$Z\:>L_]N<0;FHUG[@X>4YMP'XMR#1\8
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M-7-8B/RD;!IMUW18>0NW1T6B@3%N/&QKQ&@XG 4<ME8E&@]G@8=MS1,-A[.
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M,CFFZ\><6)3J[)<AK.2>FLICE/9Z.Y F#IHX:.)P8.)@VX[%7"E(P".+.&%
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MKF<P=U*H3UF:DL8RJ<&<8:5$^X,9U6U.HCI)\:GP29QPV=[X!YHJES@RV<0
M3<#*"5P_RPNU>.%F& JPB^#-;C!<#C8,6#L\+^ *5DEC*IGXO68%0*>\,+Y.
MD]*8=0(C08.G H,(^Y8;C$.+U[G VY9>X"]_"BSJO\)0?)7P9,;P5:Z*_+::
M*@,,C">6E6UGL'%\NEK&RLK")\%S\;WNP(2#3OR3J5:Q[,O$F$WO2O0X&C'
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MQGJCWC1&SA<C6VLF?8K[2?$Q3*-*@V*40N/TBD7#H\?PV-IQK?&A=8H&1;]
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M$S'_H4+NZ>B.8,*Y52[RM"-H6>KKB&[+8:M[8CXY<A7Q&@1X48 DWE__9A8
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MCJS4' 4EI0F86\W<QA2HV8@#K1]5W9 :;1!D96)0 R_JO(R#@"HHOA>8_IU
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M1J3.A1?>*&0IM8A&3H2.U$8N#WN"ZLN*4T]JJD\X5[WW H)6[(9$*\.T [0
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M*,>!>$2CU\F*]1%9925R=:B=X#HXOMO\Z1+J?+9"-0@=X,V"R;W<Z, U@&M
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M[(@0%HG@:L1U,J:T#@%%C44MO:,UP5VW;8JK%B(# 8<-=7MC@\P'!RPX8$M
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M]:0UWZH!L-?]>^"]^D3%<%_00?B@!G0 .AY!QX #.  <CX"#;344!^CH%SI
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MU8_C^?GG!/HFC&\%7/Y?F$Z^?B)DK_8@<'[(U^B%4Z@_XEC5BA/+"9+$)_N
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MKE/"R]&G7RS:WL]GS<R,\QN5N97O52U3O<@1]- !/=F?=DL/:]S"-.46D3/
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MX5U=63PN"J1:6X+&CHEY^<@X/L8$P("8"N#BB%0)X (B( ",SBL2\ 8?"R1
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M1DNZ8W[S;Z_DJSXC!P]P<<C9I#G>RT\>WP+ _C>8:17&/OBKOO 5(R=')Z1
MI8%5#E;YH7'3;[@ %0*T@%4.< $* V@Y.%I %>W**J?K6N6OJV8R&OJKDXS)
M( ^M% AMUSQ7_;/.U1HX>^KLH]Q=%<02B"402R"6NB66"  -@+8/H.&CTW]@
MQ.W1#_W-FS=OW[Y[UP/@=,<3O3A188_PV?^9)N9+9697QY9<'V22SR)94V#U
M!WE V??A=^H17L"M#8 !3@1X 84$>'D$+P\[!HY7,PWP#4[] 'S:SQ7$H*]
M5LAXER>TO9L:=^<DT-5;"->**LEJY(6H$;=!(BVQ1,9%K942.F+\ZL[9;NN<
MZ'8Z>[>P,WY;F1FW/KSA46WS\7#QR7^E%Z1^5?G@ANG!F[^]8J_R,8KG9O:W
M5\,OL]?C^;F?S)9_3ML@[9HT\GS>*$V[L3W2^\;C?]\%J0&LI'>F]G\=(:Z
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MZ(U2@7!4YWT^W-5&<&61)YXBKFJ.3.Y^+D7$7"K.N(C/\?FD-]\LR/[*&#C
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MZ8VNB8C&"O6<8$Q+]*_>&G_\:1;.FU_"-'LA#YG/0GK>G[9\<08T"%0=T"#
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MR6K1T(,N64(,6*^]#/MS./40'60@ 1P CD? P0<8T 'H>!@==$ !'  .T"L
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M0-H8EL@,-0XK1:CY>I@HO7C3RN-;(:*5[-Z'UT2?"/50,^ >;WOPD(!* +(
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M[TM2 'BWLZF29>G$.;YH)9^3?=\OK@$P$+$& 087R=I?_W;/ " H41(I\3(
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MX(3%+WG<C^=M,L6*'N:*?RO/&KR;\5005I'%Q.\EX4I62>9NK84;H5.> Z/
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MSH=V <DCVX!];0*(9K;.WOLM&=VRH+>1*%NCJM'].+B7%A;6$53DWJZ?S*B
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MRL%.*7_.RS?*(FTEZ+S %9O'5%:>79K'=_UB6I&SL<Z"Z-]9#_@=?3<H[P4
M6!4#(R0^S@L=2]PW,$SQ(&E=XP&R#@^*O^,2PN?KS&;'S'FVD;C?;DZ[:N#T
M(@FMWLZ)O3)?LVVWCY'^KJ?:QQ2$GY:_Y0)XRUY9KQ^?W(UT =EBXX^'FWXL
MONKS>X#<Z?_A5C,,%F2)G[[J/B'/K79OJ QGWJYSS6X.C6S@L $BIXB/-%WJ
MJ!*ICP/U<=@=O(DH:DL41\G1\C(Q*CRJ3Q(^"9P$WC2!/UYX-*#"(RH\HL*C
MK;&9YC&7VLBQ03+;O5L7AQBVV%?Q@R<DYZW)^5[F7%UEO6:@:6,"_-6.P4!
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MT(W])0^NO(_"4 1!BYTF?^F^[I_4CBH]'IV(=UY/?M'&%"Y^-RTKX#?J"&\
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MM_SB0< 6Q8UE$W)+<"O?JL/^%-C!SQ<P-KRZ$,-30I=E7%A0)9^(W\RW G:
MQ<D!,E4^1MRV),Q5Q7"RYO*P%QP1E_8*^21RI0EYFDY\)ZF]G FO.LAQYXH6
MJ'W"D=?=:(8%MYS=P;5LH25Y6^FYB@(HF;ZUJ $$T'YT*T2"==5.D)7-8F=
M[XX_ Z/UGNXHHAWYY_,2P_QSJ824^PE>/8^6W1FHRKB814E:%#3.(KC^%E,K
M\/$WPH9=HU@GI%9MG/*"@\5?,D?WVDE+1P/B&:9ODJ:S-T='-S<W'0<L%'[-
MBW 0NNQT=[K(2;WQ 5&N.L-&W)DJAM73-USN]V&J6]BDC8.MX"I[(8U:JI/#
M A)J;SH0[3;(3%#'!)@:.$"W>TS MKS.CXUZOF5"AX<(D^5G-\Y[]5<O:WR_
M?J*1QEMO]WOSSYN!IN@ E^SS=(-\:<T),+I\N9KN]KZ75^>.!#]D^<DGC-L1
M7*S:D?G22)0M#E0X$\TO+*-!4TQUUE^^6J7AI\Y?_<3QN-:DHRZO.Y1H^6U)
M9F KS@(.;^"'<F!V$&W[#.>'#?.2*][>^&XZ0=(8#'N2-=0RL7:L^=?5H9?*
MBWE;B2-@5$W$6/IV/\XPK[E7U("_7HB J]Z I0.R6,OW=''QN&_EXQJOA\FS
MHH,<-=7-\]-TDF(A1M6%Z.0+T9XOQ&B^$"NM/C11\B^CDSNJOV0-=6K7T"*N
MV -74&\(K>ND2> D\*8)_/'>$&/J#;&;G99&B*#>$,1F==X)>%$01#<R+BG3
M7V0M3@Q/4+GWE5PBGJ63"#]Q9>V_GR29;,^I+.Y*_I%3]:+- A[*TK+(RU-L
M\P[FZK>NV9)I-6]HZG<Z]8M1E T*76N*VBQ#H>ZM;OO4Z/!U8&!J-=T3J1W%
M+NIPN2U4O[0=6()\EL" BI^>(S!8GE'AZS,-X]]1.FD,_W/+9U?*<*6LB@&H
MQ\RE,A\:/FK9W^4SEWT L[7PYUQZY9N4\BS?HOB]G/?B#_G$7V/[<X<'Q>2K
M.Q5OVAMT1O)5";YKVRJIVW1TF)TA@8/ \0 XNAV+T$'H6(X.JV,0. @<#^F5
M+H&#P/$ .'J= :&#T$%ZA<"Q+G4,:,-"Z"#JV HXCJ0WC#QB.GO15\+)LD.C
MMQ3.:SZI;-A%1FA9%2UOL!&6[Q8#@XG X=0&-IMUGHUTRSEY^<'THQ=6/GW.
M\JZ2SRL*783Z2P?SJQVSH]^PCY(Q6*/V:O]2O%SHA6$_YW T$F99,I@DF7#9
M/V;K-%\D.=X;^.D/$3O8D9 6]XL&_B5+DY3+OI8DQY?(<29[8+;8GSR.>9@F
M),T7#%Q6'N%ER8%M)3;KG]B)2;BAG<0JD*&-Q Y":02:PP#-9D-LM/N\!ZT_
MY35@[!_#3/ KVC=MQ-X_C[&=,EG]9/7K(,?<ZB<AOH0G:<=$.R;:,9'Q6]LD
M$3)^'PZ]L'GX@ C^!0._$%/NAUAD>'S-_0!+HTB>+Q@XUE^>96D6"_8A+\,D
M>;Y@X/^0):RGLGR5!/F"@3_8[I($N=[ S[%LFJQAW>T:C:WA)](=?SXY.3T]
M.VL ; XSX7'G'0-.'V[N,,,#%U5KM^I9+RO25W.02+F4N]C0;Q4ORUT#-<NF
MW.BAH/U'#P65U]6(Q9C5ZG<'K?[8T %M-3:O]&L3IP6^?DVRV6^OS-> KFSV
MFPX8VQ.C;;9"NAZJ<.=H^[<#!MB&JZQ)93ZH,DVK8Y*ZU 9?S5.7%JG+#1=^
M$YL]R&:]EFF-6D.CKP/:B-&:R6C=AQAMF5>V]L B#^R>/;!AE#[+"UM[Y)''
M=6L>UP8E3)%W=5?&%4;:3>MMHSFGCF84<4ZMR]H(),T$"?DP23&18B+.V27G
MD*>1.(<X1U?.H:Q-0DYMDN7(U7<8>'G#W"C#XZP*D\?J]%]F\E":9<-M'TJS
MU YCQ%.UX:E#=![6*WFR,5 C%R2E49(Z)'6H,T>1RY*2(XFGZL53E.A8QR.8
M'@')[@)LM81&TX^:;A0R'K",ZN9_)) TACZ:?K9?HY"Q+_IH^*G3A!']_'D$
M$E(QA(S#H8^F'T#=*) 0?=06&=(]=I1B)V3XK^M?-]CSN!]?]B\_FP-C(?EV
M[P+N](UYN& %*>/7U!_\T!4A7-TV.A:&'%:2N^LGLX##B_FA'*\=1,[WO406
M%M[!*!@%W\60+Z,:9NVL.>\&T/4A=(+,A4=%\]-H5-DUB]2Y*@Q/M> W/'83
MAOVZS=9@;+6&XQ%+)CS&;WKPY1C+N:=1F'\WDXVHTXE@EF&,&'8!EO<9];KP
M56O5KYKJJQU"?RW0;]46_0BWF^*H,*Z."LOQ.)-G72'R'UXB@.-_,\U.UWP0
M^/]F=CO#D;Q-@Z!=J,^#0'>W;NB^$#"@!-XG8;V6,31:@]&CI'T/G!*Y_5'+
M,(?EAZ?361#="L$NY7?.L]B9<#P2#L',/D?,4^<YY!H#'A<$+'(<>-B2M:$7
M_+=J.&XG1MULF6UAR3QZ+GPJIAC<6GV=[V.4:D-P_]^[';6?PJPZJX_Z!#;E
MW _9A0ADQY]DXL^4;2G_ FKW:\S#A#ORP[69U@[XAO3&@R\6B#05L1Q _E8/
M+5!\J_=^+)P42/,#L-Y,H%ZY<[B-[_[G3[E4OBU(I5S)<O&XPHEB^6'N(/GI
MM\,A "+-I2;6.A;6?FR/KZ#E_=##:V1_KUC\E<&*D%V]THF?,,FU\%\_!'C/
M$.'JPUAX(L:UPKPXFDHCQ16>'_JI?XT'ST8_;L'T@*NG( EU-=XVC>!.ZJ:F
MP;@=P<4W$[@3K&=L*29XG%0,D(G@THS_Y:\L2M^NQTT=]:6Z XH68>,LEQY9
M+ENP7,YCX"A_Q@-V[#A1%J8<B.=,",40ER*^]IT[YRJB:B^_]FW^M6_XM<:K
M]Y>I*F(;4OG;5/FZ4^3(LG;-B.O/]6J<V)%O8];>5*K90M0P8KB&T-?IE$T*
M8QYAVHK MG F*<W9,IBCQ?CM]^![W^@/1H.1-5K+2I2)%__Z+PS^^57F8,"_
MF!/P)$$)1/"@$W@_V.**N&:E8>NP@4X<W!1<DL!)X$L%7M"+D_X.AK6(SR3-
MG/,K\=-OYIW^ )*2)G'QE1E<]"X6_'LY.?DCS-$L93@RYJ1MO*IMXV5O6!IG
MXBV;_Z7-/7C8&\:#&WZ;P&".%BAO(D=45\I;R]FD$2+N9 ?*2;^GF.HT$6M;
MHCO>*YX?7WQE'_Y95^(C1W1C'=%]<D1OP1%]^F/BVWZJ?"QG?LA#Q^=!Q35V
MZ4R$FP5+G-'%5QOO>SYX,NE8YF92^,P&I?"9797"Q]=(X=N?$]V+@B"Z05^U
M&SG95";P\1C^[@>8G9J (1RGF,$GO>IG<#]X<OOO;_3"H93YBWVM^<PU H;=
M87_]*H%M*9K'80A[)]DA2X9HEJB:A+WR5>ZTBT&8<P3DAP\E)F,QB^+TM6:(
MW$1R\SJ(W ^#7$C9XU3,,\]2=B&N_ 1V,S!?YYD-:"@"-T@S9WX\I:G:_50M
MK+)W/. 8 [V<")$F-!U[GHX*U<%2^C(3RE"FB=%K8BXK)X3^PF=1\I:IXT5I
MGK2:IQ.>3-@9F+6T@/8P,9^C%(O<(O:D7:?7[- >XL$]Q#JUEGKN(>;N*LWV
M"8/GH4[C]7\<!,RI3H=73D=23D=23(=T-D13/Y7Y><+A62)D"ETUNT_F\?'9
M#$"!S1]8%+.\VE!M"?'ZL* =_.6IYR=ZU0*J+*]%%)APY:-]DM>"0HW(9IW2
MU_V0S2<>\BN%8XS[QMQ)DQ;\F!\Q'\6WLMY4^<Z/XYB'5XL*3]>EV]',O;R$
M'#>[+/8CY@I^G#E^G"I^9B5^> 4_DBQA[0 -ID6NLV#)[=2. I9G\_Y'G@=;
M\&*%-D41TPG0/>/.,YK[K^S7+6!?,)DU(\;=(." PC,K2Z_),9J^D;=9L+77
M-64<5BMDT9+<V&$8SUB-^E<%8&3QKK:1ZF65V"*+0&]A'0V\6PY_UK4Z9@L3
MT)Q)WN;#%LP5H!;!OL_BT$]@/[$-W:5U/H&6BX,D1A(CB9'$2&(D,9(828PD
M1A(CB9'$2&(D,9(828PD1A(CB9'$2&(D,9(828PD1A(CB9'$2&(D,9(828PD
M1A(CB9'$]BPQ;/&6/[HR.GP=&)@\@_2^2-4ILWE_F_S(62<* CY+8$#%3\\1
M&,_2J#QOV%"'RN)IJ)7#<KGS_2J.LM!]HQJUO:W_\;G#3K_1Q^=N#[UW3U)N
M!#C@S_,<[AXA@Y"QG#:,CD7@>!$X0%7A'__S)^NG)@.E/^@,"2E$(T0C1",O
M $JO,R:@$(L0BQ"+O  H9J\S(*00C1"-$(V\ "@#8A%B$6(1 L?:X!AU3 +'
M\\%Q).,Q%),AE!P2A5!,AI!!E@?M7R@FHP]2&HP.HA&B$8K)$(L0BQ"+4$RF
M#DAI,#J(1HA&*"9#+$(L0N"@F(R.X*"8S'-0<E"':#>21+87E6DZ-GY-LID$
M2#;[K?$PV:HATG2D'/*&9M-!FH/$2H/Q052R02H9K4HE;Y@\])#];,A_\%@>
M&%I=,&-MV$NR$] X> 9EO 9FMG 4CQT%[D/(^A Z43R+XN*\N OAB5B$CB!"
MTAY;NA%2@^&Q83?+X<&CZFA9WP:NM^(:;C;5@/36V_+8PS5/9]S0PW^U8W;T
M&YZC:@S>[O_,WL>&^CGJ'!A5DR;?E2:O-ROW!P?A%-\QW[#W(G%B?Y;Z44C$
MTT \Z>8>W3@)+;]AS=)1R4:$8>&!P?OGH/W@J8YDM#:>B(MJD=2J)WAV348^
MB."*]JM/#/4]3S5P/1-G$V?7"SL4&R,?(_D8=[?5[]9NM=%6?]\AQ/IA1G>&
M!J-:N,3/3PSU=Q&+&S^=K)O]_O/)R>GIV5F]3>Q*IG,=L^#G*Y"S22R\__QI
MDJ:S-T='-S<WG40XG:OH^N@X=B;^M4B.A'O%XR.7I_S(- ;C?M<X MF:YKAK
M6GVC;_:M_L@Z<L6/KMF9I--]I$]O;;%NZKF@EZ+XC<(E@'];"_:QX4H N,+!
MM"P_@D]A.8H8L09OTNV8+WN9C<OTB#]I^#6-2AI?-%$%CF%L&CCKUU!L%4 4
M)FS6WJ%I;%/W:HI]F2ZZJ_+CJ8#?7,9#EUV())5)V">( P^0D H6>6R>H U?
M[^BB<HDQB3%U9DQ*I]@\E?WTFVFT_^L [+4%.[]^U%.OD%S3F(>2)[9"/<,C
M:WQD&4:?^*=Q8"+^V2!B*!%@&_13<;H2\30&1CLOHFD:V=2Q+%8GE#2V_1A%
M78W\1W.(B]$:'<U27[0M_+UOC'Z(']UO%(.MJ^.VV['J%X-M!)LT/O"Z]TAK
M?6%"48/]YVC6!"H47-VPA:*[QKX359615_A?BK^L%'JM*MKZB^/P$O9)&9 R
MH+CQ?KRGH_;?&\\WY#LEKJ%(L09DTS\:':$12XS3,"01XU!L6$?"63TVW @0
M$==L(S+<"&A0.'BKX>"&I)8<>D!XC$Y!<WR4\&N.[M:1:75-Z6[M4D"XIO[4
M;J>[;R$VO"2(8L [C '7&2CD^&]2!C7%@7<7!]Z$8:*[HGYQ')A*<&NX-HA&
M*8)::Q^C::P<0FT(CNK(.#KYD@Z&<"B,NIVHABJX-<=$.XT#$]$.Q5(U99VY
M'Y7XIC$P:E:=+<53ZP(.*J_5'2.%TS)W.5I6Z7+L-<;EV.WTJ$I3?U#6*T)7
M7YB08YE25P\W.M=D1;>TG>V[VX#?)!A&.^$)OCV[='P1.B)I86!MG7!:?8%,
MG$><1Z$T/7P#C8!&'2E$,V@< H,<1FR,*(0HA"B$XERZPJ2IT" &(6@<<N1J
MY]'Q_Z:*P1JB:4.)^5VK3,P?&X.N\4/\Z#6H05NO4D7?[,QZBI/M,$Y69Z"0
MUYA2$P\Y5D8*\S&%>3D3#HPB9"?1=!J%[#*-G._5TC6J5*LA]HDF*;Q6ZSTJ
MG1'92!P1X5 T3E/&&1V9%E6J-1-,1#L4P=.3=7IT(F0#8425:A3OHTHUBN)M
M(8IGJ6-9Y^VUQGD)0.^;U1BG9&]^,&*C$_HIAK?#&%Y]84*N:4JYI/@=J<IE
MJO*]2)S8G^$'JOGDE9^D,0_37WX>6>;P;<(NA9/%?NJ+A*KD:K<(B"TIC%=C
M]]8:#2<;@:(ZLHU.#HP#(1L*X6VKV>3@R *[CRBG85 BRJ'PG8Z,4W54$M<T
M T14JD>A.^U"=PT)\!YZ\$ZZ)$VS\$A:9NZ1-(T&E128!A7AU0/:]0K@U1DH
MY)2FK$L*XI'*?$!EGL$7U1EQKIB&JO(.(WK'5[$0\F Y6Z0W0H25 )]LD"FX
M,\$O^FF" !%.&L6)_"3RX"XB7BOH5^=%0PQ+#$N!/UT<8W327"-Q1(1#P3]-
M&:=[9&+L;U5_?$/ 1*Q#K$/QOSV:.52_UT <4?T>!0$U# (V(E!\L"% <]PU
MK;XQ-JQA?]@[<M&%:3:G$ %48;_J:M159?_'(65E'$90<N<8DL'+_Z#JP\8B
MBO)-*7!)BGZYHC^=SH+H5@8ER_!DB[GRF+X_LN#VEY_-@?'6;#%S/![)4"3/
M3_1[+QPQM46<7S%L,<LP1JV'8IL78NJS=SRV?1%3Z6+M5A!1+44P:^W:H]+%
MQJ&(R(:BEUJRC75D=H_ &EJU^V@CL$240Y1#H<L]ABZI>+%I,*+B18I;:A>W
M;$AT^\ CEZ9A#HVA8>8.S<;X,T$1#@ZD1H(B@QI&!NL,*')84S8J10=)F9;*
M%*LUF8H0"I$?)GB>@4AX(MAYP,,6XTD9$,0H7RR2%&.'5*=8PW5 E$E1OII[
MP>B<P0;BB B'(GV:,L[PR!KC.8.K-BEM")J(=HAV*-I'A8I$./4AG.:"@P)^
M5*AX..&^Y'D%#"/3Z@T&C7-1@BH<'D0U 47[-(SVU1=.Y+BFY$V*])$:G4?Z
M1NSTK\Q/;]F'$ T/D(4,\5&M7NU03G1(4;P:>[=&5*K7.! 1UU  3TNRZ:L
MGC$BRFD8E(AR*'BG(^.L$;QK!(J(;*A2CP)W5*E'H;MG%A=TNV;?&/>.W'YO
M:/7&#?,\@CH<'4BQ (7P- SAU1E0Y+6FK$P*XY%.O:M3C[$B3_;T_)QABTYF
MPNRS="+89N)\=5X&Q)G$F13KT\5@HXJ]1N*("(<"?IHRSDB>+&AVB74:AR5B
M'8KYZ4DZ5+#72!Q1P1[%_32,^S4B-DQ1O_L>RM6/'=IP6"4'H+[/U=TC"P;
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M88,Z@X6"L9LV:717\2<\P?=CEXXO0D<D+2QD[<CP*X//)I6ZUG=1F"6RNO5
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M1J='9-,P%%%+#DIHHY8<%'C?4F#80C=DMUNZ-*UY]6YS.@YCH'14APCE?QQ
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M\2&GQ!5.%,N5GF\??OIM_WK[L;>>=V3)W^=P5@$QAQ;,\72KH;RM$)OPA(E
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M9 1KPT&4$U$;,!'3D-%<8Z:AG(CF&MOZH^^<I['O?&>7#@]ADDLSFP[3J 7
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MH9_J6N_ZOJJ/JN^MJO4X__@+\%Q>6DX:  <'!S!^^@$\K@)TI;QL+ $ )24
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MW;P9)::YI4KSC/](\YP?#^F&K&3>S\AK(0!TQ]%(M%@Y$/<(B)[5#/IU%/9
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M)^).Q)PMRE?Q+%+(MY7E!EJW^>H9"0!MXCQB)RZ1RU7P$P/LRPWUMK5\#MI
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MUHH=Z/^"&Q-*%X.5YQ=^9?F/I&&-OFS7#*G]]Q]9 L[-9Z:UV"P> ;2<VH^
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M_J)BF4/0REB$<2<?-%!0@#$95I?Q-,P[!ZR\#P#:/ +.+@GO+\0(K8N-P."
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MK:N$:<L\AACKI$*=%^1CC+I6BV_^D+M]UN;@ PP=V'&);BS[E2VIFQH#6TV
MX@*B*L?TTKUQLV:>]N@SJUUM*ZYA6-1,;713 B?!,PTZ&T^'CS1K>'OVN%H"
ML#1GX:]!+-S((4;\%/(]J^8W['X?\'?P-/0]A3*ZZ@ANS EPEJ]\>Q4"<.\.
MX^76D1:](9OVD"N-_&/\T1R3\D7DMIKIW&G+U$7TQA<,R?QPB7JD>EE\8]P[
MTVIMP7QO>6'J-FU4G\6;HE^:VQUR7:GZ;8L8BTMM=XO<\Y<:2(_U".0'N<P=
M PGKJ%7KDE ,N<*/WQ9<_I")=)WZ,5<\(49G%GL<OR#I+:!K(T)5PYS!N>M(
M_;)SNSFM\4;+D#XO4^[OK2=B2?;RI-K,')1?4**IE(:$9$=K9^O<M<3*LE=U
M[%RVH_5,M[! ;80$"1?*F>>[S9B!5L[HLIW?1=U"B>S\<LJ9)JWS3!;/,!7D
MIC_YZ,RZ08:VU55./78852?MS@.^D7_;ER,^,)@+M3\J\^,MZ"Q"Z5UW*AZD
M!M#S;0/63LMT&<XK0_XP#< Q,1FV)(UVN]C,:8TW,G#H\AYIR.[F1#X@X,R"
MBAC@?GHIDZ9QJL3CF'@CEHU,D<IN&DQ*Y+FF*+M.4^2F)\:9/&EJFP?6R<W4
M-97&>E5!%:>DT5(%G,LPQQ9?L\E6DG!_!W(2_H'2<CTH?MEQT$CQ3O7;21B6
MN03R'&!.FCXO)U/XCPV$9:4_4A_!1;KC5:_*A1@CY?DDZ8*9L,;>M<_<*2<
M?;!J\-XI:X[".6#@K 4QM1W*'?0!RF^L3=,\%$AD&Y&Q&O%.),:)^Z]"F-G,
M*]NG_6@]BV4(4[^$XE#WR,%_"^M$)O^0&.<NTIJSG21@D9Y<A,*:+I,$E'T;
MKRNAK/DF]WA^[3[UW(<!;DA[A&2[TOK&(&\S60@V^0USFJQ/O--JJX@EO666
M]W.M(XZUX>N&U!.[K:H(E?=+-G:[D[':ORQB1M*5?=:U,O'45F%1'4]9HW+!
M[.ID/SS47EVM=0;I.VM8:1KAD%;*_D$W:$#8C,X)G-/N.I7W_H0GV=G5F4;
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MASOWI08W>*)L4>Q=FUSQY]4F]">4$*)GC:<MDYX7Y_VMW,95TP%=&MD!=H\
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M4O:>#S@0YSPJ&^)'0*VH%[6:N/UW]A_/G%/!TT+J]J8WEO.I4JW@GBTD>@B
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MC/EV!HDI(]F^90MW8Y%0C[ X,[84QO^!V7CS:^J"";VH!9AMV(\*!'JQ$NC
M$:E!V(]&L3<DB.F^M$BXJ=1T8[Q3\'0BSM&+"$(PT2(-<T$AEYE-$:DOK4NS
MX@X-MFQ,0Q\@JY>/ZT&V_\7C"H&/&\//@)*JU!GL- V#$7OO/*#6A@-QQ,<]
M@%LYL,S0WOB,]8%C[1@J9"<U-,RS"#RVZ5VE*X\0&WP;Q][H!5@+72/*K3#>
M=1=X7490GP/99:=^-8BEVE2$$"Q\C52XLTQ?/R.D$I"CU[6N(UTZ1WQM$*-!
MJ:*;E2L58),IGOG3 M32$&R&D 4?X8:\H;EN$6AR[5ZZA"Q^@A4"U3EDM:QO
MKOJLHMV_4"94EQ)$9SUT?^B:?ET "QE?F&W1H TM@J$S\;'F1U(K5B\QTV&F
M9;^1&>U'CF84?7X5HS]AXMO )6AS # (53ABU?+H0*\QV:(C!S+U" C%[WK.
M48LEP0S4)EX%VQ?VC8JA(-;S#@5W;+AXE7G7ENQ%J7?773*>0K1[+%/UH\HX
M"C60&W=55B46X+G*W#\G:!@(',Y#E&%=7GWWG9_A^J=?B( J]#<F;HVB]DT_
M9U1!6A+>;#<W:(AL5:P:D-,<%7JC2^&I_R,';/Z$OTF.W?&'%@(&%&=%]XF!
MCX"<UYE8V7]O]2(GU?I7Y #3)ZE=)3DE-QVD.0V3;6GK9\FPV;3?ZRH3]Z""
M@+%%=^#^>, 8T2/@*$YF(?,1D([S"%AY%<CX"+"W63F[)*>$Z'K>W?=KMHT@
MWQW'/%SC^:=B7Z]2WI_2/ZOX>TPH__N8."Y$\6QT#9/="Y5<VYBL4[6T^[0#
M.3LNR@.ZVO%;N*&WS1% I.:P7Y&RFYM4@<'.?:CE.9H3=J"H5V>*#3%VO$ZU
M'%S&2&C=R,CDP-1CSZY' /;5*]CFGB*PT;PA4AJZ,=/QI]P^4"#@H$SPX<-:
MSBU0^?<ZU^[<7ZR(J1%_! A1/TD'*8#& WBJ?>M00+2N]NCZ-KKLSP[=<E&>
M=8G>KK]#-/H_S22.56#AS-B+WR68'LZX(5WYMBPQ#"_Z$WW1/Q9J?P,XS)=[
M!PKBF5AZG6%H(NWK@Y-6&M_:UB&@2@YD.E%#D<09#4Q!^=HIS F01+M-6D$R
ML[)!5<*8<N*'?+2)JKI7V46J(XCXN@^GF )]OI#D!02<%!I',20EUSJ?AY8S
M77W#;1N"[QZKJMG?6B:0;O/?0@*%G909F^9[=@M+I4\LPYO:83HMHC8<WOIO
M'PP? 8?7WR#-3V)A[23I(T\>#.5(0=\["OMYV\H;=Z5Y2'-TRE/?H3'%3K91
MV7B"N?ORW#<A,OB+25E"*<0_0JF>9[G(D<7"]5HO>;5+UM;4-"5=LB\S )W)
ME ]>"SPIV[B=R'&D _P(T?!::ZXOW%K-KV==ZU[%"7)2_*(BK7[CVH\'B2'8
M3AJ?'[S\5'8U4AE-YQ&+816"<)+N.AG(2U]:>">5)^<(%# HD7)WLL^R+SO[
MB8KHXU-T5QSAM=<=YF)L+XE%G/":$-)@Q=3L@.Y\Z9H*V-XNY3YQ^'(C:1M\
MT#9<?4U#I"_7?MMFR.MP%&E9O'PUI_11YJ-&T/!LA0O+.G-I%/$6OP2O50'1
M&-?W2G)N?$FE6690!*ZW&6_*<UKE#?K![D+&CN<?LAM)C4B ,;EZ>_4"2I]\
M%*N+TY+M+.$RC 7E <JR?"-O=EQ;LQN%!?M3+6:+7 L,V.L:PR\.J$G)$ZNB
M<MN6BI5]<'4YKFJD/FN1F"WCN+:\=<;]UIVQRA:5U5J3RHRTA!_Q"$#5C+FO
MYDKP^#!K--3_]?9)8WI^X#E\TE;]/3<2>T\*+V#GTP%DHVYI?G3I"M),7I,*
MF,^NOHAHU5SF4Y>;@C:E2E/5GGD[]R$7 =)],.#E5@^,]WSD#6I%%+/ #._(
M0MP%]9 ;?OX:#YS]>X%)7RILI3Z3U1H])#-EVOBMSR)>(86$/E&\CQ>1W]37
M+!](L-:?,E5J 0H?9/K^37&X*60^E/8=1'8E&)5E,E#05G?=/890R3@IMA_Q
M*V&-..RSDL2^) FK<]1=\,(OM)W2K?C-4>*\3]W4F9:1E;0J^3)(@<Q_=1!-
M;5:SL7!9NQ/M*?T%-C<D#$5I)T9YT=14(L/'*#=D8LKK]AP_U#@7YRWR)A4Y
M>ENQA[J'*VTKPR'JP5<=PA5KMK$2+K/X8RUW.84YTF38I"C:'I86:X@34Z>W
MCT;7P1=D-Q*Y'[V@"RL]_][*J001J(T7;H742)$\ G 0D=4#D7SG#"2PLB?^
M8-( M9R6W9?RMD@.AIF4$MO\+E]![6Q< X.!JN=U -4A=I% L[-2;3\CEYM/
MV"S!K^-</>PR&\Y0OPZB4G*8P<EI=H[EH;\3 #.A&\PZ[E<PG]\S#C*5["5Z
M ]+5R6S#(N/%Z.BHR31I5V)DI[@:#]8J@Z$G>3(D42MQ9-*<H+Y]LK.IV=A]
MCPTM)U,DL0XN4(:5ISMK>+VK)$8R$L>#P0_(Q/TS_C[77>?9ZO,R7_4$71+#
MJ@)QH% EZ1>AL.$<:ZKGU_"8/W?BYE(]MIEV7'.S&]N? WWZXJ?T(3;OA@IT
M^S<7E;C[^BP.J=]AR1+O1<^HJ)_8GW,LBGS/R^M-BZHV,!2J(9JGQIR7ZARR
M1SB50L$"F4:9V^#CZYPT!A+S710QD8P9**1I,(-9PISMZGDFK8XJ2(/.J5_5
M6?^'AL7_X&P<"MTDE;T;6$=IRR\.<'B:"4]%CQ+$2+@T/6&;OR<]ZH=KKO^B
M<NYAKVYH^L=?G9:.U$V-MYH'[99B'@?]!CT^X\C.4JY-A)'G:0%O03-4\;+9
MC6J#\>5$QG&C'((^LS%_H8;+D;+Z,[W,?U&Y5HY[$G<<ED:H^ 4>X+_J%?WG
MLY:-I9U9-GV';O&*3?UDJI&UT<K/@O9T+2OOU'-$:O*E*T=C]<'#R6]D?R5B
M_8B\=2]*W-\'BHM/R^?W,@7@+_4' ($EVPD[0QX/^KC$:E(LTTC@#VK 0OQN
M2:P\:)ET]\&E[CO0U*9>J +#< 5-Q)009LY9^6;^=SL((9IS/6/-;N+!1J.,
MWI1T1?:RS<9P@$U(#O;]I(SN6O[GWM20Y12'NKD;-UAYA'"/I_-]O+GZF5]+
MXR(2,GR9#R*^U<O-U+H$*/# @P.67$9&$J^<KGB2ER-!Z3F<LFC>[^=>4G7E
M^=[@-<J'GP@E4%R?#H%'0/&9@L.H/WN_[E%A?OK'MGJAMJUN@;F%G(#JE9+Y
M74].MOERLVBYG*_QQ$0_,*QBY[F+<KUL89./@.X$_WCSZ,6E(6=81!!S7&T#
M-5UDO.L/)Z:6[+1>UV$'(:92F=R=&A3'3S#/.8?Q>?U<5P[Y]1(FWJ$I8N19
M$)<CYO*"K0AY\GYU+L^)0>V#>T?BF@T*%<$:S=D325-V8K_K2!F7O<?K2:[\
M27W)@MT#M\M0\_F3JK@@U68/Z6.45Z"7XVS)<E._?-^>O9H9F0Z7/_[^X_#F
ME F4G7:._@-S-KD"G&8)9-(R<2U&K4+/3,DZ[4H@-@NQNQ0.49VJ5?*8DDZ!
M*#8V?K\U-LS5\L1IF92IQ$X)ZEN-V3!,D;$U%%L:]>Q.TOJ9FG9QT+Y@WM[
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MT*2=:MN(79[9F?)F)\UI ,G$:<Z3FGJRV&]J.Q/)6_41,,;]I*>L_RN*;3H
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M$9C[#"(=$>TY$7_&E7SZ=O;:B3<$#4O%X7,9MC-+E.\*H0T!25AUNMPE$^,
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M#1^>XKZGTXZVX3J06-Z@XHO+\3L0N4!L#S]';Q;\_I/;5X[EH'WN)PV12AG
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M;.^(GWY.GY*@"M>YK8]?\:&EU>G1(ZOUKCS0)X@JE"P!$32$/1G _VXDA2$
MN!IY./N7Q* $8;!_!YMYFOR>@UW_/!#D5:,R$6^%@SI"0D3"K<GK5U);;B@<
M,W>;M@%SA=9]?N=17/824L'W5(:_I-$'WQ+3T^S"@V_F=&X[C/<XL=6[,<4V
MK*!-2.F5#_#7_.GN"WF]$[<LY%6B)A$,-IJO)#KFJ.NO7@1>B/4W/-$M#M;]
M,]X'B;%D7DOC&N7<9;1K4V^^KXK_PGK)X;M2!N50U53WLX%5-"<TUGTB;H>7
M\X)XXGUA16NFD<)1/;#  G(>_-#R'<&65*ST_.D9)10+ _/Z!LX]Y'&TF1(W
M+YT2?=#LNZC,KMM\']+OM0?.G\;H>KZ_LW%PX'RQX"LD^&9P!.)V-DA!>KEJ
M<;%NP"N<S?0\N)7J1-UI$4^BR"WM'B ##0SY!S#K\QK'."RB%CDCJ][;L<L!
M=%5^[AW77'(BC9VG&PKQ39V9K5SSVK-S6X662A5?-AQW;R"LN6N2,$7QTFYS
MZ[!K+-M2&-OAXJAU&S_==L:/!)>6=I?5<CP.4[!BMX:GGX5V+WFCT=KK/OA+
M\L;R[MWL-@QA[VY/]JQ<*\KW0;43)>[V'0V?0GYUD^;^L]Z!FA?=;L-B:<P*
MGAU)YI\0\9C2<#FH$!D9E_G(G9ZG)FKP'1D(R#<;O4/J+2U QBV]\=!,(B)1
M[-:RKR%E9XZ\9O6CF[M W[5BR"QYV?(.X\_AS-CG&\WRXA72]N(E1OJRS VU
M*/D]((,B]1[@6WB'[Y$"^R\.JM6(TP(V"+A9SL289XQ:,)K7-[&;_QY@,>GS
MU[&3Z2\6LE5C_!L4=M=_C;4H'B%</_V[!_S3P2?_FX-X^C%_#,V]9WB)%+\%
MCC_;^[N_[-_^(_UH_#=&\GV*K/"."4V^OW7O\V??I*:!Z:X7/NV\/]UVY/W%
M\.#S#X:'HNW#/Z43IEOG+C"Q9V>Z8%EJ?[QQ-I<>G(<JB?0,?CU CY WO*-W
MJ.]^OB]4_W+M,:^QQ%*G5P.9-BGW-[38[(<:I \AF7\<^_P"FYVGEP+>917\
M<?P[\BQ_5YQPJ^B/8YG?(6>@GX'BBCGXCY/1?V$2,NQ6O2(=L'0MY%F\:B^H
M]#Q<JNH1E5^:@Q3 !4^+9WF8;*N%?I1ZTMHDFLC$3#FF;.JAXE-QV@^0TO]9
M_[(:NM-IBNC&"(P#R8XM#_]OTANIJ<L7<L]]K'J6'$.,_;F=45&05T@+.V>;
M#ZNLW=XPPV#+?)-OF+;?*/;9!W7EP1MMFL">;8./%L4"-NZPU&S+@]N8?/D\
MN0<6?5S)4&<6^_HGX5\%-@4$'A2W)*RPB"#+5.H*7:[J"QC%U< ^*<9@+9LY
M1G*@9@SS;->HK FEN2[? [ L:_,>U5>^J/E J4LM7RAJ8=9_=J7I/17$$^HI
M0F!+HVFF\)S5/$"Q+IQ<V\$U8:EPB'_-J%DUQ+5.;TGK6DFA9;PDY_"\T#E_
MN_8HY]%C(V<0)Y(9:[_B0D D,-L\=]<7)&AL,846[]'>%+V=HQ#$:VX8QNO
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M/YRF_*<3T2& R/_P6N:OMI^]?OI:%NV@1CWVWQ-L_*?>W2_0#MM2/4W4V3V
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M.4'QV#I,M_-(5M1BYF6=YU+ L,?&6>]^'J\#N(4R:=<)^>76]SLOKLT-A?8
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M\X\?%>XM^5$/&PZF!;QU*%DP3J3E41E5DXL>@O/OM;9_TCF/&HI ]_7@3K'
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M<K7?N(M6_#P/M2?X[DQXJ"VDGCO0S<+8&E,ZVRF:CT,&__%5$MP#4;;6XYQ
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M.'ZYF7TM0TAN-Y;]J .8_M%CZL\JV=,_>Q3_644>UN/O"]FRRQ%6QS/+8\K
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MY$.8PEY]3_PN3CPY]:MSS.&BR<WJ5O/4.1[QU&[0FI%='E0J;1_5>8]H1^(
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M:3EI .$9 F "OP#8&J GY6WS$0 4%0$F  !0 (00&P )_@L!?A,#?QL".!A
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M8E_R[\HX.\NXO%]C4@;G&1A_+&,84#1BY=ET%7T! [X7/@6SBUUG^!*.W;G
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M0=T^)^CYU^1$#68YG)1GK_!$8^Z<<M\+7)^85Y)S3D2*>J=47<=4'YZS"<.
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MTNW]'F;^4O<W:;X%/L'E&V1Z-WI\6C?)JKICON-=Q,I,](DD/V+B#"C1\W"
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M7N(W!D;;X0"AU=XOA<,U[?-L=5A_RRB-^V ?KE](%0WY5^P>]7_44?E4F3(
MU\09&<"8_E+<KWM+-]BGE]S-T;*]OZ:K2Q0_B! 8!'EOVK=(.)0) X*C'?KB
M<TB+1<U__E?GO_ZE$UV(W;YE39K5)"91;F["O+_O4LZ[X_E5)IY;FH4VIW\3
M2G,<C]S4T%QNIG75K^MER[N/":92E-#O:P_F"V/+365VOZ,%\P_7;:/D,.R.
M-%N4,U5;NI*^X"UG975<@/*];O%H'2@X:ZU]Y9;F5^-4.+*Y9/ U9B"LNM'\
M88VY)!@=JJ'&2;6XGQU9(5-0<F)!NMR$?_RH_;QTF#IX??NE2+M-PS=S:Y-^
MC(YZ^>I!\\@R<(1W 4,9 @E43UXT_($-!LQ^/W&*TSOHK;L^-Y#!:YV>^--'
M.CF$UFFNDQ<SHOU\.RK=?H I?,*_$$4:U1934:UM9?K;R$'.[Z6E[5Z%4D\8
MD/2*Q2'F^B6S:<COU9BB(@5]T2WW)H$,ONY)&&"E.WP]JWTQ9/I\^/Q=+-,+
M[\0T5I:ZLQ3"8R<FUN'20%7->(^&_2L%K208<"JG+)7KBZO><VZPKP4#S,+7
MSR<NE @8T>70&MQXA?M\,FG?%2=0CM16D6B&O<ABC6^-5_JK2T6:SGQ,S\RL
MZD)KI/JR@F?% 9)\!!/-!S6MM#$PX3KVH#"8^-T(G=;;-9VR<XC?G'[E(X?!
M4KC"NG3[E/MF[4=9-JT[1RIWS3C+.FQ,MG?B%M[I#50D=@&KAFA5_G5*#Z7Z
MV\S[Y=OD/'Y+@KT.TH/G?IX1@R]Q\G.E+@;CJD0=:L&;(?1/CIS(A/TT+$NI
M\-3^M2)Q\K&]O]ZEA"\D/[!3W:]D<85(#[MN1 =%DVBJ.H(_P<'A5YL<5;*G
M/"/KB-</A=G*9:'SO=+VPD<@N>?Z]*[Z.YMB?FW;AQMQL[<]E$P5>3[+?J$9
M@7(T*@/$/T%9*%M*QCR?(NY_&ZQXN<QGA4_*XXRPEB_H+?#+.6J^P6:D%6>J
M5B0]?T. D,E@R$G(:!;Y3+4MK/0:FAB\U"1$I+Q!_[-EJN<2ISPS[=JD+.(U
MQX5G9"P=6Z\DI3O".VPZ0I9VZEG:*?LK+_K4D15+L\G;:6J?'#N2,Y%:B779
MN@5''10SVJ7K2I;(8F,6L8P&K#=KH0:9=O6&T)-;Q.US4,A=\L[9>ZI$%I.&
M*<)?]2RL26)+/93#4L/GO_CD$0G7U29B\Q(0D2J,KO46C&\)R!YLM9V(]!6X
MG76ZW#Y=+ 24"W^+DDELZ97C&GHQHT7(\,<^%F"-I:!>FK-S *T:&"Q!]E4B
M>B:,]_7\\55E9[2O)Y4,0J>_2$0$DJL,OF'Q_XU599:IZTR!F32PXGY(.E]J
M/WI=S?)?Q#(FTXPH^QXQV>9\0#=?%&M-@EE<ITK<T\1D,?5^]H/6?KSM_LIL
M_\ (O8/24)<HT\\SR\KYRVLSO+H61]X!$G-^#Z1H\7[+C^K]Z/(_B0;9,(9K
MIR R,BHJ*L@B/NOZ=JQ:"^_C+/D(!JA[!PF&GO%X.6PVF,A*1A5U\0^0QMFR
M%K*%ILT5W; =^+8(ODIHBOKE&;[D]3/RV:8%9@(7PYC('S6%E+E7S<Q@&[T$
MWYYTOM,7.A7FNBK\"($-2"_0=!"#1@ECW.0JM!U_94R/H$D*C-W*'8'^#_;>
M.ZK)KVL;#**@5.D=1)ITI/<B4@+2>^_=@/1.;(#2:Y NTJ2$GM!!1'I1NB04
M07KO$ AAHK_G?9_WFYEO9M8W,_^]:YV515CGW/N<:Y]]77O?=]:YX0HUXD-G
M^6R[# <=QL._&1KWYW?KF4_#JC.RBW>T3E<Y#@7?0=&\CHAX1/\AV\/D^\9A
MS0@AIA\.7/G9Q\6TS3(/O-*M(N$=C2:QSI 9.\=7+C2<C!9V+Q\JB#YF]B3E
MP:\6]9FUWH:U1)["\C>\#-,H<4:#?+^==7 !%\:<E#QD+#JSJ(!^@)16JZ.V
M VW2FHHT2U!$^4II>$+"QX__HL^<@_7WNV':J>V?!E]/!S2"17E2-G X EI7
M@W_EL-B9/&I"7!L-:%\Q,2DI*9*-<*7$<]*=<8/*A?MP)?7F$Q5EL@#?QV Z
MN[%V_BN6YIY\LA6?T651$W%I<S_QRW..I,H]TA&;E_=D4"%9Z6P$@/4VK64+
M+P)SPNV>]-_"?*;O>,771TFP2WZ3Y[OC_IN&RU$SK*7^H_-=PL< G!0= ,YD
MZD^"UPDNVH?^404E\ 8S:*5>3G!]I&(7R]!"DS.'%>8I/LG(T<Z<HOCRQ.KV
MBD8*[)+BPN4;?(&W_BH\I3_9R_5+NI$%=UP.KV37=\;U20(.&GSG>\>\A<J&
M4R _"Y>VCF3;J = YP<N@-QRZ7JXT.=F9]E'[,O%G/-)2'CEVM+A5-HEZR&]
MBO>9"I</*'$$H+DJ0G4<\(OEP]( <E2DQX9-?V5\Y9C7UT_Z*GA\2S2/G%G*
MR(K6S\F6('E'":\>^63 %?"1Q*O;FAMV^,Q7T[GN(SSS(UA,#^B/=0S345L<
MN=+9'\> ]0TZ^H#8'8NCR'@BSP'/-DU5,DJS[/(4,.NW>53@:(FWV!G@R$B)
M"T#/BX1!U?[90]+TKU__1R )H566&70(9^$%8:9/WSZZVYJ960\S?"'\(MC9
MB.FGD:J =C\$931;S_">4G+C"UF^=U9*] ]\B64;2L2%N:13JYFEY7 -5]KG
M;S*WE$!['ZQ)U-FOC'H%+/PF(:A 0E)*Q)9T\70L^:  GY&YJI,2'0EE_%LI
M^PB[W/[VRQ_+X_H;73+P5B8.)=6 ZG*53V8C8$GGF%FBA/NWO@GJ%F0J*1CC
M+F29!#SQ'%PJW$KV,'ZQ^(7.OEGI(3Y B/B'D+$MZ=B[\X(J$Y<?%"W-A>IV
M_[Z)8&MU\8JUV8/!5$"PZJ'N4>6M!ZS$\7F.&>1=]UT8*]UW.7^8?K2DT)"V
M:LC(1Q.F1L3JKZ57*%4^=7H3\F&NC\^'&_@P_0DD1D6.3IE$R=%6F4TXZ9M'
MAE)I>+QT<B2 $B=#H)K(Y'#342%75EB[$O"3FE/%5GL7^3[)]@X;W0"C,[08
M\Z0#+C!OR9\C;"G)8:<:@$O'2EG;JT[WY3<[T3DEI(747D[^5(S7U.LA4>V<
M"F,Y \[K_H))H=LO%=DDV5T*Y%S=1^??PB8;U9W%<Z&<%;8MZ47Z_76\PBI7
ML'1XO<!8B])]]K+>34"OL(J!<5@E<-Z*#M+!'=I:QI>JTVX&&K8.6*O]9J]K
M1IL<$DC\L?;HO :7=A2GRH)W/D)A1>O2#,.RYI^>::=(Z2^G0?P0H3GTR?B1
MJNE+TZ,G+P%[IB]E?%,4!XAY6UDE0)J347]1I?0;T2"V1L@@]<WOO7+]^;HU
M@QVOJPNG-HD6KXOAI10.;'#G6^ZIRI;R_PE7$X7[JM./-+U52!755Y,ECYQ?
M':' 5^5.)VEFL+K'D)SI<^^V?EBEEF5/RX28E;]#PV0DM+V\S4?G+-@I<X](
M.X7/5E8H/$_<?VY%=M3P;A>=H&%60OGY9C@_:BY;HA"68-[;K3]E8CZQVS$*
M:<QZ>S @4O_^DTD,5;;C$TY@X%-OYDV[1RNI3;9&\ S>P!9-#(ZXYR;(![UP
M5WQB3JP]+S,L0YL=Z#4A8M&LHO;D3EN^Z[OGY ]1\!U":>I>Y@SY&9!%HTV?
MSK<P^"S7E@<IT=R#J5L?#-W%#Y7O*O9_=H ),0U$'4UXWS$R?T(Q9_M=^#PL
M?]L;"58XXN];2K=XJAK<,0ZI(*4Q>;(8\N7A]R3V^^G]WX6.(NQ;4<4CU>E7
MO/MS 1.K\SFM0<+H;B^09$-'#"&AAU/"LEE;K,>[3T%%39IVA"I^%D%.(L'"
M+PN,U;OZ)S+=IZ:AFQXPQ/7=U5#7$QO!#'TKFF[ZOFC$J+I\GQ2\YHKQ\[$6
MK<.ZZ*MQ)2]6 '&;:-AJ-"V109I3^'GGZ>=Q]VGX-*WL[3-LRM?D6@F3&G.Q
M^%!-\YQOAD)L( 7OR)-(B[&R'^?]VV0)#KH(AWS_<G/S!7./FF;0[.7U6D]T
M5&EC2TWST0X4\L,ZN :A.J9*_/7;?57QY2>M=U-4R3Q_O>N;OS>D"IM&HBC3
MH? ,Y/#LH7:Z0&/)D(.GGF/:-R6?)_$I?:P#1@YCZK3X.2ZX61\Z3 +$JRI?
MWP T(-N&M9U/7O.*MICA<'F+5&ID _3OWB'9J?L=YY)S;U9L8?&EA>&5Y8K:
M:_H%LW$9.<XMF=B,7 '/94%93=$\QW=C=W7R:S+(*/Q)!PW%Q7,6Y1$#9L_A
M-X!7YQ1#GK'KUQ'%@F07]#< BRM'1W/M&8'>A:TMLP5-UW?&]Y5!*VVZ=I,%
M6=S*PDS[#!(#VB)Z\"UD,2ALCXMZO[':P<+D '9]M?50Q+.L#)K-*YJ"EZ#I
M'.M#=3^I?[#26+&K\8X!,VU=,3NT(P,=X>"VO>Y@O:W8E(4Y.S1_S+3ZVKSW
M'NBKBDB**>B+SH+ 7;XYEHP2)R![A@NX/V"JDY=Q.8A9TX"R9$9[,G_'>'J\
M>$TQQL+UFSV65T57^AZPRX(871[%,3I^K@*+P[QTY"\_!8/&Y*@Q-FP%XV%R
MXOE@IM^$KK\U<=P=X/$%2EQYXZF,-D*F!S]9VO@LV#^/:*9/P18N+RG3<]&5
MCAL+E!WCCA/LP^0,M)X?<[R2(RS>&RL>LCS:YZ&YP_CTGJR<04K@HH7%"@<U
M=-5WK()"\?^FMI*5^9K5#DE=#O=;M%1R9\\2BG+3Y_\I[.)Y9OF;37(S.0\V
MP3[GX.1+VU#,N^$]L74TV_E>3(&4"5(Y/?;>#F4HT@QDCZN2?YZIT=\9.$S.
MS9 V#;E@DSM]>+;F_7.F;7P'_1#!<0.(+O8-!HL"Q3D"KY[KWQ86?6=:]>."
MY9%NY57B:,P0=[,O]_-.G%FU]+[ BY0+GZ#=$P4*5"4%A74U%^, 1>\;YJIU
M]\M&W"R.0^450K>PT8C1P46]EH.IXM\-+W1<1+U@".$EA/]1(+?Q+9^G?#AW
M($\*H08!!AZ=J B+V C#*^K3NQ1/O<A<LWQK)^P;8HS>-2?;?VB023=[_P ]
M"DTQW=%=22N"K:0N8 O7CR=K,8@>8/PT5#ZQJ+W"/:"B6%DTP,;]ZJ$F9Q^>
M RN;KVHSX!8MP/LH@^C$<KP]7V1ZAG@'Z@^J=J@Y@+=77'@I^T!TRM]5Q]U7
M]O)GFNC&>=?1"YGUE'Q97D*GBSD-,D*42JEH6" UMZ#5H\BT[!C$Y7GGBCU/
MSV]!:D6QSQRU%A6X'2,K*>+.:FGLGE^466\_RGE$F%MQGL:XV(4_N._2>0I6
M"M.?T1(7$A,&B8("-1J3BR9V!'<AD]0"]V7K,LDLN%X: 7$O8A\/B5!H+L?E
M[<JDG.AK.DXE-"NLN'I= 6X NW<J,7W7[9?I9YV[$^^B%6$Z=^*#@E]C")-7
M!CF2@C77RW>?$M>J:@*;'H&%4EMA'H'?A\87"\3/@UMRYZB-,2*'LF>7QR+%
MQ>EMD+%@*/D;;-'$7K&:)C77,WJW#Z>.#> 4H5[*#)WKC#'.4"D(7>*X+LDL
M703Z>M,_]>=ZFA6L]_1M;W9$P .1ICM-J\T/TY\BC:VD2:B!E[G[WQ10-%XW
M@.WYS@^5!8>"^JL']0-.XPV=)!>J3,#Q7_-;24CDX,$<[4JZT_5ZRKA&/;L0
MROLM*)EX,):!*:ZWL35MMSA]8?%]>II#1"5T:4BJ@?2^]>:R9*5#]C,(D/]!
MGMF4O-9AY7=>\>UW4S5F0A_L';ZJ!TK)NY9VM,*\-N^%0J$-/]=9?_ ;=#E8
M,]MVOEX)%G[OR*R/VFK5PWVNES+N2< RS+ZW:_(7DX_0O6-_F28^*-IE.7CW
M=,U%4Y,WF/_3L3D'GGI!"M!DZ)%O<VP.60*NHRI@$)VL+6?1#*:$"L0JOZGI
M@$PH0Z;I%F0T1YYW^?I5!@83TSMFXM,F^XSJD.#@\Y@RF9]7@PP],S*SQBR*
MSV6R=Z47NRY/I .C9U,6+GM_S2.#H0_M'B:G.+1G>^0V&_?_HGIVC\Z"'548
M[)E5+]K(VQ "U5LO5(^9^!K0LL//%_)Z$>4]7-=/I(<Y7XE7OJW7%IR=KKS/
MM=;U$-Z^]GN\-Z#!L&7N!*=8:0E,.5*ZN?;T]3HP"ZBLON>8^KRH?_7]$'EV
M*\ ,_O(>53RJ('!<%;*:GN&0W2 M:TT,RS!HO'):S_6G>OL0F)3IZ#^G\77#
MC.:Y4WV*]J1^R;.IUN,.$Z?B_HETF_#G.F47 <=?,'2OB4<YI_:6+:: LA_9
M7!=!94GHLB9R#M^TT5690A:AHE*NE88;P..&WRPFU2CJG4Z8K*! "9RZHOB)
MZ*:3N(-NU)&ZDVY3BR$Y7<8JVYHC[X]ZJI\%,AHS@3.A%JL_0WK/C"<\%M?L
MMO-8)OC0W X5%OUK9V>FPWO. <=SF42O"OEK/K#PT!F2O6FK?\R9EB\3.PM:
MO0&0: )5Q)I/6!*KV!L.KM')Y"P[>\U,BN#D=R<RIL>3_K?]JTS#-"<7S#GM
M-N0I)F#MN.J:D\>?X%$,D8F2JBGJC60/&.LJI#A\<,FBB8K*2KGH-!9>ZVGQ
MYMP OFZ["LJRRK4C4>+'#$UKJ3XE_?/BK7NV1@%E7+ZW"ND>O#(R )8T_O@0
M)HW*)9YYT^#1SCQ/%K];E7U[_WGO4S^?0?7 QY_-Q--_$;&N",-T1-/R57=]
MFHW:(+VDKUC-T(3L^@X>76$DX81:WY>FRT,,49\<#L+7]KO#K2D/]K*95L9Z
M1+?Y=(M2>-KR#/?I*]V_T?"TXE$RWNKX5/+I/#?CU/[C]91/]'_YI89!\6%8
MI,&2%+*=9^AKUEZL?#1OII@XKU_8>L:NG@+DV1&>\_?,YJ+^K]2Z_;B<[A,^
M<6DMH-45K33SU>V+'/](-'4+\6K#MFSG\^FX)[2<%F")1T5%=6T^=][]\@3<
MTAYK-O&F%]OGA!:%JUN(K6]8CFGM1U;#*CR,8F:7QA?LO#SX)M0H7_; 8C6&
M1V2YV6B>[Q*WNMY[!41H\)_/;UZS5O0TM/I)"Q*[2HNEA0C 9ZI=P@.&QSL_
M['@YV9JK.P8X)PC5A24$)(IP"H>MJ9FFIJ[%5V7\T@>:+7P_EG1.N++0O#;:
MC<NHF4_7 IY*0B.^ZC\]^FWJY*?;+$/UX64@**ZB3*PJN<&K& [;4ZW:0RR&
M(OHL\++QWX>9PA&SWQ&BV8&01VN(U&&VUZJ)822?GAH32[_[62!4$5<^';@:
M^7M<9[43W%1A;1P>=\_? \H&G/0;(GR/ET\"92KRQ>,;LP"N9]Y2)R5XYKWN
M2;D/1FWX&FN53+<UHC:T=K(LK!?9&L)Y9KKR6,=!;9)[99\K")MN0WE&"(B*
MNU\/B\"*G9R^$L?IXK0Q[JW329T@T;&-O!IR@=P7&<MXS:%%5M5G5@N)<%$%
M-U^A+VZ%JD;\7B33MM\\B; US7?67C*MT $4^!EC;EX\/2(@NO!"XX@0RKG1
MXRO^X4C-I7U6,(>5F[=>!#<%:.KPT^QE4$W9PX9&;LZBAH[KJ)38EG#Q/6\R
M-WB@/'5J3ZKE(.)76B.B[9R<O>)!_ ,"6L'+I$J\^2Y3T$,A2H^ TIW=O;/&
M994,00GKM09I]Z"*'N/#K:UAKG'^U:;W9LLD:^S.:D>S#*Y)^XB[#,F^7WJT
M4 ]0X,R? 6N0]@01_3J5 TP!_O! \=8N4]6:PZH:*\^65!=Q+? VXV-G6KYO
M&_EM;;_+2)U;Y4C6SK^:^_?%^.TR##G56/'Z/F%/\V3VGVS5W#^^*USC(W$&
ML 7PBG%^7)W)1L>N6@[X-:(@(#]>TOM!,>=J4W5P<Y4V[Y^SJ#HU>A58X#.A
MI<R7B.'5A-U?';\J(@-IR]0"3AWJ0*5ULXQ:(]<C"Y$>E.-B/>TE30]@F:-F
M2X8<JGN5%:VK<@ 9FE7%BN*45'A\[TY"[(QRP;3@GE^[S;<9\>=CHY#I):L@
M)Q+06*:.KA'=.[O!Y*;[BF+<G!_S R_33GP:[5D(9JW=0B#IOB[N+2'S/+'1
MX?H+#F"*R/E'C2XF<T69XM\JE1Z B(2!HI.I@?"%;6-4C(26F<5Z\Y.)9PTS
MLC+E08EZ$.6*]^S$K)EI?>=4K#]I.0>4CIX(U_Q\ZAV)  1ZI]EVW*_S]@G-
M._Q%BJ+!TNSE62+*1!3#M05B2IZ9=HK\]\/]+YLS9QCZCLYHHQ09';AE=A-7
M)D2R)+XP1NZU"2+O.=];497&7=X'^O$M,(], :OGE6.$\YZ7_I+59!^JEIJG
M2L@Y<T/+W.PL/ J'B%BI@3\ +(ZOWKWO&]YZE0$HDU;35/%,ZSC_,7*^Z2=0
M?I_P]])X16&RTUGA\]9=Y>#276?V5[_GY(=6KZ&@>;K4*']/Q19?M#GB"N6U
M#NN]/-HMWFW,7VJV,(+!$K4GXR/G<\;D&AZJ^R%=HJ8LYWJI];=]O0%-/ 1I
M^BEI=W>*C8#NYR8Z$=56[10U>:,C89#LW 9QS4_;^UY%2D3V6H\=A?:$5-C?
M^S< V=A]\H78FH1IYY$O^QCC]H,6=*JKGYP%6'4:2%BU-\.FR->.&#6IDS\_
MCAD/9GI'BB?;'*<KW<SRK79/>1#RP !H/H2";,],ZJA5N]3V6PQX4*%M;#'?
MXSDG8%3)HJN@F$\/#E7D1J\;#<I+SH:%^G/J64GB1*<1B_Z=&RT/I3=!>8O3
M)24)<'LF7@P9-!]ACW]EDQ&/L9EE"&K_+G5EDKQR[^)VQ/8*E0#F7'YF8G_S
MJ'U''Y[3>GK5@NZ[L%]8'*U)]N*WG\2R>%$/<<YOO>2#B GBJ^LJ->3:+4?(
M,MG]9+W?/\4).&;4/+,J@BUT^FFTC*[%CCM*@P_.,8KB^4"%$[_T- RG98#2
MIQM ?ZC)I2EX(_,1F"C"MA',-K)[T@]%BSCXDZO<S=L$-W %/7L%?9L!(,Q-
MI$RQJ'Q]O]_)T+27886(9.8\ZV@L>+,Q;RW@W*2J\T#KUO,=D, "-TB,D-NE
M/GX)#GS>T,1NKY0"A%A\?J;U8632>\^RTMZ/V8T/!O+,S;L<.D%%X(YQU9L'
M"\ZL^1SW>7' 802$W!_OFVKG.[P9A)&D###6(0N!/$F=HCXZ=-V4#W9YOE97
M!LY#K3L5CK@ZYL5_;OK+26AU8!::$R2=$F:T7^W,BW]8)G1A4SV[BGC:!\FV
MEF4JIV1J,^2<X=F;QV"*1=OWM>27-8> #2@SOZ='554-]YP<[GZK&ZU#ON(E
M.];T?N^(9*/@%0E?[DT)O(#KH\70N%[1*(TS^!DOPU#)@AGCYHRU4WMD3JWH
M^Q6F$E3'C ^Y^L_74:O&SKX/\?@L\:L-S\T;UR=4+O!RZ6=W.N7 (@::X\]W
M5G] :!UL&F=UF!8'[S6KUB<\::2[ 5A*$+WB_%7(JHA/F>V5/5 1[/'#C6-H
M#7:5$+OTH5&'% 'MA- 94-P]>\W)$J9.DRP@OD=\_)MN5\]@.1!%19R></2O
M._.RYSWYY V+>//%\2>!PD!V32&AHF>M9O, CK6XO6$7MMNV"2&OYM4(I0]]
MW\0 D<977&/RZW(:8T4HQ[R9\<4UGQO 07N#(&H)? .(^'4#6,G:N(RT/KC"
M9DW]F>'.3,7G@L>D%]8(&O1!YPV@\P7X2(M%MV*!):P3=?]R6$9S[\\QN?_C
M!>0+3-KD4> CUM,/ 1ESG<,*2Z&N-L=?;P"8ZZX;P(!H^)/JH/ C;$_E;:%=
MP6;P!_#7LQ^=ZY$W@.NK-S> %-?_G$#TM!W"!CO#/T?5[A: OQ/> *[.\6\
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MQV^'.%A^6*Z)BRNE6M%OR,\?Q?J '</L4!2$2?]NXP[!2!A3"87$2(CRN?*
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M8=K?=:*):-!E<#.XXTK_WZH:DNKIJ+I>5)T.&B3#GA\%:Q5'U8&1W*H;Z3L
MEA0#2:;B,U[K@OG_LPCV\T?'4-T&^' ?#^5_Q4%CG!J L;-G8P'3D$,@!8JR
M&M%J<:CC08,B[)!UEC-G+Z%%!>!=\.88&K1ZFS-_!ZQYL2V]9TK/1:#QIPWM
MIP4*F18(21RN/7FS9%>V'4_J0&1Q"Z3@$IJ'@>-C'W5]Z?6G[;"=/DU:P+?8
M* ^"LWJGS1\.7J(]"6FR+(T][W3%,#B&41CYB-?PN5J_:H2=U=/G[0_2O*M
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MT'NZZ(P&>4J@0:VY$*MO/_N0$]7VF^?6IBEN@&?(##YD=PT,S8'\8/@] !]
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MG@0?6V&'A'238S08;20_7/AG#V(4*B.;L?'Y(Q*"C\W5L2*2*")L)^>NZ?[
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MY"Z <^AWP$;\CM=/_&B LWM_&P(D?Q\";OS=8&$U-XK MH5 4<S^QRN"K>?
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MV-,W^]%(!_<PJ'*V+=/=+HR+P,XC]N<W<E:(IKV21G7XCI_NJ44"E>'9];7
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M,6WM"?I6NO_/JD7^KSE(GH__/U!+ P04    " #<@%Q6DQJ[*1DG 0 E;0$
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M\6"+Q_!^. &6V"5[Q$42./Q!!7#]8#0%? JQ:H!U6?&C KW2$U3@E7\V%;A
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M]0AYA4AL=:@93H1T4T.:\F,2AKZH!'*C3/!=OMR,V@Y*'_+I'4](6=-0ING
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MT 'A+;.J6_' #URR]/GJZ/5Q22#M22=[5\1)=@<<WY;AXAR(PJ*$SGX$XMX
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M@XV,W)6@TY2@C(*5N9*0W+$8+XZ]G-?W'_P6HA!=5:C@IDT1<% _N%QZW;(
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M^G:T=>*@-4?BB>/9@JZU=['[?F2?9=INK5+O31Z_URQHU#K#X2Y+C#MOYQ!
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M3$H:<L/[Y,Z$[S2Z/S:X6EX=!$"<<,;_]_"VR']-^X1IV-HVY<, "1CA4:K
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M\<:("XCMYF&!]BXM\F)*=:I!_O:3M_4UMZ+TDR4Y3DBP8T!Z4*LG0"H__VS
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MZ"?D4^/$?M,!8AN=DI_062;#7.] ,^6PK:?IZ,/PR[ =UQ!E\!J*R@>GW7D
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MPCT(?G&?&MVI\ ZCV _R<J(6-@NIYG(;ZS59</&DP.0[?[=A) @OM@#K M7
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MOL/;M7N"U]0ZEA+<2:]^?8,J4MQIW7R6/EG%"(>3N&AJ79"CN62RQH.2YJ^
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MGU_SZ(TB;G5FJ=HH"N>/9Q??E3R86T<. *L073 6@CGP$H1CPLVN%E<86>X
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M(2EPPWS6$FUEHYII?]$86*-[Y>W3I%V7^:21Q-B_?IN@=O-3%[\0-M/D]N#
M/?I/318GI;32@EQG7IRH5$9K H!JVP"^<P&S;$?+@3.62?"RUX?H:FB8-)%O
MP8TYA]G\;BY!W  ^OJ^K;!+XLLRU_$.-S!E>J4W9FU>KN))-+X_'/YD7?0-/
MC//A!^4\L"'HUFQPR_7"+VP+Q[54KWH9:)8)IGIH\S^K9;K0?K:)[IKGS2E^
M8=L_[V\BB'_URU4U!YXUDQBV.FU5?N+OA8)X;L\VFWW4J[^U]A8K/OTR-TKD
M\&FR!46$/["U<NO<.3H_2 9803]7Z/SC)K3I)($^<N643=]2Y*M6/!FP!" #
M=F![%=>;;/ZV"[WP[\T+KG?[B,H$X (T@E\ IU;^>2VR7Q^7^N<;W96O)V4?
M':;L4@7CII\"WK$H%-&$7$.P!%,33#"(F&;)"F>4S;2\VSGK3Z<<:U)?0S>_
M*OL"9QMWC'\U)1V*G^F5G]0'?YS#5,$3LP^@!.&HMBQ/,\28E JGERM<]Z.T
M5 :(Q2E)HJJW.ZNVO%<_&0PX8T4&1(+LAZ*":0FJ)01Z#6QW=M*"E0?WE3%)
MB>=ILSL&&BB2?2_&6#C80'?5C1O)_KO&Z'9*8*68QJLX!#5!6I?@/K\E?6=8
MDK7SP;"+7555[;T'85QCUZ6TA>;/] EEYZ=8KB2>*!%$[^'J8IOONGRVB-="
M5B(YW[(O)UM8Z=OIQ:Y8R')YUKQ[<,?"TSX+J=K"KFA7I1942V$PII"S\ GC
MHV ^TS2S-YC9G1W^(6AQK2S7 _Q4HM/AM+B2U[12^18F@=[OHA:;?I%A_)TV
M(ZH0P/P9@V&]'P:S83$6@I\(I=BH3M!E""\HBFB1:^I\K-I)$^A<?RAF.SQV
M8,RM]/Q*7+9_!?W"Y"8C-F7!)FZS63W?3X.I^NOE*2N;=<6 6#.@:417U86A
M+X]OHEHB8]CR4U-HV&91*AN+;ILYV!-\S)B$M(K-PJ\#/G5=XX0)/'WQINN"
M>M]=.:;D5WVBCJ\\_)8FP-%0AUA0!+!: ;$ C.!GQ=JSSDS7Q^J,+R3K@9Y(
MW?DH97HC63-9LI?OU_S['X;/6EQC;BU_:S!>;;NMN,E2#+F#0X1MN:C1F!.%
M1_;U/":-QP^<ASCC7;6OU$'E4*9=PBE]9D+T*6][V.S=8TY2,(J=@T#,4*@W
MF-$O;&CK6 KN.I%>.^?<O7I_AGTFPC3(,-S"T$@GO\#MJF9& O(,S@YO@U5$
M,D?X\-/B-&-0Z9%R/:'E91$'@X@TVWM)P;O7.#11^0=VV85"+^IM:,B =EDU
M.@)]=Z-U0X'?HV.TX;"; *(ZM5FC1$<@0Y0I3G^;KI;[;N=9YGL78/ZY!8^T
MS6[6:S354")?^^Y_HN/@\F&W6T0 9P\Z"I43T:SWXC@RHDRSTMI">*"VQYX!
M5@=Y6''>T(%!1H;IK@"\AH]IM).'+_N3+=VTZ1I6&%XCGE6I&<-NZ/ -P-Q1
M/JPQ6\;O\,ZO&L] T%\, G4K9*1'Q$W,R8_;3<I_2#%LCI#:L4/7OF9]*NB6
M5;V\Q9A4?YG!DP2D1)\5Y )VKL&YJ'M>S'5;(I^UHS&A.*CH7MGM2VQ[*BZ$
M8A@T%X8"-_#_4(VY34DBKQUVO^!5[;%-%^G]_MZX2RC+>U7J<O9/\ZYR"?)5
M6DL70MOEU"XX!F1R7ILWM;=PO(]%@8OGAFPOA;_3*!UX>AD_E0 N#X2SO<^O
M?:Y4V'@+')-#U2R(0[33= :+4ZAU^>^/!FEU+)!OJ0OF,C>&WRF=>Z DY"7?
M3A2FS#4 <ID 7.1UN^CGV<Z1=CSXKKM\?'9Y_ 05V(V/%F+)N?>9)<5Z2(/.
M0Z<O-DUR]G,%>![]Y\-?I"$2:XHZ-NV#5XN"<X-;?GS%BP9_A_<KVCS:5K/1
M5[Q=QR?TG_@ZLZ^X6XN?9A'Y%MUBC-7DQVH2E;N.73\I))W;M1IB.1%J[WI7
M)?C&6\TNJ>71B,>-._)+$V0 5MMFBC1Q+EJ%WGU)^D'B6[@Z-]]KPYDMP5]Q
M/,>W8^ &SB]TWUC_7MQ'AU@S#0<SS1+.(COQ/-#PG4V'45>Y_CLNB\FT2<GZ
M#1>"!LJF7OO:K]Y::4X $H30;<I^J9?:37K?GBV!1<.?LC&%,,--AM\_+M%^
MU=XA[67T<]_"C?%W;8!WY@MQW0NL*&JI'P9RCTL4;_X%2<?C)6)%8O\%FQE8
M<'P.S0(A=A%VT7H=32^,HYGVLB%H'>ANN+'T.1W7QCC(EL-KG 7.**5F98+2
MZ"J&Q6D!X,#<JF):[<!D]_VZ]8]385TC>:+7:^R,U))7JO8.GW/6?B(IJ.1T
MS GCTBGBDV$-)5_8J71E5$75F2U8(ZTFN;C*D):!HZ CO3Y>D^^Y6-3W(WNU
MIU,KUC=.TVN&N)"8_4DUVH(9ZYO-X::X^SYJDO6F!W;<(LS58LGRG.[)/7??
MY@5E*ON'.XS5&(LS&SF5ZI(!E(!: NNM<FGEM8V0 =\1Q.K)XP>$42U*G 43
M@)T!\)8E,J#ZH/:+U'O,KE=Z]V' ^TL=: ]EOXH7-_L\,G?,C 35;+ZO#O*J
M6F#J(N6A<=:L-3^;K;!I:*,1+^=Z>8?:2AS-^[+*S+:T @:-;8$^].4(@3\C
M!GA5)V)<(QQ*RZ6)Z1288!W$.H.+_OL<=EL"N^?D)VO$9V7-" [.18Y[=Q:-
MZJ),8@Q;JS_J''$L=.S4TPT(F2EH^D J(.W50YO!5.UY1,;8!?ADN[*D5OMM
MNT]]7GTJ]U$Q1X^Z4R6R%YJ'X(*R:<8O%WD?(4]_3^\7L(LS&KF8VQQ)DP$"
MBID+_ 0>FR ;DMD&P4>K#TH/LK-A(#+AXG/>RB6&!'BL'W-SWELDL3IZ2U^_
M1"J7,%Z_E[NNYGN>I7";I WR:U(KQ"Z/'VQ'N2@4.C/&[Q?Q.[_\NI=V7F43
M'5J?\";DS)7%F"8-ET>9F)W;"=:UIZQ*E1_6V3_GZ3+3F>_P!T&QU_J"^OOM
M*;#YRO_+_[WV)_'4\58Z@H,EH2Z?L+ZAMP<Q^C*E6SAE$Y1KM'OE??+:<B1+
MK>?X^Z1?DT8:G,Y/E:#Q" KW@K[LUQ, <O]^O*'[>:[B2V%EMBD_RGTXO.O[
MK[544<>V7B7V@/YY& 7RXDRRU:+TIC"SZGIZ_'].2;/FR(Q;/J@\>MY<&0G8
MIF^::RRYMJ=L:FP1X=$*((@OY$201' *E5\<$;9C$+L ><9G;C6ZTM.B5"^#
M*KJ?A ^?371:+RKPD6TC7OM,O$?@PU9C!O'A"V<PS&P;_#?&O/6H] )/_/*:
M8CQ9D;)-.B5%@!=B9I9OIG>3&5\%]P6SCZD(.Y;R>7;,R=?@%+ZM!9434B@R
MPD6JP3W^BZ"N<@/QPS.;-*4[AO&W.7Q\W>QSRP?AS_SE_QRD_OQ/6RAG+8"$
MTZC3 Y+W[X-5#A#NA/ED@[@QO)%RZ>?$&0TVDYNV_XD&N_.^?V]?!;)Z7]M/
MI%KG5/CQ+$/HW&6&Q16J%C\$41)\$?I3!WRR .IHD>#C_L&(;(@PRS]0CA&/
M(@,BBC',Q[3:9 !$]$^O,/V3+N ^:PJ) ,96($H,=TFMFM83HNX:KRE8!E>Y
M2^&CUT [;_[J,G;R"R>%&4#1M"2V((/"](-=9N=+];GU4()Y]A4RX//[G,,.
M: 3P[Z/4BI_T'Q_1P*-33_2"^P/ 6R8+3:J7NGAV8FI.Z;@5Y]8:]=8MIC?$
M6Q599E847FB\;.?E9AZ8V4<66$P7%#1JL JY:WYA87E=E!<"V!2/^5?3+SPP
MKZW-F>RUQ+7\P,0LD '_.&%HQQB.YI0ZGPQHO42\]F_3!\*C9_0M0?]HKL2_
MK\6P>/D4$H[JVA:K )(X"M^"?@N+GF)S%K3^-N8OJ]W=>N;+[FM"!B0& H\/
M@<>73++^=D]QAVXHBW<I+R-[;FL28_?;-/7*X!=[EQT*/[,ST^O+U9!:U?%)
MBK__Q7U@ZZDJ"-B[EK)'_WIU8L<%8.F-)?[_"B_^/VLO-A/FOWDP[V]CQJ_[
M0VVNX"O_H[#-^S>[!)IFS?[/)/HD[5?(X\FO8^7C<&ZZFI(+OS+C$IWJ%H'1
MM^=R,+./+K@M/?C2F,1R3_H[U44:G<22L94_001[6>8U]J^F9W*@DVTSV9OS
MOXWQNMDIC.!O<?1/X_YMP:K_%>%74;=P2 Q_0094('Z:Q/\];T9;:0@QAUW9
M_$UI>)_L^_6_\D-N*!1OBN>P1V5>:U#F>9+A4:7L));;G/>Y%X<@A@#_@&RW
MB38.:M[P4X5=LCO_*_>;HB\A-&'^&]9:?UL\#$QSSS,"XSF6\6C@7UJ]L?4O
M'W*?_*\UT_]Q@?:W@Y*P6W__G?%@89>5(Y$FT,,M9R@!SS6.EZ;3[^-3C;B/
MA;-.H"=["PQ$3O^#>QF=_F5<T?\O&./_]>'T=Q$4]?<TGE+C=*KCF0R5D'+-
MEQD2"_IQA[LKC@;\5#R%^][K,(]M9QW')D$*:Q(?5+R%^._M_-:$#4PL&<!H
M[MC3LU ^ +L"$5/^QLFGU>(_]#>:8RG%[_DUO\S3,,.@^C_D.?_FSOO_FYG_
M?U$ _\-IHLG,OQM3W(%BLRXK9T-<?-PEM+:0S"V& C:'9;7Q2QUC^B[3QT?L
M/$D-B']M,';H7PN,_C\UJ?Y_6/J_LN#<+S( N0G:@>W!M&#4PZVBSG4\W?EN
M10_T5S1L*_W/10::M$R>5WC_>?)FRS61&KH_C5SW_KV#_E]=3)X8-#&E_ FI
M 4:*A.\=!%'AW$C:$\5D@.4D&:!N?G3<,@,CN(TM=D'^'"?XZAG!WDMTQ![&
M$I_,#WTCB'<I6'.,K]3'J16Z/ZM#O C/6A9P2\WY2O74>Z79/Y@O>(Q'(L5Q
M@@Q@4>/=,);-"C<=DS.3/. U&D(_N&ISI5;YEB"Z1<:B3OWW,0X= ZQ-C&P%
M$MVQ.9T;LAP-&&D6)^WGOFR<7#RW;PBIY(LS+B4(SB<E/V@;JC09 -9,=C(S
M$Y4(?5@?*V;MZM$7DZT""@5%_:S!N[N8!P6^2;]VD1*O94,S 31L5U(<7P:!
MK$47@2B832/A"X:9GJA&@"HF%&)CM$[A'L<#YO8<>P^:1B[$YAU5N= (+M/Y
MB;14-5/AKR1S-;O@?DQ%SFJK79T;%+/=\V=F4-,^=A<1HPF*CR8#7- ,6B>R
MG;BKDO+7!!L^. Z_7 "TNMSO6PZ*2P@]#$^&OG'=9\L^?UITL$RHS".H8VA"
M"K"29$#TYS0KG@7YMW!EY\EH=6VJVP*OWDLK^]-4RN\9QWHR$P4:@PL:09O7
M0(Y13?!W4KUYM2(:FBH SH&=Z80/B[,@EZ!)( \),#W-?N+I-_ PS]6TXUV*
M@I**BR!(_Z#PV:U/)G)$C1,KOT0C7'J,%QD @"@TXWIRYC^E58[O1%:R)[@F
MJ6N?:WX5-WJ;JO?(?]Z;^X Y/(=]'Y9@P^ %Y7@9+^B8,<;O=4^C*^E=MQ67
M!Y5XZ;75DHQ=:8*H\16"_V*_ Z]T.22PK "CB-96&0<IMH[ .8F7:(7=IB S
M]KR\LU##[+:(C@^,_2%:5/'M9, 0VT?]5\<",6+YIL9D0#QTB9>23"?G8:3X
MY&_BT![$+B.6##@-IZA*S3XS\&+BP<^"ZAMBN3%C*>\(4W^.854?AF[+[UQR
MNFEF<3]?G<-3=3/$G4U[?":3@=DRD\D9N."VQ5=(V,$[5!$^%4]#;1T]'9/7
MTV_4S$&GGB4&[WQRVE8"W^WK?DE\0;"EW)IS#3W=^#7% 5KJYP9NN6W5M=8\
MQ6W'.W5F_N;NZ$J/II*@*$@.9='_YY.MIN)T34K8I@;Z2:<95N1OMLLG+SXR
MU@RICX)<K5R1NI2)1S?K84<?8]&=0Y<L.\]];3QN5KQD44:T&'1W*N$10XOW
M^J"X')+/; 1+!(_RY$2V2JC/VYPCW /S^A50G+-E\=OB2>(C^&AY["MUH0'8
M7K77G0:DJGCH:=W.YC9H_F-&=&C>#?3+8QVSZW%'9:,6_K8TGC_C AS@CL%#
MTV4@5UB<PG&>4,8 2C0J7QN ,=3U9WWQB*9_A7WSUA9XP,2W\C<94(U$_E93
M\8,:.LJ5PIB=27R((&FSX6U[,^'1[4N9--9\7!>-D RR:];A-FJD 0/ZH6EI
M?'0#W-Y%"?WRG4@7ZER7#T,U_O)V3U"[ZJX'PI4,N-"YN!.'H/*R^+@CN24O
M&; [MX0:^-DG).D$Z3TL9J#ZNO3JHD]#P1AD;FNHX#<LMEGZ1,I/ 3S=V44&
M,)N &Z+:=!=B70+ S!I!,K\LK8]:'Z2.0@<C?!:5^J@3SKE_(\ ,"+Y8,)+R
M:R\]\Y/[/R]AQJQ9ZYHL/O*X !_6/]]C512J*KJ@!=L!-A3:>AZ"[OR&)8!>
MNDWIMH, P4)$5@0VHCF#UY)P"*YI_*;;9Y_X^,C>]O7ZMJ=0H,Y.C_NMOB63
MX9P:,B!1'A@)K*Z+AZCG,Q,^KO'(#PZ6LL\()MDI>2A'G* C!& M/[9C",AN
M:!7T#43ZA+4/Q_]][TDXAJ\P<K2K#S.T=8LTZ^Z_1$O";[+Y*)]EB;NQ,WB7
M)J1F!X7$CV&5_2:&*[;DF</3;F_A<U;D'L_\F(Q3Z&6)-#+W:'/@30T2^]8P
MA2]G?W+WYQ;DYI>IM=J;_ASF$%H7-P[,G.7++T8>VJ* ,\F>QFL<IL-DP)*D
M,QE@E7(4T[*X<\0O#SW^\\A775Z+(OC>P6&G/N"5ZX>)B"6_<3)@8]?FE&'"
M9A<7 $VRL>^C4$Z#_[ LM$3A*3&?9'Y":D7@-6#\,-M3"M=9,FXE V"PTR3G
MJ)LD*H4ON.PH2D'XD87DQ4V3M)?0!RC0JC6O]?+?_B*9$8$?N]\2PF+$8/?;
M_C-OE!(/Z"=I5WPA VPO@/9IQ<_7E2&6,M:!^(OA9,"=Y*K2J@.;C_HW7E)@
MX=T_']S^'PYR0PBR9(#0Y,-C2AW/XV]F:MF;'R*F6,FNB9+B O9DP0O2-GNW
M;U"*TYB^!OL"7]3'X!$;W#*EF".D=\UW8PZ@*%V22DW.X3))UUK?1HMBY#,0
M,D VK*[GSQMJ1O^'D^/_?)7O1 )WU=;0!S_)@-\BWYP#%Z*(B8V^IUZ@8]JR
M4BB3=5P1Y$'[?\HG_Y.+/AA(\?=!^BF$XO<O=,<O6E]0<(@858;8P(!.+YB,
MRF-6FI KW@NUMA1')7M%L&.EMY8I20LC*H")QC;8=V3 ,^BS]J83SKX3"B+G
MN*J@T]U@ ;^AMBVTY21A0O))^T5"#W.D+X]0KK;\DL:)WJ\V7@;U_A<VGU*7
MI.;!5X AA4@F_[*J<0UEO8YUW[0<1V3Z@T,("I@[-B_,\/76IXI).;;-A9<;
M>,,C>/KS?E@2?I#]2 .+(+$#B0)D ,X<VH$DH?8L0+]RGIU(I_>@#Q *VPU;
M(RUY^)YA%5$*2$?: .9G,2)8YZE9R]4;6>#-JEAM]Y\:*Y1_S0[!S/>^M0HV
M_KI>C[;CO:LQC9H]&8T+VO&<A>\$^52N/6N6,70?^Z8VY_LI&5%5=6A[+1#1
M? ASMM#;&4'.U9AT :LYFK"+"Y,1)$&__H6?N-'U.?Z??%8J=UQ44E84EJY?
MY1924;^EU!/D-T[0/Z$V#_Z)IB\CNF,2N0@9B]US0B%SW3[)@EJO=# 7OW^W
MPC]]71'.930=-PF+Q&P:7V>;8&8H,4Q^7U8B9<1VY#:P6.JF:S&>K28>_KI>
M>\QO1K?PD=3-IORCS$S_\MZ"7/T)XJR7UI2A21<:.T*2IRQ=8!<$+R #WJ20
M6(<(ZHA:E8D3</KRT1P%>%L0P";T8>70W%%IY9_M?M<A+-K\)WSHK-^BR2A1
MR]&;=YW3E^#GD'CEN['2N'8?]9'KLBE?0=1<N:/[\U<FXOW??N0NQQ7LB-7O
M6?>)XN0=@@SVQCI@-,,=GA+];,5JCIK\&\GIPA73-G2^QL,(2>82,5@FA"$?
MVOZH^3G2YD*/%F+(P;!9E'T?@7T,CK5[:)^HK\89X<+7HR]R [4IJF+G(UY]
M:D^ >K<X&J"/#',49OU]]F8P9("Q?/J.SQ>>::ALS#*Z4+%[N7)_EOWH4P'!
MN>.8HT: $%U*?(3E[!KU.-0K'[K04!T7)9&R];A.PL+Q3N^ HFV=2R_P\T6(
M'1;Q!G(KMZ)E$<I(7SJHQON^J:$E;,!)QQ":+\"Y<#E,4^:\>[9X3A2AECNF
M:..NP7+MGE[I?K*33.R1_-1O+QR09DC":YSV.TP5_W7$9X-;5*P/9#AIFO_C
M>\P1%8F.$_,)% .]Z 6,HG $GR2'YX6SSNF^BB;:;,P@2MK8OTV_ZM%E5ZST
MZ8K[D+HMSHOH0''"*^> N%W_C(B$>*E/$/ 3N:LF[H?VOU;_=!65CP4W1+?W
M<.+UWZ<@NC I[UU<)+U@Y0>;PNWPUH*(GN\^^)$X\V4"V[1^ZD[YD45MVFC#
M_@'["KIRA_B))I0,V&1GATR=0(.'U.BPJV^%QETJFK6+(7=Q+<>QC"+T;Q]J
M?(B0>O(=7:WT6/'YQT@F*CO(Z%MQ6X_Z%U[%UT12'(?2)DVTU4P&MD=TOJ^J
M/>E\[^Y?L]L(SS1WO5;D:9,Z5=N0?KW*I:D)Z*IO;7+"3QH2Q+\F@-P*P*)9
MI>@^_)9V^ OYC^\9HTG?2TI6&Z@/ 0$%@?5TXZ6V7TQ8F+3[K'H.ZU(W6P/X
MS]O>BV=X^'NA)/"!QI3.Q,H>?"X+?FLH%KK[" X^7D$<\TP.C>\S=R..1,T+
M3SUM3AF=5]>/X_XH#!P.>)$"PVN9"QI^L%@RP%651AW7 _O\,IB-$+'8A& >
MQ+L\LF%\B7Y5]^V#=_22P]UF7Z.A>[?#K0K;$"B:SIP:4,2V/(AYT*O<[O6$
M[X3)-][ 037OC<O#_(:DI\?8U_0?K9$NEM"NG; ,DVXH"T'WR9BK_ 4'K&N1
MO+-PK9=AVN.X3_8,93H+B72&)Y.VEH^B<(L/<#1(%\^%387CY(W;YW.8"MQE
M>\+&%]^'?.&Z]6QF+Y5JYB?3[,.=V&PJ'&=,ZTV(XIA7D);%MY%]Y?X&>&KM
M&.23>!$/@/76/+7<]G/:;ZNO[ :%6/O-;%C) +MX9@Q-E_@.FRDAMB>;8<([
MUAX^+H)=R:\--[S/!9:349KA#.F'5\XU[41GWZ8H4L=Y%W5+$G+2FPSX=KT.
M'QSOB"_=R&RL$(@5=.>M\O]-NV7!X[V*C\RA)AG^],>595OVUS[8E85'/5..
M.6?_FM.FJC!,JA4@W2F;OX4M>WTA+]I>X.6, NY&RHY_J\-0TU@FUMTLAQYJ
MK\JY4)>XU:SOBP%R^R$M1\MY^L$-.([\.@>]Z,C+]]@OGNT,Z^(0; GH9F/J
MQ>6\!58R1T%<%OD\S:IPG/%$(=(U(Y[9BM 2>@L7TQ 3KR+]UF?Y88^+K^0\
MR7F,%0VM@44&,XW6,+*.*#.*:H>Z;#U]F,3#[-FGVJ>2K"W_:1X6>ZS8Q<SC
MEW=OE!]C@;Y@J>%<5-UE()]V?^]LL4HM)[<24N62E08@>?9/@U=''9%"AJZ@
MF<F 7_+0_5>IH19_P/.=&T7\;_(@CA5TOD,O0RLB)#^&:K 9YZ?"LZ14/;4:
MJ]XW=OO3MRTS<8E?>Q*WFNW\@6"'5;]/L,!:(]M\R #'L1I>7M%1/+JJ3[A+
MNLFCU\CHD3I+1X+XM]P0%=F.G&_,;X@WBU_F6OGV'/\(76BJ#"SP\S48?W.L
M%U>:PBMA0:70H?UXNRV(EGT48G>:)@>.)<F-$A\V(J*;KV%<%*;*4HQ_2AM/
MK%CXW+K1U\!G):/-;1GF)S],="$@"HC4!+,R/X2Y;H/7(*MPFA=<PS''LP00
M^M$P>8!&0CP62[/EJ)BH8F>;K]B!B$5QM;[[@ACW$OM<73N?-:+T,2;AYL]=
M#55?T5ES/M]VZ=!C8)OT!>W\EV&[^M[>P@=;RYLKF#W]AG?+*QGJAYGSGJ$_
MW;6ZP)2LZ!KB)8"L$?5C LU8O<VZB6NNORN_[VK:"3PV3*Y7<;GN.5</>PNL
M14<ULV"VW!Y487?BB:9S7%0GKAMW1B+&*Y(?S!B;.-A\D!:Z\@QPZ[?S*)%V
M,4L<8Q->LP6]WY1 !FB/?[:(-1N]\B#JUR[S,^8K88P\D8GJ5(\(+/F..4!O
MYK=][L5\;@8CES32SB>I??^6'W;G>Y/B3N^Z99P/3(;0=R+OR'^6H(Z[O$9B
MFV@5D$Z43]S*,GEP GEMJ3GPW5Q7DR6\487&4*A2_+ )^+FHP'TW;V&'D<B&
M(%3B1A=JCJT2>YI*H33KN/4Z%*)+WMEK=&N!FZ/VNY$*,@F_[5(6K'&$RPR"
M%Z_5'O_(<G?P9?#EJ-.OD=40V-;6#V4H8WY\]TI,=HS+C(Z""A-%!_N&]WSD
MCY5^"PGRG.\MO%08\7RB;X23N5FK^NG['MZLR(<.V?#?>#+@K)PS*%$;QW1-
M^MDX!CN/;33/$Y@2+JH_N7/UK"L3;]SV=%U\PTJ3^36KQ-0_,=W/ R)&E$,W
MJJ W39J#R #!'A@98)-,(9$OBB@Z;I<#3@94]!&[K7&'Q$0>Q&FP+H4 9O23
MK*7!N^*;'^7T-9P>F##C"N<#($YUHXM0=L)B!QDPM25X'KOR[=C3TFVZJ^#N
MW/DY59D@YWJ8RFD925@/&XYWPM6]W<I$^A<ZRO*:,-8@E1.E1(:JJW(Z0E7A
M*D"\(5:SL")XU%H8Q_0)1X\1*<1.M\GHY</PA]$B+5$68]2OJEMI68XN1LZ_
M\U@PY>\<JD&@1+4(_?/E6A2N1)C&))XG%)JF^7NIRFHW-"1J8_?O:>H:-IL^
M\^L+"LT<\#>9ISN&X8T)=QVQ&WA];&$$_IN9G+WSR/G)9.<W>R)NQ?Z\,#AD
M"GL)<TC1 L^A4[I=(%J(VW-WVT756W!Q;;F\0FV);!'';+"(*<"@2CQ/,V0U
M)%R(R2FNW#ZQ4HT-7&8%D?UICSNWDE*T ;:[9#V[EF#]8_M>GDR73H5^*W:>
MR0_3G#@O&B\/I"6-V?"HB,(VS".6L\IJ6X5&S(_7EBV<;RW:R6C59R5I"<Q?
MGV?J:$3\*FR[/?G'MB;M/)QO]3$3$G+S4@*>:74S QLLAQK/GY"V_,!$MIX-
M4X+M8OFEKH"S3=9^AYV'".:OJ!8>7VW)HTU?N5]7[.T2:AK?SR8G 3?U<.G=
M*-@6+3L9$'U0;KUSC]#WU68CX%S$;%>R>@$<OA_Z-,)T@6;JH^76NL)*$_ -
M&5##IG9YDJ1(U,7YOG6;;&_T?6MR9T0R Z-=OG@B<"%G\^?9N_X%MM\3/\2M
M<LN#\</8,-)@#E4PMU_3_3<#P0SK'.Z0XD29G@<1^6VA0P,/S58G53TMP5T[
M4WOF%+$YGXE@P,#KQETK:B1?=';/7;&Z9KC.BKR:X1P5)_-NY$L]]7-39K'7
M]T9_9AEG)4*QG%OQN01$S[%-U &8T0_=KHC:57:4Q*C>=!$8F[IC=_E1E=*>
M0N:F2R%?U9V;A"'\\$_BK<5RF\YCK4B(YZ(%FBG5RAK,M.;L??[#DH-]PL@5
MZ;BLXGJL7Z] :^"HJPHO+F41U*D+I">0 9C)[NC]TV"T19;4P87<*NSQ-!$3
M&/<K#"RL\KEW@)[QNWLFE-[\-_I,L"!1>T1- /*8\!&[JM^$DURI?.;5P*$L
M&8SR84CIT:LI6-GL1PB&T#"&=:XZ-!(AA .:Q%9>R!6<=-C!]*]]Q$7BO6$7
MX>0)ASK_+_Y9+VH_WJ7A/F>ML"A(S;,/I@\>#>;#U25"M/(<]9T4:ZU9XS\9
M3QHHD0%5Y<+Z:>&#T@W+CV7:+T9LW\6T:DV2+L7"?FTLX#/22#>QS=;RA'([
MS\L9Y?L>ZY62 XE<#>>NOKT_F'C3Q/%*YM)*"QCOTY1"24WFF& JIPG:DC9)
MJ0.W\V[TS$0A!0,:?Q>A%"Y900Z#+ON*Q3BQ/I<SVN@GE95_7@I%,%_G4WZ<
MW@F\* $1+[72<G; 6&1QB:0K/S@1=)FS?2_('V=WM@6#N%63&)V#+8%<>DH&
MT 9?\=O0Q87ILM%B2TVJ4XPL'#,>5Z&*_7XB>983/]Q>+))$_B[/3]9UO*3'
MTRU[14:@%1N?<$>)NWTG5#OWB_BVM@:;@83X+Z@#Z(@=AMC8H%!E<]PZ_K^U
M]Z5!371;NU%$$ 1D!A4BLX(,"HA@("H"*@*" C)&101$B,H4(!(19!X$%$09
ME$% A,@\$X&0R#P*!)"0A$$(0\(8(,,7Z_UUWGON/??6=^O>K[XZ7=4_NJOZ
MZ;U[K_VL]72OO1J(ZV,:>:[N[K)GBEBM#W!:\Q%0\K>OI1%\8?(I2@HUDV7&
M CCE,OT(52N0?SA<G<UNV<FXDQAU,B=FXX8 /Z.._KS8HUF @G_9J%WH[!&B
M1$LLF?B]E9;JHV4K=HXP8OHAW&_6WUCCZ@Q7WR/$D@SUPFUJ9.N?KVJTU!7B
M.@8HX*=+!Q?W/#V3ZIE[#*CL?_^:%S5I72A Q.7]&L.G=>HDHP3LQ0((+C)%
MJ:$4O[368W[]CZL.#,D,P\FXG_%C=^8N[+/<JW[L-NOHIYA#R8X$F;$#YLEZ
M_=$8D#WS]%"(ED/FN75+KW-2NK:6-3RJ82:'<+5%W 6 [#/UK\UL326=IF:
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MC=AQ?,IU*C*F"@B@7V^B&&23/'I62NXQDD29:N^\DH,#)8=;5_0R=$!;$IO
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MYSZ. DFN' KD%=V( MUB],/5V9?@X^!&!#.3UM&@<#'[W@*%H4MG.Z,FWK$
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M*'1OA;D3GPRGU$NVL'W6Q\+]!U!+ P04    " #<@%Q6*>)_JMEL   LVP
M&0   '-A=F$M,C R,C$R,S%X,3!K9S P-"YJ<&?LO0D\5&W_/WZ$%"'94J*2
M;$E9HL*H;H1D*6N82O8D(;NC!9ED[O92EBS93850F II0_9"9-\2@V$P9O[7
ML44+]7V>[_-]GO_OZ7X=SES.G'-=U^?ZO#_OSW*=F_J!^AE:KJZBI@+1T-!
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MK)2*[6NPNJ]*6_K^SB^9;@!9)>0#W"CB*$(%L&TY<*,!&3,\]9D+!0C]:E*
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M+ NV^59OBE1+@?/8*YYG&\["R]J>A)^C0@0JE !7@X5\&Z=8 ;<(N5(ATW!
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MSFS,B!@%6N+:;DK3N")_2GO8J\>I)F,IO%2:1F<P=)N[L9ITK:RKX.T0>L'
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M&R!*R$([FA1)H51H"VYRIUV$03AY/Q6ZA1Y/1TJV9N<+VBMTE#T+Y\\7H'Y
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M>W @I?R)\NV) )?45],,9<,->D<Y%Y/M5[?<3VLE2$MN%R]V>KYZ3\,V@\L
M[MD1'B1MI=!8N3)/(VS0K5D7[TAG<%T=.DA>:MVNQH)8LB?D*J&'L</QSJRA
M$)()#5R[#UWSPUC\Z!K1!?'?]G=X9]HE"/ZYVA9YSA+$L1J;P_0BKH:PL S0
M@YW#F"\[WPWM#@ #QB[" &OY\XJ8*>??9>O&OX_XO66\VQP9H*Q^:1(/LX%0
M=D^=4@UL8XW]M"[ZJ!MD((I("?;=@ P5.4#N,[%RUWMI;YF\4'4V-" C4':?
M&HH,$NTX?7]6R02P\I#]O;=K4N[GL*?@O#SW9T:@_E37&WXA;GY>6,-W0%A:
M734"%A)U/VRX'U:<\(SH C]HJJ'9QU-XO&<Z_B5V@B(:0,HY(1ZEOW9T<,CI
M=A,,+\:)'A$AHB26>2,5Q;'#72N#:S#T2OR2?3+2IG9[J6ANZY*[A+A4@:'"
M8V9AT'BKE^])/N5.TIC !S8MDMJ#_2_VD<RG4Q)*M1H4QE]]"&<"$A\.V(E$
M?^PH:Y_1CA@4Z?!>9H.ES8V1-M53V'FN $,'!'*/@D3N2>Q\.P4.\B091YV)
MB;_>5B?Z(G31>>]9(:/P$]#)QX_"S/N-^352,,]%&P?;&\X;L"LW51T2B*0:
M#%<%Z%A32VMV70668'%VJ_;>=URA@!51:PE_V&5UR.>XE@%OJW1"'J6 ^R6U
M7HFL:B-;#A4VLT]HF,UHG?<9E%>][RTXEV^7$IM!LGH]G+#=+KT6HFRY-K7K
MW]FT$+>;2*H2 QZ!.W\MB4T'O6)P\4IN?)1'>)Y3\EOQ;3AKKE=6BH'Q9&9H
MCGN"M#R\0.W0X$),>.!@:'?A"=-(5;!*HV=]8M:DL?B(]NE;+ @!J7TX;1"R
MA6&D0D#JTGC3#JE*A:[.0&G E970ZBS*1T@B7"1.-4UE0Y%>VS?XVNWK!Y21
M8)*KDFZ=+8"//O1;MG:B8-P:RE5E\7DTWTS6 :3=,A6V?U?Z+%D-VBRU>R4&
M5<EPBF=36L#S?:^0E YIUM<")6#/P%=3I\4^Q%B6UV:L\#;;,SAT%E6]5 K"
MUFUTS5.A)-O&.!8\&/A/#DO]Q=?_=3GU_& IE/R-QZBQLSK)]BDG:C6R2]U7
MUKUW!$=HEY_?[[,DF9CR>>>PU1VMZS/H@W0F[&#T%?CR%^8PG$6LH;\&K+^0
MMWC+%M74H3Z=W,C?6]]S\]",GDA\^TDR:O"YE6X@=,1?8'BEY)-EWLQ8=3;&
MH5MLG7YUV$Y'M0]+?:'Q0 -/:9!<D\NAD-[/,:91Y&XG-#IH(,5N^>Q%:;_I
M)$FT1!O!=.[-K-MIH_PJDH_F&II#OZ-#W(^([KMRZ)2C@9T]BI.%X^'O[R9?
MB<CNX!-;.5*&-9;P7P>PJN93(:%<0XZ!U7TYCFB @0\-U$,3Y<"75T2#(L0R
MDYT[/RH7-[=>\@KA2!Y#9)UB.4AMM4!?7DKPT'W'7E.'_]]_D,(DB;9N[C9.
MSJU#P1PT(#W1>[(],Z?PFXZX5\#U&K+LO(;O1#-\1_^<\F[U5?JQ[B]/5J7B
MZPW#PN?[W6,N'N#Y3_-D-R]1*\*"-HU%R&?:;$*&YQ?B7)S%ME>RK77]1R5R
MD;JS1%%\=X <Z0)9QUQ?[9V_>K+P;[J((DO/HO.16OW2>'(WR/[_)=08D^6
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MH7L"DF?A$0Q2P$Z-P;SI,LQ0\VRZ[RC_@_V#_>>RL[+1P*\'YE:'(KT*3]!
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MOMEP7G_8]SRH8VK6$;;*GD)@1]HBZ$EPI WN<6&:?+FGNKLUV2(EZ)B0L&?
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M<G_(_2'WA]P?<O\'R@5A@-:O8"O/>+H#@I_*]8Q&W&]+#H"BQ_\+4$L#!!0
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M1:*H(RVYOH^VZB.LJC7AK8#+'(S!'(C&-TGV!*U8;W;--_I6Y%\4&*09&5I
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MM$:Z>G3[5K1*7=3D^<#EE@/D 9\G$I#9];PI126_R$&<E8UY3-*4.]E90J-
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M]81<3:")SWMXA,_( AB+UG6C0==*H.[.55-=BO<S?!$-NXB&7$BI5-#3 /E
M@83 I-.5C)>J0&>O\/Q2EJ48)X9RP--H7?*[A*EV 3V,NY/M>Z;E*@ZB2UMZ
M1X":+.F?1(LU&+J4JO/P>< .187Z.\Y45K0O1YU'!=7=8[42V:?A+7J6Q,6:
MUNOK4[I$.4A@JQ^'Y_E2MS5/3_8[9T7=/7KU:\6A9:J%Z4*.7XYZ>?2ID4!
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M-"FL83;\*7YV ^.^O"K3!5;RN&33L8Y/>VGW@2!!@C?/$%G"@I +[$BM)NZ
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MH>))@]@#R43M-UR&4\P=]R$!V0)'>/\?U[7JO)T"L0_2/DL*)[J:33[57O;
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M[CUP$-,MK[YSV'(]BGNY?M$"B;99P9(9,6S!6#L8]P9CBZUHZ0'+VG(050Z
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MKT[FK^!KSZZU>4;A?@K%;6#6A$\E)!>B_^NB^N_(7X[X+GT#\%!K)$FT46>
M@X.B*T([6$@MU&*4?%F8:R92;&8!&BATH\?FCN%TE9H^]&/76?US'N<]]EU
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M]>=>X]HD5 ZCS@VS__1)75VE7X0O*S"M:[KTR@&QBUXT95X37-"(6R,)*5V
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M#LMI?:I:]]/[FGNFT_.[I5VV*STI[!,N?3?X5(5)R;@B;)AHV4I(0VOVR[8
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M3IX"(H!F6-(J)#7NAW!C(9J<S [/1G2$?Z9[XKKFL9U7K]C7.>:> BY%@X/
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MTS\"G"1],WL:GJ10/C_6NM>S)%"R%N'>]-38AT@)M;4 &C7E1(ZBA8**"';
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M]B14M]LF?7!LVC2UJ]6]@)63.3GQ9:4$A'OC*XFC_#L%U>RP%G3;'&=_Z\7
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M& D@JVXE4NK!G\#QIJ>EUJ=U5NY0,,VJP):AR"<(SCTKE>@O(,224PPA^6A
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M5(+Q%=CE/IMQ?MDN?(NA,;^7,5SA?!:7/\09@I;"C!G %XRV;\4$@C,?E-O
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M>I-M92__[-6<=K"_S7BN=#W1F.MK Q-?:F51QDOKK)L6?"JVY+-^GH4!#'
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M'N#IEY^R[7H09KM4CHG1/5+40W^1,L:[S:,AL>@J/O0+5A_75 Q0UXRNE\<
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M+V./IHOZW+(5OU[411^1'8DGQ.6D^6KZW;-CAN17Y)$?? 4Z#:X8/GIF?:3
MQ\1'R0+H>EM\+F0+^G(OAZ<NMJ"IRBZYZT;0Q2OQXDYLD[TKR'X,\.R12036
MT/^=V?\7FKN_"+\L[^%KCKI[8#3]F=V%!4WVNZ2B7?-G4E$_ZT:V/ZK TY?8
M/T%\4#3*3Y_ED_4* _QB8[V"D*.:-!"IHTG3D0(><-19+)CQ%MGL-&]TK&&
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M[VYEVU:3KD+2CF3?!^DE:0<'&G&6@*X8K8LEU]0*Z)-$XSBI*1CH0M(?'.E
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MY7AJ@JO59%SW(@*-!6N\%FYH](UBT^B<&JS?EFY![+IO78P8SQ(-5MB\A1X
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M%D:K4&=*$^V"V=<"F3S7QYSQ5?CLU7($X^2>+]#XUM-5^,<5UL&)O_0JVV"
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M70HFN7IC/"O?,Z/2,2*FU:J6>LE22X86$%=Y\:TSB>B- .K=E*Z;&@=STK7
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MN!YIH&%U&. N^@8I)*QO0)N314,]E8$IZQ4]6L\%H=SF@M1".\4;2+T+"T_
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MZAWVZU@^(I4B89YU;Y9V9[\#GR_.KX:Y!A='+!<PQBZ'^[C1.#U+T/]HF40
MBH/CG'IC$ N[+V\-LIWVC?EXO=*344M,U2,RS7[@E&U9>8"VE;%4@&?2J*S\
M&!?-0ECI[2/]NM8QEV[UYYM$3BHJ6E1BAS<"&KJ\V^OQ!K]#XOS=>OB2SFHZ
M@%$._URWZO!Y1VH'=BKK8(CJR/!/B)JZ+:*@<AK$7.TUC*H>?O8L^N'G@_-$
MOFKX9?']&&8[E-)8*'D]YS(FHMN8(?Z.:1K?H6N'HT+R 3!FO ;T$% _S-,M
M/AES*:)WS&!,1RF99N@HM[8Q)J_T4JB&EPZYK,X8<<V8?2_UV=#GV.CO;?&<
MW3T+30%4OML^8&Z-P!G/;9U?1?6HV(EQ35(6*+2^@GB+*3%#0,,396?/1"@S
M6-7>TDR]T&B9/6RHO**Z-XNX8\&B'R!AOL34E\I_V3C\;BQ"[P%/K]8,<ENO
M?&N?B"LGK9'X2R8Q!."N&7)F *^F1@#"H!KX]S5$"ZSLIQ*9?@CU+]HJ;BI(
MXCV1DQM_+:?Z:[:[B#RR+:G;4V0ILCR&&W_6/CQZ5QC5U?SJ<6C45!05:"&L
M\4$9PCB@?B*M/TLMDG8:.^U;- XIU+1#E+,K6$2/G[V@',ZG/1U7)E3&FV/5
M6'E3\[UDQN6>:EFH%#DP)GT/PP6S(_X8EGJC^XZ*Z(Y>Z&K0U0DM+XE"-9@T
M:"'W"[),2^#OK7JF'3VKFY'UG\^KBG5H1](_C+&9LD6]MZ>EMPW!8>D/:\_2
M@_O0,&PE5)!*H U_K .7+R0/IF27&_.5I1<2#Q2&G,DM\>F#$0\CM/#/'9(V
M.AUB#@G1%Q94B[=,8<*%XOS__D6A'\0%<: F3]=(_43OQ\OWCT)/+VZ=JSU^
ME"O. ^V68!98USW8Q+78@$AMC]'RJ6C.,%3@?[V;O.=EM-\,?_W\T]82COJX
MJ\^* A8%5K2^?=N*!QO9,3U'IR' I?"6)$^(,R*ZI!F!*H6Z:C"]QE8-J*P?
M6=P3V;19>N?KW2I'<I>VF6.#8^M(@9#U_]^J!7^H]J9J$V]%^M?$=RR&I+.Y
M349:3<7HUTG,[9\<#DEMY[8"AV@O[3SGH,C8SE'I\I8L6*0\%QYL("\BOQQ2
MAR8+<P+850-NR$JS 5RN.:KH3X6SDRX)8NE['/%)\FO^>LYU#? !OIJ@UHL?
M5QQD69$'Z$:R 9ITD6%??;=<X'XB[5BFHV@$QSI/I!3O.7XWGI9X]=<K862^
MUOQ"'\0>5HN'ZPD3>79HQ"L7]Y.,/AR]65XC=LF*=(:-SD5W'V$A3UO\8Z==
M0LZ]:3<S#:(9.YGN*&#AR5:2IY%?65PVHGOMWWT\/T)XS 'BL#M6233)VAW3
MXVK"^BI4ISM7CC7BH98/B)F-AEI#]=)/OLTUE:OQ60M7,W%-5K9KRL4.4?U#
M'M(*#E/1&GH4>YB48#H]AZ "I4YEU0=;"VG2U2ZF%#EDPDMIO3.55>CW;6Z8
M%8KH*TIW^7!%V.OT%FT:;*$39^C9)B-3+.Y'X)'3(K>>(RXV=YNJ^YU)!\!=
M(&^H0'M>W__5F6VX)L)^PD@QF#_X?$5>(4:*>81%!7Q>C\-4IY8S>(P\A!K:
M+^ZI0 "T<J/O./&DM(NIWC?7,NW*O,&+6TQ)T'LR]7-X4!.%V"&FT5.Q (UK
M=J?V&F\D)UQ&/WN2BI9ND_<)HP%>H0*5',P:Q2X>K/Y$,$D21NO/9&M_]'0W
M<<B*A9<7[Y05A7>RSDLJ3,FTN- C1C5T"AGIZ&;(\@H,Z[2LX#7C&'#OWX(F
MG.VHK,J7/RRQ6F8K>_;,4_ M>-=3@B[+7KC<J!D6W%%G=;G[Y;T[=J_KBOM#
MDVE21Y3Z!)[5@%J6'X2U0'IL=W.5![G><?Z.YMR?XI>3-=8STV ND[LLAF_*
M69A-E4L(;59HV4Z14']R^W68.Z<Q]]-527];B4BUDLKFTO)BZT+_GF[XU5N(
M]J$HEYL>L:%D99Y+6\7K;PJ>B?3G(Q:0B6JE?MB5A9X/ VES.OXO0=%/]PO^
MF&3HO^Z!83F'IR2HY63A &5I@T-1*:(%["NTUE1S*7CF%NC-#1" NRRO;^,!
M8YAT&#0>G6<\']IV3T@=AM%_46S:"\DS5IDBZQ-"FXORI4W8DQ< :A^9[W<R
M#QG(6=F=;!@LQ%_5$Z7TLM'MQS%6N Y>5XH]=)&ZG$)&CM57G31+X0T#;?*-
M=&\!;[,:X#9H?9,>(  _MK5^_1ZH8,S!Y&)[Z*C/3(D]?\_#M\Z])N3TF"3N
MD!J[]R'8!D#W !0#X-3\9+A+T379\9L+^@U:JCQU@Z,UM4G -:IU<G&CR3O<
MV,6@IN.\!""1H8(K)ZM2)#H\(<9DV2)USNGSZYZC7F95?$,SNKI3<FV"WF.[
M3X#=?E&%[J2?BY>UDB)WX03@?;05Y;,?PB1_]O _=#$\^ ?]J>OQD$BUM.W1
M;YPJ$(T\!\DG>>8$?4X3.GR%&2%DYL=UHE8 D<W?4MD"$T8-?BWU_?T%F:WP
M!!;U,OZ$?AS\OC-E$+5Z:XT/]4NF5W#O"&T.\A? $8 -()4EO<T'LOQU-/C]
M""CA_5\ 4$L#!!0    ( -R 7%;!1$8:X5P  /EU   9    <V%V82TR,#(R
M,3(S,7@Q,&MG,# X+FIP9]R[!52;T;HM^N,.Q5U:W%N@N%.\%'<K4BCN[E"@
MQ:6% L7=B[M[<0MNP9V@ 0(\]KGWOGOVN^^,N_<Y>Y\K*V,F_TC66,FWUK?F
MG-]*\C3_M Z\4)"1EP'@X." C\\WX&D#T)/VM+(  "4E@ 4  %0 "0$.0'J^
M@GN& @+"OSS^!8#JB_]R_9<[55P \;\\C]VKBO??K__2#X +RP* JMBG)4 *
M0$5&1D%&0D5!04%#0T7'),#"Q,# ),7#QR&@)*.FHB2CH*"AXV"D><5&2T'!
MQ,?,]OH-#P\/-:. "#^7, <W#]=?!H%#0T/#Q, DP<(BX7I)\9+K[VY/G0 N
M*OQ[^%X$N%< /"X< B[<4R] _?Q)D>#^I0'_M<'!(R B(:.@HJ%C/'>H>P'
MPR$@P",B("$A/H<(Y_?\.H"(BX3W\HT$,KZJ"<HK)P*NH/AL5%K)JBY"M<DS
M.FY3YV T=")B$E(R>@9&)F86GK>\?/P"@E+OI&5DY>05U#4TM;1U=/7,S#]9
M6'ZVLG9Q=7/W\/3R#OD2&A;^]5M$0N+W'TG)/U-2<W+S\@L*BXI+JFMJZ^H;
M&IN:NWMZ^_H'!H?^3$W/S(+FYA<6-\";6]L[NWO[!Y#SB\NKZQOH[=U?XH(#
M$.#^6_O_C0OW.2YX1$0$1)2_Q 4'[_&7#KB(2"_?(.-)J**8..&_X@I")9",
MSZ[J0J/E5CLC-'6>1">BX]F@A_PEM'^)[&\++/C?%=G_&]A_CVL1P'Q.3'A<
M!%Q #+BY8\H)1/^_#I4\AHI]CWR@JT:84$57UKZWTF2-/%;$LKP+5VRF$%03
M,<HL%;AL9AV]$B. =O2LHO^.U*C[[4!P0#Q<N/ASZ'7"P#<*[%\(G=<W\*SI
MLOW^R#.77E</[DN&4V[DO3691(KVUQ6WBQK%M\DB\KL763A*.:T!W8]BH/'>
MRA<Z-LG##)$4#54+(7B,21.$IGP VBUYDPAKRO0CO>>4 QIT0+5IIMY 3\K*
MR51TG/@$STK0;SQMB\8E%;@CBX"0P#Y5[MU5AJ>*?25SB C+]:!LO3,GBJ.+
M+[VR[95'\H- 04EUFZ/NTV"*Q"5#IK.*] "' F/I;>85NI*E3"]2.'D5<9'P
M<L![FW!;5!!"56<'81B6K(/\: BKO>49KVWK&VW%>YDX8A(U%".'T&'_0_8#
MI/(K#17G;V.\!6B8")^\S9*?*6B5!W<XY,M+Y_"Y#N4B@&I(V@OGJZ]+I8ZO
MV)G=WBR^LIVA&?%BSR)::!,3N:@.N?/R]9%33)W[W #92<C9C3[H[3?;JT2K
MU[%*,^QD(LE=7S78JJH6I:AD*9SF$N .>+2_'S1TO("1YC)&O+5S']:LC<ZU
M>6!GTWJ)S@WX%J.PR01$QI9K-$/3BC\_ 205M8?[/5"=2,^&GS,8VDFO![<#
MAQ"W*'YAWJN@_)XT4 Z^>E#6@AA'E57:^R[9"=Z^JE-FUQZ6S(N/@Q,1VBFR
M%NR($%;=]%/N626;-9FTO?RZ>6]XN,C>FZ"PZ:BI=>L>-'.5A2.=T^JB YF+
MX E \^SYT-8<Y"N53>X>\8BJ;0M1. R;[PR<IZ-Z,T[)K4^%TSSK4.?#F QN
M3RMG5N8RY,(0TO0@]_Y$\KN+9I>R"&%JKX(;'/N-HY5]W2;MD#S>QON\#Q.?
M0!M5-^P#R0M_E942G+#FVN;1\JMASQTQ_'Y20LG]80O0[J]MV1$/IV#9,\AJ
MH% )ZXBPQ&:Y;"<5V\QT+W[=:JS7YSE!V9-9A3^9WIA%0V,R:.,D-V64QKU4
M_%.V,&KD4O!\K4^;M?XWCA.&FI!/.7:27Z4 _G$!FNU81OA D?J(#5]"CFS1
M4B%E"*LRY!TS&C((!%KE)J4S&9;IO:9%B?$K39^ >56LP*3";-+R'= //.8$
MW:+\U:(3WA';G/9OMH8!YE>BW^$.OVO''/K3SS% 4RH_]X"QDL/8V'*#LHBU
MZD_H. )_(TL65HHHZ^T]DGHF:\Z1&U;/O&6U,V7GW9-"+G=X$<TA02K,.1P_
M\$'@=";0XU(; USN8=@""4T.@?&Y887.U)?[> 2P47G$O[ KK<+![+V;=4T<
MR*">]/W@5JXPKA(\K9S@@Z7T4BZ?"Y$1ZP62(^KI_IHPX$U(N*M-Q0C"7Q>'
MO%HUTQ:T5KZ.91:]I66TYWTDZ7,1?0D- ALR]AD1XJ[%'C7QM"B.?N#&#.!/
M4"6O=]_RVY@(Z@-\# FWN*&[O?@P^_K)<@=)3Y]CG,^3J'&W"7E":SM+C1^K
M+T5*'3J-&&:O*D.U!4'9'KO6J!P1H]LYFR9V'4R 4]!BH AVQ#DE=?_JR^;(
MC5RE(GO!:8/()V"Y7_@XTR,'UO@$6!(>\O'AZNF-N@@A1A!P"5']09;/0OM<
MR03UV%3&M?9GT!&6<*0:UZOQ>6 6SE=FUM)"%@[$H$S39Q1&+P?C0Q 4(17A
M.=*;1P-E0Z(#CP,A#Q0TR\@"*W.4TH /$B%8,/PKS*TPEFRA#\Q9;^CISRJ_
MF7ST.BM>8<>@8CHJQAL2\\90]ENK98"?U?JA,:8A*J>OE* "'6J%60-&LU08
MHCF\D#L/W-Z,]M<E:*;QK+ TF)]#E&G_D3*B1SUI<77Q8&PV)5>]"^E/ LJ'
M!\&YXCUF'\904VT(@5[=3'S[J!8)K89O8ETP,XM3Y^$8$X)]!*3>^*L9^!54
M^9&(>'6Z?>6Z\D@_X/1XJ>9J+ !]^G<'I"':#4O]GKA7ZTXT/=^ G/!'[66J
MXE <UE%7HS1C 1/"S.=*T0DW!SS/@1[B:]82J6QH^/L.&Z'2(CLMS_E"-UD1
M$MQ;LIXSD2<@JHYUQ>@)T(;\]A.2FJ&O;PS<=ZQ<Q'N3L-2/;KDD(CB!4C%I
MI'IVVI_Q:@;V_K=G\+I(1IW%S9V:ET*&6ED9IA= ),1;_\&3< **8CQSU:;8
M]_N 6-35G:RW'M0SK'F^24F\C2"FGBA.64>8"(X<CA;JUAN]RLLP'&V+FNJ]
MEUC\\R4DI&O+HY+(F!0:@X,D"Z:%Z,NG0L5KTDF/RAMJG.YK:D_')V4W0($B
MCQ&04SS/AEX\Z(#TM&S$<2N]C4=._M&QBP-F1 V1P/OA&!^WXZEF!VRI<FM!
MT9*D)P"O[*KT&SQ]VW9Y=!.1W1!=R1NL^!CRJ4"A9M:!2]K-!]D!P=50SM@
MCUP2RK5[*IS+P$TGDD?J]UN@T\!6I=)#8_0*MW+)T[&9%X:$:</2_=U+_BK
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MM_6[#@+]+(J9Y)[>DQNZ;CA7H'WWLCBY QIG\1\I&J$?!"PZ*2Q)"> 4-YZ
ML$J82-[J:)D207-[L>=-@[_VLHRM"?$\'.PPR@'-LQH'!3JM5#M=Y59^R,7#
M.!X+ORC))^?O<!+\9B[CQ[[+,W_5SR:^3]KH&SXF?=$4K6AI71MHJV7K2!+L
M_%J \,-]O[=TSMJK,=]#G7S?4<PAC)_]AN^RT:L,*+XL]Z#$8 &.R1T8;CC8
M1E /K;.3XG+K&T'#*>;:CC:9=_6TML&O)4,W$4CW+_,GS2!S7]S6\,G%$ .L
M]0[TRAJ<E!_*$:F9A7T+&0N%-_<-RSNB:V_2=/1_5GPT%(2PPQ%-"Z2G$$1'
MX+,Y#X0N.R*XOJHP\HQ99,>;UJPUKI-P<4)$&XJ*Y=*,2D =9-'9ED.A"8D
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M=;[+ZZ5F3T5M".-U1D%S=/[H957- 7>M<7.&>)$IF]FB9&C_:G@4!5E=$;1
MSM?DV9U1#]O83BR-Q2^]GTCZZ=NWA;$=G/(ENO<%AO<$8N1Z9%-M-*=R8U,0
MT9IXFF+*-/O] "[P!Y54=;O!P!TFB"4 DXY_R+7)[T_!J%[<D:5!$O#K?_,K
M/=<"&?G#SKY!;;\5C+O8,Z7.9OY*CNI T1.T#R)XT1*$&_IA@.3]&Q;]'3K<
M?D%.XA5EG$"WM$8C19_0Z>UX,EZ6O24T$MHXB5-QM#+= [*;,';?QI<-'1=V
M%:.M4[_%)P<3"#B(:4_BTSM"U6K.^HXP\KP2EIZ [(,YCZECBVWZB^N@@54J
MZUU^"BIE?XN[N]-W$><Z96[WJ&/Q;IS))=9VSC6#0>C'G](7N>#LI5X*G ;%
M)%STIOXBOE&79!>K8>,X+BL,DUL:^[&-NSU[@Z32[NRHD;2X'!4!A'>+8C=-
M<&[:A$;GU-;;V'AUU-I;>A%47VPWG6]L$+-D-^V)D_#EG8W.9"XET/>J&JP8
M8PR3RBA_[T;=)!^@H"Q#I=1LWBWDM 3[!2A/'1\;'7,XV%?6$1%3+WCP2="&
MF;8(-Z9G)IF$C1$ZOOZ MI<]Y[9BND/B.NRC3VI6%7R^@R7#R#'*[+""2?@F
MOJJZ3[_HUE, R+<\N[)WM?%1L@>KLY&9"_H&F+2ETL&I[YH25!QU6""::,]$
M&"KV>)^4P_<5Z^SQ7?P,C+BS-$]3CBO"-.E]5T_B@.)JR4A*@IPU43?JO*CO
M4+>L;Z"S>I!\755*FY([?]&<^-*7D,IH(MN39+>.(W-328^2%TM6.^:/CGVM
MO-OGC=IOD[GGW7BA*6GN[T+BB$E.08$\--/"JOEKUN!N=@[/REU=M9.=$^D$
M[JT!4H:7N%C!:56MEOR#AZJ9X?4>6@6@ZQU(3M@0FUT47T*O.])M2C=7&'V,
MH_/KW-42:V]0 WR I34QT9JM8CJODTAP*XM9TA:MC$8+]8;)KXT0,P040=Y'
MNIE,]6 OK9E];;TO=[XJ9>\996)''C9,YS^^5SX/141&840.?*G$VG?GBQ?-
M:T@S[@L9=Z'O&:I'<R\9U)3TA^APB-.CB@P*.^P)NNP_DE5-VYN)G^F7<;$H
MF*L'A5P0JKE<$H[(@@-P_3) M\E*":![Y3258)+UQ)%H=3-$]M9P>NHBC'%;
MS7)MW:;6LSOCI='M[KN^,MY3-!8CZEJ9Z,0,*<K'/KDLM".>4P*=1=T]R&@A
M?72Q7'\6G9E0=QOQ$//O-P"SW9;;1T%@V ';6O4@Z6P0E+G@GOKE+HH;C;0P
M/N\")VE0&QWN1_O'WKBLC^:S?D*]BR.+T=^337ON12]46W[+Y83V%F][-3IO
M#PJ<?UTD;G=9K$E[[N.\WT[3FK!2NU#;T@(].@[IW]#$G30??G%<^[!.C"+L
M(DY)]&/CO@4WZ[9:,J#F*+\AV88Z)<T"'3*])>*TV&2CC D-&]N\9UC%8)0Y
M>VC/=')CE</]<"M%,M;3&NCR^WA,.W[UH2&J[F>MG>3=^?0H$2M6C]CUI[Z?
M2;QT\GAL RG$I"C\=G]><QO&Q#HY>>4N&AK^%+X%Z^H/"DBTQ,$-C<$AB-Q!
M?JF@"+AL1$M7VK.S+SZO8[+6G(L26YEE=#9N=$F:PF\'>E'3'O*TD"#=Q<*0
MNN&+4FE[D):J89]S7I^?HUDC%RO2BGUGGBP=MR">O/K B-,>CPH*1C%42+4E
MX^[=:W[![WJAO_7WRU,& R7WQLE.8@$BS+S=;,"MO9VXR1AM8?_;M6<%;4?8
MN>KN, O$D<&12FEL(&2H7YG?8-W-506%WFK#9UY;'H<-Y2BU;N4H3;<IQECL
M,X7?QDZ%MZMPQNUF5W/?:%M%H@=]E/>GC#2G0EEA-2$EEL&(B&V%P#RD+60!
MD7MM'VG D7<5K3U9H:.F+0+$>8P8!MH.RW?Q7+,T[*NO?4!;EBQ"L)=?'H!O
MH7R%4:KT"K1XUCW='<PU\0#"Z+3]^#$.CC:+$4'$^I@ 4)7^SX,FI;I<#8@F
MAK7W^ZWRCLS9V-D0^<>HTFS,5CQ^X6!IHYQ +EMA[KS]:EGZ\AK6_NJ<FE':
M7PI=>4,6 FQ_L)7%4DINC# G'&S9RRQJ$H] UT_ IW<Q.SHW4E%>]II!;INY
MYEI7!'"2IS*_V\+&F#=,ZYW9DK;I79DZ"2F*$:/P4(5?R D4K9\]_K!/^D:9
M<U1;:\.DF?*3C;V!24+LM1!Q8N) 4[D@$P*WW 3/,98YT1L%S" IX3F\]TL:
M)MJN4;U,0]TA08E!HUR[/8)O=\*=<I;GRYK]AEL3NL?6N(62S7YM4?9FX%!6
MZ<VH(!%/L=%-5]3>A/#.Z<.V5A>>1=+GUY;;D><F26>)\=FWO35[/O]WMURW
MHSB+.^=D[W>]PCV2]&G=%78]1N=2EW("7^-WI;XR(/W"9ULNT/A:!'8,%U=_
MOBKO0KTJU'Z*DCJ5+%^5IMQ<E8 %FOLT,MQ6?7_1\M_&+ZU501$I@E+W+)8/
M99S_T39]M-)L2<$?6:J5KS+@_(DBV[\1- Y?=W)YJ/_ 8<>[3Z8OG_UZ,)KV
M4US4"WVAFIC;4;WG]U?O:F:* #.;MC3IKMMXW!O";A!EUKPT!K<*'+D;2#LO
M"2T"L*VTR<J\O]>?V*N;=&9(D!.,@3[WV%H8G(V@D9 (H\\^C[)S%A8IS(XO
MX1@QAV<0@K4UR=7R\%!6@5YJGI 52K=+6KCJJ2W=KN^6.E$B\2+(+,SJE<Q7
MU^A9$C3\AR1$9\\MT"@!7 IU^&5CP@K>'(:=$_N(U(A#DCS?J7WK[H@_#H*P
M*X'$Q@/+"CN>D/2"U6>02BGW:QU]>Y5@_X_NG(R,L2YZSU:-ON%+K;ZBN@-E
M;4683CZ#3<HGW]ZN7/*52#LU+F(A66%G%V$CRJD-$+5FS$K?]!M_"Q>R)A*.
MJJ3Y,EFD0,2MBZ%R!2:$Z&E??+?" VVRB />3*OS_)A9/) # _6;$%[577M1
MU?/L:.\SSWZ8(-(7;_J8!(A7$L@4GV3(./5567A4 %Y(S(]":<!2.FO_]T/:
M</W 0H5Y2_A-]/DPP\/QW*_;V*YURYC@DB6HK%1]!U_50E6:>7S)D' L&5VF
MGQ:O:4DA12!0WLR$0#3>[?TV C%LU:(W?BBE(O_[CE@CU]&'V3')APDOA+?Y
MGSXY%.K1EY>0K+\_4NJKWTH,2NS<#9K 1B$T_<<7C/]GHI$:W[-'<THX(&\?
MW?;H<BDX)0-"0C]DVA5O3D'+@0Q'2A\N(4YY13CTV9]EQLV8PD:0?2S)MIPM
M*T:.3#W% FE%\<R1X'C=3.1^76L.IE\,]>GC=6^@7IA:,&RY=8\KK9OX]LK2
M*Z6: !B.;E%&.;6, (Z+*CE#P!]*KWT\*UY6W5OD(T5=L\6+#H;.A,(/\FW_
M,1- \G#MGK/<$+'W\Y!/U<_[9E]>L5/[LQ=5YO-RQ39B EPG_U"_4Z(X>:T&
MT4U2PZ>^NA%NVXW6)@2[N\U\97$D M7__>%"]@0$E[=*E>FNKE@3=Z^B:"<,
MRO_\Q.)<B'+R:Y/>*>ZU36%.H,"#8@^&DUN9-:^'QVMKO; ,MI"\%D1]#\)/
M-.:\!A?C$GT:=6?LSZ6W_=OIT@.NY95W<<NR3*&3FYK]G7I<!X7%Z#V,Y7\1
MVI<H/=&O,)CM'J?]C]10CW>\B/U*))? .F/+)CJ[;"097^+U%SFB[;*MNL<6
MMN-(J73IOP>?RQWIIOP&AN@R *I K>AG*>&\Q5D-F"NCOB.H\R^2?@)>WH_?
M784\ 9))E1-PT@0J_R<!";5C2\SK"3#Z';"G-GN730P+/Q4[!.$\H.MU_).7
M7XLXLE6WT)-/,EECQIC_UB14>93[6O5!V423I&E(1N@WSQ66PK!\=<*S_0P#
M+8JUL8T1RH)][K5_&?NZG2T:OJW_\:G8NCIJ?:FG[H,('^4:]-C\LQ$ZR)]^
M90#L0*E$Y^WC>ZVG\5[5G>K+#1 +Q;U"(#STMH@O_%P?//>^JJ$V, #Q32C*
M\F;QS=N9#<F8Q)O\[1QCT;R#\;>1F_W1!"6I]>%E5AOC?TY?F,"Z8$$5]^(0
MBU#P5\QFWD(DT&22-+_K778/3J]6V9F4&X:4$Z9S;P]F M,G,16;T5;%,Q>E
MYE_6&83IM91&M.V\#?2F9I?4'@>M/F3R&R56EB@WE1=8JONUVDF>VF"M;)-R
MSE!?'WNVMR:A86>!50;>YC%P(E_7+]<A1H4ZL[DL'Z:>@,#^].X(IK(P E5I
MX.^'@475ID\D#I75(VG==&YZ@4:"9=+ZNVURQQ&)1K\6>>%[S$1QRG3"D<_M
MW USOKJEG]VOM7$+TLFJFE(4T'[6,,_G.6<5D]<,H4PSY _$KM?/Y=<EC6 )
MLO9/KUZ,W7X!4_/$<CHL+_4?+XR?;:8"1T658B'@SPFS[YO5!MS<"/- +QY*
M604-FN1NZL?C@KDZD3OW])HSL6U"C*<6][JNO;(S]*W .*UT\55:/1_-S<TI
ML%'759"^_B]*3EP# RDK._;1WDB"-R^]*&/@BTCI[DU;+7OJ76!ZD)%VQEG<
MC@WRJ:TW^]=CHKHZ+@EB# Y0]'.X<N5(O;Z=RH "F.ADY@.WQB>?!NKSL1<N
M(<==9D?M5WMW5+%6&P]XTPI52DG755^,U0^4FP08E^=LC7_GCU_G-R2<7C"Z
M?U:5)NQ5>;;&<&/0@:Y4[6C7L*H9L][(1*0_.!E$5U2KN=FP:$>C%Q#[TO7*
M%YS!PC8<6_QD]GD#V_'>+ D^[HCG."CU(OY-XV2>?!\@%5_NW,Z/?CB#;M!%
M/QO/>,>J+OLC-Q>!M*XU_8FA7CEZ!S$Q$><=88\<,VQO!7Q1P/T+I0NP^L2F
MP:8H;&1E]1B)$Y$!T6)=K7P6M>V LSVKY6?%'#3Y>ZG&P"%2&-\%G&ZCE&&H
M\':ZO$#>:.7X^V!4H4"$1'!^(XK 9@%K]3/31TOUS$T>+*ZV%!A][VB9)II:
M?8.>R?&.0_-\ "69 C>&Y1O4-_%@9^< )F])/[>T4_<"T-OJV:IQ&%^F36]Q
MR8""6_28$,;7H:9X$VS-OQ,.%EEU;!GOF> 1&YPAIX9K D,]+[1ILRAMBL]V
MPGBPV,O?/P&?4ZVVFS)4TA"&:(EL.3X@?P"&UK&5;";%2=VU0-?-VP?Z710L
MH+,W.A-,C*ZMD-4ZEB_&Y]2M3T"ECM@EL_7#OV,[_FT@5-><*;_T8SA5:[&K
MOZ[BJ:;^R#W0IE_) .T(<"H[(.,,=%U ;9QET.6(> (PQ2&9]J2Q]S_JT(U
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MS 3/_Y\N2%J67^M^^HILC$II9R*QTUC!9X)M?4NAOW#Z?ZDG5B.,5*# &)X
M:I.0T_UVTG"? -?17X\^?Y[SH,:HR\CR3%$F=:Y;F^SX1.]>K]$FA3*<'NZE
MRQ7]TB.248HA?Q-'@$5]3.8N-)&RXIEPG+__#PRT:TP (W8IU^T"4V+6&KV<
MZO#!&+C)EQ@;=Q:,[?6HE,ZIS=?2*"C$?>OR'>JWJ>] #G7BU&#SF  +#:+
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M1[(,Z)ZV&;]%@%IJM(TK)U/?H5H/@9DY:TTA&EJ_UMP[XO>^:V<$=$M!\)Z
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MRH\5'AM7W2'#0C4.C->8#8R/]X'...:3>=RB>0V0GH*G7 /N2QY004=KRS>
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MJFYA2K['E75Q3]@KW*IFWW^UK(T*??]W GN(;3+PN#\3>$40A'O3! DNDUT
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MEPS]7$Q "^>W?=$V9L07MUV6 .U1S&T'J,&Z*UF T>U6MDY[;Y.L\]-&]FO
M"Q+PS],G.%$IT\R+(=) YEU2XB13-C@9BU^ UAGKF@KI?-+VH<HB#=J1D(G
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M=4>DJ#R-%CG*84RZF='R/MHY5ATRR2F]*3=^\*@A?%>E,E,BF4(]?C[OMB$
MGX]U@P4@X,N!_VF"??*S0F7]5"WQU3/@HU.L,M.JX#S(=P:F:+/NG^ &8J.B
M7],1FO9C3_@5$NKJRZK56H'03UOI )TS0?*L*YT&AE2?NM'?S$JD4+0^H?,1
MSYG7[[<@C"B0ASRCBK]9*Z^HY23[FD_!LYNFC7'L=TD95ZF0[?.EB;4/'H]J
M7RHK\!]ST-E)6>*-I U=@/.::<R#;G]P4IY[-OGH6^ZS1T':='<( 50U?Q'<
MNB2' KYV"'6$G<NPDO[<XZNF1:YWY]5VJ50<-ICB?O;I@+&T?6N&8@G(S$M=
M-^2" KTA6R&CW9LD,:EV0.">#"/I?^;!N=L\6"KG'4,Z/V-MT-+&"M<[D![B
M20'-SJ?Z]#-I,_+-+>F19/IS4&]IH8T[CW=("E5SK.*-&@<-I;Z8*XCU<D>B
M5F"[G<\)3A;<W;V84AV=Z;25\VNB%N6NQN@B(]U0V:0:L@T-S>@XGR9M;(%G
M_FQ8WH\RGGWBCNF[ UIT"?OE,,'X;-=VMF.C0'U8)L-8">\<=E0>45K.(%'V
ML/9E[&:9WMWCI9K_BI[%?]N_;IV'9O6A^RB1B([I*9A!7)Q2VK8HA_JR3^FH
M>O8UP*"PS#SI-^$Z]1I\AID!N.4P#CP8N 8<23'_]=3E2ALZVG=U@ G;.)*R
MKG(UIM@VX#IL]Y;,],Z)E2=H26B0G1SH*=&&SHDQG6P&RJ!G2*&_>,?)ZA/A
MF!A0'-32P[E']'E9N96K5_V<68VT7Y85V[(&S=5V[8UG)2"63*EN,YWX@IH$
MU#4@^+Z[A+=JL_>NDMW>$^72#5DVIX<#39FRA%_+^= AU$L-:1^4LY=\81#.
MD(W>/:=N<>(J ?\6Q\IK0&8D*9^,V4:C&KO\5/:4T -E5*O**2;_XR!I3D%?
M%,V/.Z/4$Z+[WS==G$S<Q77Z2A2\)ZE7Y]SBBK;A%!LM-1-E!Z_.W'G9DMWL
M[;F;JA@_;(,&TP0<\/@?>YR_#32L\O V2#MZH#*H\(/[H+3F&E#7HOI5DOQS
MG[GR35"*75+X_HW9E+I],DT99GE-HS>^>4L@-*<\KL[![/<>R![4&J/8F[S=
M$B6.\9!K%$7'G#?\'6/YQS "=:W5:&]["!3BR3C6[_"1.*6E$<\SJN;&]YX%
M$SJF]->$2PDKBY2@-F]N:>3@\QXS;4M36;;W=<D*9GCRHPR)<0;)NIIS<H^3
MS,VXBD)S/$F5O_^2%=M,&',5HUY-$TE> 1%+0120S9"G7T:_+DBUMA59CRF_
M=](89'2JP]_D'H@G,CP3Y75I?NHC4&')1#=IRT/0DS[]<G;PC@37 &C-QN[=
M#6X6K5L[/?Y2;N&'>[0OIZ:[MX67FV)>1V.W-S.EGKW8!%781CQ&*)&OMH,+
MOZG$2FM^A #ED".M9OGS7Y,*P#,[M$Q4#>'*=VW)1:4M9TIZZ7PHZR4#$ $R
M3*ORGH]/4V)^$1?Z</^Z>J/1,&_I2G+JU)7PK>&8ZJ7^J_)ZB?"8=,>63>J
M0K31*4@X]1'<6Z@Y4Q4BBES(^K A3"!?GX)X>9L(LL>@_MN$)9;,ZYN.5RDL
MQ]T7 A%-%8[,94B:Z31)NDNHU+X<V -A[IAKB0?-;IVEF4U&8>[;4 [$\[N
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M)0_C[FDO^>/?B"?US74T^V;U&1T/>OCRD2K4 T4L][S>8F\T-/XH:]$OTB@
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M,%P791O+Q7NU1M>1Y6@@]/_\SSC_MG_;O^W_#R.ZGOT/4$L#!!0    ( -R
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M%>%2Z'-:$ 7?R1Q^B +Q6C>O4Z2"83/W/[!XB5_I!X\9/6QBUHB7=T(J,Z5
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MK69!TFW8VZRO7V&QN1G[-U!+ P04    " #<@%Q6 #$]A+H)  #H4P  &
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MP+B0U=(@=^E.ZZ?&%).U?P*:/7COP7LWP7L[E\QW"KS#$>MK\&CS *6"O'T
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M*,5#TP[NKRU]@JQ?H;A/#?2F\9 E%%93GP,S!?@'((N6OF#F)(1.1EHP097
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M<],]JO#XHL^/UN<R%4E*D$)&L!12J*<<,@\I) 'B1[$J(>,E\CF1VB;1"&1
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MQV7GNM8Z8]>U>JU=IW(F97P(B&80S2":460I(YI!-&/7U!/1C+5!V5NB&>5
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M+./DD_4D5IK_.KKE_6ISS+@A4M,1.B:MGO%]??X9=1 ;<MM6ZO*?!X<'^+=
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M0ZTUELY\UQ$#B[V *XI_*^KPH1O.8'DQF$Z 40MPB]B-I(%7[)!MWL.B^:$
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M4$6,B;VX$:(-W>G,YABDJ.(9_=!"1!07\HF3K(?6G657V-"SII9CBD_F2'Q
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M$6C3_A]P=U24[P@R)L6ZJHH9K@*2,EA>"F8BT@9]0.8(Q""Z%]M"I#.?*0A
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M3^*+U]#,V?5N5+D._,FUK5%D$IMR[U87+%"-"0%N"0P$]1#X#\L/L!<TU Z
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M$5+%--4UD#1:V+(Z#I.KQ!-,!<PM--U64IQ$/< 5+;?ISLAU<9P,V<^5!F5
MUD\IMJ"4WFIXA<AL37CA#-,MJ%-4=>F+)D.@GO*6(;KT0E%@Q_L$)+<<!;97
M:UOHMLX4C[>%*+!.]Q(LT8(I=;H-,C4K4[,'JS7RHZXZ^9V&=8*<,DQ"$J,?
ML1!MXTQFXV'] M#F K&-;B$"_L9U_Y+ 4%>#PF8^E@,68ORQHE7Z7V )5E ]
MKA*)CF, "[/0P:XU8MIPRJTC=/F0!>9,P-W9Q W<6\^<3> W:^BYJ6]4^J:K
M,@IA2!7Q)I2^>0O&[SLTGT<I!IBR)^]=+I3OROD-34?"#^=.MMS!"E!#FYN>
MP&TVO[5 B>*D(6$22T]&E3"Y*O.47UW!=_6PRAR<OC(VLLY4+4T4R$B"3\M1
M69JJHCOADA<RX^Y5@MN6S;A[M;:%[@A-N8.;QR6U2Z/=T%F!7[Z_:=5^)W B
M ]%\KAHBQ]%BMJRV",8&/N.FC28(@2,<<>7X6.A]L\0$ 16AE+_93*<"*J6O
M$$==:&"9D8A8I^FD:P)DK3XPQZGY%X]Z[IAV-"?9N/!!WH"J2P[S3W1]]B.?
MO3ER9W'1IFFZ9-0JLI%=R[2D/.7,*EL21%_HC$*6-(*M\K^)%,3F,U,0,T_,
M3U^#J+\\NTAXA9Z M>9^.6/X@Y#7!S<,/K&Q]8./S@X> V7G@*Y WV1T/<XR
M7MG$U_&MR#<^)F; FVU.:ZG/H((R*HP=J=AIO7;1A=;8A[/<[=>:([4]N4>N
MH#R>.3N8' A^E).FE,!,ZX#1_!8<Y^X ?!M_6KH5J=5/[LNVEGQ;FEKEVQSB
M?PN?K7AM0/<^5>^RU)M#OTT^;EOY9F]UX"BW"T\5#H0(+RR(#"Y*ST*#NO:&
M<)LG@JJDVG.DAV@,9GBI/L=\A.4(1Y#,;@T#61TI<CD,' O4(%8EQ"]K4RX.
M,V-'I0P$&]JA'XT<!8BEL]5D[:6IN&L+:R-"GUQ9-DCZ -$PH7P]Z7+0'.I)
M0KEJZ#U1&R+=/CI]^[;*:C'I=CW)NQ]TKV)5^R@&%^80RA_J)GJ1_TDWXM45
ML=6MU_.S\5(]+>)0.L 3:C=T%XM$\8.GZ_VL %RO/T2L5-<8I+J*7CXM#@K)
MSO__PW_Y)IC]2T@4HZK!?KUQ1P_G,/8DF-KG_P=02P$"% ,4    " #<@%Q6
M\^&*A7 /   %G@  $0              @ $     <V%V82TR,#(R,3(S,2YX
M<V102P$"% ,4    " #<@%Q6>]5K[A<.  "0S   %0              @ &?
M#P  <V%V82TR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ W(!<5@MO1Q89
M(   >#L" !4              ( !Z1T  '-A=F$M,C R,C$R,S%?9&5F+GAM
M;%!+ 0(4 Q0    ( -R 7%836O62EEP  +G(!0 5              "  34^
M  !S879A+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #<@%Q6T-"6W/9"
M  #C" 4 %0              @ '^F@  <V%V82TR,#(R,3(S,5]P<F4N>&UL
M4$L! A0#%     @ W(!<5L^AQU^L!@0 )5%  !4              ( !)]X
M '-A=F$M,C R,C$R,S%X,3!K+FAT;5!+ 0(4 Q0    ( -R 7%9I&?3]Z;T
M (CR   9              "  0;E! !S879A+3(P,C(Q,C,Q>#$P:V<P,#$N
M:G!G4$L! A0#%     @ W(!<5C]KULW3_   _RX! !D              ( !
M)J,% '-A=F$M,C R,C$R,S%X,3!K9S P,BYJ<&=02P$"% ,4    " #<@%Q6
MDQJ[*1DG 0 E;0$ &0              @ $PH 8 <V%V82TR,#(R,3(S,7@Q
M,&MG,# S+FIP9U!+ 0(4 Q0    ( -R 7%8IXG^JV6P  "S;   9
M      "  8#'!P!S879A+3(P,C(Q,C,Q>#$P:V<P,#0N:G!G4$L! A0#%
M  @ W(!<5BH2OTYAG0  &>\  !D              ( !D#0( '-A=F$M,C R
M,C$R,S%X,3!K9S P-2YJ<&=02P$"% ,4    " #<@%Q6GN)?-41R  #*RP
M&0              @ $HT@@ <V%V82TR,#(R,3(S,7@Q,&MG,# V+FIP9U!+
M 0(4 Q0    ( -R 7%:)$DRLUE(   "0   9              "  :-$"0!S
M879A+3(P,C(Q,C,Q>#$P:V<P,#<N:G!G4$L! A0#%     @ W(!<5L%$1AKA
M7   ^74  !D              ( !L)<) '-A=F$M,C R,C$R,S%X,3!K9S P
M."YJ<&=02P$"% ,4    " #<@%Q6)PQ4L-$"   Q$   &
M@ '(] D <V%V82TR,#(R,3(S,7AE>#(Q7S$N:'1M4$L! A0#%     @ W(!<
M5HQ8%0Y/!0  DRL  !@              ( !S_<) '-A=F$M,C R,C$R,S%X
M97@R,U\Q+FAT;5!+ 0(4 Q0    ( -R 7%8 ,3V$N@D  .A3   8
M      "  53]"0!S879A+3(P,C(Q,C,Q>&5X,S%?,2YH=&U02P$"% ,4
M" #<@%Q658TULEH)  "=4P  &               @ %$!PH <V%V82TR,#(R
M,3(S,7AE>#,Q7S(N:'1M4$L! A0#%     @ W(!<5N=E[ _^!0  9RX  !@
M             ( !U! * '-A=F$M,C R,C$R,S%X97@S,E\Q+FAT;5!+ 0(4
M Q0    ( -R 7%;*]L7V%C\  +10!  7              "  0@7"@!S879A
I+3(P,C(Q,C,Q>&5X,U\T+FAT;5!+!08     %  4 &D%  !35@H    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
